<SEC-DOCUMENT>0000721371-22-000032.txt : 20220506
<SEC-HEADER>0000721371-22-000032.hdr.sgml : 20220506
<ACCEPTANCE-DATETIME>20220505161859
ACCESSION NUMBER:		0000721371-22-000032
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		83
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220505
DATE AS OF CHANGE:		20220505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CARDINAL HEALTH INC
		CENTRAL INDEX KEY:			0000721371
		STANDARD INDUSTRIAL CLASSIFICATION:	WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122]
		IRS NUMBER:				310958666
		STATE OF INCORPORATION:			OH
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11373
		FILM NUMBER:		22896601

	BUSINESS ADDRESS:	
		STREET 1:		7000 CARDINAL PLACE
		CITY:			DUBLIN
		STATE:			OH
		ZIP:			43017
		BUSINESS PHONE:		6147573033

	MAIL ADDRESS:	
		STREET 1:		7000 CARDINAL PLACE
		CITY:			DUBLIN
		STATE:			OH
		ZIP:			43017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CARDINAL DISTRIBUTION INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cah-20220331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:5843d3e5-829e-408b-801e-c8a62435530f,g:2e89d43f-ed1a-46fa-9c57-992bbbf67b50,d:af3733bf892b435689161c61a06da348--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:srt="http://fasb.org/srt/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:cah="http://www.cardinal.com/20220331" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cah-20220331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF80L2ZyYWc6YWZiNzY4NGVjYjIxNGRlYjkzNWY2OTdjMDBiNTNmY2EvdGFibGU6MzFkMDFlZjJkOTE4NDZjMzlmZTVjMmEwYzYxMDFiYTIvdGFibGVyYW5nZTozMWQwMWVmMmQ5MTg0NmMzOWZlNWMyYTBjNjEwMWJhMl8yLTEtMS0xLTk4Njk0_ae1b5646-8f98-4f64-86cb-8d898d37f87c">0000721371</ix:nonNumeric><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF80L2ZyYWc6YWZiNzY4NGVjYjIxNGRlYjkzNWY2OTdjMDBiNTNmY2EvdGFibGU6MzFkMDFlZjJkOTE4NDZjMzlmZTVjMmEwYzYxMDFiYTIvdGFibGVyYW5nZTozMWQwMWVmMmQ5MTg0NmMzOWZlNWMyYTBjNjEwMWJhMl8zLTEtMS0xLTk4Njk0_0ac62204-bfc1-4172-8c01-3dfd8b5fa2b6">--06-30</ix:nonNumeric><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF80L2ZyYWc6YWZiNzY4NGVjYjIxNGRlYjkzNWY2OTdjMDBiNTNmY2EvdGFibGU6MzFkMDFlZjJkOTE4NDZjMzlmZTVjMmEwYzYxMDFiYTIvdGFibGVyYW5nZTozMWQwMWVmMmQ5MTg0NmMzOWZlNWMyYTBjNjEwMWJhMl80LTEtMS0xLTk4Njk0_3cd89fe6-c544-48ff-a4c2-2f6e4d6adf64">2022</ix:nonNumeric><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF80L2ZyYWc6YWZiNzY4NGVjYjIxNGRlYjkzNWY2OTdjMDBiNTNmY2EvdGFibGU6MzFkMDFlZjJkOTE4NDZjMzlmZTVjMmEwYzYxMDFiYTIvdGFibGVyYW5nZTozMWQwMWVmMmQ5MTg0NmMzOWZlNWMyYTBjNjEwMWJhMl81LTEtMS0xLTk4Njk0_31a27cc1-469a-4f7e-8d65-c43ec8f678c4">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF80L2ZyYWc6YWZiNzY4NGVjYjIxNGRlYjkzNWY2OTdjMDBiNTNmY2EvdGFibGU6MzFkMDFlZjJkOTE4NDZjMzlmZTVjMmEwYzYxMDFiYTIvdGFibGVyYW5nZTozMWQwMWVmMmQ5MTg0NmMzOWZlNWMyYTBjNjEwMWJhMl82LTEtMS0xLTk4Njk0_756335cf-733d-4ddd-a646-f96b1dd99b14">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cah-20220331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a49f4b92dd448488ec3ce2514a9b527_I20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i79f0c6d48d9042059a71690df0625736_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePriceAxis">cah:A300MillionShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="id0bcebad12fc4c40a4b459a431f9432e_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePriceAxis">cah:A300MillionShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="idb40345a5fe44f68828da6e24128f448_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePriceAxis">cah:A300MillionShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a80329f29594c698d9ee74e1eaacbbe_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePriceAxis">cah:A200MillionShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bd39d7063da4c278767bc202d3ccfc3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePriceAxis">cah:A200MillionShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88bcf45d478a46e4b22b402f4b7f54c3_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePriceAxis">cah:A200MillionShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9374cb6cebc440eabca82aeeccf1677_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if22adf094ce443b8a6d548e13f36c294_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia92405f06fae4c4cb90f702005b8b2a7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c93d4e78a8c4d04b6c310720c3be878_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a93b5354aeb44f8b3cc0d0d850b2501_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1d5a08085294befb4f0b438a66e23de_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75e8b16bb97541c8bd805031f5452617_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if883c9a37b644835bbe659371a267a15_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide0abb91cd8d4383a017830f5ef299ff_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8232a7a263294a17a4f15379d0173ba2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f9edcb7c954465280f497a367eed0d4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56eb96c92b484bcaa4f9f5c171ad239f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52413ad34f00440b833f5b75a8dd4627_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaff4ed7f966c47e4962d2bf39a55b561_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a915a1a243e410f9ec96b9ace3e80d6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieed2c03cd42a4857909b008f32e31e33_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ee4d69320c340dcb7f8fca3e33c99e1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6addc7f27a0049d9963b698b876c52cf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id578e6daf1574d8eb480d856c73bbcda_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i443356fbbe284138a0f49faa34b3208e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id981bf2219e54d3eb7348670fb74ec8c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee675ac2f5dd4bb5a80f01c9e1535b8b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2703e84aa6d447f29d3aac9d09f5f094_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5214de7195b64409b6762f36bf235b55_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22fec11876c34d5ebd2c18f6a35aa182_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12146da7d33541d09f9ef291e388a502_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i359769217d5441bc9c97571164783ca2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74e91c5fe50846e4abcf66f67c9b72da_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89dbe704562b4ba5ac39a63d65dbff5a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic83e16a32c7b450083b893267a9ccda4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6ce5f003d8e47b7ac0d61aa5df61b12_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i021442adc8e24489b12297c43e3fabda_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43de0647ce12490ab30c52d836774dce_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07511c4beddc431e9241b971549f9ad5_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ec660a67cd04983b32b8b4fe7d9870a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i644e369be5f6420aa49654a4323fa93d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a430c2a1ae64753ae7b549dfc1f69c7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3c75fe6e5544a349f30d33c4e68a2ac_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8151fa2583d44a688b40d92d9d83b78_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77aa86d8f8f8485ab211b681b5f58fb3_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ed02a1c09cd4d529605f81979cbf648_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaeff0c865a8a4369ab8c5fdca6cee729_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb593644726c4c428ed6ceb42a31ff8f_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i090402a139834d23aa8e6c3a5b7f46f8_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6dfd6eb1a2c4315afc3207155a386d9_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42e7af7d759c4fa5bfb0b98fa27e974f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9744506513214bcc9e61087cf55e047e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i307f69a4e1d24b7f8e2b9180075e87b8_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69e2c38f6f454bfa9b9fece718b91fbe_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e0fd895201d4863a312198f691a8d0b_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic358c286737245819556816b3a0a5db5_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4b35350391644c2a0bdf28917ce2828_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7afc2ffa017e47fe877f56fa2b3a45d4_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ca3ba0c73594ed7bbc82421ddc8eb83_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32f5ee07df944be68a4ca171d08f3c89_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:CordisDivestitureAxis">cah:CordisDivestitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45240633cec7475d96b338fa98ea6450_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21b9f08e069e407899537ccf182d99fb_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i739eec2ece12431aa16063ab41067d2c_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e58575430c249979ddd28860b77d7ea_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8754e705bb17409ca30ddb1af53bfd62_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75ec9e64c1d7453ca7736eb6d2cd74b4_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbcce5e048774bd281968e39fa6fd1d5_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cf7100a49b8462b95d20252b5ae23fc_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8dd1990825346198258de24f42bdfab_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41161f1b8d3943d8bd64b5d48963474e_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51a8695f54ef4860b74b13f3c337f04d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb7f73d87fb74abbb28799bf351ad2cf_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2473dfc0495e42aeb265fd377f6c1a00_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">cah:MedicalUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c4e40c1def448fcb66e1d0cc8122850_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">cah:MedicalUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2843d7b87d1544cf87e968d6d3ae3124_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">cah:MedicalUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="id1a80ba5335a434499eb18f05cfe77bd_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cah:IPRDTrademarksandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04b1540e67e14f1491c2bcf9e8c40937_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e32d2dbae964ed2b9f89a485ba2d9f2_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica172f3bed03490b81be7777d6520978_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51a8e1fc38aa4e9fa1cbb316ac661cf2_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id70764894a9a471186543cece23c0235_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ac7d4f29a95405f9301d56ef3d96f7d_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58dd95f7f9f14ed4a4314c6690da932a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cah:IPRDTrademarksandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95eee9fd908844ee899640d22db70870_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i602bf6f83c0542c597ac5984f1a805f8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6be348f5aeaf4eb1a576923d8e90234e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if590433d5a9845a7a608dab6a0c258f3_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A2.616Notesdue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cb2151ddcdc4fc59c0b79ed2096beec_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:FloatingRateNotesdue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13e48b0505964bf68353a1b6f9547f38_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A2.616Notesdue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf3cd5065e6243ffbbc71550c25ca7f8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i993a04a28da74821b93ee616926e595e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id353836da7934ebb8d1cb8a20ca4a576_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cah:ShortTermCreditFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:CommittedReceivablesSalesFacilityProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea2152d45a954937a5a92441521a45ff_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cah:ShortTermCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ab6a9c65c7e4470950a3a5d6dc31d86_D20140731-20140731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cah:CVSHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-07-31</xbrli:startDate><xbrli:endDate>2014-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23ebd145540743d0ab7dda2a643e03b3_I20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5255724c8ed4493ca93e7bf150c7f600_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ee03b4ae5f340a187f4bc77f729452b_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i491c71d0bbb64a989ca7c5c82a284488_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9215c78d739b4b399eaa5fb71927062e_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i882c87a069664d07be3f57a3c4880673_I20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>cah:lawsuit</xbrli:measure></xbrli:unit><xbrli:context id="ib8066d95edcd4276b92e5941e9cf1675_I20220428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsStateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f3f37b2e6a246ca91a14261f83072a8_I20220428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="stateag"><xbrli:measure>cah:StateAG</xbrli:measure></xbrli:unit><xbrli:context id="i56ecddadc331422e91dd1962e9bd826a_I20220428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="states"><xbrli:measure>cah:states</xbrli:measure></xbrli:unit><xbrli:unit id="numberofusterritories"><xbrli:measure>cah:numberOfUSTerritories</xbrli:measure></xbrli:unit><xbrli:context id="i8d6bdce912f94701b4d5c146cec19721_D20220428-20220428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-28</xbrli:startDate><xbrli:endDate>2022-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66875ebb8eef4db4b014c5f748452b43_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic882bf829b3c4091beef8438bdf4b296_D20220428-20220428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsStateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-28</xbrli:startDate><xbrli:endDate>2022-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0247bbb36fd244a09bc9d98fe2b16dcb_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ff29a3a90e442dd8c5616657406a603_I20220502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bc140f1011640a682a782f1cae16cad_D20220428-20220428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WV</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-28</xbrli:startDate><xbrli:endDate>2022-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="plaintiff"><xbrli:measure>cah:plaintiff</xbrli:measure></xbrli:unit><xbrli:context id="i7cfeb36a6e0d45f8aa734c1879638433_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc7fdc5fa1c84d5aa2af19ed52614364_I20220504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5118cc3369704619a0d6f9362d7b4be6_I20220504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ClassActionLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ba9d001296a4abc99e1e8dbda30b7a3_D20220428-20220428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:GA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-28</xbrli:startDate><xbrli:endDate>2022-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbd0825dbe564a209ad97999fd39b901_D20220429-20220429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-29</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i967e05473aad4bdab16324a714471629_D20220429-20220429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cah:AlamedaCountyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-29</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dfeb8260c1c4f43b4a0668f4c5957f8_D20220429-20220429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-29</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia501b89dcc1041d69e1b5309d5f9f944_D20220429-20220429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cah:OtherJurisdictionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-29</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i989aea95b6504bd0b4aa8ccb22169319_D20210731-20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-31</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2ae902498a44131a91a5bebbbda2131_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e7f4d19047348f89f56bfebceea170d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie60f8b5fae944fc6a15c2435abf6b955_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:DOJInvestigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i579fe90cd44b45029f6ce1e6fd52d06e_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">cah:MedicalUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a1ee29c629542f28c59d5fc1aa744bc_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:GoodwillImpairmentAxis">cah:MedicalUnitGoodwillImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i733aa2f887dc40399537d2978ea4fed6_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:GoodwillImpairmentAxis">cah:MedicalUnitGoodwillImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia07b2306645b4f5b9983cc7a043e7f14_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:GoodwillImpairmentAxis">cah:MedicalUnitGoodwillImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if20d9caabe284cddb92eb75707c2d485_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:CordisDivestitureAxis">cah:CordisDivestitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55ae6d66a0154f618e5ff8b55c474990_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:CordisDivestitureAxis">cah:CordisDivestitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8498a443311b4f6ea73d7b6ae59ff884_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:NetOperatingLossCarrybackAxis">cah:NetOperatingLossCarrybackMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b95fd8ae52348c2a406851e857bf380_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:NetOperatingLossCarrybackAxis">cah:NetOperatingLossCarrybackMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a43d062c10d4b5dbe47ed5927846f46_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:NetOperatingLossCarrybackAxis">cah:NetOperatingLossCarrybackMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08ae81a7c49448f6a2bf594f079b609d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:NetOperatingLossCarrybackAxis">cah:NetOperatingLossCarrybackMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c3e04c844a0448ba87bfb01fae49ef6_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6880faa0fa0e4239896a55f349c38f00_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i469fd276126b4ef2a0a27b313a8c926f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34b741e645b547cba1a09aef122491a7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19311f0a545a45fabf7564bb3e12fa8f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97ee2fe5350d48a8a6d2429ec7ce8ba3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:CareFusionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97c5d03ddc3b4285af82f4a8cdd73077_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:CareFusionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib619e74f426d4144819daac0dcea199d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:PatientRecoveryBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabd8bb008ac74a12a6602b75f99f57be_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:PatientRecoveryBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a166264477c46fab57fcf607e059c5e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3682e4eb8a05493a929d3c71c120ed44_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic39a5057fc6f46779de6e92cbbdcda7a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icac6fea690094cec98b24894f11a9dc5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6a713b79a1b4db391a01b08a7955833_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dd0cc9f485540cfba812a2f569e0eec_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6b241993ad04feca1177de9a32b41d8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8196f6a78b04b869ddf71567a35ba1e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied79b20d51d24a52ac6760b96c790928_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3ce5b3abcbd46bd97aab3629e9beed9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c0359ac173741d1a3e87605773843bb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9364c217c27b48f7b6d55997d6363b7d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia89d064616e44ff0bc7a6c819fa695aa_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb3a9b89882f4cad85e3415fe62bbe64_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic064a2bc08564367b783b55fd00e3a4c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:MaturityDateAxis">cah:September2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="jpy"><xbrli:measure>iso4217:JPY</xbrli:measure></xbrli:unit><xbrli:context id="id24201ce4b9a45b3984c1578539f4366_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:MaturityDateAxis">cah:June2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5481aab2ab274715b2e24d13110e9131_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6a258e1b3d647dab58b5794f710d928_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c5d8170ec134e538d16a98b7645242a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie780eda2dbfa43b5ba1886064e5bee88_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b561ae116c44487bc2d0b64415c487c_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3d6a7b343d84263bcfd5f6081c9080a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f6a2249983a48ba948782ea8ac398ae_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida3f04fa5227480f833bb171bc91c08c_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0faba6dab9bb45eba4532f90d44b6e37_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddd5f86516724f048fca712cc799eb64_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice6d3b2a080d44b5b66bace596c4726a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePriceAxis">cah:A500MillionShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i493db659fb0e48c29fa86341836956fb_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePriceAxis">cah:A500MillionShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7b83872d6a44abb948f2abd62a0d67d_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePriceAxis">cah:A500MillionShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bc04df5c22d4ac594b0f37e4348fad8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1d975e32208495384d3c3f118607978_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib919fba7df9a4af5a962444ad795f36e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85dc1b14fefe4551abd5390650b6c712_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6973b5f7f08f491a99b32b3361d5234a_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88939d79b6fc434586eae883166fc9d8_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96f98f7a3c2b4137aadf18cea504d375_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ebf444915254c15b3d63cf748c3515a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if466229061cc43eda2992e495763f330_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>cah:segment</xbrli:measure></xbrli:unit><xbrli:context id="i271748b8420f4075b02360857adce1b3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c47eb93c86c45f18852a7d4732bcc2b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55a8895770e74654bb814d7570d0be67_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic20d148712384093a21beaae9dbb11ae_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50ba23949f524ee39edd3981f77140d5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84520ad8572840ff8aebaffcf2fc874b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35c8403b7fd7460d84fabd0ac9bdf6b9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69525c4e29b84ce794f19067c425c73f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida0bf17cdf17411ab1c3212847b430cb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74d2de9e32a34ab5b7753b90bdd5d03f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76a973b7ccb648908c98bf838383a489_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i968b05c553634c7a8ef37ffb3b2c9491_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b6fce6427cc4db58e97a1124f989059_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i940747d1739c452b84105fc820e21d0f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2b4c786f4bf4513b3347b942f655efd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50f9973da9d3455e928bdbe756cb6f44_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fc7d8e372df4069be7ed7b9e033f09f_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2178f9d823184a19a7be4b97a98bbfcd_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie832c8853e2a4345938d5c0300e49149_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i995eb07521ae4433bdc8160df2f79810_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a8fa6b7c4c04392ad18e36a04760533_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib25907ae15fa44dcb0802c504cec1c88_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b0d22bf281f4584bad7e62de864bf75_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77648cd7d3a34814beda9dcd87e2f35d_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7bcf27f7221414f96fbedd5799f6902_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i479768cce42840d6807b6cf8e3d09439_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6afdf5f1340d41c6941f5cc19ff2ef71_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i203ccf6041354aa887510c9903970c43_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7205a1910584e49b66107f75befc03d_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic84e3ea0e4fb4425b6174e7655ba01f1_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1865dd177bf446bb0808b03a8c0b8b6_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b1b3f0e63094c6ba80ba1a031e52c86_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70d8b7dbb46a4e8fa9f3548d4edd3460_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b6b3238d8dc4c6094d322879432c3a3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe5bb815566842549cff77434b3664c5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i625a7e6298c541f0ab5627a25b81a35f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic282070c0abd4da7b2e98ef29dabe2a4_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe9bf4e4c9f04b558b3d275631d67107_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60837aa8922b471583b5179248715cc5_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icadf953dd78648ce88457a23b39ed9b3_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dc2bc03fca7468582ef192514e3bfd5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab9fb6c03f2c41b09eab97067568553e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1b44ed725e04cc79bd011f2ce6f6445_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2054ef93e9f6497bb4e5e5e8c06c5afa_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a7244a5c088444480543d7621bd8890_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fa86c22fb664c2d85324c8fa396e444_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25b4b6630ae44ef28341784008cfd847_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:CordisDivestitureAxis">cah:CordisDivestitureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59ac145c43e84d588b95df88a14fdc55_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d746fa13a56425188cf694ad9491c8b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fc6f93a9a324e02934d0435deab460b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12af8121f223485cbae6b363fb276e76_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7587b0e2335a4976aed28934df90543d_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i884f8a089566407ab080d0ebb229f552_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec8a7050443b4a1cb54f2dc25501b78f_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic70067800d5143aea0895bee00acddf8_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa16d72f5cb94c3dae8ef889f5cf1b73_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i429695d6f4bd42f3954b0d838fa9cbea_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72e703868e904b989107e7bea5f5c25a_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81916c52c3fd4ebfbcb9cb988adcf939_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i563a2c8d36a84c8890168f4f9a86e549_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6804c7cefdb418480ee13a51907f380_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5833a4aca61e4135963e45569b6980df_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i160dc3f384644e66812cbec2a46665b2_D20190701-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i766ebcafc487484896f01112fb4d75ea_D20190701-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b9a407d237d4399ad21e36831394a4a_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b1fc63c210f45c4b87728a4957e3834_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i971a6ca11d6d4f408c6af2dc52b79810_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id38ff405ba8f4f46b884a396366a86de_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="iaf3733bf892b435689161c61a06da348_1"></div><div style="min-height:40.5pt;width:100%"><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.461%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:100%">UNITED STATES</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Washington,&#160;D.C. 20549</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Form <ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGV4dHJlZ2lvbjo2YzU2MDdiYzc2YmI0NjRkOGVjMTVjM2QyNDQyZTQyOV84NA_ae82131e-251e-4ad0-bab5-8fe0f77c769e">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.923%"><tr><td style="width:1.0%"></td><td style="width:5.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGFibGU6Zjg4YmM3YWY1NTJkNDA0NDlmZWQ0ODk0MzVjMGVhY2QvdGFibGVyYW5nZTpmODhiYzdhZjU1MmQ0MDQ0OWZlZDQ4OTQzNWMwZWFjZF8wLTAtMS0xLTk4Njk0_f14cc45f-bb1b-4e6c-903a-620ec6805c12">&#9745;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGV4dHJlZ2lvbjo2YzU2MDdiYzc2YmI0NjRkOGVjMTVjM2QyNDQyZTQyOV8xMjE_5829fa59-a25a-4e23-83a1-facd88888787">March 31, 2022</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.923%"><tr><td style="width:1.0%"></td><td style="width:5.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGFibGU6N2QxMjgxODdiZTQ3NDRhYzkzNGU2NjJhM2IyN2VhM2EvdGFibGVyYW5nZTo3ZDEyODE4N2JlNDc0NGFjOTM0ZTY2MmEzYjI3ZWEzYV8wLTAtMS0xLTk4Njk0_9cbeff0b-b037-46dd-a4f9-c620ee66113c">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the transition period from ________ to ________</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission File Number:&#160;<ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGV4dHJlZ2lvbjo2YzU2MDdiYzc2YmI0NjRkOGVjMTVjM2QyNDQyZTQyOV8xNTc4_092a5abf-fbb4-4e11-8846-320d1d9b792b">1-11373</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGV4dHJlZ2lvbjo2YzU2MDdiYzc2YmI0NjRkOGVjMTVjM2QyNDQyZTQyOV8xNTc5_137799e4-4713-41aa-a7ad-904d90146fe2">Cardinal Health, Inc.</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.282%"><tr><td style="width:1.0%"></td><td style="width:24.998%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.865%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.865%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.346%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGFibGU6YjBlOTk4NTZhMzI0NDk4NmJkZjA0ZjNmNmI1NTZlY2QvdGFibGVyYW5nZTpiMGU5OTg1NmEzMjQ0OTg2YmRmMDRmM2Y2YjU1NmVjZF8wLTAtMS0xLTk4Njk0_54f36145-d561-4f1c-8238-a5cfb5a4b741">Ohio</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGFibGU6YjBlOTk4NTZhMzI0NDk4NmJkZjA0ZjNmNmI1NTZlY2QvdGFibGVyYW5nZTpiMGU5OTg1NmEzMjQ0OTg2YmRmMDRmM2Y2YjU1NmVjZF8wLTYtMS0xLTk4Njk0_ba697469-6f9f-4985-8b98-91d7f000c454">31-0958666</ix:nonNumeric></span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(IRS Employer<br/>Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGFibGU6YjBlOTk4NTZhMzI0NDk4NmJkZjA0ZjNmNmI1NTZlY2QvdGFibGVyYW5nZTpiMGU5OTg1NmEzMjQ0OTg2YmRmMDRmM2Y2YjU1NmVjZF8zLTAtMS0xLTk4Njk0_8694ce50-53dd-498d-84bf-670b27fdbe0c">7000 Cardinal Place</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGFibGU6YjBlOTk4NTZhMzI0NDk4NmJkZjA0ZjNmNmI1NTZlY2QvdGFibGVyYW5nZTpiMGU5OTg1NmEzMjQ0OTg2YmRmMDRmM2Y2YjU1NmVjZF8zLTItMS0xLTk4Njk0_f7b9ee7a-5434-4a9d-bf7e-78c76ec1bc58">Dublin</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGFibGU6YjBlOTk4NTZhMzI0NDk4NmJkZjA0ZjNmNmI1NTZlY2QvdGFibGVyYW5nZTpiMGU5OTg1NmEzMjQ0OTg2YmRmMDRmM2Y2YjU1NmVjZF8zLTQtMS0xLTk4Njk0_d9b9f01e-b5d2-449a-a53c-5e5f849c67fe">Ohio</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGFibGU6YjBlOTk4NTZhMzI0NDk4NmJkZjA0ZjNmNmI1NTZlY2QvdGFibGVyYW5nZTpiMGU5OTg1NmEzMjQ0OTg2YmRmMDRmM2Y2YjU1NmVjZF8zLTYtMS0xLTk4Njk0_06fbdef0-f2c6-4eeb-b3a1-da125a367b54">43017</ix:nonNumeric></span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Zip Code)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGFibGU6YjBlOTk4NTZhMzI0NDk4NmJkZjA0ZjNmNmI1NTZlY2QvdGFibGVyYW5nZTpiMGU5OTg1NmEzMjQ0OTg2YmRmMDRmM2Y2YjU1NmVjZF82LTQtMS0xLTk4Njk0_dc36385e-cf04-43ec-811b-16448df18160">(614)</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGFibGU6YjBlOTk4NTZhMzI0NDk4NmJkZjA0ZjNmNmI1NTZlY2QvdGFibGVyYW5nZTpiMGU5OTg1NmEzMjQ0OTg2YmRmMDRmM2Y2YjU1NmVjZF82LTYtMS0xLTk4Njk0_0f031ca0-7638-462a-a852-bb177cfafa7d">757-5000</ix:nonNumeric></span></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Registrant&#8217;s telephone number, including area code)</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.435%"><tr><td style="width:1.0%"></td><td style="width:35.931%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.836%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGFibGU6NzkxOTY0MTgwMDE4NDNhMDg4Y2ExY2Q3ZTkzMjJhYzUvdGFibGVyYW5nZTo3OTE5NjQxODAwMTg0M2EwODhjYTFjZDdlOTMyMmFjNV8yLTAtMS0xLTk4Njk0_b8a259dd-2222-4f98-b0d9-43ccc7fe114f">Common shares (without par value)</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGFibGU6NzkxOTY0MTgwMDE4NDNhMDg4Y2ExY2Q3ZTkzMjJhYzUvdGFibGVyYW5nZTo3OTE5NjQxODAwMTg0M2EwODhjYTFjZDdlOTMyMmFjNV8yLTEtMS0xLTk4Njk0_625bf864-7909-4b48-8984-896e0be35738">CAH</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGFibGU6NzkxOTY0MTgwMDE4NDNhMDg4Y2ExY2Q3ZTkzMjJhYzUvdGFibGVyYW5nZTo3OTE5NjQxODAwMTg0M2EwODhjYTFjZDdlOTMyMmFjNV8yLTItMS0xLTk4Njk0_5116038e-2518-4136-9518-034a5ac50d13">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGV4dHJlZ2lvbjo2YzU2MDdiYzc2YmI0NjRkOGVjMTVjM2QyNDQyZTQyOV8xNTgw_81d9aab3-80c5-47c9-9686-8207920882b8">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGV4dHJlZ2lvbjo2YzU2MDdiYzc2YmI0NjRkOGVjMTVjM2QyNDQyZTQyOV8xNTgx_0e71d48b-167a-4dfc-8ae1-3c24dfc572ea">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act. </span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.032%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGFibGU6MGJiMWI5YmQ2YzNjNGEwZWI5NzFhYWQ4Y2I3NzUyMDEvdGFibGVyYW5nZTowYmIxYjliZDZjM2M0YTBlYjk3MWFhZDhjYjc3NTIwMV8wLTAtMS0xLTk4Njk0_1a1591f9-78ce-428e-b019-5c73242b3ef9">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9745;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGFibGU6MGJiMWI5YmQ2YzNjNGEwZWI5NzFhYWQ4Y2I3NzUyMDEvdGFibGVyYW5nZTowYmIxYjliZDZjM2M0YTBlYjk3MWFhZDhjYjc3NTIwMV8xLTQtMS0xLTk4Njk0_4dffbdda-f4bc-4ad8-80e5-840d2d5f4668">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGFibGU6MGJiMWI5YmQ2YzNjNGEwZWI5NzFhYWQ4Y2I3NzUyMDEvdGFibGVyYW5nZTowYmIxYjliZDZjM2M0YTBlYjk3MWFhZDhjYjc3NTIwMV8yLTQtMS0xLTk4Njk0_513e9ded-2549-41fb-acea-5c6ec35f0f35">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></div></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). &#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGV4dHJlZ2lvbjo2YzU2MDdiYzc2YmI0NjRkOGVjMTVjM2QyNDQyZTQyOV8xNTgy_f924a048-2ba6-4816-adf1-68e62d4be050">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of the registrant&#8217;s common shares, without par value, outstanding as of April&#160;30, 2022, was the following: <ix:nonFraction unitRef="shares" contextRef="i8a49f4b92dd448488ec3ce2514a9b527_I20220430" decimals="0" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGV4dHJlZ2lvbjo2YzU2MDdiYzc2YmI0NjRkOGVjMTVjM2QyNDQyZTQyOV8xNTc2_3eb14a10-7332-45a1-bc47-bfd7a11aa2a1">272,427,362</ix:nonFraction>.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iaf3733bf892b435689161c61a06da348_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:22pt;font-weight:700;line-height:100%">Cardinal Health</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:100%"> </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:18pt;font-weight:700;line-height:100%"> </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Q3 Fiscal 2022 Form 10-Q                                                                                                                                   </span></div></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:91.080%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_13">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_13">2</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_34">Explanation and Reconciliation of Non-GAAP Financial Measures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_34">18</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_43">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_43">23</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_46">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_46">23</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_49">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_49">24</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_52">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_52">25</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_58">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_58">26</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_64">Financial Statemen</a>ts</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_64">27</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_127">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_127">47</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_130">Form 10-Q Cross Reference Index</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_130">48</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_133">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_133">49</a></span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">About Cardinal Health</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardinal Health, Inc. is an Ohio corporation formed in 1979 and is a globally integrated healthcare services and products company providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices. We provide pharmaceuticals and medical products and cost-effective solutions that enhance supply chain efficiency. We connect patients, providers, payers, pharmacists and manufacturers for integrated care coordination and better patient management. We manage our business and report our financial results in two segments: Pharmaceutical and Medical. As used in this report, &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; and similar pronouns refer to Cardinal Health, Inc. and its subsidiaries, unless the context requires otherwise. Our fiscal year ends on June 30. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to fiscal 2022 and fiscal 2021 and to FY22 and FY21 are to the fiscal years ending or ended June&#160;30, 2022 and June 30, 2021, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2022 (this "Form 10-Q") (including information incorporated by reference) includes "forward-looking statements" addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. Many forward-looking statements appear in Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations ("MD&amp;A"), but there are others in this Form 10-Q, which may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "will," "should," "could," "would," "project," "continue," "likely," and similar expressions, and include statements reflecting future results, trends or guidance, statements of outlook and expense accruals. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those made, projected or implied. The most significant of these risks and uncertainties are described in this Form 10-Q, including Exhibit 99.1, and in "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended June 30, 2021 (our &#8220;2021 Form 10-K&#8221;). Forward-looking statements in this Form 10-Q speak only as of the date of this document. Except to the extent required by applicable law, we undertake no obligation to update or revise any forward-looking statement.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Non-GAAP Financial Measures</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the "Overview of Consolidated Results" section of MD&amp;A, we use financial measures that are derived from our consolidated financial data but are not presented in our condensed consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). These measures are considered "non-GAAP financial measures" under the United States Securities and Exchange Commission ("SEC") rules. The reasons we use these non-GAAP financial measures and the reconciliations to their most directly comparable GAAP financial measures are included in the &#8220;Explanation and Reconciliation of Non-GAAP Financial Measures&#8221; section following MD&amp;A in this Form 10-Q. </span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iaf3733bf892b435689161c61a06da348_13"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.820%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></div></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Management's Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion and analysis presented below is concerned with material changes in financial condition and results of operations between the periods specified in our condensed consolidated balance sheets at March&#160;31, 2022 and June&#160;30, 2021, and in our condensed consolidated statements of earnings/(loss) for the three and nine months ended March&#160;31, 2022 and 2021. All comparisons presented are with respect to the prior-year period, unless stated otherwise. This discussion and analysis should be read in conjunction with the MD&amp;A included in our 2021 Form 10-K.</span></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iaf3733bf892b435689161c61a06da348_16"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Overview of Consolidated Results</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><img src="cah-20220331_g1.jpg" alt="cah-20220331_g1.jpg" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:266px"/></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended March&#160;31, 2022, revenue increased 14 percent and 12 percent to $44.8 billion and $134.3 billion, respectively, primarily due to sales growth from pharmaceutical distribution and specialty pharmaceutical customers, which largely consisted of branded pharmaceutical sales to existing and net new customers.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">GAAP and Non-GAAP Operating Earnings/(Loss)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:48.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.664%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">GAAP operating earnings/(loss)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(97)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(632)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surgical gown recall costs/(income)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State opioid assessment related to prior fiscal years</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">31</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">56</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">79</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">237</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">471</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,764</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">61</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">113</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,085&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-GAAP operating earnings</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">545</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(21)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,540</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,935&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(20)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The sum of the components and certain computations may reflect rounding adjustments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had GAAP operating losses of $97 million and $632 million during the three and nine months ended March&#160;31, 2022, respectively, due to $474&#160;million and $1.8 billion pre-tax non-cash goodwill impairment charges related to the Medical segment, respectively. See "Critical Accounting Policies and Sensitive Accounting Estimates" section of this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_91">Note 4</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional detail. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March 31, 2021, we recognized a $1.02&#160;billion pre-tax charge for the estimated liability associated with lawsuits and claims brought against us by states and political subdivisions relating to the distribution of prescription opioid pain medications. See further description of opioid lawsuits and claims in the Significant Developments in Fiscal 2022 and Trends section in this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_103">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements." </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-GAAP operating earnings during the three and nine months ended March&#160;31, 2022 decreased 21 percent and 20 percent, respectively, due to the decrease in Medical segment profit largely resulting from increased inflationary impacts, primarily related to commodities and transportation, and the adverse impact of global supply chain constraints.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">GAAP and Non-GAAP Diluted EPS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:48.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.664%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">($ per share)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022 </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2,3)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022 </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2,3)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (2)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">GAAP diluted EPS </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5.05)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.40&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3.82)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.68&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State opioid assessment related to prior fiscal years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.08</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.06&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.15</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.21&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.21</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.63</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6.03</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.25&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6.71</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.22&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.18</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.33</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.03</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-GAAP diluted EPS </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.45</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.53&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4.01</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.79&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(16)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The sum of the components and certain computations may reflect rounding adjustments. </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Diluted earnings/(loss) per share attributable to Cardinal Health, Inc. ("diluted EPS").</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The reconciling items are presented within this table net of tax. See quantification of tax effect of each reconciling item in our GAAP to Non-GAAP Reconciliations in the "Explanation and Reconciliation of Non-GAAP Financial Measures."</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">For the three and nine months ended March&#160;31, 2022, GAAP diluted EPS and the EPS impact from the GAAP to non-GAAP per share reconciling items are calculated using a weighted average of 275&#160;million and 281&#160;million common shares, respectively, which excludes potentially dilutive securities from the denominator due to their anti-dilutive effects resulting from our GAAP net loss for the periods. For the three and nine months ended March&#160;31, 2022, non-GAAP diluted EPS is calculated using a weighted average of 277&#160;million and 282&#160;million common shares, which includes potentially dilutive shares.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Impairments and (gain)/loss on disposals of assets, net includes pre-tax goodwill impairment charges of $474 million and $1.8 billion related to our Medical segment recorded during the three and nine months ended March 31, 2022, respectively. For fiscal 2022, the estimated net tax benefit related to these impairments is $126 million and is included in the annual effective tax rate. As a result, the amount of tax expense in the current quarter and year-to-date periods increased by approximately $1.2 billion and approximately $180 million, respectively, and is expected to lower the provision for income taxes during the fourth quarter of fiscal 2022 by approximately $180 million.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Litigation (recoveries)/charges, net, includes a tax benefit recorded during the nine months ended March&#160;31, 2021 related to a net operating loss carryback. Our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation. This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes. The net operating loss was carried back and adjusted our taxable income for fiscal 2015, 2016, 2017 and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security (&#8220;CARES&#8221;) Act. During the nine months ended March&#160;31, 2021, the total benefit from the net operating loss carryback was $419 million; however, for purposes of Non-GAAP financial measures, we allocated $385 million of the benefit to litigation (recoveries)/charges, net, which is excluded from non-GAAP measures, based on the relative amount of the self-insurance pre-tax loss related to opioid litigation claims versus separate tax adjustments. The tax benefit allocated to the separate tax adjustments of $34 million is included in non-GAAP measures.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended March&#160;31, 2022, GAAP diluted EPS was adversely impacted by the goodwill impairment charges related to the Medical segment, which had a $(6.01) and $(6.67) per share after-tax impact, respectively. See "Critical Accounting Policies and Sensitive Accounting Estimates" section of this MD&amp;A, and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_91">Note 4</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_106">Note 7</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional detail. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2021, GAAP diluted EPS included a tax benefit from the net operating loss carryback primarily related to a self-insurance pre-tax loss. Refer to </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_106">Note 7</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional detail. During the nine months ended March&#160;31, 2021, GAAP diluted EPS was adversely impacted by the opioid litigation charge recognized for the estimated liability associated with lawsuits and claims brought against us by states and political subdivisions relating to the distribution of prescription opioid pain medications, which had a $(2.85) per share after-tax impact on GAAP diluted EPS. See the Significant Developments in Fiscal 2022 and Trends section in this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_103">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended March&#160;31, 2022, non-GAAP diluted EPS decreased 5 percent and 16 percent to $1.45 and $4.01 per share, respectively. This decrease was primarily due to the factors impacting non-GAAP operating earnings, partially offset by a lower share count as a result of share repurchases. The year-over-year comparison also benefited from a lower non-GAAP effective tax rate due to favorable discrete items during the three months ended March&#160;31, 2022 and the impact of adverse tax matters in the prior year, including adjustments to our tax provision for the resolution of certain open matters with the U.S. Internal Revenue Service ("IRS").</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Cash and Equivalents </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our cash and equivalents balance was $2.4 billion at March&#160;31, 2022 compared to $3.4 billion at June&#160;30, 2021. During the nine months ended March&#160;31, 2022, net cash provided by operating activities was $130 million, which was adversely impacted by the payment of the majority of our first annual settlement payment under the Settlement Agreement and payments for other litigation matters, the timing of collections of customer receivables and the day of the week on which a fiscal period ends. During the nine months ended March&#160;31, 2022, we deployed $1.0 billion for share repurchases, $597&#160;million for debt repayment, and $425 million for cash dividends. We also received proceeds of $923 million, net of cash transferred, from the divestiture of the Cordis business.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Significant Developments in Fiscal 2022 and Trends</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Opioid Lawsuits Development</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we and two other national distributors announced that each company had determined that a sufficient number of political subdivisions had agreed to participate in the previously disclosed settlement agreement (the &#8220;Settlement Agreement&#8221;) to settle the vast majority of the opioid lawsuits filed by states and local governmental entities. This Settlement Agreement became effective on April 2, 2022. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties to this Settlement Agreement include 46 out of 49 eligible states as well as the District of Columbia and all eligible territories. As of April 28, 2022, over 98 percent of eligible political subdivisions (as calculated by population under the Settlement Agreement) that had brought opioid-related suits against the companies have joined the settlement or otherwise had their claims addressed by state legislation. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Settlement Agreement includes a cash component, pursuant to which we will pay up to approximately $6.0 billion, the majority of which would be paid over 18 years. The exact payment amount will depend on several factors, including the extent to which states take action to foreclose opioid lawsuits by political subdivisions (e.g., by passing laws barring or limiting opioid lawsuits by political subdivisions) and the extent to which additional political subdivisions in participating states file opioid lawsuits against us.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Settlement Agreement also includes injunctive relief terms related to distributors&#8217; controlled substance anti-diversion programs, including with respect to: (1) governance; (2) independence and training of the personnel operating controlled substances monitoring programs; (3) due diligence for new and existing customers; (4) ordering limits for certain products; and (5) suspicious order monitoring. A monitor will be selected to oversee compliance with these provisions for a period of five years. In addition, we and the two other settling distributors will engage a third-party vendor to act as a clearinghouse for data aggregation and reporting, which distributors will fund for ten years.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">West Virginia subdivisions and Native American tribes are not a part of this settlement process and we have been involved in separate negotiations with these groups. In September 2021 we announced that we, along with two other national distributors, had reached an agreement with the Cherokee Nation in connection with ongoing negotiations toward a broader agreement with Native American tribes. In January 2022, we, along with two other national distributors, executed a term sheet with the Native American tribes.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The first phase of a bench trial in West Virginia State Court for a consolidated case brought by 63 West Virginia subdivisions against the Company and two other national distributors is scheduled to begin July 5, 2022.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A bench trial before a federal judge in West Virginia brought by Cabell County and City of Huntington against us and two other national distributors concluded in July 2021. The judge has not yet issued a decision. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, we and two other national distributors reached an agreement with the Washington Attorney General, under which we will pay up to approximately $160 million to the State of Washington and its participating political subdivisions to resolve opioid-related claims. This amount is consistent with the amount that would have been allocated to Washington under the Settlement Agreement, had Washington agreed to participate, plus certain attorneys&#8217; fees and costs. The terms of this agreement are consistent with the Settlement Agreement. This agreement is subject to certain contingencies, including the rate of subdivision participation. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2022, we paid into escrow the majority of our first annual payment under the Settlement Agreement. We also made payments under the separate New York, Ohio and Rhode Island settlements, as well as certain payments under Cherokee Nation settlement and Native American term sheet. During the nine months ended March&#160;31, 2022, we paid $348&#160;million in connection with these matters. In total, we have $6.70&#160;billion accrued at March&#160;31, 2022, of which $738&#160;million is included in other accrued liabilities, and the remainder is included in deferred income taxes and other liabilities in our condensed consolidated balance sheets. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the lawsuits and claims brought by states and governmental entities, described above, we are involved in other opioid-related litigation and investigations, which are described further in Note 6 of the &#8220;Notes to Condensed Consolidated Financial Statements.&#8221; </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual, whether as a result of settlement discussions, a judicial decision or verdict or otherwise. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_103">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Inflationary Impacts and Global Supply Chain Constraints, and Medical Goodwill</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical segment profit was negatively impacted by increased inflationary impacts, primarily related to transportation (including ocean and domestic freight), commodities, labor and the adverse impact of global supply chain constraints during the three and nine months ended March&#160;31, 2022. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the risks and uncertainties related to these impacts, we performed interim goodwill impairment testing at March&#160;31, 2022 and&#160;December 31, 2021, which resulted in year-to-date pre-tax non-cash goodwill impairment charges of $1.8 billion, included in impairments and (gain)/loss on disposal of assets in our condensed consolidated statements of earnings/(loss). See "Critical Accounting Policies and Sensitive Accounting Estimates" section of this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_91">Note 4</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional detail.</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For fiscal 2022, the estimated net tax benefit related to these impairments is $126 million and is included in the annual effective tax rate. As a result, the amount of tax expense in the current quarter and year-to-date periods increased by approximately $1.2 billion and approximately $180 million, respectively, and is expected to lower the provision for income taxes during the fourth quarter of fiscal 2022 by approximately $180 million. Refer to </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_106">Note 7</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional detail.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect these inflationary impacts and global supply chain constraints to continue to adversely impact Medical segment profit. In order to partially mitigate the impact, we have implemented an initial phase of price increases and we are evolving our commercial contracting processes and investing in additional supply chain capacity. If these increased costs and the adverse impact of global supply chain constraints are greater than we expect, continue beyond our expectations, or we are unable to increase prices, our results of operations will be adversely impacted to a greater extent than we currently anticipate.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also experienced increased costs in the Pharmaceutical segment, primarily related to transportation and labor, during the three and nine months ended March&#160;31, 2022.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">PPE Demand and Pricing</span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personal protective equipment ("PPE") refers to protective clothing, medical and non-medical grade gloves, face shields, face masks and other equipment designed to protect the wearer from injury or the spread of infection or illness. Demand for PPE has fluctuated during fiscal 2021 and fiscal 2022 resulting in variability in sales volumes, inventory levels and costs to manufacture and source these products. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PPE adversely impacted Medical segment profit on a year-over-year basis for the three and nine months ended March&#160;31, 2022 and we expect further adverse impacts due to lower volumes. In addition, the prior year included the timing favorability related to our cost mitigation efforts, primarily pricing.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We experienced the peak of heightened demand for PPE during the second and third quarters of fiscal 2021. This increased demand resulted in higher sales volume for certain products, increased costs to manufacture and source these products and higher inventory levels to meet customer commitments. As a result, we sought out additional sources for these products and to mitigate the impact of these cost increases, we have raised our selling prices for the affected products. During the fourth quarter of fiscal 2021, selling prices and customer demand for certain PPE decreased as compared to the peak. This resulted in inventory cost above net realizable value, requiring an inventory reserve of $197 million, primarily related to certain categories of gloves, which adversely impacted Medical segment profit.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">COVID-19</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic (&#8220;COVID-19&#8221;) began to materially affect our businesses during the third quarter of fiscal 2020.  However, due to the passage of time, intervening events and other market dynamics, the comparison to pre-COVID-19 operations has become less meaningful as a basis for us to assess our financial condition.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Pharmaceutical segment, volumes have rebounded and stabilized from the declines we experienced during the height of COVID-19 and we believe fluctuations between periods are driven by current market dynamics, rather than the ongoing effects of COVID-19.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Medical segment continues to experience the effects of inflation, global supply chain constraints and PPE dynamics, which we consider to be independent of COVID-19 for purposes of assessing our financial results and which are discussed separately above. Due to the magnitude of the impact these factors have had on our Medical segment, as well as the passage of time, we no longer believe that comparisons to pre-COVID-19 operations are relevant in assessing our results of operations or financial condition.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Cordis Divestiture</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we sold our Cordis business to Hellman &amp; Friedman for proceeds of $923 million, net of cash transferred, and we retained certain working capital accounts and certain liabilities. The purchase price is subject to adjustments based on working capital requirements as set forth in the agreement. Cardinal Health will retain product liability associated with lawsuits and claims related to inferior vena cava ("IVC") filters in the U.S. and Canada, as well as authority for these matters discussed in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_103">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements." In connection with the closing, we entered into a Transition Services Agreement ("TSA") with the buyer to provide support functions for a period of up to twenty-four months following the sale. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_85">Note 2</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As anticipated, Medical segment revenue and Medical segment profit were adversely impacted during the three and nine months ended March&#160;31, 2022 due to the divestiture of the Cordis business. We expect the divestiture will decrease Medical segment revenue by approximately $700 million and adversely impact Medical segment profit by approximately $70 million in fiscal 2022. The divestiture of the Cordis business resulted in a decrease in amortization of acquisition-related intangible assets during the three and nine months ended March&#160;31, 2022, which we expect to continue for the remainder of fiscal 2022. The divestiture of the Cordis business is subject to risks and uncertainties that may further adversely impact Medical segment profit. For example, the TSA period may be extended beyond our current expectations or could have unintended consequences, and the costs associated with the exit or disposal activities and stranded costs could be greater than anticipated.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iaf3733bf892b435689161c61a06da348_19"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.852%"><tr><td style="width:1.0%"></td><td style="width:24.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><img src="cah-20220331_g2.jpg" alt="cah-20220331_g2.jpg" style="height:250px;margin-bottom:5pt;vertical-align:text-bottom;width:266px"/><img src="cah-20220331_g3.jpg" alt="cah-20220331_g3.jpg" style="height:250px;margin-bottom:5pt;vertical-align:text-bottom;width:266px"/></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">40,957</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,104&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">122,154</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107,452&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">14</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,884</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12,118</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">44,841</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,278&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">14</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">134,272</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119,893&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">44,836</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,275&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">14</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">134,261</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119,881&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pharmaceutical Segment </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended March&#160;31, 2022, revenue increased primarily due to sales growth from pharmaceutical distribution and specialty pharmaceutical customers, which together increased revenue by $5.8&#160;billion and $14.6&#160;billion, respectively, and largely consisted of branded pharmaceutical sales to existing and net new customers.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Medical Segment</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical segment revenue decreased during the three months ended  March&#160;31, 2022 primarily due to the impact of the divestiture of the Cordis business and lower volumes within products and distribution, including the adverse impact of global supply chain constraints.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2022, the adverse impact of the divestiture of the Cordis business was partially offset by sales growth in at-Home solutions.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Cost of Products Sold</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products sold for the three and nine months ended March&#160;31, 2022 increased 15 percent to $43.2 billion and 13 percent to $129.3 billion, respectively, compared to the respective prior-year periods as a result of the factors affecting the changes in revenue and gross margin. </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.852%"><tr><td style="width:1.0%"></td><td style="width:24.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Gross Margin</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><img src="cah-20220331_g4.jpg" alt="cah-20220331_g4.jpg" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:266px"/><img src="cah-20220331_g5.jpg" alt="cah-20220331_g5.jpg" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:266px"/></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross margin</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,682</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,812&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(7)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,940</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,303&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(7)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin during the three and nine months ended March&#160;31, 2022 was adversely impacted due to the divestiture of the Cordis business and increased costs in the Medical segment due to inflationary impacts and the adverse impact of global supply chain constraints, partially offset by the performance of our generics program, which includes an improvement in volumes compared to the prior-year periods.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin rate declined 86 basis points and 74 basis points during the three and nine months ended&#160;March&#160;31, 2022, respectively, mainly due to changes in overall product mix resulting primarily from increased pharmaceutical distribution branded sales, which have a dilutive impact on our overall gross margin rate. The performance of Medical segment products and distribution, which reflects the divestiture of the Cordis business and increased costs due to inflationary impacts and the adverse impact of global supply chain constraints, also had an adverse impact on gross margin rate.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Distribution, Selling, General and Administrative ("SG&amp;A") Expenses</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:11pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SG&amp;A expenses</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,137</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,120&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,402</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,404&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended March&#160;31, 2022, SG&amp;A expenses were adversely impacted by higher operations expenses and increased expenses related to investments in information technology infrastructure, mostly offset by the divestiture of the Cordis business. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2022, the year-over-year comparison was also favorably impacted by the prior-year $41 million accrual for our estimated portion of the assessment on prescription opioid medications that were sold or distributed in New York state in calendar year 2017 and 2018, which was recognized during the three months ended September 30, 2020. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_103">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information on the New York Opioid Stewardship Act.</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.852%"><tr><td style="width:1.0%"></td><td style="width:24.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Segment Profit</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate segment performance based on segment profit, among other measures. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_121">Note 12</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information on segment profit.</span></div><div style="margin-bottom:6pt;text-align:center"><img src="cah-20220331_g6.jpg" alt="cah-20220331_g6.jpg" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:266px"/><img src="cah-20220331_g7.jpg" alt="cah-20220331_g7.jpg" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:266px"/></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.195%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.450%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">487</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,319</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,326&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">59</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">232</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">546</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">685&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(20)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,551</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,966&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(21)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(643)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(212)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2,183)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,656)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total consolidated operating earnings/(loss)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(97)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(632)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pharmaceutical Segment Profit</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended March&#160;31, 2022, Pharmaceutical segment profit decreased due to increased expenses related to investments in information technology infrastructure and higher operations expenses, partially offset by the performance of our generics program. Pharmaceutical segment profit during the nine months ended March&#160;31, 2022 was also positively impacted by improvement in volumes compared to the prior-year period.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment profit includes opioid-related litigation defense and compliance costs, but does not include a one-time contingent attorney fee of $18 million incurred during the three and nine months ended March&#160;31, 2022 related to the finalization of the Settlement Agreement. Due to the unique nature and significance of the Settlement Agreement, and the one-time, contingent nature of the fee, this related fee was included in litigation (recoveries)/charges, net in the condensed consolidated statements of earnings/(loss).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment profit during the nine months ended March&#160;31, 2022 was positively impacted by a $16 million judgment for lost profits related to an ordinary course intellectual property rights claim. </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Medical Segment Profit</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical segment profit decreased during the three and nine months ended March&#160;31, 2022 largely due to increased inflationary costs, primarily related to transportation and commodities, and the adverse impact of global supply chain constraints. Medical segment profit during the nine months ended March&#160;31, 2022 also reflects an adverse impact related to the prior-year net positive impact of PPE.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Corporate</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in Corporate during the three and nine months ended&#160;March&#160;31, 2022&#160;were due to the factors discussed in the Other Components of Consolidated Operating Earnings/(Loss) section that follows. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.852%"><tr><td style="width:1.0%"></td><td style="width:24.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Other Components of Consolidated Operating Earnings/(Loss)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to revenue, gross margin and SG&amp;A expenses discussed previously, consolidated operating earnings/(loss) were impacted by the following:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">31</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">56</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">79</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">237</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">471</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,764</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">61</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">113</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,085&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring and Employee Severance</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring costs during both the three and nine months ended March&#160;31, 2022 and 2021 were primarily related to the implementation of certain enterprise-wide cost-savings measures, which includes facility exit costs related to decreasing our overall office space, and the divestiture of the Cordis business. </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortization and Other Acquisition-Related Costs</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of acquisition-related intangible assets was $78 million and $109 million for the three months ended March 31, 2022 and 2021, respectively, and $235 million and $337 million for the nine months ended March&#160;31, 2022 and 2021, respectively. The decrease in amortization of acquisition-related intangible assets was primarily due to the divestiture of the Cordis business.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairments and (Gain)/Loss on Disposal of Assets, Net</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended March&#160;31, 2022, we recognized $474&#160;million and $1.8 billion pre-tax non-cash goodwill impairment charges related to our Medical segment, respectively, as discussed further in the "Critical Accounting Policies and Sensitive Accounting Estimates" section of this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_91">Note 4</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements."</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended March 31, 2021 we recognized a $58 million pre-tax write-down of the assets held for sale from the divestiture of the Cordis business. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation (Recoveries)/Charges, Net</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2021, we recognized a pre-tax charge of $1.02&#160;billion associated with certain opioid matters. See the Significant Developments in Fiscal 2022 and Trends section in this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_103">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the three and nine months ended March&#160;31, 2022, we incurred a one-time contingent attorney fee of $18 million related to the finalization of the Settlement Agreement resulting in the settlement of the vast majority of opioid lawsuits filed by state and local governmental entities. Due to the unique nature and significance of the Settlement Agreement, and the one-time, contingent nature of the fee, this related fee was included in litigation (recoveries)/charges, net.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized estimated losses and legal defense costs associated with the IVC filter product liability claims of $24 million and $12 million during the three months ended March&#160;31, 2022 and 2021, respectively, and $63 million and $40 million during the nine months ended March&#160;31, 2022 and 2021, respectively. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_103">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2022, we recognized income of $17 million for recoveries in class action antitrust lawsuits in which we were a class member.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2021, we recognized a $13 million charge in connection with a civil investigation by the United States Attorney&#8217;s Office for the District of Massachusetts related to discounts and rebates offered or provided to certain Specialty Solutions customers, as described further in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_103">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements."</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Earnings/(Loss) Before Income Taxes</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the items discussed above, earnings/(loss) before income taxes were impacted by the following:</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.852%"><tr><td style="width:1.0%"></td><td style="width:24.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income)/expense, net</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(14)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">115</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain)/loss on sale of equity interest in naviHealth</span></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other (Income)/Expense, Net</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended&#160;March&#160;31, 2022, other (income)/expense, net was unfavorable compared to the prior-year periods primarily due to a decrease in the value of our deferred compensation plan investments, which offsets fluctuations included within SG&amp;A expenses as discussed further in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_109">Note </a><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_109">8</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements." The year-over-year comparison was also unfavorably impacted by gains on investments in non-marketable equity securities during the three months ended March&#160;31, 2021.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Expense, Net</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in interest expense during the three and nine months ended&#160;March&#160;31, 2022 was primarily due to less debt outstanding.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss on Early Extinguishment of Debt</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During nine months ended&#160;March&#160;31, 2022, we recognized a $10 million loss in connection with the debt redemption as described further in</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"> </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_100">Note 5</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the &#8220;Notes to Condensed Consolidated Financial Statements.&#8221;</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Provision for/(Benefit from) Income Taxes</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended&#160;March&#160;31, 2022, the effective tax rate was&#160;(916.5) percent and&#160;(44.4) percent, respectively, and reflects the impact of the tax effect of the year-to-date goodwill impairment charges recognized during the nine months ended March&#160;31, 2022. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended&#160;March&#160;31, 2021, the effective tax rate was 72.8 percent and (143.3) percent, respectively, and included the impact related to the treatment of the tax effect of opioid litigation charges, adjustments to our provision for the resolution of all open matters with the IRS for fiscal years 2008 to 2010 as well as certain transfer pricing matters for fiscal years 2011 to 2014, which also impacted reserves for later years, and withholding taxes for planned distributions from foreign subsidiaries. During the nine months ended&#160;March&#160;31, 2021, the effective tax rate included the benefit from a net operating loss carryback primarily related to a self-insurance pre-tax loss.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Goodwill Impairment Charge</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2022, we recognized year-to-date pre-tax charges of $1.8 billion for goodwill impairments related to the Medical segment. The net tax benefit related to these charges is $126 million for fiscal 2022. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings/(loss) before income taxes for the year-to-date period to compute our benefit from income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effect of the goodwill impairment charges during the nine months ended March 31, 2022 was included in our estimated annual effective tax rate because it was not considered unusual or infrequent, given that we recorded goodwill impairment in prior fiscal years. The impact of the non-deductible goodwill significantly decreased the estimated annual effective tax rate for fiscal 2022. Applying the lower tax rate to the year-to-date loss resulted in recognizing an interim tax expense of approximately $1.2 billion, which impacted the provision for income taxes in the condensed consolidated statements of earnings/(loss) during the three and nine months ended March&#160;31, 2022 and prepaid expenses and other assets in the condensed consolidated balance sheet at March&#160;31, 2022. </span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iaf3733bf892b435689161c61a06da348_22"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.262%"><tr><td style="width:1.0%"></td><td style="width:24.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liquidity and Capital Resources</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently believe that, based on available capital resources (cash on hand and committed credit facilities) and projected operating cash flow, we have adequate capital resources to fund working capital needs; currently anticipated capital expenditures; currently anticipated business growth and expansion; contractual obligations; tax payments; current and projected debt service requirements, dividends and share repurchases; and opioid litigation settlement payments associated with the Settlement Agreement, the state agreements and Cherokee Nation and Native American tribes agreements. If we decide to engage in one or more acquisitions, depending on the size and timing of such transactions, we may need to access capital markets for additional financing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Cash and Equivalents</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash and equivalents balance was $2.4 billion at March&#160;31, 2022 compared to $3.4 billion at June&#160;30, 2021. At March&#160;31, 2022, our cash and equivalents were held in cash depository accounts with major banks or invested in high quality, short-term liquid investments.  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the nine months ended March&#160;31, 2022, net cash provided by operating activities was $130 million, which includes $348&#160;million of payments related to the Settlement Agreement,  payments under the separate New York, Ohio and Rhode Island settlements, as well as certain payments under Cherokee Nation settlement and Native American term sheet. Net cash provided by operating activities was also adversely impacted by the timing of collections of customer receivables and the day of the week on which a fiscal period ends. We deployed $1.0 billion for share repurchases, $597&#160;million for debt repayment, and $425 million for cash dividends. We also received proceeds of $923 million, net of cash transferred, from the divestiture of the Cordis business.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in working capital, which impact operating cash flow, can vary significantly depending on factors such as the timing of customer payments, inventory purchases, and payments to vendors in the regular course of business, as well as fluctuating working capital needs driven by customer and product mix. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash and equivalents balance at March&#160;31, 2022 includes $652 million of cash held by subsidiaries outside of the United States. </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Other Financing Arrangements and Financial Instruments</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Credit Facilities and Commercial Paper</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to cash and equivalents and operating cash flow, other sources of liquidity at March&#160;31, 2022 include a $2.0 billion commercial paper program, backed by a $2.0 billion revolving credit facility. We also have a&#160;$1.0 billion&#160;committed receivables sales facility. At&#160;March&#160;31, 2022, we had no amounts outstanding under our commercial paper program, revolving credit facility, or our committed receivables sales facility. During the nine months ended March&#160;31, 2022, we had a daily maximum amount outstanding under our commercial paper and committed receivables programs of $1.2 billion and an average daily amount outstanding of $25 million.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. As of March&#160;31, 2022, we were in compliance with this financial covenant. </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Long-Term Debt and Other Short-Term Borrowings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At&#160;March&#160;31, 2022 and June&#160;30, 2021, we had total long-term obligations, including the current portion and other short-term borrowings, of&#160;$5.6 billion and $6.2 billion, respectively. During the nine months ended March&#160;31, 2022, we redeemed $572 million of the 2.616% Notes due June 2022 with available cash. In connection with this redemption, we recorded a $10 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">loss on early extinguishment of debt. The early redemption was funded with available cash.  </span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.262%"><tr><td style="width:1.0%"></td><td style="width:24.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liquidity and Capital Resources</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Capital Resources</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Tax Effects of Self-Insurance Pre-tax Loss</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with a tax benefit from the net operating loss carryback primarily related to a self-insurance pre-tax loss as described further in our 2021 Form 10-K, we filed for a refund of $974&#160;million. Because we expected to receive the refund within 12 months, we had a current asset for this amount on our condensed consolidated balance sheets at both March&#160;31, 2022 and June&#160;30, 2021. In April 2022, we received a payment for $966 million, which is net of certain adjustments. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_106">Note</a><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_106"> </a><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_106">7</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements for additional detail.</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Capital Deployment</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Opioid Litigation Settlement Agreement</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $6.70&#160;billion accrued at March&#160;31, 2022 related to certain opioid litigation, as further described within the Significant Developments in Fiscal 2022 and Trends section in this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_103">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements." We expect the majority of the payment amounts to be spread over 18 years. During the nine months ended March&#160;31, 2022, we paid our first annual payment under the  Settlement Agreement, which is reflected in prepaid expenses and other assets in our condensed consolidated balance sheets. We also made certain payments under the separate New York and Ohio settlements. The effective date of the Settlement Agreement is April 2, 2022. We expect to make subsequent annual payments under the Settlement Agreement every July for the term of the Settlement Agreement beginning in July 2022. The amounts of these future payments may differ from the payment made during the nine months ended March&#160;31, 2022.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Capital Expenditures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital expenditures during the nine months ended March&#160;31, 2022 and 2021 were $223 million and $274 million, respectively. </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On each of May 5, 2021, August 4, 2021, November 4, 2021 and February 8, 2022,  our Board of Directors approved a quarterly dividend of $0.4908 per share, or $1.96 per share on an annualized basis, which were paid on July 15, 2021, October 15, 2021, January 15, 2022 and April 15, 2022 to shareholders of record on July 1, 2021, October 1, 2021, January 3, 2022 and April 1, 2022 respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2022, we repurchased $1.0&#160;billion of our common shares, in the aggregate, under accelerated share repurchase ("ASR") programs. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_115">Note 10</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 4, 2021, our Board of Directors approved a $3.0&#160;billion share repurchase program, which will expire on December 31, 2024. As of April 30, 2022, we had $2.7 billion remaining authorized for share repurchases under this program.</span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iaf3733bf892b435689161c61a06da348_25"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:24.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Items</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Other Items</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MD&amp;A in our 2021 Form 10-K addresses our contractual obligations and off-balance sheet arrangements, as of and for the fiscal year ended June 30, 2021. There have been no subsequent material changes outside the ordinary course of business to those items.</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div id="iaf3733bf892b435689161c61a06da348_31"></div></div></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Critical Accounting Policies and Sensitive Accounting Estimates</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion and analysis presented below is a supplemental disclosure to the critical accounting policies and sensitive accounting estimates specified in our consolidated balance sheet at June&#160;30, 2021. This discussion and analysis should be read in conjunction with the Critical Accounting Policies and Sensitive Accounting Estimates included in our 2021 Form 10-K and our Form 10-Q for the quarters ended September 30, 2021 and December 31, 2021.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical accounting policies are those accounting policies that (i) can have a significant impact on our financial condition and results of operations and (ii) require the use of complex and subjective estimates based upon past experience and management&#8217;s judgment. Other people applying reasonable judgment to the same facts and circumstances could develop different estimates. Because estimates are inherently uncertain, actual results may differ, including due to the risks discussed in "Risk Factors" and other risks discussed in our 2021 Form 10-K and our other filings with the SEC since June 30, 2021.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of our inventories are valued at the lower of cost, using the last-in, first-out ("LIFO") method, or market. These are primarily merchandise inventories at the core pharmaceutical distribution facilities within our Pharmaceutical segment (&#8220;distribution facilities&#8221;).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our remaining inventory, including inventory in our Medical segment, that is not valued at the lower of LIFO cost or market is stated at the lower of cost, using the first-in, first-out method ("FIFO"), or net realizable value. We reserve for the lower of cost or net realizable value using the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. Due to the unprecedented demand for certain PPE as a result of COVID-19, our Medical segment manufactured and sourced inventory at higher costs than </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in periods prior to COVID-19. As selling prices and customer demand decreased compared to the peak of COVID-19, we recorded a reserve of $197&#160;million in fiscal 2021, primarily related to certain categories of gloves, to reduce the carrying value of certain PPE to its net realizable value. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continued to monitor and assess changes in selling prices and customer demand related to PPE during the nine months ended March&#160;31, 2022. While we consider that our assumptions continue to be reasonable and appropriate, our estimates for selling prices and demand are inherently uncertain and if our assumptions decline in the future, additional inventory reserves may be required. </span></div></div></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchased goodwill is tested for impairment annually or when indicators of impairment exist. Goodwill impairment testing involves a comparison of the estimated fair value of reporting units to the respective carrying amount, which may be performed utilizing either a qualitative or quantitative assessment. Qualitative factors are first assessed to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If it is determined that it is more likely than not that the fair value does not exceed the carrying amount, then a quantitative test is performed. The quantitative goodwill impairment test involves a comparison of the estimated fair value of the reporting unit to the respective carrying amount. A reporting unit is defined as an operating segment or one level below an operating segment (also known as a component).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reporting units are: Pharmaceutical operating segment (excluding our Nuclear and Precision Health Solutions division); </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nuclear and Precision Health Solutions division; Medical operating segment (excluding our Cardinal Health at-Home Solutions division) (&#8220;Medical Unit&#8221;); and Cardinal Health at-Home Solutions division. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill impairment testing involves judgment, including the identification of reporting units, qualitative evaluation of events and circumstances to determine if it is more likely than not that an impairment exists, and, if necessary, the estimation of the fair value of the applicable reporting unit. Our qualitative evaluation considers the weight of evidence and significance of all identified events and circumstances and most relevant drivers of fair value, both positive and negative, in determining whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount.</span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.820%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Items</span></div></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Medical Unit Goodwill </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended March&#160;31, 2022, the Medical Unit continued to experience adverse financial results related to inflationary impacts and the adverse impact of global supply chain constraints. Due to the risks and uncertainties related to these impacts, we elected to bypass the qualitative assessment in the second and third quarters of fiscal 2022 and perform interim goodwill impairment testing for the Medical Unit. This quantitative testing resulted in the carrying amount of the Medical Unit exceeding the fair value, resulting in pre-tax impairment charges of $474&#160;million and $1.3&#160;billion, which were recognized during the three months ended March&#160;31, 2022 and&#160;December 31, 2021, respectively, and are included in impairments and (gain)/loss on disposal of assets in our condensed consolidated statements of earnings/(loss). </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our determination of the estimated fair value of the Medical Unit is based on a combination of the income-based approach (using a terminal growth rate of 2 percent), and the market-based approach. For the income-based approach, we also used discount rates of 9.5 percent and 9 percent for the interim testing at March&#160;31, 2022 and&#160;December 31, 2021, respectively. The increase in the discount rate was primarily due to an increase in the risk-free interest rate. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the interim testing performed at December 31, 2021, we updated our assumptions from prior periods to include the increased magnitude and breadth of the inflationary impacts to supply chain and commodities costs as well as adverse impacts due to global supply chain constraints. In addition, our planned price increases did not impact the second quarter of fiscal 2022 and therefore, we updated our assumptions to reflect a longer duration to implement such actions.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the interim testing performed at March&#160;31, 2022, we further updated our assumptions for the adverse impact of global supply chain constraints, the timing of inflationary impacts and lower volumes from PPE. These changes did not have a meaningful impact on the fair value of the Medical Unit. The decrease in the fair value of the Medical Unit at March&#160;31, 2022 was due to the increase in the discount rate described above. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Medical Unit at March&#160;31, 2022 after recognizing the impairment charge was $7.6 billion, of which $2.3&#160;billion was goodwill. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_91">Note 4</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for further discussion. </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we consider these assumptions to be reasonable and appropriate, they are complex and subjective, and additional adverse changes in one key assumption or a combination of key assumptions may significantly affect future estimates. These assumptions include, among other things, a failure to meet expected earnings or other financial plans, or unanticipated events and circumstances, such as changes in assumptions about the duration and magnitude of increased supply chain and commodities costs and our planned efforts to mitigate such impact, including price increases or surcharges; further disruptions in the supply chain; the impact of the Cordis divestiture; the COVID-19 pandemic, including estimated demand and selling prices for PPE; an increase in the discount rate; a decrease in the terminal growth rate; increases in tax rates (including potential tax reform); or a significant change in industry or economic trends. Adverse changes in key assumptions may result in further decline in fair value below the carrying value in the future and therefore, an impairment of our Medical Unit goodwill in future periods, which could adversely affect our results of operations. For example, if we were to increase the discount rate by a hypothetical 0.5 percent or decrease the terminal growth rate by a hypothetical 1.5 percent, the fair value for the Medical Unit would have further decreased by approximately $400 million.</span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iaf3733bf892b435689161c61a06da348_34"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The "Overview of Consolidated Results" section within MD&amp;A in this Form 10-Q contains financial measures that are not calculated in accordance with GAAP. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to analyzing our business based on financial information prepared in accordance with GAAP, we use these non-GAAP financial measures internally to evaluate our performance, engage in financial and operational planning, and determine incentive compensation because we believe that these measures provide additional perspective on and, in some circumstances are more closely correlated to, the performance of our underlying, ongoing business. We provide these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on our financial and operating results on a year-over-year basis and in comparing our performance to that of our competitors. However, the non-GAAP financial measures that we use may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. The non-GAAP financial measures disclosed by us should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements set forth below should be carefully evaluated. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Exclusions from Non-GAAP Financial Measures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes it is useful to exclude the following items from the non-GAAP measures presented in this report for its own and for investors&#8217; assessment of the business for the reasons identified below:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">LIFO charges and credits</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are excluded because the factors that drive last-in first-out ("LIFO") inventory charges or credits, such as pharmaceutical manufacturer price appreciation or deflation and year-end inventory levels (which can be meaningfully influenced by customer buying behavior immediately preceding our fiscal year-end), are largely out of our control and cannot be accurately predicted. The exclusion of LIFO charges and credits from non-GAAP metrics facilitates comparison of our current financial results to our historical financial results and to our peer group companies&#8217; financial results. We did not recognize any LIFO charges or credits during the periods presented. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Surgical gown recall costs or income</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> includes inventory write-offs and certain remediation and supply disruption costs, net of related insurance recoveries, arising from the January 2020 recall of select Association for the Advancement of Medical Instrumentation ("AAMI") Level 3 surgical gowns and voluntary field actions (a recall of some packs and a corrective action allowing overlabeling of other packs) for Presource Procedure Packs containing affected gowns. Income from surgical gown recall costs represents insurance recoveries of these certain costs. We have excluded these costs from our non-GAAP metrics to allow investors to better understand the underlying operating results of the business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies&#8217; financial results.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.13pt;text-decoration:underline">State opioid assessments related to prior fiscal years</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> is the portion of state assessments for prescription opioid medications that were sold or distributed in periods prior to the period in which the expense is incurred. This portion is excluded from non-GAAP financial measures because it is retrospectively applied to sales in prior fiscal years and inclusion would obscure analysis of the current fiscal year results of our underlying, ongoing business. Additionally, while states' laws may require us to make payments on an ongoing basis, the portion of the assessment related to sales in prior periods are contemplated to be one-time, nonrecurring items. Income from state opioid assessments related to prior fiscal years represents reversals of accruals when the underlying assessments were invalidated by a Court or reimbursed by manufacturers.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Restructuring and employee severance costs</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are excluded because they are not part of the ongoing operations of our underlying business. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Amortization and other acquisition-related costs</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which include transaction costs, integration costs, and changes in the fair value of contingent consideration obligations, are excluded because they are not part of the ongoing operations of our underlying business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies' financial results. Additionally, costs for amortization of acquisition-related intangible assets are non-cash amounts, which are variable in amount and frequency and are significantly impacted by the timing and size of acquisitions, so their exclusion facilitates comparison of historical, current and forecasted financial results. We also exclude other acquisition-related costs, which are directly related to an acquisition but do not meet the criteria to be recognized on the acquired entity&#8217;s initial balance sheet as part of the purchase price allocation. These costs are also significantly impacted by the timing, complexity and size of acquisitions. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Impairments and gain or loss on disposal of assets</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;are excluded because they do not occur in or reflect the ordinary course of our ongoing business operations and are inherently unpredictable in timing and amount, and in the case of impairments, are non-cash amounts, so their exclusion facilitates comparison of historical, current and forecasted financial results. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.13pt;text-decoration:underline">Litigation recoveries or charges, net</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> are excluded because they often relate to events that may have occurred in prior or multiple periods, do not occur in or reflect the ordinary course of our business and are inherently unpredictable in timing and amount. During fiscal 2021, we incurred a tax benefit related to a carryback of a net operating loss. Some pre-tax amounts, which contributed to this loss, relate to litigation charges. As a result, we allocated substantially all of the tax benefit to litigation charges. During fiscal 2022, we incurred a one-time contingent attorney fee of $18 million related to the finalization of the settlement agreement (the &#8220;Settlement Agreement&#8221;) resulting in the settlement of the vast majority of opioid lawsuits filed by state and local governmental entities. Due to the unique nature and significance of the Settlement Agreement, and the one-time, contingent nature of the fee, this related fee was included in litigation recoveries or charges, net. Additionally, during fiscal 2022 our Pharmaceutical segment profit was positively impacted by a $16 million judgment for lost profits. This judgment was the result of an ordinary course intellectual property rights claim and, therefore, is not adjusted in calculating the litigation recoveries or charges, net adjustment. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Loss on early extinguishment of debt</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is excluded because it does not typically occur in the normal course of business and may obscure analysis of trends and financial performance. Additionally, the amount and frequency of this type of charge is not consistent and is significantly impacted by the timing and size of debt extinguishment transactions. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">(Gain)/Loss on sale of equity interest in naviHealth</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was incurred in connection with the sale of our remaining equity interest in naviHealth in fiscal 2020. The equity interest was retained in connection with the initial sale of our majority interest in naviHealth during fiscal 2019. We exclude this significant gain because gains or losses on investments of this magnitude do not typically occur in the normal course of business and are similar in nature to a gain or loss from a divestiture of a majority interest, which we exclude from non-GAAP results. The gain on the initial sale of our majority interest in naviHealth in fiscal 2019 was also excluded from our non-GAAP measures.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Transitional tax benefit, net</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to the Tax Cuts and Jobs Act is excluded because it results from the one-time impact of a very significant change in the U.S. federal corporate tax rate and, due to the significant size of the benefit, obscures analysis of trends and financial performance. The transitional tax benefit includes the initial estimate and subsequent adjustments for the re-measurement of deferred tax assets and liabilities due to the reduction of the U.S. federal corporate income tax rate and the repatriation tax on undistributed foreign earnings. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effect for each of the items listed above, other than the transitional tax benefit item, is determined using the tax rate and other tax attributes applicable to the item and the jurisdiction(s) in which the item is recorded. The gross, tax and net impact of each item are presented with our GAAP to non-GAAP reconciliations. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Definitions</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Growth rate calculation:</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> growth rates in this report are determined by dividing the difference between current-period results and prior-period results by prior-period results. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP operating earnings</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: operating earnings/(loss) excluding (1) LIFO charges/(credits), (2) surgical gown recall costs/(income), (3) state opioid assessment related to prior fiscal years, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, and (7) litigation (recoveries)/charges, net. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP earnings before income taxes</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: earnings/(loss) before income taxes excluding (1) LIFO charges/(credits), (2) surgical gown recall costs/(income), (3) state opioid assessment related to prior fiscal years, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, (7) litigation (recoveries)/charges, net, (8) loss on early extinguishment of debt and (9) (gain)/loss on sale of equity interest in naviHealth. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP net earnings attributable to Cardinal Health, Inc.</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: net earnings/(loss) attributable to Cardinal Health, Inc. excluding (1) LIFO charges/(credits), (2) surgical gown recall costs/(income), (3) state opioid assessment related to prior fiscal years, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, (7) litigation (recoveries)/charges, net, (8) loss on early extinguishment of debt and (9) (gain)/loss on sale of equity interest in naviHealth, each net of tax, and (10) transitional tax benefit, net. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP effective tax rate: </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provision for/(benefit from) income taxes adjusted for (1) LIFO charges/(credits), (2) surgical gown recall costs/(income), (3) state opioid assessment related to prior fiscal years, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, (7) litigation (recoveries)/charges, net, (8) loss on </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">early extinguishment of debt and (9) (gain)/loss on sale of equity interest in naviHealth, each net of tax, and (10) transitional tax benefit, net divided by (earnings/(loss) before income taxes adjusted for the first nine items).</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP diluted earnings per share attributable to Cardinal Health, Inc.</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: non-GAAP net earnings attributable to Cardinal Health, Inc. divided by diluted weighted-average shares outstanding. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iaf3733bf892b435689161c61a06da348_37"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">GAAP to Non-GAAP Reconciliation</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:6.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.019%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.298%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.452%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per common share amounts)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Earnings/(Loss)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Earnings Growth Rate</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Earnings/(Loss) Before Income Taxes</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Provision for/<br/>(Benefit from) Income Taxes</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Earnings/(Loss)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Earnings</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> Growth Rate</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diluted EPS</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1,2</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diluted EPS</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> Growth Rate</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="24" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(97)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(137)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,253</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,391)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5.05)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.21&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">3</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,189)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">4</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.18&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain)/Loss on sale of equity interest in naviHealth</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">545</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(21)</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">504</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">101</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">402</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(11)</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.45</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="24" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N.M</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.40&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N.M</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surgical gown recall costs/(income)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State opioid assessment related to prior fiscal years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.28&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">6</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(144)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.54&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">657&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.53&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="24" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">GAAP</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(632)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(741)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">328</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,071)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3.82)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surgical gown recall costs/(income)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.15&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">3</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,764&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,764&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,883&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.71&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4) (5)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain)/Loss on sale of equity interest in naviHealth</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-GAAP</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,540</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(20)</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,438</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">306</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,131</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(20)</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4.01</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(16)</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="24" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N.M.</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(293)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N.M.</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.68&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surgical gown recall costs/(income)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State opioid assessment related to prior fiscal years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.88&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">6</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,085&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,085&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">584&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.70&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,935&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,830&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,411&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.79&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">1&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Attributable to Cardinal Health, Inc.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">2&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the three and nine months ended March&#160;31, 2022, GAAP diluted loss per share attributable to Cardinal Health, Inc. ("GAAP diluted EPS") and the EPS impact from the GAAP to non-GAAP per share reconciling items are calculated using a weighted average of 275&#160;million and 281&#160;million common shares, respectively, which excludes potentially dilutive securities from the denominator due to their anti-dilutive effects resulting from our GAAP net loss for the periods. For the three and nine months ended March&#160;31, 2022, non-GAAP diluted EPS is calculated using a weighted average of 277&#160;million and 282&#160;million common shares, which includes potentially dilutive shares.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">3&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impairments and (gain)/loss on disposals of assets, net includes pre-tax goodwill impairment charges of $474&#160;million and $1.8 billion</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">related to our Medical segment recorded in the third quarter and year-to-date periods of fiscal 2022, respectively. For fiscal 2022, the estimated net tax benefit related to these impairments is $126 million and is included in the annual effective tax rate. As a result, the amount of tax expense in the current quarter and year-to-date periods increased by approximately $1.2 billion and approximately $180 million, respectively, and is expected to lower the provision for income taxes during the fourth quarter of fiscal 2022 by approximately $180 million.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">4&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Litigation (recoveries)/charges, net includes a one-time contingent attorney fee of $18 million recorded during the third quarter of fiscal 2022 related to the finalization of the settlement agreement (the &#8220;Settlement Agreement&#8221;) resulting in the settlement of the vast majority of opioid lawsuits filed by state and local governmental entities. Due to the unique nature and significance of the Settlement Agreement, and the one-time, contingent nature of the fee, this related fee was included in litigation (recoveries)/charges, net.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">5&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Litigation (recoveries)/charges, net for fiscal 2022 does not include a $16 million judgement for lost profits related to an ordinary course intellectual property claim, which positively impacted Pharmaceutical segment profit.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">6&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Litigation (recoveries)/charges, net includes a pre-tax charge of $1.02 billion recorded in the first quarter of fiscal 2021 related to the opioid litigation. For fiscal 2021, the amount of tax expense increased by approximately $140&#160;million during the three months ended March 31, 2021 while the amount of tax benefit increased by approximately $180 million during the nine months ended March 31, 2021 compared to the tax impacts that would have been recognized without the opioid litigation charge. The net tax benefit associated with the opioid litigation charges was $228 million for fiscal 2021. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Litigation(recoveries)/charges, net also includes a tax benefit recorded during the nine months ended March&#160;31, 2021 related to a net operating loss carryback. Our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation. This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes. The net operating loss was carried back and adjusted our taxable income for fiscal 2015, 2016, 2017 and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security (&#8220;CARES&#8221;) Act. During the nine months ended</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">March&#160;31, 2021,</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> t</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">he total net benefit was $419 million; however, for purposes of reconciling Non-GAAP financial measures, we allocated $385 million of the benefit to litigation (recoveries)/charges, net, which is excluded from non-GAAP measures, based on the relative amount of the self-insurance pre-tax loss related to opioid litigation claims versus separate tax adjustments. The tax benefit allocated to the separate tax adjustments of $34 million is included in non-GAAP measures. </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sum of the components and certain computations may reflect rounding adjustments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iaf3733bf892b435689161c61a06da348_40"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.158%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="text-align:justify"><span><br/></span></div><div id="iaf3733bf892b435689161c61a06da348_43"></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in the quantitative and qualitative market risk disclosures included in our&#160;2021&#160;Form 10-K since the end of fiscal&#160;2021&#160;through&#160;March&#160;31, 2022.</span></div><div id="iaf3733bf892b435689161c61a06da348_46"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Controls and Procedures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluated, with the participation of our principal executive officer and principal financial officer, the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the "Exchange Act")) as of March&#160;31, 2022. Based on this evaluation, our principal executive officer and principal financial officer have concluded that as of March&#160;31, 2022, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms and that such information is accumulated and communicated to management as appropriate to allow timely decisions regarding required disclosure. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As explained below, there were changes in our internal control over financial reporting during the quarter ended March&#160;31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Pharmaceutical Segment Information Technology Initiative </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Pharmaceutical segment is in a multi-year project to implement a replacement of certain finance and operating information systems. During the three and nine months ended March 31, 2022, we transitioned selected processes to the new systems which affected our internal control over financial reporting. It is possible that ongoing transitions to new systems may adversely impact internal control over financial reporting.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iaf3733bf892b435689161c61a06da348_49"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the proceeding described below, the legal proceedings described in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_103">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" are incorporated in this "Legal Proceedings" section by reference.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, Melissa Cohen, a purported shareholder, filed an action on behalf of Cardinal Health, Inc. in the U.S. District Court for the Southern District of Ohio against certain current and former members of our Board of Directors alleging that the defendants breached their fiduciary duties by failing to effectively monitor Cardinal Health's distribution of controlled substances and approving certain payments of executive compensation. In December 2019 and January 2020, similar complaints were filed in the U.S. District Court for the Southern District of Ohio by purported shareholders, Stanley M. Malone and Michael Splaine, respectively. In January, 2020, the court consolidated the derivative cases under the caption In re Cardinal Health, Inc. Derivative Litigation and in March 2020, plaintiffs filed an amended complaint. The amended consolidated derivative complaint seeks, among other things, unspecified money damages against the defendants and an award of attorneys' fees. In February 2021, the court granted in part and denied in part defendants' motion to dismiss. The court dismissed the claim with respect to executive compensation but declined to dismiss the failure to monitor claim.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to definitive documentation and court approval and notice process, in December 2021, the parties reached an agreement in principle to resolve these lawsuits. Under this agreement, our director and officer's liability insurance carriers, on behalf of the defendants, would pay Cardinal Health $124 million, less any attorneys' fees and expenses awarded by the court to plaintiffs' counsel. This settlement does not include any admission of liability. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iaf3733bf892b435689161c61a06da348_52"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.158%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Risk Factors</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should carefully consider the information in this Form 10-Q, including the risk factors below, and the risk factors discussed in "Risk Factors" and other risks discussed in our 2021 Form 10-K and our filings with the SEC since June&#160;30, 2021. These risks could materially and adversely affect our results of operations, financial condition, liquidity, and cash flows. Our business also could be affected by risks that we are not presently aware of or that we currently consider immaterial to our operations.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We depend on direct and indirect suppliers to make their products and raw materials available to us and are subject to fluctuations in costs, availability and regulatory risk associated with these products and raw materials. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing businesses use oil-based resins, pulp, cotton, latex and other commodities as raw materials in many products. Prices of oil and gas also affect our distribution and transportation costs. Prices of these commodities are volatile and can fluctuate significantly, causing our costs to produce and distribute our products to fluctuate. Beginning in the fourth quarter of fiscal year 2021, we have experienced higher supply chain costs, primarily related to international freight and commodities, which had a negative impact on Medical segment profit in fiscal 2021 and the first three quarters of fiscal 2022. Supply chain constraints have also had a negative impact on sales within our Medical segment. We expect these cost increases and supply chain constraints to continue to have a negative impact on segment profit, primarily in the Medical segment, in fiscal 2022. Due to competitive dynamics and contractual limitations, passing along cost increases is challenging and it unlikely that we will be able to offset the impact of these costs increases through higher prices. If we continue to have challenges sufficiently offsetting these cost increases through other cost reductions, or recovering these costs through price increases or surcharges, Medical segment profit could be negatively impacted to a greater extent than we currently anticipate.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on others to manufacture some products that we market and distribute. Our operations are also dependent on various components, compounds, raw materials and energy supplied by others. We purchase many of these components, raw materials and energy, and source certain products from numerous suppliers in various countries. In some instances, for reasons of quality assurance, cost effectiveness, or availability, we procure certain components and raw materials from a sole supplier. Our supplier relationships could be interrupted, become less favorable to us or be terminated and the supply of these components, compounds, raw materials or products could be interrupted or become insufficient. These supply interruptions or other disruptions in manufacturing processes could be caused by events </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">beyond our control, including natural disasters, supplier facility shut-downs, defective raw materials, the impact of epidemics or pandemics, such as COVID-19, and actions by U.S. or international governments, including export restrictions or tariffs.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, due to the stringent regulatory requirements regarding the manufacture and sourcing of our products, we may not be able to quickly establish additional or replacement sources for certain components, materials or products. A sustained supply reduction or interruption, and an inability to develop alternative and additional sources for such supply, could result in lost sales, increased cost, damage to our reputation, and may have an adverse effect on our business.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our goodwill may become further impaired, which could require us to record additional significant charges to earnings in accordance with generally accepted accounting principles.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. GAAP requires us to test our goodwill for impairment on an annual basis, or more frequently if indicators for potential impairment exist. As a result of adverse financial results in our Medical Unit resulting from inflationary impacts and global supply chain constraints, we performed interim goodwill impairment testing for the Medical Unit for the periods ended December 31, 2021 and March 31, 2022. As a result of both of these interim tests, we recorded an aggregate $1.8 billion impairment to goodwill related to our Medical Unit in the nine months ended March 31, 2022. This testing involves estimates and significant judgments by management. We believe our assumptions and estimates are reasonable and appropriate; however additional adverse changes in key assumptions,</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> including a failure to meet expected earnings or other financial plans, unanticipated events and circumstances such as changes in assumptions about the duration and magnitude of increased supply chain and commodities costs and our planned efforts to mitigate such impacts, further disruptions in the supply chain, the impact of the Cordis divestiture, estimated demand and selling prices for PPE, a further increase in the discount rate, a decrease in the terminal growth rate, increases in tax rates (including potential tax reform) or a significant change in industry or economic trends </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">could affect the accuracy or validity of such estimates and may result in an additional goodwill impairment in our Medical Unit. It is also possible that we may record significant charges related to other reporting units. Any charge or charges could adversely affect our results of operations. See "Critical Accounting Policies and Sensitive Accounting Estimates" in MD&amp;A above for more information regarding goodwill impairment testing.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iaf3733bf892b435689161c61a06da348_58"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.158%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.370%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.694%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number<br/>of Shares<br/>Purchased&#160;(1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Price Paid&#160;per Share (2,3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares<br/>Purchased<br/>as Part of Publicly Announced Programs&#160;(2,3,4)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate<br/>Dollar Value of<br/>Shares That May<br/>Yet be Purchased<br/>Under the Program&#160;(4)<br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 2022</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,304,012&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.05&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,303,017&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,943&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,962,630&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.01&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,962,414&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,783&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,266,868</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">51.58</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,265,431</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,783</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Reflects 995, 226, and 216 common shares purchased in January, February, and March 2022, respectively, through a rabbi trust as investments of participants in our Deferred Compensation Plan.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">On November 10, 2021, we entered into an ASR program to purchase common shares for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i79f0c6d48d9042059a71690df0625736_D20211001-20211231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF81OC9mcmFnOjMxNThiZTMxNGJiMTRjODBiOWViZWNjM2NhYjg2ZDkxL3RleHRyZWdpb246MzE1OGJlMzE0YmIxNGM4MGI5ZWJlY2MzY2FiODZkOTFfODc2_64a9fece-fd6e-420f-91b2-8b4dc583125a">300</ix:nonFraction> million and received an initial delivery of <ix:nonFraction unitRef="shares" contextRef="id0bcebad12fc4c40a4b459a431f9432e_D20211001-20211231" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF81OC9mcmFnOjMxNThiZTMxNGJiMTRjODBiOWViZWNjM2NhYjg2ZDkxL3RleHRyZWdpb246MzE1OGJlMzE0YmIxNGM4MGI5ZWJlY2MzY2FiODZkOTFfOTE1_b1cf531b-f8bc-4212-ab03-44fa4f994195">4.8</ix:nonFraction> million common shares using a reference price of $<ix:nonFraction unitRef="usdPerShare" contextRef="id0bcebad12fc4c40a4b459a431f9432e_D20211001-20211231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF81OC9mcmFnOjMxNThiZTMxNGJiMTRjODBiOWViZWNjM2NhYjg2ZDkxL3RleHRyZWdpb246MzE1OGJlMzE0YmIxNGM4MGI5ZWJlY2MzY2FiODZkOTFfOTU5_a7d816fb-c1e0-4e73-a781-d7c74b11c87d">50.30</ix:nonFraction>. The program concluded on January&#160;31, 2022 at a volume weighted average price per common share of $<ix:nonFraction unitRef="usdPerShare" contextRef="idb40345a5fe44f68828da6e24128f448_D20220101-20220331" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF81OC9mcmFnOjMxNThiZTMxNGJiMTRjODBiOWViZWNjM2NhYjg2ZDkxL3RleHRyZWdpb246MzE1OGJlMzE0YmIxNGM4MGI5ZWJlY2MzY2FiODZkOTFfMTA0Ng_d303f17c-6e71-4a62-9522-cf6d9d5308f9">49.39</ix:nonFraction> resulting in a final delivery of <ix:nonFraction unitRef="shares" contextRef="idb40345a5fe44f68828da6e24128f448_D20220101-20220331" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF81OC9mcmFnOjMxNThiZTMxNGJiMTRjODBiOWViZWNjM2NhYjg2ZDkxL3RleHRyZWdpb246MzE1OGJlMzE0YmIxNGM4MGI5ZWJlY2MzY2FiODZkOTFfMTA4Mg_19162380-0d76-414b-b32b-1d9379a729d0">1.3</ix:nonFraction> million common shares. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_115">Note 10</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information. </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8pt">On February 28, 2022, we entered into an ASR program to purchase common shares for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i4a80329f29594c698d9ee74e1eaacbbe_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF81OC9mcmFnOjMxNThiZTMxNGJiMTRjODBiOWViZWNjM2NhYjg2ZDkxL3RleHRyZWdpb246MzE1OGJlMzE0YmIxNGM4MGI5ZWJlY2MzY2FiODZkOTFfNzE0NjgyNTU4MjY0Mw_491620b1-1c8a-4cd6-bca1-8635a37d6660">200</ix:nonFraction> million and received an initial delivery of <ix:nonFraction unitRef="shares" contextRef="i3bd39d7063da4c278767bc202d3ccfc3_D20220101-20220331" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF81OC9mcmFnOjMxNThiZTMxNGJiMTRjODBiOWViZWNjM2NhYjg2ZDkxL3RleHRyZWdpb246MzE1OGJlMzE0YmIxNGM4MGI5ZWJlY2MzY2FiODZkOTFfNzE0NjgyNTU4MjY1NA_b60ce76f-c995-46ab-8e84-c2532dc8056b">3.0</ix:nonFraction> million common shares using a reference price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i3bd39d7063da4c278767bc202d3ccfc3_D20220101-20220331" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF81OC9mcmFnOjMxNThiZTMxNGJiMTRjODBiOWViZWNjM2NhYjg2ZDkxL3RleHRyZWdpb246MzE1OGJlMzE0YmIxNGM4MGI5ZWJlY2MzY2FiODZkOTFfNzE0NjgyNTU4MjY1OQ_ffa1ff47-afaa-4f28-b5a0-97e6926b03fa">54.01</ix:nonFraction>. The program concluded on April&#160;18, 2022 at a volume weighted average price per common share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i88bcf45d478a46e4b22b402f4b7f54c3_D20220401-20220630" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF81OC9mcmFnOjMxNThiZTMxNGJiMTRjODBiOWViZWNjM2NhYjg2ZDkxL3RleHRyZWdpb246MzE1OGJlMzE0YmIxNGM4MGI5ZWJlY2MzY2FiODZkOTFfNzE0NjgyNTU4MjcxMw_05ee8c00-a37f-44f1-b1cd-d2b715cb8a1c">56.02</ix:nonFraction> resulting in a final delivery of <ix:nonFraction unitRef="shares" contextRef="i88bcf45d478a46e4b22b402f4b7f54c3_D20220401-20220630" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF81OC9mcmFnOjMxNThiZTMxNGJiMTRjODBiOWViZWNjM2NhYjg2ZDkxL3RleHRyZWdpb246MzE1OGJlMzE0YmIxNGM4MGI5ZWJlY2MzY2FiODZkOTFfNzE0NjgyNTU4MjY4Nw_e7f5a586-e334-4067-a9aa-34ade3f5ad82">0.6</ix:nonFraction> million common shares. See <a style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#iaf3733bf892b435689161c61a06da348_115">Note 10</a> of the "Notes to Condensed Consolidated Financial Statements" for additional information. </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8pt">On November 7, 2018, our Board of Directors approved a $1.0 billion share repurchase program that expired on December 31, 2021. On November 4, 2021, our Board of Directors approved a new $3.0&#160;billion share repurchase program, which will expire on December 31, 2024. The ASR program with an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i4a80329f29594c698d9ee74e1eaacbbe_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF81OC9mcmFnOjMxNThiZTMxNGJiMTRjODBiOWViZWNjM2NhYjg2ZDkxL3RleHRyZWdpb246MzE1OGJlMzE0YmIxNGM4MGI5ZWJlY2MzY2FiODZkOTFfMzI5ODUzNDg4NjQwMw_491620b1-1c8a-4cd6-bca1-8635a37d6660">200</ix:nonFraction> million concluded on April&#160;18, 2022, which reduced the amount remaining under our existing share repurchase authorization to $2.7 billion.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iaf3733bf892b435689161c61a06da348_61"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span><br/></span></div><div id="iaf3733bf892b435689161c61a06da348_64"></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Earnings/(Loss)</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:51.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.228%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per common share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMi0xLTEtMS05ODY5NA_e2b16488-d85c-48b6-a187-17bcff475651">44,836</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMi0zLTEtMS05ODY5NA_e055d9ca-61e9-48e6-a640-fd6c6d9e84ac">39,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMi01LTEtMS05ODY5NA_a62a8b08-a175-4441-80c1-dff36364843b">134,261</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMi03LTEtMS05ODY5NA_16796090-e505-4e42-b4a9-5b1d538f520b">119,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMy0xLTEtMS05ODY5NA_4fce27fa-66d0-4a92-a6a9-4b01003cfc6f">43,154</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMy0zLTEtMS05ODY5NA_4f86cc2b-f8fb-4e5f-b5ad-a765a839ccaa">37,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMy01LTEtMS05ODY5NA_49d0050a-fab8-4769-a49e-992a4cedf2f0">129,321</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMy03LTEtMS05ODY5NA_ba84819b-a30c-48be-9ca8-d4c683478185">114,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfNC0xLTEtMS05ODY5NA_2c672e37-0063-4cb4-89ec-ca4d9a295983">1,682</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfNC0zLTEtMS05ODY5NA_24eb8305-21b2-428b-81ed-4f9822bccf79">1,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfNC01LTEtMS05ODY5NA_74aa8e0d-26e0-4a58-9f8b-14cff8793914">4,940</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfNC03LTEtMS05ODY5NA_36e1254b-a9d4-4dfd-acfc-02d00b7ee417">5,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distribution, selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfNy0xLTEtMS05ODY5NA_a4e631df-64c5-497b-965f-239f7922cc91">1,137</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfNy0zLTEtMS05ODY5NA_62c920bb-2fe4-4eb0-8247-302245d244b0">1,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfNy01LTEtMS05ODY5NA_2498b4f5-c8ad-468a-9c41-b350f37ed9cf">3,402</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfNy03LTEtMS05ODY5NA_aa539fa4-2244-4d6f-9d04-4817cde462cb">3,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfOC0xLTEtMS05ODY5NA_25a5286a-61cb-412f-a85a-9f27faf257e4">31</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfOC0zLTEtMS05ODY5NA_2bade189-99ff-407f-bc36-18fbafb6b806">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfOC01LTEtMS05ODY5NA_c8875dc2-a69b-4277-9269-4fbd073200f1">56</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfOC03LTEtMS05ODY5NA_4c14253c-bc25-41ba-a964-1ff5e9a02a1c">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" name="cah:Amortizationandotheracquisitionrelatedcosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfOS0xLTEtMS05ODY5NA_d719c4f7-0257-4204-bde2-97f83877bfe7">79</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="cah:Amortizationandotheracquisitionrelatedcosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfOS0zLTEtMS05ODY5NA_172dbb98-c675-433e-b62b-d18dceab734a">111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="cah:Amortizationandotheracquisitionrelatedcosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfOS01LTEtMS05ODY5NA_7c6e4a84-cfd2-46a9-87cd-b01b5423402c">237</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="cah:Amortizationandotheracquisitionrelatedcosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfOS03LTEtMS05ODY5NA_e2b585ef-8e06-4fd2-9024-c5b9aee2034d">345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTAtMS0xLTEtOTg2OTQ_e5385782-163e-4d46-aa92-1be60dde9905">471</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTAtMy0xLTEtOTg2OTQ_28d60dc6-edc6-48d7-8245-a9b7d2308bca">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTAtNS0xLTEtOTg2OTQ_b45481df-6def-48da-9ddc-4feb562e4200">1,764</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTAtNy0xLTEtOTg2OTQ_d6d7a77a-b911-4645-b354-e66b2031fdc5">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTEtMS0xLTEtOTg2OTQ_7a1b7567-824e-4817-b100-1d93da2205d4">61</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTEtMy0xLTEtOTg2OTQ_b4ca148c-8924-4846-a83b-7eb030edeff4">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTEtNS0xLTEtOTg2OTQ_f43644b1-d95b-43a2-bce1-4a6b662c2a95">113</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTEtNy0xLTEtOTg2OTQ_2ca814bd-8989-4d9c-b68e-770b5e01e964">1,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating earnings/(loss)</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTItMS0xLTEtOTg2OTQ_63b9a3a5-21d1-4bf1-89ce-1fc2c1709ec2">97</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTItMy0xLTEtOTg2OTQ_c0f01cb6-f1d1-4dae-a71f-2dea53357ab9">473</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTItNS0xLTEtOTg2OTQ_37c77578-dfc6-41c2-856a-8bddfeda9b4b">632</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTItNy0xLTEtOTg2OTQ_c6372f64-8e29-414c-acb4-be97380386b7">310</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income)/expense, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTQtMS0xLTEtOTg2OTQ_87591de2-f6e9-4c5a-8dea-d2be2ffc4b5b">3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTQtMy0xLTEtOTg2OTQ_bb4cde22-6bf2-4eb6-bf3d-516545224a38">12</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTQtNS0xLTEtOTg2OTQ_f1a30c38-e1c2-4b5d-94e0-2b1e21808bb3">14</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTQtNy0xLTEtOTg2OTQ_655e890f-9b47-43f3-87df-edd2531a798c">31</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTUtMS0xLTEtOTg2OTQ_ff76ebbe-0cd3-4280-9a76-a59bd971900b">38</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTUtMy0xLTEtOTg2OTQ_7ad9ccda-346b-4f94-bbe1-917157d39dfb">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTUtNS0xLTEtOTg2OTQ_dfb16510-fb43-4619-872d-3c2528fd949f">115</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTUtNy0xLTEtOTg2OTQ_ec378f60-771f-4c9f-9c1d-0c46ffa1fe09">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTYtMS0xLTEtOTg2OTQ_55e45728-22d3-4627-8501-3a187bc1932b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTYtMy0xLTEtOTg2OTQ_605cb7e8-6bb2-4449-8658-c932114670f0"><ix:nonFraction unitRef="usd" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTYtMy0xLTEtOTg2OTQ_cde64219-3c78-4ee5-b3bf-7ff3809a309c">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTYtNS0xLTEtOTg2OTQ_1666657b-8fea-480e-8819-db4b3bb7b043">10</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTYtNy0xLTEtOTg2OTQ_7959ed66-aca2-47f1-9b29-071ae7996abd">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain)/loss on sale of equity interest in naviHealth</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" name="us-gaap:GainLossOnSaleOfInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTctMS0xLTEtOTg2OTQ_a15cb902-e258-4de4-a3a5-2607ff699eac">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="us-gaap:GainLossOnSaleOfInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTctMy0xLTEtOTg2OTQ_af825b88-a98b-4fc0-adee-35747efb7236">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:GainLossOnSaleOfInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTctNS0xLTEtOTg2OTQ_ffeda087-8804-49cc-99d1-dad1365d02c6">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:GainLossOnSaleOfInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTctNy0xLTEtOTg2OTQ_87db69d9-006b-48d6-8ccc-70d91cc48e49">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Earnings/(loss) before income taxes</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTgtMS0xLTEtOTg2OTQ_4f9a96fc-3f45-457f-acf6-dfd92247cc53">137</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTgtMy0xLTEtOTg2OTQ_c207d938-7cd3-44d8-9961-5762928709d5">440</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTgtNS0xLTEtOTg2OTQ_c1541ae7-276a-45b9-8a22-2d5ad4225a79">741</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTgtNy0xLTEtOTg2OTQ_a0fb6641-fab4-461b-8a5e-243128cc3f5c">204</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for/(benefit from) income taxes</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMjAtMS0xLTEtOTg2OTQ_44fe0585-91c0-4005-acd0-86e1ef855cdd">1,253</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMjAtMy0xLTEtOTg2OTQ_fdd499b7-f611-4f75-bc86-9d4e6f3886e0">320</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMjAtNS0xLTEtOTg2OTQ_c9fe8f3e-b91b-4e69-acec-ba76a751c8da">328</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMjAtNy0xLTEtOTg2OTQ_1d2ab9e2-f124-45fa-bffd-3d9723d04971">293</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings/(loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMjEtMS0xLTEtOTg2OTQ_df6683a1-140c-46e0-b64c-5af884cfaf9b">1,390</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMjEtMy0xLTEtOTg2OTQ_7b252768-b694-4883-9bad-0d98bc7807e7">120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMjEtNS0xLTEtOTg2OTQ_f26bb9a6-6e1f-4232-973d-2f8424033a46">1,069</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMjEtNy0xLTEtOTg2OTQ_6e8d05c9-f155-4842-a0e4-7f82076b53d3">497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net earnings attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMjYtMS0xLTEtOTg2OTQ_23dcc8bb-3ba9-49b6-8688-62731112dbe5">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMjYtMy0xLTEtOTg2OTQ_1de159ce-ab99-4e1a-abca-5be63fe1eaf0">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMjYtNS0xLTEtOTg2OTQ_419d2378-a222-4f10-9d0a-c03e805366eb">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMjYtNy0xLTEtOTg2OTQ_ea8aa778-2b3e-4223-9f1b-3d65b1632125">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net earnings/(loss) attributable to Cardinal Health, Inc. </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMjctMS0xLTEtOTg2OTQ_44f97a0c-f528-4ea4-90dd-7ed82bd91459">1,391</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMjctMy0xLTEtOTg2OTQ_496e0e89-9521-47c2-b9f7-3ec2203923ab">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMjctNS0xLTEtOTg2OTQ_48717c83-5726-47b1-bf64-f060fbd222f6">1,071</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMjctNy0xLTEtOTg2OTQ_5e66f6e3-ccb3-4dd9-9ac9-b725e7089a71">495</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Earnings/(Loss) per common share attributable to Cardinal Health, Inc.:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMzAtMS0xLTEtOTg2OTQ_883a99a1-e952-42e8-8295-7d87eaf44c1e">5.05</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMzAtMy0xLTEtOTg2OTQ_a1cc1388-8759-4050-afea-45841fbd3eb9">0.41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMzAtNS0xLTEtOTg2OTQ_7f348c47-e13a-4629-94b5-dcaf5eb7293f">3.82</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMzAtNy0xLTEtOTg2OTQ_099b9ff6-9e42-46be-a421-93a2859fad8e">1.69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMzEtMS0xLTEtOTg2OTQ_3c7b5805-80ba-4dc8-9981-0f7da3865e8c">5.05</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMzEtMy0xLTEtOTg2OTQ_e6407440-ffc3-4699-9685-e36133cb9ad7">0.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMzEtNS0xLTEtOTg2OTQ_b7980380-f13c-443d-8c0a-3e554e50a77e">3.82</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMzEtNy0xLTEtOTg2OTQ_e9d07d6c-c23d-4da3-bb25-aae629dbe4dd">1.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average number of common shares outstanding:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMzQtMS0xLTEtOTg2OTQ_e9e8bf03-cb64-4976-8707-8f6129cd082b">275</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMzQtMy0xLTEtOTg2OTQ_4f1df5bc-2f09-4190-bd07-5ebef1144e6c">292</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMzQtNS0xLTEtOTg2OTQ_e063b0d3-d8f4-46cb-b97c-ab9fb46e4e26">281</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMzQtNy0xLTEtOTg2OTQ_92fd0fbe-05d2-4526-b292-02d4e9d7c7d4">293</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMzUtMS0xLTEtOTg2OTQ_b1d20440-b5bc-4355-9a6d-ba264d115d97">275</ix:nonFraction></span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMzUtMy0xLTEtOTg2OTQ_a7007c79-fc7f-41ae-912c-bdb92301d7f3">294</ix:nonFraction></span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMzUtNS0xLTEtOTg2OTQ_86cf409c-b548-4310-b3aa-54a4152c8d4e">281</ix:nonFraction></span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMzUtNy0xLTEtOTg2OTQ_bdb19207-be4e-4632-af6f-96b7615d64a3">294</ix:nonFraction></span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared per common share</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMzctMS0xLTEtOTg2OTQ_188d0ac9-3ad5-4c49-95d5-8f73748de47a">0.4908</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMzctMy0xLTEtOTg2OTQ_b8e408a1-ec1d-4ad6-9abf-2be981435b08">0.4859</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="4" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMzctNS0xLTEtOTg2OTQ_22a8ec7f-0e03-4aa6-857f-df94e5a56b10">1.4724</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="4" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMzctNy0xLTEtOTg2OTQ_0b7b0c55-6eca-4d36-b262-7cde6f5e0809">1.4577</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iaf3733bf892b435689161c61a06da348_67"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Comprehensive Income/(Loss)</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:51.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.228%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings/(loss)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfMi0xLTEtMS05ODY5NA_fadcaf21-d261-4711-975b-184bb4c6ba15">1,390</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfMi0zLTEtMS05ODY5NA_26362b9c-4913-4190-b385-3026cf4f757c">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfMi01LTEtMS05ODY5NA_2343395a-70b8-453d-8a88-3dc7daaaa40c">1,069</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfMi03LTEtMS05ODY5NA_c8c48aa8-5d4f-4537-b777-0caf53ea5a97">497</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfNS0xLTEtMS05ODY5NA_1d22d645-03f5-46af-a5e2-b900d7abfe0f">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfNS0zLTEtMS05ODY5NA_511a052c-a5c3-439e-9380-5dbbcf2b33ad">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfNS01LTEtMS05ODY5NA_84316675-f8d4-4d6e-84fc-e86dfda58312">47</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfNS03LTEtMS05ODY5NA_a0a7e718-d2a3-4bb4-80dd-d166d97040a0">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized gain/(loss) on derivative instruments, net of tax</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfNy0xLTEtMS05ODY5NA_bb060f62-cae6-457a-a47c-5e436cad9dd5">12</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfNy0zLTEtMS05ODY5NA_fe851769-14f9-4ed0-abf9-e0de82a32003">4</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfNy01LTEtMS05ODY5NA_7a42bf40-d590-4344-ba82-358c549242a5">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfNy03LTEtMS05ODY5NA_99aa46e6-48b2-447d-b350-c9b6763e0919">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive income/(loss), net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfOC0xLTEtMS05ODY5NA_f6334d1f-2946-4064-a168-c7787ea297d3">8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfOC0zLTEtMS05ODY5NA_49aa837a-bd41-4b2b-963f-37330090e67a">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfOC01LTEtMS05ODY5NA_3659b7d2-8ff9-4127-9f7d-2149ff77a07e">43</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfOC03LTEtMS05ODY5NA_276e1f7e-c8f0-4ccf-8b6b-b24e6a652cdb">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total comprehensive income/(loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfMTAtMS0xLTEtOTg2OTQ_c6377cc0-8c61-4fba-b74f-5f8b0e49d875">1,382</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfMTAtMy0xLTEtOTg2OTQ_7104c298-811e-42a1-a1f8-aee2a0879d1c">125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfMTAtNS0xLTEtOTg2OTQ_7ab93797-c983-4bc0-bcee-16738ed695a4">1,112</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfMTAtNy0xLTEtOTg2OTQ_c236c0ec-c556-4a1c-aef5-70be4ea395ca">553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: comprehensive income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfMTItMS0xLTEtOTg2OTQ_9ca7f7ff-268e-4148-9092-665b9c321bb8">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfMTItMy0xLTEtOTg2OTQ_ec7a8b84-b6d5-463e-8da3-f284eed123b4">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfMTItNS0xLTEtOTg2OTQ_38659b39-a512-436c-a227-92890f224c1a">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfMTItNy0xLTEtOTg2OTQ_a2224f23-9b36-4bb4-91c5-7fbaa1838dad">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total comprehensive income/(loss) attributable to Cardinal Health, Inc. </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfMTQtMS0xLTEtOTg2OTQ_f97b539b-c9ef-431c-bbb2-c7210b1e0001">1,383</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfMTQtMy0xLTEtOTg2OTQ_a021119f-1e1c-4d8d-94c2-ffc750d457c4">124</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfMTQtNS0xLTEtOTg2OTQ_ac3d4811-6212-4bcb-8ec8-698b03da950e">1,114</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfMTQtNy0xLTEtOTg2OTQ_ae4c537f-6350-46ae-b222-048132a660a8">551</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iaf3733bf892b435689161c61a06da348_70"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.114%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and equivalents</span></td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfNC0xLTEtMS05ODY5NA_aae6b31e-7b4d-4644-949a-32d133d207ca">2,356</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfNC0zLTEtMS05ODY5NA_b7043949-cd9e-4094-99b8-c1e719d042db">3,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfNS0xLTEtMS05ODY5NA_a70c83a1-1001-4e78-97ab-174718cfd1ff">10,250</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfNS0zLTEtMS05ODY5NA_dd2a97d1-a265-4a93-a642-7e0104d58274">9,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfNi0xLTEtMS05ODY5NA_1a4ce09a-d129-4bdb-82da-44bd55863832">15,493</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfNi0zLTEtMS05ODY5NA_4debe60d-0656-4833-bcf7-889d509fa165">14,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfNy0xLTEtMS05ODY5NA_984bce2e-7347-4dba-a1c2-b2af3d5f85e9">2,785</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfNy0zLTEtMS05ODY5NA_52f6023e-b700-485d-bbbc-033e835da3f9">2,843</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets held for sale</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfOC0xLTEtMS05ODY5NA_1c43747d-ae59-445f-b03a-f20b9024a719">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfOC0zLTEtMS05ODY5NA_8ffabeb5-d194-4c7e-b3ad-5c5e0bba8e51">1,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfOS0xLTEtMS05ODY5NA_6c41228b-f23d-4b1b-bd4e-ff35a1c58276">30,884</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfOS0zLTEtMS05ODY5NA_dfc444ea-b377-449d-9c84-d69558fe4a45">31,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMTEtMS0xLTEtOTg2OTQ_c82142e1-f9f1-4390-8f6f-a2acba4f4193">2,298</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMTEtMy0xLTEtOTg2OTQ_ae8b95d0-722a-4b81-b992-24de2f5d18de">2,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill and other intangibles, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMTItMS0xLTEtOTg2OTQ_c12722b8-b2cd-40cd-9e2e-1820e485b104">8,022</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMTItMy0xLTEtOTg2OTQ_4664cf13-06d3-4c1a-a01d-f03944a4b140">10,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMTQtMS0xLTEtOTg2OTQ_9247706a-e3cc-4593-8484-5ad1d02b1e32">907</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMTQtMy0xLTEtOTg2OTQ_a7ba91d0-0cd2-4c48-a7f0-27fa9209cbe8">951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMTUtMS0xLTEtOTg2OTQ_0a043dc1-f234-4e75-b6c5-04ab90b84cd9">42,111</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMTUtMy0xLTEtOTg2OTQ_6ed72fbc-c1b1-4154-a969-e42ce86806c0">44,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities and Shareholders&#8217; Equity/(Deficit)</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMTktMS0xLTEtOTg2OTQ_d907a166-ab7c-458f-b5ae-bd5ab1383bc9">24,821</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMTktMy0xLTEtOTg2OTQ_557e3b88-064c-4d4b-bdd2-422d369fa074">23,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of long-term obligations and other short-term borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMjAtMS0xLTEtOTg2OTQ_808f18d0-8dc2-426a-abf7-8602a3ff4a12">861</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMjAtMy0xLTEtOTg2OTQ_43881be3-c836-4a70-b4d7-0739a03128e7">871</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMjEtMS0xLTEtOTg2OTQ_84d25d06-ef96-4892-93bd-3c89efc4cddd">3,033</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMjEtMy0xLTEtOTg2OTQ_d2bc0ff6-b49f-4ab5-b7c3-88675a103752">2,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities related to assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMjItMS0xLTEtOTg2OTQ_c310b535-50dd-4a3b-ab0e-61021e0de41b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMjItMy0xLTEtOTg2OTQ_b6754526-24f9-4fb7-a2f3-fd6554cab19d">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMjMtMS0xLTEtOTg2OTQ_f6d40c49-0ee5-4338-b603-49af9df8b05f">28,715</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMjMtMy0xLTEtOTg2OTQ_cea04f59-f374-4652-b7e0-b953b277c815">27,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term obligations, less current portion</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMjUtMS0xLTEtOTg2OTQ_3ee5e22a-1110-4cf4-a3de-3ba679b2cdd2">4,751</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMjUtMy0xLTEtOTg2OTQ_d46970cf-0839-4d6b-9c60-84ccd7ac4694">5,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMjYtMS0xLTEtOTg2OTQ_f1060e6e-a014-4680-b375-ed1b774d7a18">9,338</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMjYtMy0xLTEtOTg2OTQ_026600e1-20b2-4456-b37f-95264447e359">9,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders&#8217; equity/(deficit):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred shares, without par value:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Authorized&#8212;<ix:nonFraction unitRef="shares" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzAtMC0xLTEtOTg2OTQvdGV4dHJlZ2lvbjoxNDFlMmUzZjkzY2Q0OWQxYTMzZDZiZjdkZmFiYTY5Yl8xNQ_b979d46f-d304-4cec-b6fd-e303a59b431e"><ix:nonFraction unitRef="shares" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzAtMC0xLTEtOTg2OTQvdGV4dHJlZ2lvbjoxNDFlMmUzZjkzY2Q0OWQxYTMzZDZiZjdkZmFiYTY5Yl8xNQ_f9edd006-5ac8-4a9e-a718-8026cebe7a72">500</ix:nonFraction></ix:nonFraction> thousand shares, Issued&#8212;<ix:nonFraction unitRef="shares" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzAtMC0xLTEtOTg2OTQvdGV4dHJlZ2lvbjoxNDFlMmUzZjkzY2Q0OWQxYTMzZDZiZjdkZmFiYTY5Yl8zMw_b6fe99cc-4c4b-474b-a863-75ac7b5b99a4"><ix:nonFraction unitRef="shares" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzAtMC0xLTEtOTg2OTQvdGV4dHJlZ2lvbjoxNDFlMmUzZjkzY2Q0OWQxYTMzZDZiZjdkZmFiYTY5Yl8zMw_c890aa9a-0ed7-465f-9621-87454f0ae14c">none</ix:nonFraction></ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzAtMS0xLTEtOTg2OTQ_42060602-7a5c-4a1f-8f51-51bfcb45df13">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzAtMy0xLTEtOTg2OTQ_3f79a0c3-3732-4b09-a73f-1356edbebf19">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common shares, without par value:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Authorized&#8212;<ix:nonFraction unitRef="shares" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzItMC0xLTEtOTg2OTQvdGV4dHJlZ2lvbjo0ZDgxYWFmMGIyYmU0MTUyODA0NmE3MjExY2M1MjQxZV8xNg_6cb60285-2627-4d03-b506-2fd38817c365"><ix:nonFraction unitRef="shares" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzItMC0xLTEtOTg2OTQvdGV4dHJlZ2lvbjo0ZDgxYWFmMGIyYmU0MTUyODA0NmE3MjExY2M1MjQxZV8xNg_d35572f0-a3e3-4252-b9fa-25f9dfc11792">755</ix:nonFraction></ix:nonFraction> million shares, Issued&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzItMC0xLTEtOTg2OTQvdGV4dHJlZ2lvbjo0ZDgxYWFmMGIyYmU0MTUyODA0NmE3MjExY2M1MjQxZV8zNA_56632999-55a3-41e5-b4b2-973f3d444672"><ix:nonFraction unitRef="shares" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzItMC0xLTEtOTg2OTQvdGV4dHJlZ2lvbjo0ZDgxYWFmMGIyYmU0MTUyODA0NmE3MjExY2M1MjQxZV8zNA_a0af6484-35e6-44bf-bafd-1f17a46d3cc0">327</ix:nonFraction></ix:nonFraction> million</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> shares at </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March&#160;31, 2022</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and June 30, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzItMS0xLTEtOTg2OTQ_e04af131-e194-48eb-8e82-cc2aaea75f54">2,761</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzItMy0xLTEtOTg2OTQ_452a67ee-9b8b-4aa8-b208-eb1257aa6aad">2,806</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained earnings/(accumulated deficit)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzMtMS0xLTEtOTg2OTQ_dafed80f-6cb8-4c49-bbd9-89f26241853c">281</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzMtMy0xLTEtOTg2OTQ_6d204eb5-e973-456c-9f29-e2806d670096">1,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Common shares in treasury, at cost: </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzQtMC0xLTEtOTg2OTQvdGV4dHJlZ2lvbjoyM2ZjNTFkZjJjODc0MDY0Yjg3OTQ4YmYxYzI0NWExNl80MQ_dc3dcae0-ccf5-447d-93e0-bd8794f2d00f">54</ix:nonFraction> million </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">shares and <ix:nonFraction unitRef="shares" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzQtMC0xLTEtOTg2OTQvdGV4dHJlZ2lvbjoyM2ZjNTFkZjJjODc0MDY0Yjg3OTQ4YmYxYzI0NWExNl81NQ_e062c988-f34e-44f7-b855-2081c900db92">36</ix:nonFraction> million shares at</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> March&#160;31, 2022</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and June 30, 2021, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzQtMS0xLTEtOTg2OTQ_d388c913-b137-408b-8b29-025736e38046">3,100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzQtMy0xLTEtOTg2OTQ_eb0124df-d842-4dbe-8e34-8d37937ae72b">2,186</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzUtMS0xLTEtOTg2OTQ_48b37887-302c-4856-9fde-5f476442d961">77</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzUtMy0xLTEtOTg2OTQ_cb99d7db-012e-4840-85a4-de12808463bd">34</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Cardinal Health, Inc. shareholders' equity/(deficit)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzYtMS0xLTEtOTg2OTQ_8a8e6893-cdc7-44b7-b58a-91f9ab76beaf">697</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzYtMy0xLTEtOTg2OTQ_9e4dea9b-ee01-45e1-9a5b-40dd57701e71">1,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzctMS0xLTEtOTg2OTQ_353b3d9e-1ef3-46f6-af04-6ad1eb87bc1a">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzctMy0xLTEtOTg2OTQ_266482e9-5b12-4e44-a32a-8897ac0d21cc">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total shareholders&#8217; equity/(deficit)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzgtMS0xLTEtOTg2OTQ_cda16a44-3b84-4cc7-a7ef-14ecf156bb91">693</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzgtMy0xLTEtOTg2OTQ_588a557c-2dfb-4b26-962f-c5f7329ba8df">1,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total liabilities and shareholders&#8217; equity/(deficit)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzktMS0xLTEtOTg2OTQ_de9c511b-8363-4d40-b89b-29b2f509410f">42,111</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzktMy0xLTEtOTg2OTQ_a6af76fc-551b-4191-b271-50013eac62ac">44,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iaf3733bf892b435689161c61a06da348_73"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Shareholders' </span></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Equity/(Deficit)</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:30.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.070%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling Interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Shareholders&#8217;<br/>Equity/ (Deficit)</span></td></tr><tr style="height:36pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares Issued</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained<br/>Earnings/ (Accumulated Deficit)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if22adf094ce443b8a6d548e13f36c294_I20211231" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfMy0xLTEtMS05ODY5NA_0a9e9a6f-5b0c-4b43-a118-ff051392cd44">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if22adf094ce443b8a6d548e13f36c294_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfMy0zLTEtMS05ODY5NA_76528e3a-d30e-4393-848a-d7fc9ceca49f">2,721</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92405f06fae4c4cb90f702005b8b2a7_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfMy01LTEtMS05ODY5NA_b56855d1-1ae8-41e3-a342-652c5492dab4">1,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7c93d4e78a8c4d04b6c310720c3be878_I20211231" decimals="-6" sign="-" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfMy03LTEtMS05ODY5NA_cdd59d00-d7b6-4d15-a7f8-4bc3e5521994">50</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c93d4e78a8c4d04b6c310720c3be878_I20211231" decimals="-6" sign="-" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfMy05LTEtMS05ODY5NA_f529854f-461b-479f-bda1-44ddff5cea5d">2,883</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a93b5354aeb44f8b3cc0d0d850b2501_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfMy0xMS0xLTEtOTg2OTQ_5e447634-162a-4e26-bfcf-e303a52bb317">85</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1d5a08085294befb4f0b438a66e23de_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfMy0xMy0xLTEtOTg2OTQ_1bf54f9f-df50-4928-b08f-9c7f2378f5b8">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e8b16bb97541c8bd805031f5452617_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfMy0xNS0xLTEtOTg2OTQ_ffce4ff3-81cb-4351-b12f-31678e695e41">1,002</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings/(loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfNC01LTEtMS05ODY5NA_44f97a0c-f528-4ea4-90dd-7ed82bd91459">1,391</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if883c9a37b644835bbe659371a267a15_D20220101-20220331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfNC0xMy0xLTEtOTg2OTQ_2268543c-d249-4230-8c25-1219de94f28a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfNC0xNS0xLTEtOTg2OTQ_03540a09-f903-48ea-8429-f9827eb1d1ee">1,390</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfNS0xMS0xLTEtOTg2OTQ_f6334d1f-2946-4064-a168-c7787ea297d3">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfNS0xNS0xLTEtOTg2OTQ_4c51f96c-b82a-4a58-9756-6da0cb5b52ba">8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock plans activity, net of shares withheld for employee taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide0abb91cd8d4383a017830f5ef299ff_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfNy0xLTEtMS05ODY5NA_ad037230-e8e4-49a1-ae74-b1d2f85157ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide0abb91cd8d4383a017830f5ef299ff_D20220101-20220331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfNy0zLTEtMS05ODY5NA_9ad306d3-9650-4ca9-b7fa-e508a5d14006">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="shares" contextRef="i8232a7a263294a17a4f15379d0173ba2_D20220101-20220331" xsi:nil="true" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfNy03LTEtMS05ODY5NA_51acd8cc-0f61-4ee9-b784-b9210d5bbed4"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8232a7a263294a17a4f15379d0173ba2_D20220101-20220331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfNy05LTEtMS05ODY5NA_e0a4caf9-6b25-4cad-acba-1fbc129161b0">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfNy0xNS0xLTEtOTg2OTQ_23067795-3263-4610-af55-25b9d1a8db7b">23</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share repurchase program activity</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide0abb91cd8d4383a017830f5ef299ff_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfOC0zLTEtMS05ODY5NA_d48772b4-6e65-49d9-bb80-99df9cb5f55d">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8232a7a263294a17a4f15379d0173ba2_D20220101-20220331" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfOC03LTEtMS05ODY5NA_ef45fff2-45d7-4239-97c2-912c3d2796ce">4</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8232a7a263294a17a4f15379d0173ba2_D20220101-20220331" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfOC05LTEtMS05ODY5NA_92a71149-f11d-4b3f-a868-15651a946737">220</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfOC0xNS0xLTEtOTg2OTQ_ab5ac632-5870-4ac4-9c68-4debc33ac13f">200</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f9edcb7c954465280f497a367eed0d4_D20220101-20220331" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfOS01LTEtMS05ODY5NA_987c2064-d387-4af0-b148-38b9ba9c5df5">135</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfOS0xNS0xLTEtOTg2OTQ_82a8cf2b-7961-4fe2-9757-bfc02ccaaa37">135</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ide0abb91cd8d4383a017830f5ef299ff_D20220101-20220331" sign="-" xsi:nil="true" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfMTAtMy0xLTEtOTg2OTQ_e13f1622-f4ae-4cff-9997-01fbfa3bf5c1"></ix:nonFraction></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i5f9edcb7c954465280f497a367eed0d4_D20220101-20220331" sign="-" xsi:nil="true" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfMTAtNS0xLTEtOTg2OTQ_e65262f9-7cd7-48d2-9251-87ba4a3e8143"></ix:nonFraction></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"><ix:nonFraction unitRef="shares" contextRef="i8232a7a263294a17a4f15379d0173ba2_D20220101-20220331" sign="-" xsi:nil="true" name="us-gaap:StockholdersEquityOtherShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfMTAtNy0xLTEtOTg2OTQ_57ebf3e3-3c74-4d8c-b750-42ef88d35294"></ix:nonFraction></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if883c9a37b644835bbe659371a267a15_D20220101-20220331" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfMTAtMTMtMS0xLTk4Njk0_93a9c9e0-3027-4547-941b-732495010366">1</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfMTAtMTUtMS0xLTk4Njk0_96b27278-8bd2-4fb3-aea6-171c4a4fa9be">1</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i56eb96c92b484bcaa4f9f5c171ad239f_I20220331" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfMTItMS0xLTEtOTg2OTQ_1301f506-a6b9-4025-8179-46eeea80789a">327</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56eb96c92b484bcaa4f9f5c171ad239f_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfMTItMy0xLTEtOTg2OTQ_fc637a8b-2fe2-4cb3-8692-1a67704032f4">2,761</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52413ad34f00440b833f5b75a8dd4627_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfMTItNS0xLTEtOTg2OTQ_233c2dbc-8f3a-4e98-bd68-b56dc0559706">281</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iaff4ed7f966c47e4962d2bf39a55b561_I20220331" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfMTItNy0xLTEtOTg2OTQ_54554288-a069-402f-8555-100f193cb180">54</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaff4ed7f966c47e4962d2bf39a55b561_I20220331" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfMTItOS0xLTEtOTg2OTQ_55a4db5a-c4d2-420f-89ef-5bd505c284f8">3,100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a915a1a243e410f9ec96b9ace3e80d6_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfMTItMTEtMS0xLTk4Njk0_82b7560d-ce6b-4b68-9a74-be462dbe0dc5">77</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieed2c03cd42a4857909b008f32e31e33_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfMTItMTMtMS0xLTk4Njk0_9623bd78-39ef-4652-b945-af19d76d74ba">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfMTItMTUtMS0xLTk4Njk0_bdc79150-9eed-4c42-a01a-4c91d175afe4">693</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:30.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4ee4d69320c340dcb7f8fca3e33c99e1_I20201231" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfMS0xLTEtMS05ODY5NA_68ed12fb-8c5b-4862-a9ad-18efa9aab5b7">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ee4d69320c340dcb7f8fca3e33c99e1_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfMS0zLTEtMS05ODY5NA_dbf1d512-5883-451a-858b-ebf1341711ba">2,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6addc7f27a0049d9963b698b876c52cf_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfMS01LTEtMS05ODY5NA_16c8fb81-35d4-4177-91a0-eb25353b6f14">1,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id578e6daf1574d8eb480d856c73bbcda_I20201231" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfMS03LTEtMS05ODY5NA_4a41763d-0dfb-42af-a293-6bc2c477ed06">33</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id578e6daf1574d8eb480d856c73bbcda_I20201231" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfMS05LTEtMS05ODY5NA_3c7f7ae3-70d1-4457-9efb-e372c432f458">2,009</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i443356fbbe284138a0f49faa34b3208e_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfMS0xMS0xLTEtOTg2OTQ_620a585d-adba-4c4a-bf25-d363ae998af8">53</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id981bf2219e54d3eb7348670fb74ec8c_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfMS0xMy0xLTEtOTg2OTQ_12ced7b1-6bcf-4f5c-9927-2f09fe3f8409">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee675ac2f5dd4bb5a80f01c9e1535b8b_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfMS0xNS0xLTEtOTg2OTQ_b2533ddf-99e8-4992-ad48-ef06f92e6b56">1,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfMi01LTEtMS05ODY5NA_763bd76d-645c-4a48-86a2-bb1a2f5146a4">119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2703e84aa6d447f29d3aac9d09f5f094_D20210101-20210331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfMi0xMy0xLTEtOTg2OTQ_4541ba7a-55db-4891-9e3e-1c7e4e271276">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfMi0xNS0xLTEtOTg2OTQ_6a300478-56ac-4c50-8a3b-acb550aab0e9">120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5214de7195b64409b6762f36bf235b55_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfMy0xMS0xLTEtOTg2OTQ_8c55e23c-39a1-406f-a2f7-fbe6a7fed6a0">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfMy0xNS0xLTEtOTg2OTQ_3112e970-9f0a-4e9a-9e32-791c500c4c2b">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock plans activity, net of shares withheld for employee taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i22fec11876c34d5ebd2c18f6a35aa182_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfNS0xLTEtMS05ODY5NA_8252486b-a8d4-4010-91f6-c7a6e4bfa168">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22fec11876c34d5ebd2c18f6a35aa182_D20210101-20210331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfNS0zLTEtMS05ODY5NA_40a1ef45-4f8a-49d4-8f3a-c45e9b8d68a5">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i12146da7d33541d09f9ef291e388a502_D20210101-20210331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfNS03LTEtMS05ODY5NA_5a9bda85-0ba2-412b-960b-c21b53f8385c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12146da7d33541d09f9ef291e388a502_D20210101-20210331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfNS05LTEtMS05ODY5NA_9bd23fcd-cbb7-4b5c-ad34-5cf89b6f4cea">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfNS0xNS0xLTEtOTg2OTQ_9b759009-8b9f-4841-b99e-102a35a62140">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share repurchase program activity</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i22fec11876c34d5ebd2c18f6a35aa182_D20210101-20210331" xsi:nil="true" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfNi0zLTEtMS05ODY5NA_158ac71b-92d0-4abf-89fc-7dc5c8923fe1"></ix:nonFraction></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i12146da7d33541d09f9ef291e388a502_D20210101-20210331" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfNi03LTEtMS05ODY5NA_8623a11d-f4a3-47fb-8f14-2ec11610ec54">4</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12146da7d33541d09f9ef291e388a502_D20210101-20210331" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfNi05LTEtMS05ODY5NA_96f55bf8-57cc-4be2-8e4d-e2c6f0c224ec">200</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfNi0xNS0xLTEtOTg2OTQ_100480bc-b335-4e9e-9245-92437b302693">200</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i359769217d5441bc9c97571164783ca2_D20210101-20210331" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfNy01LTEtMS05ODY5NA_c82cfd1d-633e-4cb7-9040-d949f628136b">143</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfNy0xNS0xLTEtOTg2OTQ_b25bcc0a-ece1-44d5-8b40-a00e0d17cb15">143</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i22fec11876c34d5ebd2c18f6a35aa182_D20210101-20210331" sign="-" xsi:nil="true" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfOC0zLTEtMS05ODY5NA_62057991-5727-4bed-a5c4-a53645e968f4"></ix:nonFraction></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i359769217d5441bc9c97571164783ca2_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfOC01LTEtMS05ODY5NA_23c3d0c0-bc54-4d59-bf0a-ba27368bcc70">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i12146da7d33541d09f9ef291e388a502_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOtherShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfOC03LTEtMS0xMzAxNzU_9b154764-4918-46c5-9902-28a839a4cf20">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2703e84aa6d447f29d3aac9d09f5f094_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfOC0xMy0xLTEtOTg2OTQ_1e0f5c76-ce94-46d7-ae1b-c67cb997db40">1</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfOC0xNS0xLTEtOTg2OTQ_9d85929e-1bdc-4c70-b396-2cba7366afc5">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i74e91c5fe50846e4abcf66f67c9b72da_I20210331" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfMTAtMS0xLTEtOTg2OTQ_4dc29e2e-fbaa-4d2e-bc82-063cfce282b9">327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74e91c5fe50846e4abcf66f67c9b72da_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfMTAtMy0xLTEtOTg2OTQ_4ec365a1-dd7e-4863-8584-5e1dade83d1a">2,807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89dbe704562b4ba5ac39a63d65dbff5a_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfMTAtNS0xLTEtOTg2OTQ_b2cff4cd-914a-4a83-b25d-e638ef5321c2">1,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic83e16a32c7b450083b893267a9ccda4_I20210331" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfMTAtNy0xLTEtOTg2OTQ_07091de0-eadd-47d7-9d37-d2c4d7da6810">36</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic83e16a32c7b450083b893267a9ccda4_I20210331" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfMTAtOS0xLTEtOTg2OTQ_b7981f5a-a1d1-4ec1-aa1b-50932557ef77">2,202</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6ce5f003d8e47b7ac0d61aa5df61b12_I20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfMTAtMTEtMS0xLTk4Njk0_1ceca789-afb0-4cbd-8234-81aa254ffca0">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i021442adc8e24489b12297c43e3fabda_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfMTAtMTMtMS0xLTk4Njk0_e71ac74a-0560-40f8-a399-4a4900581038">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43de0647ce12490ab30c52d836774dce_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfMTAtMTUtMS0xLTk4Njk0_aff886f6-7391-40fa-93fd-6d33a61bb35b">1,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:30.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i07511c4beddc431e9241b971549f9ad5_I20210630" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfMy0xLTEtMS05ODY5NA_52b1da83-baae-40b9-8ff0-f4a51af13897">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07511c4beddc431e9241b971549f9ad5_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfMy0zLTEtMS05ODY5NA_53f3865d-54ad-4da6-bd25-0eb1b67bb0a9">2,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ec660a67cd04983b32b8b4fe7d9870a_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfMy01LTEtMS05ODY5NA_930a121b-b3fb-433e-a16c-6c09b8b3e730">1,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i644e369be5f6420aa49654a4323fa93d_I20210630" decimals="-6" sign="-" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfMy03LTEtMS05ODY5NA_c16a8851-47b5-457f-907e-e53b4c15ff53">36</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i644e369be5f6420aa49654a4323fa93d_I20210630" decimals="-6" sign="-" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfMy05LTEtMS05ODY5NA_e5e38451-98e3-4799-8952-3906e501ee81">2,186</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a430c2a1ae64753ae7b549dfc1f69c7_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfMy0xMS0xLTEtOTg2OTQ_cf5eac75-7053-40e5-b867-6562a4aa1dc1">34</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3c75fe6e5544a349f30d33c4e68a2ac_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfMy0xMy0xLTEtOTg2OTQ_f3cbccbf-e474-451b-be5b-128260b14515">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfMy0xNS0xLTEtOTg2OTQ_d04898d1-cfb4-4814-bd08-5f643ad05a6e">1,794</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings/(loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfNC01LTEtMS05ODY5NA_3ff0a8f8-b2df-46e3-a519-cb5e81cb793d">1,071</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8151fa2583d44a688b40d92d9d83b78_D20210701-20220331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfNC0xMy0xLTEtOTg2OTQ_8667d47e-bc0d-4dae-bfd4-f7fc4c964c20">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfNC0xNS0xLTEtOTg2OTQ_6deb16a9-ae08-4702-9455-ea699ef3b16b">1,069</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77aa86d8f8f8485ab211b681b5f58fb3_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfNS0xMS0xLTEtOTg2OTQ_06992a6d-0540-4505-bf96-265ea7971691">43</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfNS0xNS0xLTEtOTg2OTQ_d3fed633-eec6-460f-bfca-d8dc88c12456">43</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock plans activity, net of shares withheld for employee taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2ed02a1c09cd4d529605f81979cbf648_D20210701-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfNy0xLTEtMS05ODY5NA_aa4ce2a1-5d1d-47cd-9004-f500dc3745c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ed02a1c09cd4d529605f81979cbf648_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfNy0zLTEtMS05ODY5NA_1c15d0e7-f825-49ac-bb2a-47a07d231a55">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfNy03LTEtMS05ODY5NA_61a17171-f9aa-4aa3-a444-90b7d9b49dac">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeff0c865a8a4369ab8c5fdca6cee729_D20210701-20220331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfNy05LTEtMS05ODY5NA_2219c901-852a-4b40-b810-25a19e4e435e">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfNy0xNS0xLTEtOTg2OTQ_a6e0db59-509c-41a4-a616-b52c5337d52b">41</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share repurchase program activity</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ed02a1c09cd4d529605f81979cbf648_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfOC0zLTEtMS05ODY5NA_c411dae0-74c8-4e77-98ed-d628f29016bd">40</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iaeff0c865a8a4369ab8c5fdca6cee729_D20210701-20220331" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfOC03LTEtMS05ODY5NA_cc87aa3d-c58c-456e-bcda-a7867d713fce">19</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaeff0c865a8a4369ab8c5fdca6cee729_D20210701-20220331" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfOC05LTEtMS05ODY5NA_8f80a017-489c-403a-a551-c4522fa40020">960</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfOC0xNS0xLTEtOTg2OTQ_f2f00b7d-1096-453b-9caa-26e4c4f012cf">1,000</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb593644726c4c428ed6ceb42a31ff8f_D20210701-20220331" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfOS01LTEtMS05ODY5NA_58f2aa70-8b6c-45ef-acfc-99a40d82a2c4">415</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfOS0xNS0xLTEtOTg2OTQ_c506ace3-936d-435a-8fe1-46a515d8f4bb">415</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="idb593644726c4c428ed6ceb42a31ff8f_D20210701-20220331" xsi:nil="true" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfMTAtNS0xLTEtOTg2OTQ_1c5b69ce-1f31-46b3-8327-d7fc74c0ccdc"></ix:nonFraction></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"><ix:nonFraction unitRef="shares" contextRef="iaeff0c865a8a4369ab8c5fdca6cee729_D20210701-20220331" sign="-" xsi:nil="true" name="us-gaap:StockholdersEquityOtherShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfMTAtNy0xLTEtOTg2OTQ_575bc1be-f3e1-43ec-b438-53dd7a33555d"></ix:nonFraction></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8151fa2583d44a688b40d92d9d83b78_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfMTAtMTMtMS0xLTk4Njk0_d890be05-0d9f-4f7c-bf02-4589c6041fe5">1</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfMTAtMTUtMS0xLTk4Njk0_bde4dce7-5041-45f6-8ea4-6117410a0b56">1</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i56eb96c92b484bcaa4f9f5c171ad239f_I20220331" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfMTItMS0xLTEtOTg2OTQ_2a5e74ab-c691-4d4c-92d6-91416694843e">327</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56eb96c92b484bcaa4f9f5c171ad239f_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfMTItMy0xLTEtOTg2OTQ_4a7362d7-888f-4a26-8e12-fb9e55b131c8">2,761</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52413ad34f00440b833f5b75a8dd4627_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfMTItNS0xLTEtOTg2OTQ_be9f0c37-310a-4771-86f0-bc9432d1bf7e">281</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iaff4ed7f966c47e4962d2bf39a55b561_I20220331" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfMTItNy0xLTEtOTg2OTQ_dfd8ea08-f335-4ecb-9e11-ecbe43a9d0cd">54</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaff4ed7f966c47e4962d2bf39a55b561_I20220331" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfMTItOS0xLTEtOTg2OTQ_68b236eb-3551-481d-bc65-9ae2638ce710">3,100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a915a1a243e410f9ec96b9ace3e80d6_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfMTItMTEtMS0xLTk4Njk0_d232bf8c-a427-4270-a4fb-950354e20807">77</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieed2c03cd42a4857909b008f32e31e33_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfMTItMTMtMS0xLTk4Njk0_8c0a6b62-15e2-40c4-8b49-527f227b4e1a">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfMTItMTUtMS0xLTk4Njk0_7a5f2195-33be-48b5-a57f-47911795c909">693</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:30.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i090402a139834d23aa8e6c3a5b7f46f8_I20200630" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfMS0xLTEtMS05ODY5NA_265cf6db-9345-47db-82c8-6aff5890421b">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090402a139834d23aa8e6c3a5b7f46f8_I20200630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfMS0zLTEtMS05ODY5NA_822a6a7b-b5cf-4f76-81d3-20e006d669b8">2,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6dfd6eb1a2c4315afc3207155a386d9_I20200630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfMS01LTEtMS05ODY5NA_be009a12-6722-4480-b0b7-f07e68cb2b11">1,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i42e7af7d759c4fa5bfb0b98fa27e974f_I20200630" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfMS03LTEtMS05ODY5NA_b47cb329-d45d-48e1-bd9c-8c279a12cdcd">35</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42e7af7d759c4fa5bfb0b98fa27e974f_I20200630" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfMS05LTEtMS05ODY5NA_b27da814-5492-497e-808f-c1eb61d6d5b8">2,066</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9744506513214bcc9e61087cf55e047e_I20200630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfMS0xMS0xLTEtOTg2OTQ_9f7ea8a6-2362-435b-bef4-e06da66cb6ab">104</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i307f69a4e1d24b7f8e2b9180075e87b8_I20200630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfMS0xMy0xLTEtOTg2OTQ_a396dbae-307d-49e7-bfa1-eb645b41afef">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69e2c38f6f454bfa9b9fece718b91fbe_I20200630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfMS0xNS0xLTEtOTg2OTQ_1f531491-0287-475f-ace9-5215f1a17118">1,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfMi01LTEtMS05ODY5NA_844ee0d8-e2b3-4cfc-964e-73323b864f89">495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e0fd895201d4863a312198f691a8d0b_D20200701-20210331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfMi0xMy0xLTEtOTg2OTQ_11840138-befb-4878-ba36-aac643e7b22b">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfMi0xNS0xLTEtOTg2OTQ_8b9fd812-4522-4b1a-9e4a-c12758e2fc31">497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic358c286737245819556816b3a0a5db5_D20200701-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfMy0xMS0xLTEtOTg2OTQ_db187cbb-f9cc-4ea9-9b35-16020a06dd74">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfMy0xNS0xLTEtOTg2OTQ_419e0835-5348-44fc-a14a-8edcd1ae7c42">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock plans activity, net of shares withheld for employee taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia4b35350391644c2a0bdf28917ce2828_D20200701-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfNS0xLTEtMS05ODY5NA_8a691f61-3172-4c59-a437-4387f597cb97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4b35350391644c2a0bdf28917ce2828_D20200701-20210331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfNS0zLTEtMS05ODY5NA_23bbbea3-1b23-4b20-a5b2-682c07ddfcf0">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7afc2ffa017e47fe877f56fa2b3a45d4_D20200701-20210331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfNS03LTEtMS05ODY5NA_da814726-12bc-479e-a466-e4115d52271c">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7afc2ffa017e47fe877f56fa2b3a45d4_D20200701-20210331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfNS05LTEtMS05ODY5NA_f54e33fb-82ff-4e1a-97d9-d94ef32381c1">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfNS0xNS0xLTEtOTg2OTQ_b1820ff1-c72b-4a4d-8bc5-98b6b446e267">82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share repurchase program activity</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7afc2ffa017e47fe877f56fa2b3a45d4_D20200701-20210331" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfNi03LTEtMS05ODY5NA_d0e51c66-2bcc-4cc5-b74e-5703dadca69e">4</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7afc2ffa017e47fe877f56fa2b3a45d4_D20200701-20210331" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfNi05LTEtMS05ODY5NA_169a4347-ea9a-46f0-8bab-dbd1246a0bcf">200</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfNi0xNS0xLTEtOTg2OTQ_be134a88-a82d-4ee7-9b4b-00008653da7d">200</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ca3ba0c73594ed7bbc82421ddc8eb83_D20200701-20210331" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfNy01LTEtMS05ODY5NA_ecef678f-2859-487d-a6e0-5a98eea8bae5">432</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfNy0xNS0xLTEtOTg2OTQ_598df841-cb56-46f4-bbf9-9197153fd5eb">432</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i6ca3ba0c73594ed7bbc82421ddc8eb83_D20200701-20210331" sign="-" xsi:nil="true" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfOC01LTEtMS05ODY5NA_296a6599-ebe4-467a-a11f-1a441391544b"></ix:nonFraction></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7afc2ffa017e47fe877f56fa2b3a45d4_D20200701-20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOtherShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfOC03LTEtMS0xNDQ2ODk_83a7b859-5862-4336-92bb-301fe3cf8118">1</ix:nonFraction></span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e0fd895201d4863a312198f691a8d0b_D20200701-20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfOC0xMy0xLTEtOTg2OTQ_fe4351f7-a187-42c1-a5cd-ae4e62f687e5">1</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfOC0xNS0xLTEtOTg2OTQ_424c8d09-ece6-48e3-8e84-12bf21cf926b">1</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i74e91c5fe50846e4abcf66f67c9b72da_I20210331" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfOS0xLTEtMS05ODY5NA_42a9f217-33f4-49df-abea-d20b09262cad">327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74e91c5fe50846e4abcf66f67c9b72da_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfOS0zLTEtMS05ODY5NA_d0d63631-31f0-4f05-b66e-0b7726390621">2,807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89dbe704562b4ba5ac39a63d65dbff5a_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfOS01LTEtMS05ODY5NA_e2f8faf1-38a9-42d1-a5ba-80038d9c45c3">1,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic83e16a32c7b450083b893267a9ccda4_I20210331" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfOS03LTEtMS05ODY5NA_c71d63e2-34aa-49ed-bef7-44a458d907c7">36</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic83e16a32c7b450083b893267a9ccda4_I20210331" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfOS05LTEtMS05ODY5NA_20daeb92-2fc9-4eb1-8855-382094796959">2,202</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6ce5f003d8e47b7ac0d61aa5df61b12_I20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfOS0xMS0xLTEtOTg2OTQ_ffc07249-4d7f-4236-8cdb-f3ba32fb95e8">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i021442adc8e24489b12297c43e3fabda_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfOS0xMy0xLTEtOTg2OTQ_3b5ce89c-c47d-456c-9c71-df0e7183b715">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43de0647ce12490ab30c52d836774dce_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfOS0xNS0xLTEtOTg2OTQ_f2922bc0-bacc-4cfc-bca2-487b17fbb9d4">1,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iaf3733bf892b435689161c61a06da348_76"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.775%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.591%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings/(loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMy0xLTEtMS05ODY5NA_4f3f8626-7418-471d-a2d9-e7a7b91d40c2">1,069</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMy0zLTEtMS05ODY5NA_21c2cb23-8b4b-4467-82ce-d9277b0fb28b">497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfNi0xLTEtMS05ODY5NA_19fee9cb-1a1b-4c72-9f52-84106502c8e1">513</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfNi0zLTEtMS05ODY5NA_d01d0e95-6cf6-44ab-a0cf-279b96c888a7">603</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and loss on sale of other investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:GainLossOnSaleOfOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfNy0xLTEtMS05ODY5NA_0d79cb47-4437-4a80-93ff-5c16b712ae32">3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:GainLossOnSaleOfOtherInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfNy0zLTEtMS05ODY5NA_210b8585-1669-4992-955d-c2edf79bcd91">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain)/loss on sale of equity interest in naviHealth</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:GainLossOnSaleOfInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfOC0xLTEtMS05ODY5NA_3b625f38-b0c8-4eba-af16-042660ad637e">2</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:GainLossOnSaleOfInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfOC0zLTEtMS05ODY5NA_f9419ef3-a032-4631-8ccf-d1f0f914f96d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfOS0xLTEtMS05ODY5NA_4f7dbd8e-464f-4288-9978-9763e722806a">1,764</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfOS0zLTEtMS05ODY5NA_2ee224ea-655b-4eaf-828a-09f9e0e613b6">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMTAtMS0xLTEtOTg2OTQ_633079c5-6e2a-4c72-afa7-eed91e2706a8">10</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMTAtMy0xLTEtOTg2OTQ_597d4a88-d811-4dcb-8f9e-42497645dccb">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMTEtMS0xLTEtOTg2OTQ_e44b7855-1d54-4bc6-880a-e74a6c089d08">65</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMTEtMy0xLTEtOTg2OTQ_dea43c98-d624-4c2f-a4c1-17f6ced91293">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for bad debts</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMTMtMS0xLTEtOTg2OTQ_656c4124-3062-471d-af3a-f91198ddc1e6">46</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMTMtMy0xLTEtOTg2OTQ_2a71a518-56c4-4d16-bdb0-3df5083f356e">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in operating assets and liabilities, net of effects from acquisitions and divestitures:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase in trade receivables</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:IncreaseDecreaseInReceivables" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMTUtMS0xLTEtOTg2OTQ_4e9e680f-ce81-447f-8883-73473766e9d9">1,193</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:IncreaseDecreaseInReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMTUtMy0xLTEtOTg2OTQ_e856c73d-5c4b-4093-a6ae-f3e948a4dfa8">511</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase in inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMTYtMS0xLTEtOTg2OTQ_6e91829e-cdf6-48f9-8237-e4f77416fa8a">922</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMTYtMy0xLTEtOTg2OTQ_db9dd9cd-fa8f-49d1-94bd-c5e01cfb5083">1,323</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase in accounts payable</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMTctMS0xLTEtOTg2OTQ_bf6f029f-3016-40b6-ab57-a2701bb07ff7">1,121</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMTctMy0xLTEtOTg2OTQ_f418bce3-9652-4c29-b163-5c099f9301e7">1,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accrued liabilities and operating items, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMTgtMS0xLTEtOTg2OTQ_3e4f1bbd-3468-4a21-9843-0345597b2f70">206</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMTgtMy0xLTEtOTg2OTQ_b9cb5e92-987b-462c-99fd-e0b4e8010644">1,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMTktMS0xLTEtOTg2OTQ_805976db-1a46-45be-a226-086e73cf730a">130</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMTktMy0xLTEtOTg2OTQ_5e57c01a-abfb-41fa-a122-dfbd714d232b">1,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from divestitures, net of cash transferred, and disposal of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="cah:Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMjItMS0xLTEtOTg2OTQ_0a9746a4-28f0-4b97-80ba-324b7a5b81cc">934</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="cah:Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMjItMy0xLTEtOTg2OTQ_adac57dd-8c6a-406e-b8f1-51d6428967ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition of subsidiaries, net of cash acquired</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMjMtMS0xLTEtOTg2OTQ_245bfac0-ba90-4f69-a2c4-8f4cfa233f25">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMjMtMy0xLTEtOTg2OTQ_58de76bb-7475-4224-a8db-bf7e35e6f53b">3</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions to property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMjQtMS0xLTEtOTg2OTQ_06ec19f0-2741-4eb7-8ef3-3691a47ee46f">223</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMjQtMy0xLTEtOTg2OTQ_f6448451-3ec2-49dc-b8c4-f70e48647c5b">274</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="cah:Purchaseofavailableforsalesecuritiesandotherinvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMjUtMS0xLTEtOTg2OTQ_367f2a5b-3a33-4643-ab57-ba45552aed7d">38</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="cah:Purchaseofavailableforsalesecuritiesandotherinvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMjUtMy0xLTEtOTg2OTQ_4108271a-07fb-43e3-9dbe-175fc0fca88e">18</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMjYtMS0xLTEtOTg2OTQ_19b97990-a120-43af-b71f-d8994ea12914">27</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMjYtMy0xLTEtOTg2OTQ_d24a41b5-77c1-4851-91b8-99b5a80f2028">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from net investment hedge terminations</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:ProceedsFromHedgeInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMjctMS0xLTEtOTg2OTQ_b6e607d6-ec65-4a70-b66d-80e96e2e90ba">71</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:ProceedsFromHedgeInvestingActivities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMjctMy0xLTEtOTg2OTQ_f1ff3fff-af39-4790-bb9e-014e993450ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by/(used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMjgtMS0xLTEtOTg2OTQ_98bc3bb0-32da-4873-ac13-6a27c13ff9c7">771</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMjgtMy0xLTEtOTg2OTQ_d973c37b-eb26-47c8-8c8b-66febee0a128">290</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from interest rate swap terminations</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:PaymentsForProceedsFromHedgeFinancingActivities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMzItMS0xLTEtOTg2OTQ_fcf04c07-1333-417e-be0a-5efe6b08c859">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromHedgeFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMzItMy0xLTEtOTg2OTQ_8d0d466b-3b73-4f60-acec-3b3dbaf619ea">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMzMtMS0xLTEtOTg2OTQ_b026b888-9c1b-46de-a7f6-688a6bdb4cd1">597</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMzMtMy0xLTEtOTg2OTQ_d349954e-f495-4d90-9be7-71c32b07b702">53</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net tax withholdings from share-based compensation</span></div></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" sign="-" name="cah:Netproceedstaxwithholdingsfromsharebasedcompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMzQtMS0xLTEtOTg2OTQ_d5df1f44-3cee-4e36-864b-5df1edf3b533">26</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" sign="-" name="cah:Netproceedstaxwithholdingsfromsharebasedcompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMzQtMy0xLTEtOTg2OTQ_392a2986-c32c-4f58-87a5-5378a6f52f1e">1</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends on common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMzYtMS0xLTEtOTg2OTQ_bd354a72-eacd-4e1c-a142-7d0c6a471710">425</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMzYtMy0xLTEtOTg2OTQ_3e0073dd-a8b9-469f-9f0f-32a25eef10ea">432</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of treasury shares</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMzctMS0xLTEtOTg2OTQ_aea7c5f2-b0db-4b3c-9184-24f5dc037b38">1,000</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMzctMy0xLTEtOTg2OTQ_928b5cd3-8a2e-4f50-a084-db32633ba6fd">200</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMzgtMS0xLTEtOTg2OTQ_68d646e9-52e0-4527-adb8-9a3fd69bd2dc">2,048</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMzgtMy0xLTEtOTg2OTQ_f8c34efa-ac79-4a16-bd28-cdd536110d31">668</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfNDAtMS0xLTEtOTg2OTQ_06693036-ba23-4984-b605-3c01fd3ddef3">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfNDAtMy0xLTEtOTg2OTQ_f7c93750-c630-460a-9369-a1591c9be4dc">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and equivalents reclassified from/(to) assets held for sale</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="cah:CashReclassifiedToAssetHeldForSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfNDEtMS0xLTEtOTg2OTQ_8ae6891f-f3be-4a38-b629-828eb050ec30">109</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" sign="-" name="cah:CashReclassifiedToAssetHeldForSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfNDEtMy0xLTEtOTg2OTQ_531e378d-5079-48e0-a6c1-bed10c4c92a4">86</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net increase/(decrease) in cash and equivalents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfNDMtMS0xLTEtOTg2OTQ_5705c031-db9d-4b90-987b-d4b4a84ba31e">1,051</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfNDMtMy0xLTEtOTg2OTQ_06ea5326-f498-4086-809c-905491c2ec7c">728</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfNDQtMS0xLTEtOTg2OTQ_825eb851-f3ed-436f-8c39-5e5f7c12f341">3,407</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69e2c38f6f454bfa9b9fece718b91fbe_I20200630" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfNDQtMy0xLTEtOTg2OTQ_95a7dedf-b9bc-4114-a799-e124160259c1">2,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and equivalents at end of period</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfNDUtMS0xLTEtOTg2OTQ_897bc6c1-22db-4232-a1f2-13e294bdf53e">2,356</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43de0647ce12490ab30c52d836774dce_I20210331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfNDUtMy0xLTEtOTg2OTQ_ea4ce765-b36d-4a41-bb85-7074bdf86877">3,499</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iaf3733bf892b435689161c61a06da348_79"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div id="iaf3733bf892b435689161c61a06da348_82"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84Mi9mcmFnOjI5ZDUxNGQwOGU4MDQ2YWI5YzhlMTI5Yzg4MDgwODkxL3RleHRyZWdpb246MjlkNTE0ZDA4ZTgwNDZhYjljOGUxMjljODgwODA4OTFfMzEwNQ_174069d5-adaa-4d5c-92d8-da97db342566" continuedAt="i25a0ba18fd014441b684af5333f24268" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">1. Basis of Presentation and Summary of Significant Accounting Policies </span></div><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84Mi9mcmFnOjI5ZDUxNGQwOGU4MDQ2YWI5YzhlMTI5Yzg4MDgwODkxL3RleHRyZWdpb246MjlkNTE0ZDA4ZTgwNDZhYjljOGUxMjljODgwODA4OTFfMzExMA_423c995f-d075-45ef-93f6-674c1cb7e811" continuedAt="i40f28e69fcf24af297af4ebdd96ec3d7" escape="true"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2022 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fiscal year ends on June 30. References to fiscal 2022 and  2021 in these condensed consolidated financial statements are to the fiscal years ending or ended June&#160;30, 2022 and June&#160;30, 2021, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic ("COVID-19") continues to affect the U.S. and global economies, and as previously disclosed, the pandemic began to materially affect our businesses during the third quarter of fiscal 2020. The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2022 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2022. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2021 (the "2021 Form 10-K").</span></div></ix:nonNumeric></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="i25a0ba18fd014441b684af5333f24268"><ix:continuation id="i40f28e69fcf24af297af4ebdd96ec3d7"><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84Mi9mcmFnOjI5ZDUxNGQwOGU4MDQ2YWI5YzhlMTI5Yzg4MDgwODkxL3RleHRyZWdpb246MjlkNTE0ZDA4ZTgwNDZhYjljOGUxMjljODgwODA4OTFfMzExMg_ad24c5a1-0348-4a67-8fe1-71c47ca4448b" escape="true"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Issued Financial Accounting Standards</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Not Yet Adopted</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2021 Form 10-K. There were no accounting standards issued in fiscal 2022 that will have a material impact on our condensed consolidated financial statements.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Adopted Financial Accounting Standards</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted in the nine months ended March 31, 2022.</span></div></ix:nonNumeric></ix:continuation></ix:continuation><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div id="iaf3733bf892b435689161c61a06da348_85"></div><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84NS9mcmFnOjdiODg5MGQ4MGM5ZDRmYjQ4MTQ5NDMwYTgyOTI2NjlhL3RleHRyZWdpb246N2I4ODkwZDgwYzlkNGZiNDgxNDk0MzBhODI5MjY2OWFfNTc3_5a18986b-7691-42fa-9812-eb55ccc76dcd" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">2. Divestitures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we sold the Cordis business to Hellman &amp; Friedman for proceeds of $<ix:nonFraction unitRef="usd" contextRef="i32f5ee07df944be68a4ca171d08f3c89_D20210701-20220331" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84NS9mcmFnOjdiODg5MGQ4MGM5ZDRmYjQ4MTQ5NDMwYTgyOTI2NjlhL3RleHRyZWdpb246N2I4ODkwZDgwYzlkNGZiNDgxNDk0MzBhODI5MjY2OWFfOTA_b3d3abb5-600e-416f-b14f-98498fbcb11a">923</ix:nonFraction> million, net of cash transferred, and we retained certain working capital accounts and certain liabilities. The purchase price is subject to adjustments based on working capital requirements as set forth in the agreement. Cardinal Health will retain product liability associated with lawsuits and claims related to inferior vena cava ("IVC") filters in the U.S. and Canada, as well as authority for these matters discussed in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_103">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Cordis business operated within our Medical segment.</span></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iaf3733bf892b435689161c61a06da348_88"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RleHRyZWdpb246MDQ5MzM5OGZjMjc3NGY4NWIyZGRkODVmYTM2ODQyOWJfMTAwMg_c6407174-893e-4ca2-942c-6cbd4bd5232e" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">3. Restructuring and Employee Severance</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RleHRyZWdpb246MDQ5MzM5OGZjMjc3NGY4NWIyZGRkODVmYTM2ODQyOWJfOTgz_f2c6ef5d-aa44-4d73-bc79-3ed517dbda76" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restructuring and employee severance:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOjk3OGZlZjEwZDlkZDQwMzk4YWM4MzM0MWEyMDc2ODAzL3RhYmxlcmFuZ2U6OTc4ZmVmMTBkOWRkNDAzOThhYzgzMzQxYTIwNzY4MDNfMi0xLTEtMS05ODY5NA_bd7cf314-6765-4615-a963-cf2548b2bc56">12</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOjk3OGZlZjEwZDlkZDQwMzk4YWM4MzM0MWEyMDc2ODAzL3RhYmxlcmFuZ2U6OTc4ZmVmMTBkOWRkNDAzOThhYzgzMzQxYTIwNzY4MDNfMi0zLTEtMS05ODY5NA_7784d9ac-84b6-40c1-bd37-ac591f04a540">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" name="cah:FacilityExitAndOtherCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOjk3OGZlZjEwZDlkZDQwMzk4YWM4MzM0MWEyMDc2ODAzL3RhYmxlcmFuZ2U6OTc4ZmVmMTBkOWRkNDAzOThhYzgzMzQxYTIwNzY4MDNfMy0xLTEtMS05ODY5NA_a5888658-3080-4d61-add4-fed726d40904">19</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="cah:FacilityExitAndOtherCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOjk3OGZlZjEwZDlkZDQwMzk4YWM4MzM0MWEyMDc2ODAzL3RhYmxlcmFuZ2U6OTc4ZmVmMTBkOWRkNDAzOThhYzgzMzQxYTIwNzY4MDNfMy0zLTEtMS05ODY5NA_ab8dfc37-3994-4e71-9b34-88b19a1a26bc">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOjk3OGZlZjEwZDlkZDQwMzk4YWM4MzM0MWEyMDc2ODAzL3RhYmxlcmFuZ2U6OTc4ZmVmMTBkOWRkNDAzOThhYzgzMzQxYTIwNzY4MDNfNC0xLTEtMS05ODY5NA_cea0e59e-f24c-4152-89e8-050464c212af">31</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOjk3OGZlZjEwZDlkZDQwMzk4YWM4MzM0MWEyMDc2ODAzL3RhYmxlcmFuZ2U6OTc4ZmVmMTBkOWRkNDAzOThhYzgzMzQxYTIwNzY4MDNfNC0zLTEtMS05ODY5NA_fc246d48-3d22-4574-a787-a0fc2723f0e1">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOmQzOTY0MzhiNmQ2NjQ0OGQ4MzNhODNkZTdjYzFiZDg5L3RhYmxlcmFuZ2U6ZDM5NjQzOGI2ZDY2NDQ4ZDgzM2E4M2RlN2NjMWJkODlfMi0xLTEtMS05ODY5NA_6a3e7347-a3dc-4e40-ba26-793cb8a47a1d">22</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOmQzOTY0MzhiNmQ2NjQ0OGQ4MzNhODNkZTdjYzFiZDg5L3RhYmxlcmFuZ2U6ZDM5NjQzOGI2ZDY2NDQ4ZDgzM2E4M2RlN2NjMWJkODlfMi0zLTEtMS05ODY5NA_63cb8db2-5bcf-467e-a9d6-21f517b9e5b6">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="cah:FacilityExitAndOtherCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOmQzOTY0MzhiNmQ2NjQ0OGQ4MzNhODNkZTdjYzFiZDg5L3RhYmxlcmFuZ2U6ZDM5NjQzOGI2ZDY2NDQ4ZDgzM2E4M2RlN2NjMWJkODlfMy0xLTEtMS05ODY5NA_4e5cab96-7ab7-4041-af9c-ee7c17b81f2b">34</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="cah:FacilityExitAndOtherCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOmQzOTY0MzhiNmQ2NjQ0OGQ4MzNhODNkZTdjYzFiZDg5L3RhYmxlcmFuZ2U6ZDM5NjQzOGI2ZDY2NDQ4ZDgzM2E4M2RlN2NjMWJkODlfMy0zLTEtMS05ODY5NA_5049a2fc-b1c3-499e-b7e0-20625e66fb52">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOmQzOTY0MzhiNmQ2NjQ0OGQ4MzNhODNkZTdjYzFiZDg5L3RhYmxlcmFuZ2U6ZDM5NjQzOGI2ZDY2NDQ4ZDgzM2E4M2RlN2NjMWJkODlfNC0xLTEtMS05ODY5NA_303453b5-b265-461b-89f6-0b5f56de6f69">56</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOmQzOTY0MzhiNmQ2NjQ0OGQ4MzNhODNkZTdjYzFiZDg5L3RhYmxlcmFuZ2U6ZDM5NjQzOGI2ZDY2NDQ4ZDgzM2E4M2RlN2NjMWJkODlfNC0zLTEtMS05ODY5NA_e257053e-00b3-406e-ad27-5d586b23256e">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of accelerated depreciation, lease costs associated with vacant facilities, professional, project management and other service fees to support divestitures, vendor transition fees, project consulting fees, and certain other divestiture-related costs.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring costs during both the three and nine months ended March&#160;31, 2022 and 2021 were primarily related to the implementation of certain enterprise-wide cost-savings measures, which includes facility exit costs related to decreasing our overall office space, and the divestiture of the Cordis business. </span></div><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RleHRyZWdpb246MDQ5MzM5OGZjMjc3NGY4NWIyZGRkODVmYTM2ODQyOWJfOTky_dc5651da-d76b-42ac-a564-1a6cf13c9d17" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity related to liabilities associated with restructuring and employee severance:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:43.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.237%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.237%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-<br/>Related Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility Exit<br/>and Other Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45240633cec7475d96b338fa98ea6450_I20210630" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOjAzYmFhOTdhNDg3ZTQxN2FiYTQ1NzY3YjQ4MzBhOTNiL3RhYmxlcmFuZ2U6MDNiYWE5N2E0ODdlNDE3YWJhNDU3NjdiNDgzMGE5M2JfMS0xLTEtMS05ODY5NA_6b31c735-8fea-4cac-b564-6a2ca28360a2">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21b9f08e069e407899537ccf182d99fb_I20210630" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOjAzYmFhOTdhNDg3ZTQxN2FiYTQ1NzY3YjQ4MzBhOTNiL3RhYmxlcmFuZ2U6MDNiYWE5N2E0ODdlNDE3YWJhNDU3NjdiNDgzMGE5M2JfMS0zLTEtMS05ODY5NA_456a957d-ed27-4f97-abfa-988754f1b7f3">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOjAzYmFhOTdhNDg3ZTQxN2FiYTQ1NzY3YjQ4MzBhOTNiL3RhYmxlcmFuZ2U6MDNiYWE5N2E0ODdlNDE3YWJhNDU3NjdiNDgzMGE5M2JfMS01LTEtMS05ODY5NA_0a36f1ce-6e7f-4e74-a244-b9fb5bf06eec">79</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i739eec2ece12431aa16063ab41067d2c_D20210701-20220331" decimals="-6" name="us-gaap:RestructuringCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOjAzYmFhOTdhNDg3ZTQxN2FiYTQ1NzY3YjQ4MzBhOTNiL3RhYmxlcmFuZ2U6MDNiYWE5N2E0ODdlNDE3YWJhNDU3NjdiNDgzMGE5M2JfMi0xLTEtMS05ODY5NA_961cd696-8481-416e-897c-338549e81d14">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e58575430c249979ddd28860b77d7ea_D20210701-20220331" decimals="-6" name="us-gaap:RestructuringCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOjAzYmFhOTdhNDg3ZTQxN2FiYTQ1NzY3YjQ4MzBhOTNiL3RhYmxlcmFuZ2U6MDNiYWE5N2E0ODdlNDE3YWJhNDU3NjdiNDgzMGE5M2JfMi0zLTEtMS05ODY5NA_1e86f3fa-72a6-4e84-8a6d-5c7ca3b710b0">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:RestructuringCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOjAzYmFhOTdhNDg3ZTQxN2FiYTQ1NzY3YjQ4MzBhOTNiL3RhYmxlcmFuZ2U6MDNiYWE5N2E0ODdlNDE3YWJhNDU3NjdiNDgzMGE5M2JfMi01LTEtMS05ODY5NA_02e6bd91-8d05-4d33-bfca-ea94975cfc81">35</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i739eec2ece12431aa16063ab41067d2c_D20210701-20220331" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOjAzYmFhOTdhNDg3ZTQxN2FiYTQ1NzY3YjQ4MzBhOTNiL3RhYmxlcmFuZ2U6MDNiYWE5N2E0ODdlNDE3YWJhNDU3NjdiNDgzMGE5M2JfMy0xLTEtMS05ODY5NA_d8bed1e9-cde8-44c3-af5b-2fe1e917e461">38</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e58575430c249979ddd28860b77d7ea_D20210701-20220331" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOjAzYmFhOTdhNDg3ZTQxN2FiYTQ1NzY3YjQ4MzBhOTNiL3RhYmxlcmFuZ2U6MDNiYWE5N2E0ODdlNDE3YWJhNDU3NjdiNDgzMGE5M2JfMy0zLTEtMS05ODY5NA_5856110c-fb0b-42b0-9600-037174037093">10</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOjAzYmFhOTdhNDg3ZTQxN2FiYTQ1NzY3YjQ4MzBhOTNiL3RhYmxlcmFuZ2U6MDNiYWE5N2E0ODdlNDE3YWJhNDU3NjdiNDgzMGE5M2JfMy01LTEtMS05ODY5NA_34848bb8-eb57-4264-9989-a17839f6b1d8">48</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8754e705bb17409ca30ddb1af53bfd62_I20220331" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOjAzYmFhOTdhNDg3ZTQxN2FiYTQ1NzY3YjQ4MzBhOTNiL3RhYmxlcmFuZ2U6MDNiYWE5N2E0ODdlNDE3YWJhNDU3NjdiNDgzMGE5M2JfNC0xLTEtMS05ODY5NA_86cdb893-f2a5-4f22-a984-7cbc5c6eedde">49</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75ec9e64c1d7453ca7736eb6d2cd74b4_I20220331" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOjAzYmFhOTdhNDg3ZTQxN2FiYTQ1NzY3YjQ4MzBhOTNiL3RhYmxlcmFuZ2U6MDNiYWE5N2E0ODdlNDE3YWJhNDU3NjdiNDgzMGE5M2JfNC0zLTEtMS05ODY5NA_e2f546d6-2b38-402b-870f-f625bda0431d">17</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOjAzYmFhOTdhNDg3ZTQxN2FiYTQ1NzY3YjQ4MzBhOTNiL3RhYmxlcmFuZ2U6MDNiYWE5N2E0ODdlNDE3YWJhNDU3NjdiNDgzMGE5M2JfNC01LTEtMS05ODY5NA_8e6dd30a-ec3a-4f9e-a9e3-d6262e119f27">66</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div id="iaf3733bf892b435689161c61a06da348_91"></div><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfMTg1Mw_397fd644-c359-43ed-8f4a-1ebb768b7af1" continuedAt="i41b589f87ecd46e0a55948ec39e808f0" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">4. Goodwill and Other Intangible Assets</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfMTg4Mg_9cc5b7f3-a030-4d33-badc-9d9ad5037043" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill by segment and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.517%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.640%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.556%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical (1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical (2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbcce5e048774bd281968e39fa6fd1d5_I20210630" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjU2NDVhNTIzM2EyYTQ1MGViNzgwNGZkYmFmYjBmODQ0L3RhYmxlcmFuZ2U6NTY0NWE1MjMzYTJhNDUwZWI3ODA0ZmRiYWZiMGY4NDRfMS0xLTEtMS05ODY5NA_49de33cb-f080-4190-a8d2-b8efdc355d68">2,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cf7100a49b8462b95d20252b5ae23fc_I20210630" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjU2NDVhNTIzM2EyYTQ1MGViNzgwNGZkYmFmYjBmODQ0L3RhYmxlcmFuZ2U6NTY0NWE1MjMzYTJhNDUwZWI3ODA0ZmRiYWZiMGY4NDRfMS0zLTEtMS05ODY5NA_36d5efa9-05ee-4424-8429-4520df8c090e">5,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjU2NDVhNTIzM2EyYTQ1MGViNzgwNGZkYmFmYjBmODQ0L3RhYmxlcmFuZ2U6NTY0NWE1MjMzYTJhNDUwZWI3ODA0ZmRiYWZiMGY4NDRfMS01LTEtMS05ODY5NA_84dc6b2f-f461-417b-bc18-48039919fbb5">7,989</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill acquired, net of purchase price adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8dd1990825346198258de24f42bdfab_D20210701-20220331" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjU2NDVhNTIzM2EyYTQ1MGViNzgwNGZkYmFmYjBmODQ0L3RhYmxlcmFuZ2U6NTY0NWE1MjMzYTJhNDUwZWI3ODA0ZmRiYWZiMGY4NDRfMi0xLTEtMS05ODY5NA_5ece25a7-56b2-4e8d-bfda-8415c70bee66">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41161f1b8d3943d8bd64b5d48963474e_D20210701-20220331" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjU2NDVhNTIzM2EyYTQ1MGViNzgwNGZkYmFmYjBmODQ0L3RhYmxlcmFuZ2U6NTY0NWE1MjMzYTJhNDUwZWI3ODA0ZmRiYWZiMGY4NDRfMi0zLTEtMS05ODY5NA_1f3490ab-64ff-4f30-81bc-c8c979fa34be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjU2NDVhNTIzM2EyYTQ1MGViNzgwNGZkYmFmYjBmODQ0L3RhYmxlcmFuZ2U6NTY0NWE1MjMzYTJhNDUwZWI3ODA0ZmRiYWZiMGY4NDRfMi01LTEtMS05ODY5NA_d3def9cb-76dc-4668-a9a4-64b6fc999998">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8dd1990825346198258de24f42bdfab_D20210701-20220331" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjU2NDVhNTIzM2EyYTQ1MGViNzgwNGZkYmFmYjBmODQ0L3RhYmxlcmFuZ2U6NTY0NWE1MjMzYTJhNDUwZWI3ODA0ZmRiYWZiMGY4NDRfMy0xLTEtMS05ODY5NA_59d70690-2bdd-4a90-b36a-c84c71ed677b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41161f1b8d3943d8bd64b5d48963474e_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjU2NDVhNTIzM2EyYTQ1MGViNzgwNGZkYmFmYjBmODQ0L3RhYmxlcmFuZ2U6NTY0NWE1MjMzYTJhNDUwZWI3ODA0ZmRiYWZiMGY4NDRfMy0zLTEtMS05ODY5NA_7519ee4c-8aad-47e1-acf8-723b98fe20f9">41</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjU2NDVhNTIzM2EyYTQ1MGViNzgwNGZkYmFmYjBmODQ0L3RhYmxlcmFuZ2U6NTY0NWE1MjMzYTJhNDUwZWI3ODA0ZmRiYWZiMGY4NDRfMy01LTEtMS05ODY5NA_a83ea62b-214f-48ea-8cd6-62ad180cfcbf">41</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8dd1990825346198258de24f42bdfab_D20210701-20220331" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjU2NDVhNTIzM2EyYTQ1MGViNzgwNGZkYmFmYjBmODQ0L3RhYmxlcmFuZ2U6NTY0NWE1MjMzYTJhNDUwZWI3ODA0ZmRiYWZiMGY4NDRfNC0xLTEtMS05ODY5NA_ba101fe0-eac5-4068-b782-8a6f0dd71ba2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41161f1b8d3943d8bd64b5d48963474e_D20210701-20220331" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjU2NDVhNTIzM2EyYTQ1MGViNzgwNGZkYmFmYjBmODQ0L3RhYmxlcmFuZ2U6NTY0NWE1MjMzYTJhNDUwZWI3ODA0ZmRiYWZiMGY4NDRfNC0zLTEtMS05ODY5NA_ffba26d8-c8a2-4c2c-babf-1ece72ff739a">1,781</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjU2NDVhNTIzM2EyYTQ1MGViNzgwNGZkYmFmYjBmODQ0L3RhYmxlcmFuZ2U6NTY0NWE1MjMzYTJhNDUwZWI3ODA0ZmRiYWZiMGY4NDRfNC01LTEtMS05ODY5NA_cc2897f0-6540-4430-aea9-0189bd009fa3">1,781</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51a8695f54ef4860b74b13f3c337f04d_I20220331" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjU2NDVhNTIzM2EyYTQ1MGViNzgwNGZkYmFmYjBmODQ0L3RhYmxlcmFuZ2U6NTY0NWE1MjMzYTJhNDUwZWI3ODA0ZmRiYWZiMGY4NDRfNS0xLTEtMS05ODY5NA_f969a31d-f40a-4948-bff7-bba06ae55df2">2,659</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7f73d87fb74abbb28799bf351ad2cf_I20220331" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjU2NDVhNTIzM2EyYTQ1MGViNzgwNGZkYmFmYjBmODQ0L3RhYmxlcmFuZ2U6NTY0NWE1MjMzYTJhNDUwZWI3ODA0ZmRiYWZiMGY4NDRfNS0zLTEtMS05ODY5NA_12f6ad2a-56a8-4695-ab1a-264095064e7f">3,508</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjU2NDVhNTIzM2EyYTQ1MGViNzgwNGZkYmFmYjBmODQ0L3RhYmxlcmFuZ2U6NTY0NWE1MjMzYTJhNDUwZWI3ODA0ZmRiYWZiMGY4NDRfNS01LTEtMS05ODY5NA_e19dc664-e613-4fd9-a298-6d198ba2bc31">6,167</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">At March 31, 2022 and June 30, 2021, the Pharmaceutical segment accumulated goodwill impairment loss was $<ix:nonFraction unitRef="usd" contextRef="ifbcce5e048774bd281968e39fa6fd1d5_I20210630" decimals="-6" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfMjMy_64209b03-fd34-4758-91c0-22f65a1eeff6"><ix:nonFraction unitRef="usd" contextRef="i51a8695f54ef4860b74b13f3c337f04d_I20220331" decimals="-6" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfMjMy_c5e1e651-945f-4163-a523-ae3f72bc63d8">829</ix:nonFraction></ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">At March 31, 2022 and June 30, 2021, the Medical segment accumulated goodwill impairment loss was $<ix:nonFraction unitRef="usd" contextRef="idb7f73d87fb74abbb28799bf351ad2cf_I20220331" decimals="-6" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfMzM3_891fedb9-ecdd-48ae-a85b-ca0a26fe27dc">3.2</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i1cf7100a49b8462b95d20252b5ae23fc_I20210630" decimals="-6" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfMzQ0_32525e9a-0dd7-4154-a8c6-30183e03a48e">1.4</ix:nonFraction>&#160;billion, respectively.</span></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended March&#160;31, 2022, the Medical Unit, which is our Medical operating segment excluding our Cardinal Health at-Home Solutions division, continued to experience adverse financial results related to inflationary impacts and the adverse impact of global supply chain constraints. Due to the risks and uncertainties related to these impacts, we elected to bypass the qualitative assessment in the second and third quarters of fiscal 2022 and perform interim goodwill impairment testing for the Medical Unit. This quantitative testing resulted in the carrying amount of the Medical Unit exceeding the fair value, resulting in pre-tax impairment charges of $<ix:nonFraction unitRef="usd" contextRef="i2473dfc0495e42aeb265fd377f6c1a00_D20220101-20220331" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfNzE0NjgyNTU4NTE4MQ_c7e51357-5524-44a3-9a05-2d4ebe1fb89e">474</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i8c4e40c1def448fcb66e1d0cc8122850_D20211001-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfNzE0NjgyNTU4NjYwMA_c8fea723-0b81-4792-801b-8881053de36e">1.3</ix:nonFraction>&#160;billion, which were recognized during the three months ended March&#160;31, 2022 and&#160;December 31, 2021, respectively, and are included in impairments and (gain)/loss on disposal of assets in our condensed consolidated statements of earnings/(loss). The goodwill balance of the Medical Unit, after recognizing the impairment, was $<ix:nonFraction unitRef="usd" contextRef="i2843d7b87d1544cf87e968d6d3ae3124_I20220331" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfNzE0NjgyNTU4NDAyMQ_f818626a-67b5-488c-8bfa-085c47c72a77">2.3</ix:nonFraction>&#160;billion at March&#160;31, 2022.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our determination of the estimated fair value of the Medical Unit is based on a combination of the income-based approach (using a terminal growth rate of <ix:nonFraction unitRef="number" contextRef="i8c4e40c1def448fcb66e1d0cc8122850_D20211001-20211231" decimals="3" name="cah:TerminalGrowthRateFairValueInput" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfMzI5ODUzNDg5MDUwMw_80a59695-66bc-4503-bda7-558de15faf02"><ix:nonFraction unitRef="number" contextRef="i2473dfc0495e42aeb265fd377f6c1a00_D20220101-20220331" decimals="3" name="cah:TerminalGrowthRateFairValueInput" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfMzI5ODUzNDg5MDUwMw_85492539-6c2a-4f2e-9fd2-cd445119ee5d">2</ix:nonFraction></ix:nonFraction> percent), and the market-based approach. For the income-based approach, we also used discount rates of <ix:nonFraction unitRef="number" contextRef="i2473dfc0495e42aeb265fd377f6c1a00_D20220101-20220331" decimals="3" name="cah:DiscountRateFairValueInput" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfMzI5ODUzNDg5MDQ3NA_7686170d-8d23-48e4-8940-0ba6bfefd059">9.5</ix:nonFraction> percent and <ix:nonFraction unitRef="number" contextRef="i8c4e40c1def448fcb66e1d0cc8122850_D20211001-20211231" decimals="3" name="cah:DiscountRateFairValueInput" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfMzI5ODUzNDg5MDQ4NQ_0e48a5e1-9e79-465f-9d00-f5864272c2db">9</ix:nonFraction> percent for the interim testing at March&#160;31, 2022 and&#160;December 31, 2021, respectively. The increase in the discount rate was primarily due to an increase in the risk-free interest rate. Our fair value estimates utilize significant unobservable inputs and thus represent Level 3 fair value measurements.</span></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="i41b589f87ecd46e0a55948ec39e808f0"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Intangible Assets</span></div><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfMTg1OQ_46aaffda-5afa-4b30-8428-4fa46fa8d4d2" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize other intangible assets by class at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:24.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.409%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted- Average Remaining Amortization Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1a80ba5335a434499eb18f05cfe77bd_I20220331" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfMy0xLTEtMS05ODY5NA_fa936c18-53d0-4307-b32c-9712d4e500f6">13</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1a80ba5335a434499eb18f05cfe77bd_I20220331" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfMy01LTEtMS05ODY5NA_3c6f5987-952f-4496-b69d-3bb3ec57b785">13</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfNC0xLTEtMS05ODY5NA_3f2672e1-7771-428d-bbda-20680345fdd6">13</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfNC01LTEtMS05ODY5NA_84103872-4578-414d-aeae-28d9f84799bd">13</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b1540e67e14f1491c2bcf9e8c40937_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfNy0xLTEtMS05ODY5NA_66b4708b-a923-49d6-b180-6419f7321bdf">3,293</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b1540e67e14f1491c2bcf9e8c40937_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfNy0zLTEtMS05ODY5NA_2a8f8431-e9e6-4414-b8c9-0672206d18e2">2,130</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b1540e67e14f1491c2bcf9e8c40937_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfNy01LTEtMS05ODY5NA_20320af7-bcc5-462d-ac36-cebb766ee73f">1,163</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i1e32d2dbae964ed2b9f89a485ba2d9f2_D20210701-20220331" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfNy03LTEtMS05ODY5NA_a9a81e3a-af5d-49f1-a520-a2ae3cec456c">10</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica172f3bed03490b81be7777d6520978_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfOC0xLTEtMS05ODY5NA_7fe02b79-a5c5-4724-aeb6-473d1443625a">552</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica172f3bed03490b81be7777d6520978_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfOC0zLTEtMS05ODY5NA_66911105-a46f-4181-90ba-b9b474998293">352</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica172f3bed03490b81be7777d6520978_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfOC01LTEtMS05ODY5NA_2eb75f14-40c1-413e-b5d5-bcbd9b623b90">200</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i51a8e1fc38aa4e9fa1cbb316ac661cf2_D20210701-20220331" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfOC03LTEtMS05ODY5NA_2a0c7b79-6ced-47cc-aa96-40e265773bfa">9</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id70764894a9a471186543cece23c0235_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfOS0xLTEtMS05ODY5NA_9a0691a0-cd3d-44b9-ade8-8145a0c155c4">1,036</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id70764894a9a471186543cece23c0235_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfOS0zLTEtMS05ODY5NA_308ff19f-5334-4cf6-8d84-353a09dccd91">557</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id70764894a9a471186543cece23c0235_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfOS01LTEtMS05ODY5NA_92b06ac1-cf34-4fc8-b029-f3f0e6434d03">479</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3ac7d4f29a95405f9301d56ef3d96f7d_D20210701-20220331" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfOS03LTEtMS05ODY5NA_b8ebcd8b-0ca6-44c1-bdfd-c7320fa2786a">9</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfMTAtMS0xLTEtOTg2OTQ_d726eb3e-3bd0-450b-8386-e5cb733f7d52">4,881</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfMTAtMy0xLTEtOTg2OTQ_6ecca467-9dc0-49d8-bb33-f3abf0995e8e">3,039</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfMTAtNS0xLTEtOTg2OTQ_3ea5ee82-fb73-42d5-b870-ca92a31e8363">1,842</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfMTAtNy0xLTEtOTg2OTQ_76e9a307-5694-48bc-8b90-bf5a2fca139f">10</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfMTEtMS0xLTEtOTg2OTQ_f4b56a86-7d5c-4e45-bad7-7723a3d62bea">4,894</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfMTEtMy0xLTEtOTg2OTQ_ed2a85f1-63d9-42f5-a694-93bbacc111ea">3,039</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfMTEtNS0xLTEtOTg2OTQ_749eebc3-14db-44aa-a0d4-9b7cb9a67094">1,855</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:42.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.308%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.643%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.312%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58dd95f7f9f14ed4a4314c6690da932a_I20210630" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOmI1MDk3OTkzMTFmNjQ1MTViNWVmNzU0ODQ1MjgxMjQ2L3RhYmxlcmFuZ2U6YjUwOTc5OTMxMWY2NDUxNWI1ZWY3NTQ4NDUyODEyNDZfMy0xLTEtMS05ODY5NA_69c1d985-347e-4868-b4ca-c645986e3592">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58dd95f7f9f14ed4a4314c6690da932a_I20210630" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOmI1MDk3OTkzMTFmNjQ1MTViNWVmNzU0ODQ1MjgxMjQ2L3RhYmxlcmFuZ2U6YjUwOTc5OTMxMWY2NDUxNWI1ZWY3NTQ4NDUyODEyNDZfMy01LTEtMS05ODY5NA_a280a94d-b5a7-47e7-8d62-e1f86c6c6453">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOmI1MDk3OTkzMTFmNjQ1MTViNWVmNzU0ODQ1MjgxMjQ2L3RhYmxlcmFuZ2U6YjUwOTc5OTMxMWY2NDUxNWI1ZWY3NTQ4NDUyODEyNDZfNC0xLTEtMS05ODY5NA_f4181567-91f5-49cc-9a7a-80bb150c38b0">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOmI1MDk3OTkzMTFmNjQ1MTViNWVmNzU0ODQ1MjgxMjQ2L3RhYmxlcmFuZ2U6YjUwOTc5OTMxMWY2NDUxNWI1ZWY3NTQ4NDUyODEyNDZfNC01LTEtMS05ODY5NA_36dfbb89-5c3e-4240-83e6-d28ae8519ad2">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95eee9fd908844ee899640d22db70870_I20210630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOmI1MDk3OTkzMTFmNjQ1MTViNWVmNzU0ODQ1MjgxMjQ2L3RhYmxlcmFuZ2U6YjUwOTc5OTMxMWY2NDUxNWI1ZWY3NTQ4NDUyODEyNDZfNy0xLTEtMS05ODY5NA_b4279286-944a-4b1a-b44e-bcfd3e833138">3,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95eee9fd908844ee899640d22db70870_I20210630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOmI1MDk3OTkzMTFmNjQ1MTViNWVmNzU0ODQ1MjgxMjQ2L3RhYmxlcmFuZ2U6YjUwOTc5OTMxMWY2NDUxNWI1ZWY3NTQ4NDUyODEyNDZfNy0zLTEtMS05ODY5NA_342acc55-ab75-46d0-8783-e0dacc263ab3">1,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95eee9fd908844ee899640d22db70870_I20210630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOmI1MDk3OTkzMTFmNjQ1MTViNWVmNzU0ODQ1MjgxMjQ2L3RhYmxlcmFuZ2U6YjUwOTc5OTMxMWY2NDUxNWI1ZWY3NTQ4NDUyODEyNDZfNy01LTEtMS05ODY5NA_178a9a0d-1894-4b7a-975c-7c817db97341">1,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i602bf6f83c0542c597ac5984f1a805f8_I20210630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOmI1MDk3OTkzMTFmNjQ1MTViNWVmNzU0ODQ1MjgxMjQ2L3RhYmxlcmFuZ2U6YjUwOTc5OTMxMWY2NDUxNWI1ZWY3NTQ4NDUyODEyNDZfOC0xLTEtMS05ODY5NA_280d9b75-ad81-46a1-9357-6a0a5cb4075f">551</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i602bf6f83c0542c597ac5984f1a805f8_I20210630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOmI1MDk3OTkzMTFmNjQ1MTViNWVmNzU0ODQ1MjgxMjQ2L3RhYmxlcmFuZ2U6YjUwOTc5OTMxMWY2NDUxNWI1ZWY3NTQ4NDUyODEyNDZfOC0zLTEtMS05ODY5NA_daeceb27-d97c-4e88-8971-68957abdda16">328</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i602bf6f83c0542c597ac5984f1a805f8_I20210630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOmI1MDk3OTkzMTFmNjQ1MTViNWVmNzU0ODQ1MjgxMjQ2L3RhYmxlcmFuZ2U6YjUwOTc5OTMxMWY2NDUxNWI1ZWY3NTQ4NDUyODEyNDZfOC01LTEtMS05ODY5NA_10c7b3b9-9e42-4e02-a8ca-94622163bb06">223</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6be348f5aeaf4eb1a576923d8e90234e_I20210630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOmI1MDk3OTkzMTFmNjQ1MTViNWVmNzU0ODQ1MjgxMjQ2L3RhYmxlcmFuZ2U6YjUwOTc5OTMxMWY2NDUxNWI1ZWY3NTQ4NDUyODEyNDZfOS0xLTEtMS05ODY5NA_2809b151-1578-43dd-a569-8ba4f9dd8e33">1,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6be348f5aeaf4eb1a576923d8e90234e_I20210630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOmI1MDk3OTkzMTFmNjQ1MTViNWVmNzU0ODQ1MjgxMjQ2L3RhYmxlcmFuZ2U6YjUwOTc5OTMxMWY2NDUxNWI1ZWY3NTQ4NDUyODEyNDZfOS0zLTEtMS05ODY5NA_58305d76-c625-4b51-9b81-ffc5f5bd7f4e">506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6be348f5aeaf4eb1a576923d8e90234e_I20210630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOmI1MDk3OTkzMTFmNjQ1MTViNWVmNzU0ODQ1MjgxMjQ2L3RhYmxlcmFuZ2U6YjUwOTc5OTMxMWY2NDUxNWI1ZWY3NTQ4NDUyODEyNDZfOS01LTEtMS05ODY5NA_48f85f70-1299-4fa7-a821-4ffaad92da74">529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOmI1MDk3OTkzMTFmNjQ1MTViNWVmNzU0ODQ1MjgxMjQ2L3RhYmxlcmFuZ2U6YjUwOTc5OTMxMWY2NDUxNWI1ZWY3NTQ4NDUyODEyNDZfMTAtMS0xLTEtOTg2OTQ_18d829df-0ed1-4728-a3e7-1418a4ea7107">4,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOmI1MDk3OTkzMTFmNjQ1MTViNWVmNzU0ODQ1MjgxMjQ2L3RhYmxlcmFuZ2U6YjUwOTc5OTMxMWY2NDUxNWI1ZWY3NTQ4NDUyODEyNDZfMTAtMy0xLTEtOTg2OTQ_fbc98ebd-2d19-4a8e-9bc2-811502a62cb9">2,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOmI1MDk3OTkzMTFmNjQ1MTViNWVmNzU0ODQ1MjgxMjQ2L3RhYmxlcmFuZ2U6YjUwOTc5OTMxMWY2NDUxNWI1ZWY3NTQ4NDUyODEyNDZfMTAtNS0xLTEtOTg2OTQ_9e4cc332-93ab-4dc7-a71a-7d786e19f455">2,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOmI1MDk3OTkzMTFmNjQ1MTViNWVmNzU0ODQ1MjgxMjQ2L3RhYmxlcmFuZ2U6YjUwOTc5OTMxMWY2NDUxNWI1ZWY3NTQ4NDUyODEyNDZfMTEtMS0xLTEtOTg2OTQ_053890bd-1521-4ec0-9497-0c5403a690c0">4,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOmI1MDk3OTkzMTFmNjQ1MTViNWVmNzU0ODQ1MjgxMjQ2L3RhYmxlcmFuZ2U6YjUwOTc5OTMxMWY2NDUxNWI1ZWY3NTQ4NDUyODEyNDZfMTEtMy0xLTEtOTg2OTQ_2957d35d-4ec7-4433-9910-25f616cc07b7">2,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOmI1MDk3OTkzMTFmNjQ1MTViNWVmNzU0ODQ1MjgxMjQ2L3RhYmxlcmFuZ2U6YjUwOTc5OTMxMWY2NDUxNWI1ZWY3NTQ4NDUyODEyNDZfMTEtNS0xLTEtOTg2OTQ_2dd0c81c-af63-462a-a6e1-5e30e96564f6">2,105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amortization of intangible assets was $<ix:nonFraction unitRef="usd" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfMTYxMA_b535b9e3-92bc-48b2-888c-203ebeb85de0">78</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfMTYxNw_019cc769-61cd-43a9-854e-ffc1a6b3c125">109</ix:nonFraction> million for the three months ended March 31, 2022 and 2021, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfMTY3Ng_633b202a-17d7-4d9e-8ee4-541de091afd2">235</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfMTY4Mw_9dfe52ce-6043-430f-8efd-a39ea38239c3">337</ix:nonFraction> million for the nine months ended March&#160;31, 2022 and 2021, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2022 through 2026 is as follows: $<ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfMTgzMA_99d99713-a76b-4e16-8db7-4269b515a6b9">78</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfMTgzNA_7cc9fd94-8e5c-4632-97e8-2e729ef8a50a">284</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfMTgzOA_966d478f-5c02-4d54-987e-1a7933f9c8c3">260</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfMTg0Mg_8d4df3b0-1f40-4fb4-831c-334774d58e00">235</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfMTg1MA_119cdbed-123a-4ff0-9079-ee359d97c298">208</ix:nonFraction> million.</span></div></ix:continuation><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div id="iaf3733bf892b435689161c61a06da348_100"></div><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDAvZnJhZzpkNDRjYzYwN2MzM2Y0ZDhjOTNkNGEzNGRkYmZlMGZhYy90ZXh0cmVnaW9uOmQ0NGNjNjA3YzMzZjRkOGM5M2Q0YTM0ZGRiZmUwZmFjXzIzMTA_644a011e-cbe6-4df2-9ba1-803bd0d497d2" continuedAt="i3e5e1fc73ba645d18f38e65e2d757538" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">5. Long-Term Obligations and Other Short-Term Borrowings</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Long-Term Debt and Other Short-Term Borrowings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had total long-term obligations, including the current portion and other short-term borrowings, of $<ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-8" name="cah:TotalLongTermandShortTermObligations" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDAvZnJhZzpkNDRjYzYwN2MzM2Y0ZDhjOTNkNGEzNGRkYmZlMGZhYy90ZXh0cmVnaW9uOmQ0NGNjNjA3YzMzZjRkOGM5M2Q0YTM0ZGRiZmUwZmFjXzE1Nw_e5714bb0-bfea-4dc3-a4b0-87c0902d8b8b">5.6</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-8" name="cah:TotalLongTermandShortTermObligations" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDAvZnJhZzpkNDRjYzYwN2MzM2Y0ZDhjOTNkNGEzNGRkYmZlMGZhYy90ZXh0cmVnaW9uOmQ0NGNjNjA3YzMzZjRkOGM5M2Q0YTM0ZGRiZmUwZmFjXzE2NA_4d2c15f6-336c-43be-85c5-f0fb4e7de1ca">6.2</ix:nonFraction> billion at March&#160;31, 2022 and June&#160;30, 2021, respectively. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $<ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-8" name="us-gaap:AccountsPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDAvZnJhZzpkNDRjYzYwN2MzM2Y0ZDhjOTNkNGEzNGRkYmZlMGZhYy90ZXh0cmVnaW9uOmQ0NGNjNjA3YzMzZjRkOGM5M2Q0YTM0ZGRiZmUwZmFjXzU1MA_e4da3a41-afcf-4461-a1ff-fd7513f28d01">24.8</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-8" name="us-gaap:AccountsPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDAvZnJhZzpkNDRjYzYwN2MzM2Y0ZDhjOTNkNGEzNGRkYmZlMGZhYy90ZXh0cmVnaW9uOmQ0NGNjNjA3YzMzZjRkOGM5M2Q0YTM0ZGRiZmUwZmFjXzU1Nw_e11036b0-9c1c-4b4f-a5b1-bc868ca400b0">23.7</ix:nonFraction> billion at March&#160;31, 2022 and June&#160;30, 2021, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2022, we redeemed all outstanding $<ix:nonFraction unitRef="usd" contextRef="if590433d5a9845a7a608dab6a0c258f3_D20210701-20220331" decimals="-6" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDAvZnJhZzpkNDRjYzYwN2MzM2Y0ZDhjOTNkNGEzNGRkYmZlMGZhYy90ZXh0cmVnaW9uOmQ0NGNjNjA3YzMzZjRkOGM5M2Q0YTM0ZGRiZmUwZmFjXzYzNA_57d17b3c-177b-4eba-ae50-4568e0a82c8d">572</ix:nonFraction> million principal amount of 2.616% Notes due June 2022 at a redemption price equal to 100% of the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes. In connection with this redemption, we recorded a $<ix:nonFraction unitRef="usd" contextRef="if590433d5a9845a7a608dab6a0c258f3_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDAvZnJhZzpkNDRjYzYwN2MzM2Y0ZDhjOTNkNGEzNGRkYmZlMGZhYy90ZXh0cmVnaW9uOmQ0NGNjNjA3YzMzZjRkOGM5M2Q0YTM0ZGRiZmUwZmFjXzg4MA_0655dcb4-6b6d-4a3d-bd26-1dafafa50233">10</ix:nonFraction>&#160;million loss on early extinguishment of debt. The early redemption was funded with available cash.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2021, we early repurchased a total of $<ix:nonFraction unitRef="usd" contextRef="i9cb2151ddcdc4fc59c0b79ed2096beec_D20200701-20210331" decimals="-6" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDAvZnJhZzpkNDRjYzYwN2MzM2Y0ZDhjOTNkNGEzNGRkYmZlMGZhYy90ZXh0cmVnaW9uOmQ0NGNjNjA3YzMzZjRkOGM5M2Q0YTM0ZGRiZmUwZmFjXzEwMjQ_7ed045d0-d421-4f4a-93fe-4e111acdd4ed">40</ix:nonFraction> million of the Floating Rate Notes due 2022 and $<ix:nonFraction unitRef="usd" contextRef="i13e48b0505964bf68353a1b6f9547f38_D20200701-20210331" decimals="-6" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDAvZnJhZzpkNDRjYzYwN2MzM2Y0ZDhjOTNkNGEzNGRkYmZlMGZhYy90ZXh0cmVnaW9uOmQ0NGNjNjA3YzMzZjRkOGM5M2Q0YTM0ZGRiZmUwZmFjXzEwNjc_e8c2b314-ec65-46eb-b7fc-5f6d0ca7e618">2</ix:nonFraction> million of the 2.616% Notes due June 2022. The repurchases were funded with available cash. In connection with the early debt repurchases, we recorded a $<ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDAvZnJhZzpkNDRjYzYwN2MzM2Y0ZDhjOTNkNGEzNGRkYmZlMGZhYy90ZXh0cmVnaW9uOmQ0NGNjNjA3YzMzZjRkOGM5M2Q0YTM0ZGRiZmUwZmFjXzEyMTA_7959ed66-aca2-47f1-9b29-071ae7996abd">1</ix:nonFraction> million loss on early extinguishment of debt during the nine months ended March&#160;31, 2021.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Financing Arrangements</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to cash and equivalents and operating cash flow, other sources of liquidity include a&#160;$<ix:nonFraction unitRef="usd" contextRef="iaf3cd5065e6243ffbbc71550c25ca7f8_I20220331" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDAvZnJhZzpkNDRjYzYwN2MzM2Y0ZDhjOTNkNGEzNGRkYmZlMGZhYy90ZXh0cmVnaW9uOmQ0NGNjNjA3YzMzZjRkOGM5M2Q0YTM0ZGRiZmUwZmFjXzE0MDk_3f7c319f-a156-4898-9f64-8aa8ce6eeef2">2.0</ix:nonFraction> billion&#160;commercial paper program backed by a $<ix:nonFraction unitRef="usd" contextRef="i993a04a28da74821b93ee616926e595e_I20220331" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDAvZnJhZzpkNDRjYzYwN2MzM2Y0ZDhjOTNkNGEzNGRkYmZlMGZhYy90ZXh0cmVnaW9uOmQ0NGNjNjA3YzMzZjRkOGM5M2Q0YTM0ZGRiZmUwZmFjXzE0NDk_f4621f1c-af61-4042-b262-d7ad144eb3ec">2.0</ix:nonFraction> billion&#160;revolving credit facility. We also have a&#160;$<ix:nonFraction unitRef="usd" contextRef="id353836da7934ebb8d1cb8a20ca4a576_I20220331" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDAvZnJhZzpkNDRjYzYwN2MzM2Y0ZDhjOTNkNGEzNGRkYmZlMGZhYy90ZXh0cmVnaW9uOmQ0NGNjNjA3YzMzZjRkOGM5M2Q0YTM0ZGRiZmUwZmFjXzE0OTQ_34c92881-694c-4746-8d5b-3df9623d3304">1.0</ix:nonFraction> billion&#160;committed receivables sales facility. At&#160;March&#160;31, 2022, we had <ix:nonFraction unitRef="usd" contextRef="iea2152d45a954937a5a92441521a45ff_I20220331" decimals="-6" name="us-gaap:OtherShortTermBorrowings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDAvZnJhZzpkNDRjYzYwN2MzM2Y0ZDhjOTNkNGEzNGRkYmZlMGZhYy90ZXh0cmVnaW9uOmQ0NGNjNjA3YzMzZjRkOGM5M2Q0YTM0ZGRiZmUwZmFjXzE1NDk_c2f39945-216d-406d-a83b-30b82be51d78">no</ix:nonFraction> amounts outstanding under our commercial paper program, revolving credit facility, or our committed receivables sales facility. During the nine months ended March&#160;31, 2022, we had a daily maximum amount outstanding under our commercial paper and committed receivables programs of $<ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDAvZnJhZzpkNDRjYzYwN2MzM2Y0ZDhjOTNkNGEzNGRkYmZlMGZhYy90ZXh0cmVnaW9uOmQ0NGNjNjA3YzMzZjRkOGM5M2Q0YTM0ZGRiZmUwZmFjXzMyOTg1MzQ4ODU5ODQ_c7ddb1b2-36e5-490e-9100-289453d62322">1.2</ix:nonFraction>&#160;billion and an average daily amount outstanding of $<ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:LineOfCreditFacilityAverageOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDAvZnJhZzpkNDRjYzYwN2MzM2Y0ZDhjOTNkNGEzNGRkYmZlMGZhYy90ZXh0cmVnaW9uOmQ0NGNjNjA3YzMzZjRkOGM5M2Q0YTM0ZGRiZmUwZmFjXzMyOTg1MzQ4ODU5OTg_a0cc265f-59e0-40f0-93a5-4c77b1dd4045">25</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (&#8220;CHF&#8221;) through September 30, 2022. CHF was organized for</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, CHF is a separate legal entity from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF. CHF is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its creditors. </span></div></ix:nonNumeric></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3e5e1fc73ba645d18f38e65e2d757538">Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. As of March&#160;31, 2022, we were in compliance with this financial covenant.</ix:continuation> </span></div><div id="iaf3733bf892b435689161c61a06da348_103"></div><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzIyNzIy_55f34d5d-5f48-495d-a50b-f205172c2d0e" continuedAt="ie58b26314c6b4d619314ecaa71cb5efd" escape="true"><div style="margin-bottom:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">6. Commitments, Contingent Liabilities and Litigation</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commitments</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Generic Sourcing Venture with CVS Health Corporation ("CVS Health")</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of <ix:nonNumeric contextRef="i0ab6a9c65c7e4470950a3a5d6dc31d86_D20140731-20140731" name="us-gaap:LongtermPurchaseCommitmentPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzI1NA_9ed2ee31-dfbd-49ac-8095-fc019d76bc0b">10</ix:nonNumeric> years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. In August 2021, we amended our agreement to extend the term through June 2029. We are required to make quarterly payments to CVS Health for the term of the arrangement.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New York Opioid Stewardship Act</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $<ix:nonFraction unitRef="usd" contextRef="i23ebd145540743d0ab7dda2a643e03b3_I20180430" decimals="-6" name="cah:AggregateAnnualAssessment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzcwOQ_e0a8744c-a4cb-4788-b3bf-e79ecf8c2a80">100</ix:nonFraction>&#160;million annual assessment on all manufacturers and distributors licensed to sell or distribute opioids in New York. Under the OSA, each licensed manufacturer and distributor would be required to pay a portion of the assessment based on its share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The constitutionality of portions of the OSA has been challenged in court. In December 2018, the OSA was ruled unconstitutional by the U.S. district court for the Southern District of New York. Subsequently, New York passed a new statute that modified the assessment going forward and limited the OSA to two years (2017 and 2018). The U.S. Court of Appeals for the Second Circuit reversed the district court's decision on procedural grounds. In February 2021, the Second Circuit stayed the effect of the ruling pending a petition to the U.S. Supreme Court to review the Second Circuit's opinion. In October 2021, the U.S. Supreme Court declined to review the decision. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. Because of the Second Circuit ruling, we recorded an aggregate accrual of $<ix:nonFraction unitRef="usd" contextRef="i5255724c8ed4493ca93e7bf150c7f600_D20200701-20210331" decimals="-6" name="cah:EstimatedLiabilityForNewYorkOpioidStewardshipAct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzE5MzY_95606654-26e1-471c-9464-54da04c6d3f7">41</ix:nonFraction>&#160;million for calendar year 2017 and 2018 during the nine months ended March 31, 2021 based on the probable estimated payment amount. In the three months ended December 31, 2021, we paid the State of New York $<ix:nonFraction unitRef="usd" contextRef="i5ee03b4ae5f340a187f4bc77f729452b_D20211001-20211231" decimals="-6" name="us-gaap:LossContingencyAccrualPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzIxMjU_9c534a15-bbab-44d7-abc0-27e1648e92d8">20</ix:nonFraction>&#160;million, our portion of the assessment for calendar year 2017. As a result, as of March 31, 2022, we had an accrual of $<ix:nonFraction unitRef="usd" contextRef="i491c71d0bbb64a989ca7c5c82a284488_I20220331" decimals="-6" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzIyNDI_ee579d95-e86c-4b3a-b461-477f1457cbcc">20</ix:nonFraction>&#160;million, which reflects our best estimate of the portion of the assessment that we may owe for sales during calendar year 2018.</span></div></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="ie58b26314c6b4d619314ecaa71cb5efd" continuedAt="i85957f6be76c44eb97a0d918629d7ff3"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We become involved from time to time in disputes, litigation and regulatory matters.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we determine that products we source, manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, product liability claims and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we become aware through employees, internal audits or other parties of possible compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.</span></div></ix:continuation></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><ix:continuation id="i85957f6be76c44eb97a0d918629d7ff3" continuedAt="ie44e8b9c01ac47b3b928de961904ee6e"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges in our condensed consolidated statements of earnings/(loss); however, losses and recoveries of lost profits from disputes that occur in the ordinary course of business are included within segment profit. For example, in the second quarter of fiscal year 2022, our Pharmaceutical segment profit was positively impacted by a $<ix:nonFraction unitRef="usd" contextRef="i9215c78d739b4b399eaa5fb71927062e_D20211001-20211231" decimals="-6" name="cah:JudgmentForLostProfits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzU5MzM_d231b28d-ffe5-451b-966b-a98e78bf5dca">16</ix:nonFraction>&#160;million judgment for lost profits related to an ordinary course intellectual property rights claim.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opioid Lawsuits and Investigations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 2022, pharmaceutical wholesale distributors, including us, were defendants in approximately <ix:nonFraction unitRef="lawsuit" contextRef="i882c87a069664d07be3f57a3c4880673_I20220228" decimals="-2" name="cah:LossContingencyLawsuitsNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzYxNjM_6dfc12d5-ed30-4175-ba40-90d3b41de5a6">3,400</ix:nonFraction> lawsuits relating to the distribution of prescription opioid pain medications. The lawsuits sought equitable relief and monetary damages based on a variety of legal theories including various common law claims, such as public nuisance, negligence and unjust enrichment as well as violations of controlled substance laws, the Racketeer Influenced and Corrupt Organizations Act and various other statutes. These lawsuits also name pharmaceutical manufacturers, retail pharmacy chains and other entities as defendants.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">States &amp; Political Subdivisions</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately <ix:nonFraction unitRef="lawsuit" contextRef="ib8066d95edcd4276b92e5941e9cf1675_I20220428" decimals="-2" name="cah:LossContingencyLawsuitsNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzY3MjY_77b34ea9-4830-4e03-9c9d-5db382200915">2,700</ix:nonFraction> of these lawsuits were filed by counties, municipalities, cities and political subdivisions in various federal, state, and other courts. The vast majority of these lawsuits were filed in U.S. federal court and were transferred for consolidated pre-trial proceedings in a Multi-District Litigation proceeding in the U.S. District Court for the Northern District of Ohio (the &#8220;MDL&#8221;).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, <ix:nonFraction unitRef="stateag" contextRef="i3f3f37b2e6a246ca91a14261f83072a8_I20220428" decimals="0" name="cah:NumberofStateAttorneysGeneralfilinglawsuits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzcxMzQ_b2155dee-bc34-49dc-852b-70523c14d818">25</ix:nonFraction> state attorneys general filed lawsuits against distributors, including us, in various state courts. We have also received requests, civil investigative demands, subpoenas or requests for information from additional state attorneys general offices and governmental authorities. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we determined that there was sufficient participation to proceed with a settlement agreement (the "Settlement Agreement") to settle the vast majority of opioid lawsuits filed by state attorneys general and political subdivisions. This Settlement Agreement became effective on April 2, 2022. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to us and two other national distributors, parties to the Settlement Agreement include <ix:nonFraction unitRef="states" contextRef="i56ecddadc331422e91dd1962e9bd826a_I20220428" decimals="0" name="cah:SettlingStates" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzMyOTg1MzQ5MjE5NDA_97ca6e15-0936-4058-ae55-d46cdc387f91">46</ix:nonFraction> states, the District of Columbia and <ix:nonFraction unitRef="numberofusterritories" contextRef="i56ecddadc331422e91dd1962e9bd826a_I20220428" decimals="0" name="cah:SettlingUSTerritories" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzMyOTg1MzQ5MjE5NDE_c4b9fd20-9ee7-448f-839f-45c47a4534f4">5</ix:nonFraction> U.S. territories. As of April 28, 2022, over <ix:nonFraction unitRef="number" contextRef="i8d6bdce912f94701b4d5c146cec19721_D20220428-20220428" decimals="2" name="cah:LossContingencyClaimsSettledPercent" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzMyOTg1MzQ5MjQ5OTk_afa36aac-163b-46e0-84c2-ca2dc5887b92">98</ix:nonFraction> percent of political subdivisions (by population as calculated under the Settlement Agreement) that had brought opioid-related suits against us as calculated under the Settlement Agreement had chosen to join the Settlement Agreement or have had their claims addressed by state legislation. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this Settlement Agreement, we will pay up to approximately $<ix:nonFraction unitRef="usd" contextRef="i66875ebb8eef4db4b014c5f748452b43_I20220331" decimals="-6" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzMyOTg1MzQ5MjE5NjU_34940a89-27b7-4ec4-8a82-88d1f097d3dc">6.0</ix:nonFraction>&#160;billion, the majority of which will be paid over 18 years. The exact payment amount will depend on several factors, including the extent to which states take action to foreclose opioid lawsuits by political subdivisions (e.g., by passing laws barring or limiting opioid lawsuits by political subdivisions), and the extent to which </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional political subdivisions in participating states file additional opioid lawsuits against us. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Settlement Agreement also includes injunctive relief terms related to distributors&#8217; controlled substance anti-diversion programs, including with respect to: (1) governance; (2) independence and training of the personnel operating controlled substances monitoring programs; (3) due diligence for new and existing customers; (4) ordering limits for certain products; and (5) suspicious order monitoring. A monitor will be selected to oversee compliance with these provisions for a period of five years. In addition, we and the two other settling distributors will engage a third-party vendor to act as a clearinghouse for data aggregation and reporting, which distributors will fund the for ten years.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The participating states and the distributors are cooperating to obtain consent judgments embodying the terms of the Settlement Agreement in each participating state and the participating states and subdivisions are dismissing their lawsuits. As a result, as of April 28, 2022, approximately <ix:nonFraction unitRef="lawsuit" contextRef="ic882bf829b3c4091beef8438bdf4b296_D20220428-20220428" decimals="-2" name="us-gaap:LossContingencyClaimsSettledNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzMyOTg1MzQ5MjE5NDM_b8cc1bbf-9bcb-4d1f-b769-ff57399f3ece">2,000</ix:nonFraction> lawsuits against us have been dismissed. We expect additional lawsuits to be dismissed over the coming months. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, we had separately negotiated settlements with each of Florida, New York, Ohio, Rhode Island, Texas and their participating subdivisions; however, as contemplated, these states and their participating subdivisions are now participating in the Settlement Agreement.  </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2022, we paid into escrow the majority of our first annual payment under the Settlement Agreement, which is reflected in prepaid expenses and other assets in our condensed consolidated balance sheets. We also made certain payments under the separate New York, Ohio and Rhode Island settlements, as well as certain payments under Cherokee Nation settlement and Native American term sheet. During the nine months ended March 31, 2022, we paid $<ix:nonFraction unitRef="usd" contextRef="i0247bbb36fd244a09bc9d98fe2b16dcb_D20210701-20220331" decimals="-6" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzMyOTg1MzQ5MjIyMTY_d76d65d4-3e9e-4b65-90fe-8a6ebce93e8b">348</ix:nonFraction>&#160;million in connection with these matters. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, we and two other national distributors reached an agreement with the Washington Attorney General, under which we will pay up to approximately $<ix:nonFraction unitRef="usd" contextRef="i4ff29a3a90e442dd8c5616657406a603_I20220502" decimals="-6" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzMyOTg1MzQ5MjE5NTA_69ee2d04-6399-4a44-9899-d63d131f2094">160</ix:nonFraction>&#160;million to the State of Washington and its participating subdivisions to resolve opioid-related claims. This amount is consistent with the amount that would have been allocated to Washington under the Settlement Agreement, had Washington agreed to participate, plus certain attorneys' fees and costs. The terms of this agreement in principle are substantially consistent with the Settlement Agreement. This agreement is subject to certain contingencies, including the rate of subdivision participation. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">West Virginia subdivisions and Native American tribes were not a part of the broader settlement process and we have been involved in separate negotiations with these groups. In September 2021 we announced that we, along with two other national distributors, had reached an agreement with the Cherokee Nation in connection with ongoing negotiations toward a broader agreement with Native American tribes. In January 2022, we, along with two other </span></div></div></ix:continuation></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><ix:continuation id="ie44e8b9c01ac47b3b928de961904ee6e" continuedAt="i40c7890a970d4e7a8d5e89adfedd848c"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">national distributors, entered into a term sheet with the Native American tribes.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first phase of a bench trial in West Virginia State Court for a consolidated case brought by <ix:nonFraction unitRef="plaintiff" contextRef="i0bc140f1011640a682a782f1cae16cad_D20220428-20220428" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzMyOTg1MzQ5MjUwMDc_20b8770d-46c7-48a1-912f-5a8771306bd2">63</ix:nonFraction> West Virginia subdivisions against the Company and two other national distributors is scheduled to begin July 5, 2022. A bench trial before a federal judge in West Virginia brought by Cabell County and City of Huntington against us and two other national distributors concluded in July 2021. The judge has not yet issued a decision. Trials are inherently unpredictable and it is possible that the outcome of these trials could materially negatively impact our financial results, cash flows or results of operations.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Settlement Agreement did not resolve all opioid lawsuits and claims brought by states and political subdivisions. The Attorney General of Oklahoma filed a lawsuit against us in January 2020, and did not agree to join the Settlement Agreement. As of April 28, 2022, we are still defendants in approximately <ix:nonFraction unitRef="lawsuit" contextRef="ib8066d95edcd4276b92e5941e9cf1675_I20220428" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzMyOTg1MzQ5MjE5Nzg_3d75a19a-4f68-4dbb-8f3e-d316c2dae094">700</ix:nonFraction> lawsuits brought by counties, municipalities and other political subdivisions; however, we expect this number to decline as additional cases are dismissed as a result of the Settlement Agreement.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In total, we have $<ix:nonFraction unitRef="usd" contextRef="i66875ebb8eef4db4b014c5f748452b43_I20220331" decimals="-7" name="us-gaap:LitigationReserve" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzE4MTQxOTQxODkzMDM3_0a475714-64fa-45cf-b1df-2ebf9d7fb753">6.70</ix:nonFraction>&#160;billion accrued at March&#160;31, 2022, of which $<ix:nonFraction unitRef="usd" contextRef="i66875ebb8eef4db4b014c5f748452b43_I20220331" decimals="-6" name="us-gaap:LitigationReserveCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzE4MTQxOTQxODkzMDY4_41f1cef0-f392-43c6-b835-e1da61e1593e">738</ix:nonFraction>&#160;million is included in other accrued liabilities and the remainder is included in deferred income taxes and other liabilities in our condensed consolidated balance sheets. During the nine months ended March 31, 2021, we recorded total pre-tax charges of $<ix:nonFraction unitRef="usd" contextRef="i7cfeb36a6e0d45f8aa734c1879638433_D20200701-20210331" decimals="-7" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzE4MTQxOTQxODkzMzE5_a3f7e46d-9941-4c9b-9a80-f9745ce1b3c5">1.02</ix:nonFraction>&#160;billion in litigation (recoveries)/charges, net in our condensed consolidated statements of earnings/(loss). </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual, whether as a result of settlement discussions, a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters. We continue to strongly dispute the allegations made in these lawsuits none of these agreements is an admission of liability or wrongdoing.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Justice Investigations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). We have also received civil requests for information from other DOJ offices. We believe that these investigations concern operation of our anti-diversion program, our anti-diversion policies and procedures, and distribution of certain controlled substances. We are cooperating with these investigations. We are unable to predict the outcome of any of these investigations. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Private Plaintiffs</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Settlement Agreement does not address claims by private parties, which includes unions and other health and welfare funds, </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hospital systems and other healthcare providers, businesses and individuals alleging personal injury. Private parties had brought approximately <ix:nonFraction unitRef="lawsuit" contextRef="ifc7fdc5fa1c84d5aa2af19ed52614364_I20220504" decimals="0" name="cah:LossContingencyLawsuitsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzE1MjAx_dfcfb3dc-b884-4cc8-9566-4e098861ecad">453</ix:nonFraction> lawsuits as of May 4, 2022. Of these, <ix:nonFraction unitRef="lawsuit" contextRef="i5118cc3369704619a0d6f9362d7b4be6_I20220504" decimals="0" name="cah:LossContingencyLawsuitsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzE1MjQ3_e9549b11-0350-4250-bc23-5c2644c8a98a">141</ix:nonFraction> are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A trial in a case involving <ix:nonFraction unitRef="plaintiff" contextRef="i9ba9d001296a4abc99e1e8dbda30b7a3_D20220428-20220428" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzE1NDEw_925b5cda-744b-4a8b-b6cd-6bfbaf4fb8b1">21</ix:nonFraction> plaintiffs is scheduled to begin in state court in Georgia in July 2022. We are vigorously defending ourselves in all of these matters; however, trials are inherently unpredictable and it is possible that an unfavorable outcome in these matters, individually or in the aggregate, could have a negative impact on our financial results.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Insurance Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in legal proceedings with two insurers related to the availability of insurance coverage for the lawsuits described above. In October 2020, we filed a complaint for declaratory judgment against National Union Fire Insurance Company of Pittsburgh, PA (&#8220;National Union&#8221;) seeking a declaration that National Union is obligated to reimburse us for defense costs incurred in connection with the lawsuits described above. In January 2021, Swiss Re International SE commenced an arbitration in London seeking a determination that it does not have an obligation to reimburse us for defense and indemnity expenses incurred in connection with the lawsuits described above. We have not recorded a receivable for any recoveries related to these insurance litigation matters as of</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cordis IVC Filter Matters </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Liability Lawsuits</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April 29, 2022, we are named as a defendant in <ix:nonFraction unitRef="lawsuit" contextRef="icbd0825dbe564a209ad97999fd39b901_D20220429-20220429" decimals="0" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzE2NjY3_9f42f656-c31c-4c31-af1b-ee820d84a9ca">457</ix:nonFraction> product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately <ix:nonFraction unitRef="plaintiff" contextRef="i967e05473aad4bdab16324a714471629_D20220429-20220429" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzE2Nzkw_0ee76c62-3aa3-40df-b2fb-cffa59100be6">5,872</ix:nonFraction> plaintiffs that allege personal injuries associated with the use of Cordis OptEase and TrapEase inferior vena cava ("IVC") filter products. Another <ix:nonFraction unitRef="lawsuit" contextRef="i9dfeb8260c1c4f43b4a0668f4c5957f8_D20220429-20220429" decimals="0" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzE2OTQx_77ab065c-5845-414d-809d-1422e1aa92ed">26</ix:nonFraction> lawsuits involving similar claims by approximately <ix:nonFraction unitRef="plaintiff" contextRef="ia501b89dcc1041d69e1b5309d5f9f944_D20220429-20220429" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzE2OTk1_4638e099-9095-4691-9c76-dedc902dd49c">30</ix:nonFraction> plaintiffs are pending in other jurisdictions. These lawsuits seek a variety of remedies, including unspecified monetary damages. In July 2021, we entered into an agreement to settle approximately <ix:nonFraction unitRef="lawsuit" contextRef="i989aea95b6504bd0b4aa8ccb22169319_D20210731-20210731" decimals="-2" name="us-gaap:LossContingencyClaimsSettledNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzE3MTk1_2e706ee1-6a9f-48bd-a642-dd109b2c66fd">1,300</ix:nonFraction> claims. We continue to vigorously defend ourselves in these lawsuits and are engaged in ongoing resolution discussions with certain plaintiffs.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2022, we had a total of $<ix:nonFraction unitRef="usd" contextRef="ic2ae902498a44131a91a5bebbbda2131_I20220331" decimals="-6" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzE3NDE5_da01f7a2-d510-4f84-87f6-3ad5a5e83ec7">494</ix:nonFraction>&#160;million net of estimated insurance recoveries, accrued for losses and legal defense costs, related to the Cordis IVC filter lawsuits in our condensed consolidated balance sheets. We believe there is a range of estimated losses with respect to these matters. Because no amount within the range is a better estimate than any other amount within the range, we have accrued the minimum amount in the range. We estimate the high end of the range to be approximately $<ix:nonFraction unitRef="usd" contextRef="i9e7f4d19047348f89f56bfebceea170d_I20220331" decimals="-7" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzE3ODc1_a367b38f-6c4e-427d-9dfb-aaa521a0f62e">1.05</ix:nonFraction>&#160;billion, net of estimated insurance recoveries. The sale of the Cordis disposal group does not include product liability related to the IVC filters in the U.S. and Canada, which we retained.</span></div></div></ix:continuation></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="i40c7890a970d4e7a8d5e89adfedd848c" continuedAt="i075d09e3f6cc4665acf7c2a7165b59d6"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Mexico Attorney General Action </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Attorney General for the State of New Mexico filed an action against certain IVC filter manufacturers, including us, alleging claims under New Mexico's Unfair Practices Act, Medicaid Fraud Act and Fraud Against Taxpayers Act. The allegations made are similar to those made in the product liability lawsuits, described above. We intend to vigorously defend ourselves against these claims.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SEC Investigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we received a subpoena from the U.S. Securities and Exchange Commission ("SEC") requesting the production of documents from 2015 through 2019 relating to inventory in the Cordis business, analysis of goodwill of the Medical segment and other matters. In March 2022, the SEC informed us that it had concluded its investigation and did not intend to recommend an enforcement action. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholder Securities Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Louisiana Sheriffs' Pension &amp; Relief Fund filed a purported class action complaint against Cardinal Health and certain current and former officers and employees in the United States District Court for the Southern District of Ohio purportedly on behalf of all purchasers of our common shares between March 2015 and May 2018. In June 2020, the court appointed 1199 SEIU Health Care Employees Pension Fund as lead plaintiff and a consolidated amended complaint was filed in September 2020. The amended complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 by making misrepresentations and omissions related to the acquisition and integration of the Cordis business and inventory and supply chain problems within the Cordis business, and seeks to recover unspecified damages and equitable relief for the alleged misstatements and omissions. The complaint also alleges that one of the individual defendants violated Section 20A of the Exchange Act because he sold shares of Cardinal Health stock during the time period. In September 2021, the court denied our motion to dismiss. We are vigorously defending ourselves against these claims. </span></div></ix:continuation></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="i075d09e3f6cc4665acf7c2a7165b59d6" continuedAt="ia5f6b6c12886470d85920329278513ec"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Specialty Solutions DOJ Investigation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the United States Attorney&#8217;s Office for the District of Massachusetts (the "USAO") commenced an investigation of Cardinal Health regarding possible violations of the U.S. healthcare fraud and abuse laws. The USAO sought, among other things, documents and information relating to discounts and rebates offered or provided to certain Specialty Solutions customers. In January 2022, without admitting liability, we settled this matter with the DOJ for approximately $<ix:nonFraction unitRef="usd" contextRef="ie60f8b5fae944fc6a15c2435abf6b955_D20200701-20210331" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzIwNzMx_65cfd2e7-eb20-4c50-98d8-10e97d31da9a">13</ix:nonFraction> million, which was recorded as expense within litigation (recoveries)/charges net in our consolidated statement of earnings/(loss) during the fiscal year ended June 30, 2021. Additionally, our Specialty Pharmaceutical Distribution business entered into a five-year corporate integrity agreement with the Department of Health and Human Services, Office of Inspector General, under which it agreed to certain remedial measures, including no longer offering term-based up-front discounts.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Civil Litigation </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Pharmaceutical Pricing Antitrust Litigation </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and improperly engaged in customer allocation. We have filed a motion to dismiss the complaints and we intend to vigorously defend ourselves. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Active Pharmaceutical Ingredient Impurity Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many participants in the pharmaceutical supply chain, including active pharmaceutical ingredient ("API") manufacturers, finished dose manufacturers, repackagers, distributors, and retailers have been named as defendants in lawsuits arising out of recalls of certain medications due to alleged impurities in the active pharmaceutical ingredients or finished product. </span></div></ix:continuation><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia5f6b6c12886470d85920329278513ec">In February 2019, a Multidistrict Litigation was created in the U.S. District Court for the District of New Jersey (the &#8220;Sartan MDL&#8221;) alleging API impurities in certain generic blood pressure medications. We have been named as a defendant in the Sartan MDL. We are vigorously defending ourselves in this matter.</ix:continuation> </span></div><div id="iaf3733bf892b435689161c61a06da348_106"></div><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzg3NTg_abfec452-f7f9-406f-a448-8c746b625c74" continuedAt="i599922757b0a4b26a64e8574791ff976" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">7. Income Taxes</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in our benefit from income taxes as a percentage of pretax earnings/(loss) (&#8220;effective tax rate&#8221;) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items. </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effective Tax Rate</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended&#160;March&#160;31, 2022, the effective tax rate was&#160;(<ix:nonFraction unitRef="number" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzMyOTg1MzQ5MTY3OTE_27fd1242-5c09-42d4-8c6a-f486e831cc4f">916.5</ix:nonFraction>) percent and&#160;(<ix:nonFraction unitRef="number" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzMyOTg1MzQ5MTg4ODc_c1fd9c1e-d79c-4c85-bc1a-28bcf64af988">44.4</ix:nonFraction>) percent, </span></div></ix:nonNumeric></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><ix:continuation id="i599922757b0a4b26a64e8574791ff976" continuedAt="i767a82f42f764909ad9610bd8e21e018"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively, and reflects the impact of the tax effect of the year-to-date goodwill impairment charges recognized during the nine months ended March&#160;31, 2022. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended&#160;March&#160;31, 2021, the effective tax rate was <ix:nonFraction unitRef="number" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzMyOTg1MzQ5MTkwOTk_042b08ae-1fc5-4f42-b2ee-f10c32942465">72.8</ix:nonFraction> percent and (<ix:nonFraction unitRef="number" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzMyOTg1MzQ5MTczNDk_b7982b2e-59e3-459e-9b3b-41db72983a48">143.3</ix:nonFraction>) percent, respectively, and included the impact related to the treatment of the tax effect of opioid litigation charges, the resolution of certain transfer pricing matters with the U.S. Internal Revenue Service ("IRS") and withholding taxes for planned distributions from foreign subsidiaries. During the nine months ended&#160;March&#160;31, 2021, the effective tax rate included the benefit from a net operating loss carryback primarily related to a self-insurance pre-tax loss.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Goodwill Impairment Charge</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2022, we recognized year-to-date pre-tax charges of $<ix:nonFraction unitRef="usd" contextRef="i579fe90cd44b45029f6ce1e6fd52d06e_D20210701-20220331" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzMyOTg1MzQ5MjA1MDU_763bb6ac-9d1d-427a-afce-ec39ac0de8bb">1.8</ix:nonFraction>&#160;billion for goodwill impairments related to the Medical Unit. The net tax benefit related to these charges is $<ix:nonFraction unitRef="usd" contextRef="i7a1ee29c629542f28c59d5fc1aa744bc_D20210701-20220630" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzMyOTg1MzQ5MjAyNzM_28048dfa-68a1-4e6d-8ebd-a6190b155fc7">126</ix:nonFraction>&#160;million for fiscal 2022. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings/(loss) before income taxes for the year-to-date period to compute our benefit from income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effect of the goodwill impairment charges during the nine months ended March 31, 2022 was included in our estimated annual effective tax rate because it was not considered unusual or infrequent, given that we recorded goodwill impairment in prior fiscal years. The impact of the non-deductible goodwill significantly decreased the estimated annual effective tax rate for fiscal 2022. Applying the lower tax rate to the year-to-date loss resulted in recognizing an interim tax expense of approximately $<ix:nonFraction unitRef="usd" contextRef="i733aa2f887dc40399537d2978ea4fed6_D20210701-20220331" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzMyOTg1MzQ5MjAzMDE_f10660e7-eb4a-49d2-a8cf-f3daaa7ad9b6">1.2</ix:nonFraction>&#160;billion, which impacted the provision for income taxes in the condensed consolidated statements of earnings/(loss) during the three and nine months ended March&#160;31, 2022 and prepaid expenses and other assets in the condensed consolidated balance sheet at March&#160;31, 2022. Approximately $<ix:nonFraction unitRef="usd" contextRef="ia07b2306645b4f5b9983cc7a043e7f14_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzMyOTg1MzQ5MjAyODc_6a0a637a-bb4f-4297-970c-b8f1c7764486">180</ix:nonFraction>&#160;million of this interim tax expense will reverse in the fourth quarter of fiscal 2022.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cordis Divestiture</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2022, we completed the divestiture of the Cordis business. In connection with the closing, we recorded net tax expense of $<ix:nonFraction unitRef="usd" contextRef="if20d9caabe284cddb92eb75707c2d485_D20220101-20220331" decimals="-6" name="us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzIwMjg_b6d01f49-6d87-4ffd-9f32-6caae84671bd">9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i32f5ee07df944be68a4ca171d08f3c89_D20210701-20220331" decimals="-6" name="us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzE0ODQzNDA2OTg1ODkx_3b26dd24-57f7-4cda-a667-cc274bc0a5ea">29</ix:nonFraction>&#160;million during the three and nine months ended March&#160;31, 2022, respectively. The tax effects of these matters during the nine months ended March 31, 2022 were included in our full year effective tax rate forecast. We currently estimate the tax expense associated with this matter for the full fiscal 2022 will be $<ix:nonFraction unitRef="usd" contextRef="i55ae6d66a0154f618e5ff8b55c474990_D20210701-20220630" decimals="-6" name="us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzMyOTg1MzQ5MjA0Mzk_3456aae0-f4bd-42c8-b58c-aa59e86732e0">38</ix:nonFraction>&#160;million.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Self-Insurance Pre-tax Loss</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2021, our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fiscal 2020 statutory financial statements primarily related to opioid litigation. This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes. The net operating loss was carried back and applied to adjust our taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security ("CARES") Act enacted by the United States Congress in March 2020.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, our provision for income taxes during the nine months ended March&#160;31, 2021 included a $<ix:nonFraction unitRef="usd" contextRef="i8498a443311b4f6ea73d7b6ae59ff884_D20200701-20210331" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzMxNTQ_11b346b8-8136-43b0-b334-44ff3d983abc">419</ix:nonFraction>&#160;million benefit from the net operating loss carryback primarily to reflect the difference between the federal statutory income tax rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In fiscal 2021, we filed for a refund of $<ix:nonFraction unitRef="usd" contextRef="i7b95fd8ae52348c2a406851e857bf380_I20210630" decimals="-6" name="us-gaap:IncomeTaxReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzE1MzkzMTYyNzk4NDY0_e115854f-d3a7-40b2-b4ff-00782deb9b59">974</ix:nonFraction>&#160;million, which we expect to receive within 12 months. Accordingly, we had a current asset for this amounts on our condensed consolidated balance sheets at both March 31, 2022  and June 30, 2021. In April 2022, we received a payment for $<ix:nonFraction unitRef="usd" contextRef="i4a43d062c10d4b5dbe47ed5927846f46_D20220401-20220630" decimals="-6" name="us-gaap:ProceedsFromIncomeTaxRefunds" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzMyOTg1MzQ5MjA0NTQ_35d7dbdd-6d17-47a3-8018-9c2008a0f62e">966</ix:nonFraction>&#160;million, which is net of certain adjustments. We also increased our non-current deferred tax liability by approximately $<ix:nonFraction unitRef="usd" contextRef="i08ae81a7c49448f6a2bf594f079b609d_I20210331" decimals="-6" name="us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzM4MDM_2f50d8c6-80f4-43cf-83be-0d757fa56f10">700</ix:nonFraction>&#160;million during the nine months ended March&#160;31, 2021 related to this matter.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of tax law; however, it is possible that the tax authorities could challenge these tax benefits. The actual amount of the tax benefit may differ materially from these estimates.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Opioid Litigation Charges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the $<ix:nonFraction unitRef="usd" contextRef="i7cfeb36a6e0d45f8aa734c1879638433_D20200701-20210331" decimals="-6" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzQyMTk_edd60dcc-f530-4718-a7b4-a3f66549c5f2">1.02</ix:nonFraction>&#160;billion pre-tax charges for the opioid litigation recorded during the nine months ended March&#160;31, 2021, the net tax benefits were approximately $<ix:nonFraction unitRef="usd" contextRef="i7cfeb36a6e0d45f8aa734c1879638433_D20200701-20210331" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzQzMzE_983cae9a-c436-447f-b47d-33107b1335e8">180</ix:nonFraction> million for the nine months ended March&#160;31, 2021 and $<ix:nonFraction unitRef="usd" contextRef="i4c3e04c844a0448ba87bfb01fae49ef6_D20200701-20210630" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzQzNTI_b7b49c3b-0c4a-4364-989f-abb255618e4f">228</ix:nonFraction> million for fiscal 2021. Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $<ix:nonFraction unitRef="usd" contextRef="i6880faa0fa0e4239896a55f349c38f00_I20210331" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzQ2MTk_08206bcb-e406-42a9-99d1-e28d1e37682b">35</ix:nonFraction> million during the nine months ended March&#160;31, 2021, and $<ix:nonFraction unitRef="usd" contextRef="i469fd276126b4ef2a0a27b313a8c926f_I20210630" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzQ2NDQ_ec67321f-bf5c-41ea-a10b-95581ce091dd">219</ix:nonFraction> million for fiscal 2021. We have recognized <ix:nonFraction unitRef="usd" contextRef="i0247bbb36fd244a09bc9d98fe2b16dcb_D20210701-20220331" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzQ2ODM_ade3f799-a3a8-4a20-b183-6ca9c8535603">no</ix:nonFraction> tax benefit associated with Opioid accruals made in fiscal 2022. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the U.S. Tax Cuts and Jobs Act ("Tax Act"); however, these estimates require significant judgment since the U.S. tax law governing deductibility was changed by the Tax Act. Further, it is possible Congress or the tax authorities could challenge our interpretation of the Tax Act or the estimates and assumptions used to assess the future deductibility of these benefits. The actual amount of the tax benefit may differ materially from these estimates.</span></div></div></ix:continuation></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="i767a82f42f764909ad9610bd8e21e018" continuedAt="i7f35aa4cb6ee4b0f90ad10a2760b4fc1"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrecognized Tax Benefits</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $<ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzY0OTA_c3c61e95-6a4f-4b4e-b29e-b3325bba9fe2">938</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzY0OTc_2be0e674-5706-48d0-8989-328427251521">932</ix:nonFraction> million of unrecognized tax benefits, at March&#160;31, 2022 and June&#160;30, 2021 respectively. The March&#160;31, 2022 and June&#160;30, 2021 balances include $<ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzY1ODg_5ef1a189-18b8-43f6-bde7-51e36bafc40d">856</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzY1OTU_c84a43f3-92fd-49c4-95ac-af063e62c195">849</ix:nonFraction> million of unrecognized tax benefits, respectively, that if recognized, would have an impact on the effective tax rate. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2022 and June&#160;30, 2021, we had $<ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzY3MzI_ac53703a-edb5-4dce-ae43-a07506d7c75c">46</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzY3Mzk_68b9bbae-11e2-433e-b0af-b45941403445">49</ix:nonFraction> million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for/(benefit from) income taxes in the condensed consolidated statements of earnings/(loss). These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the IRS or other taxing authorities, possible settlement of IRS and other audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between <ix:nonFraction unitRef="usd" contextRef="i34b741e645b547cba1a09aef122491a7_I20220331" decimals="-6" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzc2MTU_13b92bcf-0963-4c3d-a6a6-7004ac761e0d">zero</ix:nonFraction> and a net decrease of up to $<ix:nonFraction unitRef="usd" contextRef="i19311f0a545a45fabf7564bb3e12fa8f_I20220331" decimals="-6" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzc2NDY_056cc14f-6b69-41e6-abf8-24196e072c94">5</ix:nonFraction> million, exclusive of penalties and interest.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Tax Matters</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions, and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through 2020.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expiring or unusable loss and credit carryforwards and the required valuation allowances are adjusted quarterly based on available information. This information may support either an increase or a decrease in the required valuation allowance. After applying the valuation allowances, we do not anticipate any limitations on our use of any of the other net deferred income tax assets described above. We operate in a complex multinational tax environment and are subject to tax treaty arrangements and transfer pricing guidelines for intercompany transactions that are subject to interpretation. Uncertainty in a tax position may arise as tax laws are subject to interpretation.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), a subsidiary of Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $<ix:nonFraction unitRef="usd" contextRef="i97ee2fe5350d48a8a6d2429ec7ce8ba3_I20220331" decimals="-6" name="cah:IndemnificationReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzgyNzQ_b31d66f7-704f-4ddb-ae7e-0b55ae3dd6df">73</ix:nonFraction> million at March&#160;31, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i97c5d03ddc3b4285af82f4a8cdd73077_I20210630" decimals="-6" name="cah:IndemnificationReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzMyOTg1MzQ5MjA0Njg_cc8b9bd4-33cd-4da0-bb89-89d2bf7ca03f">72</ix:nonFraction>&#160;million at June&#160;30, 2021, and is included in other assets in the condensed consolidated balance sheets.</span></div></ix:continuation></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7f35aa4cb6ee4b0f90ad10a2760b4fc1">As a result of the acquisition of the Patient Recovery Business, Medtronic plc is obligated to indemnify us for certain tax exposures and transaction taxes related to periods prior to the acquisition under the purchase agreement. The indemnification receivable was <ix:nonFraction unitRef="usd" contextRef="ib619e74f426d4144819daac0dcea199d_I20220331" decimals="-6" name="cah:IndemnificationReceivable" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzMyOTg1MzQ5MjA0ODg_a1b81f33-01e4-4d2a-858f-8262a3b8abba">zero</ix:nonFraction> at March&#160;31, 2022 and $<ix:nonFraction unitRef="usd" contextRef="iabd8bb008ac74a12a6602b75f99f57be_I20210630" decimals="-6" name="cah:IndemnificationReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzg2NTI_835ea7f6-7b50-4039-8c7e-86101c2feeb6">12</ix:nonFraction>&#160;million at June&#160;30, 2021, respectively, and is included in other assets in the condensed consolidated balance sheets.</ix:continuation></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div id="iaf3733bf892b435689161c61a06da348_109"></div><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90ZXh0cmVnaW9uOmFmNzhiYmNhOWQ2NTRjZjRhYTkyZGZmYWYyNDYwMTI5XzEyMTU_f74047b3-e58b-44e3-93d0-f37eb4d94797" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">8. Fair Value Measurements</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90ZXh0cmVnaW9uOmFmNzhiYmNhOWQ2NTRjZjRhYTkyZGZmYWYyNDYwMTI5XzEyMjI_bed1497a-76d7-4c2d-ae9f-8c59aeda9b50" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a166264477c46fab57fcf607e059c5e_I20220331" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZTo1ZDI4MzY4MzExNTk0NGU0YTAxNjBkOTBjMTRjOTY4NS90YWJsZXJhbmdlOjVkMjgzNjgzMTE1OTQ0ZTRhMDE2MGQ5MGMxNGM5Njg1XzMtMS0xLTEtOTg2OTQ_5a6bc57f-7974-4edf-99de-f0c4d9966945">671</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3682e4eb8a05493a929d3c71c120ed44_I20220331" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZTo1ZDI4MzY4MzExNTk0NGU0YTAxNjBkOTBjMTRjOTY4NS90YWJsZXJhbmdlOjVkMjgzNjgzMTE1OTQ0ZTRhMDE2MGQ5MGMxNGM5Njg1XzMtMy0xLTEtOTg2OTQ_c336dac7-c8d7-4af6-abcb-bbab21116289">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic39a5057fc6f46779de6e92cbbdcda7a_I20220331" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZTo1ZDI4MzY4MzExNTk0NGU0YTAxNjBkOTBjMTRjOTY4NS90YWJsZXJhbmdlOjVkMjgzNjgzMTE1OTQ0ZTRhMDE2MGQ5MGMxNGM5Njg1XzMtNS0xLTEtOTg2OTQ_57755524-a029-4fbf-8a3f-c0a1cac5984a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icac6fea690094cec98b24894f11a9dc5_I20220331" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZTo1ZDI4MzY4MzExNTk0NGU0YTAxNjBkOTBjMTRjOTY4NS90YWJsZXJhbmdlOjVkMjgzNjgzMTE1OTQ0ZTRhMDE2MGQ5MGMxNGM5Njg1XzMtNy0xLTEtOTg2OTQ_8729ff9e-7506-4131-a43d-b9367a2a2022">671</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a166264477c46fab57fcf607e059c5e_I20220331" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZTo1ZDI4MzY4MzExNTk0NGU0YTAxNjBkOTBjMTRjOTY4NS90YWJsZXJhbmdlOjVkMjgzNjgzMTE1OTQ0ZTRhMDE2MGQ5MGMxNGM5Njg1XzUtMS0xLTEtOTg2OTQ_45247b22-25d4-4345-b823-16dfc619bda9">112</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3682e4eb8a05493a929d3c71c120ed44_I20220331" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZTo1ZDI4MzY4MzExNTk0NGU0YTAxNjBkOTBjMTRjOTY4NS90YWJsZXJhbmdlOjVkMjgzNjgzMTE1OTQ0ZTRhMDE2MGQ5MGMxNGM5Njg1XzUtMy0xLTEtOTg2OTQ_9d506670-f399-42f8-9ea0-243bb3eca78c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic39a5057fc6f46779de6e92cbbdcda7a_I20220331" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZTo1ZDI4MzY4MzExNTk0NGU0YTAxNjBkOTBjMTRjOTY4NS90YWJsZXJhbmdlOjVkMjgzNjgzMTE1OTQ0ZTRhMDE2MGQ5MGMxNGM5Njg1XzUtNS0xLTEtOTg2OTQ_3d063113-7483-4cd8-88c7-1b82573fa947">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icac6fea690094cec98b24894f11a9dc5_I20220331" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZTo1ZDI4MzY4MzExNTk0NGU0YTAxNjBkOTBjMTRjOTY4NS90YWJsZXJhbmdlOjVkMjgzNjgzMTE1OTQ0ZTRhMDE2MGQ5MGMxNGM5Njg1XzUtNy0xLTEtOTg2OTQ_44449764-84b0-449a-a095-586dc67f3b86">112</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a166264477c46fab57fcf607e059c5e_I20220331" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZTo1ZDI4MzY4MzExNTk0NGU0YTAxNjBkOTBjMTRjOTY4NS90YWJsZXJhbmdlOjVkMjgzNjgzMTE1OTQ0ZTRhMDE2MGQ5MGMxNGM5Njg1XzgtMS0xLTEtMTM4OTMx_5d4ae2fd-818b-4cac-b789-f2d0086a9d97">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3682e4eb8a05493a929d3c71c120ed44_I20220331" decimals="-6" sign="-" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZTo1ZDI4MzY4MzExNTk0NGU0YTAxNjBkOTBjMTRjOTY4NS90YWJsZXJhbmdlOjVkMjgzNjgzMTE1OTQ0ZTRhMDE2MGQ5MGMxNGM5Njg1XzgtMy0xLTEtMTM4OTM0_5565fd4c-801a-4ba5-81fc-fa8389d297e1">12</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic39a5057fc6f46779de6e92cbbdcda7a_I20220331" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZTo1ZDI4MzY4MzExNTk0NGU0YTAxNjBkOTBjMTRjOTY4NS90YWJsZXJhbmdlOjVkMjgzNjgzMTE1OTQ0ZTRhMDE2MGQ5MGMxNGM5Njg1XzgtNS0xLTEtMTM4OTM3_df8a4f14-107b-4412-a8d6-1f2edfb7d96e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icac6fea690094cec98b24894f11a9dc5_I20220331" decimals="-6" sign="-" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZTo1ZDI4MzY4MzExNTk0NGU0YTAxNjBkOTBjMTRjOTY4NS90YWJsZXJhbmdlOjVkMjgzNjgzMTE1OTQ0ZTRhMDE2MGQ5MGMxNGM5Njg1XzgtNy0xLTEtMTM4OTQw_7b3bdcc2-b68c-4290-8087-0d1f3862e9ee">12</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6a713b79a1b4db391a01b08a7955833_I20210630" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZToyYzMwNWU2ZWUyMDc0YTM2YWY3YjljNThhMjM5YTE1Ni90YWJsZXJhbmdlOjJjMzA1ZTZlZTIwNzRhMzZhZjdiOWM1OGEyMzlhMTU2XzMtMS0xLTEtOTg2OTQ_07a3b8a3-9489-4b62-aeeb-2d503f9e797d">1,883</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dd0cc9f485540cfba812a2f569e0eec_I20210630" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZToyYzMwNWU2ZWUyMDc0YTM2YWY3YjljNThhMjM5YTE1Ni90YWJsZXJhbmdlOjJjMzA1ZTZlZTIwNzRhMzZhZjdiOWM1OGEyMzlhMTU2XzMtMy0xLTEtOTg2OTQ_a09fbbfe-8d51-4daa-8d61-3c703c02c293">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6b241993ad04feca1177de9a32b41d8_I20210630" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZToyYzMwNWU2ZWUyMDc0YTM2YWY3YjljNThhMjM5YTE1Ni90YWJsZXJhbmdlOjJjMzA1ZTZlZTIwNzRhMzZhZjdiOWM1OGEyMzlhMTU2XzMtNS0xLTEtOTg2OTQ_25dee99e-6e56-4d8c-9bd1-f2edc4c58865">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8196f6a78b04b869ddf71567a35ba1e_I20210630" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZToyYzMwNWU2ZWUyMDc0YTM2YWY3YjljNThhMjM5YTE1Ni90YWJsZXJhbmdlOjJjMzA1ZTZlZTIwNzRhMzZhZjdiOWM1OGEyMzlhMTU2XzMtNy0xLTEtOTg2OTQ_8e6b1801-17b3-4829-8da9-5fc0b65b36fa">1,883</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6a713b79a1b4db391a01b08a7955833_I20210630" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZToyYzMwNWU2ZWUyMDc0YTM2YWY3YjljNThhMjM5YTE1Ni90YWJsZXJhbmdlOjJjMzA1ZTZlZTIwNzRhMzZhZjdiOWM1OGEyMzlhMTU2XzUtMS0xLTEtOTg2OTQ_29ce876b-18ae-4ee5-bf13-e4d246b178a7">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dd0cc9f485540cfba812a2f569e0eec_I20210630" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZToyYzMwNWU2ZWUyMDc0YTM2YWY3YjljNThhMjM5YTE1Ni90YWJsZXJhbmdlOjJjMzA1ZTZlZTIwNzRhMzZhZjdiOWM1OGEyMzlhMTU2XzUtMy0xLTEtOTg2OTQ_ea75c283-6b99-411f-a594-a626454c6327">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6b241993ad04feca1177de9a32b41d8_I20210630" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZToyYzMwNWU2ZWUyMDc0YTM2YWY3YjljNThhMjM5YTE1Ni90YWJsZXJhbmdlOjJjMzA1ZTZlZTIwNzRhMzZhZjdiOWM1OGEyMzlhMTU2XzUtNS0xLTEtOTg2OTQ_599e53a3-a27d-4d95-aca1-ee0ed1c1c21e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8196f6a78b04b869ddf71567a35ba1e_I20210630" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZToyYzMwNWU2ZWUyMDc0YTM2YWY3YjljNThhMjM5YTE1Ni90YWJsZXJhbmdlOjJjMzA1ZTZlZTIwNzRhMzZhZjdiOWM1OGEyMzlhMTU2XzUtNy0xLTEtOTg2OTQ_e94b23af-99ca-4093-88d8-a8fa98230a1f">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6a713b79a1b4db391a01b08a7955833_I20210630" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZToyYzMwNWU2ZWUyMDc0YTM2YWY3YjljNThhMjM5YTE1Ni90YWJsZXJhbmdlOjJjMzA1ZTZlZTIwNzRhMzZhZjdiOWM1OGEyMzlhMTU2XzYtMS0xLTEtOTg2OTQ_bfa7a210-9075-4f6d-8a83-3d60f64f01d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dd0cc9f485540cfba812a2f569e0eec_I20210630" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZToyYzMwNWU2ZWUyMDc0YTM2YWY3YjljNThhMjM5YTE1Ni90YWJsZXJhbmdlOjJjMzA1ZTZlZTIwNzRhMzZhZjdiOWM1OGEyMzlhMTU2XzYtMy0xLTEtOTg2OTQ_822afb06-66c9-4cbb-a4ae-62d8a6da689a">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6b241993ad04feca1177de9a32b41d8_I20210630" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZToyYzMwNWU2ZWUyMDc0YTM2YWY3YjljNThhMjM5YTE1Ni90YWJsZXJhbmdlOjJjMzA1ZTZlZTIwNzRhMzZhZjdiOWM1OGEyMzlhMTU2XzYtNS0xLTEtOTg2OTQ_a4dcee88-4081-47ac-bfab-d850f4c18ff3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8196f6a78b04b869ddf71567a35ba1e_I20210630" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZToyYzMwNWU2ZWUyMDc0YTM2YWY3YjljNThhMjM5YTE1Ni90YWJsZXJhbmdlOjJjMzA1ZTZlZTIwNzRhMzZhZjdiOWM1OGEyMzlhMTU2XzYtNy0xLTEtOTg2OTQ_d177cdc3-a260-4640-a604-77c6cad73e57">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.</span></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div id="iaf3733bf892b435689161c61a06da348_112"></div><ix:nonNumeric contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzc5MDY_b61595a5-6be4-4992-be29-aeeb0aa86aed" continuedAt="i868d19163b42479f8bba7ef280f53de3" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">9. Financial Instruments </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative </span></div></ix:nonNumeric></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><ix:continuation id="i868d19163b42479f8bba7ef280f53de3" continuedAt="id2afb38e07884f8fa8fa4fb955f3fbca"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Interest Rate Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities along with both fixed-rate and variable-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Currency Exchange Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commodity Price Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of earnings/(loss). For the three and nine months ended March&#160;31, 2022 and 2021, there was <ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzMyNzM_2166a6d4-1d4f-4c11-990b-01c2ef8e3f6b"><ix:nonFraction unitRef="usd" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzMyNzM_8557b0d3-fc96-41de-9c2a-1e3aee3a4579"><ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzMyNzM_a3e318fa-1484-4094-8503-2ffff8317b14"><ix:nonFraction unitRef="usd" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzMyNzM_b0bc40f6-9b7a-43bc-992b-57240c074402">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> gain or loss recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the nine months ended March 31, 2022, we entered into pay-floating interest rate swaps with notional amounts of $<ix:nonFraction unitRef="usd" contextRef="ied79b20d51d24a52ac6760b96c790928_I20210930" decimals="-6" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzM1MzA_98ad61f4-693a-45e3-ad65-8d61e0fab5ac">100</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id3ce5b3abcbd46bd97aab3629e9beed9_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzM1Mzc_dad4f46b-1424-4f2e-91e6-cbdeba51fd4f">200</ix:nonFraction> million. These swaps have been designated as fair value hedges of our fixed rate debt and are included in </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">deferred income taxes and other liabilities in the condensed consolidated balance sheets.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cash Flow Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax gains recognized in other comprehensive loss were $<ix:nonFraction unitRef="usd" contextRef="i3c0359ac173741d1a3e87605773843bb_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzQ0MDI_21c61452-9b83-45f4-89a2-2053e2d7b2c6">1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i9364c217c27b48f7b6d55997d6363b7d_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzQ0MDk_86aa8d61-dfae-4ce5-a0a5-1a0a4bbb9c81">13</ix:nonFraction>&#160;million for the three months ended March&#160;31, 2022 and 2021, respectively, and $<ix:nonFraction unitRef="usd" contextRef="ia89d064616e44ff0bc7a6c819fa695aa_D20210701-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzQ0NzA_22da46cd-f97e-4b5c-988f-aeeaadc9fe73">4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ibb3a9b89882f4cad85e3415fe62bbe64_D20200701-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzQ0Nzc_65f181e9-2765-4f6d-913a-ec90da0324c1">20</ix:nonFraction>&#160;million for the nine months ended March&#160;31, 2022 and 2021, respectively. Gains and losses recognized in accumulated other comprehensive loss and reclassified into earnings were immaterial for the three and nine months ended March&#160;31, 2022 and 2021. All gains and losses currently included within accumulated other comprehensive loss associated with our cash flow hedges to be reclassified into net earnings within the next 12 months are immaterial.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net Investment Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended&#160;March&#160;31, 2022, we entered into a &#165;<ix:nonFraction unitRef="jpy" contextRef="ic064a2bc08564367b783b55fd00e3a4c_I20220331" decimals="-6" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzcxNDY4MjU1ODg2MTA_ed84531b-84f5-4b79-aed4-727b84949cbb">24</ix:nonFraction> billion ($<ix:nonFraction unitRef="usd" contextRef="ic064a2bc08564367b783b55fd00e3a4c_I20220331" decimals="-6" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzcxNDY4MjU1ODg2MzE_a8c0eb08-e28b-4281-bad6-8d1c6cd38725">200</ix:nonFraction> million) cross-currency swap maturing in September 2025 and a &#165;<ix:nonFraction unitRef="jpy" contextRef="id24201ce4b9a45b3984c1578539f4366_I20220331" decimals="-6" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzMyOTg1MzQ4OTIyNDU_470dc0e2-31bb-442c-8e48-29973e6bc681">24</ix:nonFraction>&#160;billion ($<ix:nonFraction unitRef="usd" contextRef="id24201ce4b9a45b3984c1578539f4366_I20220331" decimals="-6" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzMyOTg1MzQ4OTIyMTk_36d3864c-3e25-4f50-88a4-1d3495651dcc">200</ix:nonFraction>&#160;million) cross-currency swap maturing in June 2027.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended&#160;March&#160;31, 2022, we terminated the &#165;<ix:nonFraction unitRef="jpy" contextRef="i5481aab2ab274715b2e24d13110e9131_I20220331" decimals="-6" name="cah:DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzcxNDY4MjU1ODg5MzI_23a464ca-7ae1-4090-bb2d-84c7d178ec05">64</ix:nonFraction> billion ($<ix:nonFraction unitRef="usd" contextRef="i5481aab2ab274715b2e24d13110e9131_I20220331" decimals="-6" name="cah:DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzcxNDY4MjU1ODg5NDg_b8f4315b-41d0-4a28-bea4-1505629516cb">600</ix:nonFraction> million) cross-currency swap entered into in August 2019 and received a net settlement of $<ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:ProceedsFromHedgeInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzcxNDY4MjU1ODkwODU_4286d028-1846-46c9-a8e2-0694cc29cba2">71</ix:nonFraction> million in cash recorded in proceeds from net investment hedge terminations in our condensed consolidated statements of cash flows. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax gain and loss from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive loss was a $<ix:nonFraction unitRef="usd" contextRef="ia6a258e1b3d647dab58b5794f710d928_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzU3ODM_5d3c39d8-e08b-4dd1-bd05-b97a43390310">22</ix:nonFraction>&#160;million gain and a $<ix:nonFraction unitRef="usd" contextRef="i5c5d8170ec134e538d16a98b7645242a_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzU3OTc_ab3efc38-f266-4447-82a4-b53e12218fd0">49</ix:nonFraction>&#160;million gain during the three months ended March&#160;31, 2022 and 2021, respectively, and a $<ix:nonFraction unitRef="usd" contextRef="ie780eda2dbfa43b5ba1886064e5bee88_D20210701-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzU4NjY_664ee8b3-460c-4d0c-b757-6546b2fad0c5">44</ix:nonFraction>&#160;million gain and a $<ix:nonFraction unitRef="usd" contextRef="i8b561ae116c44487bc2d0b64415c487c_D20200701-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzU4ODA_22810f98-77d3-441a-a15b-f4840de80079">3</ix:nonFraction>&#160;million loss during the nine months ended March&#160;31, 2022 and 2021, respectively. Gains </span></div></div></ix:continuation></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="id2afb38e07884f8fa8fa4fb955f3fbca"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognized in interest expense, net in the condensed consolidated statements of earnings/(loss) for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were $<ix:nonFraction unitRef="usd" contextRef="ia6a258e1b3d647dab58b5794f710d928_D20220101-20220331" decimals="-6" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzIxOTkwMjMyNjM1MjE_c5b57aff-2d23-4b19-8b3a-0ab86c8e9f8a"><ix:nonFraction unitRef="usd" contextRef="i5c5d8170ec134e538d16a98b7645242a_D20210101-20210331" decimals="-6" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzIxOTkwMjMyNjM1MjE_e36de2fb-73c4-4696-a3f7-3f00b596cb98">5</ix:nonFraction></ix:nonFraction>&#160;million during both the three months ended March&#160;31, 2022 and 2021 and $<ix:nonFraction unitRef="usd" contextRef="ie780eda2dbfa43b5ba1886064e5bee88_D20210701-20220331" decimals="-6" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzYxNzY_7be7a33a-0f5a-4f8a-931f-20396f1a48d8">16</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i8b561ae116c44487bc2d0b64415c487c_D20200701-20210331" decimals="-6" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzYxODM_adf0db81-0fdc-4d93-9aed-f80fdd0b7a26">14</ix:nonFraction>&#160;million during the nine months ended March&#160;31, 2022 and 2021, respectively. </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Economic (Non-Designated) Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. We recorded a $<ix:nonFraction unitRef="usd" contextRef="id3d6a7b343d84263bcfd5f6081c9080a_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzcwMDQ_b5bc943c-7811-4af3-83cf-ef161fc0672a">4</ix:nonFraction> million loss and a $<ix:nonFraction unitRef="usd" contextRef="i5f6a2249983a48ba948782ea8ac398ae_D20210101-20210331" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzcwMTg_8addda90-88ba-41bb-ba48-d846096c8918">1</ix:nonFraction> million gain during the three months ended March 31, 2022 and 2021, respectively, and an immaterial loss and $<ix:nonFraction unitRef="usd" contextRef="ida3f04fa5227480f833bb171bc91c08c_D20200701-20210331" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzcwOTk_493642fb-c46d-4135-9470-7e211d4a6e18">4</ix:nonFraction> million loss during the nine months ended March&#160;31, 2022 and 2021, respectively. The principal currencies managed through foreign currency contracts are Euro, Chinese renminbi, Canadian dollar.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and equivalents, trade receivables, accounts payable, and other accrued liabilities at March&#160;31, 2022 and June&#160;30, 2021 approximate fair value due to their short-term maturities.</span></div><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzc5MTU_4bb0662f-ccca-4a3c-8736-8c40d1699b38" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.109%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.986%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated fair value</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faba6dab9bb45eba4532f90d44b6e37_I20220331" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90YWJsZTo5YTliZTJmMDk0MDk0MDExODUxYWI0Mjk5MTFkMDA4Mi90YWJsZXJhbmdlOjlhOWJlMmYwOTQwOTQwMTE4NTFhYjQyOTkxMWQwMDgyXzEtMS0xLTEtOTg2OTQ_b4d1bbac-02ae-4e54-80d7-bd236ca7f490">5,645</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddd5f86516724f048fca712cc799eb64_I20210630" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90YWJsZTo5YTliZTJmMDk0MDk0MDExODUxYWI0Mjk5MTFkMDA4Mi90YWJsZXJhbmdlOjlhOWJlMmYwOTQwOTQwMTE4NTFhYjQyOTkxMWQwMDgyXzEtMy0xLTEtOTg2OTQ_40079c2b-70b3-461a-8f8c-ddc9ee8a0b3a">6,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying amount</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="cah:CarryingAmountofLongTermandotherShortTermBorrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90YWJsZTo5YTliZTJmMDk0MDk0MDExODUxYWI0Mjk5MTFkMDA4Mi90YWJsZXJhbmdlOjlhOWJlMmYwOTQwOTQwMTE4NTFhYjQyOTkxMWQwMDgyXzItMS0xLTEtOTg2OTQ_83371a17-6407-4372-baff-ccccb0c36050">5,612</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="cah:CarryingAmountofLongTermandotherShortTermBorrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90YWJsZTo5YTliZTJmMDk0MDk0MDExODUxYWI0Mjk5MTFkMDA4Mi90YWJsZXJhbmdlOjlhOWJlMmYwOTQwOTQwMTE4NTFhYjQyOTkxMWQwMDgyXzItMy0xLTEtOTg2OTQ_ed61e05c-e062-4ece-a3a9-5b1658fa9dd3">6,236</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.</span></div></ix:continuation><div id="iaf3733bf892b435689161c61a06da348_115"></div><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90ZXh0cmVnaW9uOmUzYmJiNmRhNjY3NTRhZTliNzFiNmRkYzU4Y2QwYjYwXzEyMTY_637e27ed-0794-4522-91ea-365f34f2445b" continuedAt="i6add161f9c364cf99528d3d3e5dd19dc" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">10. Shareholders' Equity/(Deficit)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We repurchased $<ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90ZXh0cmVnaW9uOmUzYmJiNmRhNjY3NTRhZTliNzFiNmRkYzU4Y2QwYjYwXzI0_3831f46b-75b8-4b65-a1ee-3c2dabca1049">1.0</ix:nonFraction>&#160;billion of our common shares, in the aggregate, through share repurchase programs during the nine months ended March&#160;31, 2022. We funded the repurchases with available cash. The common shares repurchased are held in treasury to be used for general corporate purposes.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022, we entered into an accelerated share repurchase ("ASR") program to repurchase common shares for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i4a80329f29594c698d9ee74e1eaacbbe_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90ZXh0cmVnaW9uOmUzYmJiNmRhNjY3NTRhZTliNzFiNmRkYzU4Y2QwYjYwXzc2OTY1ODEzOTYxMDQ_491620b1-1c8a-4cd6-bca1-8635a37d6660">200</ix:nonFraction> million. </span></div></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="i6add161f9c364cf99528d3d3e5dd19dc"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received an initial delivery of <ix:nonFraction unitRef="shares" contextRef="i3bd39d7063da4c278767bc202d3ccfc3_D20220101-20220331" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90ZXh0cmVnaW9uOmUzYmJiNmRhNjY3NTRhZTliNzFiNmRkYzU4Y2QwYjYwXzc2OTY1ODEzOTYxMDk_b60ce76f-c995-46ab-8e84-c2532dc8056b">3.0</ix:nonFraction> million common shares using a reference price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i3bd39d7063da4c278767bc202d3ccfc3_D20220101-20220331" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90ZXh0cmVnaW9uOmUzYmJiNmRhNjY3NTRhZTliNzFiNmRkYzU4Y2QwYjYwXzc2OTY1ODEzOTYxMTQ_ffa1ff47-afaa-4f28-b5a0-97e6926b03fa">54.01</ix:nonFraction>. The program concluded on April 18, 2022 at a volume weighted average price per common share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i88bcf45d478a46e4b22b402f4b7f54c3_D20220401-20220630" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90ZXh0cmVnaW9uOmUzYmJiNmRhNjY3NTRhZTliNzFiNmRkYzU4Y2QwYjYwXzc2OTY1ODEzOTYxNjU_05ee8c00-a37f-44f1-b1cd-d2b715cb8a1c">56.02</ix:nonFraction> resulting in a final delivery of <ix:nonFraction unitRef="shares" contextRef="i88bcf45d478a46e4b22b402f4b7f54c3_D20220401-20220630" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90ZXh0cmVnaW9uOmUzYmJiNmRhNjY3NTRhZTliNzFiNmRkYzU4Y2QwYjYwXzc2OTY1ODEzOTYxNjk_e7f5a586-e334-4067-a9aa-34ade3f5ad82">0.6</ix:nonFraction> million common shares.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December 31, 2021, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i79f0c6d48d9042059a71690df0625736_D20211001-20211231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90ZXh0cmVnaW9uOmUzYmJiNmRhNjY3NTRhZTliNzFiNmRkYzU4Y2QwYjYwXzQzNQ_64a9fece-fd6e-420f-91b2-8b4dc583125a">300</ix:nonFraction>&#160;million. We received an initial delivery of <ix:nonFraction unitRef="shares" contextRef="id0bcebad12fc4c40a4b459a431f9432e_D20211001-20211231" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90ZXh0cmVnaW9uOmUzYmJiNmRhNjY3NTRhZTliNzFiNmRkYzU4Y2QwYjYwXzQ3NA_b1cf531b-f8bc-4212-ab03-44fa4f994195">4.8</ix:nonFraction> million common shares using a reference price of $<ix:nonFraction unitRef="usdPerShare" contextRef="id0bcebad12fc4c40a4b459a431f9432e_D20211001-20211231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90ZXh0cmVnaW9uOmUzYmJiNmRhNjY3NTRhZTliNzFiNmRkYzU4Y2QwYjYwXzUxOA_a7d816fb-c1e0-4e73-a781-d7c74b11c87d">50.30</ix:nonFraction>. The program concluded on January 31, 2022 at a volume weighted average price per common share of $<ix:nonFraction unitRef="usdPerShare" contextRef="idb40345a5fe44f68828da6e24128f448_D20220101-20220331" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90ZXh0cmVnaW9uOmUzYmJiNmRhNjY3NTRhZTliNzFiNmRkYzU4Y2QwYjYwXzYwNQ_d303f17c-6e71-4a62-9522-cf6d9d5308f9">49.39</ix:nonFraction> resulting in a final delivery of <ix:nonFraction unitRef="shares" contextRef="idb40345a5fe44f68828da6e24128f448_D20220101-20220331" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90ZXh0cmVnaW9uOmUzYmJiNmRhNjY3NTRhZTliNzFiNmRkYzU4Y2QwYjYwXzY0MQ_19162380-0d76-414b-b32b-1d9379a729d0">1.3</ix:nonFraction> million common shares.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2021, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="ice6d3b2a080d44b5b66bace596c4726a_D20210701-20210930" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90ZXh0cmVnaW9uOmUzYmJiNmRhNjY3NTRhZTliNzFiNmRkYzU4Y2QwYjYwXzgwMw_2aecc427-6ef6-40e8-a4d6-fda8c514ed76">500</ix:nonFraction>&#160;million. We received an initial delivery of <ix:nonFraction unitRef="shares" contextRef="i493db659fb0e48c29fa86341836956fb_D20210701-20210930" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90ZXh0cmVnaW9uOmUzYmJiNmRhNjY3NTRhZTliNzFiNmRkYzU4Y2QwYjYwXzg0Mg_49b94844-7ee9-441f-add8-9694ec9fe8d3">7.8</ix:nonFraction> million common shares using a reference price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i493db659fb0e48c29fa86341836956fb_D20210701-20210930" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90ZXh0cmVnaW9uOmUzYmJiNmRhNjY3NTRhZTliNzFiNmRkYzU4Y2QwYjYwXzg4Ng_75671f0a-824c-4bf3-b777-ad5cbb12f598">51.53</ix:nonFraction>. The program concluded on October 4, 2021 at a volume weighted average price per common share of $<ix:nonFraction unitRef="usdPerShare" contextRef="id7b83872d6a44abb948f2abd62a0d67d_D20211001-20211231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90ZXh0cmVnaW9uOmUzYmJiNmRhNjY3NTRhZTliNzFiNmRkYzU4Y2QwYjYwXzk4Ng_1e8726ca-60b5-41bb-ab61-7e7b7a2a3e6f">51.10</ix:nonFraction> resulting in a final delivery of <ix:nonFraction unitRef="shares" contextRef="id7b83872d6a44abb948f2abd62a0d67d_D20211001-20211231" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90ZXh0cmVnaW9uOmUzYmJiNmRhNjY3NTRhZTliNzFiNmRkYzU4Y2QwYjYwXzEwMjI_6be65f9b-32e9-4e17-850e-e356f5ed3ed3">2.0</ix:nonFraction> million common shares. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90ZXh0cmVnaW9uOmUzYmJiNmRhNjY3NTRhZTliNzFiNmRkYzU4Y2QwYjYwXzEwNDQ1MzYwNDY5MzA3_ab749c49-3050-41ad-9f0c-fcd9c2eb219d">200</ix:nonFraction>&#160;million. The program began on February 9, 2021 and concluded on March 31, 2021. The average price paid per common share was $<ix:nonFraction unitRef="usdPerShare" contextRef="i12146da7d33541d09f9ef291e388a502_D20210101-20210331" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90ZXh0cmVnaW9uOmUzYmJiNmRhNjY3NTRhZTliNzFiNmRkYzU4Y2QwYjYwXzEwNDQ1MzYwNDY5MzIw_8b09ed22-0dc4-4bba-aa41-b7cd61b77b3a">54.40</ix:nonFraction>, resulting in a total delivery of <ix:nonFraction unitRef="shares" contextRef="i12146da7d33541d09f9ef291e388a502_D20210101-20210331" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90ZXh0cmVnaW9uOmUzYmJiNmRhNjY3NTRhZTliNzFiNmRkYzU4Y2QwYjYwXzEwNDQ1MzYwNDY5MzM0_8e484754-ab8a-4b38-b361-512f024a44a9">3.7</ix:nonFraction> million common shares.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></div><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90ZXh0cmVnaW9uOmUzYmJiNmRhNjY3NTRhZTliNzFiNmRkYzU4Y2QwYjYwXzEyMTA_6629bc2f-16ac-4edc-a478-2d20658c706c" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.492%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1bc04df5c22d4ac594b0f37e4348fad8_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90YWJsZToyYWYzMGFkOWEwYTU0YjdmYjE3OGNlMDQ3MGU0MzFmOS90YWJsZXJhbmdlOjJhZjMwYWQ5YTBhNTRiN2ZiMTc4Y2UwNDcwZTQzMWY5XzEtMS0xLTEtOTg2OTQ_42638427-7673-45ae-be5c-f9ce4f162a00">46</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1d975e32208495384d3c3f118607978_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90YWJsZToyYWYzMGFkOWEwYTU0YjdmYjE3OGNlMDQ3MGU0MzFmOS90YWJsZXJhbmdlOjJhZjMwYWQ5YTBhNTRiN2ZiMTc4Y2UwNDcwZTQzMWY5XzEtMy0xLTEtOTg2OTQ_fa24d933-a4fc-40ed-9f3b-909c54a1e0aa">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib919fba7df9a4af5a962444ad795f36e_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90YWJsZToyYWYzMGFkOWEwYTU0YjdmYjE3OGNlMDQ3MGU0MzFmOS90YWJsZXJhbmdlOjJhZjMwYWQ5YTBhNTRiN2ZiMTc4Y2UwNDcwZTQzMWY5XzEtNS0xLTEtOTg2OTQ_cccd7ad7-e5ee-4133-9280-eec976acf769">34</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85dc1b14fefe4551abd5390650b6c712_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90YWJsZToyYWYzMGFkOWEwYTU0YjdmYjE3OGNlMDQ3MGU0MzFmOS90YWJsZXJhbmdlOjJhZjMwYWQ5YTBhNTRiN2ZiMTc4Y2UwNDcwZTQzMWY5XzItMS0xLTEtOTg2OTQ_faff0914-1c26-4c02-ba14-47839877fd4b">47</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6973b5f7f08f491a99b32b3361d5234a_D20210701-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90YWJsZToyYWYzMGFkOWEwYTU0YjdmYjE3OGNlMDQ3MGU0MzFmOS90YWJsZXJhbmdlOjJhZjMwYWQ5YTBhNTRiN2ZiMTc4Y2UwNDcwZTQzMWY5XzItMy0xLTEtOTg2OTQ_0c195b1d-74ed-4aa8-8ac6-a6e3adcf3b5c">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77aa86d8f8f8485ab211b681b5f58fb3_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90YWJsZToyYWYzMGFkOWEwYTU0YjdmYjE3OGNlMDQ3MGU0MzFmOS90YWJsZXJhbmdlOjJhZjMwYWQ5YTBhNTRiN2ZiMTc4Y2UwNDcwZTQzMWY5XzItNS0xLTEtOTg2OTQ_01f713c2-3b27-4010-8ae2-288edb9e05fc">38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85dc1b14fefe4551abd5390650b6c712_D20210701-20220331" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90YWJsZToyYWYzMGFkOWEwYTU0YjdmYjE3OGNlMDQ3MGU0MzFmOS90YWJsZXJhbmdlOjJhZjMwYWQ5YTBhNTRiN2ZiMTc4Y2UwNDcwZTQzMWY5XzMtMS0xLTEtOTg2OTQ_fe4cf154-d696-44a6-ab12-3d9cf992c6a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6973b5f7f08f491a99b32b3361d5234a_D20210701-20220331" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90YWJsZToyYWYzMGFkOWEwYTU0YjdmYjE3OGNlMDQ3MGU0MzFmOS90YWJsZXJhbmdlOjJhZjMwYWQ5YTBhNTRiN2ZiMTc4Y2UwNDcwZTQzMWY5XzMtMy0xLTEtOTg2OTQ_222ddf8f-b14a-42d7-8c64-045e257c15f1">5</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77aa86d8f8f8485ab211b681b5f58fb3_D20210701-20220331" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90YWJsZToyYWYzMGFkOWEwYTU0YjdmYjE3OGNlMDQ3MGU0MzFmOS90YWJsZXJhbmdlOjJhZjMwYWQ5YTBhNTRiN2ZiMTc4Y2UwNDcwZTQzMWY5XzMtNS0xLTEtOTg2OTQ_0cecb22f-487c-4539-9306-ea317a0e8071">5</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive loss attributable to Cardinal Health, Inc. net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85dc1b14fefe4551abd5390650b6c712_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90YWJsZToyYWYzMGFkOWEwYTU0YjdmYjE3OGNlMDQ3MGU0MzFmOS90YWJsZXJhbmdlOjJhZjMwYWQ5YTBhNTRiN2ZiMTc4Y2UwNDcwZTQzMWY5XzQtMS0xLTEtOTg2OTQ_93299643-763a-48ce-a6d1-ce30b4778f40">47</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6973b5f7f08f491a99b32b3361d5234a_D20210701-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90YWJsZToyYWYzMGFkOWEwYTU0YjdmYjE3OGNlMDQ3MGU0MzFmOS90YWJsZXJhbmdlOjJhZjMwYWQ5YTBhNTRiN2ZiMTc4Y2UwNDcwZTQzMWY5XzQtMy0xLTEtOTg2OTQ_19fefaaa-8ee0-404f-ae1e-272cb89c26f4">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88939d79b6fc434586eae883166fc9d8_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90YWJsZToyYWYzMGFkOWEwYTU0YjdmYjE3OGNlMDQ3MGU0MzFmOS90YWJsZXJhbmdlOjJhZjMwYWQ5YTBhNTRiN2ZiMTc4Y2UwNDcwZTQzMWY5XzQtNS0xLTEtOTg2OTQ_16e60841-a588-4902-989b-533de36a6dde">43</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96f98f7a3c2b4137aadf18cea504d375_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90YWJsZToyYWYzMGFkOWEwYTU0YjdmYjE3OGNlMDQ3MGU0MzFmOS90YWJsZXJhbmdlOjJhZjMwYWQ5YTBhNTRiN2ZiMTc4Y2UwNDcwZTQzMWY5XzUtMS0xLTEtOTg2OTQ_1146a9d1-cd37-4556-8e6d-3e326fc8b391">93</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ebf444915254c15b3d63cf748c3515a_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90YWJsZToyYWYzMGFkOWEwYTU0YjdmYjE3OGNlMDQ3MGU0MzFmOS90YWJsZXJhbmdlOjJhZjMwYWQ5YTBhNTRiN2ZiMTc4Y2UwNDcwZTQzMWY5XzUtMy0xLTEtOTg2OTQ_797415de-c390-49e9-8cbc-6825a434cb49">16</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if466229061cc43eda2992e495763f330_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90YWJsZToyYWYzMGFkOWEwYTU0YjdmYjE3OGNlMDQ3MGU0MzFmOS90YWJsZXJhbmdlOjJhZjMwYWQ5YTBhNTRiN2ZiMTc4Y2UwNDcwZTQzMWY5XzUtNS0xLTEtOTg2OTQ_b185dbac-18cb-4a0e-913a-65c1088cbc0c">77</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span><br/></span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iaf3733bf892b435689161c61a06da348_118"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTgvZnJhZzpiYjNjZWZiMjU2YzE0NDk0YjQ1OWYwY2FhMTJjNDFmYy90ZXh0cmVnaW9uOmJiM2NlZmIyNTZjMTQ0OTRiNDU5ZjBjYWExMmM0MWZjXzQxNw_49482284-4356-4980-805c-893a4da432e3" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">11. Earnings/(Loss) Per Share Attributable to Cardinal Health, Inc.</span></div><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTgvZnJhZzpiYjNjZWZiMjU2YzE0NDk0YjQ1OWYwY2FhMTJjNDFmYy90ZXh0cmVnaW9uOmJiM2NlZmIyNTZjMTQ0OTRiNDU5ZjBjYWExMmM0MWZjXzQyNg_cdeb6fdb-082c-4929-86c7-b1122e13053a" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the number of common shares used to compute basic and diluted loss per share attributable to Cardinal Health, Inc.:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.407%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTgvZnJhZzpiYjNjZWZiMjU2YzE0NDk0YjQ1OWYwY2FhMTJjNDFmYy90YWJsZToxOGJhOGM3Mjk2M2Y0M2U0ODVlYmZjMzk4NzUyOThlYS90YWJsZXJhbmdlOjE4YmE4YzcyOTYzZjQzZTQ4NWViZmMzOTg3NTI5OGVhXzItMS0xLTEtOTg2OTQ_32981608-9e4d-4347-8745-2f29da10505a">275</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTgvZnJhZzpiYjNjZWZiMjU2YzE0NDk0YjQ1OWYwY2FhMTJjNDFmYy90YWJsZToxOGJhOGM3Mjk2M2Y0M2U0ODVlYmZjMzk4NzUyOThlYS90YWJsZXJhbmdlOjE4YmE4YzcyOTYzZjQzZTQ4NWViZmMzOTg3NTI5OGVhXzItMy0xLTEtOTg2OTQ_6e3c9f7f-190c-41cd-9312-5f3ad2af10bf">292</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTgvZnJhZzpiYjNjZWZiMjU2YzE0NDk0YjQ1OWYwY2FhMTJjNDFmYy90YWJsZToxOGJhOGM3Mjk2M2Y0M2U0ODVlYmZjMzk4NzUyOThlYS90YWJsZXJhbmdlOjE4YmE4YzcyOTYzZjQzZTQ4NWViZmMzOTg3NTI5OGVhXzQtMS0xLTEtOTg2OTQ_76da29bc-55ab-4dca-a2e6-e2ea5cb3c4f2">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTgvZnJhZzpiYjNjZWZiMjU2YzE0NDk0YjQ1OWYwY2FhMTJjNDFmYy90YWJsZToxOGJhOGM3Mjk2M2Y0M2U0ODVlYmZjMzk4NzUyOThlYS90YWJsZXJhbmdlOjE4YmE4YzcyOTYzZjQzZTQ4NWViZmMzOTg3NTI5OGVhXzQtMy0xLTEtOTg2OTQ_137b565e-cc7e-47d5-91f4-9938bd3172cb">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTgvZnJhZzpiYjNjZWZiMjU2YzE0NDk0YjQ1OWYwY2FhMTJjNDFmYy90YWJsZToxOGJhOGM3Mjk2M2Y0M2U0ODVlYmZjMzk4NzUyOThlYS90YWJsZXJhbmdlOjE4YmE4YzcyOTYzZjQzZTQ4NWViZmMzOTg3NTI5OGVhXzUtMS0xLTEtOTg2OTQ_dd8ef7c6-a8ed-438f-b14f-93e819ed457d">275</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTgvZnJhZzpiYjNjZWZiMjU2YzE0NDk0YjQ1OWYwY2FhMTJjNDFmYy90YWJsZToxOGJhOGM3Mjk2M2Y0M2U0ODVlYmZjMzk4NzUyOThlYS90YWJsZXJhbmdlOjE4YmE4YzcyOTYzZjQzZTQ4NWViZmMzOTg3NTI5OGVhXzUtMy0xLTEtOTg2OTQ_fb4b52d9-4b07-4beb-be61-34860f4bba99">294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.407%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTgvZnJhZzpiYjNjZWZiMjU2YzE0NDk0YjQ1OWYwY2FhMTJjNDFmYy90YWJsZTo2ZmVjNDUyZmJlMzE0ZmFjOTVlZTVkNjIwNmEwY2U4MC90YWJsZXJhbmdlOjZmZWM0NTJmYmUzMTRmYWM5NWVlNWQ2MjA2YTBjZTgwXzItMS0xLTEtOTg2OTQ_d64f0b49-f12e-4ac9-9f7a-2ecb6198b8a1">281</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTgvZnJhZzpiYjNjZWZiMjU2YzE0NDk0YjQ1OWYwY2FhMTJjNDFmYy90YWJsZTo2ZmVjNDUyZmJlMzE0ZmFjOTVlZTVkNjIwNmEwY2U4MC90YWJsZXJhbmdlOjZmZWM0NTJmYmUzMTRmYWM5NWVlNWQ2MjA2YTBjZTgwXzItMy0xLTEtOTg2OTQ_d4034d3a-7e80-44da-b208-bdb83246c777">293</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTgvZnJhZzpiYjNjZWZiMjU2YzE0NDk0YjQ1OWYwY2FhMTJjNDFmYy90YWJsZTo2ZmVjNDUyZmJlMzE0ZmFjOTVlZTVkNjIwNmEwY2U4MC90YWJsZXJhbmdlOjZmZWM0NTJmYmUzMTRmYWM5NWVlNWQ2MjA2YTBjZTgwXzQtMS0xLTEtOTg2OTQ_08d959cf-d67b-438f-919d-a69c67c3925f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTgvZnJhZzpiYjNjZWZiMjU2YzE0NDk0YjQ1OWYwY2FhMTJjNDFmYy90YWJsZTo2ZmVjNDUyZmJlMzE0ZmFjOTVlZTVkNjIwNmEwY2U4MC90YWJsZXJhbmdlOjZmZWM0NTJmYmUzMTRmYWM5NWVlNWQ2MjA2YTBjZTgwXzQtMy0xLTEtOTg2OTQ_26195f0d-307f-4979-be85-ae3f3b09c1d0">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTgvZnJhZzpiYjNjZWZiMjU2YzE0NDk0YjQ1OWYwY2FhMTJjNDFmYy90YWJsZTo2ZmVjNDUyZmJlMzE0ZmFjOTVlZTVkNjIwNmEwY2U4MC90YWJsZXJhbmdlOjZmZWM0NTJmYmUzMTRmYWM5NWVlNWQ2MjA2YTBjZTgwXzUtMS0xLTEtOTg2OTQ_93643ef7-4f0b-4cd2-85ae-46315c73e661">281</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTgvZnJhZzpiYjNjZWZiMjU2YzE0NDk0YjQ1OWYwY2FhMTJjNDFmYy90YWJsZTo2ZmVjNDUyZmJlMzE0ZmFjOTVlZTVkNjIwNmEwY2U4MC90YWJsZXJhbmdlOjZmZWM0NTJmYmUzMTRmYWM5NWVlNWQ2MjA2YTBjZTgwXzUtMy0xLTEtOTg2OTQ_35453892-0c6e-48c1-9c1c-352d4f741258">294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive were <ix:nonFraction unitRef="shares" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTgvZnJhZzpiYjNjZWZiMjU2YzE0NDk0YjQ1OWYwY2FhMTJjNDFmYy90ZXh0cmVnaW9uOmJiM2NlZmIyNTZjMTQ0OTRiNDU5ZjBjYWExMmM0MWZjXzI5Mg_2530b25d-8d74-4c5b-9444-2842ee4d1253"><ix:nonFraction unitRef="shares" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTgvZnJhZzpiYjNjZWZiMjU2YzE0NDk0YjQ1OWYwY2FhMTJjNDFmYy90ZXh0cmVnaW9uOmJiM2NlZmIyNTZjMTQ0OTRiNDU5ZjBjYWExMmM0MWZjXzI5Mg_339402ef-ae97-4240-9bdc-f99a6557315c">5</ix:nonFraction></ix:nonFraction> million for both the three and nine months March&#160;31, 2022. For the three and nine months ended March&#160;31, 2022, there were <ix:nonFraction unitRef="shares" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" name="cah:SharesThatWouldBeAntidilutiveAsAResultOfNetLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTgvZnJhZzpiYjNjZWZiMjU2YzE0NDk0YjQ1OWYwY2FhMTJjNDFmYy90ZXh0cmVnaW9uOmJiM2NlZmIyNTZjMTQ0OTRiNDU5ZjBjYWExMmM0MWZjXzEwNDQ1MzYwNDY2OTM0_d7c7ea75-565d-4402-bd4d-b2c9e7027e7c">2</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="cah:SharesThatWouldBeAntidilutiveAsAResultOfNetLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTgvZnJhZzpiYjNjZWZiMjU2YzE0NDk0YjQ1OWYwY2FhMTJjNDFmYy90ZXh0cmVnaW9uOmJiM2NlZmIyNTZjMTQ0OTRiNDU5ZjBjYWExMmM0MWZjXzEwNDQ1MzYwNDY2OTQy_5daeb057-e44d-4c1d-85c4-f0286cf8923c">1</ix:nonFraction> million potentially dilutive employee stock options, restricted share units and performance share units, respectively, not included in the computation of diluted loss per common share attributable to Cardinal Health, Inc. because their effect would have been anti-dilutive as a result of the net loss during those periods.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive were <ix:nonFraction unitRef="shares" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTgvZnJhZzpiYjNjZWZiMjU2YzE0NDk0YjQ1OWYwY2FhMTJjNDFmYy90ZXh0cmVnaW9uOmJiM2NlZmIyNTZjMTQ0OTRiNDU5ZjBjYWExMmM0MWZjXzIxOTkwMjMyNTgzODM_a7acd22f-a4ea-41b4-8920-a47851e00f5c">3</ix:nonFraction> million for the three months ended March 31, 2021 and <ix:nonFraction unitRef="shares" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTgvZnJhZzpiYjNjZWZiMjU2YzE0NDk0YjQ1OWYwY2FhMTJjNDFmYy90ZXh0cmVnaW9uOmJiM2NlZmIyNTZjMTQ0OTRiNDU5ZjBjYWExMmM0MWZjXzIxOTkwMjMyNTg0MzE_9e22decb-f62a-4a77-8615-f72a81c26336">4</ix:nonFraction> million for the nine months ended March 31, 2021.</span></div></ix:nonNumeric><div id="iaf3733bf892b435689161c61a06da348_121"></div><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90ZXh0cmVnaW9uOmVkNzE0MTJiOTQ5MjRlZDQ5ZDUyZDE3ZjYxYjcyYWM1XzU1NDY_ff191fac-43db-43f9-8bf8-c35fe1c5f528" continuedAt="i564cd52689f44835a3ce97ba8934aca8" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">12. Segment Information</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are principally managed on a products and services basis and are comprised of <ix:nonFraction unitRef="segment" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="0" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90ZXh0cmVnaW9uOmVkNzE0MTJiOTQ5MjRlZDQ5ZDUyZDE3ZjYxYjcyYWM1XzEwMQ_c757bf8a-ff5d-4b36-b8f9-ec93ee053b26"><ix:nonFraction unitRef="segment" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="0" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90ZXh0cmVnaW9uOmVkNzE0MTJiOTQ5MjRlZDQ5ZDUyZDE3ZjYxYjcyYWM1XzEwMQ_ca3994f2-bd23-449d-8506-935ebcdddabf">two</ix:nonFraction></ix:nonFraction> operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.</span></div></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="i564cd52689f44835a3ce97ba8934aca8" continuedAt="i2c258fbabd884e7dbf568540ff2e6068"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; provides pharmacy management services to hospitals as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers and payers; and repackages generic pharmaceuticals and over-the-counter healthcare products. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present revenue for each reportable segment and disaggregated revenue within our <ix:nonFraction unitRef="segment" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="0" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90ZXh0cmVnaW9uOmVkNzE0MTJiOTQ5MjRlZDQ5ZDUyZDE3ZjYxYjcyYWM1XzE4NDc_c757bf8a-ff5d-4b36-b8f9-ec93ee053b26"><ix:nonFraction unitRef="segment" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="0" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90ZXh0cmVnaW9uOmVkNzE0MTJiOTQ5MjRlZDQ5ZDUyZDE3ZjYxYjcyYWM1XzE4NDc_ca3994f2-bd23-449d-8506-935ebcdddabf">two</ix:nonFraction></ix:nonFraction> reportable segments and Corporate:</span></div><div style="margin-top:5pt;text-align:center"><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90ZXh0cmVnaW9uOmVkNzE0MTJiOTQ5MjRlZDQ5ZDUyZDE3ZjYxYjcyYWM1XzU1NTI_6ce6f0de-6d25-4f9b-b838-f9ddc79275cb" continuedAt="i0f669596d5204e829524078e2d7b70d1" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.593%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i271748b8420f4075b02360857adce1b3_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo4ZmRiZDg0NmI2NWI0OThmOThmNDQwN2M4ZjhjOGMwZC90YWJsZXJhbmdlOjhmZGJkODQ2YjY1YjQ5OGY5OGY0NDA3YzhmOGM4YzBkXzItMS0xLTEtOTg2OTQ_a9092969-0e66-4d9f-9894-48e6bdda2b46">40,723</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c47eb93c86c45f18852a7d4732bcc2b_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo4ZmRiZDg0NmI2NWI0OThmOThmNDQwN2M4ZjhjOGMwZC90YWJsZXJhbmdlOjhmZGJkODQ2YjY1YjQ5OGY5OGY0NDA3YzhmOGM4YzBkXzItMy0xLTEtOTg2OTQ_3dd40769-71de-4d5a-a7ee-7dc1ebbbe87f">34,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55a8895770e74654bb814d7570d0be67_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo4ZmRiZDg0NmI2NWI0OThmOThmNDQwN2M4ZjhjOGMwZC90YWJsZXJhbmdlOjhmZGJkODQ2YjY1YjQ5OGY5OGY0NDA3YzhmOGM4YzBkXzMtMS0xLTEtOTg2OTQ_da0a76cd-b9da-4367-bbe9-6b3a3ff5fe60">234</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic20d148712384093a21beaae9dbb11ae_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo4ZmRiZDg0NmI2NWI0OThmOThmNDQwN2M4ZjhjOGMwZC90YWJsZXJhbmdlOjhmZGJkODQ2YjY1YjQ5OGY5OGY0NDA3YzhmOGM4YzBkXzMtMy0xLTEtOTg2OTQ_e252e51a-933b-4a76-aa7b-920cae4a65dd">201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50ba23949f524ee39edd3981f77140d5_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo4ZmRiZDg0NmI2NWI0OThmOThmNDQwN2M4ZjhjOGMwZC90YWJsZXJhbmdlOjhmZGJkODQ2YjY1YjQ5OGY5OGY0NDA3YzhmOGM4YzBkXzQtMS0xLTEtOTg2OTQ_2f009fae-f6e6-40d2-b875-9256e49571bf">40,957</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84520ad8572840ff8aebaffcf2fc874b_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo4ZmRiZDg0NmI2NWI0OThmOThmNDQwN2M4ZjhjOGMwZC90YWJsZXJhbmdlOjhmZGJkODQ2YjY1YjQ5OGY5OGY0NDA3YzhmOGM4YzBkXzQtMy0xLTEtOTg2OTQ_e241e0b4-850b-4109-808d-d3d7eece00ab">35,104</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35c8403b7fd7460d84fabd0ac9bdf6b9_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo4ZmRiZDg0NmI2NWI0OThmOThmNDQwN2M4ZjhjOGMwZC90YWJsZXJhbmdlOjhmZGJkODQ2YjY1YjQ5OGY5OGY0NDA3YzhmOGM4YzBkXzUtMS0xLTEtOTg2OTQ_e2693c79-c148-49d1-a944-9a92ada4de44">3,283</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69525c4e29b84ce794f19067c425c73f_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo4ZmRiZDg0NmI2NWI0OThmOThmNDQwN2M4ZjhjOGMwZC90YWJsZXJhbmdlOjhmZGJkODQ2YjY1YjQ5OGY5OGY0NDA3YzhmOGM4YzBkXzUtMy0xLTEtOTg2OTQ_ede28ba8-3a09-4351-985a-b666ad81ca3a">3,638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida0bf17cdf17411ab1c3212847b430cb_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo4ZmRiZDg0NmI2NWI0OThmOThmNDQwN2M4ZjhjOGMwZC90YWJsZXJhbmdlOjhmZGJkODQ2YjY1YjQ5OGY5OGY0NDA3YzhmOGM4YzBkXzYtMS0xLTEtOTg2OTQ_325857b2-e59d-465f-9e64-1c1802b2dfc3">601</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74d2de9e32a34ab5b7753b90bdd5d03f_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo4ZmRiZDg0NmI2NWI0OThmOThmNDQwN2M4ZjhjOGMwZC90YWJsZXJhbmdlOjhmZGJkODQ2YjY1YjQ5OGY5OGY0NDA3YzhmOGM4YzBkXzYtMy0xLTEtOTg2OTQ_1fc1c6ad-35e0-455a-bc8c-c86f5a3f8f97">536</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76a973b7ccb648908c98bf838383a489_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo4ZmRiZDg0NmI2NWI0OThmOThmNDQwN2M4ZjhjOGMwZC90YWJsZXJhbmdlOjhmZGJkODQ2YjY1YjQ5OGY5OGY0NDA3YzhmOGM4YzBkXzctMS0xLTEtOTg2OTQ_5ad6d88b-fdcd-408f-a826-a0673e61663d">3,884</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i968b05c553634c7a8ef37ffb3b2c9491_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo4ZmRiZDg0NmI2NWI0OThmOThmNDQwN2M4ZjhjOGMwZC90YWJsZXJhbmdlOjhmZGJkODQ2YjY1YjQ5OGY5OGY0NDA3YzhmOGM4YzBkXzctMy0xLTEtOTg2OTQ_2ce18b14-2cac-42b2-99e5-059cece0fab4">4,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b6fce6427cc4db58e97a1124f989059_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo4ZmRiZDg0NmI2NWI0OThmOThmNDQwN2M4ZjhjOGMwZC90YWJsZXJhbmdlOjhmZGJkODQ2YjY1YjQ5OGY5OGY0NDA3YzhmOGM4YzBkXzgtMS0xLTEtOTg2OTQ_3604869e-ac76-4506-8baa-1de6f3213ca8">44,841</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940747d1739c452b84105fc820e21d0f_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo4ZmRiZDg0NmI2NWI0OThmOThmNDQwN2M4ZjhjOGMwZC90YWJsZXJhbmdlOjhmZGJkODQ2YjY1YjQ5OGY5OGY0NDA3YzhmOGM4YzBkXzgtMy0xLTEtOTg2OTQ_0a11c800-5cf1-4f68-a7df-1f2e1338dca1">39,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2b4c786f4bf4513b3347b942f655efd_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo4ZmRiZDg0NmI2NWI0OThmOThmNDQwN2M4ZjhjOGMwZC90YWJsZXJhbmdlOjhmZGJkODQ2YjY1YjQ5OGY5OGY0NDA3YzhmOGM4YzBkXzktMS0xLTEtOTg2OTQ_857886d0-59fa-4628-95a4-76fbc4538792">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50f9973da9d3455e928bdbe756cb6f44_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo4ZmRiZDg0NmI2NWI0OThmOThmNDQwN2M4ZjhjOGMwZC90YWJsZXJhbmdlOjhmZGJkODQ2YjY1YjQ5OGY5OGY0NDA3YzhmOGM4YzBkXzktMy0xLTEtOTg2OTQ_f64e4950-7e39-4b75-bed9-7f8259cd7d32">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo4ZmRiZDg0NmI2NWI0OThmOThmNDQwN2M4ZjhjOGMwZC90YWJsZXJhbmdlOjhmZGJkODQ2YjY1YjQ5OGY5OGY0NDA3YzhmOGM4YzBkXzEwLTEtMS0xLTk4Njk0_0b894353-4c3c-4676-af91-2ae5f55918a4">44,836</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo4ZmRiZDg0NmI2NWI0OThmOThmNDQwN2M4ZjhjOGMwZC90YWJsZXJhbmdlOjhmZGJkODQ2YjY1YjQ5OGY5OGY0NDA3YzhmOGM4YzBkXzEwLTMtMS0xLTk4Njk0_61b7b56a-48b4-4f56-ae1b-014d2d4d0cd4">39,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">43</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><ix:continuation id="i2c258fbabd884e7dbf568540ff2e6068" continuedAt="id202b45e94df4116ac33a0b73eb21bc3"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="i0f669596d5204e829524078e2d7b70d1"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.593%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fc7d8e372df4069be7ed7b9e033f09f_D20210701-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkMDEzNDUwYjZjNzM0N2M2OGJhMjQyMjI5YzJhMmVmNi90YWJsZXJhbmdlOmQwMTM0NTBiNmM3MzQ3YzY4YmEyNDIyMjljMmEyZWY2XzItMS0xLTEtOTg2OTQ_cbe07802-aee7-4a4f-98f2-15e01a663c71">121,501</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2178f9d823184a19a7be4b97a98bbfcd_D20200701-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkMDEzNDUwYjZjNzM0N2M2OGJhMjQyMjI5YzJhMmVmNi90YWJsZXJhbmdlOmQwMTM0NTBiNmM3MzQ3YzY4YmEyNDIyMjljMmEyZWY2XzItMy0xLTEtOTg2OTQ_65858fe2-6393-4768-8650-174a791bfe4f">106,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie832c8853e2a4345938d5c0300e49149_D20210701-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkMDEzNDUwYjZjNzM0N2M2OGJhMjQyMjI5YzJhMmVmNi90YWJsZXJhbmdlOmQwMTM0NTBiNmM3MzQ3YzY4YmEyNDIyMjljMmEyZWY2XzMtMS0xLTEtOTg2OTQ_b86e91b6-981c-4fd5-9571-9a02bc9ebc96">653</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i995eb07521ae4433bdc8160df2f79810_D20200701-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkMDEzNDUwYjZjNzM0N2M2OGJhMjQyMjI5YzJhMmVmNi90YWJsZXJhbmdlOmQwMTM0NTBiNmM3MzQ3YzY4YmEyNDIyMjljMmEyZWY2XzMtMy0xLTEtOTg2OTQ_b82130d6-1e91-454a-b9e5-d501cddfc873">593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a8fa6b7c4c04392ad18e36a04760533_D20210701-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkMDEzNDUwYjZjNzM0N2M2OGJhMjQyMjI5YzJhMmVmNi90YWJsZXJhbmdlOmQwMTM0NTBiNmM3MzQ3YzY4YmEyNDIyMjljMmEyZWY2XzQtMS0xLTEtOTg2OTQ_01f0deb1-acb4-4eed-9ce0-ae0fcdc0714a">122,154</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib25907ae15fa44dcb0802c504cec1c88_D20200701-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkMDEzNDUwYjZjNzM0N2M2OGJhMjQyMjI5YzJhMmVmNi90YWJsZXJhbmdlOmQwMTM0NTBiNmM3MzQ3YzY4YmEyNDIyMjljMmEyZWY2XzQtMy0xLTEtOTg2OTQ_1b0dc512-d3cf-400a-aa30-908a3e4a806a">107,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b0d22bf281f4584bad7e62de864bf75_D20210701-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkMDEzNDUwYjZjNzM0N2M2OGJhMjQyMjI5YzJhMmVmNi90YWJsZXJhbmdlOmQwMTM0NTBiNmM3MzQ3YzY4YmEyNDIyMjljMmEyZWY2XzUtMS0xLTEtOTg2OTQ_3ff7cd59-23ac-434a-83a8-b578f6c8aadd">10,296</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77648cd7d3a34814beda9dcd87e2f35d_D20200701-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkMDEzNDUwYjZjNzM0N2M2OGJhMjQyMjI5YzJhMmVmNi90YWJsZXJhbmdlOmQwMTM0NTBiNmM3MzQ3YzY4YmEyNDIyMjljMmEyZWY2XzUtMy0xLTEtOTg2OTQ_79206474-81ce-4bbd-b46e-56eee5eec15c">10,805</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7bcf27f7221414f96fbedd5799f6902_D20210701-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkMDEzNDUwYjZjNzM0N2M2OGJhMjQyMjI5YzJhMmVmNi90YWJsZXJhbmdlOmQwMTM0NTBiNmM3MzQ3YzY4YmEyNDIyMjljMmEyZWY2XzYtMS0xLTEtOTg2OTQ_428123cb-9e84-4fd9-acc4-3eac5acbe027">1,822</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i479768cce42840d6807b6cf8e3d09439_D20200701-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkMDEzNDUwYjZjNzM0N2M2OGJhMjQyMjI5YzJhMmVmNi90YWJsZXJhbmdlOmQwMTM0NTBiNmM3MzQ3YzY4YmEyNDIyMjljMmEyZWY2XzYtMy0xLTEtOTg2OTQ_05d5127c-5ba7-435a-b2b0-9967dd7d7f91">1,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6afdf5f1340d41c6941f5cc19ff2ef71_D20210701-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkMDEzNDUwYjZjNzM0N2M2OGJhMjQyMjI5YzJhMmVmNi90YWJsZXJhbmdlOmQwMTM0NTBiNmM3MzQ3YzY4YmEyNDIyMjljMmEyZWY2XzctMS0xLTEtOTg2OTQ_537f5729-6f8a-4acc-b9a5-815914678c7a">12,118</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i203ccf6041354aa887510c9903970c43_D20200701-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkMDEzNDUwYjZjNzM0N2M2OGJhMjQyMjI5YzJhMmVmNi90YWJsZXJhbmdlOmQwMTM0NTBiNmM3MzQ3YzY4YmEyNDIyMjljMmEyZWY2XzctMy0xLTEtOTg2OTQ_cc57f125-b83a-4e12-8943-72fb9060f12a">12,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7205a1910584e49b66107f75befc03d_D20210701-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkMDEzNDUwYjZjNzM0N2M2OGJhMjQyMjI5YzJhMmVmNi90YWJsZXJhbmdlOmQwMTM0NTBiNmM3MzQ3YzY4YmEyNDIyMjljMmEyZWY2XzgtMS0xLTEtOTg2OTQ_c3a4e330-fe0f-4c77-bddd-f516b7aefcbf">134,272</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic84e3ea0e4fb4425b6174e7655ba01f1_D20200701-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkMDEzNDUwYjZjNzM0N2M2OGJhMjQyMjI5YzJhMmVmNi90YWJsZXJhbmdlOmQwMTM0NTBiNmM3MzQ3YzY4YmEyNDIyMjljMmEyZWY2XzgtMy0xLTEtOTg2OTQ_56e7a76c-7daa-41b4-bf09-20fba60fe548">119,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1865dd177bf446bb0808b03a8c0b8b6_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkMDEzNDUwYjZjNzM0N2M2OGJhMjQyMjI5YzJhMmVmNi90YWJsZXJhbmdlOmQwMTM0NTBiNmM3MzQ3YzY4YmEyNDIyMjljMmEyZWY2XzktMS0xLTEtOTg2OTQ_39f37f84-e866-4077-a00a-eac5387d1b2b">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b1b3f0e63094c6ba80ba1a031e52c86_D20200701-20210331" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkMDEzNDUwYjZjNzM0N2M2OGJhMjQyMjI5YzJhMmVmNi90YWJsZXJhbmdlOmQwMTM0NTBiNmM3MzQ3YzY4YmEyNDIyMjljMmEyZWY2XzktMy0xLTEtOTg2OTQ_432d444c-f050-4f15-8b4a-37af5237c206">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkMDEzNDUwYjZjNzM0N2M2OGJhMjQyMjI5YzJhMmVmNi90YWJsZXJhbmdlOmQwMTM0NTBiNmM3MzQ3YzY4YmEyNDIyMjljMmEyZWY2XzEwLTEtMS0xLTk4Njk0_1cc0d5bb-5924-4d36-a9c6-460664397c60">134,261</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkMDEzNDUwYjZjNzM0N2M2OGJhMjQyMjI5YzJhMmVmNi90YWJsZXJhbmdlOmQwMTM0NTBiNmM3MzQ3YzY4YmEyNDIyMjljMmEyZWY2XzEwLTMtMS0xLTk4Njk0_16796090-e505-4e42-b4a9-5b1d538f520b">119,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Products and services offered by our Specialty Solutions division are referred to as &#8220;specialty pharmaceutical products and services."</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div></ix:continuation><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90ZXh0cmVnaW9uOmVkNzE0MTJiOTQ5MjRlZDQ5ZDUyZDE3ZjYxYjcyYWM1XzU1NTQ_6e9bd9b7-c1e5-4782-9b02-577b0ee18fa8" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present revenue by geographic area:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:43.482%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.215%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.217%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70d8b7dbb46a4e8fa9f3548d4edd3460_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTplMjRlMDA5MmQzNjc0NGMzODA0M2M1Y2NjOWY1ZjNjYy90YWJsZXJhbmdlOmUyNGUwMDkyZDM2NzQ0YzM4MDQzYzVjY2M5ZjVmM2NjXzItMS0xLTEtOTg2OTQ_62fb6e96-4171-4663-9d60-41a34254bf81">43,710</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b6b3238d8dc4c6094d322879432c3a3_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTplMjRlMDA5MmQzNjc0NGMzODA0M2M1Y2NjOWY1ZjNjYy90YWJsZXJhbmdlOmUyNGUwMDkyZDM2NzQ0YzM4MDQzYzVjY2M5ZjVmM2NjXzItMy0xLTEtOTg2OTQ_0f35a960-df7e-4a42-b9fb-b82b32b5c5d3">38,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe5bb815566842549cff77434b3664c5_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTplMjRlMDA5MmQzNjc0NGMzODA0M2M1Y2NjOWY1ZjNjYy90YWJsZXJhbmdlOmUyNGUwMDkyZDM2NzQ0YzM4MDQzYzVjY2M5ZjVmM2NjXzMtMS0xLTEtOTg2OTQ_9e152cc2-2b9c-4678-a1ff-abded710f0a5">1,131</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625a7e6298c541f0ab5627a25b81a35f_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTplMjRlMDA5MmQzNjc0NGMzODA0M2M1Y2NjOWY1ZjNjYy90YWJsZXJhbmdlOmUyNGUwMDkyZDM2NzQ0YzM4MDQzYzVjY2M5ZjVmM2NjXzMtMy0xLTEtOTg2OTQ_83cdb456-75bc-4c9b-960d-dca3d4811a08">1,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b6fce6427cc4db58e97a1124f989059_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTplMjRlMDA5MmQzNjc0NGMzODA0M2M1Y2NjOWY1ZjNjYy90YWJsZXJhbmdlOmUyNGUwMDkyZDM2NzQ0YzM4MDQzYzVjY2M5ZjVmM2NjXzQtMS0xLTEtOTg2OTQ_380861eb-57d5-445e-a18f-c2f21f21717d">44,841</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940747d1739c452b84105fc820e21d0f_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTplMjRlMDA5MmQzNjc0NGMzODA0M2M1Y2NjOWY1ZjNjYy90YWJsZXJhbmdlOmUyNGUwMDkyZDM2NzQ0YzM4MDQzYzVjY2M5ZjVmM2NjXzQtMy0xLTEtOTg2OTQ_3062b02f-a4ed-4836-8121-7225eb68243b">39,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2b4c786f4bf4513b3347b942f655efd_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTplMjRlMDA5MmQzNjc0NGMzODA0M2M1Y2NjOWY1ZjNjYy90YWJsZXJhbmdlOmUyNGUwMDkyZDM2NzQ0YzM4MDQzYzVjY2M5ZjVmM2NjXzUtMS0xLTEtOTg2OTQ_466c1ac5-2b02-4c02-8d89-e9ff2ee25e2a">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50f9973da9d3455e928bdbe756cb6f44_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTplMjRlMDA5MmQzNjc0NGMzODA0M2M1Y2NjOWY1ZjNjYy90YWJsZXJhbmdlOmUyNGUwMDkyZDM2NzQ0YzM4MDQzYzVjY2M5ZjVmM2NjXzUtMy0xLTEtOTg2OTQ_8f0a0d12-4bdd-4136-8b27-c0341faefbd9">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTplMjRlMDA5MmQzNjc0NGMzODA0M2M1Y2NjOWY1ZjNjYy90YWJsZXJhbmdlOmUyNGUwMDkyZDM2NzQ0YzM4MDQzYzVjY2M5ZjVmM2NjXzYtMS0xLTEtOTg2OTQ_8f97f7f1-c619-4b01-800a-be4f5b12b4b8">44,836</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTplMjRlMDA5MmQzNjc0NGMzODA0M2M1Y2NjOWY1ZjNjYy90YWJsZXJhbmdlOmUyNGUwMDkyZDM2NzQ0YzM4MDQzYzVjY2M5ZjVmM2NjXzYtMy0xLTEtOTg2OTQ_98e2972f-a74f-4b01-816b-ee47eb771dcb">39,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:43.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.906%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.217%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic282070c0abd4da7b2e98ef29dabe2a4_D20210701-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpjZjlkZjBhYmIxNGU0YzU5ODU4MDdmNjUzYzNmMGQ2Ni90YWJsZXJhbmdlOmNmOWRmMGFiYjE0ZTRjNTk4NTgwN2Y2NTNjM2YwZDY2XzItMS0xLTEtOTg2OTQ_ec18bc17-28da-4021-ad77-b349c7e09849">130,933</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe9bf4e4c9f04b558b3d275631d67107_D20200701-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpjZjlkZjBhYmIxNGU0YzU5ODU4MDdmNjUzYzNmMGQ2Ni90YWJsZXJhbmdlOmNmOWRmMGFiYjE0ZTRjNTk4NTgwN2Y2NTNjM2YwZDY2XzItMy0xLTEtOTg2OTQ_477d1a7f-11d0-469c-8f88-715ae9c5acab">116,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60837aa8922b471583b5179248715cc5_D20210701-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpjZjlkZjBhYmIxNGU0YzU5ODU4MDdmNjUzYzNmMGQ2Ni90YWJsZXJhbmdlOmNmOWRmMGFiYjE0ZTRjNTk4NTgwN2Y2NTNjM2YwZDY2XzMtMS0xLTEtOTg2OTQ_bf4f0ed4-9ac9-4385-a247-fe130c661e22">3,339</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icadf953dd78648ce88457a23b39ed9b3_D20200701-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpjZjlkZjBhYmIxNGU0YzU5ODU4MDdmNjUzYzNmMGQ2Ni90YWJsZXJhbmdlOmNmOWRmMGFiYjE0ZTRjNTk4NTgwN2Y2NTNjM2YwZDY2XzMtMy0xLTEtOTg2OTQ_69e1eda8-2f55-4d8d-93c2-0e86a18faac9">3,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7205a1910584e49b66107f75befc03d_D20210701-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpjZjlkZjBhYmIxNGU0YzU5ODU4MDdmNjUzYzNmMGQ2Ni90YWJsZXJhbmdlOmNmOWRmMGFiYjE0ZTRjNTk4NTgwN2Y2NTNjM2YwZDY2XzQtMS0xLTEtOTg2OTQ_6a014bc4-c856-437b-8854-a09a33e72225">134,272</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic84e3ea0e4fb4425b6174e7655ba01f1_D20200701-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpjZjlkZjBhYmIxNGU0YzU5ODU4MDdmNjUzYzNmMGQ2Ni90YWJsZXJhbmdlOmNmOWRmMGFiYjE0ZTRjNTk4NTgwN2Y2NTNjM2YwZDY2XzQtMy0xLTEtOTg2OTQ_e58c1bb0-b9e7-407e-b91c-b9959ee106f5">119,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1865dd177bf446bb0808b03a8c0b8b6_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpjZjlkZjBhYmIxNGU0YzU5ODU4MDdmNjUzYzNmMGQ2Ni90YWJsZXJhbmdlOmNmOWRmMGFiYjE0ZTRjNTk4NTgwN2Y2NTNjM2YwZDY2XzUtMS0xLTEtOTg2OTQ_353a2b1b-bf8c-429d-8163-1c5b07f5edc7">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b1b3f0e63094c6ba80ba1a031e52c86_D20200701-20210331" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpjZjlkZjBhYmIxNGU0YzU5ODU4MDdmNjUzYzNmMGQ2Ni90YWJsZXJhbmdlOmNmOWRmMGFiYjE0ZTRjNTk4NTgwN2Y2NTNjM2YwZDY2XzUtMy0xLTEtOTg2OTQ_a0c4db4f-874c-4b55-9b17-2403e7ab6b47">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpjZjlkZjBhYmIxNGU0YzU5ODU4MDdmNjUzYzNmMGQ2Ni90YWJsZXJhbmdlOmNmOWRmMGFiYjE0ZTRjNTk4NTgwN2Y2NTNjM2YwZDY2XzYtMS0xLTEtOTg2OTQ_b9d20cc1-c116-4ae2-8600-19c0b3d6b2fb">134,261</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpjZjlkZjBhYmIxNGU0YzU5ODU4MDdmNjUzYzNmMGQ2Ni90YWJsZXJhbmdlOmNmOWRmMGFiYjE0ZTRjNTk4NTgwN2Y2NTNjM2YwZDY2XzYtMy0xLTEtOTg2OTQ_c0055819-8766-4fd9-b86c-dd839eeedcab">119,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Profit</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&amp;A") expenses. Segment SG&amp;A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology, and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">methodologies. The results attributable to noncontrolling interests are recorded within segment profit.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not allocate the following items to our segments: </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">last-in first-out, or ("LIFO"), inventory charges/(credits); </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">surgical gown recall costs/(income);</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">restructuring and employee severance;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">amortization and other acquisition-related costs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">impairments and (gain)/loss on disposal of assets;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">litigation (recoveries)/charges, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">state opioid assessment related to prior fiscal years;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">other (income)/expense, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">interest expense, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">loss on early extinguishment of debt; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">(gain)/loss on sale of equity interest in naviHealth; or</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">provision for income taxes </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $<ix:nonFraction unitRef="usd" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" name="cah:ProjectCostsOnInvestmentAndOtherSpending" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90ZXh0cmVnaW9uOmVkNzE0MTJiOTQ5MjRlZDQ5ZDUyZDE3ZjYxYjcyYWM1XzQzODE_ce7f7523-cc9c-4a3f-b6c5-9f6029260952">20</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="cah:ProjectCostsOnInvestmentAndOtherSpending" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90ZXh0cmVnaW9uOmVkNzE0MTJiOTQ5MjRlZDQ5ZDUyZDE3ZjYxYjcyYWM1XzQzODg_7796d2af-c0ae-48dc-a35b-f5380d7bcae9">4</ix:nonFraction> million for the three months ended March&#160;31, 2022 and 2021, and $<ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="cah:ProjectCostsOnInvestmentAndOtherSpending" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90ZXh0cmVnaW9uOmVkNzE0MTJiOTQ5MjRlZDQ5ZDUyZDE3ZjYxYjcyYWM1XzQ0MzM_96364cf7-673f-4397-a183-c5dcf3c35fd0">38</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="cah:ProjectCostsOnInvestmentAndOtherSpending" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90ZXh0cmVnaW9uOmVkNzE0MTJiOTQ5MjRlZDQ5ZDUyZDE3ZjYxYjcyYWM1XzQ0NDA_cc9ded5a-2bc2-45fa-b0ac-49a3633b7714">15</ix:nonFraction> million for the nine months ended March&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the interim goodwill impairment testing for the Medical Unit as discussed further in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_91">Note 4</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we recognized goodwill impairment charges of $<ix:nonFraction unitRef="usd" contextRef="i2473dfc0495e42aeb265fd377f6c1a00_D20220101-20220331" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90ZXh0cmVnaW9uOmVkNzE0MTJiOTQ5MjRlZDQ5ZDUyZDE3ZjYxYjcyYWM1XzcxNDY4MjU1ODYxODA_45c80bc3-ace0-4335-ae56-d25daa119b13">474</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i579fe90cd44b45029f6ce1e6fd52d06e_D20210701-20220331" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90ZXh0cmVnaW9uOmVkNzE0MTJiOTQ5MjRlZDQ5ZDUyZDE3ZjYxYjcyYWM1XzMyOTg1MzQ4OTU3NjM_763bb6ac-9d1d-427a-afce-ec39ac0de8bb">1.8</ix:nonFraction>&#160;billion during the three and nine months ended March&#160;31, 2022, respectively, which were retained at Corporate. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the opioid litigation as discussed further in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_103">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we recognized a pre-tax charge of $<ix:nonFraction unitRef="usd" contextRef="i7cfeb36a6e0d45f8aa734c1879638433_D20200701-20210331" decimals="-7" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90ZXh0cmVnaW9uOmVkNzE0MTJiOTQ5MjRlZDQ5ZDUyZDE3ZjYxYjcyYWM1XzQ4MTk_a3f7e46d-9941-4c9b-9a80-f9745ce1b3c5">1.02</ix:nonFraction>&#160;billion</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the nine months ended March&#160;31, 2021 which was retained at Corporate.</span></div><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90ZXh0cmVnaW9uOmVkNzE0MTJiOTQ5MjRlZDQ5ZDUyZDE3ZjYxYjcyYWM1XzU1NjE_1ba37bc8-354e-48b9-ba7a-de0b54ab1cc7" continuedAt="ia491b192cc564177977da7ea1a6c2b09" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present segment profit by reportable segment and Corporate:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:50.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.429%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.122%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical (1)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50ba23949f524ee39edd3981f77140d5_D20220101-20220331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo1Mjc1NjgyZTE5YjY0NzNiODUzMDRhYjE5NWEzZTM5MC90YWJsZXJhbmdlOjUyNzU2ODJlMTliNjQ3M2I4NTMwNGFiMTk1YTNlMzkwXzItMS0xLTEtOTg2OTQ_622804fd-591f-46d1-be6d-7b4456217b3c">487</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84520ad8572840ff8aebaffcf2fc874b_D20210101-20210331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo1Mjc1NjgyZTE5YjY0NzNiODUzMDRhYjE5NWEzZTM5MC90YWJsZXJhbmdlOjUyNzU2ODJlMTliNjQ3M2I4NTMwNGFiMTk1YTNlMzkwXzItMy0xLTEtOTg2OTQ_e170ddb4-aaee-4083-bd1f-96815342846f">511</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76a973b7ccb648908c98bf838383a489_D20220101-20220331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo1Mjc1NjgyZTE5YjY0NzNiODUzMDRhYjE5NWEzZTM5MC90YWJsZXJhbmdlOjUyNzU2ODJlMTliNjQ3M2I4NTMwNGFiMTk1YTNlMzkwXzMtMS0xLTEtOTg2OTQ_79db3d73-94a2-41cb-8f6b-dc598d6e82c4">59</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i968b05c553634c7a8ef37ffb3b2c9491_D20210101-20210331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo1Mjc1NjgyZTE5YjY0NzNiODUzMDRhYjE5NWEzZTM5MC90YWJsZXJhbmdlOjUyNzU2ODJlMTliNjQ3M2I4NTMwNGFiMTk1YTNlMzkwXzMtMy0xLTEtOTg2OTQ_17c08b1a-e2e8-4cc8-8bf0-7160816505e5">174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b6fce6427cc4db58e97a1124f989059_D20220101-20220331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo1Mjc1NjgyZTE5YjY0NzNiODUzMDRhYjE5NWEzZTM5MC90YWJsZXJhbmdlOjUyNzU2ODJlMTliNjQ3M2I4NTMwNGFiMTk1YTNlMzkwXzQtMS0xLTEtOTg2OTQ_fa883a9f-c02d-4a82-b716-28ba7ab03059">546</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940747d1739c452b84105fc820e21d0f_D20210101-20210331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo1Mjc1NjgyZTE5YjY0NzNiODUzMDRhYjE5NWEzZTM5MC90YWJsZXJhbmdlOjUyNzU2ODJlMTliNjQ3M2I4NTMwNGFiMTk1YTNlMzkwXzQtMy0xLTEtOTg2OTQ_241f8d7b-6bea-4a37-9647-a20e1467ff98">685</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2b4c786f4bf4513b3347b942f655efd_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo1Mjc1NjgyZTE5YjY0NzNiODUzMDRhYjE5NWEzZTM5MC90YWJsZXJhbmdlOjUyNzU2ODJlMTliNjQ3M2I4NTMwNGFiMTk1YTNlMzkwXzUtMS0xLTEtOTg2OTQ_3611b00b-5330-4274-8bf0-ff8fc6d88186">643</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50f9973da9d3455e928bdbe756cb6f44_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo1Mjc1NjgyZTE5YjY0NzNiODUzMDRhYjE5NWEzZTM5MC90YWJsZXJhbmdlOjUyNzU2ODJlMTliNjQ3M2I4NTMwNGFiMTk1YTNlMzkwXzUtMy0xLTEtOTg2OTQ_6b60f439-03dd-48d8-9b56-27d3bfaf62ec">212</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings/(loss)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo1Mjc1NjgyZTE5YjY0NzNiODUzMDRhYjE5NWEzZTM5MC90YWJsZXJhbmdlOjUyNzU2ODJlMTliNjQ3M2I4NTMwNGFiMTk1YTNlMzkwXzYtMS0xLTEtOTg2OTQ_3cf54a40-f57c-4f73-b8d5-323f35ad7c98">97</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo1Mjc1NjgyZTE5YjY0NzNiODUzMDRhYjE5NWEzZTM5MC90YWJsZXJhbmdlOjUyNzU2ODJlMTliNjQ3M2I4NTMwNGFiMTk1YTNlMzkwXzYtMy0xLTEtOTg2OTQ_c2084606-45bf-47be-8fd3-1cc5927174d5">473</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span><br/></span></div></div></ix:continuation></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="id202b45e94df4116ac33a0b73eb21bc3" continuedAt="i9e0d2166514e498da84bb65bdbf4a3d1"><ix:continuation id="ia491b192cc564177977da7ea1a6c2b09"><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical (1)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a8fa6b7c4c04392ad18e36a04760533_D20210701-20220331" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpiMDY2YWEyMzQzYTU0Mzc1YWFmZWYwOWZiNmM0YjhhYy90YWJsZXJhbmdlOmIwNjZhYTIzNDNhNTQzNzVhYWZlZjA5ZmI2YzRiOGFjXzItMS0xLTEtOTg2OTQ_ec9464a4-7db4-482a-afeb-5efb7b6f2dca">1,319</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib25907ae15fa44dcb0802c504cec1c88_D20200701-20210331" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpiMDY2YWEyMzQzYTU0Mzc1YWFmZWYwOWZiNmM0YjhhYy90YWJsZXJhbmdlOmIwNjZhYTIzNDNhNTQzNzVhYWZlZjA5ZmI2YzRiOGFjXzItMy0xLTEtOTg2OTQ_bd31cc84-8cf9-4145-b22c-2ff08732f3f2">1,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6afdf5f1340d41c6941f5cc19ff2ef71_D20210701-20220331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpiMDY2YWEyMzQzYTU0Mzc1YWFmZWYwOWZiNmM0YjhhYy90YWJsZXJhbmdlOmIwNjZhYTIzNDNhNTQzNzVhYWZlZjA5ZmI2YzRiOGFjXzMtMS0xLTEtOTg2OTQ_b12ae61c-9127-4b69-95cc-b7b7b5bdc19b">232</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i203ccf6041354aa887510c9903970c43_D20200701-20210331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpiMDY2YWEyMzQzYTU0Mzc1YWFmZWYwOWZiNmM0YjhhYy90YWJsZXJhbmdlOmIwNjZhYTIzNDNhNTQzNzVhYWZlZjA5ZmI2YzRiOGFjXzMtMy0xLTEtOTg2OTQ_b0f1a0e9-f32f-4f8e-8d55-78659f570965">640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7205a1910584e49b66107f75befc03d_D20210701-20220331" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpiMDY2YWEyMzQzYTU0Mzc1YWFmZWYwOWZiNmM0YjhhYy90YWJsZXJhbmdlOmIwNjZhYTIzNDNhNTQzNzVhYWZlZjA5ZmI2YzRiOGFjXzQtMS0xLTEtOTg2OTQ_cb1e10f7-b523-419e-9ff8-e46056f29475">1,551</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic84e3ea0e4fb4425b6174e7655ba01f1_D20200701-20210331" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpiMDY2YWEyMzQzYTU0Mzc1YWFmZWYwOWZiNmM0YjhhYy90YWJsZXJhbmdlOmIwNjZhYTIzNDNhNTQzNzVhYWZlZjA5ZmI2YzRiOGFjXzQtMy0xLTEtOTg2OTQ_8cb0f77d-eedb-49e7-bc3c-91f9994d05e9">1,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1865dd177bf446bb0808b03a8c0b8b6_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpiMDY2YWEyMzQzYTU0Mzc1YWFmZWYwOWZiNmM0YjhhYy90YWJsZXJhbmdlOmIwNjZhYTIzNDNhNTQzNzVhYWZlZjA5ZmI2YzRiOGFjXzUtMS0xLTEtOTg2OTQ_6976d3f1-ba19-4c77-aab3-e2bd8eb9531b">2,183</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b1b3f0e63094c6ba80ba1a031e52c86_D20200701-20210331" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpiMDY2YWEyMzQzYTU0Mzc1YWFmZWYwOWZiNmM0YjhhYy90YWJsZXJhbmdlOmIwNjZhYTIzNDNhNTQzNzVhYWZlZjA5ZmI2YzRiOGFjXzUtMy0xLTEtOTg2OTQ_089b27cd-7a85-49bc-a4d3-dd09c7d049b1">1,656</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings/(loss)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpiMDY2YWEyMzQzYTU0Mzc1YWFmZWYwOWZiNmM0YjhhYy90YWJsZXJhbmdlOmIwNjZhYTIzNDNhNTQzNzVhYWZlZjA5ZmI2YzRiOGFjXzYtMS0xLTEtOTg2OTQ_65467ab8-e438-4181-8de8-db9f79520f00">632</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpiMDY2YWEyMzQzYTU0Mzc1YWFmZWYwOWZiNmM0YjhhYy90YWJsZXJhbmdlOmIwNjZhYTIzNDNhNTQzNzVhYWZlZjA5ZmI2YzRiOGFjXzYtMy0xLTEtOTg2OTQ_67494005-0267-4a0c-afad-3a064646e38a">310</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Pharmaceutical segment profit includes opioid-related litigation defense and compliance costs, but does not include a one-time contingent attorney fee of $<ix:nonFraction unitRef="usd" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" name="cah:ContingentAttorneyFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90ZXh0cmVnaW9uOmVkNzE0MTJiOTQ5MjRlZDQ5ZDUyZDE3ZjYxYjcyYWM1XzMyOTg1MzQ4OTU3NDg_4657fb9e-7543-4874-b8a4-4012408dd76d">18</ix:nonFraction>&#160;million incurred during the three and nine months ended March&#160;31, 2022 related to the finalization of the Settlement Agreement. Due to the unique nature and significance of the Settlement Agreement, and the one-time, contingent nature of the fee, this related fee was included in litigation (recoveries)/charges, net in the condensed consolidated statements of earnings/(loss). Additionally, pharmaceutical segment profit during nine months ended March 31, 2022 was positively impacted by a $<ix:nonFraction unitRef="usd" contextRef="i9215c78d739b4b399eaa5fb71927062e_D20211001-20211231" decimals="-6" name="cah:JudgmentForLostProfits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90ZXh0cmVnaW9uOmVkNzE0MTJiOTQ5MjRlZDQ5ZDUyZDE3ZjYxYjcyYWM1XzUwNzQ_d231b28d-ffe5-451b-966b-a98e78bf5dca">16</ix:nonFraction>&#160;million judgment for lost profits related to an ordinary course intellectual property rights claim.</span></div></ix:continuation><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90ZXh0cmVnaW9uOmVkNzE0MTJiOTQ5MjRlZDQ5ZDUyZDE3ZjYxYjcyYWM1XzU1NjI_f0599fa6-5a84-4e12-9988-e73583e9941f" continuedAt="ic8dbcc86bdf543689ce3dffa177f5540" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total assets for each reportable segment and Corporate at: </span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:52.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dc2bc03fca7468582ef192514e3bfd5_I20220331" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkOGMzOWNiNjNjMzc0ZmJmOWYwM2I3NDJjNmE4YmZkZi90YWJsZXJhbmdlOmQ4YzM5Y2I2M2MzNzRmYmY5ZjAzYjc0MmM2YThiZmRmXzEtMS0xLTEtOTg2OTQ_70326003-5480-4bd5-bc74-7cd7cc89fff1">25,470</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab9fb6c03f2c41b09eab97067568553e_I20210630" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkOGMzOWNiNjNjMzc0ZmJmOWYwM2I3NDJjNmE4YmZkZi90YWJsZXJhbmdlOmQ4YzM5Y2I2M2MzNzRmYmY5ZjAzYjc0MmM2YThiZmRmXzEtMy0xLTEtOTg2OTQ_eabaab82-4894-4e32-8174-77ef1da0a1f2">23,624</ix:nonFraction>&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical (1) (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b44ed725e04cc79bd011f2ce6f6445_I20220331" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkOGMzOWNiNjNjMzc0ZmJmOWYwM2I3NDJjNmE4YmZkZi90YWJsZXJhbmdlOmQ4YzM5Y2I2M2MzNzRmYmY5ZjAzYjc0MmM2YThiZmRmXzItMS0xLTEtOTg2OTQ_9897a988-fada-484b-9206-21e6e65a7934">12,166</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2054ef93e9f6497bb4e5e5e8c06c5afa_I20210630" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkOGMzOWNiNjNjMzc0ZmJmOWYwM2I3NDJjNmE4YmZkZi90YWJsZXJhbmdlOmQ4YzM5Y2I2M2MzNzRmYmY5ZjAzYjc0MmM2YThiZmRmXzItMy0xLTEtOTg2OTQ_973e8af5-4b4b-4be1-8963-5c39e8f58ac7">15,408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate </span></td><td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a7244a5c088444480543d7621bd8890_I20220331" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkOGMzOWNiNjNjMzc0ZmJmOWYwM2I3NDJjNmE4YmZkZi90YWJsZXJhbmdlOmQ4YzM5Y2I2M2MzNzRmYmY5ZjAzYjc0MmM2YThiZmRmXzMtMS0xLTEtOTg2OTQ_c93911e1-747b-4b74-a2eb-b30512415f78">4,475</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"></td><td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fa86c22fb664c2d85324c8fa396e444_I20210630" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkOGMzOWNiNjNjMzc0ZmJmOWYwM2I3NDJjNmE4YmZkZi90YWJsZXJhbmdlOmQ4YzM5Y2I2M2MzNzRmYmY5ZjAzYjc0MmM2YThiZmRmXzMtMy0xLTEtOTg2OTQ_509214e3-db10-4034-b694-0fb237a125f7">5,421</ix:nonFraction>&#160;</span></td><td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkOGMzOWNiNjNjMzc0ZmJmOWYwM2I3NDJjNmE4YmZkZi90YWJsZXJhbmdlOmQ4YzM5Y2I2M2MzNzRmYmY5ZjAzYjc0MmM2YThiZmRmXzQtMS0xLTEtOTg2OTQ_ae690cbf-b351-4e8a-bb9b-b65bb98fa12c">42,111</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkOGMzOWNiNjNjMzc0ZmJmOWYwM2I3NDJjNmE4YmZkZi90YWJsZXJhbmdlOmQ4YzM5Y2I2M2MzNzRmYmY5ZjAzYjc0MmM2YThiZmRmXzQtMy0xLTEtOTg2OTQ_83f3deed-124a-4c14-9560-778362bd81c1">44,453</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Assets of $<ix:nonFraction unitRef="usd" contextRef="i25b4b6630ae44ef28341784008cfd847_I20210630" decimals="-6" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90ZXh0cmVnaW9uOmVkNzE0MTJiOTQ5MjRlZDQ5ZDUyZDE3ZjYxYjcyYWM1XzUyNzE_55ae735d-501e-4785-9cf4-ec49822c81e7">1.1</ix:nonFraction> billion classified as held for sale related to the Cordis divestiture were included within Medical at June 30, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="i9e0d2166514e498da84bb65bdbf4a3d1" continuedAt="ib9824dc84f6d4db1822160bf13e57ae8"><ix:continuation id="ic8dbcc86bdf543689ce3dffa177f5540" continuedAt="i991467ce084e422b867d04320b280c0e">(2)</ix:continuation></ix:continuation></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"><ix:continuation id="ib9824dc84f6d4db1822160bf13e57ae8"><ix:continuation id="i991467ce084e422b867d04320b280c0e">Medical reflects $<ix:nonFraction unitRef="usd" contextRef="i579fe90cd44b45029f6ce1e6fd52d06e_D20210701-20220331" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90ZXh0cmVnaW9uOmVkNzE0MTJiOTQ5MjRlZDQ5ZDUyZDE3ZjYxYjcyYWM1XzMyOTg1MzQ4OTU4NDI_2e674973-267c-4563-a406-242c84b0c40a">1.8</ix:nonFraction>&#160;billion of goodwill impairment charges recorded in connection with interim goodwill impairment testing for the Medical Unit at March 31, 2022, and December 31, 2021.</ix:continuation></ix:continuation> </span></div><div id="iaf3733bf892b435689161c61a06da348_124"></div><ix:nonNumeric contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzI0Njk_fe68d5da-7def-4ed8-b4bb-70830a1d6c73" continuedAt="i7db82b06741043faaa959733b899031d" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">13. Share-Based Compensation</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain stock incentive plans (collectively, the &#8220;Plans&#8221;) for the benefit of certain of our officers, directors and employees. </span></div><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzI0NTE_4fe48fb1-057c-43fd-a8a0-c36365db794d" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides total share-based compensation expense by type of award:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ac145c43e84d588b95df88a14fdc55_D20220101-20220331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTozMzc0YWYwZWZjNzI0MDI4YTQ0OTE0MGI1Y2QwYzE3MS90YWJsZXJhbmdlOjMzNzRhZjBlZmM3MjQwMjhhNDQ5MTQwYjVjZDBjMTcxXzItMS0xLTEtOTg2OTQ_7ac2e562-ddec-41f7-8c2e-070695b46516">18</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d746fa13a56425188cf694ad9491c8b_D20210101-20210331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTozMzc0YWYwZWZjNzI0MDI4YTQ0OTE0MGI1Y2QwYzE3MS90YWJsZXJhbmdlOjMzNzRhZjBlZmM3MjQwMjhhNDQ5MTQwYjVjZDBjMTcxXzItMy0xLTEtOTg2OTQ_adf5cf9e-5a42-4883-80a3-150e6b722749">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fc6f93a9a324e02934d0435deab460b_D20220101-20220331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTozMzc0YWYwZWZjNzI0MDI4YTQ0OTE0MGI1Y2QwYzE3MS90YWJsZXJhbmdlOjMzNzRhZjBlZmM3MjQwMjhhNDQ5MTQwYjVjZDBjMTcxXzQtMS0xLTEtOTg2OTQ_bd7846d0-a846-4932-aa5b-12add703b466">5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12af8121f223485cbae6b363fb276e76_D20210101-20210331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTozMzc0YWYwZWZjNzI0MDI4YTQ0OTE0MGI1Y2QwYzE3MS90YWJsZXJhbmdlOjMzNzRhZjBlZmM3MjQwMjhhNDQ5MTQwYjVjZDBjMTcxXzQtMy0xLTEtOTg2OTQ_47cc5379-1b2d-45c2-a88a-2d299242ca51">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTozMzc0YWYwZWZjNzI0MDI4YTQ0OTE0MGI1Y2QwYzE3MS90YWJsZXJhbmdlOjMzNzRhZjBlZmM3MjQwMjhhNDQ5MTQwYjVjZDBjMTcxXzUtMS0xLTEtOTg2OTQ_4e80e6e8-b2a0-4052-a503-d281189b4880">23</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTozMzc0YWYwZWZjNzI0MDI4YTQ0OTE0MGI1Y2QwYzE3MS90YWJsZXJhbmdlOjMzNzRhZjBlZmM3MjQwMjhhNDQ5MTQwYjVjZDBjMTcxXzUtMy0xLTEtOTg2OTQ_3d13f886-3929-479a-aebb-ccf7ae3f9b5f">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7587b0e2335a4976aed28934df90543d_D20210701-20220331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTpjNzliMTQ1MzA4NDM0YWNhOTkyNzFmNWQyYWI2NWJhNS90YWJsZXJhbmdlOmM3OWIxNDUzMDg0MzRhY2E5OTI3MWY1ZDJhYjY1YmE1XzItMS0xLTEtOTg2OTQ_0dafac9c-5e77-4247-84c6-ff582c421f61">53</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884f8a089566407ab080d0ebb229f552_D20200701-20210331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTpjNzliMTQ1MzA4NDM0YWNhOTkyNzFmNWQyYWI2NWJhNS90YWJsZXJhbmdlOmM3OWIxNDUzMDg0MzRhY2E5OTI3MWY1ZDJhYjY1YmE1XzItMy0xLTEtOTg2OTQ_021b034b-9984-4de1-915e-23991a6a325a">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec8a7050443b4a1cb54f2dc25501b78f_D20210701-20220331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTpjNzliMTQ1MzA4NDM0YWNhOTkyNzFmNWQyYWI2NWJhNS90YWJsZXJhbmdlOmM3OWIxNDUzMDg0MzRhY2E5OTI3MWY1ZDJhYjY1YmE1XzQtMS0xLTEtOTg2OTQ_00d0ce7d-6891-4b8c-8d3e-3a4512e1942b">12</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic70067800d5143aea0895bee00acddf8_D20200701-20210331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTpjNzliMTQ1MzA4NDM0YWNhOTkyNzFmNWQyYWI2NWJhNS90YWJsZXJhbmdlOmM3OWIxNDUzMDg0MzRhY2E5OTI3MWY1ZDJhYjY1YmE1XzQtMy0xLTEtOTg2OTQ_230416b4-dca9-4c8a-95c6-c249cdef7e6d">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTpjNzliMTQ1MzA4NDM0YWNhOTkyNzFmNWQyYWI2NWJhNS90YWJsZXJhbmdlOmM3OWIxNDUzMDg0MzRhY2E5OTI3MWY1ZDJhYjY1YmE1XzUtMS0xLTEtOTg2OTQ_4716e75b-f53b-4a3b-9a23-e81b3c8e5414">65</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTpjNzliMTQ1MzA4NDM0YWNhOTkyNzFmNWQyYWI2NWJhNS90YWJsZXJhbmdlOmM3OWIxNDUzMDg0MzRhY2E5OTI3MWY1ZDJhYjY1YmE1XzUtMy0xLTEtOTg2OTQ_874a1f0d-a011-416d-80c5-21b589c0f83e">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total tax benefit related to share-based compensation was $<ix:nonFraction unitRef="usd" contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzI5Mw_7fefb17e-3da4-4006-a8df-06d7d756979c">3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzMwMA_55a3e022-915f-4577-aae0-181af55ac7fb">5</ix:nonFraction> million for the three months ended March&#160;31, 2022 and 2021, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzM0NQ_3542c9a7-8fc2-4efd-9c2c-284643496372">9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzM1Mg_de5ac30c-e4b3-4bd7-b1b5-fcc5ea9c675d">12</ix:nonFraction> million for the nine months ended March&#160;31, 2022 and 2021, respectively.</span></div></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="i7db82b06741043faaa959733b899031d" continuedAt="i5c74820f88a4457d83756eb3ff0b2ded"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted share units granted under the Plans generally vest in equal annual installments over <ix:nonNumeric contextRef="i7587b0e2335a4976aed28934df90543d_D20210701-20220331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzQ4Nw_ab6335ae-d6b5-46ed-b6a2-f475aeb36a58">three years</ix:nonNumeric>. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzI0MTc_b250c6dd-1311-458b-af3c-1e6621311049" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to restricted share units under the Plans:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:51.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.218%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa16d72f5cb94c3dae8ef889f5cf1b73_I20210630" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTozMzY1ZjZmNGI0YjQ0YmYxOWMwZTAzNGJlZDY2Yzk0MS90YWJsZXJhbmdlOjMzNjVmNmY0YjRiNDRiZjE5YzBlMDM0YmVkNjZjOTQxXzEtMS0xLTEtOTg2OTQ_7d5920e9-840c-4ff4-97c7-0501e18a1eaf">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaa16d72f5cb94c3dae8ef889f5cf1b73_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTozMzY1ZjZmNGI0YjQ0YmYxOWMwZTAzNGJlZDY2Yzk0MS90YWJsZXJhbmdlOjMzNjVmNmY0YjRiNDRiZjE5YzBlMDM0YmVkNjZjOTQxXzEtMy0xLTEtOTg2OTQ_8f8a8fb4-72d1-47af-9aad-03a7e1306a08">49.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7587b0e2335a4976aed28934df90543d_D20210701-20220331" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTozMzY1ZjZmNGI0YjQ0YmYxOWMwZTAzNGJlZDY2Yzk0MS90YWJsZXJhbmdlOjMzNjVmNmY0YjRiNDRiZjE5YzBlMDM0YmVkNjZjOTQxXzItMS0xLTEtOTg2OTQ_3e2a09d4-8169-4b43-9199-4c42ba5c2140">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7587b0e2335a4976aed28934df90543d_D20210701-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTozMzY1ZjZmNGI0YjQ0YmYxOWMwZTAzNGJlZDY2Yzk0MS90YWJsZXJhbmdlOjMzNjVmNmY0YjRiNDRiZjE5YzBlMDM0YmVkNjZjOTQxXzItMy0xLTEtOTg2OTQ_91448682-aa44-4ec9-8c79-5cd606c73a22">51.78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7587b0e2335a4976aed28934df90543d_D20210701-20220331" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTozMzY1ZjZmNGI0YjQ0YmYxOWMwZTAzNGJlZDY2Yzk0MS90YWJsZXJhbmdlOjMzNjVmNmY0YjRiNDRiZjE5YzBlMDM0YmVkNjZjOTQxXzMtMS0xLTEtOTg2OTQ_45219d79-f50b-4888-ad26-aa08b9796e2c">2</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7587b0e2335a4976aed28934df90543d_D20210701-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTozMzY1ZjZmNGI0YjQ0YmYxOWMwZTAzNGJlZDY2Yzk0MS90YWJsZXJhbmdlOjMzNjVmNmY0YjRiNDRiZjE5YzBlMDM0YmVkNjZjOTQxXzMtMy0xLTEtOTg2OTQ_f3b38bb4-9ef4-414c-b433-912b13fa6ee9">49.61</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7587b0e2335a4976aed28934df90543d_D20210701-20220331" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTozMzY1ZjZmNGI0YjQ0YmYxOWMwZTAzNGJlZDY2Yzk0MS90YWJsZXJhbmdlOjMzNjVmNmY0YjRiNDRiZjE5YzBlMDM0YmVkNjZjOTQxXzQtMS0xLTEtOTg2OTQ_d8a9d472-36a7-4dad-ab2d-ccbd07a889de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7587b0e2335a4976aed28934df90543d_D20210701-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTozMzY1ZjZmNGI0YjQ0YmYxOWMwZTAzNGJlZDY2Yzk0MS90YWJsZXJhbmdlOjMzNjVmNmY0YjRiNDRiZjE5YzBlMDM0YmVkNjZjOTQxXzQtMy0xLTEtOTg2OTQ_7c0fa659-8942-4152-b185-aef95320e559">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at March 31, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i429695d6f4bd42f3954b0d838fa9cbea_I20220331" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTozMzY1ZjZmNGI0YjQ0YmYxOWMwZTAzNGJlZDY2Yzk0MS90YWJsZXJhbmdlOjMzNjVmNmY0YjRiNDRiZjE5YzBlMDM0YmVkNjZjOTQxXzUtMS0xLTEtOTg2OTQ_c971563b-9d6a-4451-833a-a951a352af71">3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i429695d6f4bd42f3954b0d838fa9cbea_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTozMzY1ZjZmNGI0YjQ0YmYxOWMwZTAzNGJlZDY2Yzk0MS90YWJsZXJhbmdlOjMzNjVmNmY0YjRiNDRiZjE5YzBlMDM0YmVkNjZjOTQxXzUtMy0xLTEtOTg2OTQ_fb4af8c5-c6ab-4880-95af-48fffb11333a">45.99</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2022, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $<ix:nonFraction unitRef="usd" contextRef="i429695d6f4bd42f3954b0d838fa9cbea_I20220331" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzgzNA_2ee2cf29-2e82-48e8-a7f8-f312e85883b6">89</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i7587b0e2335a4976aed28934df90543d_D20210701-20220331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzkwNw_d70daecd-4a0b-45cb-b722-a0d166237bc0">two years</ix:nonNumeric>.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee stock options granted under the Plans generally vest in equal annual installments over <ix:nonNumeric contextRef="i72e703868e904b989107e7bea5f5c25a_D20210701-20220331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzEwMjE_9d3d2a80-13b4-42c5-af07-79782b439a91">three years</ix:nonNumeric> and are exercisable for <ix:nonNumeric contextRef="i72e703868e904b989107e7bea5f5c25a_D20210701-20220331" name="cah:ExercisablePeriodOfPlansInYears" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzEwNDg_b7650d6e-a3b1-4218-ae60-083fe0e1c58f">ten years</ix:nonNumeric> from the grant date. All stock options are exercisable at a price equal to the market value of the common shares underlying the option on the grant date.</span></div><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzI0Mzg_06d55ee5-2f90-41ba-9ec3-cbb0ef9cdfd9" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all stock option transactions under the Plans:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.616%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.480%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price per<br/>Common Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at June 30, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTo1NTU4NDIyNDg0MGU0ZTkzYjU0M2FjOGM2YmMxM2RlZC90YWJsZXJhbmdlOjU1NTg0MjI0ODQwZTRlOTNiNTQzYWM4YzZiYzEzZGVkXzEtMS0xLTEtOTg2OTQ_8074e00e-4bd5-4012-89c6-7984dccbc691">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTo1NTU4NDIyNDg0MGU0ZTkzYjU0M2FjOGM2YmMxM2RlZC90YWJsZXJhbmdlOjU1NTg0MjI0ODQwZTRlOTNiNTQzYWM4YzZiYzEzZGVkXzEtMy0xLTEtOTg2OTQ_5da3d60d-376e-4146-9a1e-761ec381c345">68.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTo1NTU4NDIyNDg0MGU0ZTkzYjU0M2FjOGM2YmMxM2RlZC90YWJsZXJhbmdlOjU1NTg0MjI0ODQwZTRlOTNiNTQzYWM4YzZiYzEzZGVkXzItMS0xLTEtOTg2OTQ_bad6a345-a573-45a4-82ad-23c5033436de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTo1NTU4NDIyNDg0MGU0ZTkzYjU0M2FjOGM2YmMxM2RlZC90YWJsZXJhbmdlOjU1NTg0MjI0ODQwZTRlOTNiNTQzYWM4YzZiYzEzZGVkXzItMy0xLTEtOTg2OTQ_c90b67fa-ef7f-450c-8c1a-f3f8aedae419">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTo1NTU4NDIyNDg0MGU0ZTkzYjU0M2FjOGM2YmMxM2RlZC90YWJsZXJhbmdlOjU1NTg0MjI0ODQwZTRlOTNiNTQzYWM4YzZiYzEzZGVkXzMtMS0xLTEtOTg2OTQ_01c4dcd2-07f6-44d1-bd23-8dabf4363c02">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTo1NTU4NDIyNDg0MGU0ZTkzYjU0M2FjOGM2YmMxM2RlZC90YWJsZXJhbmdlOjU1NTg0MjI0ODQwZTRlOTNiNTQzYWM4YzZiYzEzZGVkXzMtMy0xLTEtOTg2OTQ_20af5b29-e7a2-4325-96a7-9bd7ba1eb3ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTo1NTU4NDIyNDg0MGU0ZTkzYjU0M2FjOGM2YmMxM2RlZC90YWJsZXJhbmdlOjU1NTg0MjI0ODQwZTRlOTNiNTQzYWM4YzZiYzEzZGVkXzQtMS0xLTEtOTg2OTQ_712dcbee-bb55-4626-a845-c8e991ac589e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTo1NTU4NDIyNDg0MGU0ZTkzYjU0M2FjOGM2YmMxM2RlZC90YWJsZXJhbmdlOjU1NTg0MjI0ODQwZTRlOTNiNTQzYWM4YzZiYzEzZGVkXzQtMy0xLTEtOTg2OTQ_8ddc2965-962c-4163-a5dd-5920e45f68a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding at March 31, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTo1NTU4NDIyNDg0MGU0ZTkzYjU0M2FjOGM2YmMxM2RlZC90YWJsZXJhbmdlOjU1NTg0MjI0ODQwZTRlOTNiNTQzYWM4YzZiYzEzZGVkXzUtMS0xLTEtOTg2OTQ_7704ebb0-3f32-4a3f-9bcc-fc9e66ca94c8">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTo1NTU4NDIyNDg0MGU0ZTkzYjU0M2FjOGM2YmMxM2RlZC90YWJsZXJhbmdlOjU1NTg0MjI0ODQwZTRlOTNiNTQzYWM4YzZiYzEzZGVkXzUtMy0xLTEtOTg2OTQ_de58241d-34ef-406d-95c5-1474066593b3">69.41</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercisable at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTo1NTU4NDIyNDg0MGU0ZTkzYjU0M2FjOGM2YmMxM2RlZC90YWJsZXJhbmdlOjU1NTg0MjI0ODQwZTRlOTNiNTQzYWM4YzZiYzEzZGVkXzYtMS0xLTEtOTg2OTQ_ecf47edc-e426-4f5a-a754-c32e62a684a0">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTo1NTU4NDIyNDg0MGU0ZTkzYjU0M2FjOGM2YmMxM2RlZC90YWJsZXJhbmdlOjU1NTg0MjI0ODQwZTRlOTNiNTQzYWM4YzZiYzEzZGVkXzYtMy0xLTEtOTg2OTQ_cb5eeb1f-d969-48fd-b407-bdf0ef631c59">69.58</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2022, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested stock options not yet recognized was $<ix:nonFraction unitRef="usd" contextRef="i81916c52c3fd4ebfbcb9cb988adcf939_I20220331" decimals="5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzE0MTc_54d8c077-505c-46af-97a1-978dfd4d0b50">0.2</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i72e703868e904b989107e7bea5f5c25a_D20210701-20220331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzE0OTA_d99f2ea8-c7ac-45cb-a801-95c7523f22b8">two years</ix:nonNumeric>.</span></div><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="cah:AdditionalStockOptionPlanDataTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzIzOTc_a4f4197b-7523-4f41-9583-358d626ed464" continuedAt="i24e5205bd0fa4507b8b09cc257ec1294" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide additional detail related to stock options:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate intrinsic value of outstanding options at period end</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81916c52c3fd4ebfbcb9cb988adcf939_I20220331" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTowNjZmMGQ5YTQ3MGQ0OTJkODAzMzI1NGQ5YTg4YjAxZC90YWJsZXJhbmdlOjA2NmYwZDlhNDcwZDQ5MmQ4MDMzMjU0ZDlhODhiMDFkXzEtMS0xLTEtOTg2OTQ_e31042e6-add3-40f8-b1de-8ef46accc49d">8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i563a2c8d36a84c8890168f4f9a86e549_I20210630" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTowNjZmMGQ5YTQ3MGQ0OTJkODAzMzI1NGQ5YTg4YjAxZC90YWJsZXJhbmdlOjA2NmYwZDlhNDcwZDQ5MmQ4MDMzMjU0ZDlhODhiMDFkXzEtMy0xLTEtOTg2OTQ_7477af0f-a334-44df-9ec4-18125b55990a">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate intrinsic value of exercisable options at period end</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81916c52c3fd4ebfbcb9cb988adcf939_I20220331" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTowNjZmMGQ5YTQ3MGQ0OTJkODAzMzI1NGQ5YTg4YjAxZC90YWJsZXJhbmdlOjA2NmYwZDlhNDcwZDQ5MmQ4MDMzMjU0ZDlhODhiMDFkXzItMS0xLTEtOTg2OTQ_f99d8755-7680-4116-8e85-b20dcb6c3070">7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i563a2c8d36a84c8890168f4f9a86e549_I20210630" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTowNjZmMGQ5YTQ3MGQ0OTJkODAzMzI1NGQ5YTg4YjAxZC90YWJsZXJhbmdlOjA2NmYwZDlhNDcwZDQ5MmQ4MDMzMjU0ZDlhODhiMDFkXzItMy0xLTEtOTg2OTQ_c9a0bdc5-43e2-40ff-95f7-3487746efddd">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="i5c74820f88a4457d83756eb3ff0b2ded"><div style="text-align:justify"><ix:continuation id="i24e5205bd0fa4507b8b09cc257ec1294"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining contractual life of outstanding options</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i72e703868e904b989107e7bea5f5c25a_D20210701-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTowNWFlOTg0Y2UwYzA0NjRmYjBkZWJkODkxOTY3MWVlMi90YWJsZXJhbmdlOjA1YWU5ODRjZTBjMDQ2NGZiMGRlYmQ4OTE5NjcxZWUyXzEtMS0xLTEtOTg2OTQ_f72a76d2-bdea-4ebe-ad90-4e9578e8d69b">3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if6804c7cefdb418480ee13a51907f380_D20200701-20210331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTowNWFlOTg0Y2UwYzA0NjRmYjBkZWJkODkxOTY3MWVlMi90YWJsZXJhbmdlOjA1YWU5ODRjZTBjMDQ2NGZiMGRlYmQ4OTE5NjcxZWUyXzEtMy0xLTEtOTg2OTQ_0717d0ac-82fb-41aa-9acf-bb7b8e6e515d">4</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining contractual life of exercisable options</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i72e703868e904b989107e7bea5f5c25a_D20210701-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTowNWFlOTg0Y2UwYzA0NjRmYjBkZWJkODkxOTY3MWVlMi90YWJsZXJhbmdlOjA1YWU5ODRjZTBjMDQ2NGZiMGRlYmQ4OTE5NjcxZWUyXzItMS0xLTEtOTg2OTQ_05b9ec33-282e-4ee1-bed6-a53376d5f29d">3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if6804c7cefdb418480ee13a51907f380_D20200701-20210331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTowNWFlOTg0Y2UwYzA0NjRmYjBkZWJkODkxOTY3MWVlMi90YWJsZXJhbmdlOjA1YWU5ODRjZTBjMDQ2NGZiMGRlYmQ4OTE5NjcxZWUyXzItMy0xLTEtOTg2OTQ_47f1c45f-84d5-4f77-b909-21064ef0f7d5">4</ix:nonNumeric></span></td></tr></table></ix:continuation></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Performance Share Units</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance share units vest over a <ix:nonFraction unitRef="number" contextRef="iec8a7050443b4a1cb54f2dc25501b78f_D20210701-20220331" decimals="INF" name="cah:VestingPeriodinyearsforShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzE2MzM_60b0f886-e752-42dd-ad87-22091cfe4902">3</ix:nonFraction>-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from <ix:nonFraction unitRef="number" contextRef="i5833a4aca61e4135963e45569b6980df_D20210701-20220331" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzE3OTY_29f7dd63-6961-48ba-954e-245f99c6c0f0"><ix:nonFraction unitRef="number" contextRef="i160dc3f384644e66812cbec2a46665b2_D20190701-20200331" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzE3OTY_7ed9587e-6632-4a79-a98b-d2d90bbf4b20">zero</ix:nonFraction></ix:nonFraction> to <ix:nonFraction unitRef="number" contextRef="i766ebcafc487484896f01112fb4d75ea_D20190701-20200331" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzE4MDI_0165a295-6057-4ae9-8e79-48401d89fbb1"><ix:nonFraction unitRef="number" contextRef="i3b9a407d237d4399ad21e36831394a4a_D20200701-20210331" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzE4MDI_260d97aa-669b-4560-8b07-ea43f058c03c">240</ix:nonFraction></ix:nonFraction> percent of the target award amount for the fiscal 2020 and 2021 grants and <ix:nonFraction unitRef="number" contextRef="i5833a4aca61e4135963e45569b6980df_D20210701-20220331" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzE4NzI_62a91cf6-621e-438f-873b-cb2b985518f4">zero</ix:nonFraction> to <ix:nonFraction unitRef="number" contextRef="i8b1fc63c210f45c4b87728a4957e3834_D20210701-20220331" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzE4Nzg_2c178b22-67cb-4de7-9a5f-d0a8abbfd5c2">234</ix:nonFraction> percent for the fiscal 2022 grant. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div><ix:nonNumeric contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331" name="us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzI0NjQ_7f3b4175-f85d-4b95-833c-83d34b17024c" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:49.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.023%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance<br/>Share Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i971a6ca11d6d4f408c6af2dc52b79810_I20210630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTo3NzAxMzRlNDQzNzE0YjFiYjU1MTcyNGZjNDU0NWFmMC90YWJsZXJhbmdlOjc3MDEzNGU0NDM3MTRiMWJiNTUxNzI0ZmM0NTQ1YWYwXzEtMS0xLTEtOTg2OTQ_87357c7c-6d4a-44b7-a472-cbaf9eed9aeb">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i971a6ca11d6d4f408c6af2dc52b79810_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTo3NzAxMzRlNDQzNzE0YjFiYjU1MTcyNGZjNDU0NWFmMC90YWJsZXJhbmdlOjc3MDEzNGU0NDM3MTRiMWJiNTUxNzI0ZmM0NTQ1YWYwXzEtMy0xLTEtOTg2OTQ_fc85264b-7b4e-4d01-92ac-d159fca7681a">54.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iec8a7050443b4a1cb54f2dc25501b78f_D20210701-20220331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTo3NzAxMzRlNDQzNzE0YjFiYjU1MTcyNGZjNDU0NWFmMC90YWJsZXJhbmdlOjc3MDEzNGU0NDM3MTRiMWJiNTUxNzI0ZmM0NTQ1YWYwXzItMS0xLTEtOTg2OTQ_a78198ba-649e-4eff-b181-5a31526a9fef">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iec8a7050443b4a1cb54f2dc25501b78f_D20210701-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTo3NzAxMzRlNDQzNzE0YjFiYjU1MTcyNGZjNDU0NWFmMC90YWJsZXJhbmdlOjc3MDEzNGU0NDM3MTRiMWJiNTUxNzI0ZmM0NTQ1YWYwXzItMy0xLTEtOTg2OTQ_90543cdf-4346-4188-9e4d-16f35cc3a41f">51.91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iec8a7050443b4a1cb54f2dc25501b78f_D20210701-20220331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTo3NzAxMzRlNDQzNzE0YjFiYjU1MTcyNGZjNDU0NWFmMC90YWJsZXJhbmdlOjc3MDEzNGU0NDM3MTRiMWJiNTUxNzI0ZmM0NTQ1YWYwXzMtMS0xLTEtOTg2OTQ_e549b20a-3543-4fd1-9c43-4d3df5b6fc86">0.3</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iec8a7050443b4a1cb54f2dc25501b78f_D20210701-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTo3NzAxMzRlNDQzNzE0YjFiYjU1MTcyNGZjNDU0NWFmMC90YWJsZXJhbmdlOjc3MDEzNGU0NDM3MTRiMWJiNTUxNzI0ZmM0NTQ1YWYwXzMtMy0xLTEtOTg2OTQ_ba5c3c67-5160-4236-8b06-42dd011dbdb4">52.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iec8a7050443b4a1cb54f2dc25501b78f_D20210701-20220331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTo3NzAxMzRlNDQzNzE0YjFiYjU1MTcyNGZjNDU0NWFmMC90YWJsZXJhbmdlOjc3MDEzNGU0NDM3MTRiMWJiNTUxNzI0ZmM0NTQ1YWYwXzQtMS0xLTEtOTg2OTQ_39575636-8d0e-46ac-b8e5-31a6c92e300b">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iec8a7050443b4a1cb54f2dc25501b78f_D20210701-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTo3NzAxMzRlNDQzNzE0YjFiYjU1MTcyNGZjNDU0NWFmMC90YWJsZXJhbmdlOjc3MDEzNGU0NDM3MTRiMWJiNTUxNzI0ZmM0NTQ1YWYwXzQtMy0xLTEtOTg2OTQ_67796469-b0f9-495d-bab5-883a0b7293ef">52.36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at March 31, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id38ff405ba8f4f46b884a396366a86de_I20220331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTo3NzAxMzRlNDQzNzE0YjFiYjU1MTcyNGZjNDU0NWFmMC90YWJsZXJhbmdlOjc3MDEzNGU0NDM3MTRiMWJiNTUxNzI0ZmM0NTQ1YWYwXzUtMS0xLTEtOTg2OTQ_d5c5a657-6f67-47ae-9fdc-8adae2c3457d">1.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id38ff405ba8f4f46b884a396366a86de_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTo3NzAxMzRlNDQzNzE0YjFiYjU1MTcyNGZjNDU0NWFmMC90YWJsZXJhbmdlOjc3MDEzNGU0NDM3MTRiMWJiNTUxNzI0ZmM0NTQ1YWYwXzUtMy0xLTEtOTg2OTQ_b2435d4a-f85a-4ffd-bf23-550e0ccbcd3e">57.27</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2022, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $<ix:nonFraction unitRef="usd" contextRef="id38ff405ba8f4f46b884a396366a86de_I20220331" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzIyODY_90210966-916c-41cc-8175-27caaa8a5977">25</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="iec8a7050443b4a1cb54f2dc25501b78f_D20210701-20220331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzIzNTk_2cf9e642-986f-4c65-9864-5b151cfddd5b">two years</ix:nonNumeric> if performance goals are achieved.</span></div></ix:continuation></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iaf3733bf892b435689161c61a06da348_127"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="-sec-extract:summary;margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibits</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="-sec-extract:summary;margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Exhibits</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit<br/>Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/721371/000119312508230011/dex31.htm">Amended and Restated Articles of Incorporation of Cardinal Health, Inc., as amended (incorporated by reference to Exhibit 3.1 to Cardinal Health&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2008, File No. 1-11373)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/721371/000072137121000116/restatedcodeofregulationsn.htm">Cardinal Health, Inc. Restated Code of Regulations, as amended  (incorporated by reference to Exhibit 3.2 to Cardinal Health&#8217;s Quarterly Report on Form 10-Q filed on November 9, 2021, File No. 1-11373)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/721371/000072137122000013/a22q2_10qx123121xexhibit107.htm">Aircraft Time Sharing Agreement, effective as of January 1, 2022, by and between Cardinal Health, Inc. and Michael C. Kaufmann</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/721371/000072137122000013/a22q2_10qx123121xexhibit107.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/721371/000072137122000013/a22q2_10qx123121xexhibit107.htm">(incorporated by reference to Exhibit 10.7 to Cardinal Health's Quarterly Report on form 10-Q filed on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/721371/000072137122000013/a22q2_10qx123121xexhibit107.htm">February 3, 2022, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/721371/000072137122000013/a22q2_10qx123121xexhibit107.htm">File No. 1-11373)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a22q3_10qx033122xexhibit102.htm">First Amendment to the Cardinal Health Deferred Compensation Plan, as amended and restated on January 1, 2020</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001140859/000110465922055245/tm2212023d1_ex10-1.htm">Distributor Settlement Agreement related to opioids claims, entered into on February 25, 2022, among the Settling States, the Settling Distributors and the Participating Subdivisions (as defined therein</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001140859/000110465922055245/tm2212023d1_ex10-1.htm">) </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001140859/000110465922055245/tm2212023d1_ex10-1.htm">(incorporated by reference to Exhibit 10.1 to AmerisourceBergen Corporation's current report on form 8-K filed on May 2, 2022, File No. 1-16671)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a22q3_10qx033122xexhibit311.htm">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a22q3_10qx033122xexhibit312.htm">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a22q3_10qx033122xexhibit321.htm">Certification of the Chief Executive Officer and the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a22q3_10qx033122xexhibit991.htm">Statement Regarding Forward-Looking Information</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Instance Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cover Page Interactive Data File - formatted in Inline XBRL (included as Exhibit 101)</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Cardinal Health Website</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardinal Health&#160;uses its website as a channel of distribution for material company information. Important information, including news releases, financial information, earnings and analyst presentations and information about upcoming presentations and events is routinely posted and accessible at ir.cardinalhealth.com. In addition, the website allows investors and other interested persons to sign up automatically to receive e-mail alerts when we post news releases,&#160;SEC filings and certain other information on its website.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="-sec-extract:summary;margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">47</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iaf3733bf892b435689161c61a06da348_130"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.115%"><tr><td style="width:1.0%"></td><td style="width:27.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.306%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Form 10-Q Cross Reference Index</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Form 10-Q Cross Reference Index</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part I. Financial Information</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_64">Financial Statements </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_64">27</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_13">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_13">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_43">Quantitative and Qualitative Disclosures about Market Risk </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_43">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_46">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_46">23</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part II. Other Information</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_49">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_49">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_52">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_52">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_58">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_58">26</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defaults Upon Senior Securities </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mine Safety Disclosures </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Information</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_127">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_127">47</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_133">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iaf3733bf892b435689161c61a06da348_133">49</a></span></div></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:3.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.739%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Not applicable</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">48</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iaf3733bf892b435689161c61a06da348_133"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:24.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.075%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional Information</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Signatures</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.182%"><tr><td style="width:1.0%"></td><td style="width:4.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 5, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;MICHAEL C. KAUFMANN</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Michael C. Kaufmann</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;JASON M. HOLLAR</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jason M. Hollar</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>2
<FILENAME>a22q3_10qx033122xexhibit102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i96a951247dfd481f86dac417679ebfd2_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 10.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">FIRST AMENDMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">TO THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">CARDINAL HEALTH DEFERRED COMPENSATION PLAN</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(As Amended and Restated January 1, 2020)</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Background Information</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A.         Cardinal Health, Inc. (&#8220;Cardinal Health&#8221;) previously adopted and currently maintains the Cardinal Health Deferred Compensation Plan (the &#8220;Plan&#8221;) for the benefit of a select group of management and highly compensated employees of Cardinal Health and its subsidiaries and affiliates.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">B.         Section 7.1 of the Plan provides that the Plan may be amended at any time through a written resolution adopted or approved by the Financial Benefit Plans Committee (&#8220;FBPC&#8221;), with respect to any amendment that, when aggregated with any other amendment or amendments approved on the same date, is reasonably expected to have an annual financial impact on Cardinal Health of $5 million or less.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">C.        The FBPC has concluded that the amendment set forth below, when aggregated with any other amendments set to be approved on the same date, is reasonably expected to have an annual financial impact on Cardinal Health of less than $5 million.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">D.        The FBPC desires to amend the Plan to clarify that participants who are non-employee directors of Cardinal Health will continue to be treated as &#8220;Reporting Persons&#8221; for purposes of the dividend equivalent credit investment rules under Section 3.5 of the Plan.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Amendment of the Cardinal Health Deferred Compensation Plan</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Plan is hereby amended as set forth below, effective as of the date signed below.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.         Section 3.5 of the Plan is hereby amended to add the following sentence to the end thereof&#58;</font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;For purposes of this paragraph and the immediately preceding paragraph, the term &#8220;Reporting Person&#8221; shall include a Participant who was a Director at the time of his or her Separation from Service, regardless of whether such Participant is a Director on the Dividend Payment Date.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.         All other provisions of the Plan shall remain in full force and effect.</font></div><div><font><br></font></div><div style="text-indent:216pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">CARDINAL HEALTH, INC.</font></div><div style="text-indent:216pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">FINANCIAL BENEFIT PLANS COMMITTEE</font></div><div><font><br></font></div><div style="text-indent:216pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">By&#58;  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">&#47;s&#47; Kendell Sherrer________________</font></div><div><font><br></font></div><div style="text-indent:216pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Its&#58;  ________________________________</font></div><div><font><br></font></div><div style="text-indent:216pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Date&#58;  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">3&#47;14&#47;2022______________________</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>a22q3_10qx033122xexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iac6cb267417b4184bbde50659a3d1d55_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:31.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 31.1</font></td></tr></table></div><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael C. Kaufmann, certify that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">I have reviewed this Form 10-Q of Cardinal Health, Inc.&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.46pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;5, 2022 </font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:470.25pt"><tr><td style="width:1.0pt"></td><td style="width:147.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:319.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; MICHAEL C. KAUFMANN</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael C. Kaufmann</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>a22q3_10qx033122xexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i43d79284f2834221937dedce095861ce_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:31.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 31.2</font></td></tr></table></div><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Jason M. Hollar, certify that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">I have reviewed this Form 10-Q of Cardinal Health, Inc.&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.46pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;5, 2022 </font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:136.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:372.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> JASON M. HOLLAR</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jason M. Hollar</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>a22q3_10qx033122xexhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ia81bca94366c44d1a8d0d4abeefd3205_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:31.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 32.1</font></td></tr></table></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Certification of the Chief Executive Officer and the Chief Financial Officer Pursuant to 18 U.S.C. Section&#160;1350, as Adopted </font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Michael C. Kaufmann, Chief Executive Officer of Cardinal Health, Inc. (the &#8220;Company&#8221;) and Jason M. Hollar, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26pt">the Periodic Report on Form 10-Q for the quarter ended March&#160;31, 2022 containing the financial statements of the Company (the &#8220;Periodic Report&#8221;), which this statement accompanies, fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d))&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26pt">the information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; May&#160;5, 2022 </font></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.769%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; MICHAEL C. KAUFMANN</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael C. Kaufmann</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer </font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.769%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; JASON M. HOLLAR</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jason M. Hollar</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>6
<FILENAME>a22q3_10qx033122xexhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i33a5e5629844405aa305844f7820410f_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:31.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 99.1</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Statement Regarding Forward-Looking Information </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used in this exhibit, &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; and similar pronouns refer to Cardinal Health, Inc. and its subsidiaries, unless the context requires otherwise. Our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended June&#160;30, 2021 (the &#8220;2021 Form 10-K&#8221;), and our quarterly reports on Form 10-Q, including this one, and our current reports on Form 8-K (along with any exhibits and amendments to such reports), as well as our news releases or any other written or oral statements made by or on behalf of us, including materials posted on our website, may include, directly or by incorporation by reference, forward-looking statements that reflect our current view (as of the date the forward-looking statement is first made) about future events, prospects, projections or financial performance. The matters discussed in these forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied in or by such statements. These risks and uncertainties include&#58;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from the COVID-19 pandemic, including the possibility that we will experience additional inventory reserves as a result of future decreases in demand or selling price&#59; the risk that we may not be able to offset significant cost increases for certain personal protective equipment (PPE) products or inflationary pressures impacting our Medical segment&#59; the possibility that sustained reduced demand for generic pharmaceutical product may continue to adversely impact our pharmaceutical generics program&#59; and the possibility that we could experience employee attrition as a result of our COVID-19 vaccine mandate or the expected governmental mandates&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">competitive pressures in the markets in which we operate, including pricing pressures&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties relating to the pricing of and demand for generic pharmaceuticals&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties relating to the timing, frequency and profitability of generic pharmaceutical launches or other components of our pharmaceutical generics program&#59;  </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in manufacturer approaches to pricing branded pharmaceutical products and risks related to our compensation under contractual arrangements with manufacturers being set as a percentage of the wholesale acquisition cost of branded pharmaceuticals and where a part of our compensation is based on branded pharmaceutical price appreciation, changes in the magnitude of such price appreciation&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in the timing or frequency of the introduction of branded pharmaceuticals&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with the resolution and defense of the lawsuits and investigations in which we have been or will be named relating to the distribution of prescription opioid pain medication, including risks associated with the proposed settlement agreement and process designed to resolve lawsuits and claims brought by states and local governmental entities, including the risk that we could fail to reach a final resolution and that any injunctive or non-monetary relief that we may agree to could have unintended consequences&#59; and the risk that the outcome of other opioid-related lawsuits and investigations could have a material adverse effect on our results of operations, financial condition, cash flows or liquidity or the operations of our business&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">potential damage to our reputation, adverse operational impacts or other effects that may result from the national opioid epidemic, the allegations that have been made about our role in such epidemic and the ongoing unfavorable publicity surrounding the lawsuits and investigations against us&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with the tax benefit from our self-insurance loss claims, including risks associated with the letter certain industry participants, including us, received from the U.S. House of Representatives' Committee on Oversight and Reform questioning, among other things, our plans to take tax deductions for opioid-related losses, including the net operating loss carryback provisions under the CARES Act and deductibility under the Tax Act&#59; the possibility that we may receive additional negative or unfavorable publicity or that the IRS may not agree with our underlying assumptions and judgments&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">potential adverse impact to our financial results from enacted and proposed state taxes or other assessments on the sale or distribution of opioid medications&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our high sales concentration with certain key customers, including CVS Health Corporation and OptumRx&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our ability to maintain the benefits of our generic pharmaceutical sourcing venture with CVS Health Corporation&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">costs or claims resulting from quality issues, whether related to the manufacture of some of our sterile surgical gowns or pre-filled syringes, or other potential errors or defects in our manufacturing of medical devices or other products or in our compounding, repackaging, information systems or pharmacy management services that may injure persons or damage property or operations, including costs from recalls, remediation efforts, and related product liability claims and lawsuits, including class action lawsuits&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">actions of regulatory bodies and other governmental authorities, including the U.S. Drug Enforcement Administration, certain agencies within the U.S. Department of Health and Human Services (including the U.S. Food and Drug Administration, Centers for Medicare and Medicaid Services, the Office of Inspector General and the Office for Civil Rights), the U.S. Nuclear Regulatory Commission, the U.S. Federal Trade Commission, the U.S. Customs and Border Protection, various state boards of pharmacy, state controlled substance authorities, state health departments, state insurance departments, state Medicaid departments or comparable regulatory bodies or governmental authorities or foreign equivalents that, in each case, could delay, limit or suspend product development, manufacturing, distribution, importation or sales or result in warning letters, recalls, seizures, injunctions or monetary sanctions&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">any compromise of our information systems or of those of a third-party service provider, including unauthorized access to or use or disclosure of company or customer information, disruption of access and ancillary risks associated with our ability to effectively manage any issues arising from any such compromise or disruption&#59;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">significantly increased costs for commodities and other materials used in the Medical segment manufacturing, including various components, compounds, raw materials or energy such as oil-based resins, pulp, cotton, latex and other commodities and the possibility that we may not successfully offset or mitigate these increases&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">shortages in commodities, components, compounds, raw materials or energy used by our businesses, including supply disruptions of radioisotopes&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the loss of, or default by, one or more key suppliers for which alternative suppliers may not be readily available&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties related to our Medical segment's Cardinal Health Brand products, including our ability to manage cost, infrastructure and to retain margin or improve its performance&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with the realignment of our Medical segment's supply chain and other businesses, including our ability to achieve the expected benefits from such realignment&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties with respect to our cost-savings initiatives or IT infrastructure activities, including the ability to achieve the expected benefits from such initiatives, the risk that we could incur unexpected charges, and the risk that we may fail to retain key personnel&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">difficulties or delays in the development, production, manufacturing, sourcing and marketing of new or existing products and services, including difficulties or delays associated with obtaining or maintaining requisite regulatory consents, whether our own or third parties', or approvals associated with those activities&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">manufacturing disruptions, whether due to regulatory action, including regulatory action to reduce Ethylene Oxide emissions, production quality deviations, safety issues or raw material shortages or defects, or because a key product is manufactured at a single manufacturing facility with limited alternate facilities&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with industry reliance on ethylene oxide (&#34;EtO&#34;) to sterilize certain medical products that we manufacture or distribute, including the possibility that regulatory actions to reduce EtO emissions could become more widespread, which may result in increased costs or supply shortages&#59; and risks that the lawsuits against us alleging personal injury resulting from EtO exposure could become more widespread&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the possibility that we could be subject to adverse changes in the tax laws or challenges to our tax positions, including the possibility that the corporate tax rate in the U.S. could be increased&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from possible violations of healthcare fraud and abuse laws&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from possible violations of the U.S. Foreign Corrupt Practices Act and other similar anti-corruption laws in other jurisdictions and U.S. and foreign export control, trade embargo and customs laws&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from our collecting, handling and maintaining patient-identifiable health information and other sensitive personal and financial information, which are subject to federal, state and foreign laws that regulate the use and disclosure of such information&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from certain of our businesses being Medicare-certified suppliers or participating in other federal and state healthcare programs, such as state Medicaid programs and the federal 340B drug pricing program, which businesses are subject to accreditation and quality standards and other rules and regulations, including applicable reporting, billing, payment and record-keeping requirements&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from certain of our businesses manufacturing pharmaceutical and medical products or repackaging pharmaceuticals that are purchased or reimbursed through, or are otherwise governed by, federal or state healthcare programs, which businesses are subject to federal and state laws that establish eligibility for reimbursement by such programs and other applicable standards and regulations&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in laws or changes in the interpretation or application of laws or regulations, as well as possible failures to comply with applicable laws or regulations, including as a result of possible misinterpretations or misapplications&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">material reductions in purchases, pricing changes, non-renewal, early termination, or delinquencies or defaults under contracts with key customers&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">unfavorable changes to the terms or with our ability to meet contractual obligations of key customer or supplier relationships, or changes in customer mix&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from changes in U.S. or foreign tax laws and unfavorable challenges to our tax positions and payments to settle these challenges, which may adversely affect our effective tax rate or tax payments&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties due to possible government healthcare reform, including proposals related to Medicare drug rebate arrangements, possible repeal or replacement of major parts of the Patient Protection and Affordable Care Act, proposals related to prescription drug pricing transparency and the possible adoption of Medicare-For-All&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">reductions or limitations on governmental funding at the state or federal level or efforts by healthcare insurance companies to limit payments for products and services&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in manufacturers' pricing, selling, inventory, distribution or supply policies or practices&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in legislation or regulations governing prescription drug pricing, healthcare services or mandated benefits&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in hospital buying groups or hospital buying practices&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in distribution or sourcing models for pharmaceutical and medical and surgical products, including an increase in direct and limited distribution&#59;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes to the prescription drug reimbursement formula and related reporting requirements for generic pharmaceuticals under Medicaid&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">continuing consolidation in the healthcare industry, which could give the resulting enterprises greater bargaining power and may increase pressure on prices for our products and services or result in the loss of customers&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">disruption, damage or lack of access to, or failure of, our or our third-party service providers' information systems, our critical facilities, including our national logistics center, or our distribution networks&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks to our business and information and controls systems in the event that business process improvements, infrastructure modernizations or initiatives to use third-party service providers for key systems and processes are not effectively implemented&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the results, costs, effects or timing of any commercial disputes, government contract compliance matters, patent infringement claims, </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> actions, government investigations, shareholder lawsuits or other legal proceedings&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">possible losses relating to product liability lawsuits and claims regarding products for which we cannot obtain product liability insurance or for which such insurance may not be adequate to cover our losses, including the product liability lawsuits we are currently defending relating to alleged personal injuries associated with the use of Cordis inferior vena cava filter products&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our ability to maintain adequate intellectual property protections&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the costs, difficulties and uncertainties related to the integration of acquired businesses, including liabilities relating to the operations or activities of such businesses prior to their acquisition, and uncertainties relating to our ability to achieve the anticipated results from acquisitions&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with the divestiture of the Cordis business, including the risk that the costs associated with exit or disposal activities could ultimately be greater than we currently expect or that we could incur greater stranded costs than expected&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our ability to manage and complete divestitures or other strategic business combination transactions, including our ability to find buyers or other strategic exit opportunities and risks associated with the possibility that we could experience greater dis-synergies than anticipated or otherwise fail to achieve our strategic objectives&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">bankruptcy, insolvency or other credit failure of a customer or supplier that owes us a substantial amount&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with global operations, including the effect of local economic environments, inflation, recession, currency volatility and global competition, in addition to risks associated with compliance with U.S. and international laws relating to global operations&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties with respect to U.S. or international trade policies, tariffs, excise or border taxes and their impact on our ability to source products or materials that we need to conduct our business&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with our use of and reliance on the global capital and credit markets, including our ability to access credit and our cost of credit, which may adversely affect our ability to efficiently fund our operations or undertake certain expenditures&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our ability to introduce and market new products and our ability to keep pace with advances in technology&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">significant charges to earnings if goodwill or intangible assets become impaired&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties relating to general political, business, industry, regulatory and market conditions&#59; and</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">other factors described in the &#8220;Risk Factors&#8221; section of the 2021 Form 10-K.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The words &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;project,&#8221; &#8220;continue,&#8221; &#8220;likely,&#8221; and similar expressions generally identify &#8220;forward-looking statements,&#8221; which speak only as of the date the statements were made, and also include statements reflecting future results or guidance, statements of outlook and expense accruals. We undertake no obligation to update or revise any forward-looking statements, except to the extent required by applicable law.</font></div><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>cah-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:5843d3e5-829e-408b-801e-c8a62435530f,g:2e89d43f-ed1a-46fa-9c57-992bbbf67b50-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cah="http://www.cardinal.com/20220331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cardinal.com/20220331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cah-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cah-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cah-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cah-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.cardinal.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofEarnings" roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings">
        <link:definition>1001002 - Statement - Condensed Consolidated Statements of Earnings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome">
        <link:definition>1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1003004 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1004005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofShareholdersEquity" roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1006007 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPolicies" roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails" roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails">
        <link:definition>2403401 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Recent Financial Accounting Standards) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Divestitures" roleURI="http://www.cardinal.com/role/Divestitures">
        <link:definition>2104102 - Disclosure - Divestitures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsandDisposalGroupsTables" roleURI="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsTables">
        <link:definition>2305301 - Disclosure - Discontinued Operations and Disposal Groups (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsandDisposalGroupsDetails" roleURI="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails">
        <link:definition>2406402 - Disclosure - Discontinued Operations and Disposal Groups (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeverance" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeverance">
        <link:definition>2107103 - Disclosure - Restructuring and Employee Severance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeveranceTables" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables">
        <link:definition>2308302 - Disclosure - Restructuring and Employee Severance (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails">
        <link:definition>2409403 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails">
        <link:definition>2410404 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeveranceNarativeDetails" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails">
        <link:definition>2411405 - Disclosure - Restructuring and Employee Severance Narative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssets" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets">
        <link:definition>2112104 - Disclosure - Goodwill and Other Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsTables" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables">
        <link:definition>2313303 - Disclosure - Goodwill and Other Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails">
        <link:definition>2414406 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails">
        <link:definition>2415407 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsNarrativeDetails" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails">
        <link:definition>2416408 - Disclosure - Goodwill and Other Intangible Assets (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermObligationsandOtherShortTermBorrowings" roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings">
        <link:definition>2117105 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermObligationsandOtherShortTermBorrowingsTables" roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsTables">
        <link:definition>2318304 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermObligationsandOtherShortTermBorrowingsDetails" roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails">
        <link:definition>2419409 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails">
        <link:definition>2420410 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsContingentLiabilitiesandLitigation" roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation">
        <link:definition>2121106 - Disclosure - Commitments, Contingent Liabilities and Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsContingentLiabilitiesandLitigationDetails" roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails">
        <link:definition>2422411 - Disclosure - Commitments, Contingent Liabilities and Litigation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.cardinal.com/role/IncomeTaxes">
        <link:definition>2123107 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2424412 - Disclosure - Income Taxes (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.cardinal.com/role/FairValueMeasurements">
        <link:definition>2125108 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.cardinal.com/role/FairValueMeasurementsTables">
        <link:definition>2326305 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" roleURI="http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails">
        <link:definition>2427413 - Disclosure - Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.cardinal.com/role/FinancialInstruments">
        <link:definition>2128109 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.cardinal.com/role/FinancialInstrumentsTables">
        <link:definition>2329306 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsNarrativeDetails" roleURI="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails">
        <link:definition>2430414 - Disclosure - Financial Instruments (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" roleURI="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails">
        <link:definition>2431415 - Disclosure - Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquity" roleURI="http://www.cardinal.com/role/ShareholdersEquity">
        <link:definition>2132110 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityTables" roleURI="http://www.cardinal.com/role/ShareholdersEquityTables">
        <link:definition>2333307 - Disclosure - Shareholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityNarrativeDetails" roleURI="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails">
        <link:definition>2434416 - Disclosure - Shareholders' Equity (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2435417 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAttributabletoCardinalHealthInc" roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc">
        <link:definition>2136111 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc.</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAttributabletoCardinalHealthIncTables" roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables">
        <link:definition>2337308 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails">
        <link:definition>2438418 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails">
        <link:definition>2439419 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://www.cardinal.com/role/SegmentInformation">
        <link:definition>2140112 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://www.cardinal.com/role/SegmentInformationTables">
        <link:definition>2341309 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationNarrativeDetails" roleURI="http://www.cardinal.com/role/SegmentInformationNarrativeDetails">
        <link:definition>2442420 - Disclosure - Segment Information (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationRevenuebyReportableSegmentDetails" roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails">
        <link:definition>2443421 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationSegmentProfitbyReportableSegmentDetails" roleURI="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails">
        <link:definition>2444422 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" roleURI="http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails">
        <link:definition>2445423 - Disclosure - Segment Information Revenue From External Customers By Geographic Areas (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationAssetsbyReportableSegmentDetails" roleURI="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails">
        <link:definition>2446424 - Disclosure - Segment Information (Assets by Reportable Segment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.cardinal.com/role/ShareBasedCompensation">
        <link:definition>2147113 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.cardinal.com/role/ShareBasedCompensationTables">
        <link:definition>2348310 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationNarrativeDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails">
        <link:definition>2449425 - Disclosure - Share-Based Compensation (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails">
        <link:definition>2450426 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails">
        <link:definition>2451427 - Disclosure - Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails">
        <link:definition>2452428 - Disclosure - Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails">
        <link:definition>2453429 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails">
        <link:definition>2454430 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="cah_TaxMatterDomain" abstract="true" name="TaxMatterDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_IndemnificationReceivable" abstract="false" name="IndemnificationReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_OpioidLawsuitsStateMember" abstract="true" name="OpioidLawsuitsStateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_September2025Member" abstract="true" name="September2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_ShortTermCreditFacilitiesMember" abstract="true" name="ShortTermCreditFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_OpioidLitigationDomain" abstract="true" name="OpioidLitigationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_OtherJurisdictionsMember" abstract="true" name="OtherJurisdictionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_CordisDivestitureDomain" abstract="true" name="CordisDivestitureDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_TotalOpioidLitigationMember" abstract="true" name="TotalOpioidLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_A200MillionShareRepurchaseProgramMember" abstract="true" name="A200MillionShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_CordisDivestitureAxis" abstract="true" name="CordisDivestitureAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_SettlingStates" abstract="false" name="SettlingStates" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cah_FloatingRateNotesdue2022Member" abstract="true" name="FloatingRateNotesdue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_MaturityDateAxis" abstract="true" name="MaturityDateAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" abstract="false" name="Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_TaxMattersAgreementAxis" abstract="true" name="TaxMattersAgreementAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_IPRDTrademarksandOtherMember" abstract="true" name="IPRDTrademarksandOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_NumberofStateAttorneysGeneralfilinglawsuits" abstract="false" name="NumberofStateAttorneysGeneralfilinglawsuits" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cah_LossContingencyClaimsSettledPercent" abstract="false" name="LossContingencyClaimsSettledPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cah_NuclearPrecisionHealthSolutionsMember" abstract="true" name="NuclearPrecisionHealthSolutionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_ProjectCostsOnInvestmentAndOtherSpending" abstract="false" name="ProjectCostsOnInvestmentAndOtherSpending" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_A300MillionShareRepurchaseProgramMember" abstract="true" name="A300MillionShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_CardinalHealthAtHomeMember" abstract="true" name="CardinalHealthAtHomeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_CARESActDomain" abstract="true" name="CARESActDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_AdditionalStockOptionPlanDataTableTextBlock" abstract="false" name="AdditionalStockOptionPlanDataTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cah_DOJInvestigationMember" abstract="true" name="DOJInvestigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_PrivatePartiesMember" abstract="true" name="PrivatePartiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_Amortizationandotheracquisitionrelatedcosts" abstract="false" name="Amortizationandotheracquisitionrelatedcosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_MedicalMember" abstract="true" name="MedicalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_ExercisablePeriodOfPlansInYears" abstract="false" name="ExercisablePeriodOfPlansInYears" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cah_A2.616Notesdue2022Member" abstract="true" name="A2.616Notesdue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_CordisDivestitureMember" abstract="true" name="CordisDivestitureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_MaturityDateDomain" abstract="true" name="MaturityDateDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_AggregateAnnualAssessment" abstract="false" name="AggregateAnnualAssessment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_CommittedReceivablesSalesFacilityProgramMember" abstract="true" name="CommittedReceivablesSalesFacilityProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_LawsuitTypeAxis" abstract="true" name="LawsuitTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_LossContingencyLawsuitsNumber" abstract="false" name="LossContingencyLawsuitsNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cah_CarryingAmountofLongTermandotherShortTermBorrowings" abstract="false" name="CarryingAmountofLongTermandotherShortTermBorrowings" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_ClassActionLawsuitsMember" abstract="true" name="ClassActionLawsuitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_MedicaldistributionandproductsMember" abstract="true" name="MedicaldistributionandproductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_ProductLiabilityLawsuitsMember" abstract="true" name="ProductLiabilityLawsuitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_JudgmentForLostProfits" abstract="false" name="JudgmentForLostProfits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_Netproceedstaxwithholdingsfromsharebasedcompensation" abstract="false" name="Netproceedstaxwithholdingsfromsharebasedcompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_OpioidLawsuitsMember" abstract="true" name="OpioidLawsuitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_SettlingUSTerritories" abstract="false" name="SettlingUSTerritories" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount" abstract="false" name="DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_PharmaceuticalMember" abstract="true" name="PharmaceuticalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable" abstract="true" name="SegmentRevenuefromExternalCustomersbyGeographicAreaTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_CareFusionMember" abstract="true" name="CareFusionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_FacilityExitAndOtherCosts" abstract="false" name="FacilityExitAndOtherCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_MedicalUnitMember" abstract="true" name="MedicalUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_ContingentAttorneyFee" abstract="false" name="ContingentAttorneyFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_GoodwillImpairmentAxis" abstract="true" name="GoodwillImpairmentAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_TotalLongTermandShortTermObligations" abstract="false" name="TotalLongTermandShortTermObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" abstract="false" name="EstimatedLiabilityForNewYorkOpioidStewardshipAct" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_ShareRepurchaseProgramAggregatePurchasePriceDomain" abstract="true" name="ShareRepurchaseProgramAggregatePurchasePriceDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" abstract="false" name="Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_CVSHealthMember" abstract="true" name="CVSHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_PatientRecoveryBusinessMember" abstract="true" name="PatientRecoveryBusinessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_AlamedaCountyMember" abstract="true" name="AlamedaCountyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_TrademarksAndPatentsMember" abstract="true" name="TrademarksAndPatentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss" abstract="false" name="SharesThatWouldBeAntidilutiveAsAResultOfNetLoss" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cah_GoodwillImpairmentDomain" abstract="true" name="GoodwillImpairmentDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" abstract="true" name="SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cah_Purchaseofavailableforsalesecuritiesandotherinvestments" abstract="false" name="Purchaseofavailableforsalesecuritiesandotherinvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_TaxMattersAgreementDomain" abstract="true" name="TaxMattersAgreementDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_NetOperatingLossCarrybackMember" abstract="true" name="NetOperatingLossCarrybackMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_ShareRepurchaseProgramAggregatePurchasePriceAxis" abstract="true" name="ShareRepurchaseProgramAggregatePurchasePriceAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_PlaintiffTypeAxis" abstract="true" name="PlaintiffTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_NetOperatingLossCarrybackAxis" abstract="true" name="NetOperatingLossCarrybackAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_LongTermObligationsandOtherShortTermBorrowingsAbstract" abstract="true" name="LongTermObligationsandOtherShortTermBorrowingsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cah_LawsuitTypeDomain" abstract="true" name="LawsuitTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_CashReclassifiedToAssetHeldForSale" abstract="false" name="CashReclassifiedToAssetHeldForSale" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_VestingPeriodinyearsforShares" abstract="false" name="VestingPeriodinyearsforShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cah_NarativeAbstract" abstract="true" name="NarativeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cah_June2027Member" abstract="true" name="June2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_TerminalGrowthRateFairValueInput" abstract="false" name="TerminalGrowthRateFairValueInput" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cah_PharmaceuticalDistributionandSpecialtyMember" abstract="true" name="PharmaceuticalDistributionandSpecialtyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_A500MillionShareRepurchaseProgramMember" abstract="true" name="A500MillionShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_DiscountRateFairValueInput" abstract="false" name="DiscountRateFairValueInput" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cah_TaxMatterAxis" abstract="true" name="TaxMatterAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_NewYorkOpioidStewardshipActMember" abstract="true" name="NewYorkOpioidStewardshipActMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_OpioidLitigationAxis" abstract="true" name="OpioidLitigationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_PlaintiffTypeDomain" abstract="true" name="PlaintiffTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_MedicalUnitGoodwillImpairmentMember" abstract="true" name="MedicalUnitGoodwillImpairmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>cah-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:5843d3e5-829e-408b-801e-c8a62435530f,g:2e89d43f-ed1a-46fa-9c57-992bbbf67b50-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="cah-20220331.xsd#CondensedConsolidatedStatementsofEarnings"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ac7de588-9f27-4db6-86f7-ee480778921b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dd64a3bb-289b-4b41-81bb-8d11986cc2ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_ac7de588-9f27-4db6-86f7-ee480778921b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dd64a3bb-289b-4b41-81bb-8d11986cc2ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_68294c68-f70f-4379-8528-5700a903f9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_ac7de588-9f27-4db6-86f7-ee480778921b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_68294c68-f70f-4379-8528-5700a903f9c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5710b188-0014-4009-a57d-a59234dce2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4c7b75b3-3616-4bc5-8ede-689543d883e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5710b188-0014-4009-a57d-a59234dce2a7" xlink:to="loc_us-gaap_OperatingIncomeLoss_4c7b75b3-3616-4bc5-8ede-689543d883e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_8402719f-d571-401a-9569-c20569ae0670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5710b188-0014-4009-a57d-a59234dce2a7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_8402719f-d571-401a-9569-c20569ae0670" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_22069e6c-79be-44e9-93e6-1cc63cad9e73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5710b188-0014-4009-a57d-a59234dce2a7" xlink:to="loc_us-gaap_InterestExpense_22069e6c-79be-44e9-93e6-1cc63cad9e73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_962e0c94-fdb1-46ae-b1ad-99b1e89f9d65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5710b188-0014-4009-a57d-a59234dce2a7" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_962e0c94-fdb1-46ae-b1ad-99b1e89f9d65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_66f203f7-4bac-4310-a5a2-5c82948b6d23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5710b188-0014-4009-a57d-a59234dce2a7" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_66f203f7-4bac-4310-a5a2-5c82948b6d23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_14aed947-a316-497f-be49-0695ac4b890f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_580ce950-205e-408b-ba2d-65a08e7a44c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_14aed947-a316-497f-be49-0695ac4b890f" xlink:to="loc_us-gaap_Revenues_580ce950-205e-408b-ba2d-65a08e7a44c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_1295d628-0443-4489-8489-b8bce21e3062" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_14aed947-a316-497f-be49-0695ac4b890f" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_1295d628-0443-4489-8489-b8bce21e3062" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_588272da-bb68-4b46-aa0d-337a5cb85c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_cdc94985-de5a-417f-a78a-6bc6faf74ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_588272da-bb68-4b46-aa0d-337a5cb85c7a" xlink:to="loc_us-gaap_GrossProfit_cdc94985-de5a-417f-a78a-6bc6faf74ac6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_21ad3877-00a4-49a9-891d-2b3386700951" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_588272da-bb68-4b46-aa0d-337a5cb85c7a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_21ad3877-00a4-49a9-891d-2b3386700951" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_09a28427-f69e-4ca9-b7ae-650359accc05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_588272da-bb68-4b46-aa0d-337a5cb85c7a" xlink:to="loc_us-gaap_RestructuringCharges_09a28427-f69e-4ca9-b7ae-650359accc05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Amortizationandotheracquisitionrelatedcosts_b3cf10f5-54c0-4c0f-bb4f-dba8fd3d0895" xlink:href="cah-20220331.xsd#cah_Amortizationandotheracquisitionrelatedcosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_588272da-bb68-4b46-aa0d-337a5cb85c7a" xlink:to="loc_cah_Amortizationandotheracquisitionrelatedcosts_b3cf10f5-54c0-4c0f-bb4f-dba8fd3d0895" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_c6eb9551-04a4-476b-89d5-28a570577ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_588272da-bb68-4b46-aa0d-337a5cb85c7a" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_c6eb9551-04a4-476b-89d5-28a570577ba8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_474ef24b-cc8e-43aa-9caf-6ade6d1c404b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_588272da-bb68-4b46-aa0d-337a5cb85c7a" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_474ef24b-cc8e-43aa-9caf-6ade6d1c404b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_177483f8-65b5-4531-a523-e707ffb420e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_bbed8265-aac7-4c58-b8b3-647fed4903d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_177483f8-65b5-4531-a523-e707ffb420e6" xlink:to="loc_us-gaap_ProfitLoss_bbed8265-aac7-4c58-b8b3-647fed4903d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_deafb565-066f-41d5-819a-b4ef0a97aebf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_177483f8-65b5-4531-a523-e707ffb420e6" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_deafb565-066f-41d5-819a-b4ef0a97aebf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="cah-20220331.xsd#CondensedConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_4306b965-7231-471e-a522-2a9934c19950" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_e0c9fc1e-f52f-4639-847c-5ccf78cb4810" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_4306b965-7231-471e-a522-2a9934c19950" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_e0c9fc1e-f52f-4639-847c-5ccf78cb4810" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8191dd97-7348-48dc-9f34-c492bf012a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_4306b965-7231-471e-a522-2a9934c19950" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8191dd97-7348-48dc-9f34-c492bf012a3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a655e34a-d372-4136-8293-fdd2b84faeb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_92fbef20-87c9-4bac-8507-5e41f8462289" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a655e34a-d372-4136-8293-fdd2b84faeb5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_92fbef20-87c9-4bac-8507-5e41f8462289" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_9210d314-805f-44d9-a2df-f995aad2bf67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a655e34a-d372-4136-8293-fdd2b84faeb5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_9210d314-805f-44d9-a2df-f995aad2bf67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_875827b0-2606-4ef2-9623-d6a76544a864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_17ea90e6-d906-4fc1-be2a-608ee8118422" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_875827b0-2606-4ef2-9623-d6a76544a864" xlink:to="loc_us-gaap_ProfitLoss_17ea90e6-d906-4fc1-be2a-608ee8118422" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3e905137-2ed1-4d17-a02c-31f9d454d41a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_875827b0-2606-4ef2-9623-d6a76544a864" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3e905137-2ed1-4d17-a02c-31f9d454d41a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cah-20220331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_718eaef5-231e-426f-bf6b-b29aed6660f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_8be4aeb6-1cc6-430b-ac7d-c72bfa840886" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_718eaef5-231e-426f-bf6b-b29aed6660f5" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_8be4aeb6-1cc6-430b-ac7d-c72bfa840886" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e0f0aa4f-07be-41a0-9fce-99c4ac8df31c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_718eaef5-231e-426f-bf6b-b29aed6660f5" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e0f0aa4f-07be-41a0-9fce-99c4ac8df31c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_1bfda49d-1928-42e5-b129-2bca65fe14a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_718eaef5-231e-426f-bf6b-b29aed6660f5" xlink:to="loc_us-gaap_AccountsPayableCurrent_1bfda49d-1928-42e5-b129-2bca65fe14a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_fdd1d809-0a16-463e-ad2c-3b76279ab8e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_718eaef5-231e-426f-bf6b-b29aed6660f5" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_fdd1d809-0a16-463e-ad2c-3b76279ab8e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_18cf727d-351b-48ed-ab5d-80df932e46d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_77db8d11-ea39-4749-85f3-f0eb3f32e2c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_18cf727d-351b-48ed-ab5d-80df932e46d1" xlink:to="loc_us-gaap_CommonStockValue_77db8d11-ea39-4749-85f3-f0eb3f32e2c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d82d8644-a144-40ba-9923-22cb96a27eac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_18cf727d-351b-48ed-ab5d-80df932e46d1" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d82d8644-a144-40ba-9923-22cb96a27eac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_84951b48-16b8-47ed-aeec-295ca93c95e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_18cf727d-351b-48ed-ab5d-80df932e46d1" xlink:to="loc_us-gaap_TreasuryStockValue_84951b48-16b8-47ed-aeec-295ca93c95e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f22162d8-fcf1-4200-9f0c-4839b708c23a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_18cf727d-351b-48ed-ab5d-80df932e46d1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f22162d8-fcf1-4200-9f0c-4839b708c23a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_8df69207-1f26-47fd-9432-412f201d3839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_18cf727d-351b-48ed-ab5d-80df932e46d1" xlink:to="loc_us-gaap_MinorityInterest_8df69207-1f26-47fd-9432-412f201d3839" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f5a6134f-3657-45a6-a2e5-441423ef2407" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f31870bf-d829-4a6c-b560-58de2f0647ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f5a6134f-3657-45a6-a2e5-441423ef2407" xlink:to="loc_us-gaap_LiabilitiesCurrent_f31870bf-d829-4a6c-b560-58de2f0647ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_eef39357-ab48-4256-bbc5-668156a0f7c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f5a6134f-3657-45a6-a2e5-441423ef2407" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_eef39357-ab48-4256-bbc5-668156a0f7c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_29535342-2f4e-45fb-8bf6-3bcbfeb70c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f5a6134f-3657-45a6-a2e5-441423ef2407" xlink:to="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_29535342-2f4e-45fb-8bf6-3bcbfeb70c2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1829958c-63f9-439c-a3dc-9300c10ac427" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f5a6134f-3657-45a6-a2e5-441423ef2407" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1829958c-63f9-439c-a3dc-9300c10ac427" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8bd00b19-7eb0-46ab-a088-b8a8fecc4107" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_83c857bc-45bc-42b0-a79e-ae7067885de9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8bd00b19-7eb0-46ab-a088-b8a8fecc4107" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_83c857bc-45bc-42b0-a79e-ae7067885de9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_ecfdb676-ca96-46e7-8922-9aa3fb7123ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8bd00b19-7eb0-46ab-a088-b8a8fecc4107" xlink:to="loc_us-gaap_ReceivablesNetCurrent_ecfdb676-ca96-46e7-8922-9aa3fb7123ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_4aa01f28-7871-4114-b261-c5a56928dbe7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8bd00b19-7eb0-46ab-a088-b8a8fecc4107" xlink:to="loc_us-gaap_InventoryNet_4aa01f28-7871-4114-b261-c5a56928dbe7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_5850934e-a010-4e8d-9432-12c1ba6cae73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8bd00b19-7eb0-46ab-a088-b8a8fecc4107" xlink:to="loc_us-gaap_OtherAssetsCurrent_5850934e-a010-4e8d-9432-12c1ba6cae73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_bc878021-3e1b-4f06-8d0b-e888c3fdf09a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8bd00b19-7eb0-46ab-a088-b8a8fecc4107" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_bc878021-3e1b-4f06-8d0b-e888c3fdf09a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3f61927e-feeb-4e35-8bdf-82bce4301a35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ebd15e2e-d911-4f35-81e5-c6addefac976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3f61927e-feeb-4e35-8bdf-82bce4301a35" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ebd15e2e-d911-4f35-81e5-c6addefac976" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_8a53acfa-807e-4faf-a4d9-ad00079ae4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3f61927e-feeb-4e35-8bdf-82bce4301a35" xlink:to="loc_us-gaap_PreferredStockValue_8a53acfa-807e-4faf-a4d9-ad00079ae4ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_73c493b8-3256-459d-9b7f-301ef0898cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3f61927e-feeb-4e35-8bdf-82bce4301a35" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_73c493b8-3256-459d-9b7f-301ef0898cdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f4f81cb1-c2ff-4e8d-aee2-de14e48a80ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3f61927e-feeb-4e35-8bdf-82bce4301a35" xlink:to="loc_us-gaap_CommonStockValue_f4f81cb1-c2ff-4e8d-aee2-de14e48a80ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_bc1a68e5-c551-42ad-97dc-70de16bf0b52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3f61927e-feeb-4e35-8bdf-82bce4301a35" xlink:to="loc_us-gaap_TreasuryStockValue_bc1a68e5-c551-42ad-97dc-70de16bf0b52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f0c2fb0d-7c03-4a32-99ab-06c45e235f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_83b2290f-724a-44a0-a3b6-789c268344d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f0c2fb0d-7c03-4a32-99ab-06c45e235f1d" xlink:to="loc_us-gaap_AssetsCurrent_83b2290f-724a-44a0-a3b6-789c268344d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_da37ce47-7af3-4ea8-8497-837fa55253e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f0c2fb0d-7c03-4a32-99ab-06c45e235f1d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_da37ce47-7af3-4ea8-8497-837fa55253e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_3877bc62-0bf6-48ef-98cf-ce3bcf44a5b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f0c2fb0d-7c03-4a32-99ab-06c45e235f1d" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_3877bc62-0bf6-48ef-98cf-ce3bcf44a5b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_eaa5faf4-3648-46b5-abeb-082451800204" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f0c2fb0d-7c03-4a32-99ab-06c45e235f1d" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_eaa5faf4-3648-46b5-abeb-082451800204" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cah-20220331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f6aad37b-0b3e-4a26-a2ed-cfd75bbe4b05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c31c76dc-7f1b-4d80-af58-5f4e90eb5244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f6aad37b-0b3e-4a26-a2ed-cfd75bbe4b05" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c31c76dc-7f1b-4d80-af58-5f4e90eb5244" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_11e8958c-e653-442f-af6a-0efe40281b53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f6aad37b-0b3e-4a26-a2ed-cfd75bbe4b05" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_11e8958c-e653-442f-af6a-0efe40281b53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3946a862-da9c-489d-be06-9a9b222e2fee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f6aad37b-0b3e-4a26-a2ed-cfd75bbe4b05" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3946a862-da9c-489d-be06-9a9b222e2fee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6c624dd2-2b2f-48d1-94f9-0a0102dc4170" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f6aad37b-0b3e-4a26-a2ed-cfd75bbe4b05" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6c624dd2-2b2f-48d1-94f9-0a0102dc4170" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CashReclassifiedToAssetHeldForSale_1e9d58ca-8b40-4eaf-972a-e2c1222f30f8" xlink:href="cah-20220331.xsd#cah_CashReclassifiedToAssetHeldForSale"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f6aad37b-0b3e-4a26-a2ed-cfd75bbe4b05" xlink:to="loc_cah_CashReclassifiedToAssetHeldForSale_1e9d58ca-8b40-4eaf-972a-e2c1222f30f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_08f2c5b4-dc55-40fe-89ff-d6e0cf22fd00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_26200b7c-0c3c-48d8-ae8d-523c305e499d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_08f2c5b4-dc55-40fe-89ff-d6e0cf22fd00" xlink:to="loc_us-gaap_ProfitLoss_26200b7c-0c3c-48d8-ae8d-523c305e499d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_58d71a4c-bf46-46a7-940f-4acd9bf7f1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_08f2c5b4-dc55-40fe-89ff-d6e0cf22fd00" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_58d71a4c-bf46-46a7-940f-4acd9bf7f1b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_16970e7d-bfce-45f4-af42-549ed029c7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_08f2c5b4-dc55-40fe-89ff-d6e0cf22fd00" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_16970e7d-bfce-45f4-af42-549ed029c7e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_38aa2b2f-cc2d-4595-9e54-72cd4bec293c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_08f2c5b4-dc55-40fe-89ff-d6e0cf22fd00" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_38aa2b2f-cc2d-4595-9e54-72cd4bec293c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7939b6b9-308d-4d1c-b71b-dd2944646ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_08f2c5b4-dc55-40fe-89ff-d6e0cf22fd00" xlink:to="loc_us-gaap_ShareBasedCompensation_7939b6b9-308d-4d1c-b71b-dd2944646ecd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_944b1eed-d905-4fe3-bbc0-e8cb1625921e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_08f2c5b4-dc55-40fe-89ff-d6e0cf22fd00" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_944b1eed-d905-4fe3-bbc0-e8cb1625921e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_c8e87bb7-8fb0-4ef0-b70d-a07e188d4a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_08f2c5b4-dc55-40fe-89ff-d6e0cf22fd00" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_c8e87bb7-8fb0-4ef0-b70d-a07e188d4a9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_9ff6da48-a463-4615-90cf-906f63df03bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_08f2c5b4-dc55-40fe-89ff-d6e0cf22fd00" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_9ff6da48-a463-4615-90cf-906f63df03bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0e805ed3-cc27-4479-bdf1-db2899240a67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_08f2c5b4-dc55-40fe-89ff-d6e0cf22fd00" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0e805ed3-cc27-4479-bdf1-db2899240a67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_46e34611-d081-446d-a7e4-b138868728c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_08f2c5b4-dc55-40fe-89ff-d6e0cf22fd00" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_46e34611-d081-446d-a7e4-b138868728c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_fffe68f0-857b-43ad-8a99-a606510d0e47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_08f2c5b4-dc55-40fe-89ff-d6e0cf22fd00" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_fffe68f0-857b-43ad-8a99-a606510d0e47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_0b063c50-f7fa-45a8-89a5-39d3bcf3f922" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfOtherInvestments"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_08f2c5b4-dc55-40fe-89ff-d6e0cf22fd00" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherInvestments_0b063c50-f7fa-45a8-89a5-39d3bcf3f922" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d00eb574-605c-47db-bc86-b39c220bfd58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_3c3cbcd6-c10f-4845-9f3c-4ecff6e5bfe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d00eb574-605c-47db-bc86-b39c220bfd58" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_3c3cbcd6-c10f-4845-9f3c-4ecff6e5bfe3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_117de0a5-5b5f-46b5-b08b-164e6411dd7b" xlink:href="cah-20220331.xsd#cah_Netproceedstaxwithholdingsfromsharebasedcompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d00eb574-605c-47db-bc86-b39c220bfd58" xlink:to="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_117de0a5-5b5f-46b5-b08b-164e6411dd7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_690f106b-e0d6-4b69-8238-700987e3d5e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d00eb574-605c-47db-bc86-b39c220bfd58" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_690f106b-e0d6-4b69-8238-700987e3d5e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_0c7c458e-6c95-4717-aafd-5c896162f88e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d00eb574-605c-47db-bc86-b39c220bfd58" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_0c7c458e-6c95-4717-aafd-5c896162f88e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromHedgeFinancingActivities_12b89600-5b83-46bd-a27d-1899671f521e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromHedgeFinancingActivities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d00eb574-605c-47db-bc86-b39c220bfd58" xlink:to="loc_us-gaap_PaymentsForProceedsFromHedgeFinancingActivities_12b89600-5b83-46bd-a27d-1899671f521e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7519f6c9-9220-4ddc-a887-e20ed55e3229" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_7c21cdb7-47c2-4094-ab7a-11990e64a7f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7519f6c9-9220-4ddc-a887-e20ed55e3229" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_7c21cdb7-47c2-4094-ab7a-11990e64a7f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_81b429c8-c25b-4783-9bd2-289f9a2c6c43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7519f6c9-9220-4ddc-a887-e20ed55e3229" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_81b429c8-c25b-4783-9bd2-289f9a2c6c43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_c0f8d330-98bb-45c7-bad8-4db654360d1a" xlink:href="cah-20220331.xsd#cah_Purchaseofavailableforsalesecuritiesandotherinvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7519f6c9-9220-4ddc-a887-e20ed55e3229" xlink:to="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_c0f8d330-98bb-45c7-bad8-4db654360d1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_072ad301-da4e-4f49-bd18-b68cd2e76441" xlink:href="cah-20220331.xsd#cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7519f6c9-9220-4ddc-a887-e20ed55e3229" xlink:to="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_072ad301-da4e-4f49-bd18-b68cd2e76441" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets_fe06e3d6-fae1-40d0-823f-f9c1924b58f6" xlink:href="cah-20220331.xsd#cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7519f6c9-9220-4ddc-a887-e20ed55e3229" xlink:to="loc_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets_fe06e3d6-fae1-40d0-823f-f9c1924b58f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeInvestingActivities_41c80ffa-6869-44b8-ab30-4723172210bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromHedgeInvestingActivities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7519f6c9-9220-4ddc-a887-e20ed55e3229" xlink:to="loc_us-gaap_ProceedsFromHedgeInvestingActivities_41c80ffa-6869-44b8-ab30-4723172210bc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_14282b34-2be3-4eab-b9fa-90655e8b4173" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_6f3a2a98-b107-4a73-92e9-eacd0440fdd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_14282b34-2be3-4eab-b9fa-90655e8b4173" xlink:to="loc_us-gaap_SeveranceCosts1_6f3a2a98-b107-4a73-92e9-eacd0440fdd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts_46f1f26f-c769-4c7e-aed9-0456a808119d" xlink:href="cah-20220331.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_14282b34-2be3-4eab-b9fa-90655e8b4173" xlink:to="loc_cah_FacilityExitAndOtherCosts_46f1f26f-c769-4c7e-aed9-0456a808119d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_bb7a0a5e-98c2-4301-b395-b5640165bb81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_400570a1-550a-4179-b35d-067925bbb297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_bb7a0a5e-98c2-4301-b395-b5640165bb81" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_400570a1-550a-4179-b35d-067925bbb297" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_5dedeb99-2479-420e-82d3-ea41994df911" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_bb7a0a5e-98c2-4301-b395-b5640165bb81" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_5dedeb99-2479-420e-82d3-ea41994df911" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9f43284b-8636-4326-bd50-f4eba0a8d0fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b3316ef6-895b-4049-b211-9cd8d1e26b62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9f43284b-8636-4326-bd50-f4eba0a8d0fa" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b3316ef6-895b-4049-b211-9cd8d1e26b62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ecadff1b-7b88-48ca-8aa5-0faa89e7d025" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9f43284b-8636-4326-bd50-f4eba0a8d0fa" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ecadff1b-7b88-48ca-8aa5-0faa89e7d025" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>cah-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:5843d3e5-829e-408b-801e-c8a62435530f,g:2e89d43f-ed1a-46fa-9c57-992bbbf67b50-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="cah-20220331.xsd#CondensedConsolidatedStatementsofShareholdersEquity"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="extended" id="i2b86ff675e5d49a6b987164615c61d8e_CondensedConsolidatedStatementsofShareholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4d9ee6af-2306-4826-bf49-1768968daa02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_ae96a2d2-3ed3-4cf2-b377-764ebfd127db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4d9ee6af-2306-4826-bf49-1768968daa02" xlink:to="loc_us-gaap_CommonStockSharesIssued_ae96a2d2-3ed3-4cf2-b377-764ebfd127db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1ba7c23b-1741-49bf-98c6-ff3fa80c525b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4d9ee6af-2306-4826-bf49-1768968daa02" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1ba7c23b-1741-49bf-98c6-ff3fa80c525b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_c763019c-6f4d-4f2b-8e30-e4989f96540b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4d9ee6af-2306-4826-bf49-1768968daa02" xlink:to="loc_us-gaap_TreasuryStockShares_c763019c-6f4d-4f2b-8e30-e4989f96540b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_ff0c98c7-654d-42d2-939d-fc817757f3d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4d9ee6af-2306-4826-bf49-1768968daa02" xlink:to="loc_us-gaap_TreasuryStockValue_ff0c98c7-654d-42d2-939d-fc817757f3d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ecebcb6f-c273-43a3-b5fd-e94e58bb87b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4d9ee6af-2306-4826-bf49-1768968daa02" xlink:to="loc_us-gaap_ProfitLoss_ecebcb6f-c273-43a3-b5fd-e94e58bb87b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_53c9320e-6ed0-4d0f-bb0a-cd7f6ed1ea21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4d9ee6af-2306-4826-bf49-1768968daa02" xlink:to="loc_us-gaap_NetIncomeLoss_53c9320e-6ed0-4d0f-bb0a-cd7f6ed1ea21" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1859e6c3-f974-44c1-a0f8-3f8493a16c67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4d9ee6af-2306-4826-bf49-1768968daa02" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1859e6c3-f974-44c1-a0f8-3f8493a16c67" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3e8974c3-1950-48e0-acc3-9d8c65190fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4d9ee6af-2306-4826-bf49-1768968daa02" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3e8974c3-1950-48e0-acc3-9d8c65190fb8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_78adea2c-3525-497f-ae39-6e495ab14ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4d9ee6af-2306-4826-bf49-1768968daa02" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_78adea2c-3525-497f-ae39-6e495ab14ab3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_153e9b7d-562d-4e51-8d39-769fe2802f81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4d9ee6af-2306-4826-bf49-1768968daa02" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_153e9b7d-562d-4e51-8d39-769fe2802f81" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_db671bbc-2a17-4a85-ac33-cd674f2b8f04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4d9ee6af-2306-4826-bf49-1768968daa02" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_db671bbc-2a17-4a85-ac33-cd674f2b8f04" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_a61c3dd8-8733-4c45-81d1-63bfa22252f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4d9ee6af-2306-4826-bf49-1768968daa02" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_a61c3dd8-8733-4c45-81d1-63bfa22252f8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_22084a36-49a7-4376-9e1d-07d53f7f42f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4d9ee6af-2306-4826-bf49-1768968daa02" xlink:to="loc_us-gaap_Dividends_22084a36-49a7-4376-9e1d-07d53f7f42f9" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOtherShares_da7e73ba-54d9-47ad-9068-ee2f20077cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOtherShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4d9ee6af-2306-4826-bf49-1768968daa02" xlink:to="loc_us-gaap_StockholdersEquityOtherShares_da7e73ba-54d9-47ad-9068-ee2f20077cf1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_b112e525-0bc3-4dfe-8a42-a92c99c5da48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4d9ee6af-2306-4826-bf49-1768968daa02" xlink:to="loc_us-gaap_StockholdersEquityOther_b112e525-0bc3-4dfe-8a42-a92c99c5da48" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_e2052b2d-47a5-4a6d-8eb6-2e4e09337443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8f05a75e-3d7f-4afd-9640-cca9a0371a74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_049a1603-8c80-4c04-9d93-ea3be87351da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_b5710ca9-17b7-4b84-910e-d37316dc33d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_34676ea7-e1d5-4541-a108-d0d5cc03781f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4d9ee6af-2306-4826-bf49-1768968daa02" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_34676ea7-e1d5-4541-a108-d0d5cc03781f" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_920f5301-ab9f-4fd1-92aa-7fab822e55b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4d9ee6af-2306-4826-bf49-1768968daa02" xlink:to="loc_us-gaap_StatementTable_920f5301-ab9f-4fd1-92aa-7fab822e55b8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f5e15a8c-50b9-4ccf-b2a7-54a946cce68a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_920f5301-ab9f-4fd1-92aa-7fab822e55b8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f5e15a8c-50b9-4ccf-b2a7-54a946cce68a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f5e15a8c-50b9-4ccf-b2a7-54a946cce68a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f5e15a8c-50b9-4ccf-b2a7-54a946cce68a" xlink:to="loc_us-gaap_EquityComponentDomain_f5e15a8c-50b9-4ccf-b2a7-54a946cce68a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e6cdc23e-d283-42cf-b069-3e484e29df6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f5e15a8c-50b9-4ccf-b2a7-54a946cce68a" xlink:to="loc_us-gaap_EquityComponentDomain_e6cdc23e-d283-42cf-b069-3e484e29df6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1d7c08f8-a2cd-40e9-ba30-787938f6c03f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e6cdc23e-d283-42cf-b069-3e484e29df6b" xlink:to="loc_us-gaap_CommonStockMember_1d7c08f8-a2cd-40e9-ba30-787938f6c03f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_3fca4ba7-fc62-4e11-bde4-ab1401d71a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e6cdc23e-d283-42cf-b069-3e484e29df6b" xlink:to="loc_us-gaap_RetainedEarningsMember_3fca4ba7-fc62-4e11-bde4-ab1401d71a6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_f17d25e8-ee43-4810-9a85-0c01fe8cab4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e6cdc23e-d283-42cf-b069-3e484e29df6b" xlink:to="loc_us-gaap_TreasuryStockMember_f17d25e8-ee43-4810-9a85-0c01fe8cab4f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a77773c0-9d39-4d07-9235-0356c83152d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e6cdc23e-d283-42cf-b069-3e484e29df6b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a77773c0-9d39-4d07-9235-0356c83152d8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_c3ac6677-0302-492b-9c74-9bfe14ff3886" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e6cdc23e-d283-42cf-b069-3e484e29df6b" xlink:to="loc_us-gaap_NoncontrollingInterestMember_c3ac6677-0302-492b-9c74-9bfe14ff3886" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#DiscontinuedOperationsandDisposalGroupsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails" xlink:type="extended" id="i78f64b1306d4466f99c316265ee94867_DiscontinuedOperationsandDisposalGroupsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c7fc58af-fa67-464e-bf28-ae8391833979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_764f2fb8-c819-44cc-8837-9c5b53b53b69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c7fc58af-fa67-464e-bf28-ae8391833979" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_764f2fb8-c819-44cc-8837-9c5b53b53b69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_bb334688-274f-447e-b1e6-b5fb179fb33d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c7fc58af-fa67-464e-bf28-ae8391833979" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_bb334688-274f-447e-b1e6-b5fb179fb33d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7f6ddcf4-f00f-4052-8e61-617487635e60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_bb334688-274f-447e-b1e6-b5fb179fb33d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7f6ddcf4-f00f-4052-8e61-617487635e60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7f6ddcf4-f00f-4052-8e61-617487635e60_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7f6ddcf4-f00f-4052-8e61-617487635e60" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7f6ddcf4-f00f-4052-8e61-617487635e60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9f1def4d-b91d-4712-bac8-dae90634ccba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7f6ddcf4-f00f-4052-8e61-617487635e60" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9f1def4d-b91d-4712-bac8-dae90634ccba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_1083c0b8-b7c8-4157-8678-3756f13368ce" xlink:href="cah-20220331.xsd#cah_CordisDivestitureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_bb334688-274f-447e-b1e6-b5fb179fb33d" xlink:to="loc_cah_CordisDivestitureAxis_1083c0b8-b7c8-4157-8678-3756f13368ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_1083c0b8-b7c8-4157-8678-3756f13368ce_default" xlink:href="cah-20220331.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_CordisDivestitureAxis_1083c0b8-b7c8-4157-8678-3756f13368ce" xlink:to="loc_cah_CordisDivestitureDomain_1083c0b8-b7c8-4157-8678-3756f13368ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_7f2dcaad-3271-4715-8fdd-5afc7c0c88ef" xlink:href="cah-20220331.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_CordisDivestitureAxis_1083c0b8-b7c8-4157-8678-3756f13368ce" xlink:to="loc_cah_CordisDivestitureDomain_7f2dcaad-3271-4715-8fdd-5afc7c0c88ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_d8109d45-da6e-47e5-9d46-f63b814ae35a" xlink:href="cah-20220331.xsd#cah_CordisDivestitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_CordisDivestitureDomain_7f2dcaad-3271-4715-8fdd-5afc7c0c88ef" xlink:to="loc_cah_CordisDivestitureMember_d8109d45-da6e-47e5-9d46-f63b814ae35a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="extended" id="ie0fd0b7eb6db42488e720008b58e15f6_RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_c8777029-1354-429b-a997-e68e99127be5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_fe126553-615b-45fb-b6fa-89b6834b91fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c8777029-1354-429b-a997-e68e99127be5" xlink:to="loc_us-gaap_RestructuringReserveRollForward_fe126553-615b-45fb-b6fa-89b6834b91fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_8c97a303-36d8-4eeb-a19a-987279d8e276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_fe126553-615b-45fb-b6fa-89b6834b91fd" xlink:to="loc_us-gaap_RestructuringReserve_8c97a303-36d8-4eeb-a19a-987279d8e276" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts_b56540aa-5592-4855-9d3b-b170e14d86cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_fe126553-615b-45fb-b6fa-89b6834b91fd" xlink:to="loc_us-gaap_RestructuringCosts_b56540aa-5592-4855-9d3b-b170e14d86cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_58b11da0-0945-4bb3-b935-f2a219d5daab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_fe126553-615b-45fb-b6fa-89b6834b91fd" xlink:to="loc_us-gaap_PaymentsForRestructuring_58b11da0-0945-4bb3-b935-f2a219d5daab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_6e5e5df3-f221-4fa4-b063-cc53b619d17f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6dceffaa-39ea-44d1-af45-a5475732d19a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c8777029-1354-429b-a997-e68e99127be5" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6dceffaa-39ea-44d1-af45-a5475732d19a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_2903709f-8d3e-4c34-92b0-ef274fbc745e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6dceffaa-39ea-44d1-af45-a5475732d19a" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_2903709f-8d3e-4c34-92b0-ef274fbc745e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_2903709f-8d3e-4c34-92b0-ef274fbc745e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_2903709f-8d3e-4c34-92b0-ef274fbc745e" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_2903709f-8d3e-4c34-92b0-ef274fbc745e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_97011ea7-ea55-45f6-84a9-d0e33027721f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_2903709f-8d3e-4c34-92b0-ef274fbc745e" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_97011ea7-ea55-45f6-84a9-d0e33027721f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_5e906129-72cb-45ff-a42f-c748a7601686" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_97011ea7-ea55-45f6-84a9-d0e33027721f" xlink:to="loc_us-gaap_EmployeeSeveranceMember_5e906129-72cb-45ff-a42f-c748a7601686" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember_683cdc91-6c3d-4b7e-b564-3a22cf8a21e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FacilityClosingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_97011ea7-ea55-45f6-84a9-d0e33027721f" xlink:to="loc_us-gaap_FacilityClosingMember_683cdc91-6c3d-4b7e-b564-3a22cf8a21e2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#RestructuringandEmployeeSeveranceNarativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails" xlink:type="extended" id="icc61ec1ab04b4906991e2ac7714d8d09_RestructuringandEmployeeSeveranceNarativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_874efa7c-a14e-4ded-b394-b40b96dbe989" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_56541126-7620-468e-8e0a-eb2a49a6307c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_874efa7c-a14e-4ded-b394-b40b96dbe989" xlink:to="loc_us-gaap_SeveranceCosts1_56541126-7620-468e-8e0a-eb2a49a6307c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts_7d0669f7-9217-4de9-8760-bb25d73ada7e" xlink:href="cah-20220331.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_874efa7c-a14e-4ded-b394-b40b96dbe989" xlink:to="loc_cah_FacilityExitAndOtherCosts_7d0669f7-9217-4de9-8760-bb25d73ada7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0185f001-532f-4857-8915-8afe571b796a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_874efa7c-a14e-4ded-b394-b40b96dbe989" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0185f001-532f-4857-8915-8afe571b796a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_67a15464-8826-4981-9508-078544f1e5d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0185f001-532f-4857-8915-8afe571b796a" xlink:to="loc_us-gaap_RestructuringPlanAxis_67a15464-8826-4981-9508-078544f1e5d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_67a15464-8826-4981-9508-078544f1e5d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_67a15464-8826-4981-9508-078544f1e5d5" xlink:to="loc_us-gaap_RestructuringPlanDomain_67a15464-8826-4981-9508-078544f1e5d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_c13be742-e221-48c6-80c1-a8ffe439ef2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_67a15464-8826-4981-9508-078544f1e5d5" xlink:to="loc_us-gaap_RestructuringPlanDomain_c13be742-e221-48c6-80c1-a8ffe439ef2a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="extended" id="ie623073fc3804bbe915f6fbdeeb5e5ce_GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_41515d92-c7d5-4678-a03e-5244833a6675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_84438e62-1d41-4732-b8cf-a4447647f523" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_41515d92-c7d5-4678-a03e-5244833a6675" xlink:to="loc_us-gaap_GoodwillRollForward_84438e62-1d41-4732-b8cf-a4447647f523" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ac9010a7-793f-47e2-82cc-4b5c0adfa81b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_84438e62-1d41-4732-b8cf-a4447647f523" xlink:to="loc_us-gaap_Goodwill_ac9010a7-793f-47e2-82cc-4b5c0adfa81b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_3a1d0af8-3475-43e7-a531-5f017f4e47c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_84438e62-1d41-4732-b8cf-a4447647f523" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_3a1d0af8-3475-43e7-a531-5f017f4e47c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_f7ca7ae7-8fd9-4ac1-8fcc-428a90b79c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_84438e62-1d41-4732-b8cf-a4447647f523" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_f7ca7ae7-8fd9-4ac1-8fcc-428a90b79c9b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_f828a3a3-1e10-47a7-a09a-dd432301948b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_84438e62-1d41-4732-b8cf-a4447647f523" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_f828a3a3-1e10-47a7-a09a-dd432301948b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_77b55242-831d-4f97-97a4-babb8b537371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_7c089d84-973e-4ad6-8fda-fbdc67380c00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_41515d92-c7d5-4678-a03e-5244833a6675" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_7c089d84-973e-4ad6-8fda-fbdc67380c00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_563460a0-d57e-4432-b56d-2557cffdf3e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_41515d92-c7d5-4678-a03e-5244833a6675" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_563460a0-d57e-4432-b56d-2557cffdf3e0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_2752f9d3-b17a-4de1-aec0-c5a2a93ab442" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_563460a0-d57e-4432-b56d-2557cffdf3e0" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_2752f9d3-b17a-4de1-aec0-c5a2a93ab442" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2752f9d3-b17a-4de1-aec0-c5a2a93ab442_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2752f9d3-b17a-4de1-aec0-c5a2a93ab442" xlink:to="loc_us-gaap_SegmentDomain_2752f9d3-b17a-4de1-aec0-c5a2a93ab442_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_bd321051-e9f3-46d3-9916-d6a9566f8f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2752f9d3-b17a-4de1-aec0-c5a2a93ab442" xlink:to="loc_us-gaap_SegmentDomain_bd321051-e9f3-46d3-9916-d6a9566f8f5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_5bc8463b-58c1-4d98-981b-a10b24f563c7" xlink:href="cah-20220331.xsd#cah_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_bd321051-e9f3-46d3-9916-d6a9566f8f5b" xlink:to="loc_cah_PharmaceuticalMember_5bc8463b-58c1-4d98-981b-a10b24f563c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_0e37cd23-0a03-4873-9b46-3b069cc24b09" xlink:href="cah-20220331.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_bd321051-e9f3-46d3-9916-d6a9566f8f5b" xlink:to="loc_cah_MedicalMember_0e37cd23-0a03-4873-9b46-3b069cc24b09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_3298a960-b674-492f-887f-6cc335ea8c34" xlink:href="cah-20220331.xsd#cah_CordisDivestitureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_563460a0-d57e-4432-b56d-2557cffdf3e0" xlink:to="loc_cah_CordisDivestitureAxis_3298a960-b674-492f-887f-6cc335ea8c34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_3298a960-b674-492f-887f-6cc335ea8c34_default" xlink:href="cah-20220331.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_CordisDivestitureAxis_3298a960-b674-492f-887f-6cc335ea8c34" xlink:to="loc_cah_CordisDivestitureDomain_3298a960-b674-492f-887f-6cc335ea8c34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_ea08640f-5a5d-402b-a669-be5494da86ee" xlink:href="cah-20220331.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_CordisDivestitureAxis_3298a960-b674-492f-887f-6cc335ea8c34" xlink:to="loc_cah_CordisDivestitureDomain_ea08640f-5a5d-402b-a669-be5494da86ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_d7845ac1-341e-4e4c-a79a-d59d4f695d2e" xlink:href="cah-20220331.xsd#cah_CordisDivestitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_CordisDivestitureDomain_ea08640f-5a5d-402b-a669-be5494da86ee" xlink:to="loc_cah_CordisDivestitureMember_d7845ac1-341e-4e4c-a79a-d59d4f695d2e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended" id="i15114a12259642fbbbee100429cc8a01_GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_e0b6a1da-e9de-43a3-8dd7-a5dbf9777217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_d7a26c9b-002e-46f8-9d0b-bae4563d69ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_e0b6a1da-e9de-43a3-8dd7-a5dbf9777217" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_d7a26c9b-002e-46f8-9d0b-bae4563d69ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_9f672a81-5ee1-48e5-bdda-a9582f61b87b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_e0b6a1da-e9de-43a3-8dd7-a5dbf9777217" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_9f672a81-5ee1-48e5-bdda-a9582f61b87b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8167558a-3849-4088-b6af-db1271fd7e19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_9f672a81-5ee1-48e5-bdda-a9582f61b87b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8167558a-3849-4088-b6af-db1271fd7e19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8167558a-3849-4088-b6af-db1271fd7e19_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8167558a-3849-4088-b6af-db1271fd7e19" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8167558a-3849-4088-b6af-db1271fd7e19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_69ed395e-9d25-40aa-91a0-74bf1dd1b298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8167558a-3849-4088-b6af-db1271fd7e19" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_69ed395e-9d25-40aa-91a0-74bf1dd1b298" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IPRDTrademarksandOtherMember_984c6604-7d0b-4f52-ba8b-cce53009e446" xlink:href="cah-20220331.xsd#cah_IPRDTrademarksandOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_69ed395e-9d25-40aa-91a0-74bf1dd1b298" xlink:to="loc_cah_IPRDTrademarksandOtherMember_984c6604-7d0b-4f52-ba8b-cce53009e446" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2d44ce79-dbf6-4be2-b157-ec9e5c49c54b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_77ca4578-a5a9-4a8e-9e4e-13266a317f37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2d44ce79-dbf6-4be2-b157-ec9e5c49c54b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_77ca4578-a5a9-4a8e-9e4e-13266a317f37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0a38602c-7923-4d6a-a566-44ac8d91d3ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2d44ce79-dbf6-4be2-b157-ec9e5c49c54b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0a38602c-7923-4d6a-a566-44ac8d91d3ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2bbf2509-2c54-4ac0-875e-e547cbd65928" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2d44ce79-dbf6-4be2-b157-ec9e5c49c54b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2bbf2509-2c54-4ac0-875e-e547cbd65928" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_3b464b69-2873-48f3-9f50-019753105499" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2d44ce79-dbf6-4be2-b157-ec9e5c49c54b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_3b464b69-2873-48f3-9f50-019753105499" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_690c5562-c8f2-4032-83ff-75d4932f1143" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2d44ce79-dbf6-4be2-b157-ec9e5c49c54b" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_690c5562-c8f2-4032-83ff-75d4932f1143" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9c264c54-bbf6-4c90-bae6-744ec5f2194b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_690c5562-c8f2-4032-83ff-75d4932f1143" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9c264c54-bbf6-4c90-bae6-744ec5f2194b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9c264c54-bbf6-4c90-bae6-744ec5f2194b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9c264c54-bbf6-4c90-bae6-744ec5f2194b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9c264c54-bbf6-4c90-bae6-744ec5f2194b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c1844ebe-3021-479c-b995-4e3be19693a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9c264c54-bbf6-4c90-bae6-744ec5f2194b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c1844ebe-3021-479c-b995-4e3be19693a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_ad910104-4d61-42c0-8f9b-2016aac05a58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c1844ebe-3021-479c-b995-4e3be19693a7" xlink:to="loc_us-gaap_CustomerRelationshipsMember_ad910104-4d61-42c0-8f9b-2016aac05a58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TrademarksAndPatentsMember_32d31008-b140-49f6-b1a0-0708bf228a04" xlink:href="cah-20220331.xsd#cah_TrademarksAndPatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c1844ebe-3021-479c-b995-4e3be19693a7" xlink:to="loc_cah_TrademarksAndPatentsMember_32d31008-b140-49f6-b1a0-0708bf228a04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_523fbb69-3ac3-4819-b8e6-8bf0575e871f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c1844ebe-3021-479c-b995-4e3be19693a7" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_523fbb69-3ac3-4819-b8e6-8bf0575e871f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#GoodwillandOtherIntangibleAssetsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="extended" id="i91a0dd38054048228cdd1d943f44c0f3_GoodwillandOtherIntangibleAssetsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_754a524a-800b-46df-8fc9-24e3cbd4fa5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_70584c31-ee59-43d6-94f9-9c37e818e25d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_754a524a-800b-46df-8fc9-24e3cbd4fa5c" xlink:to="loc_us-gaap_Goodwill_70584c31-ee59-43d6-94f9-9c37e818e25d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_4d44cdad-931e-4939-8072-54e48d650008" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_754a524a-800b-46df-8fc9-24e3cbd4fa5c" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_4d44cdad-931e-4939-8072-54e48d650008" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DiscountRateFairValueInput_b2082015-2dc1-43f3-8dfd-38fc36dd0b34" xlink:href="cah-20220331.xsd#cah_DiscountRateFairValueInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_754a524a-800b-46df-8fc9-24e3cbd4fa5c" xlink:to="loc_cah_DiscountRateFairValueInput_b2082015-2dc1-43f3-8dfd-38fc36dd0b34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TerminalGrowthRateFairValueInput_de797fbc-39e4-4663-9ea8-2b05778bd32b" xlink:href="cah-20220331.xsd#cah_TerminalGrowthRateFairValueInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_754a524a-800b-46df-8fc9-24e3cbd4fa5c" xlink:to="loc_cah_TerminalGrowthRateFairValueInput_de797fbc-39e4-4663-9ea8-2b05778bd32b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_c865eb11-f061-4316-9773-dd7a7ef3646d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_754a524a-800b-46df-8fc9-24e3cbd4fa5c" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_c865eb11-f061-4316-9773-dd7a7ef3646d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_d8ab273c-2879-4c9a-b674-9a25a73fd5a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_c865eb11-f061-4316-9773-dd7a7ef3646d" xlink:to="loc_us-gaap_ReportingUnitAxis_d8ab273c-2879-4c9a-b674-9a25a73fd5a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_d8ab273c-2879-4c9a-b674-9a25a73fd5a6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_d8ab273c-2879-4c9a-b674-9a25a73fd5a6" xlink:to="loc_us-gaap_ReportingUnitDomain_d8ab273c-2879-4c9a-b674-9a25a73fd5a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_1caf5c1d-cfd6-4e36-8275-d419c9a08d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_d8ab273c-2879-4c9a-b674-9a25a73fd5a6" xlink:to="loc_us-gaap_ReportingUnitDomain_1caf5c1d-cfd6-4e36-8275-d419c9a08d4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_408c4d5e-4c18-4be0-964e-5194d8df7fe5" xlink:href="cah-20220331.xsd#cah_MedicalUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_1caf5c1d-cfd6-4e36-8275-d419c9a08d4a" xlink:to="loc_cah_MedicalUnitMember_408c4d5e-4c18-4be0-964e-5194d8df7fe5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_dd252a5b-96f8-414c-a081-91fde0328a19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_c865eb11-f061-4316-9773-dd7a7ef3646d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_dd252a5b-96f8-414c-a081-91fde0328a19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_dd252a5b-96f8-414c-a081-91fde0328a19_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_dd252a5b-96f8-414c-a081-91fde0328a19" xlink:to="loc_us-gaap_SegmentDomain_dd252a5b-96f8-414c-a081-91fde0328a19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3c7ecaf4-5773-4fb0-87b1-0335a358d853" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_dd252a5b-96f8-414c-a081-91fde0328a19" xlink:to="loc_us-gaap_SegmentDomain_3c7ecaf4-5773-4fb0-87b1-0335a358d853" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_5b8a2f68-b831-448f-a563-c6fcb0b6c7cc" xlink:href="cah-20220331.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3c7ecaf4-5773-4fb0-87b1-0335a358d853" xlink:to="loc_cah_MedicalMember_5b8a2f68-b831-448f-a563-c6fcb0b6c7cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentAxis_cb9e756a-967d-4d57-a205-1e0883bfdd2b" xlink:href="cah-20220331.xsd#cah_GoodwillImpairmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_c865eb11-f061-4316-9773-dd7a7ef3646d" xlink:to="loc_cah_GoodwillImpairmentAxis_cb9e756a-967d-4d57-a205-1e0883bfdd2b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentDomain_cb9e756a-967d-4d57-a205-1e0883bfdd2b_default" xlink:href="cah-20220331.xsd#cah_GoodwillImpairmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_GoodwillImpairmentAxis_cb9e756a-967d-4d57-a205-1e0883bfdd2b" xlink:to="loc_cah_GoodwillImpairmentDomain_cb9e756a-967d-4d57-a205-1e0883bfdd2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentDomain_91e6d611-bb90-4899-99c7-b97200011986" xlink:href="cah-20220331.xsd#cah_GoodwillImpairmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_GoodwillImpairmentAxis_cb9e756a-967d-4d57-a205-1e0883bfdd2b" xlink:to="loc_cah_GoodwillImpairmentDomain_91e6d611-bb90-4899-99c7-b97200011986" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_c638d509-24e8-427c-b89c-c60ff7738d65" xlink:href="cah-20220331.xsd#cah_MedicalUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_GoodwillImpairmentDomain_91e6d611-bb90-4899-99c7-b97200011986" xlink:to="loc_cah_MedicalUnitMember_c638d509-24e8-427c-b89c-c60ff7738d65" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#LongTermObligationsandOtherShortTermBorrowingsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" xlink:type="extended" id="ic7cb0b52337748489b44698d889f50c7_LongTermObligationsandOtherShortTermBorrowingsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_059ce8d2-d1fb-4dc8-9ca5-5d76330a6d37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalLongTermandShortTermObligations_094e127c-8d37-4707-95d7-e07f74f571dd" xlink:href="cah-20220331.xsd#cah_TotalLongTermandShortTermObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_059ce8d2-d1fb-4dc8-9ca5-5d76330a6d37" xlink:to="loc_cah_TotalLongTermandShortTermObligations_094e127c-8d37-4707-95d7-e07f74f571dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_c6b32cdd-f043-418f-8c57-e3421244a525" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_059ce8d2-d1fb-4dc8-9ca5-5d76330a6d37" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_c6b32cdd-f043-418f-8c57-e3421244a525" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a4ef28b5-e5a8-4dda-8f32-467123517e19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_059ce8d2-d1fb-4dc8-9ca5-5d76330a6d37" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a4ef28b5-e5a8-4dda-8f32-467123517e19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_b7c69fdf-2877-44dc-8cc0-8a06f7c9f89d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_059ce8d2-d1fb-4dc8-9ca5-5d76330a6d37" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_b7c69fdf-2877-44dc-8cc0-8a06f7c9f89d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_a41b5ce8-7917-49f3-99e9-e45f69c09eca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_059ce8d2-d1fb-4dc8-9ca5-5d76330a6d37" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_a41b5ce8-7917-49f3-99e9-e45f69c09eca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermBorrowings_89a38c6f-6252-4dd3-94ec-4387d340e994" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_059ce8d2-d1fb-4dc8-9ca5-5d76330a6d37" xlink:to="loc_us-gaap_OtherShortTermBorrowings_89a38c6f-6252-4dd3-94ec-4387d340e994" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_4afc8cea-287f-4681-8125-c31d8de31965" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_059ce8d2-d1fb-4dc8-9ca5-5d76330a6d37" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_4afc8cea-287f-4681-8125-c31d8de31965" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_b35e28d0-7367-4a0a-a008-9c8715af73d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAverageOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_059ce8d2-d1fb-4dc8-9ca5-5d76330a6d37" xlink:to="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_b35e28d0-7367-4a0a-a008-9c8715af73d4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_f56aeda6-58ea-434b-9c45-cc6a5da82b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_059ce8d2-d1fb-4dc8-9ca5-5d76330a6d37" xlink:to="loc_us-gaap_DebtInstrumentTable_f56aeda6-58ea-434b-9c45-cc6a5da82b5f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a9dd8439-b5c1-456c-ad55-bde7088a1bae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f56aeda6-58ea-434b-9c45-cc6a5da82b5f" xlink:to="loc_us-gaap_DebtInstrumentAxis_a9dd8439-b5c1-456c-ad55-bde7088a1bae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a9dd8439-b5c1-456c-ad55-bde7088a1bae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_a9dd8439-b5c1-456c-ad55-bde7088a1bae" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a9dd8439-b5c1-456c-ad55-bde7088a1bae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_92fcd9d0-d408-4156-91dc-c4bbe6e5284c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_a9dd8439-b5c1-456c-ad55-bde7088a1bae" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_92fcd9d0-d408-4156-91dc-c4bbe6e5284c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.616Notesdue2022Member_57fa9a9f-9b99-42c7-920f-f5fb50b32d0d" xlink:href="cah-20220331.xsd#cah_A2.616Notesdue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_92fcd9d0-d408-4156-91dc-c4bbe6e5284c" xlink:to="loc_cah_A2.616Notesdue2022Member_57fa9a9f-9b99-42c7-920f-f5fb50b32d0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember_5ce7381d-adf0-4ed5-b135-9ece8874ec74" xlink:href="cah-20220331.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_92fcd9d0-d408-4156-91dc-c4bbe6e5284c" xlink:to="loc_cah_CommittedReceivablesSalesFacilityProgramMember_5ce7381d-adf0-4ed5-b135-9ece8874ec74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FloatingRateNotesdue2022Member_3a8eac71-65e4-44ce-90a8-23a3d3ba4a02" xlink:href="cah-20220331.xsd#cah_FloatingRateNotesdue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_92fcd9d0-d408-4156-91dc-c4bbe6e5284c" xlink:to="loc_cah_FloatingRateNotesdue2022Member_3a8eac71-65e4-44ce-90a8-23a3d3ba4a02" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_e7fdde95-5bf5-4901-9df8-49432db40275" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f56aeda6-58ea-434b-9c45-cc6a5da82b5f" xlink:to="loc_us-gaap_CreditFacilityAxis_e7fdde95-5bf5-4901-9df8-49432db40275" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_e7fdde95-5bf5-4901-9df8-49432db40275_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_e7fdde95-5bf5-4901-9df8-49432db40275" xlink:to="loc_us-gaap_CreditFacilityDomain_e7fdde95-5bf5-4901-9df8-49432db40275_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_80766d8c-93a0-4d10-9e9e-e12f0778eedc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_e7fdde95-5bf5-4901-9df8-49432db40275" xlink:to="loc_us-gaap_CreditFacilityDomain_80766d8c-93a0-4d10-9e9e-e12f0778eedc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_244a63fb-461c-4a2b-a544-a020696494ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_80766d8c-93a0-4d10-9e9e-e12f0778eedc" xlink:to="loc_us-gaap_CommercialPaperMember_244a63fb-461c-4a2b-a544-a020696494ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_c6cf4e72-8a1f-4fbc-90bd-22cc8ea4f7f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_80766d8c-93a0-4d10-9e9e-e12f0778eedc" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_c6cf4e72-8a1f-4fbc-90bd-22cc8ea4f7f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShortTermCreditFacilitiesMember_d1aa86fb-2d2e-4b1f-9dce-a0fda512fcee" xlink:href="cah-20220331.xsd#cah_ShortTermCreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_80766d8c-93a0-4d10-9e9e-e12f0778eedc" xlink:to="loc_cah_ShortTermCreditFacilitiesMember_d1aa86fb-2d2e-4b1f-9dce-a0fda512fcee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember_1d1f8339-f489-489d-8f47-1bf6e93c4de0" xlink:href="cah-20220331.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_80766d8c-93a0-4d10-9e9e-e12f0778eedc" xlink:to="loc_cah_CommittedReceivablesSalesFacilityProgramMember_1d1f8339-f489-489d-8f47-1bf6e93c4de0" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" xlink:type="extended" id="i3f473220b05d49feaf2024d3a6c905be_LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_865d7cf9-49c6-4f78-a549-9ae1bf1fecc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalLongTermandShortTermObligations_f2615682-20ca-45b0-86f0-504ca550ddc9" xlink:href="cah-20220331.xsd#cah_TotalLongTermandShortTermObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_865d7cf9-49c6-4f78-a549-9ae1bf1fecc9" xlink:to="loc_cah_TotalLongTermandShortTermObligations_f2615682-20ca-45b0-86f0-504ca550ddc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_39090efd-2f2a-4134-ac03-be4d8fe62d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_865d7cf9-49c6-4f78-a549-9ae1bf1fecc9" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_39090efd-2f2a-4134-ac03-be4d8fe62d9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_ea6eee57-548f-450c-9dd3-1d0a4c3799bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_865d7cf9-49c6-4f78-a549-9ae1bf1fecc9" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_ea6eee57-548f-450c-9dd3-1d0a4c3799bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_d004e6de-7e57-4c17-8b4c-a4d2eca60b58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_865d7cf9-49c6-4f78-a549-9ae1bf1fecc9" xlink:to="loc_us-gaap_DebtInstrumentTable_d004e6de-7e57-4c17-8b4c-a4d2eca60b58" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_100a7184-c606-4cc7-a45c-cbe3f7d3e314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d004e6de-7e57-4c17-8b4c-a4d2eca60b58" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_100a7184-c606-4cc7-a45c-cbe3f7d3e314" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_100a7184-c606-4cc7-a45c-cbe3f7d3e314_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_100a7184-c606-4cc7-a45c-cbe3f7d3e314" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_100a7184-c606-4cc7-a45c-cbe3f7d3e314_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4471fb98-6eca-4cb9-836a-7b4bd4bc4e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_100a7184-c606-4cc7-a45c-cbe3f7d3e314" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4471fb98-6eca-4cb9-836a-7b4bd4bc4e77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c67762a4-edbd-438b-9093-7aa12ffec363" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d004e6de-7e57-4c17-8b4c-a4d2eca60b58" xlink:to="loc_us-gaap_DebtInstrumentAxis_c67762a4-edbd-438b-9093-7aa12ffec363" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c67762a4-edbd-438b-9093-7aa12ffec363_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_c67762a4-edbd-438b-9093-7aa12ffec363" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c67762a4-edbd-438b-9093-7aa12ffec363_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_edb57655-6ef6-4aee-94fa-04eb347e2941" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_c67762a4-edbd-438b-9093-7aa12ffec363" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_edb57655-6ef6-4aee-94fa-04eb347e2941" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.616Notesdue2022Member_9f0bf180-6118-4ac1-af0d-a28f940fa43d" xlink:href="cah-20220331.xsd#cah_A2.616Notesdue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_edb57655-6ef6-4aee-94fa-04eb347e2941" xlink:to="loc_cah_A2.616Notesdue2022Member_9f0bf180-6118-4ac1-af0d-a28f940fa43d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FloatingRateNotesdue2022Member_687ff881-21ad-4f36-8a94-50ea651e17e7" xlink:href="cah-20220331.xsd#cah_FloatingRateNotesdue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_edb57655-6ef6-4aee-94fa-04eb347e2941" xlink:to="loc_cah_FloatingRateNotesdue2022Member_687ff881-21ad-4f36-8a94-50ea651e17e7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#CommitmentsContingentLiabilitiesandLitigationDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" xlink:type="extended" id="iec35074c3e9640b1851fdf3a2d86a1cf_CommitmentsContingentLiabilitiesandLitigationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod_94df7c5f-79ec-4bba-b53e-a3921eac3610" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:to="loc_us-gaap_LongtermPurchaseCommitmentPeriod_94df7c5f-79ec-4bba-b53e-a3921eac3610" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AggregateAnnualAssessment_0b3e2a01-3d85-48dc-b057-6052d6083ba5" xlink:href="cah-20220331.xsd#cah_AggregateAnnualAssessment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:to="loc_cah_AggregateAnnualAssessment_0b3e2a01-3d85-48dc-b057-6052d6083ba5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_51d9f0c2-61a1-4375-bd4c-455e03b76f32" xlink:href="cah-20220331.xsd#cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:to="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_51d9f0c2-61a1-4375-bd4c-455e03b76f32" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments_a016a065-b7d3-4944-85ef-70b1547a0201" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:to="loc_us-gaap_LossContingencyAccrualPayments_a016a065-b7d3-4944-85ef-70b1547a0201" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_07fad293-111b-482d-954c-5f473f95ad6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_07fad293-111b-482d-954c-5f473f95ad6a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LossContingencyLawsuitsNumber_e106aa88-363e-4bcd-a53f-158746de17ca" xlink:href="cah-20220331.xsd#cah_LossContingencyLawsuitsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:to="loc_cah_LossContingencyLawsuitsNumber_e106aa88-363e-4bcd-a53f-158746de17ca" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NumberofStateAttorneysGeneralfilinglawsuits_36987a76-0840-4af1-9027-1aa38fdde3e3" xlink:href="cah-20220331.xsd#cah_NumberofStateAttorneysGeneralfilinglawsuits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:to="loc_cah_NumberofStateAttorneysGeneralfilinglawsuits_36987a76-0840-4af1-9027-1aa38fdde3e3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_65922a08-9229-401f-bf4d-d7253d4d732b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_65922a08-9229-401f-bf4d-d7253d4d732b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_97eaa1ed-22a4-4238-9f5a-5be12ccc87c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:to="loc_us-gaap_LitigationReserve_97eaa1ed-22a4-4238-9f5a-5be12ccc87c8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_44b335dd-038c-45a9-9d6b-a4ad7e05aaa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:to="loc_us-gaap_LitigationReserveCurrent_44b335dd-038c-45a9-9d6b-a4ad7e05aaa6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_8bdd2131-ad42-472e-b065-07efc33bfe36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:to="loc_us-gaap_LitigationSettlementExpense_8bdd2131-ad42-472e-b065-07efc33bfe36" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_c00c3749-7525-4e02-8415-d6e871a7fa54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_c00c3749-7525-4e02-8415-d6e871a7fa54" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_2309800a-6b9e-4d0e-a027-1b2a323afde9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_2309800a-6b9e-4d0e-a027-1b2a323afde9" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsSettledNumber_5c649eb5-e14d-4c25-95b6-75e352b68f02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyClaimsSettledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:to="loc_us-gaap_LossContingencyClaimsSettledNumber_5c649eb5-e14d-4c25-95b6-75e352b68f02" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_b353c4fe-04d9-4c36-aeb5-7ad52a0df53c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_b353c4fe-04d9-4c36-aeb5-7ad52a0df53c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_JudgmentForLostProfits_c35cbdeb-040f-408b-8dcc-56f389a0f123" xlink:href="cah-20220331.xsd#cah_JudgmentForLostProfits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:to="loc_cah_JudgmentForLostProfits_c35cbdeb-040f-408b-8dcc-56f389a0f123" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SettlingStates_fa890b43-b79e-4e04-a20c-25d5e4ac5eb1" xlink:href="cah-20220331.xsd#cah_SettlingStates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:to="loc_cah_SettlingStates_fa890b43-b79e-4e04-a20c-25d5e4ac5eb1" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SettlingUSTerritories_cfbd6092-2724-478e-82ef-9c30f88c157d" xlink:href="cah-20220331.xsd#cah_SettlingUSTerritories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:to="loc_cah_SettlingUSTerritories_cfbd6092-2724-478e-82ef-9c30f88c157d" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_4ccbb706-5ad2-4696-bd8e-b8728df221ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_4ccbb706-5ad2-4696-bd8e-b8728df221ec" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_e2127a53-5672-40a4-bc90-220ae80e2339" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_e2127a53-5672-40a4-bc90-220ae80e2339" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LossContingencyClaimsSettledPercent_1c2aa088-1584-4aa7-a271-9bbc97e588f5" xlink:href="cah-20220331.xsd#cah_LossContingencyClaimsSettledPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:to="loc_cah_LossContingencyClaimsSettledPercent_1c2aa088-1584-4aa7-a271-9bbc97e588f5" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_c691539b-ca68-44d9-9c4d-6a5a38c8824a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:to="loc_us-gaap_LossContingenciesTable_c691539b-ca68-44d9-9c4d-6a5a38c8824a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_56edc9ba-9e2c-4453-ad03-d9e586e2f969" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c691539b-ca68-44d9-9c4d-6a5a38c8824a" xlink:to="loc_srt_MajorCustomersAxis_56edc9ba-9e2c-4453-ad03-d9e586e2f969" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_56edc9ba-9e2c-4453-ad03-d9e586e2f969_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_56edc9ba-9e2c-4453-ad03-d9e586e2f969" xlink:to="loc_srt_NameOfMajorCustomerDomain_56edc9ba-9e2c-4453-ad03-d9e586e2f969_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_4fe7fe13-60d0-4a66-817a-4045d2ccf575" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_56edc9ba-9e2c-4453-ad03-d9e586e2f969" xlink:to="loc_srt_NameOfMajorCustomerDomain_4fe7fe13-60d0-4a66-817a-4045d2ccf575" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CVSHealthMember_ee43aa36-b0bf-4aaa-941a-96b7799157ed" xlink:href="cah-20220331.xsd#cah_CVSHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_4fe7fe13-60d0-4a66-817a-4045d2ccf575" xlink:to="loc_cah_CVSHealthMember_ee43aa36-b0bf-4aaa-941a-96b7799157ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_31f4b215-3b17-4f22-b161-116779032b26" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c691539b-ca68-44d9-9c4d-6a5a38c8824a" xlink:to="loc_srt_LitigationCaseAxis_31f4b215-3b17-4f22-b161-116779032b26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_31f4b215-3b17-4f22-b161-116779032b26_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_31f4b215-3b17-4f22-b161-116779032b26" xlink:to="loc_srt_LitigationCaseTypeDomain_31f4b215-3b17-4f22-b161-116779032b26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_1329071c-b758-4f83-b846-90cf4970cfb1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_31f4b215-3b17-4f22-b161-116779032b26" xlink:to="loc_srt_LitigationCaseTypeDomain_1329071c-b758-4f83-b846-90cf4970cfb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NewYorkOpioidStewardshipActMember_240ea4af-5907-475e-ba40-d86451931ac5" xlink:href="cah-20220331.xsd#cah_NewYorkOpioidStewardshipActMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_1329071c-b758-4f83-b846-90cf4970cfb1" xlink:to="loc_cah_NewYorkOpioidStewardshipActMember_240ea4af-5907-475e-ba40-d86451931ac5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember_a2803e3d-05ce-43bc-9a44-9839ca0abae7" xlink:href="cah-20220331.xsd#cah_OpioidLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_1329071c-b758-4f83-b846-90cf4970cfb1" xlink:to="loc_cah_OpioidLawsuitsMember_a2803e3d-05ce-43bc-9a44-9839ca0abae7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsStateMember_612b0457-613b-4901-966d-1a66a69209c0" xlink:href="cah-20220331.xsd#cah_OpioidLawsuitsStateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_1329071c-b758-4f83-b846-90cf4970cfb1" xlink:to="loc_cah_OpioidLawsuitsStateMember_612b0457-613b-4901-966d-1a66a69209c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_a94191ee-86ec-4df3-bfd6-51b0164d5d06" xlink:href="cah-20220331.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_1329071c-b758-4f83-b846-90cf4970cfb1" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_a94191ee-86ec-4df3-bfd6-51b0164d5d06" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DOJInvestigationMember_32caba85-7a37-4246-ab65-f14d141ebf65" xlink:href="cah-20220331.xsd#cah_DOJInvestigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_1329071c-b758-4f83-b846-90cf4970cfb1" xlink:to="loc_cah_DOJInvestigationMember_32caba85-7a37-4246-ab65-f14d141ebf65" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_385d4101-557a-4eb5-9f94-4a93ca2c6293" xlink:href="cah-20220331.xsd#cah_OpioidLitigationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c691539b-ca68-44d9-9c4d-6a5a38c8824a" xlink:to="loc_cah_OpioidLitigationAxis_385d4101-557a-4eb5-9f94-4a93ca2c6293" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_385d4101-557a-4eb5-9f94-4a93ca2c6293_default" xlink:href="cah-20220331.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_OpioidLitigationAxis_385d4101-557a-4eb5-9f94-4a93ca2c6293" xlink:to="loc_cah_OpioidLitigationDomain_385d4101-557a-4eb5-9f94-4a93ca2c6293_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_a06a5e2f-4a84-4787-8131-bdeb99288d54" xlink:href="cah-20220331.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_OpioidLitigationAxis_385d4101-557a-4eb5-9f94-4a93ca2c6293" xlink:to="loc_cah_OpioidLitigationDomain_a06a5e2f-4a84-4787-8131-bdeb99288d54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_6dc0968b-c7d1-48c7-bba4-4470f1459e6b" xlink:href="cah-20220331.xsd#cah_TotalOpioidLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_OpioidLitigationDomain_a06a5e2f-4a84-4787-8131-bdeb99288d54" xlink:to="loc_cah_TotalOpioidLitigationMember_6dc0968b-c7d1-48c7-bba4-4470f1459e6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeAxis_a1f9f89c-3b4d-4656-b59d-779801dd65fe" xlink:href="cah-20220331.xsd#cah_LawsuitTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c691539b-ca68-44d9-9c4d-6a5a38c8824a" xlink:to="loc_cah_LawsuitTypeAxis_a1f9f89c-3b4d-4656-b59d-779801dd65fe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeDomain_a1f9f89c-3b4d-4656-b59d-779801dd65fe_default" xlink:href="cah-20220331.xsd#cah_LawsuitTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_LawsuitTypeAxis_a1f9f89c-3b4d-4656-b59d-779801dd65fe" xlink:to="loc_cah_LawsuitTypeDomain_a1f9f89c-3b4d-4656-b59d-779801dd65fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeDomain_0347b3b3-fff1-47fc-9eb8-ceffbd8dd0eb" xlink:href="cah-20220331.xsd#cah_LawsuitTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_LawsuitTypeAxis_a1f9f89c-3b4d-4656-b59d-779801dd65fe" xlink:to="loc_cah_LawsuitTypeDomain_0347b3b3-fff1-47fc-9eb8-ceffbd8dd0eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ClassActionLawsuitsMember_7d3baafa-9e19-47d7-9008-194bdbac2bd5" xlink:href="cah-20220331.xsd#cah_ClassActionLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_LawsuitTypeDomain_0347b3b3-fff1-47fc-9eb8-ceffbd8dd0eb" xlink:to="loc_cah_ClassActionLawsuitsMember_7d3baafa-9e19-47d7-9008-194bdbac2bd5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_58d417ad-a2cf-425c-8eff-b01a04b2a037" xlink:href="cah-20220331.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_LawsuitTypeDomain_0347b3b3-fff1-47fc-9eb8-ceffbd8dd0eb" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_58d417ad-a2cf-425c-8eff-b01a04b2a037" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeAxis_8d35c700-3db9-40e7-94b5-dca05dc0cfc8" xlink:href="cah-20220331.xsd#cah_PlaintiffTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c691539b-ca68-44d9-9c4d-6a5a38c8824a" xlink:to="loc_cah_PlaintiffTypeAxis_8d35c700-3db9-40e7-94b5-dca05dc0cfc8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeDomain_8d35c700-3db9-40e7-94b5-dca05dc0cfc8_default" xlink:href="cah-20220331.xsd#cah_PlaintiffTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_PlaintiffTypeAxis_8d35c700-3db9-40e7-94b5-dca05dc0cfc8" xlink:to="loc_cah_PlaintiffTypeDomain_8d35c700-3db9-40e7-94b5-dca05dc0cfc8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeDomain_46aa1b53-bdcd-4bd1-8799-e19f243db6ed" xlink:href="cah-20220331.xsd#cah_PlaintiffTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_PlaintiffTypeAxis_8d35c700-3db9-40e7-94b5-dca05dc0cfc8" xlink:to="loc_cah_PlaintiffTypeDomain_46aa1b53-bdcd-4bd1-8799-e19f243db6ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PrivatePartiesMember_a706e2ee-9284-4230-8c7f-f501402284e2" xlink:href="cah-20220331.xsd#cah_PrivatePartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_PlaintiffTypeDomain_46aa1b53-bdcd-4bd1-8799-e19f243db6ed" xlink:to="loc_cah_PrivatePartiesMember_a706e2ee-9284-4230-8c7f-f501402284e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_1a8b0dbc-f2db-469e-b939-55050db0e092" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c691539b-ca68-44d9-9c4d-6a5a38c8824a" xlink:to="loc_srt_StatementGeographicalAxis_1a8b0dbc-f2db-469e-b939-55050db0e092" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1a8b0dbc-f2db-469e-b939-55050db0e092_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_1a8b0dbc-f2db-469e-b939-55050db0e092" xlink:to="loc_srt_SegmentGeographicalDomain_1a8b0dbc-f2db-469e-b939-55050db0e092_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_137f4820-e6c7-49e4-9e7a-552be5a8c96b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_1a8b0dbc-f2db-469e-b939-55050db0e092" xlink:to="loc_srt_SegmentGeographicalDomain_137f4820-e6c7-49e4-9e7a-552be5a8c96b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_GA_c91ae4c4-a01a-4d4d-b528-2c1a35f3b316" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_GA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_137f4820-e6c7-49e4-9e7a-552be5a8c96b" xlink:to="loc_stpr_GA_c91ae4c4-a01a-4d4d-b528-2c1a35f3b316" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WV_2a7309da-2e2d-4dd7-967b-98d83f6f9fa2" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WV"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_137f4820-e6c7-49e4-9e7a-552be5a8c96b" xlink:to="loc_stpr_WV_2a7309da-2e2d-4dd7-967b-98d83f6f9fa2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WA_8830074d-8eb7-4193-9ee4-2cb3ce932ca7" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_137f4820-e6c7-49e4-9e7a-552be5a8c96b" xlink:to="loc_stpr_WA_8830074d-8eb7-4193-9ee4-2cb3ce932ca7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AlamedaCountyMember_8b18c5bc-0378-41e7-8eec-aea056b0ecc9" xlink:href="cah-20220331.xsd#cah_AlamedaCountyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_137f4820-e6c7-49e4-9e7a-552be5a8c96b" xlink:to="loc_cah_AlamedaCountyMember_8b18c5bc-0378-41e7-8eec-aea056b0ecc9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OtherJurisdictionsMember_58a4254e-0f97-46d4-842e-96e3c9e9303f" xlink:href="cah-20220331.xsd#cah_OtherJurisdictionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_137f4820-e6c7-49e4-9e7a-552be5a8c96b" xlink:to="loc_cah_OtherJurisdictionsMember_58a4254e-0f97-46d4-842e-96e3c9e9303f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7cdedaab-8bf8-4455-b92e-fe9f418b9a06" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c691539b-ca68-44d9-9c4d-6a5a38c8824a" xlink:to="loc_srt_RangeAxis_7cdedaab-8bf8-4455-b92e-fe9f418b9a06" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7cdedaab-8bf8-4455-b92e-fe9f418b9a06_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7cdedaab-8bf8-4455-b92e-fe9f418b9a06" xlink:to="loc_srt_RangeMember_7cdedaab-8bf8-4455-b92e-fe9f418b9a06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b9ad9c3f-869e-4f3e-b5ef-5d13e6e73506" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7cdedaab-8bf8-4455-b92e-fe9f418b9a06" xlink:to="loc_srt_RangeMember_b9ad9c3f-869e-4f3e-b5ef-5d13e6e73506" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_59e41b56-7632-42c3-8021-89a642460305" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b9ad9c3f-869e-4f3e-b5ef-5d13e6e73506" xlink:to="loc_srt_MinimumMember_59e41b56-7632-42c3-8021-89a642460305" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_aed5dea0-5f93-4715-9940-d1b9a2137eab" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b9ad9c3f-869e-4f3e-b5ef-5d13e6e73506" xlink:to="loc_srt_MaximumMember_aed5dea0-5f93-4715-9940-d1b9a2137eab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_f7979af0-60d6-4485-9324-f739ae8dc737" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c691539b-ca68-44d9-9c4d-6a5a38c8824a" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_f7979af0-60d6-4485-9324-f739ae8dc737" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_f7979af0-60d6-4485-9324-f739ae8dc737_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_f7979af0-60d6-4485-9324-f739ae8dc737" xlink:to="loc_us-gaap_LossContingencyNatureDomain_f7979af0-60d6-4485-9324-f739ae8dc737_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_8730f1ba-fd39-4fba-8ab8-6585efa039e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_f7979af0-60d6-4485-9324-f739ae8dc737" xlink:to="loc_us-gaap_LossContingencyNatureDomain_8730f1ba-fd39-4fba-8ab8-6585efa039e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember_0eb6284d-790e-4f7e-a445-c8a4eecd6445" xlink:href="cah-20220331.xsd#cah_OpioidLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_8730f1ba-fd39-4fba-8ab8-6585efa039e3" xlink:to="loc_cah_OpioidLawsuitsMember_0eb6284d-790e-4f7e-a445-c8a4eecd6445" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_0ba8afc8-b43f-40a6-97e9-50718a25807a" xlink:href="cah-20220331.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_8730f1ba-fd39-4fba-8ab8-6585efa039e3" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_0ba8afc8-b43f-40a6-97e9-50718a25807a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1239258a-b982-4ef8-84a5-4205e8958d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c691539b-ca68-44d9-9c4d-6a5a38c8824a" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1239258a-b982-4ef8-84a5-4205e8958d1c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1239258a-b982-4ef8-84a5-4205e8958d1c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1239258a-b982-4ef8-84a5-4205e8958d1c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1239258a-b982-4ef8-84a5-4205e8958d1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_47f4d7cb-5e08-44a4-bba0-ba271645cbf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1239258a-b982-4ef8-84a5-4205e8958d1c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_47f4d7cb-5e08-44a4-bba0-ba271645cbf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_d2cd7ff3-82ff-48bd-b367-c56a62cfcd93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_47f4d7cb-5e08-44a4-bba0-ba271645cbf6" xlink:to="loc_us-gaap_SubsequentEventMember_d2cd7ff3-82ff-48bd-b367-c56a62cfcd93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_28278dcb-4714-46ab-a345-d84c5761c0c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c691539b-ca68-44d9-9c4d-6a5a38c8824a" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_28278dcb-4714-46ab-a345-d84c5761c0c8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_28278dcb-4714-46ab-a345-d84c5761c0c8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_28278dcb-4714-46ab-a345-d84c5761c0c8" xlink:to="loc_us-gaap_SegmentDomain_28278dcb-4714-46ab-a345-d84c5761c0c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_afe16565-c6bc-4f31-82dd-ce5cd9bab4bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_28278dcb-4714-46ab-a345-d84c5761c0c8" xlink:to="loc_us-gaap_SegmentDomain_afe16565-c6bc-4f31-82dd-ce5cd9bab4bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_c165d777-f907-492e-922f-3bfd09bedd5d" xlink:href="cah-20220331.xsd#cah_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_afe16565-c6bc-4f31-82dd-ce5cd9bab4bf" xlink:to="loc_cah_PharmaceuticalMember_c165d777-f907-492e-922f-3bfd09bedd5d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="ia8ff96f4c68c4ab8ad5b265d3a5acef6_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_39038186-fb51-48d6-9811-a85d4a2a277e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_46f1208b-4b70-47ab-bbbd-273577c53db0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_39038186-fb51-48d6-9811-a85d4a2a277e" xlink:to="loc_us-gaap_LitigationReserve_46f1208b-4b70-47ab-bbbd-273577c53db0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e8166959-ce75-4a39-b187-ee514d780e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_39038186-fb51-48d6-9811-a85d4a2a277e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e8166959-ce75-4a39-b187-ee514d780e5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_37c93067-4b3d-4d0e-aeee-3c43f0f1b5d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_39038186-fb51-48d6-9811-a85d4a2a277e" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_37c93067-4b3d-4d0e-aeee-3c43f0f1b5d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_575ef562-13ff-44ac-bac0-a42146555984" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_39038186-fb51-48d6-9811-a85d4a2a277e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_575ef562-13ff-44ac-bac0-a42146555984" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_aaf06605-4288-4c15-945c-a0ae0b83515f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_39038186-fb51-48d6-9811-a85d4a2a277e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_aaf06605-4288-4c15-945c-a0ae0b83515f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_baa0eb49-3ed2-4517-bbbf-d66f19267cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_39038186-fb51-48d6-9811-a85d4a2a277e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_baa0eb49-3ed2-4517-bbbf-d66f19267cf8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_621c171c-b931-4faf-8412-d925ef845338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_39038186-fb51-48d6-9811-a85d4a2a277e" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_621c171c-b931-4faf-8412-d925ef845338" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IndemnificationReceivable_79760650-3144-4ecb-8f38-99940b964425" xlink:href="cah-20220331.xsd#cah_IndemnificationReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_39038186-fb51-48d6-9811-a85d4a2a277e" xlink:to="loc_cah_IndemnificationReceivable_79760650-3144-4ecb-8f38-99940b964425" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8d1de096-adf8-46ad-9e13-733a159f874f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_39038186-fb51-48d6-9811-a85d4a2a277e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8d1de096-adf8-46ad-9e13-733a159f874f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_64bc85ab-5f4d-4fef-aa1c-215383cee44c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_39038186-fb51-48d6-9811-a85d4a2a277e" xlink:to="loc_us-gaap_LitigationSettlementExpense_64bc85ab-5f4d-4fef-aa1c-215383cee44c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_1047adee-3900-4126-b2a7-bc5039590cce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_39038186-fb51-48d6-9811-a85d4a2a277e" xlink:to="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_1047adee-3900-4126-b2a7-bc5039590cce" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReceivable_fce45cba-04f7-4412-a211-dc110da9122a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_39038186-fb51-48d6-9811-a85d4a2a277e" xlink:to="loc_us-gaap_IncomeTaxReceivable_fce45cba-04f7-4412-a211-dc110da9122a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_3643ef4a-15e4-41bb-98e2-9e02fe9c960a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_39038186-fb51-48d6-9811-a85d4a2a277e" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_3643ef4a-15e4-41bb-98e2-9e02fe9c960a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIncomeTaxRefunds_bef45656-03d2-467d-9ef2-e554a3a2eae8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_39038186-fb51-48d6-9811-a85d4a2a277e" xlink:to="loc_us-gaap_ProceedsFromIncomeTaxRefunds_bef45656-03d2-467d-9ef2-e554a3a2eae8" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_40afb215-fc8b-453e-a378-f09db444ebb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_39038186-fb51-48d6-9811-a85d4a2a277e" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_40afb215-fc8b-453e-a378-f09db444ebb2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_8b13161b-bad9-4328-bb75-6b8a1395434d" xlink:href="cah-20220331.xsd#cah_OpioidLitigationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_40afb215-fc8b-453e-a378-f09db444ebb2" xlink:to="loc_cah_OpioidLitigationAxis_8b13161b-bad9-4328-bb75-6b8a1395434d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_8b13161b-bad9-4328-bb75-6b8a1395434d_default" xlink:href="cah-20220331.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_OpioidLitigationAxis_8b13161b-bad9-4328-bb75-6b8a1395434d" xlink:to="loc_cah_OpioidLitigationDomain_8b13161b-bad9-4328-bb75-6b8a1395434d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_618bd82f-0721-49a0-87d1-cb4438656a1a" xlink:href="cah-20220331.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_OpioidLitigationAxis_8b13161b-bad9-4328-bb75-6b8a1395434d" xlink:to="loc_cah_OpioidLitigationDomain_618bd82f-0721-49a0-87d1-cb4438656a1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_61e557fc-27ba-4307-8b4d-2b8e56e3dc2e" xlink:href="cah-20220331.xsd#cah_TotalOpioidLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_OpioidLitigationDomain_618bd82f-0721-49a0-87d1-cb4438656a1a" xlink:to="loc_cah_TotalOpioidLitigationMember_61e557fc-27ba-4307-8b4d-2b8e56e3dc2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterAxis_157cffec-f414-4b05-bea6-58923519715c" xlink:href="cah-20220331.xsd#cah_TaxMatterAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_40afb215-fc8b-453e-a378-f09db444ebb2" xlink:to="loc_cah_TaxMatterAxis_157cffec-f414-4b05-bea6-58923519715c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterDomain_157cffec-f414-4b05-bea6-58923519715c_default" xlink:href="cah-20220331.xsd#cah_TaxMatterDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_TaxMatterAxis_157cffec-f414-4b05-bea6-58923519715c" xlink:to="loc_cah_TaxMatterDomain_157cffec-f414-4b05-bea6-58923519715c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterDomain_67a3535a-38af-4f20-a6a3-d9f569a6dbbd" xlink:href="cah-20220331.xsd#cah_TaxMatterDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_TaxMatterAxis_157cffec-f414-4b05-bea6-58923519715c" xlink:to="loc_cah_TaxMatterDomain_67a3535a-38af-4f20-a6a3-d9f569a6dbbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PatientRecoveryBusinessMember_70bba0ce-aa9d-40d1-8f8a-f10139eb9699" xlink:href="cah-20220331.xsd#cah_PatientRecoveryBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_TaxMatterDomain_67a3535a-38af-4f20-a6a3-d9f569a6dbbd" xlink:to="loc_cah_PatientRecoveryBusinessMember_70bba0ce-aa9d-40d1-8f8a-f10139eb9699" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CareFusionMember_eefdcfa5-78ee-40a8-b5c6-d2313cc31abe" xlink:href="cah-20220331.xsd#cah_CareFusionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_TaxMatterDomain_67a3535a-38af-4f20-a6a3-d9f569a6dbbd" xlink:to="loc_cah_CareFusionMember_eefdcfa5-78ee-40a8-b5c6-d2313cc31abe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e5da45df-f786-4e56-b81f-c0e748c514ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_40afb215-fc8b-453e-a378-f09db444ebb2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e5da45df-f786-4e56-b81f-c0e748c514ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e5da45df-f786-4e56-b81f-c0e748c514ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e5da45df-f786-4e56-b81f-c0e748c514ac" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e5da45df-f786-4e56-b81f-c0e748c514ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0c6c6601-e768-409a-827f-2425595ed4f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e5da45df-f786-4e56-b81f-c0e748c514ac" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0c6c6601-e768-409a-827f-2425595ed4f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PatientRecoveryBusinessMember_c8a8b2d4-db52-4a29-939b-408029edb219" xlink:href="cah-20220331.xsd#cah_PatientRecoveryBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0c6c6601-e768-409a-827f-2425595ed4f6" xlink:to="loc_cah_PatientRecoveryBusinessMember_c8a8b2d4-db52-4a29-939b-408029edb219" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementAxis_337306ff-91fd-430a-9f39-e176c3913b4b" xlink:href="cah-20220331.xsd#cah_TaxMattersAgreementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_40afb215-fc8b-453e-a378-f09db444ebb2" xlink:to="loc_cah_TaxMattersAgreementAxis_337306ff-91fd-430a-9f39-e176c3913b4b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementDomain_337306ff-91fd-430a-9f39-e176c3913b4b_default" xlink:href="cah-20220331.xsd#cah_TaxMattersAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_TaxMattersAgreementAxis_337306ff-91fd-430a-9f39-e176c3913b4b" xlink:to="loc_cah_TaxMattersAgreementDomain_337306ff-91fd-430a-9f39-e176c3913b4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementDomain_cebf405f-fb18-4f8a-bd20-f4052ee244ff" xlink:href="cah-20220331.xsd#cah_TaxMattersAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_TaxMattersAgreementAxis_337306ff-91fd-430a-9f39-e176c3913b4b" xlink:to="loc_cah_TaxMattersAgreementDomain_cebf405f-fb18-4f8a-bd20-f4052ee244ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CareFusionMember_a5eaf060-32b3-4c4e-81cf-762b9ba63d60" xlink:href="cah-20220331.xsd#cah_CareFusionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_TaxMattersAgreementDomain_cebf405f-fb18-4f8a-bd20-f4052ee244ff" xlink:to="loc_cah_CareFusionMember_a5eaf060-32b3-4c4e-81cf-762b9ba63d60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_90fa59be-5759-4972-8575-2753e39db5e5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_40afb215-fc8b-453e-a378-f09db444ebb2" xlink:to="loc_srt_RangeAxis_90fa59be-5759-4972-8575-2753e39db5e5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_90fa59be-5759-4972-8575-2753e39db5e5_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_90fa59be-5759-4972-8575-2753e39db5e5" xlink:to="loc_srt_RangeMember_90fa59be-5759-4972-8575-2753e39db5e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_adff6e9d-e4e5-4d8f-a5cd-a154c4839438" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_90fa59be-5759-4972-8575-2753e39db5e5" xlink:to="loc_srt_RangeMember_adff6e9d-e4e5-4d8f-a5cd-a154c4839438" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6d7df18c-0e6f-4f97-aed5-66ef0d45e5cb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_adff6e9d-e4e5-4d8f-a5cd-a154c4839438" xlink:to="loc_srt_MinimumMember_6d7df18c-0e6f-4f97-aed5-66ef0d45e5cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cc79d287-d256-4fae-bb86-ebac916a7651" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_adff6e9d-e4e5-4d8f-a5cd-a154c4839438" xlink:to="loc_srt_MaximumMember_cc79d287-d256-4fae-bb86-ebac916a7651" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NetOperatingLossCarrybackAxis_0206a96e-aa68-4890-ac14-ba786505a648" xlink:href="cah-20220331.xsd#cah_NetOperatingLossCarrybackAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_40afb215-fc8b-453e-a378-f09db444ebb2" xlink:to="loc_cah_NetOperatingLossCarrybackAxis_0206a96e-aa68-4890-ac14-ba786505a648" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CARESActDomain_0206a96e-aa68-4890-ac14-ba786505a648_default" xlink:href="cah-20220331.xsd#cah_CARESActDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_NetOperatingLossCarrybackAxis_0206a96e-aa68-4890-ac14-ba786505a648" xlink:to="loc_cah_CARESActDomain_0206a96e-aa68-4890-ac14-ba786505a648_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CARESActDomain_d99dfc24-6c21-4263-835a-359360d8c4bf" xlink:href="cah-20220331.xsd#cah_CARESActDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_NetOperatingLossCarrybackAxis_0206a96e-aa68-4890-ac14-ba786505a648" xlink:to="loc_cah_CARESActDomain_d99dfc24-6c21-4263-835a-359360d8c4bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NetOperatingLossCarrybackMember_5fb9f0f2-93bf-4339-905b-9ba198dc01d8" xlink:href="cah-20220331.xsd#cah_NetOperatingLossCarrybackMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_CARESActDomain_d99dfc24-6c21-4263-835a-359360d8c4bf" xlink:to="loc_cah_NetOperatingLossCarrybackMember_5fb9f0f2-93bf-4339-905b-9ba198dc01d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_3f754502-a867-43c7-ab59-d5b176829f3a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_40afb215-fc8b-453e-a378-f09db444ebb2" xlink:to="loc_srt_StatementScenarioAxis_3f754502-a867-43c7-ab59-d5b176829f3a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_3f754502-a867-43c7-ab59-d5b176829f3a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_3f754502-a867-43c7-ab59-d5b176829f3a" xlink:to="loc_srt_ScenarioUnspecifiedDomain_3f754502-a867-43c7-ab59-d5b176829f3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_03492b61-bee3-4e2a-a3a6-20b897c182a9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_3f754502-a867-43c7-ab59-d5b176829f3a" xlink:to="loc_srt_ScenarioUnspecifiedDomain_03492b61-bee3-4e2a-a3a6-20b897c182a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_c78d971e-190b-431e-9720-98f256925816" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_03492b61-bee3-4e2a-a3a6-20b897c182a9" xlink:to="loc_srt_ScenarioForecastMember_c78d971e-190b-431e-9720-98f256925816" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentAxis_deaf3252-8aa2-4e75-a1f0-3dfb458c4784" xlink:href="cah-20220331.xsd#cah_GoodwillImpairmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_40afb215-fc8b-453e-a378-f09db444ebb2" xlink:to="loc_cah_GoodwillImpairmentAxis_deaf3252-8aa2-4e75-a1f0-3dfb458c4784" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentDomain_deaf3252-8aa2-4e75-a1f0-3dfb458c4784_default" xlink:href="cah-20220331.xsd#cah_GoodwillImpairmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_GoodwillImpairmentAxis_deaf3252-8aa2-4e75-a1f0-3dfb458c4784" xlink:to="loc_cah_GoodwillImpairmentDomain_deaf3252-8aa2-4e75-a1f0-3dfb458c4784_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentDomain_ff533701-ca6f-444b-924d-0a600ccc0f38" xlink:href="cah-20220331.xsd#cah_GoodwillImpairmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_GoodwillImpairmentAxis_deaf3252-8aa2-4e75-a1f0-3dfb458c4784" xlink:to="loc_cah_GoodwillImpairmentDomain_ff533701-ca6f-444b-924d-0a600ccc0f38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_d2c8d128-3d09-4296-9d03-6387cbfb3208" xlink:href="cah-20220331.xsd#cah_MedicalUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_GoodwillImpairmentDomain_ff533701-ca6f-444b-924d-0a600ccc0f38" xlink:to="loc_cah_MedicalUnitMember_d2c8d128-3d09-4296-9d03-6387cbfb3208" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitGoodwillImpairmentMember_44978d58-b93f-4b4e-96c3-57abf1fe24f3" xlink:href="cah-20220331.xsd#cah_MedicalUnitGoodwillImpairmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_GoodwillImpairmentDomain_ff533701-ca6f-444b-924d-0a600ccc0f38" xlink:to="loc_cah_MedicalUnitGoodwillImpairmentMember_44978d58-b93f-4b4e-96c3-57abf1fe24f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_560f520a-4aac-4dbd-9af9-b03b36788377" xlink:href="cah-20220331.xsd#cah_CordisDivestitureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_40afb215-fc8b-453e-a378-f09db444ebb2" xlink:to="loc_cah_CordisDivestitureAxis_560f520a-4aac-4dbd-9af9-b03b36788377" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_560f520a-4aac-4dbd-9af9-b03b36788377_default" xlink:href="cah-20220331.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_CordisDivestitureAxis_560f520a-4aac-4dbd-9af9-b03b36788377" xlink:to="loc_cah_CordisDivestitureDomain_560f520a-4aac-4dbd-9af9-b03b36788377_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_3ce71296-5591-411e-9955-cd08b3a91a28" xlink:href="cah-20220331.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_CordisDivestitureAxis_560f520a-4aac-4dbd-9af9-b03b36788377" xlink:to="loc_cah_CordisDivestitureDomain_3ce71296-5591-411e-9955-cd08b3a91a28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_22a033ab-d822-40c6-a30a-899d5149a570" xlink:href="cah-20220331.xsd#cah_CordisDivestitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_CordisDivestitureDomain_3ce71296-5591-411e-9955-cd08b3a91a28" xlink:to="loc_cah_CordisDivestitureMember_22a033ab-d822-40c6-a30a-899d5149a570" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_cc957468-4910-4275-a74b-c0c6ebeee497" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_40afb215-fc8b-453e-a378-f09db444ebb2" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_cc957468-4910-4275-a74b-c0c6ebeee497" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_cc957468-4910-4275-a74b-c0c6ebeee497_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_cc957468-4910-4275-a74b-c0c6ebeee497" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_cc957468-4910-4275-a74b-c0c6ebeee497_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7afe013d-3e57-4461-9424-5705055e78d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_cc957468-4910-4275-a74b-c0c6ebeee497" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7afe013d-3e57-4461-9424-5705055e78d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_d64dccda-b38a-4956-8759-7a1ddf2c02c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7afe013d-3e57-4461-9424-5705055e78d2" xlink:to="loc_us-gaap_SubsequentEventMember_d64dccda-b38a-4956-8759-7a1ddf2c02c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_4467267c-e2e6-496d-88e6-577d07a25aae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_40afb215-fc8b-453e-a378-f09db444ebb2" xlink:to="loc_us-gaap_ReportingUnitAxis_4467267c-e2e6-496d-88e6-577d07a25aae" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_4467267c-e2e6-496d-88e6-577d07a25aae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_4467267c-e2e6-496d-88e6-577d07a25aae" xlink:to="loc_us-gaap_ReportingUnitDomain_4467267c-e2e6-496d-88e6-577d07a25aae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_4d47c3b0-8ca9-41ff-b4f3-a6ecba4546fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_4467267c-e2e6-496d-88e6-577d07a25aae" xlink:to="loc_us-gaap_ReportingUnitDomain_4d47c3b0-8ca9-41ff-b4f3-a6ecba4546fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_1f520f09-ed63-450d-a770-6a66e2a1481b" xlink:href="cah-20220331.xsd#cah_MedicalUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_4d47c3b0-8ca9-41ff-b4f3-a6ecba4546fa" xlink:to="loc_cah_MedicalUnitMember_1f520f09-ed63-450d-a770-6a66e2a1481b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="extended" id="i7c9f48f006444e6b9285619e5e120cda_FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_71afe7b8-f483-4be3-b931-f9856853c03f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_0bbe542d-e6ef-4019-9460-ccd06d87ae67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_71afe7b8-f483-4be3-b931-f9856853c03f" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_0bbe542d-e6ef-4019-9460-ccd06d87ae67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_71cc3651-aee1-4950-8603-aa3003e08efc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0bbe542d-e6ef-4019-9460-ccd06d87ae67" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_71cc3651-aee1-4950-8603-aa3003e08efc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_4e9ee395-2c7f-4cd6-9479-f9f32b0dcaed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0bbe542d-e6ef-4019-9460-ccd06d87ae67" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_4e9ee395-2c7f-4cd6-9479-f9f32b0dcaed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_a36a31e4-978e-4031-81e4-2ced27b4ec9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0bbe542d-e6ef-4019-9460-ccd06d87ae67" xlink:to="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_a36a31e4-978e-4031-81e4-2ced27b4ec9e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_b7d66bcc-c668-4929-83af-80500e7bcbe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_71afe7b8-f483-4be3-b931-f9856853c03f" xlink:to="loc_us-gaap_LiabilitiesAbstract_b7d66bcc-c668-4929-83af-80500e7bcbe8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_064b8358-d6ec-4ea8-ad75-76244a1ab3e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11dc99ee-0cca-48b9-a7ca-66a07c8b5f64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_71afe7b8-f483-4be3-b931-f9856853c03f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11dc99ee-0cca-48b9-a7ca-66a07c8b5f64" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c6e4794c-d46c-4812-a37e-48ee0a715965" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11dc99ee-0cca-48b9-a7ca-66a07c8b5f64" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c6e4794c-d46c-4812-a37e-48ee0a715965" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c6e4794c-d46c-4812-a37e-48ee0a715965_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c6e4794c-d46c-4812-a37e-48ee0a715965" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c6e4794c-d46c-4812-a37e-48ee0a715965_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d432612-1b7f-4202-ba91-1fcf370dbd2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c6e4794c-d46c-4812-a37e-48ee0a715965" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d432612-1b7f-4202-ba91-1fcf370dbd2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_142985a8-a9b8-4d90-ad57-3dd8768b8854" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d432612-1b7f-4202-ba91-1fcf370dbd2b" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_142985a8-a9b8-4d90-ad57-3dd8768b8854" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_100ecb3a-f3fc-4a8a-b80a-55df396e4f77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d432612-1b7f-4202-ba91-1fcf370dbd2b" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_100ecb3a-f3fc-4a8a-b80a-55df396e4f77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e4e96755-1d5f-4e53-a9d1-ac981326c688" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d432612-1b7f-4202-ba91-1fcf370dbd2b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e4e96755-1d5f-4e53-a9d1-ac981326c688" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_80fcd692-33eb-4983-a0a9-748933a1d477" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11dc99ee-0cca-48b9-a7ca-66a07c8b5f64" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_80fcd692-33eb-4983-a0a9-748933a1d477" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_80fcd692-33eb-4983-a0a9-748933a1d477_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_80fcd692-33eb-4983-a0a9-748933a1d477" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_80fcd692-33eb-4983-a0a9-748933a1d477_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e90d7c70-2436-4b58-b592-93181ddff2ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_80fcd692-33eb-4983-a0a9-748933a1d477" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e90d7c70-2436-4b58-b592-93181ddff2ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_60233ab8-e725-4385-9011-3879cc450b14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e90d7c70-2436-4b58-b592-93181ddff2ae" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_60233ab8-e725-4385-9011-3879cc450b14" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended" id="idc2b10e2b58c480289ed5b01eb8f9283_FinancialInstrumentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_561b956c-c47c-46e6-bbf7-02cd30ce0cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_5a8144be-44d6-4f70-b4a3-2c269e926347" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_561b956c-c47c-46e6-bbf7-02cd30ce0cd4" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_5a8144be-44d6-4f70-b4a3-2c269e926347" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_fa81eb60-9274-4036-a1de-2b4059379286" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_561b956c-c47c-46e6-bbf7-02cd30ce0cd4" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_fa81eb60-9274-4036-a1de-2b4059379286" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_ab1fcaf0-a099-47ed-9cb7-48a40d84ce8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_561b956c-c47c-46e6-bbf7-02cd30ce0cd4" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_ab1fcaf0-a099-47ed-9cb7-48a40d84ce8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_02956f99-c424-418a-9419-c085d84edb31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_561b956c-c47c-46e6-bbf7-02cd30ce0cd4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_02956f99-c424-418a-9419-c085d84edb31" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_5511bf92-a2c1-4d24-abea-0aaa9677b33a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_561b956c-c47c-46e6-bbf7-02cd30ce0cd4" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_5511bf92-a2c1-4d24-abea-0aaa9677b33a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_7accfd99-2cc3-4ee7-afad-b6aee1f5cf53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_561b956c-c47c-46e6-bbf7-02cd30ce0cd4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_7accfd99-2cc3-4ee7-afad-b6aee1f5cf53" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount_1e977684-75e8-4c61-8b12-e550ddc72d8c" xlink:href="cah-20220331.xsd#cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_561b956c-c47c-46e6-bbf7-02cd30ce0cd4" xlink:to="loc_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount_1e977684-75e8-4c61-8b12-e550ddc72d8c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeInvestingActivities_4e0a823c-ffba-4f1e-b77e-4adfc1afbe20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromHedgeInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_561b956c-c47c-46e6-bbf7-02cd30ce0cd4" xlink:to="loc_us-gaap_ProceedsFromHedgeInvestingActivities_4e0a823c-ffba-4f1e-b77e-4adfc1afbe20" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_97c4dcd9-4453-46ff-81fc-3db739cbb703" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_561b956c-c47c-46e6-bbf7-02cd30ce0cd4" xlink:to="loc_us-gaap_DerivativeTable_97c4dcd9-4453-46ff-81fc-3db739cbb703" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a5f48065-556e-49f1-97d7-607e4d7f1bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_97c4dcd9-4453-46ff-81fc-3db739cbb703" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a5f48065-556e-49f1-97d7-607e4d7f1bdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a5f48065-556e-49f1-97d7-607e4d7f1bdb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a5f48065-556e-49f1-97d7-607e4d7f1bdb" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a5f48065-556e-49f1-97d7-607e4d7f1bdb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_83ff1db3-a7b9-447e-b40f-62ececd6b0b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a5f48065-556e-49f1-97d7-607e4d7f1bdb" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_83ff1db3-a7b9-447e-b40f-62ececd6b0b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_85a53948-755f-4979-93fa-c4ec2ac8d8ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_83ff1db3-a7b9-447e-b40f-62ececd6b0b8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_85a53948-755f-4979-93fa-c4ec2ac8d8ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cce14e93-2901-458c-8539-a9ac38d8ace3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_97c4dcd9-4453-46ff-81fc-3db739cbb703" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cce14e93-2901-458c-8539-a9ac38d8ace3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cce14e93-2901-458c-8539-a9ac38d8ace3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cce14e93-2901-458c-8539-a9ac38d8ace3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cce14e93-2901-458c-8539-a9ac38d8ace3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f050fb92-9b41-4b9a-99c5-368134568a18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cce14e93-2901-458c-8539-a9ac38d8ace3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f050fb92-9b41-4b9a-99c5-368134568a18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_aeb9e163-09c9-482f-bfc1-d8e8e4e25762" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f050fb92-9b41-4b9a-99c5-368134568a18" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_aeb9e163-09c9-482f-bfc1-d8e8e4e25762" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_dec68e4e-2fe3-432d-ad47-55fbb266dc71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_97c4dcd9-4453-46ff-81fc-3db739cbb703" xlink:to="loc_us-gaap_HedgingDesignationAxis_dec68e4e-2fe3-432d-ad47-55fbb266dc71" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_dec68e4e-2fe3-432d-ad47-55fbb266dc71_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_dec68e4e-2fe3-432d-ad47-55fbb266dc71" xlink:to="loc_us-gaap_HedgingDesignationDomain_dec68e4e-2fe3-432d-ad47-55fbb266dc71_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_890c5000-25ab-42df-8d1a-0b6548689d72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_dec68e4e-2fe3-432d-ad47-55fbb266dc71" xlink:to="loc_us-gaap_HedgingDesignationDomain_890c5000-25ab-42df-8d1a-0b6548689d72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_09333417-fe84-4b84-9f33-7cce3409c862" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_890c5000-25ab-42df-8d1a-0b6548689d72" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_09333417-fe84-4b84-9f33-7cce3409c862" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_0001e222-8605-4e3b-a719-52560274e1cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_890c5000-25ab-42df-8d1a-0b6548689d72" xlink:to="loc_us-gaap_NondesignatedMember_0001e222-8605-4e3b-a719-52560274e1cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_62eb23a1-acdf-46dd-aeaa-4f8dbcab23b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_97c4dcd9-4453-46ff-81fc-3db739cbb703" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_62eb23a1-acdf-46dd-aeaa-4f8dbcab23b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_62eb23a1-acdf-46dd-aeaa-4f8dbcab23b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_62eb23a1-acdf-46dd-aeaa-4f8dbcab23b4" xlink:to="loc_us-gaap_HedgingRelationshipDomain_62eb23a1-acdf-46dd-aeaa-4f8dbcab23b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_ea194233-39bf-4d78-be00-92f7d417b648" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_62eb23a1-acdf-46dd-aeaa-4f8dbcab23b4" xlink:to="loc_us-gaap_HedgingRelationshipDomain_ea194233-39bf-4d78-be00-92f7d417b648" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_bcc428f7-f125-4dbc-8fec-fbad1ad196b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_ea194233-39bf-4d78-be00-92f7d417b648" xlink:to="loc_us-gaap_FairValueHedgingMember_bcc428f7-f125-4dbc-8fec-fbad1ad196b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_90fe7ed7-d35d-4591-813b-f8a00522c2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_ea194233-39bf-4d78-be00-92f7d417b648" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_90fe7ed7-d35d-4591-813b-f8a00522c2e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_ead3eba8-a690-4c45-9c5b-5b5a57cb728a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_97c4dcd9-4453-46ff-81fc-3db739cbb703" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_ead3eba8-a690-4c45-9c5b-5b5a57cb728a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ead3eba8-a690-4c45-9c5b-5b5a57cb728a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ead3eba8-a690-4c45-9c5b-5b5a57cb728a" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ead3eba8-a690-4c45-9c5b-5b5a57cb728a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9940cb68-82e5-4528-9228-5d936b9b4130" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ead3eba8-a690-4c45-9c5b-5b5a57cb728a" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9940cb68-82e5-4528-9228-5d936b9b4130" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_a7195dce-c190-4de6-a30f-b527ac51527a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9940cb68-82e5-4528-9228-5d936b9b4130" xlink:to="loc_us-gaap_CashFlowHedgingMember_a7195dce-c190-4de6-a30f-b527ac51527a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_3890b0e1-f8de-4eee-bf1e-86b7d7f90406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9940cb68-82e5-4528-9228-5d936b9b4130" xlink:to="loc_us-gaap_InterestRateSwapMember_3890b0e1-f8de-4eee-bf1e-86b7d7f90406" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_f7e3a7a0-dd1f-4efd-81d8-1088a867b852" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9940cb68-82e5-4528-9228-5d936b9b4130" xlink:to="loc_us-gaap_ForeignExchangeContractMember_f7e3a7a0-dd1f-4efd-81d8-1088a867b852" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_a555e861-93b1-4083-ba3c-43014aa1ab4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9940cb68-82e5-4528-9228-5d936b9b4130" xlink:to="loc_us-gaap_CurrencySwapMember_a555e861-93b1-4083-ba3c-43014aa1ab4b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MaturityDateAxis_da9c2bcf-d03f-4947-a1bd-b0fc131ce176" xlink:href="cah-20220331.xsd#cah_MaturityDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_97c4dcd9-4453-46ff-81fc-3db739cbb703" xlink:to="loc_cah_MaturityDateAxis_da9c2bcf-d03f-4947-a1bd-b0fc131ce176" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MaturityDateDomain_da9c2bcf-d03f-4947-a1bd-b0fc131ce176_default" xlink:href="cah-20220331.xsd#cah_MaturityDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_MaturityDateAxis_da9c2bcf-d03f-4947-a1bd-b0fc131ce176" xlink:to="loc_cah_MaturityDateDomain_da9c2bcf-d03f-4947-a1bd-b0fc131ce176_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MaturityDateDomain_d891740a-152d-4fdb-a857-2727ec5dd22f" xlink:href="cah-20220331.xsd#cah_MaturityDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_MaturityDateAxis_da9c2bcf-d03f-4947-a1bd-b0fc131ce176" xlink:to="loc_cah_MaturityDateDomain_d891740a-152d-4fdb-a857-2727ec5dd22f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_September2025Member_5cf89fc5-f68a-43c9-9913-f8dc774e9481" xlink:href="cah-20220331.xsd#cah_September2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_MaturityDateDomain_d891740a-152d-4fdb-a857-2727ec5dd22f" xlink:to="loc_cah_September2025Member_5cf89fc5-f68a-43c9-9913-f8dc774e9481" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_June2027Member_266a0569-dfe1-4915-8a96-58b1db741d29" xlink:href="cah-20220331.xsd#cah_June2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_MaturityDateDomain_d891740a-152d-4fdb-a857-2727ec5dd22f" xlink:to="loc_cah_June2027Member_266a0569-dfe1-4915-8a96-58b1db741d29" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="extended" id="i4082c9a3a5404878990af4a06b5d8803_FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3180af18-514e-4652-90b2-93224b6115ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_ce3f15bc-7b3a-448b-8dbf-1292e0816116" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3180af18-514e-4652-90b2-93224b6115ae" xlink:to="loc_us-gaap_DebtInstrumentFairValue_ce3f15bc-7b3a-448b-8dbf-1292e0816116" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings_9369b24f-ecd7-41ee-a169-2462e9e28041" xlink:href="cah-20220331.xsd#cah_CarryingAmountofLongTermandotherShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3180af18-514e-4652-90b2-93224b6115ae" xlink:to="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings_9369b24f-ecd7-41ee-a169-2462e9e28041" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6420cd82-c732-48c9-a9f3-d171372c5a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3180af18-514e-4652-90b2-93224b6115ae" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6420cd82-c732-48c9-a9f3-d171372c5a9f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_43911dc0-ba38-4fa1-9973-3959994020fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6420cd82-c732-48c9-a9f3-d171372c5a9f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_43911dc0-ba38-4fa1-9973-3959994020fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_43911dc0-ba38-4fa1-9973-3959994020fe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_43911dc0-ba38-4fa1-9973-3959994020fe" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_43911dc0-ba38-4fa1-9973-3959994020fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9480e044-14f8-4cb7-ba6a-6b7655f251c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_43911dc0-ba38-4fa1-9973-3959994020fe" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9480e044-14f8-4cb7-ba6a-6b7655f251c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_abf87f38-8589-44a5-a0ec-7ae1416c227d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9480e044-14f8-4cb7-ba6a-6b7655f251c5" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_abf87f38-8589-44a5-a0ec-7ae1416c227d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#ShareholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="extended" id="i1d4b989fe2674991b8e1d873ada6fd2c_ShareholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_f32c4b5f-a1cd-4469-9ccd-4f0e1e68fd79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_af725f13-d3bb-490a-9e37-3a24794eb6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f32c4b5f-a1cd-4469-9ccd-4f0e1e68fd79" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_af725f13-d3bb-490a-9e37-3a24794eb6d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_27cea91d-16cf-43e3-9841-1966275ad152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f32c4b5f-a1cd-4469-9ccd-4f0e1e68fd79" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_27cea91d-16cf-43e3-9841-1966275ad152" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_544714b2-1a80-4554-bfb0-5b6cda8847ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f32c4b5f-a1cd-4469-9ccd-4f0e1e68fd79" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_544714b2-1a80-4554-bfb0-5b6cda8847ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_8827a2e6-2bed-49d3-9fb0-104e2f20129d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_f32c4b5f-a1cd-4469-9ccd-4f0e1e68fd79" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_8827a2e6-2bed-49d3-9fb0-104e2f20129d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_70f2e179-6f80-4150-9b88-f3d4ea7c2036" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8827a2e6-2bed-49d3-9fb0-104e2f20129d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_70f2e179-6f80-4150-9b88-f3d4ea7c2036" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_70f2e179-6f80-4150-9b88-f3d4ea7c2036_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_70f2e179-6f80-4150-9b88-f3d4ea7c2036" xlink:to="loc_us-gaap_EquityComponentDomain_70f2e179-6f80-4150-9b88-f3d4ea7c2036_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7173d174-fe97-4891-97dc-afdbdbe774d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_70f2e179-6f80-4150-9b88-f3d4ea7c2036" xlink:to="loc_us-gaap_EquityComponentDomain_7173d174-fe97-4891-97dc-afdbdbe774d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_31800238-a1f7-4f08-ad5c-c634a24d51e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7173d174-fe97-4891-97dc-afdbdbe774d9" xlink:to="loc_us-gaap_TreasuryStockMember_31800238-a1f7-4f08-ad5c-c634a24d51e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis_dcb99d25-2cf7-46c6-9005-e7959d6a2135" xlink:href="cah-20220331.xsd#cah_ShareRepurchaseProgramAggregatePurchasePriceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8827a2e6-2bed-49d3-9fb0-104e2f20129d" xlink:to="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis_dcb99d25-2cf7-46c6-9005-e7959d6a2135" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain_dcb99d25-2cf7-46c6-9005-e7959d6a2135_default" xlink:href="cah-20220331.xsd#cah_ShareRepurchaseProgramAggregatePurchasePriceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis_dcb99d25-2cf7-46c6-9005-e7959d6a2135" xlink:to="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain_dcb99d25-2cf7-46c6-9005-e7959d6a2135_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain_29f50603-ab11-48cc-9b3a-27162628c34b" xlink:href="cah-20220331.xsd#cah_ShareRepurchaseProgramAggregatePurchasePriceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis_dcb99d25-2cf7-46c6-9005-e7959d6a2135" xlink:to="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain_29f50603-ab11-48cc-9b3a-27162628c34b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A500MillionShareRepurchaseProgramMember_4aa041a2-8920-45a7-97ad-1d9706eff4bc" xlink:href="cah-20220331.xsd#cah_A500MillionShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain_29f50603-ab11-48cc-9b3a-27162628c34b" xlink:to="loc_cah_A500MillionShareRepurchaseProgramMember_4aa041a2-8920-45a7-97ad-1d9706eff4bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A300MillionShareRepurchaseProgramMember_e813c3ee-d451-4541-b12f-3aba17ed8b17" xlink:href="cah-20220331.xsd#cah_A300MillionShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain_29f50603-ab11-48cc-9b3a-27162628c34b" xlink:to="loc_cah_A300MillionShareRepurchaseProgramMember_e813c3ee-d451-4541-b12f-3aba17ed8b17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A200MillionShareRepurchaseProgramMember_df4cab39-8b9b-4ece-91f4-712b09631a67" xlink:href="cah-20220331.xsd#cah_A200MillionShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain_29f50603-ab11-48cc-9b3a-27162628c34b" xlink:to="loc_cah_A200MillionShareRepurchaseProgramMember_df4cab39-8b9b-4ece-91f4-712b09631a67" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_d48a2894-1063-40ef-934b-33a4370a2c02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8827a2e6-2bed-49d3-9fb0-104e2f20129d" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_d48a2894-1063-40ef-934b-33a4370a2c02" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d48a2894-1063-40ef-934b-33a4370a2c02_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d48a2894-1063-40ef-934b-33a4370a2c02" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d48a2894-1063-40ef-934b-33a4370a2c02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3d0f54a1-7aac-4d71-8df7-2fca10d0db5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d48a2894-1063-40ef-934b-33a4370a2c02" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3d0f54a1-7aac-4d71-8df7-2fca10d0db5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_7dc29d9a-2404-4ce9-b583-d64b71594e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3d0f54a1-7aac-4d71-8df7-2fca10d0db5f" xlink:to="loc_us-gaap_SubsequentEventMember_7dc29d9a-2404-4ce9-b583-d64b71594e7a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" id="i39d93d8932c24925904cf0426a6e7b89_ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_30069e80-64df-4148-8305-346a5be50616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_4aff9e90-0923-4307-b0c4-f6f8c32aeff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_30069e80-64df-4148-8305-346a5be50616" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_4aff9e90-0923-4307-b0c4-f6f8c32aeff7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f93271c7-c519-4673-bf34-179e3dc29a70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_4aff9e90-0923-4307-b0c4-f6f8c32aeff7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f93271c7-c519-4673-bf34-179e3dc29a70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_508baac2-7ef5-4109-9242-73703cf9a829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_4aff9e90-0923-4307-b0c4-f6f8c32aeff7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_508baac2-7ef5-4109-9242-73703cf9a829" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_9804bc84-3c64-4261-82a0-c41194e8f26a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_4aff9e90-0923-4307-b0c4-f6f8c32aeff7" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_9804bc84-3c64-4261-82a0-c41194e8f26a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0c187688-e59e-4bcc-86dc-112f859a4efa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_4aff9e90-0923-4307-b0c4-f6f8c32aeff7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0c187688-e59e-4bcc-86dc-112f859a4efa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_efd26d3e-4dbf-4fb2-b63d-f9bf91224c11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_b9790122-6db0-48cd-9e0f-4b69391aae02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_30069e80-64df-4148-8305-346a5be50616" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_b9790122-6db0-48cd-9e0f-4b69391aae02" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3746ea3b-677a-445d-a103-188400ab2c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_b9790122-6db0-48cd-9e0f-4b69391aae02" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3746ea3b-677a-445d-a103-188400ab2c6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3746ea3b-677a-445d-a103-188400ab2c6a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3746ea3b-677a-445d-a103-188400ab2c6a" xlink:to="loc_us-gaap_EquityComponentDomain_3746ea3b-677a-445d-a103-188400ab2c6a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_867a83ce-ee43-4222-b652-8d52c54d84ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3746ea3b-677a-445d-a103-188400ab2c6a" xlink:to="loc_us-gaap_EquityComponentDomain_867a83ce-ee43-4222-b652-8d52c54d84ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_84f38134-062d-4fe6-9494-126e6b934cba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_867a83ce-ee43-4222-b652-8d52c54d84ea" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_84f38134-062d-4fe6-9494-126e6b934cba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_f8539cb6-17d7-4afb-9486-1aac07aea030" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_867a83ce-ee43-4222-b652-8d52c54d84ea" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_f8539cb6-17d7-4afb-9486-1aac07aea030" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_7cbeb081-a451-4e8b-a780-62b130f1b7fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_867a83ce-ee43-4222-b652-8d52c54d84ea" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_7cbeb081-a451-4e8b-a780-62b130f1b7fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b737a379-d8e5-4698-bbdd-da9e7a855c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_867a83ce-ee43-4222-b652-8d52c54d84ea" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b737a379-d8e5-4698-bbdd-da9e7a855c3f" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#SegmentInformationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="extended" id="i859c7f3dcc21423eb22d75e361da612b_SegmentInformationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_6cb1abd9-be5c-4810-aee6-0d3329d87a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_3d85075b-b9e9-4b2b-8d0f-712879cd1645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6cb1abd9-be5c-4810-aee6-0d3329d87a4f" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_3d85075b-b9e9-4b2b-8d0f-712879cd1645" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_6780e4cb-50eb-4ea0-802e-053c029044b8" xlink:href="cah-20220331.xsd#cah_ProjectCostsOnInvestmentAndOtherSpending"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6cb1abd9-be5c-4810-aee6-0d3329d87a4f" xlink:to="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_6780e4cb-50eb-4ea0-802e-053c029044b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_447356c7-d2aa-4b62-a5a9-d6ae67f10183" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6cb1abd9-be5c-4810-aee6-0d3329d87a4f" xlink:to="loc_us-gaap_NumberOfReportableSegments_447356c7-d2aa-4b62-a5a9-d6ae67f10183" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_24d66495-b487-4c68-9476-42252c0e9396" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6cb1abd9-be5c-4810-aee6-0d3329d87a4f" xlink:to="loc_us-gaap_NumberOfOperatingSegments_24d66495-b487-4c68-9476-42252c0e9396" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_1b05d8b8-26dd-447e-8256-81169f9caa07" xlink:href="cah-20220331.xsd#cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6cb1abd9-be5c-4810-aee6-0d3329d87a4f" xlink:to="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_1b05d8b8-26dd-447e-8256-81169f9caa07" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_b2eaef7b-0f8f-49ac-ae58-e50be91ae567" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6cb1abd9-be5c-4810-aee6-0d3329d87a4f" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_b2eaef7b-0f8f-49ac-ae58-e50be91ae567" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_25ef9f96-bb16-49d6-b3c1-1d8ed3791cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6cb1abd9-be5c-4810-aee6-0d3329d87a4f" xlink:to="loc_us-gaap_LitigationSettlementExpense_25ef9f96-bb16-49d6-b3c1-1d8ed3791cb8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f8c2efc4-e532-4c3d-9e18-2522a37b2f87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6cb1abd9-be5c-4810-aee6-0d3329d87a4f" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f8c2efc4-e532-4c3d-9e18-2522a37b2f87" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_8ea6a49f-6041-4137-8213-948e11634577" xlink:href="cah-20220331.xsd#cah_OpioidLitigationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f8c2efc4-e532-4c3d-9e18-2522a37b2f87" xlink:to="loc_cah_OpioidLitigationAxis_8ea6a49f-6041-4137-8213-948e11634577" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_8ea6a49f-6041-4137-8213-948e11634577_default" xlink:href="cah-20220331.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_OpioidLitigationAxis_8ea6a49f-6041-4137-8213-948e11634577" xlink:to="loc_cah_OpioidLitigationDomain_8ea6a49f-6041-4137-8213-948e11634577_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_76f186aa-b90f-4893-b38e-76e05a70c589" xlink:href="cah-20220331.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_OpioidLitigationAxis_8ea6a49f-6041-4137-8213-948e11634577" xlink:to="loc_cah_OpioidLitigationDomain_76f186aa-b90f-4893-b38e-76e05a70c589" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_e7edb98b-faf3-4fc1-bbae-d2adb37325d0" xlink:href="cah-20220331.xsd#cah_TotalOpioidLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_OpioidLitigationDomain_76f186aa-b90f-4893-b38e-76e05a70c589" xlink:to="loc_cah_TotalOpioidLitigationMember_e7edb98b-faf3-4fc1-bbae-d2adb37325d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_f1aa0f0d-a7e1-487e-a7a7-0921ec40381f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f8c2efc4-e532-4c3d-9e18-2522a37b2f87" xlink:to="loc_srt_LitigationCaseAxis_f1aa0f0d-a7e1-487e-a7a7-0921ec40381f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_f1aa0f0d-a7e1-487e-a7a7-0921ec40381f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_f1aa0f0d-a7e1-487e-a7a7-0921ec40381f" xlink:to="loc_srt_LitigationCaseTypeDomain_f1aa0f0d-a7e1-487e-a7a7-0921ec40381f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_287bf6c6-4085-49d4-940e-e1e33cb49b3b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_f1aa0f0d-a7e1-487e-a7a7-0921ec40381f" xlink:to="loc_srt_LitigationCaseTypeDomain_287bf6c6-4085-49d4-940e-e1e33cb49b3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NewYorkOpioidStewardshipActMember_aa5b2153-26d5-4166-8882-86dec45c19ed" xlink:href="cah-20220331.xsd#cah_NewYorkOpioidStewardshipActMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_287bf6c6-4085-49d4-940e-e1e33cb49b3b" xlink:to="loc_cah_NewYorkOpioidStewardshipActMember_aa5b2153-26d5-4166-8882-86dec45c19ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_e63df0c7-8d2a-4f53-83ac-f53cb7dc8fe8" xlink:href="cah-20220331.xsd#cah_CordisDivestitureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f8c2efc4-e532-4c3d-9e18-2522a37b2f87" xlink:to="loc_cah_CordisDivestitureAxis_e63df0c7-8d2a-4f53-83ac-f53cb7dc8fe8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_e63df0c7-8d2a-4f53-83ac-f53cb7dc8fe8_default" xlink:href="cah-20220331.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_CordisDivestitureAxis_e63df0c7-8d2a-4f53-83ac-f53cb7dc8fe8" xlink:to="loc_cah_CordisDivestitureDomain_e63df0c7-8d2a-4f53-83ac-f53cb7dc8fe8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_34f7e371-c2f7-4e64-9632-a18756da3fb0" xlink:href="cah-20220331.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_CordisDivestitureAxis_e63df0c7-8d2a-4f53-83ac-f53cb7dc8fe8" xlink:to="loc_cah_CordisDivestitureDomain_34f7e371-c2f7-4e64-9632-a18756da3fb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_c4cb91a1-930f-4013-8257-1a78c954631c" xlink:href="cah-20220331.xsd#cah_CordisDivestitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_CordisDivestitureDomain_34f7e371-c2f7-4e64-9632-a18756da3fb0" xlink:to="loc_cah_CordisDivestitureMember_c4cb91a1-930f-4013-8257-1a78c954631c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_85496725-7cf3-4d81-ac81-62c6ba9559a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f8c2efc4-e532-4c3d-9e18-2522a37b2f87" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_85496725-7cf3-4d81-ac81-62c6ba9559a0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_85496725-7cf3-4d81-ac81-62c6ba9559a0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_85496725-7cf3-4d81-ac81-62c6ba9559a0" xlink:to="loc_us-gaap_SegmentDomain_85496725-7cf3-4d81-ac81-62c6ba9559a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_803e4b42-b951-44ed-a37e-a4cb9e9a659d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_85496725-7cf3-4d81-ac81-62c6ba9559a0" xlink:to="loc_us-gaap_SegmentDomain_803e4b42-b951-44ed-a37e-a4cb9e9a659d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_2dc58bef-1822-4d0d-84b4-c03f8e271349" xlink:href="cah-20220331.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_803e4b42-b951-44ed-a37e-a4cb9e9a659d" xlink:to="loc_cah_MedicalMember_2dc58bef-1822-4d0d-84b4-c03f8e271349" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_a765de79-f1bb-48e1-b9c6-e296524ffbce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f8c2efc4-e532-4c3d-9e18-2522a37b2f87" xlink:to="loc_us-gaap_ReportingUnitAxis_a765de79-f1bb-48e1-b9c6-e296524ffbce" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_a765de79-f1bb-48e1-b9c6-e296524ffbce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_a765de79-f1bb-48e1-b9c6-e296524ffbce" xlink:to="loc_us-gaap_ReportingUnitDomain_a765de79-f1bb-48e1-b9c6-e296524ffbce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_c7a5d129-1e1e-43f2-9d29-2eeda38f0a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_a765de79-f1bb-48e1-b9c6-e296524ffbce" xlink:to="loc_us-gaap_ReportingUnitDomain_c7a5d129-1e1e-43f2-9d29-2eeda38f0a6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_1578ed15-eeae-4085-9dee-4023f17c8856" xlink:href="cah-20220331.xsd#cah_MedicalUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_c7a5d129-1e1e-43f2-9d29-2eeda38f0a6a" xlink:to="loc_cah_MedicalUnitMember_1578ed15-eeae-4085-9dee-4023f17c8856" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#SegmentInformationRevenuebyReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="extended" id="i284ccf8e604240e1b758b7579612150f_SegmentInformationRevenuebyReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_8a585630-b759-4b15-a151-3fd8a1c31202" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_abd7d2b8-66cb-4832-934b-d5d07f085982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8a585630-b759-4b15-a151-3fd8a1c31202" xlink:to="loc_us-gaap_Revenues_abd7d2b8-66cb-4832-934b-d5d07f085982" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_191b761a-4314-4941-9d0a-bfa9fd07f498" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8a585630-b759-4b15-a151-3fd8a1c31202" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_191b761a-4314-4941-9d0a-bfa9fd07f498" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_d29524ff-dd9d-483f-883f-d4fb68d92385" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_191b761a-4314-4941-9d0a-bfa9fd07f498" xlink:to="loc_us-gaap_SubsegmentsAxis_d29524ff-dd9d-483f-883f-d4fb68d92385" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_d29524ff-dd9d-483f-883f-d4fb68d92385_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_d29524ff-dd9d-483f-883f-d4fb68d92385" xlink:to="loc_us-gaap_SubsegmentsDomain_d29524ff-dd9d-483f-883f-d4fb68d92385_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_3aabd574-6260-4b18-bdfc-a2cc921dcb00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_d29524ff-dd9d-483f-883f-d4fb68d92385" xlink:to="loc_us-gaap_SubsegmentsDomain_3aabd574-6260-4b18-bdfc-a2cc921dcb00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalDistributionandSpecialtyMember_1224fba2-3b58-4745-bdbc-9892b9494237" xlink:href="cah-20220331.xsd#cah_PharmaceuticalDistributionandSpecialtyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_3aabd574-6260-4b18-bdfc-a2cc921dcb00" xlink:to="loc_cah_PharmaceuticalDistributionandSpecialtyMember_1224fba2-3b58-4745-bdbc-9892b9494237" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NuclearPrecisionHealthSolutionsMember_12e7e6a5-ae67-4a38-95a6-9bc7925e41e9" xlink:href="cah-20220331.xsd#cah_NuclearPrecisionHealthSolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_3aabd574-6260-4b18-bdfc-a2cc921dcb00" xlink:to="loc_cah_NuclearPrecisionHealthSolutionsMember_12e7e6a5-ae67-4a38-95a6-9bc7925e41e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicaldistributionandproductsMember_3f286595-05f8-4ae5-92bf-c7092cb2182b" xlink:href="cah-20220331.xsd#cah_MedicaldistributionandproductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_3aabd574-6260-4b18-bdfc-a2cc921dcb00" xlink:to="loc_cah_MedicaldistributionandproductsMember_3f286595-05f8-4ae5-92bf-c7092cb2182b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CardinalHealthAtHomeMember_7ec3798f-3241-4ed4-a870-6984ad5950a8" xlink:href="cah-20220331.xsd#cah_CardinalHealthAtHomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_3aabd574-6260-4b18-bdfc-a2cc921dcb00" xlink:to="loc_cah_CardinalHealthAtHomeMember_7ec3798f-3241-4ed4-a870-6984ad5950a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_12d5560f-6132-4b28-a1ae-db0ba4d149ec" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_191b761a-4314-4941-9d0a-bfa9fd07f498" xlink:to="loc_srt_ConsolidationItemsAxis_12d5560f-6132-4b28-a1ae-db0ba4d149ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_12d5560f-6132-4b28-a1ae-db0ba4d149ec_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_12d5560f-6132-4b28-a1ae-db0ba4d149ec" xlink:to="loc_srt_ConsolidationItemsDomain_12d5560f-6132-4b28-a1ae-db0ba4d149ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_49777c3f-3563-4041-863b-bbedbb346c7e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_12d5560f-6132-4b28-a1ae-db0ba4d149ec" xlink:to="loc_srt_ConsolidationItemsDomain_49777c3f-3563-4041-863b-bbedbb346c7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_4d763bb7-763f-4b63-bbe8-82b4b7ddb1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_49777c3f-3563-4041-863b-bbedbb346c7e" xlink:to="loc_us-gaap_OperatingSegmentsMember_4d763bb7-763f-4b63-bbe8-82b4b7ddb1bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_6981c0e7-c9c2-4b63-a82c-ebeb43a8179b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_49777c3f-3563-4041-863b-bbedbb346c7e" xlink:to="loc_us-gaap_CorporateNonSegmentMember_6981c0e7-c9c2-4b63-a82c-ebeb43a8179b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7002c49a-ec5e-49fa-a52d-53c78ba53213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_191b761a-4314-4941-9d0a-bfa9fd07f498" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7002c49a-ec5e-49fa-a52d-53c78ba53213" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7002c49a-ec5e-49fa-a52d-53c78ba53213_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7002c49a-ec5e-49fa-a52d-53c78ba53213" xlink:to="loc_us-gaap_SegmentDomain_7002c49a-ec5e-49fa-a52d-53c78ba53213_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_25a9fecf-04e7-4540-a1f5-a5c104a1570a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7002c49a-ec5e-49fa-a52d-53c78ba53213" xlink:to="loc_us-gaap_SegmentDomain_25a9fecf-04e7-4540-a1f5-a5c104a1570a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_c90c3298-101a-40c6-8828-0e0ae0f13f3b" xlink:href="cah-20220331.xsd#cah_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_25a9fecf-04e7-4540-a1f5-a5c104a1570a" xlink:to="loc_cah_PharmaceuticalMember_c90c3298-101a-40c6-8828-0e0ae0f13f3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_048e3cb2-3b34-49c5-8391-c139d7c224e6" xlink:href="cah-20220331.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_25a9fecf-04e7-4540-a1f5-a5c104a1570a" xlink:to="loc_cah_MedicalMember_048e3cb2-3b34-49c5-8391-c139d7c224e6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#SegmentInformationSegmentProfitbyReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="extended" id="i4ffbd95db75e463fb4e72961a23e5b32_SegmentInformationSegmentProfitbyReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b6664ed3-d32a-49ef-ac36-f53cde210949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_306769ad-c3b1-4246-a1c1-24dbbdb456d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b6664ed3-d32a-49ef-ac36-f53cde210949" xlink:to="loc_us-gaap_OperatingIncomeLoss_306769ad-c3b1-4246-a1c1-24dbbdb456d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_JudgmentForLostProfits_9449e8aa-a2c6-4620-be8c-78e1df51c22e" xlink:href="cah-20220331.xsd#cah_JudgmentForLostProfits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b6664ed3-d32a-49ef-ac36-f53cde210949" xlink:to="loc_cah_JudgmentForLostProfits_9449e8aa-a2c6-4620-be8c-78e1df51c22e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ContingentAttorneyFee_0eae6662-d0df-4f06-88f5-52095b2d0a35" xlink:href="cah-20220331.xsd#cah_ContingentAttorneyFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b6664ed3-d32a-49ef-ac36-f53cde210949" xlink:to="loc_cah_ContingentAttorneyFee_0eae6662-d0df-4f06-88f5-52095b2d0a35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_7e8ff4a0-3ea8-466d-883a-6d6d161b2fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b6664ed3-d32a-49ef-ac36-f53cde210949" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_7e8ff4a0-3ea8-466d-883a-6d6d161b2fb2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_05201d45-5084-4162-b1d5-61a2d9eb517f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_7e8ff4a0-3ea8-466d-883a-6d6d161b2fb2" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_05201d45-5084-4162-b1d5-61a2d9eb517f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_05201d45-5084-4162-b1d5-61a2d9eb517f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_05201d45-5084-4162-b1d5-61a2d9eb517f" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_05201d45-5084-4162-b1d5-61a2d9eb517f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_02a5ce0f-f045-4f27-a45b-d6879d26ea37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_05201d45-5084-4162-b1d5-61a2d9eb517f" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_02a5ce0f-f045-4f27-a45b-d6879d26ea37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_a407902e-aabe-4552-b655-73e4aa023c2c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_7e8ff4a0-3ea8-466d-883a-6d6d161b2fb2" xlink:to="loc_srt_ConsolidationItemsAxis_a407902e-aabe-4552-b655-73e4aa023c2c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_a407902e-aabe-4552-b655-73e4aa023c2c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_a407902e-aabe-4552-b655-73e4aa023c2c" xlink:to="loc_srt_ConsolidationItemsDomain_a407902e-aabe-4552-b655-73e4aa023c2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_4cac9bdc-7777-4bbf-b0db-cdc173923152" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_a407902e-aabe-4552-b655-73e4aa023c2c" xlink:to="loc_srt_ConsolidationItemsDomain_4cac9bdc-7777-4bbf-b0db-cdc173923152" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_ae73d261-12d5-4c0d-83c9-d2b10e26b9ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_4cac9bdc-7777-4bbf-b0db-cdc173923152" xlink:to="loc_us-gaap_OperatingSegmentsMember_ae73d261-12d5-4c0d-83c9-d2b10e26b9ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_59c1e96e-cb63-4dfe-90eb-242731902ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_4cac9bdc-7777-4bbf-b0db-cdc173923152" xlink:to="loc_us-gaap_CorporateNonSegmentMember_59c1e96e-cb63-4dfe-90eb-242731902ccb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_c1c2048f-c7e6-4411-b82a-ab23bf381b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_7e8ff4a0-3ea8-466d-883a-6d6d161b2fb2" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_c1c2048f-c7e6-4411-b82a-ab23bf381b8d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c1c2048f-c7e6-4411-b82a-ab23bf381b8d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c1c2048f-c7e6-4411-b82a-ab23bf381b8d" xlink:to="loc_us-gaap_SegmentDomain_c1c2048f-c7e6-4411-b82a-ab23bf381b8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0f4e9bca-eddc-4638-8a0e-2e6926db867a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c1c2048f-c7e6-4411-b82a-ab23bf381b8d" xlink:to="loc_us-gaap_SegmentDomain_0f4e9bca-eddc-4638-8a0e-2e6926db867a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_8d3928ef-1206-4891-b812-ede50dc95a8d" xlink:href="cah-20220331.xsd#cah_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_0f4e9bca-eddc-4638-8a0e-2e6926db867a" xlink:to="loc_cah_PharmaceuticalMember_8d3928ef-1206-4891-b812-ede50dc95a8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_7aef55da-1322-4a1c-a587-4e1051d2de27" xlink:href="cah-20220331.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_0f4e9bca-eddc-4638-8a0e-2e6926db867a" xlink:to="loc_cah_MedicalMember_7aef55da-1322-4a1c-a587-4e1051d2de27" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" xlink:type="extended" id="i71995c3330a644abb868488adf8e7540_SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails">
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_40160d18-8ae5-4411-ab02-9a1e401dd5b9" xlink:href="cah-20220331.xsd#cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_4d1bf7b1-08d8-4b0f-8861-efba743b1491" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_40160d18-8ae5-4411-ab02-9a1e401dd5b9" xlink:to="loc_us-gaap_Revenues_4d1bf7b1-08d8-4b0f-8861-efba743b1491" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_69e591b2-ef36-4d43-8725-0f0b5a93bfa5" xlink:href="cah-20220331.xsd#cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_40160d18-8ae5-4411-ab02-9a1e401dd5b9" xlink:to="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_69e591b2-ef36-4d43-8725-0f0b5a93bfa5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_cf3c2524-566f-4e87-96b5-c7ee052f4dab" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_69e591b2-ef36-4d43-8725-0f0b5a93bfa5" xlink:to="loc_srt_ConsolidationItemsAxis_cf3c2524-566f-4e87-96b5-c7ee052f4dab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_cf3c2524-566f-4e87-96b5-c7ee052f4dab_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_cf3c2524-566f-4e87-96b5-c7ee052f4dab" xlink:to="loc_srt_ConsolidationItemsDomain_cf3c2524-566f-4e87-96b5-c7ee052f4dab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_278bc9fd-525a-4e74-9ff0-ca4d9b53089d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_cf3c2524-566f-4e87-96b5-c7ee052f4dab" xlink:to="loc_srt_ConsolidationItemsDomain_278bc9fd-525a-4e74-9ff0-ca4d9b53089d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_0e37becd-bd02-4ec7-b00d-2b02a28547f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_278bc9fd-525a-4e74-9ff0-ca4d9b53089d" xlink:to="loc_us-gaap_OperatingSegmentsMember_0e37becd-bd02-4ec7-b00d-2b02a28547f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_dfea25e5-495b-41e7-a88a-cfac34558250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_278bc9fd-525a-4e74-9ff0-ca4d9b53089d" xlink:to="loc_us-gaap_CorporateNonSegmentMember_dfea25e5-495b-41e7-a88a-cfac34558250" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_fd5a2702-a984-4149-81a4-7d8fb8a29879" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_69e591b2-ef36-4d43-8725-0f0b5a93bfa5" xlink:to="loc_srt_StatementGeographicalAxis_fd5a2702-a984-4149-81a4-7d8fb8a29879" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_fd5a2702-a984-4149-81a4-7d8fb8a29879_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_fd5a2702-a984-4149-81a4-7d8fb8a29879" xlink:to="loc_srt_SegmentGeographicalDomain_fd5a2702-a984-4149-81a4-7d8fb8a29879_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2331aa09-8c10-45fe-956f-dfcee56b46ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_fd5a2702-a984-4149-81a4-7d8fb8a29879" xlink:to="loc_srt_SegmentGeographicalDomain_2331aa09-8c10-45fe-956f-dfcee56b46ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_5a1ce02f-16fe-46bc-85e5-2647b398a0a2" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2331aa09-8c10-45fe-956f-dfcee56b46ad" xlink:to="loc_country_US_5a1ce02f-16fe-46bc-85e5-2647b398a0a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_b53305a7-a608-4ffd-b709-73cef24400fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2331aa09-8c10-45fe-956f-dfcee56b46ad" xlink:to="loc_us-gaap_NonUsMember_b53305a7-a608-4ffd-b709-73cef24400fc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#SegmentInformationAssetsbyReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="extended" id="i37ebf8f8efcd44fa92b1d78b9be228c9_SegmentInformationAssetsbyReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_cbe60118-8223-4d4c-9f55-2901147aa953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_67a81620-143b-4de1-8719-04c0b0a0988e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cbe60118-8223-4d4c-9f55-2901147aa953" xlink:to="loc_us-gaap_Assets_67a81620-143b-4de1-8719-04c0b0a0988e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_c65fb181-30a1-4bfb-bd2e-80a60d246d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cbe60118-8223-4d4c-9f55-2901147aa953" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_c65fb181-30a1-4bfb-bd2e-80a60d246d9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_2f80f137-fe8f-4b63-90da-9c70928a2fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cbe60118-8223-4d4c-9f55-2901147aa953" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_2f80f137-fe8f-4b63-90da-9c70928a2fd0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0de17507-2c94-4af7-a65a-08334eb5bab7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cbe60118-8223-4d4c-9f55-2901147aa953" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0de17507-2c94-4af7-a65a-08334eb5bab7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_df7cc149-c90c-4be7-8385-60be78789125" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0de17507-2c94-4af7-a65a-08334eb5bab7" xlink:to="loc_srt_ConsolidationItemsAxis_df7cc149-c90c-4be7-8385-60be78789125" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_df7cc149-c90c-4be7-8385-60be78789125_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_df7cc149-c90c-4be7-8385-60be78789125" xlink:to="loc_srt_ConsolidationItemsDomain_df7cc149-c90c-4be7-8385-60be78789125_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_243debfb-b2f2-486e-907a-278b06bbe619" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_df7cc149-c90c-4be7-8385-60be78789125" xlink:to="loc_srt_ConsolidationItemsDomain_243debfb-b2f2-486e-907a-278b06bbe619" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_7090de0f-3963-4464-8ac4-a29b4b298ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_243debfb-b2f2-486e-907a-278b06bbe619" xlink:to="loc_us-gaap_OperatingSegmentsMember_7090de0f-3963-4464-8ac4-a29b4b298ce2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_706a4fd9-b9d4-490c-b181-dfaabec72927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_243debfb-b2f2-486e-907a-278b06bbe619" xlink:to="loc_us-gaap_CorporateNonSegmentMember_706a4fd9-b9d4-490c-b181-dfaabec72927" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_b0ae1041-23df-4dfe-b248-53370f5d03e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0de17507-2c94-4af7-a65a-08334eb5bab7" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_b0ae1041-23df-4dfe-b248-53370f5d03e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b0ae1041-23df-4dfe-b248-53370f5d03e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b0ae1041-23df-4dfe-b248-53370f5d03e8" xlink:to="loc_us-gaap_SegmentDomain_b0ae1041-23df-4dfe-b248-53370f5d03e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8fd2999c-d2a8-48e1-a840-3e88a57146ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b0ae1041-23df-4dfe-b248-53370f5d03e8" xlink:to="loc_us-gaap_SegmentDomain_8fd2999c-d2a8-48e1-a840-3e88a57146ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_93d0afec-7caa-420c-827f-defdefa1774e" xlink:href="cah-20220331.xsd#cah_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8fd2999c-d2a8-48e1-a840-3e88a57146ae" xlink:to="loc_cah_PharmaceuticalMember_93d0afec-7caa-420c-827f-defdefa1774e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_a1016de9-915b-4e66-ba2b-22e1013586e1" xlink:href="cah-20220331.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8fd2999c-d2a8-48e1-a840-3e88a57146ae" xlink:to="loc_cah_MedicalMember_a1016de9-915b-4e66-ba2b-22e1013586e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_5e8e0dca-e635-4475-b785-8ffcf42d6332" xlink:href="cah-20220331.xsd#cah_CordisDivestitureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0de17507-2c94-4af7-a65a-08334eb5bab7" xlink:to="loc_cah_CordisDivestitureAxis_5e8e0dca-e635-4475-b785-8ffcf42d6332" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_5e8e0dca-e635-4475-b785-8ffcf42d6332_default" xlink:href="cah-20220331.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_CordisDivestitureAxis_5e8e0dca-e635-4475-b785-8ffcf42d6332" xlink:to="loc_cah_CordisDivestitureDomain_5e8e0dca-e635-4475-b785-8ffcf42d6332_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_a3e37009-76b8-462f-b7f2-348b4d8975e8" xlink:href="cah-20220331.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_CordisDivestitureAxis_5e8e0dca-e635-4475-b785-8ffcf42d6332" xlink:to="loc_cah_CordisDivestitureDomain_a3e37009-76b8-462f-b7f2-348b4d8975e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_f7586dc3-25ab-464f-bdbe-b5682231eaa8" xlink:href="cah-20220331.xsd#cah_CordisDivestitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_CordisDivestitureDomain_a3e37009-76b8-462f-b7f2-348b4d8975e8" xlink:to="loc_cah_CordisDivestitureMember_f7586dc3-25ab-464f-bdbe-b5682231eaa8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_ff01bac1-ae60-417b-9a2c-bbe1705e101e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0de17507-2c94-4af7-a65a-08334eb5bab7" xlink:to="loc_us-gaap_ReportingUnitAxis_ff01bac1-ae60-417b-9a2c-bbe1705e101e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_ff01bac1-ae60-417b-9a2c-bbe1705e101e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_ff01bac1-ae60-417b-9a2c-bbe1705e101e" xlink:to="loc_us-gaap_ReportingUnitDomain_ff01bac1-ae60-417b-9a2c-bbe1705e101e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_a7ec8adf-ec19-4ce9-bf13-515edd377439" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_ff01bac1-ae60-417b-9a2c-bbe1705e101e" xlink:to="loc_us-gaap_ReportingUnitDomain_a7ec8adf-ec19-4ce9-bf13-515edd377439" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_3dd20027-f9dd-411c-acb3-9b8b178b69d6" xlink:href="cah-20220331.xsd#cah_MedicalUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_a7ec8adf-ec19-4ce9-bf13-515edd377439" xlink:to="loc_cah_MedicalUnitMember_3dd20027-f9dd-411c-acb3-9b8b178b69d6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#ShareBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended" id="i32440019f40e4b1a8aa52043b0eb1548_ShareBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b00ef9b-586e-4ce6-a96f-aa3ab6e4ecfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_VestingPeriodinyearsforShares_1e95f302-1fc9-4bc0-89c5-404a7812a205" xlink:href="cah-20220331.xsd#cah_VestingPeriodinyearsforShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b00ef9b-586e-4ce6-a96f-aa3ab6e4ecfc" xlink:to="loc_cah_VestingPeriodinyearsforShares_1e95f302-1fc9-4bc0-89c5-404a7812a205" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_48ea71c5-a07f-46f0-9426-cf7721c3dc93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b00ef9b-586e-4ce6-a96f-aa3ab6e4ecfc" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_48ea71c5-a07f-46f0-9426-cf7721c3dc93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_73d4a297-e623-4013-be72-60317de0f4c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b00ef9b-586e-4ce6-a96f-aa3ab6e4ecfc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_73d4a297-e623-4013-be72-60317de0f4c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_60218e30-79cc-4136-9bb6-ef1469bb0af9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b00ef9b-586e-4ce6-a96f-aa3ab6e4ecfc" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_60218e30-79cc-4136-9bb6-ef1469bb0af9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7235367e-ed48-42b1-a6a6-ccdc1b64c5b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b00ef9b-586e-4ce6-a96f-aa3ab6e4ecfc" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7235367e-ed48-42b1-a6a6-ccdc1b64c5b5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ExercisablePeriodOfPlansInYears_839b26c4-6b04-4e8c-84ed-331009981c41" xlink:href="cah-20220331.xsd#cah_ExercisablePeriodOfPlansInYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b00ef9b-586e-4ce6-a96f-aa3ab6e4ecfc" xlink:to="loc_cah_ExercisablePeriodOfPlansInYears_839b26c4-6b04-4e8c-84ed-331009981c41" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_9bf3abd9-4815-42ca-af0c-149872c52114" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b00ef9b-586e-4ce6-a96f-aa3ab6e4ecfc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_9bf3abd9-4815-42ca-af0c-149872c52114" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_08196976-4c0e-402e-9df3-1e78294461dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b00ef9b-586e-4ce6-a96f-aa3ab6e4ecfc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_08196976-4c0e-402e-9df3-1e78294461dd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1a7980c7-c3e4-46c2-8c44-f27559a415df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_08196976-4c0e-402e-9df3-1e78294461dd" xlink:to="loc_us-gaap_AwardTypeAxis_1a7980c7-c3e4-46c2-8c44-f27559a415df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1a7980c7-c3e4-46c2-8c44-f27559a415df_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1a7980c7-c3e4-46c2-8c44-f27559a415df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1a7980c7-c3e4-46c2-8c44-f27559a415df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e952c874-e83e-4c26-8473-1ba4207ae701" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1a7980c7-c3e4-46c2-8c44-f27559a415df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e952c874-e83e-4c26-8473-1ba4207ae701" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_412b3363-8867-41ac-92d9-2f1aed723820" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e952c874-e83e-4c26-8473-1ba4207ae701" xlink:to="loc_us-gaap_EmployeeStockOptionMember_412b3363-8867-41ac-92d9-2f1aed723820" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6be94425-d973-4990-b733-b9b2b6073bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e952c874-e83e-4c26-8473-1ba4207ae701" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6be94425-d973-4990-b733-b9b2b6073bb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_e2c88527-bde0-442d-8f66-7fe3f944fd3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e952c874-e83e-4c26-8473-1ba4207ae701" xlink:to="loc_us-gaap_PerformanceSharesMember_e2c88527-bde0-442d-8f66-7fe3f944fd3f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c0b4c040-cda9-40f4-8d11-91ae97907726" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_08196976-4c0e-402e-9df3-1e78294461dd" xlink:to="loc_srt_RangeAxis_c0b4c040-cda9-40f4-8d11-91ae97907726" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c0b4c040-cda9-40f4-8d11-91ae97907726_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c0b4c040-cda9-40f4-8d11-91ae97907726" xlink:to="loc_srt_RangeMember_c0b4c040-cda9-40f4-8d11-91ae97907726_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bd63e62d-d1d6-4fbf-8173-e23c4f4313dd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c0b4c040-cda9-40f4-8d11-91ae97907726" xlink:to="loc_srt_RangeMember_bd63e62d-d1d6-4fbf-8173-e23c4f4313dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cebfa431-16b3-4990-bc36-2231d3b5ddb9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bd63e62d-d1d6-4fbf-8173-e23c4f4313dd" xlink:to="loc_srt_MinimumMember_cebfa431-16b3-4990-bc36-2231d3b5ddb9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_51db0901-0423-4c18-b727-2a5d07730012" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bd63e62d-d1d6-4fbf-8173-e23c4f4313dd" xlink:to="loc_srt_MaximumMember_51db0901-0423-4c18-b727-2a5d07730012" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="extended" id="i8c92a643e6de41748d4f534604f0f6c4_ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_822d68ce-2572-4449-97fb-dd72fd0da8c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_eaaebb88-16fc-4567-9d91-40fde2bd1fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_822d68ce-2572-4449-97fb-dd72fd0da8c9" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_eaaebb88-16fc-4567-9d91-40fde2bd1fc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_429a7b9e-da1f-4cd4-a4d6-ac9a6c5de4cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_822d68ce-2572-4449-97fb-dd72fd0da8c9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_429a7b9e-da1f-4cd4-a4d6-ac9a6c5de4cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6e7efaed-8576-4dbe-8cd4-d50cccd03653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_429a7b9e-da1f-4cd4-a4d6-ac9a6c5de4cc" xlink:to="loc_us-gaap_AwardTypeAxis_6e7efaed-8576-4dbe-8cd4-d50cccd03653" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e7efaed-8576-4dbe-8cd4-d50cccd03653_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6e7efaed-8576-4dbe-8cd4-d50cccd03653" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e7efaed-8576-4dbe-8cd4-d50cccd03653_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abd8e6e0-31e7-441f-83c5-6b95f4f7c099" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6e7efaed-8576-4dbe-8cd4-d50cccd03653" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abd8e6e0-31e7-441f-83c5-6b95f4f7c099" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_03c1069e-b297-43e7-947b-adae6d34054e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abd8e6e0-31e7-441f-83c5-6b95f4f7c099" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_03c1069e-b297-43e7-947b-adae6d34054e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1a75cad2-c709-411a-a321-34222e0cb328" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abd8e6e0-31e7-441f-83c5-6b95f4f7c099" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1a75cad2-c709-411a-a321-34222e0cb328" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_55cc78a3-c8e2-4043-ae19-81c4665a7532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abd8e6e0-31e7-441f-83c5-6b95f4f7c099" xlink:to="loc_us-gaap_PerformanceSharesMember_55cc78a3-c8e2-4043-ae19-81c4665a7532" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" xlink:type="extended" id="icdeffafbc2034519902218828e085095_ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_43dc0f44-9b54-4380-b36c-54e8b4f9c0be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_9f8cd815-fc14-4ea2-8b84-03b4e5de2487" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_43dc0f44-9b54-4380-b36c-54e8b4f9c0be" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_9f8cd815-fc14-4ea2-8b84-03b4e5de2487" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_76d8f731-3143-4420-ab31-86c957402a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_43dc0f44-9b54-4380-b36c-54e8b4f9c0be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_76d8f731-3143-4420-ab31-86c957402a6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_e96edc64-0e1d-4441-98db-cd670c2781f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_43dc0f44-9b54-4380-b36c-54e8b4f9c0be" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_e96edc64-0e1d-4441-98db-cd670c2781f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_00a7c2d5-a824-4e73-b9b5-acc1551c700c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_43dc0f44-9b54-4380-b36c-54e8b4f9c0be" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_00a7c2d5-a824-4e73-b9b5-acc1551c700c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_c19619f3-a29e-4e15-a550-a1e447b4deec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_43dc0f44-9b54-4380-b36c-54e8b4f9c0be" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_c19619f3-a29e-4e15-a550-a1e447b4deec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bab5de0a-2b3f-40dc-8852-087fc78954f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_43dc0f44-9b54-4380-b36c-54e8b4f9c0be" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bab5de0a-2b3f-40dc-8852-087fc78954f6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_41e23038-1149-4486-ba8d-ebb78077ad6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bab5de0a-2b3f-40dc-8852-087fc78954f6" xlink:to="loc_us-gaap_AwardTypeAxis_41e23038-1149-4486-ba8d-ebb78077ad6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41e23038-1149-4486-ba8d-ebb78077ad6d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_41e23038-1149-4486-ba8d-ebb78077ad6d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41e23038-1149-4486-ba8d-ebb78077ad6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_174fbb27-f3e7-4926-80e9-f0005cd37fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_41e23038-1149-4486-ba8d-ebb78077ad6d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_174fbb27-f3e7-4926-80e9-f0005cd37fdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f72f4f6d-d55b-4949-a86e-6ee31d78b8e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_174fbb27-f3e7-4926-80e9-f0005cd37fdf" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f72f4f6d-d55b-4949-a86e-6ee31d78b8e1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="extended" id="i392c229b662b4b6686bf9cde9c0af4eb_ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e2d4ca2b-d88d-4807-be6b-0f3c6cb14d74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_fa684d46-019b-439b-a0d6-cd0ec233bb88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e2d4ca2b-d88d-4807-be6b-0f3c6cb14d74" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_fa684d46-019b-439b-a0d6-cd0ec233bb88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_bd962c13-dc6c-4a46-992e-8526c9cb8482" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e2d4ca2b-d88d-4807-be6b-0f3c6cb14d74" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_bd962c13-dc6c-4a46-992e-8526c9cb8482" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_65a5360d-c8fd-4c5e-aec1-5aff105aedce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e2d4ca2b-d88d-4807-be6b-0f3c6cb14d74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_65a5360d-c8fd-4c5e-aec1-5aff105aedce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_805d3cb0-7ade-46d6-bcdf-cc24cfef672c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_65a5360d-c8fd-4c5e-aec1-5aff105aedce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_805d3cb0-7ade-46d6-bcdf-cc24cfef672c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7d260a0c-d73a-49ee-b78f-12b2f1445c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_65a5360d-c8fd-4c5e-aec1-5aff105aedce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7d260a0c-d73a-49ee-b78f-12b2f1445c9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_22549a0b-5a89-4d34-942b-cefaed0792ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_65a5360d-c8fd-4c5e-aec1-5aff105aedce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_22549a0b-5a89-4d34-942b-cefaed0792ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1c3bd42b-36fd-4632-bf11-90bdafe85634" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_65a5360d-c8fd-4c5e-aec1-5aff105aedce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1c3bd42b-36fd-4632-bf11-90bdafe85634" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a408129c-29df-489e-8ebe-59aed807e467" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_498e2703-9536-48e0-9a6f-919b71c5ce62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e2d4ca2b-d88d-4807-be6b-0f3c6cb14d74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_498e2703-9536-48e0-9a6f-919b71c5ce62" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ad0b6e12-fe82-4638-8754-71f2939b5e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_498e2703-9536-48e0-9a6f-919b71c5ce62" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ad0b6e12-fe82-4638-8754-71f2939b5e3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_61f3f5d7-1f77-4e28-afa2-dfd0a16de11a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_498e2703-9536-48e0-9a6f-919b71c5ce62" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_61f3f5d7-1f77-4e28-afa2-dfd0a16de11a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_bb7fcee1-1921-447a-8304-6e436923e944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_498e2703-9536-48e0-9a6f-919b71c5ce62" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_bb7fcee1-1921-447a-8304-6e436923e944" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ba84b913-3d23-4941-8570-b61fa975a569" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_498e2703-9536-48e0-9a6f-919b71c5ce62" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ba84b913-3d23-4941-8570-b61fa975a569" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5bfa56da-f0a2-4425-8cca-d8cfed21779c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_792ae3b6-0e3e-4c71-9682-dbf9b98a5595" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e2d4ca2b-d88d-4807-be6b-0f3c6cb14d74" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_792ae3b6-0e3e-4c71-9682-dbf9b98a5595" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ddbdffc9-9b68-47fb-9ad9-8400aa12416f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_792ae3b6-0e3e-4c71-9682-dbf9b98a5595" xlink:to="loc_us-gaap_AwardTypeAxis_ddbdffc9-9b68-47fb-9ad9-8400aa12416f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ddbdffc9-9b68-47fb-9ad9-8400aa12416f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ddbdffc9-9b68-47fb-9ad9-8400aa12416f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ddbdffc9-9b68-47fb-9ad9-8400aa12416f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3ee1223d-2252-4a3d-b5ed-6946a8451c52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ddbdffc9-9b68-47fb-9ad9-8400aa12416f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3ee1223d-2252-4a3d-b5ed-6946a8451c52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1e748fac-c035-4deb-879a-1490131cf278" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3ee1223d-2252-4a3d-b5ed-6946a8451c52" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1e748fac-c035-4deb-879a-1490131cf278" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2bcfd2eb-6103-4e94-a160-1402bd569659" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3ee1223d-2252-4a3d-b5ed-6946a8451c52" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2bcfd2eb-6103-4e94-a160-1402bd569659" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="extended" id="iec389159c65542fa8bf77b4637ccfee9_ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f5cb980a-682d-4191-ae8d-6456a6bd7a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2cb76339-ef4c-4dd5-99ef-caec6cc535f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f5cb980a-682d-4191-ae8d-6456a6bd7a4e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2cb76339-ef4c-4dd5-99ef-caec6cc535f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_dba04b4d-b27f-47b8-8b35-732f0f2814b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f5cb980a-682d-4191-ae8d-6456a6bd7a4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_dba04b4d-b27f-47b8-8b35-732f0f2814b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_76012fe7-4757-4eda-bf19-505a6b9dd954" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_dba04b4d-b27f-47b8-8b35-732f0f2814b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_76012fe7-4757-4eda-bf19-505a6b9dd954" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2e1ac68f-5bf9-4d42-a7f8-6ceb8c9cc1c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_dba04b4d-b27f-47b8-8b35-732f0f2814b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2e1ac68f-5bf9-4d42-a7f8-6ceb8c9cc1c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_48b3b26c-b88d-4d1e-82f2-f58c1f25b5bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_dba04b4d-b27f-47b8-8b35-732f0f2814b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_48b3b26c-b88d-4d1e-82f2-f58c1f25b5bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_737645d9-9fba-4c72-b86f-d8949395095b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_dba04b4d-b27f-47b8-8b35-732f0f2814b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_737645d9-9fba-4c72-b86f-d8949395095b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_33b4d35c-d979-414e-894e-d7095dcaac87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c9251145-970a-4b67-8730-6ba52fda3775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f5cb980a-682d-4191-ae8d-6456a6bd7a4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c9251145-970a-4b67-8730-6ba52fda3775" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_df4be35c-6cae-4399-b48e-b48d30a361b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c9251145-970a-4b67-8730-6ba52fda3775" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_df4be35c-6cae-4399-b48e-b48d30a361b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_316a67d5-d901-4f82-95d3-a839cb3b9b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c9251145-970a-4b67-8730-6ba52fda3775" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_316a67d5-d901-4f82-95d3-a839cb3b9b4f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3fad475c-43a1-451c-b5cc-74c91edb60af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c9251145-970a-4b67-8730-6ba52fda3775" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3fad475c-43a1-451c-b5cc-74c91edb60af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ab1fd0d4-c811-45fa-b4d0-25f8ef268852" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c9251145-970a-4b67-8730-6ba52fda3775" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ab1fd0d4-c811-45fa-b4d0-25f8ef268852" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_812c982e-72ad-4b40-9c46-f0ccab1e9484" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5a7d34d5-4a7f-41ca-be71-76159fb5a1e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f5cb980a-682d-4191-ae8d-6456a6bd7a4e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5a7d34d5-4a7f-41ca-be71-76159fb5a1e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f184cc0d-68fc-4073-b76f-ae926e616eda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f5cb980a-682d-4191-ae8d-6456a6bd7a4e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f184cc0d-68fc-4073-b76f-ae926e616eda" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7e1fbae3-3602-4417-bda2-11dd740391e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f5cb980a-682d-4191-ae8d-6456a6bd7a4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7e1fbae3-3602-4417-bda2-11dd740391e7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98ac066f-2103-41c0-89b7-0bcc6f6e4500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f5cb980a-682d-4191-ae8d-6456a6bd7a4e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98ac066f-2103-41c0-89b7-0bcc6f6e4500" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cc9d86c9-1e64-49fa-905c-467131ef697f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98ac066f-2103-41c0-89b7-0bcc6f6e4500" xlink:to="loc_us-gaap_AwardTypeAxis_cc9d86c9-1e64-49fa-905c-467131ef697f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc9d86c9-1e64-49fa-905c-467131ef697f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_cc9d86c9-1e64-49fa-905c-467131ef697f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc9d86c9-1e64-49fa-905c-467131ef697f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_05bf7c84-a4f8-42fd-a955-4359da95fa1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_cc9d86c9-1e64-49fa-905c-467131ef697f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_05bf7c84-a4f8-42fd-a955-4359da95fa1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_bb9e03e5-1ee9-4052-80ef-218f17160abc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_05bf7c84-a4f8-42fd-a955-4359da95fa1c" xlink:to="loc_us-gaap_PerformanceSharesMember_bb9e03e5-1ee9-4052-80ef-218f17160abc" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>cah-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:5843d3e5-829e-408b-801e-c8a62435530f,g:2e89d43f-ed1a-46fa-9c57-992bbbf67b50-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_4854ed59-6722-48cb-b5cc-28bf0cd5d935_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_93bb3415-4274-4e96-b2fc-b90907e3ab09_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherShortTermBorrowings_d3eceb7a-c96f-48a0-b81a-1a81e97a081f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Short-term Borrowings</link:label>
    <link:label id="lab_us-gaap_OtherShortTermBorrowings_label_en-US" xlink:label="lab_us-gaap_OtherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Short-Term Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherShortTermBorrowings" xlink:to="lab_us-gaap_OtherShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_b66dcacb-2db6-4d5c-8327-822946c3c5b3_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings/(loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_5b420994-9a55-4f4a-b20f-7fe04fe96c84_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings/(loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_c9cb63e5-022c-4886-b64f-0f9f5a37382a_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_7881ffac-6cfe-4f1e-a4f4-27e6a842f606_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_43532f03-6055-4199-8ac1-c48b1c2b8e13_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for bad debts</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_a47169c4-42a4-4331-b258-bb2ba1861740_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PharmaceuticalMember_2947464d-bc54-4844-9bc9-ad7a1081eaea_terseLabel_en-US" xlink:label="lab_cah_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical</link:label>
    <link:label id="lab_cah_PharmaceuticalMember_label_en-US" xlink:label="lab_cah_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Member</link:label>
    <link:label id="lab_cah_PharmaceuticalMember_documentation_en-US" xlink:label="lab_cah_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember" xlink:href="cah-20220331.xsd#cah_PharmaceuticalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PharmaceuticalMember" xlink:to="lab_cah_PharmaceuticalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_c927ccfe-0d20-4798-be94-ea54bc627fd3_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_b374383f-24e0-46e2-803c-0433b8f939d6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_e7619ff8-f04b-416c-8b76-d8a85a11f4a3_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_d3f4c100-b948-4dbf-bdb7-bd680a352225_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends on common shares</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:to="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_1f8e7c6b-11bf-477c-852b-eae3e19320d5_terseLabel_en-US" xlink:label="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue from External Customers by Geographic Area [Table]</link:label>
    <link:label id="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_label_en-US" xlink:label="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue from External Customers by Geographic Area [Table]</link:label>
    <link:label id="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_documentation_en-US" xlink:label="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue from External Customers by Geographic Area [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable" xlink:href="cah-20220331.xsd#cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable" xlink:to="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_15db66c9-4d01-40a9-afa1-0bad409bc5d5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_cc1e252c-6895-45ca-8d75-166fe1f8e678_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_a4cf86f5-bc6a-4286-a736-f05bd0d6181e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term obligations and other short-term borrowings</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_9422fcd8-64e0-49c6-bd88-1e1feffdd113_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation, Current</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt and Lease Obligation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_6623da5e-82fd-419e-9a5f-bcae34fe2bed_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_330c6d45-7893-4fef-97f6-6fc76d313840_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_ffd5763d-3c4f-4b04-bb9e-8d2fea78f3b8_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_119b46e0-429e-43dc-956e-f1dddb4284dd_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_LossContingencyClaimsSettledPercent_1b36ccaf-7bf5-4823-8dd0-e536ff6860ab_terseLabel_en-US" xlink:label="lab_cah_LossContingencyClaimsSettledPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Claims Settled Percent</link:label>
    <link:label id="lab_cah_LossContingencyClaimsSettledPercent_label_en-US" xlink:label="lab_cah_LossContingencyClaimsSettledPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Claims Settled Percent</link:label>
    <link:label id="lab_cah_LossContingencyClaimsSettledPercent_documentation_en-US" xlink:label="lab_cah_LossContingencyClaimsSettledPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Claims Settled Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LossContingencyClaimsSettledPercent" xlink:href="cah-20220331.xsd#cah_LossContingencyClaimsSettledPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_LossContingencyClaimsSettledPercent" xlink:to="lab_cah_LossContingencyClaimsSettledPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_VestingPeriodinyearsforShares_169d1e31-b66d-45ec-adf6-de943bceff54_terseLabel_en-US" xlink:label="lab_cah_VestingPeriodinyearsforShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period in years for Shares</link:label>
    <link:label id="lab_cah_VestingPeriodinyearsforShares_label_en-US" xlink:label="lab_cah_VestingPeriodinyearsforShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period in years for Shares</link:label>
    <link:label id="lab_cah_VestingPeriodinyearsforShares_documentation_en-US" xlink:label="lab_cah_VestingPeriodinyearsforShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period in years for Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_VestingPeriodinyearsforShares" xlink:href="cah-20220331.xsd#cah_VestingPeriodinyearsforShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_VestingPeriodinyearsforShares" xlink:to="lab_cah_VestingPeriodinyearsforShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_0525bb05-0b4c-4fc3-832f-09d4c3904b07_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:to="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ProductLiabilityLawsuitsMember_ddaea8ae-8800-46a7-9299-2ce66cfeda62_terseLabel_en-US" xlink:label="lab_cah_ProductLiabilityLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Lawsuits</link:label>
    <link:label id="lab_cah_ProductLiabilityLawsuitsMember_label_en-US" xlink:label="lab_cah_ProductLiabilityLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Lawsuits [Member]</link:label>
    <link:label id="lab_cah_ProductLiabilityLawsuitsMember_documentation_en-US" xlink:label="lab_cah_ProductLiabilityLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Lawsuits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember" xlink:href="cah-20220331.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ProductLiabilityLawsuitsMember" xlink:to="lab_cah_ProductLiabilityLawsuitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_99dac5b0-dc59-4d0e-8752-2e821f37aa30_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5c503d3c-c7b4-4fea-8b60-2940f58bf2cd_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_763f945c-78b4-4355-b029-ba7efa656379_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ClassActionLawsuitsMember_6ad682bf-4880-4a84-8dd1-4c2a95ede57d_terseLabel_en-US" xlink:label="lab_cah_ClassActionLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Action Lawsuits [Member]</link:label>
    <link:label id="lab_cah_ClassActionLawsuitsMember_label_en-US" xlink:label="lab_cah_ClassActionLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Action Lawsuits [Member]</link:label>
    <link:label id="lab_cah_ClassActionLawsuitsMember_documentation_en-US" xlink:label="lab_cah_ClassActionLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Action Lawsuits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ClassActionLawsuitsMember" xlink:href="cah-20220331.xsd#cah_ClassActionLawsuitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ClassActionLawsuitsMember" xlink:to="lab_cah_ClassActionLawsuitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_38456829-2670-42c6-adf2-bed94acdff29_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bf168dde-433b-435b-ba10-0d8775bbd55a_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NumberofStateAttorneysGeneralfilinglawsuits_10da879b-19ad-4feb-85a3-58255f333424_terseLabel_en-US" xlink:label="lab_cah_NumberofStateAttorneysGeneralfilinglawsuits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of State Attorneys General filing lawsuits</link:label>
    <link:label id="lab_cah_NumberofStateAttorneysGeneralfilinglawsuits_label_en-US" xlink:label="lab_cah_NumberofStateAttorneysGeneralfilinglawsuits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of State Attorneys General filing lawsuits</link:label>
    <link:label id="lab_cah_NumberofStateAttorneysGeneralfilinglawsuits_documentation_en-US" xlink:label="lab_cah_NumberofStateAttorneysGeneralfilinglawsuits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of State Attorneys General filing lawsuits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NumberofStateAttorneysGeneralfilinglawsuits" xlink:href="cah-20220331.xsd#cah_NumberofStateAttorneysGeneralfilinglawsuits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NumberofStateAttorneysGeneralfilinglawsuits" xlink:to="lab_cah_NumberofStateAttorneysGeneralfilinglawsuits" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CordisDivestitureDomain_4c180ce1-f413-4d62-b90e-fa934b93cb41_terseLabel_en-US" xlink:label="lab_cah_CordisDivestitureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture [Domain]</link:label>
    <link:label id="lab_cah_CordisDivestitureDomain_label_en-US" xlink:label="lab_cah_CordisDivestitureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture [Domain]</link:label>
    <link:label id="lab_cah_CordisDivestitureDomain_documentation_en-US" xlink:label="lab_cah_CordisDivestitureDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain" xlink:href="cah-20220331.xsd#cah_CordisDivestitureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CordisDivestitureDomain" xlink:to="lab_cah_CordisDivestitureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_bcb8538d-fc6e-4ab2-be88-dd6c025b8325_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_125c548e-45c2-46ee-8fd4-756fd994d191_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings/(loss) attributable to Cardinal Health, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_a6e69926-d6d0-4e45-b5bd-c3d9fe896b07_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_MaturityDateAxis_bd17620b-c31b-430a-86ac-6209f3273ef0_terseLabel_en-US" xlink:label="lab_cah_MaturityDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Date</link:label>
    <link:label id="lab_cah_MaturityDateAxis_label_en-US" xlink:label="lab_cah_MaturityDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Date [Axis]</link:label>
    <link:label id="lab_cah_MaturityDateAxis_documentation_en-US" xlink:label="lab_cah_MaturityDateAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MaturityDateAxis" xlink:href="cah-20220331.xsd#cah_MaturityDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_MaturityDateAxis" xlink:to="lab_cah_MaturityDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_671a014d-64b9-4f3c-85c0-f13bcb9dc5e7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_324cad67-3594-4735-810e-41b96cf3cca7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_6006f91c-2aca-4ca2-a76d-e670ec4b710a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_f3bb82ab-ff5f-4ba8-9226-c52a937d8fb3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_6575316e-5075-4722-8d97-fb8faf8d92ca_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_7e39d3b2-1585-423b-85c5-bd2aadafe297_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:to="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_WV_b9a98cc2-b90d-47a5-8f2f-ee81c8168f58_terseLabel_en-US" xlink:label="lab_stpr_WV" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WEST VIRGINIA</link:label>
    <link:label id="lab_stpr_WV_label_en-US" xlink:label="lab_stpr_WV" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WEST VIRGINIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WV" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WV"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_WV" xlink:to="lab_stpr_WV" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_e603e018-e9b8-492f-9b67-f830f0cfed7e_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_June2027Member_0c79d412-1626-499f-a268-25654533a962_terseLabel_en-US" xlink:label="lab_cah_June2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2027</link:label>
    <link:label id="lab_cah_June2027Member_label_en-US" xlink:label="lab_cah_June2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2027 [Member]</link:label>
    <link:label id="lab_cah_June2027Member_documentation_en-US" xlink:label="lab_cah_June2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_June2027Member" xlink:href="cah-20220331.xsd#cah_June2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_June2027Member" xlink:to="lab_cah_June2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CashReclassifiedToAssetHeldForSale_bcf36904-3cd5-4739-aee9-9ec339bde941_terseLabel_en-US" xlink:label="lab_cah_CashReclassifiedToAssetHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and equivalents reclassified from/(to) assets held for sale</link:label>
    <link:label id="lab_cah_CashReclassifiedToAssetHeldForSale_label_en-US" xlink:label="lab_cah_CashReclassifiedToAssetHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Reclassified to Asset Held for Sale</link:label>
    <link:label id="lab_cah_CashReclassifiedToAssetHeldForSale_documentation_en-US" xlink:label="lab_cah_CashReclassifiedToAssetHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Reclassified to Asset Held for Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CashReclassifiedToAssetHeldForSale" xlink:href="cah-20220331.xsd#cah_CashReclassifiedToAssetHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CashReclassifiedToAssetHeldForSale" xlink:to="lab_cah_CashReclassifiedToAssetHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_d1812beb-f33a-4b94-b5ea-da8aa0c0fdec_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Target performance goal (as a percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_d52d1a50-63cb-494e-adc7-b20bf5db6e76_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_cdddec60-1685-4d23-9b87-c788f47d6d6c_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_6a50d60c-e729-4d21-a3fb-ee2998e6df0e_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_ede38846-ce8f-488c-b31e-580832498375_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_6d5cb258-d39b-47ab-967b-230be81bb00b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_cdd7fefc-d5a1-447f-acf3-46272c4ac80e_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CommittedReceivablesSalesFacilityProgramMember_4b42a084-a2e8-42a0-91df-1cc7c1fa8b43_terseLabel_en-US" xlink:label="lab_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Committed Receivables Sales Facility Program [Member]</link:label>
    <link:label id="lab_cah_CommittedReceivablesSalesFacilityProgramMember_label_en-US" xlink:label="lab_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Committed Receivables Sales Facility Program [Member]</link:label>
    <link:label id="lab_cah_CommittedReceivablesSalesFacilityProgramMember_documentation_en-US" xlink:label="lab_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Committed receivables sales facility program that exists largely to provide liquidity by selling interests in trade receivables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:href="cah-20220331.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:to="lab_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_6e74e38e-cc44-463e-a27e-b5d3b2571b02_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_87030c57-10b7-45cd-b50e-701f86e756f4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_bfcbff91-52fb-4e19-9713-44527e87b837_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_f54623b8-7ca7-4653-9809-f23ab99e4821_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ProjectCostsOnInvestmentAndOtherSpending_efc43177-7e17-4a27-97c6-7bebd87cff66_terseLabel_en-US" xlink:label="lab_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project costs on investment and other spending</link:label>
    <link:label id="lab_cah_ProjectCostsOnInvestmentAndOtherSpending_label_en-US" xlink:label="lab_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project Costs On Investment And Other Spending</link:label>
    <link:label id="lab_cah_ProjectCostsOnInvestmentAndOtherSpending_documentation_en-US" xlink:label="lab_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment spending at the Corporate level. Investment spending generally includes the first year spend for certain projects that require incremental investments in the form of additional operating expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:href="cah-20220331.xsd#cah_ProjectCostsOnInvestmentAndOtherSpending"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:to="lab_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_234b524d-5858-426f-825d-499497ebb53d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_MedicalMember_2e8f61ac-339f-4bcd-9a8d-b244133cd429_terseLabel_en-US" xlink:label="lab_cah_MedicalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical</link:label>
    <link:label id="lab_cah_MedicalMember_label_en-US" xlink:label="lab_cah_MedicalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Member</link:label>
    <link:label id="lab_cah_MedicalMember_documentation_en-US" xlink:label="lab_cah_MedicalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember" xlink:href="cah-20220331.xsd#cah_MedicalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_MedicalMember" xlink:to="lab_cah_MedicalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_September2025Member_b6320262-73fb-494e-8196-2adf47f6e88c_terseLabel_en-US" xlink:label="lab_cah_September2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">September 2025</link:label>
    <link:label id="lab_cah_September2025Member_label_en-US" xlink:label="lab_cah_September2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">September 2025 [Member]</link:label>
    <link:label id="lab_cah_September2025Member_documentation_en-US" xlink:label="lab_cah_September2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">September 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_September2025Member" xlink:href="cah-20220331.xsd#cah_September2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_September2025Member" xlink:to="lab_cah_September2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6c4c2f72-4d4b-491c-b1aa-8327c8bf1b25_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income/(loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3791ef0d-2ae9-4a8c-8fd7-690723f3842f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_DOJInvestigationMember_1f856b19-acba-45c0-85dc-9343184c2f2b_terseLabel_en-US" xlink:label="lab_cah_DOJInvestigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DOJ Investigation [Member]</link:label>
    <link:label id="lab_cah_DOJInvestigationMember_label_en-US" xlink:label="lab_cah_DOJInvestigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DOJ Investigation [Member]</link:label>
    <link:label id="lab_cah_DOJInvestigationMember_documentation_en-US" xlink:label="lab_cah_DOJInvestigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DOJ Investigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DOJInvestigationMember" xlink:href="cah-20220331.xsd#cah_DOJInvestigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_DOJInvestigationMember" xlink:to="lab_cah_DOJInvestigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_248e9605-f377-431a-8c5f-fcf55948c61b_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_b215e811-3313-410d-95e2-43c0e2ce9aea_verboseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_IndemnificationReceivable_9f14c52b-f6e3-4cf0-a25e-05e43747a7f0_terseLabel_en-US" xlink:label="lab_cah_IndemnificationReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Receivable</link:label>
    <link:label id="lab_cah_IndemnificationReceivable_label_en-US" xlink:label="lab_cah_IndemnificationReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Receivable</link:label>
    <link:label id="lab_cah_IndemnificationReceivable_documentation_en-US" xlink:label="lab_cah_IndemnificationReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification receivable from Patient recovery related to certain pre-acquisition tax exposures and transaction taxes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IndemnificationReceivable" xlink:href="cah-20220331.xsd#cah_IndemnificationReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_IndemnificationReceivable" xlink:to="lab_cah_IndemnificationReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_6e65ddb0-8b0e-4e2b-93af-7b8a3b58b268_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCosts_1b253f0c-fce8-4854-8268-c971eb41657c_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_RestructuringCosts_label_en-US" xlink:label="lab_us-gaap_RestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCosts" xlink:to="lab_us-gaap_RestructuringCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_9e355ff4-917e-4003-a423-2b45485913b8_terseLabel_en-US" xlink:label="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds/(tax withholdings) from share-based compensation</link:label>
    <link:label id="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_label_en-US" xlink:label="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds/(tax withholdings) from share-based compensation</link:label>
    <link:label id="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_documentation_en-US" xlink:label="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The net cash inflow/(outflow) associated with the amount received from holders exercising their stock options and paid by the company to satisfy an employee's income tax withholding obligation when shares are withheld from settlement of a share-based award to cover taxes. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:href="cah-20220331.xsd#cah_Netproceedstaxwithholdingsfromsharebasedcompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:to="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_7a98bec3-e0da-4c7e-9aaa-be57c308f36b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PlaintiffTypeDomain_73aba224-e691-436d-9279-516f819cb3a0_terseLabel_en-US" xlink:label="lab_cah_PlaintiffTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Type [Domain]</link:label>
    <link:label id="lab_cah_PlaintiffTypeDomain_label_en-US" xlink:label="lab_cah_PlaintiffTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Type [Domain]</link:label>
    <link:label id="lab_cah_PlaintiffTypeDomain_documentation_en-US" xlink:label="lab_cah_PlaintiffTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Plaintiff Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeDomain" xlink:href="cah-20220331.xsd#cah_PlaintiffTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PlaintiffTypeDomain" xlink:to="lab_cah_PlaintiffTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherInvestments_32cd6f8b-3ed5-454e-b2bf-13a610750fdf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairments and Loss on Sale of Other Investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:to="lab_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_521341d5-b216-4d9c-bbaa-4976751ae42e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_78f0d831-97d0-40fa-ad45-993ddcb1d73f_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_103aae13-e36c-437a-8caa-85c78c32189f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_3098e82c-e031-42cc-96f7-653aec6cf8bd_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bc5e83b4-ab92-4587-838f-a87a796dd3ae_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_SettlingUSTerritories_669d3e21-8813-494a-bc5b-67ef43ad097a_terseLabel_en-US" xlink:label="lab_cah_SettlingUSTerritories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settling U.S Territories</link:label>
    <link:label id="lab_cah_SettlingUSTerritories_label_en-US" xlink:label="lab_cah_SettlingUSTerritories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settling U.S Territories</link:label>
    <link:label id="lab_cah_SettlingUSTerritories_documentation_en-US" xlink:label="lab_cah_SettlingUSTerritories" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settling U.S Territories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SettlingUSTerritories" xlink:href="cah-20220331.xsd#cah_SettlingUSTerritories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_SettlingUSTerritories" xlink:to="lab_cah_SettlingUSTerritories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_270f518a-0f3e-42d4-b076-708dd36d4b3b_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_15c8a670-da9b-4546-ae9e-5c349d020afb_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_8250dde8-3988-40b9-839c-69da42e3bb16_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_dfd1c723-4bc9-40a2-be10-46a1e34f4578_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price per Common Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_37d28641-2fc5-47c7-8b29-65a7ded99ba5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_18db4ef5-9645-4384-8818-c40bd44424c5_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_4f1d49a1-9c8c-4a43-bc7b-36b70401ad45_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled and forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_4eca8a89-4a76-4fc0-be0e-d872bf4acc93_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a8153623-ceb0-443b-9838-a4dd64e4df6b_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_ecbd4e2a-0344-4545-9776-c7d5dc7443cd_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_27cd5907-a0ac-4ffe-8521-6a365066bbd4_verboseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related costs</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d51826bb-8d9c-4170-916a-328c254600d6_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at beginning of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9ccf2394-98c7-41b6-83a7-d6882e81e361_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at end of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_18870c04-4742-4cda-b1df-b039999c81f9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Obligations and Other Short-Term Borrowings</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_450d5fdb-b1bc-4939-8e7e-49392615d5d3_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating and Reportable Segment</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_0c83239f-476c-4647-9065-887f52fcdc71_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_5e1bc0dd-50f3-4357-b0b8-4aec4083c1d2_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CordisDivestitureMember_512dc39a-29a0-4f46-8c93-b0710cd9c238_terseLabel_en-US" xlink:label="lab_cah_CordisDivestitureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture</link:label>
    <link:label id="lab_cah_CordisDivestitureMember_label_en-US" xlink:label="lab_cah_CordisDivestitureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture [Member]</link:label>
    <link:label id="lab_cah_CordisDivestitureMember_documentation_en-US" xlink:label="lab_cah_CordisDivestitureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember" xlink:href="cah-20220331.xsd#cah_CordisDivestitureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CordisDivestitureMember" xlink:to="lab_cah_CordisDivestitureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_A2.616Notesdue2022Member_9d4bd63b-ab03-46a4-879d-bce33eb8da43_terseLabel_en-US" xlink:label="lab_cah_A2.616Notesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.616% Notes due 2022 [Member]</link:label>
    <link:label id="lab_cah_A2.616Notesdue2022Member_label_en-US" xlink:label="lab_cah_A2.616Notesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.616% Notes due 2022 [Member]</link:label>
    <link:label id="lab_cah_A2.616Notesdue2022Member_documentation_en-US" xlink:label="lab_cah_A2.616Notesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.616% Notes due 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.616Notesdue2022Member" xlink:href="cah-20220331.xsd#cah_A2.616Notesdue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_A2.616Notesdue2022Member" xlink:to="lab_cah_A2.616Notesdue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_49d0961b-4009-47f6-9c5f-de120d401fb6_terseLabel_en-US" xlink:label="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from investments</link:label>
    <link:label id="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_label_en-US" xlink:label="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of available-for-sale securities and other investments</link:label>
    <link:label id="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_documentation_en-US" xlink:label="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash inflow from sales of available-for-sale securities and other investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:href="cah-20220331.xsd#cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:to="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_fac727d3-36cc-45ef-918b-f7917ea2ea8d_verboseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed technology and other</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_9e3884ce-499d-4b90-ac74-3fe791487244_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_beed894b-9b06-40e6-8184-b33788cd9d0c_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Average Outstanding Amount</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Average Outstanding Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAverageOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:to="lab_us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_74ae8b32-e250-4a83-8e60-4e1d32489494_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_ef65d1ad-ea73-45de-aedc-35b3175c05ae_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_b618b14d-af5e-49d8-a754-5a64e27b3f11_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_5dcf1c25-06db-4c90-a0fb-e5e38df05350_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_5ba0bbe5-b480-4ae3-94be-289cc717a4f1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain)/Loss on sale of equity interest in naviHealth</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfInvestments" xlink:to="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_FacilityExitAndOtherCosts_e2142a43-2040-4f0e-a6f2-2de2f5ecd135_terseLabel_en-US" xlink:label="lab_cah_FacilityExitAndOtherCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Exit and Other Costs</link:label>
    <link:label id="lab_cah_FacilityExitAndOtherCosts_label_en-US" xlink:label="lab_cah_FacilityExitAndOtherCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Exit and Other Costs</link:label>
    <link:label id="lab_cah_FacilityExitAndOtherCosts_documentation_en-US" xlink:label="lab_cah_FacilityExitAndOtherCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts" xlink:href="cah-20220331.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_FacilityExitAndOtherCosts" xlink:to="lab_cah_FacilityExitAndOtherCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_564f3bb7-887b-4fba-b59c-611db21345a8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_cb41122f-e6e9-48df-a29f-1eacc2f2cc94_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_7cbbbc4e-e034-4849-a3b5-04f54fe2f0db_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_0c163070-292e-4883-ac3f-adc049ab08fa_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_78404089-79e8-4cd6-b1bb-b19a3e360c94_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_66773565-cf70-4c71-99bc-9d779caed0dc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_eda4d3f3-dc4a-417c-a69a-0997b1604622_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_fdcf60aa-b29f-45e8-80c0-b3f96721d35b_verboseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Unit</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_b9f04ddf-2899-49cc-8ab6-e47994a19d80_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_996d683e-9c0e-49ff-88cd-33fc29e0373d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_257126f9-65dc-4682-a9e3-62ecb181f0e3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_5e55d015-ef99-4fd1-85fb-e1d8fcfe9a5b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_1e9cde5b-b48a-4c03-bd77-b61fc1fa10c6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NetOperatingLossCarrybackMember_4af53ab4-7b33-4652-80f7-9fa823cfcf72_terseLabel_en-US" xlink:label="lab_cah_NetOperatingLossCarrybackMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryback [Member]</link:label>
    <link:label id="lab_cah_NetOperatingLossCarrybackMember_label_en-US" xlink:label="lab_cah_NetOperatingLossCarrybackMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryback [Member]</link:label>
    <link:label id="lab_cah_NetOperatingLossCarrybackMember_documentation_en-US" xlink:label="lab_cah_NetOperatingLossCarrybackMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryback</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NetOperatingLossCarrybackMember" xlink:href="cah-20220331.xsd#cah_NetOperatingLossCarrybackMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NetOperatingLossCarrybackMember" xlink:to="lab_cah_NetOperatingLossCarrybackMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_bdd4ad44-c8a5-4fbe-bd4b-5d094a5d13de_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity/(deficit):</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2021f2ff-6906-4a05-850e-951d04b47f3d_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings/(loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_5dc366a5-1466-4c34-baa1-0241ea7b9c2b_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_da236442-7ffc-4759-a64a-7acc58b15e90_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_1f2ae0f8-4a74-40af-a609-574e5c61cc2d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_44346fa1-fbd7-415e-a1d7-dddc4da3f785_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_27336f89-9cd0-401e-b362-ed7ce0b5f68c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Amortizationandotheracquisitionrelatedcosts_ec7cbfa7-9879-4cc1-ab80-2fd5c2da6458_terseLabel_en-US" xlink:label="lab_cah_Amortizationandotheracquisitionrelatedcosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and other acquisition-related costs</link:label>
    <link:label id="lab_cah_Amortizationandotheracquisitionrelatedcosts_label_en-US" xlink:label="lab_cah_Amortizationandotheracquisitionrelatedcosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and other acquisition-related costs</link:label>
    <link:label id="lab_cah_Amortizationandotheracquisitionrelatedcosts_documentation_en-US" xlink:label="lab_cah_Amortizationandotheracquisitionrelatedcosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The aggregate expense charged against earnings to allocate the cost of acquired intangible assets and changes in the fair value of contingent consideration obligations. This also represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Amortizationandotheracquisitionrelatedcosts" xlink:href="cah-20220331.xsd#cah_Amortizationandotheracquisitionrelatedcosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Amortizationandotheracquisitionrelatedcosts" xlink:to="lab_cah_Amortizationandotheracquisitionrelatedcosts" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_GoodwillImpairmentAxis_cc3b0d76-6b75-421d-8eaa-de1e0e27e840_terseLabel_en-US" xlink:label="lab_cah_GoodwillImpairmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Impairment [Axis]</link:label>
    <link:label id="lab_cah_GoodwillImpairmentAxis_label_en-US" xlink:label="lab_cah_GoodwillImpairmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Impairment [Axis]</link:label>
    <link:label id="lab_cah_GoodwillImpairmentAxis_documentation_en-US" xlink:label="lab_cah_GoodwillImpairmentAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentAxis" xlink:href="cah-20220331.xsd#cah_GoodwillImpairmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_GoodwillImpairmentAxis" xlink:to="lab_cah_GoodwillImpairmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_f113d021-4570-4c06-97dd-09b7d223c23e_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive income/(loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_3e96456c-d6aa-4fa7-bdeb-02e3602b0400_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyClaimsSettledNumber_5daaeb89-e2e6-4d78-8331-a5e7db4d8685_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsSettledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Settled, Number</link:label>
    <link:label id="lab_us-gaap_LossContingencyClaimsSettledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsSettledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Settled, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsSettledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyClaimsSettledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyClaimsSettledNumber" xlink:to="lab_us-gaap_LossContingencyClaimsSettledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1127b120-c0d7-4f15-a75d-d3470f1a8e26_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b33383e7-af0d-4c0d-bb0b-b51edc90e36b_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d266660e-6dc1-49b5-a0ec-c6db9fd18989_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_8793258a-927d-4d0b-ab56-49c606b8b46b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on Extinguishment of Debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_d6e86db9-7813-4904-86a3-2db999e45878_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_9c84a29e-c34d-4fce-b3cc-b7f9af1ece44_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1b0bddc7-cc2a-4f68-a062-5c009bcd2cfb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_0b8d82d0-d57c-4ad0-80b1-48a60c925858_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_a6b51c7e-062e-467b-9c95-b4088ae3cf65_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_bca7f56e-6a96-45d3-90d9-5c1acf4cbabe_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_cb6fd2dd-6cdd-49c3-8e22-14c9f64cf8db_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_1cab6803-9d6a-4d97-80b0-c526d72bb579_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross margin</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_b2e479a0-2e61-4485-a32c-e02b443e193a_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_0b8a302d-5839-4863-acaa-7dfa05bd9159_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_96b6695d-d7a0-4019-84ce-4a8a1faa8d46_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments and other</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_02616f98-99bd-4232-8bcc-54ee463e8b02_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_7e78d72a-374d-4a11-b647-3dfcd81a710a_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_615d21c7-bd62-4272-85af-e893039f08dc_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsAxis_e79033ec-7fe0-4355-b25a-c9d7436e4550_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsAxis_label_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsAxis" xlink:to="lab_us-gaap_SubsegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_94648941-7b28-4a4b-ac93-e122dd6976b0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_591a61ea-1b17-4c1e-9eac-170143d3b934_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity/(deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_dc06641e-b5e0-4beb-a579-ffc4136a6399_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c1253f05-861d-44f0-9db4-ab8c48c6bdab_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TerminalGrowthRateFairValueInput_85066ac9-eaa3-4531-89c6-4927754529fe_terseLabel_en-US" xlink:label="lab_cah_TerminalGrowthRateFairValueInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Terminal Growth Rate, Fair Value Input</link:label>
    <link:label id="lab_cah_TerminalGrowthRateFairValueInput_label_en-US" xlink:label="lab_cah_TerminalGrowthRateFairValueInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Terminal Growth Rate, Fair Value Input</link:label>
    <link:label id="lab_cah_TerminalGrowthRateFairValueInput_documentation_en-US" xlink:label="lab_cah_TerminalGrowthRateFairValueInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Terminal Growth Rate, Fair Value Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TerminalGrowthRateFairValueInput" xlink:href="cah-20220331.xsd#cah_TerminalGrowthRateFairValueInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TerminalGrowthRateFairValueInput" xlink:to="lab_cah_TerminalGrowthRateFairValueInput" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_32d06641-25e6-470a-993b-6d12b44070e7_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_fb8b1e87-85bf-4a19-97ec-64c2ca3c4da2_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_7283cff8-5c04-4aa2-9482-02c24a87eaeb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_98f1c6a0-bf6d-4fbe-a049-9f953fc745bb_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a7050276-0547-47dd-a76e-0a571bef9229_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_069033ad-7267-4e79-afdc-1ae4cb83dabf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_21369462-f65e-479d-9837-52a2f60432d1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_2d82e8d1-41c1-4e10-b0cd-4e6e08982c51_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_f4e67b8d-ca78-40d3-8574-3751cecd56f7_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_5c3eac02-0291-439d-b187-11cd71f71bea_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_3831fc31-8af4-4402-9efe-826c27a04043_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares acquired, average price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ShortTermCreditFacilitiesMember_f866f8f3-0fbc-4d44-9ec0-16eb663074ad_terseLabel_en-US" xlink:label="lab_cah_ShortTermCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Credit Facilities Member</link:label>
    <link:label id="lab_cah_ShortTermCreditFacilitiesMember_label_en-US" xlink:label="lab_cah_ShortTermCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Credit Facilities Member</link:label>
    <link:label id="lab_cah_ShortTermCreditFacilitiesMember_documentation_en-US" xlink:label="lab_cah_ShortTermCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other short-term credit facilities and an unsecured line of credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShortTermCreditFacilitiesMember" xlink:href="cah-20220331.xsd#cah_ShortTermCreditFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ShortTermCreditFacilitiesMember" xlink:to="lab_cah_ShortTermCreditFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_3ccf98eb-1a47-406c-b88a-561b689613ef_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual amortization of intangible assets - Year Four</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7c29c907-9577-4895-821c-1f441616bc74_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_3c8a5026-1985-4dac-a334-50a82957bb92_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_908a89e0-96ad-467b-94be-5122765a7568_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Unit</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_20b6fc0c-c041-4772-9371-2fbf816068f3_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_e0e0ba4d-ae1d-4a6c-be37-ccc837bcfd9a_terseLabel_en-US" xlink:label="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Liability for New York Opioid Stewardship Act</link:label>
    <link:label id="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_label_en-US" xlink:label="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Liability for New York Opioid Stewardship Act</link:label>
    <link:label id="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_documentation_en-US" xlink:label="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Liability for New York Opioid Stewardship Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" xlink:href="cah-20220331.xsd#cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" xlink:to="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_JudgmentForLostProfits_66768f2e-50cb-4ce2-a9f7-8e2416a7a535_terseLabel_en-US" xlink:label="lab_cah_JudgmentForLostProfits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment for lost profits</link:label>
    <link:label id="lab_cah_JudgmentForLostProfits_label_en-US" xlink:label="lab_cah_JudgmentForLostProfits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment for lost profits</link:label>
    <link:label id="lab_cah_JudgmentForLostProfits_documentation_en-US" xlink:label="lab_cah_JudgmentForLostProfits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment for lost profits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_JudgmentForLostProfits" xlink:href="cah-20220331.xsd#cah_JudgmentForLostProfits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_JudgmentForLostProfits" xlink:to="lab_cah_JudgmentForLostProfits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_c49d477f-e19d-4441-853c-2685db374984_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Notional Amount</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:to="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7f0db3f6-0528-49da-9a4a-f2abe502510c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_e5008075-989d-40a4-ac9c-ba24ef42a4fa_terseLabel_en-US" xlink:label="lab_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Obligations and Other Short-Term Borrowings [Abstract]</link:label>
    <link:label id="lab_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_label_en-US" xlink:label="lab_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Obligations and Other Short-Term Borrowings [Abstract]</link:label>
    <link:label id="lab_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_documentation_en-US" xlink:label="lab_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Obligations and Other Short-Term Borrowings [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract" xlink:href="cah-20220331.xsd#cah_LongTermObligationsandOtherShortTermBorrowingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract" xlink:to="lab_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_8e40e46b-e998-4634-9cfc-220669ab4414_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_d04e63db-8d8b-4a92-bec8-88087e14b332_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_5310e36b-a746-4ec9-9d7f-2b6815b3e339_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_5bd8eaf7-73c2-441f-9857-c6a722c4a408_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain/(loss) on derivative instruments, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_bfccceca-3960-4036-84b1-0b092948e5a7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_e3f491bc-82d3-43e2-8c16-adc74551a6bb_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TrademarksAndPatentsMember_619055c1-1032-4481-b89a-a281bd11b46c_terseLabel_en-US" xlink:label="lab_cah_TrademarksAndPatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks, trade names and patents</link:label>
    <link:label id="lab_cah_TrademarksAndPatentsMember_label_en-US" xlink:label="lab_cah_TrademarksAndPatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks And Patents Member</link:label>
    <link:label id="lab_cah_TrademarksAndPatentsMember_documentation_en-US" xlink:label="lab_cah_TrademarksAndPatentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, and the exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TrademarksAndPatentsMember" xlink:href="cah-20220331.xsd#cah_TrademarksAndPatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TrademarksAndPatentsMember" xlink:to="lab_cah_TrademarksAndPatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_d4f188b8-3569-4ba4-b497-22e5fe774354_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_4b4ae99d-4df3-42d8-9164-710b5ce5ed31_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Intangible, Total other intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_afb44659-db56-40bf-8947-e4357d9064c3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill by Reportable Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_a6338612-bc98-44e8-b5e8-16d4d1b95532_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Amount Outstanding During Period</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Amount Outstanding During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TotalLongTermandShortTermObligations_a7b86e02-eca4-45aa-9997-e70aaffaad17_terseLabel_en-US" xlink:label="lab_cah_TotalLongTermandShortTermObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Long-Term and Short-Term Obligations</link:label>
    <link:label id="lab_cah_TotalLongTermandShortTermObligations_label_en-US" xlink:label="lab_cah_TotalLongTermandShortTermObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Long-Term and Short-Term Obligations</link:label>
    <link:label id="lab_cah_TotalLongTermandShortTermObligations_documentation_en-US" xlink:label="lab_cah_TotalLongTermandShortTermObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Long-Term and Short-Term Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalLongTermandShortTermObligations" xlink:href="cah-20220331.xsd#cah_TotalLongTermandShortTermObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TotalLongTermandShortTermObligations" xlink:to="lab_cah_TotalLongTermandShortTermObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_fd01adcd-2b08-41af-a27b-b9a71569650d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_1245d7bf-7089-4da2-8c2a-3a5acc1de4be_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CARESActDomain_8e01f0e2-1e01-4f90-8fea-1ce4b32fa1d3_terseLabel_en-US" xlink:label="lab_cah_CARESActDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryback [Domain]</link:label>
    <link:label id="lab_cah_CARESActDomain_label_en-US" xlink:label="lab_cah_CARESActDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act [Domain]</link:label>
    <link:label id="lab_cah_CARESActDomain_documentation_en-US" xlink:label="lab_cah_CARESActDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CARESActDomain" xlink:href="cah-20220331.xsd#cah_CARESActDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CARESActDomain" xlink:to="lab_cah_CARESActDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_0e5919b3-891d-4c93-9bf8-6f1d76333926_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_f9ac7207-8040-4b5a-bdbb-5d500f0c34b4_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4c99dbad-332b-44e9-9cb2-c35c09bf8df1_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_f05bb13a-5cd6-4f96-be10-2b9affa13402_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Cardinal Health, Inc. shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9c5e0c27-692a-4c92-84d0-6c5c8c0b9d0d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled and forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_ce0c8134-2f45-4ddc-8752-43d027d25aae_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5318da7f-48cd-4428-8334-9a12fb130e36_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_IPRDTrademarksandOtherMember_280fced7-5ad5-4d7a-ad7a-98ea77786b58_terseLabel_en-US" xlink:label="lab_cah_IPRDTrademarksandOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks and patents</link:label>
    <link:label id="lab_cah_IPRDTrademarksandOtherMember_label_en-US" xlink:label="lab_cah_IPRDTrademarksandOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D,TrademarksandOther [Member]</link:label>
    <link:label id="lab_cah_IPRDTrademarksandOtherMember_documentation_en-US" xlink:label="lab_cah_IPRDTrademarksandOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Includes in process investigation of new knowledge useful in developing new product or service or new process or techniques or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for the improvements to existing product or process and rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IPRDTrademarksandOtherMember" xlink:href="cah-20220331.xsd#cah_IPRDTrademarksandOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_IPRDTrademarksandOtherMember" xlink:to="lab_cah_IPRDTrademarksandOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2eb09e3a-57de-4a0a-8aad-304fc6c76691_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in operating assets and liabilities, net of effects from acquisitions and divestitures:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_dfbfb762-6ede-491e-8f4a-4366c71c488c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual amortization of intangible assets - Year Three</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_70c543ca-2b58-46fd-a852-05367c1d6412_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_4d609162-1f4b-499f-a3f0-358950f5706c_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_GA_c7830255-01ba-414b-be9b-8fc640270fea_terseLabel_en-US" xlink:label="lab_stpr_GA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GEORGIA</link:label>
    <link:label id="lab_stpr_GA_label_en-US" xlink:label="lab_stpr_GA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GEORGIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_GA" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_GA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_GA" xlink:to="lab_stpr_GA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_629c0138-ccd4-4f4a-a443-15bda2c18422_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_6b9a6178-d1b8-4e50-977a-9a659e99e4b7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation (recoveries)/charges, net</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_79a564d4-c75b-4fb1-9e8c-57d0990031a7_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Related to Litigation Settlement</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NuclearPrecisionHealthSolutionsMember_c9705f7a-9adb-46f4-8bbb-3d2e0152bc97_terseLabel_en-US" xlink:label="lab_cah_NuclearPrecisionHealthSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuclear Precision Health Services [Member]</link:label>
    <link:label id="lab_cah_NuclearPrecisionHealthSolutionsMember_label_en-US" xlink:label="lab_cah_NuclearPrecisionHealthSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuclear Precision Health Solutions [Member]</link:label>
    <link:label id="lab_cah_NuclearPrecisionHealthSolutionsMember_documentation_en-US" xlink:label="lab_cah_NuclearPrecisionHealthSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuclear Precision Health Solutions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NuclearPrecisionHealthSolutionsMember" xlink:href="cah-20220331.xsd#cah_NuclearPrecisionHealthSolutionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NuclearPrecisionHealthSolutionsMember" xlink:to="lab_cah_NuclearPrecisionHealthSolutionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_76afca52-f37d-41a0-af87-d26535fe7698_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b66e5cea-1d6c-4a17-bd6d-2500e4498cb9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_3e37a1c5-8f3f-493e-9211-9b72ff076c35_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_3426200c-0558-48e7-929a-6d27214353ff_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_3381c25c-b03f-4b80-922f-e4cf331d45de_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury shares</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_fce3171a-f6b3-481b-bbe7-43edcd847b3f_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury shares</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_00e8c89e-14ef-4f3a-8d91-1c2575c0024b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1d58360d-e36e-4415-a5d7-4182b130c8fb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_020dc040-3a3a-4f38-aeaa-fb443b715365_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Transactions Related to Performance Share Units Under the Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Performance-Based Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_6c5774b3-6314-47cb-b62e-8d46678bf617_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_7f6a2ce0-e09f-4d34-8113-869eff5d37f5_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_MedicaldistributionandproductsMember_4fb38bb1-c4f7-499c-aae4-058c777db396_terseLabel_en-US" xlink:label="lab_cah_MedicaldistributionandproductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical distribution and products [Member]</link:label>
    <link:label id="lab_cah_MedicaldistributionandproductsMember_label_en-US" xlink:label="lab_cah_MedicaldistributionandproductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical distribution and products [Member]</link:label>
    <link:label id="lab_cah_MedicaldistributionandproductsMember_documentation_en-US" xlink:label="lab_cah_MedicaldistributionandproductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical distribution and products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicaldistributionandproductsMember" xlink:href="cah-20220331.xsd#cah_MedicaldistributionandproductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_MedicaldistributionandproductsMember" xlink:to="lab_cah_MedicaldistributionandproductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TaxMatterDomain_38b6ffff-f14c-4ca1-a223-9fc8e21a62a7_terseLabel_en-US" xlink:label="lab_cah_TaxMatterDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matter [Domain]</link:label>
    <link:label id="lab_cah_TaxMatterDomain_label_en-US" xlink:label="lab_cah_TaxMatterDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matter [Domain]</link:label>
    <link:label id="lab_cah_TaxMatterDomain_documentation_en-US" xlink:label="lab_cah_TaxMatterDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Tax Matter [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterDomain" xlink:href="cah-20220331.xsd#cah_TaxMatterDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TaxMatterDomain" xlink:to="lab_cah_TaxMatterDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_8f4e0f8d-f375-4742-8936-44617e364b0e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_48c7e05e-9b57-4ac1-8849-59546ab74cae_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_a2052192-e398-46a3-88d6-2915c3c2afaa_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares acquired (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_4aed7357-1ed4-4fa7-8bce-d69834f5a5c0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_e53c7f92-c5da-4b88-9e33-2a0abc1f3f23_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Intangible</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromHedgeInvestingActivities_0d46d3df-4d69-400f-b7d7-43708d1843d8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromHedgeInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Hedge, Investing Activities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromHedgeInvestingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromHedgeInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Hedge, Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromHedgeInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromHedgeInvestingActivities" xlink:to="lab_us-gaap_ProceedsFromHedgeInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_d287f091-31d2-422c-be4c-947a57d6f96c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_608e893c-4f5e-4be3-b9d7-d82b0dfd5371_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings/(accumulated deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_c58521bf-eebf-41bd-800d-4eb3f9ac9c56_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_9cb56fa1-ad24-4c4c-8850-d7b9baa31498_terseLabel_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_MedicalUnitGoodwillImpairmentMember_ed948fbb-dd70-4c3f-8061-96d7f809f7b3_terseLabel_en-US" xlink:label="lab_cah_MedicalUnitGoodwillImpairmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Unit Goodwill Impairment [Member]</link:label>
    <link:label id="lab_cah_MedicalUnitGoodwillImpairmentMember_label_en-US" xlink:label="lab_cah_MedicalUnitGoodwillImpairmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Unit Goodwill Impairment [Member]</link:label>
    <link:label id="lab_cah_MedicalUnitGoodwillImpairmentMember_documentation_en-US" xlink:label="lab_cah_MedicalUnitGoodwillImpairmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Unit Goodwill Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitGoodwillImpairmentMember" xlink:href="cah-20220331.xsd#cah_MedicalUnitGoodwillImpairmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_MedicalUnitGoodwillImpairmentMember" xlink:to="lab_cah_MedicalUnitGoodwillImpairmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_SettlingStates_d4d0927a-938c-4429-9b7f-d02f66525299_terseLabel_en-US" xlink:label="lab_cah_SettlingStates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settling States</link:label>
    <link:label id="lab_cah_SettlingStates_label_en-US" xlink:label="lab_cah_SettlingStates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settling States</link:label>
    <link:label id="lab_cah_SettlingStates_documentation_en-US" xlink:label="lab_cah_SettlingStates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settling States</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SettlingStates" xlink:href="cah-20220331.xsd#cah_SettlingStates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_SettlingStates" xlink:to="lab_cah_SettlingStates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_63ed95df-d221-4aca-823f-2306b03abaed_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_c298a83f-445d-4e18-a047-68eeb861d9b7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_4352450e-d3bd-4f12-9d6b-96d2aa05b499_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_1791d482-182d-48e8-9e2a-5ddc2e17e206_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_07a2b444-41f3-4a81-b72c-ba9a669bb32c_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_f8a734e9-9f0a-4242-9c45-b6b8b82ce9fe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_1041ed84-e512-4c5a-bd4a-18cdfbcf7b37_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_07fbf938-a692-4f2d-88b3-ad470cf4af5b_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_FloatingRateNotesdue2022Member_2aacfc12-75d7-4ba2-abba-e51249bf14e9_terseLabel_en-US" xlink:label="lab_cah_FloatingRateNotesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating Rate Notes due 2022 [Member]</link:label>
    <link:label id="lab_cah_FloatingRateNotesdue2022Member_label_en-US" xlink:label="lab_cah_FloatingRateNotesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating Rate Notes due 2022 [Member]</link:label>
    <link:label id="lab_cah_FloatingRateNotesdue2022Member_documentation_en-US" xlink:label="lab_cah_FloatingRateNotesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating Rate Notes due 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FloatingRateNotesdue2022Member" xlink:href="cah-20220331.xsd#cah_FloatingRateNotesdue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_FloatingRateNotesdue2022Member" xlink:to="lab_cah_FloatingRateNotesdue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e2aae3bd-cf9b-4889-893d-0f930a4c18ed_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_1eb7c252-fc68-4989-8fa8-ad00406f3896_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain_79589f53-e25c-4d23-8da9-3deeaad6f742_terseLabel_en-US" xlink:label="lab_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share repurchase program aggregate purchase price [Domain]</link:label>
    <link:label id="lab_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain_label_en-US" xlink:label="lab_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share repurchase program aggregate purchase price [Domain]</link:label>
    <link:label id="lab_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain_documentation_en-US" xlink:label="lab_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share repurchase program aggregate purchase price [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain" xlink:href="cah-20220331.xsd#cah_ShareRepurchaseProgramAggregatePurchasePriceDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain" xlink:to="lab_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_f914ebf0-4cd0-4e4e-815c-7aa2c523fd4e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairments and (gain)/loss on disposal of assets, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Assets and Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:to="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_298b34e0-6c2d-422f-b04f-f3aa811047de_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_20c4cf1f-a95a-4141-a425-3032f04fc878_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_c2bf1673-096c-4efe-88b9-cd8128faaf37_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_A300MillionShareRepurchaseProgramMember_b64ba2a3-f9ba-4241-8a8a-6f6b517d4ad7_terseLabel_en-US" xlink:label="lab_cah_A300MillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$300 million share repurchase program [Member]</link:label>
    <link:label id="lab_cah_A300MillionShareRepurchaseProgramMember_label_en-US" xlink:label="lab_cah_A300MillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$300 million share repurchase program [Member]</link:label>
    <link:label id="lab_cah_A300MillionShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_cah_A300MillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$300 million share repurchase program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A300MillionShareRepurchaseProgramMember" xlink:href="cah-20220331.xsd#cah_A300MillionShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_A300MillionShareRepurchaseProgramMember" xlink:to="lab_cah_A300MillionShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_29abc89e-eb47-4fce-a0b3-0f035c32ea11_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_12f18d30-8017-44d0-b70f-3eb365358a03_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Intangible</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_266cd87c-64ad-4c0e-8407-d908c9343715_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution, selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_b00ee87a-ce7f-4f44-9525-d3c3204d67be_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6bc5176f-1de0-407c-83d3-c70edc02eae5_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income/(Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_990fbac4-9750-477b-bf64-afb7406ee1d6_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OtherJurisdictionsMember_dba3d2e3-a6a6-4025-9ef0-21bb238da61c_terseLabel_en-US" xlink:label="lab_cah_OtherJurisdictionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Jurisdictions [Member]</link:label>
    <link:label id="lab_cah_OtherJurisdictionsMember_label_en-US" xlink:label="lab_cah_OtherJurisdictionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Jurisdictions [Member]</link:label>
    <link:label id="lab_cah_OtherJurisdictionsMember_documentation_en-US" xlink:label="lab_cah_OtherJurisdictionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Jurisdictions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OtherJurisdictionsMember" xlink:href="cah-20220331.xsd#cah_OtherJurisdictionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OtherJurisdictionsMember" xlink:to="lab_cah_OtherJurisdictionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings_43655a5c-c581-4beb-9328-f8c32414816d_terseLabel_en-US" xlink:label="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount of Long-Term and other Short-Term Borrowings</link:label>
    <link:label id="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings_label_en-US" xlink:label="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount of Long-Term and other Short-Term Borrowings</link:label>
    <link:label id="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings_documentation_en-US" xlink:label="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount of Long-Term and other Short-Term Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:href="cah-20220331.xsd#cah_CarryingAmountofLongTermandotherShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:to="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_LawsuitTypeDomain_7456e141-bfce-4f2c-8711-c8f61bed5aab_terseLabel_en-US" xlink:label="lab_cah_LawsuitTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lawsuit Type [Domain]</link:label>
    <link:label id="lab_cah_LawsuitTypeDomain_label_en-US" xlink:label="lab_cah_LawsuitTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lawsuit Type [Domain]</link:label>
    <link:label id="lab_cah_LawsuitTypeDomain_documentation_en-US" xlink:label="lab_cah_LawsuitTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Lawsuit Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeDomain" xlink:href="cah-20220331.xsd#cah_LawsuitTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_LawsuitTypeDomain" xlink:to="lab_cah_LawsuitTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_a44051fb-a85e-48e3-8a2c-228e07fb5aac_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_44ece89d-1737-44fd-9090-ea5f6af524af_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_e01c3be9-0244-49d0-bef5-c7ad11ceb8cd_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OpioidLitigationDomain_fe579601-a500-4208-9854-f2fa3c5999af_terseLabel_en-US" xlink:label="lab_cah_OpioidLitigationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation [Domain]</link:label>
    <link:label id="lab_cah_OpioidLitigationDomain_label_en-US" xlink:label="lab_cah_OpioidLitigationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation [Domain]</link:label>
    <link:label id="lab_cah_OpioidLitigationDomain_documentation_en-US" xlink:label="lab_cah_OpioidLitigationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain" xlink:href="cah-20220331.xsd#cah_OpioidLitigationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OpioidLitigationDomain" xlink:to="lab_cah_OpioidLitigationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d4d75981-9217-4ea4-b0f5-e280985fa815_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Transactions Under the Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_835bfd5c-5889-4de6-8464-71c6c20f38e2_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating earnings/(loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_18fe281a-5258-4c24-b32f-58ee4eae35ed_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating earnings</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_d8999046-cd31-40a0-849c-7a035276a9af_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_A500MillionShareRepurchaseProgramMember_97b7db73-5eda-4a71-b5ea-9a0d9da83fb0_terseLabel_en-US" xlink:label="lab_cah_A500MillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$500 million share repurchase program [Domain]</link:label>
    <link:label id="lab_cah_A500MillionShareRepurchaseProgramMember_label_en-US" xlink:label="lab_cah_A500MillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$500 million share repurchase program [Member]</link:label>
    <link:label id="lab_cah_A500MillionShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_cah_A500MillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$500 million share repurchase program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A500MillionShareRepurchaseProgramMember" xlink:href="cah-20220331.xsd#cah_A500MillionShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_A500MillionShareRepurchaseProgramMember" xlink:to="lab_cah_A500MillionShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_84a9ec26-529a-4069-a0b7-94b068f2b155_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Financial Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CareFusionMember_2888efe8-a691-4873-ad46-773bd4a1091b_terseLabel_en-US" xlink:label="lab_cah_CareFusionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CareFusion [Member]</link:label>
    <link:label id="lab_cah_CareFusionMember_label_en-US" xlink:label="lab_cah_CareFusionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CareFusion [Member]</link:label>
    <link:label id="lab_cah_CareFusionMember_documentation_en-US" xlink:label="lab_cah_CareFusionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CareFusion [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CareFusionMember" xlink:href="cah-20220331.xsd#cah_CareFusionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CareFusionMember" xlink:to="lab_cah_CareFusionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_6f10e8c4-0082-4b68-8e70-8d5d5ac954f5_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_GoodwillImpairmentDomain_c7adfa27-8f08-4c87-b1e8-d24a19205183_terseLabel_en-US" xlink:label="lab_cah_GoodwillImpairmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Impairment [Domain]</link:label>
    <link:label id="lab_cah_GoodwillImpairmentDomain_label_en-US" xlink:label="lab_cah_GoodwillImpairmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Impairment [Domain]</link:label>
    <link:label id="lab_cah_GoodwillImpairmentDomain_documentation_en-US" xlink:label="lab_cah_GoodwillImpairmentDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Impairment [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentDomain" xlink:href="cah-20220331.xsd#cah_GoodwillImpairmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_GoodwillImpairmentDomain" xlink:to="lab_cah_GoodwillImpairmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_e662eeee-f8d2-4462-a894-7f45ceb36ee9_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_84f50d23-5f83-4a37-b7cf-c7e3f1031a55_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_fe80ca6d-a090-466c-9fdb-cbca4ddf522e_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_cb12629f-2b95-4028-a906-044b7041a742_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_7808e609-c691-405e-846d-05b7abf238db_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares in treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_f77e0ad8-8786-4ef4-98b2-edec0b404d24_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury, balance at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_3e59f994-4fbf-4a8f-a40e-3f8f9ae23455_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury, balance at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReceivable_0de03afc-3f89-4c74-a5a4-85d05e8b476c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Receivable</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReceivable" xlink:to="lab_us-gaap_IncomeTaxReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c0c55dc2-5304-4974-951f-afb138b59a41_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_1864596c-d042-4d05-96b6-a0391c957727_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Other Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_4c0623fc-8d8c-4f5a-bb0d-a9f4551e66e4_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for/(benefit from) income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_837bd4c2-163d-4ee3-b55a-b88f0bb8795e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_45b752ff-6c99-4841-adc5-63c56d1a9f25_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_0f7c1040-cacc-4964-b470-146adc97b193_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ea7e2a88-de01-4b82-9c5a-612b13a2d226_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_97cd6846-4aa1-4229-9237-38e2e761fd0b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss_ca956b51-b6a5-4716-a1c4-69df7380d057_terseLabel_en-US" xlink:label="lab_cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares that would be antidilutive as a result of net loss</link:label>
    <link:label id="lab_cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss_label_en-US" xlink:label="lab_cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares that would be antidilutive as a result of net loss</link:label>
    <link:label id="lab_cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss_documentation_en-US" xlink:label="lab_cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares that would be antidilutive as a result of net loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss" xlink:href="cah-20220331.xsd#cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss" xlink:to="lab_cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_6d573737-9692-4d4d-9823-66cecbe143ac_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_aa38e74e-fe41-44a2-b9fc-b63eb5576d67_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings/(Loss) per common share attributable to Cardinal Health, Inc.:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_39e92dd1-81d1-4117-a66e-3fba2b56a136_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_529f6723-fb14-4b63-a852-37931edad834_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f0bc2267-f990-44ab-91ad-03642d9737c2_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8247884a-6dda-4482-ab4e-22916d839ac8_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares&#8211;diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_635569a1-2c8b-4fbc-a724-8335bb82afdb_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_71b747df-05b6-4438-b616-b3e8097cc67d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Contract</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Assets (Liabilities), at Fair Value, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:to="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PatientRecoveryBusinessMember_021429cc-d5c5-46c9-917f-4fb22858ad98_terseLabel_en-US" xlink:label="lab_cah_PatientRecoveryBusinessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Recovery Business</link:label>
    <link:label id="lab_cah_PatientRecoveryBusinessMember_label_en-US" xlink:label="lab_cah_PatientRecoveryBusinessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Recovery Business [Member]</link:label>
    <link:label id="lab_cah_PatientRecoveryBusinessMember_documentation_en-US" xlink:label="lab_cah_PatientRecoveryBusinessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Recovery Business [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PatientRecoveryBusinessMember" xlink:href="cah-20220331.xsd#cah_PatientRecoveryBusinessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PatientRecoveryBusinessMember" xlink:to="lab_cah_PatientRecoveryBusinessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_MedicalUnitMember_1a187b61-5e4b-47af-921b-7b6a165f4e3a_terseLabel_en-US" xlink:label="lab_cah_MedicalUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Unit</link:label>
    <link:label id="lab_cah_MedicalUnitMember_label_en-US" xlink:label="lab_cah_MedicalUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Unit [Member]</link:label>
    <link:label id="lab_cah_MedicalUnitMember_documentation_en-US" xlink:label="lab_cah_MedicalUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember" xlink:href="cah-20220331.xsd#cah_MedicalUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_MedicalUnitMember" xlink:to="lab_cah_MedicalUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_3c908ecf-147a-4251-a242-7dd4c54c8909_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_c7ce308c-52d2-4ec3-83f9-24fcd438009d_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PharmaceuticalDistributionandSpecialtyMember_35b9da95-29b5-4df9-a36b-f07da8bd2c60_terseLabel_en-US" xlink:label="lab_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Distribution and Specialty [Member]</link:label>
    <link:label id="lab_cah_PharmaceuticalDistributionandSpecialtyMember_label_en-US" xlink:label="lab_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Distribution and Specialty [Member]</link:label>
    <link:label id="lab_cah_PharmaceuticalDistributionandSpecialtyMember_documentation_en-US" xlink:label="lab_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Distribution and Specialty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:href="cah-20220331.xsd#cah_PharmaceuticalDistributionandSpecialtyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:to="lab_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_4533a457-7fe3-490d-aaff-e1acb0adeb64_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized&#8212;755 million shares, Issued&#8212;327 million shares at March&#160;31, 2022 and June 30, 2021</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_5ee2197e-7cd2-4b7b-a775-4b632274f6e2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_4fbf9acd-259d-4d57-b1e2-056e0a787a99_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e477675e-506a-4f87-af63-ce37a3ae509f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromHedgeFinancingActivities_f0dc607b-1cb9-4e51-8af6-031479626d5d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromHedgeFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from interest rate swap terminations</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromHedgeFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromHedgeFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Hedge, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromHedgeFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromHedgeFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromHedgeFinancingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromHedgeFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_MaturityDateDomain_1ff70d35-f108-44ef-a6d2-43733610dcf1_terseLabel_en-US" xlink:label="lab_cah_MaturityDateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Date [Domain]</link:label>
    <link:label id="lab_cah_MaturityDateDomain_label_en-US" xlink:label="lab_cah_MaturityDateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Date [Domain]</link:label>
    <link:label id="lab_cah_MaturityDateDomain_documentation_en-US" xlink:label="lab_cah_MaturityDateDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Date [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MaturityDateDomain" xlink:href="cah-20220331.xsd#cah_MaturityDateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_MaturityDateDomain" xlink:to="lab_cah_MaturityDateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ContingentAttorneyFee_d10f5c45-c474-48c9-b40f-65c739e09d84_terseLabel_en-US" xlink:label="lab_cah_ContingentAttorneyFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Attorney Fee</link:label>
    <link:label id="lab_cah_ContingentAttorneyFee_label_en-US" xlink:label="lab_cah_ContingentAttorneyFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Attorney Fee</link:label>
    <link:label id="lab_cah_ContingentAttorneyFee_documentation_en-US" xlink:label="lab_cah_ContingentAttorneyFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Attorney Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ContingentAttorneyFee" xlink:href="cah-20220331.xsd#cah_ContingentAttorneyFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ContingentAttorneyFee" xlink:to="lab_cah_ContingentAttorneyFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_fd5c8757-d19c-4673-8d46-900be9e80b0e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_1752f1e1-9652-416b-b8f5-654dcfe9257c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1d09595f-782f-4419-b6ea-f915ab81016d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of exercisable options at period end</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_a0cdb5a6-77c4-4338-8597-5abd162fa4bc_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_d7eab87d-b879-413b-98cc-a29e3dd74aa8_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated range of decrease in unrecognized tax benefits within the next 12 months</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_412f8da9-8d4d-45d0-b484-c9ed98a0229f_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3c3faab4-1f2e-4776-ab3e-cc502c3c7534_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_47b98f2b-fb6c-4f5c-8127-839d4d0e8470_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments and other</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1dbdf04a-a503-4b4e-a629-1b6676a589be_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net earnings attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_7084ce52-637c-4cbf-89d9-f479617303a6_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments, Contingent Liabilities and Litigation</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_b50189c0-b81b-4d24-bda5-bb8a4af5efc9_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_803149bb-31a3-40d4-8925-56b0d8012d8f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_191c81f7-91a5-4bca-9ac1-7a8911bdbe95_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_152d30bd-cd73-4424-9b25-eb78b479be03_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_07459455-7409-4750-bd15-b70e09247b1b_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CardinalHealthAtHomeMember_24023d9c-7f81-4c32-b337-a74f300a482d_terseLabel_en-US" xlink:label="lab_cah_CardinalHealthAtHomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health At Home [Member]</link:label>
    <link:label id="lab_cah_CardinalHealthAtHomeMember_label_en-US" xlink:label="lab_cah_CardinalHealthAtHomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health At Home [Member]</link:label>
    <link:label id="lab_cah_CardinalHealthAtHomeMember_documentation_en-US" xlink:label="lab_cah_CardinalHealthAtHomeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health At Home [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CardinalHealthAtHomeMember" xlink:href="cah-20220331.xsd#cah_CardinalHealthAtHomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CardinalHealthAtHomeMember" xlink:to="lab_cah_CardinalHealthAtHomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_0b39d9e1-9b9a-48e8-8951-a6e39470f7bf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_2cf044eb-b222-4be3-9981-5a7f4902514e_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2ebdcffb-db96-40c6-8684-f7bca53559cc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FacilityClosingMember_13981d2d-a85d-4751-841e-566ea4005d3a_terseLabel_en-US" xlink:label="lab_us-gaap_FacilityClosingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Exit and Other Costs</link:label>
    <link:label id="lab_us-gaap_FacilityClosingMember_label_en-US" xlink:label="lab_us-gaap_FacilityClosingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Closing [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FacilityClosingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FacilityClosingMember" xlink:to="lab_us-gaap_FacilityClosingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_6b7e6195-4e76-415b-98f8-9a75c9ecd1a0_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_3876324f-e303-465f-b26a-146a702cf3b4_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by/(used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueHedgingMember_19a63a63-08da-46c8-9f38-ce215950aceb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging</link:label>
    <link:label id="lab_us-gaap_FairValueHedgingMember_label_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueHedgingMember" xlink:to="lab_us-gaap_FairValueHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_a8f470fa-c379-4f8b-ab10-81d279f2e746_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Amortization Period (Years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_791b1db4-a5a4-43cc-baca-6445b11408ce_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_67e0e667-518e-40be-ac89-a540c8503990_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive income/(loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_cea69e7a-4138-4713-b457-2d776eb9024e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_1e0a6706-7123-4c1b-a6fc-fc9b7dbdc0fc_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive income attributable to Cardinal Health, Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_5b9a41f3-9ff6-458e-a1be-579be8d6fc41_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_a0410752-2b22-4b3a-865a-ec8b89c15d0c_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Transfers</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_5788e713-ce52-49e2-93e8-1ec24122a63b_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_24e95840-96c9-49bc-a527-3b5889b57f77_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_b673fb69-062b-4567-958b-94adf4b8e600_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_ca2f819f-c737-405c-94dd-2e979243935a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments and other adjustments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_431066cc-f765-41be-a848-c0eea8c8bb15_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_51b266d8-7587-4236-bfa3-4bf032a46076_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis_ff195f56-b0e0-4df9-a9ad-d20ebbf44417_terseLabel_en-US" xlink:label="lab_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share repurchase program aggregate purchase price [Axis]</link:label>
    <link:label id="lab_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis_label_en-US" xlink:label="lab_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share repurchase program aggregate purchase price [Axis]</link:label>
    <link:label id="lab_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis_documentation_en-US" xlink:label="lab_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share repurchase program aggregate purchase price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis" xlink:href="cah-20220331.xsd#cah_ShareRepurchaseProgramAggregatePurchasePriceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis" xlink:to="lab_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_cb4115e1-1ee3-450b-ab4d-7c773b6ff8ee_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_9474b2d9-c2c1-45fc-9083-7d0c5a08b30e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee- Related Costs</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TotalOpioidLitigationMember_37ea5989-0811-4a99-99a9-bfa994112aa4_terseLabel_en-US" xlink:label="lab_cah_TotalOpioidLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Opioid Litigation [Member]</link:label>
    <link:label id="lab_cah_TotalOpioidLitigationMember_label_en-US" xlink:label="lab_cah_TotalOpioidLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Opioid Litigation [Member]</link:label>
    <link:label id="lab_cah_TotalOpioidLitigationMember_documentation_en-US" xlink:label="lab_cah_TotalOpioidLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Opioid Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember" xlink:href="cah-20220331.xsd#cah_TotalOpioidLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TotalOpioidLitigationMember" xlink:to="lab_cah_TotalOpioidLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OpioidLawsuitsStateMember_7a81321d-2db1-4187-aceb-4be9ce21b269_terseLabel_en-US" xlink:label="lab_cah_OpioidLawsuitsStateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Lawsuits State [Member]</link:label>
    <link:label id="lab_cah_OpioidLawsuitsStateMember_label_en-US" xlink:label="lab_cah_OpioidLawsuitsStateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Lawsuits State [Member]</link:label>
    <link:label id="lab_cah_OpioidLawsuitsStateMember_documentation_en-US" xlink:label="lab_cah_OpioidLawsuitsStateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Lawsuits State and Political Subdivisions [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsStateMember" xlink:href="cah-20220331.xsd#cah_OpioidLawsuitsStateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OpioidLawsuitsStateMember" xlink:to="lab_cah_OpioidLawsuitsStateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_ec3228f9-4a57-4742-a22c-839becf51a66_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7a256989-adf9-407b-93ff-f2fb6a15a798_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_82bbe996-fcaa-432c-855b-40fe4f1b99bc_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_866a7d5f-c45c-404c-b29b-c5ea5daf938d_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Loss [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_d8acd56d-f6a0-4310-a115-49166a836a8d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_03abf19c-676f-4427-865a-5f3697dc589a_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and other intangibles, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_df5490f7-8901-48ba-b010-30a9f9ef3606_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability, Current</link:label>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_label_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserveCurrent" xlink:to="lab_us-gaap_LitigationReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_a0c7c6cd-d16e-414b-995d-3c9079d1c823_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_d8d0d5fe-088f-41a9-ad2c-88c2504855e7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_LawsuitTypeAxis_178d4486-63d6-46c6-bcce-1fb9ce554ad5_terseLabel_en-US" xlink:label="lab_cah_LawsuitTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lawsuit Type [Axis]</link:label>
    <link:label id="lab_cah_LawsuitTypeAxis_label_en-US" xlink:label="lab_cah_LawsuitTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lawsuit Type [Axis]</link:label>
    <link:label id="lab_cah_LawsuitTypeAxis_documentation_en-US" xlink:label="lab_cah_LawsuitTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lawsuit Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeAxis" xlink:href="cah-20220331.xsd#cah_LawsuitTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_LawsuitTypeAxis" xlink:to="lab_cah_LawsuitTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_41e4f7e2-4940-4626-a085-5d88a08a1a60_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0173a0ba-09a2-482e-ba8d-4c6ac7f9220d_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fa96f0eb-339c-4c85-972d-0e510c36690f_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_bd12ff28-553d-431d-a263-5543ab80886f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIncomeTaxRefunds_20a85a98-bdfa-48bd-b39d-1b2b8daca990_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Income Tax Refunds</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIncomeTaxRefunds_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Income Tax Refunds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:to="lab_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_ceebc6c9-d331-41e0-a03c-f6daf5ecee03_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of long-term obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_d2121e62-46ed-4401-859a-95e1f1ba2dff_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_5614193a-b5e2-41d2-a2c5-daa20091ec38_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_2f59ac9e-7e2c-4d2e-86c0-14f42decf5cf_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares in treasury, at cost: 54 million shares and 36 million shares at March&#160;31, 2022 and June 30, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_43640b61-082d-4630-bdeb-83a7dbfb5777_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury, balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_38408183-cdc6-436c-a48e-f73d663ced6c_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury, balance at end of period</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_41d87ab8-c4bc-4cbf-8e8f-96162ac7e177_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, without par value:</link:label>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Dividends_a259c921-9829-48b3-bdb2-d27cf187365d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:label id="lab_us-gaap_Dividends_label_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends" xlink:to="lab_us-gaap_Dividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_33b697c8-0e3f-4b48-9923-f942396f1b94_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled and forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_329ec274-2c7e-483d-83bb-6ad4fffe77f7_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income)/expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_bf8f60b7-863e-4387-9397-41cd3d313117_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Employee Severance</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_87cb432d-d354-42c7-850f-440e589353be_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_8a7634b2-2e2a-4dfc-bf9d-629ed94e9635_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b38287f6-c328-4917-b460-25484d9c6fed_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_909e6a2a-3c0f-448e-824a-768c7a6cda4a_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e02d177b-0b8b-499b-9e79-b6ec6d3204cc_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_558978d1-2ba1-4116-bc6f-7c3034bdaae8_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_c9932d32-e18b-4a56-967a-d186cd94960a_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_62ac9bc7-e9ee-4a2a-82e2-0a4976f171e1_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_045748fd-8d78-4740-b545-5cd760dd639e_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_8e975b01-a768-480f-bcc4-796070278fd2_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_fe41b3e9-dca1-4721-8959-a64bc2070f58_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_f52c2d9a-b03f-4fd2-ac4e-0da57a548c49_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_7bbe6cb7-6708-4d94-9dd9-4e229264e3e2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends declared per common share</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_3fcfd90f-c045-4bd9-aa4e-e0bc4ce0b4cf_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Intangible</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_d89c94c5-ae53-4cd5-b0a2-884870ee5ec5_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets by Reportable Segment</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Assets from Segment to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets_379f5360-a21c-44a4-8a0e-3e8b7a22ddc4_terseLabel_en-US" xlink:label="lab_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from divestitures and disposal of property and equipment and held for sale assets</link:label>
    <link:label id="lab_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets_label_en-US" xlink:label="lab_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from divestitures and disposal of property and equipment and held for sale assets</link:label>
    <link:label id="lab_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets_documentation_en-US" xlink:label="lab_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from divestitures and disposal of property and equipment and held for sale assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" xlink:href="cah-20220331.xsd#cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" xlink:to="lab_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CordisDivestitureAxis_c17dc00c-dcc0-4d63-a9f7-4ef9d3fb896e_terseLabel_en-US" xlink:label="lab_cah_CordisDivestitureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture [Axis]</link:label>
    <link:label id="lab_cah_CordisDivestitureAxis_label_en-US" xlink:label="lab_cah_CordisDivestitureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture [Axis]</link:label>
    <link:label id="lab_cah_CordisDivestitureAxis_documentation_en-US" xlink:label="lab_cah_CordisDivestitureAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis" xlink:href="cah-20220331.xsd#cah_CordisDivestitureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CordisDivestitureAxis" xlink:to="lab_cah_CordisDivestitureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0373735f-ed58-4c8f-84f7-1a752805656a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_a0305a9b-7e3f-4576-a3aa-ef0e37342425_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cd536310-daee-4ce5-9973-6d245a639fe4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_2ad73752-cc45-4cef-8252-b032d0d24b84_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit related to share-based compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringChargesAbstract_c713a4b3-4ae3-46c6-9877-1deb7cb2c761_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringChargesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringChargesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringChargesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringChargesAbstract" xlink:to="lab_us-gaap_RestructuringChargesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4fbd6e14-aeee-4089-93a9-ebd3bb451925_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of outstanding options at period end</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_922d89d8-a7bf-465d-9d20-60ded56ef8c5_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NetOperatingLossCarrybackAxis_bb555631-b0b7-41b8-8c1e-5404e2947fe0_terseLabel_en-US" xlink:label="lab_cah_NetOperatingLossCarrybackAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryback [Axis]</link:label>
    <link:label id="lab_cah_NetOperatingLossCarrybackAxis_label_en-US" xlink:label="lab_cah_NetOperatingLossCarrybackAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryback [Axis]</link:label>
    <link:label id="lab_cah_NetOperatingLossCarrybackAxis_documentation_en-US" xlink:label="lab_cah_NetOperatingLossCarrybackAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryback</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NetOperatingLossCarrybackAxis" xlink:href="cah-20220331.xsd#cah_NetOperatingLossCarrybackAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NetOperatingLossCarrybackAxis" xlink:to="lab_cah_NetOperatingLossCarrybackAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_2698f11e-c017-4359-8c0f-0c1ed4f8da5f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitAxis_9ba95e5d-64df-4c08-bea8-eff7ba1394b8_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitAxis_label_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitAxis" xlink:to="lab_us-gaap_ReportingUnitAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_a94ef6e8-67e5-4bf5-9c7d-0fdda6cee0f0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, without par value:</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CVSHealthMember_71d8d364-d7f7-4066-80ee-52333ecc2350_terseLabel_en-US" xlink:label="lab_cah_CVSHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CVS Health</link:label>
    <link:label id="lab_cah_CVSHealthMember_label_en-US" xlink:label="lab_cah_CVSHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CVS Health [Member]</link:label>
    <link:label id="lab_cah_CVSHealthMember_documentation_en-US" xlink:label="lab_cah_CVSHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CVS Health [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CVSHealthMember" xlink:href="cah-20220331.xsd#cah_CVSHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CVSHealthMember" xlink:to="lab_cah_CVSHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_b716ac86-076c-4dec-ac6c-4c234a1ce396_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NewYorkOpioidStewardshipActMember_cfc56201-9f11-44b9-855f-3a66f8a06ea7_terseLabel_en-US" xlink:label="lab_cah_NewYorkOpioidStewardshipActMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York Opioid Stewardship Act [Member]</link:label>
    <link:label id="lab_cah_NewYorkOpioidStewardshipActMember_label_en-US" xlink:label="lab_cah_NewYorkOpioidStewardshipActMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York Opioid Stewardship Act [Member]</link:label>
    <link:label id="lab_cah_NewYorkOpioidStewardshipActMember_documentation_en-US" xlink:label="lab_cah_NewYorkOpioidStewardshipActMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York Opioid Stewardship Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NewYorkOpioidStewardshipActMember" xlink:href="cah-20220331.xsd#cah_NewYorkOpioidStewardshipActMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NewYorkOpioidStewardshipActMember" xlink:to="lab_cah_NewYorkOpioidStewardshipActMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_3708a514-babf-4fb0-9601-527bc55cd533_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_7b6348ff-1a00-46e3-ae29-bc885a56af4a_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ExercisablePeriodOfPlansInYears_29c66c53-6730-46cd-8bc0-1203e28efec6_terseLabel_en-US" xlink:label="lab_cah_ExercisablePeriodOfPlansInYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable period of plans (in years)</link:label>
    <link:label id="lab_cah_ExercisablePeriodOfPlansInYears_label_en-US" xlink:label="lab_cah_ExercisablePeriodOfPlansInYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable period of plans, in years</link:label>
    <link:label id="lab_cah_ExercisablePeriodOfPlansInYears_documentation_en-US" xlink:label="lab_cah_ExercisablePeriodOfPlansInYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The instrument's contractual term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ExercisablePeriodOfPlansInYears" xlink:href="cah-20220331.xsd#cah_ExercisablePeriodOfPlansInYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ExercisablePeriodOfPlansInYears" xlink:to="lab_cah_ExercisablePeriodOfPlansInYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_63c2c0fe-034c-4cf8-8789-c29cad9fd9fd_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual amortization of intangible assets - Year Two</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8bd0ac48-90e6-456c-932f-1a63b70423a0_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Shareholders&#8217; Equity/(Deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3ff7bc61-0f65-48be-bb65-e32bdac87bf9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsDomain_ad8f329b-da95-4695-860c-1ab778d32c4c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsDomain_label_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsDomain" xlink:to="lab_us-gaap_SubsegmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1c53e83d-27da-47be-9218-94b582fc746b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ac9eeb0d-36f2-4920-b15c-8fb0f39722e7_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_598cc0d8-4b9c-4895-8298-7c73e7076dc2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled and forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3c79e857-274a-4533-8091-743927f1d109_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_7d3b3f58-93c2-4bbd-89db-f256047f87f7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_b0be0001-a885-4b21-96a1-ddbc6523f6cd_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_e85ccb29-679d-475a-9957-91cfd05eeffc_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and employee severance</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_589d99e7-dead-4040-bbe5-eb3c4faf7cd7_totalLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total restructuring and employee severance</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_9a9c6881-eabc-4b6b-b36c-f7de1f8dfdcf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_a3514acf-379e-4a46-bc41-10bbc3422b79_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_9e01e330-bf5f-43bb-b9ee-de16c5546ef1_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_70d47593-a0be-4be4-8157-654a981ec13f_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8d378b4f-448a-4016-9c9b-66a8a9e94685_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f585dbab-b652-48ff-a54a-da95d74cb6ce_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares&#8211;basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_24659605-6da7-4e40-ba95-8474cdb6f0aa_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0b31f5d6-7564-4357-a134-f40cf899b416_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets and Liabilities Held for Sale [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_34eae118-d83f-4436-b80e-2db091829186_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_a2abce5d-a940-4a0e-8f66-7a6ca666fae6_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_5123c3e4-e17d-4827-8dd5-da91c2d8e986_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_81b01a99-106b-4cff-9b50-b08c0a6321a5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_134bc109-c60c-4614-986d-d67f224adcc6_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_cf551344-734d-435c-8181-7949cd6eb1d7_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized&#8212;500 thousand shares, Issued&#8212;none</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_0cf632e3-7116-4b4b-a18e-18724dc93407_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_d3f86788-2215-4f8e-b8e0-b4ceab860e05_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_25999c22-771c-4e1e-9b69-77745425d28f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_cf7fc29e-e18a-42c4-a757-10728c8a3f23_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_99670f9c-de1a-46ce-a250-4547ed3f02ac_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_74a77fc0-cf0a-4b65-a4bb-806d21478104_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_15ce5a7f-2d68-44c6-8bec-f76b928d01dc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Total Share-based Compensation Expense by Type of Award</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PlaintiffTypeAxis_d2b67e20-5704-48a1-928f-920a0dcb6f33_terseLabel_en-US" xlink:label="lab_cah_PlaintiffTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Type [Axis]</link:label>
    <link:label id="lab_cah_PlaintiffTypeAxis_label_en-US" xlink:label="lab_cah_PlaintiffTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Type [Axis]</link:label>
    <link:label id="lab_cah_PlaintiffTypeAxis_documentation_en-US" xlink:label="lab_cah_PlaintiffTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeAxis" xlink:href="cah-20220331.xsd#cah_PlaintiffTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PlaintiffTypeAxis" xlink:to="lab_cah_PlaintiffTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_2f43edf8-90e7-4c3b-b978-63f38a8a5a64_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_c7ddd036-e794-46e7-b9e2-3e7acb516315_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_d8cc2ab3-bc88-4e9a-a462-e47436d2cfbf_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NarativeAbstract_da2e2574-e669-4308-95db-68744928ab41_terseLabel_en-US" xlink:label="lab_cah_NarativeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Narative [Abstract]</link:label>
    <link:label id="lab_cah_NarativeAbstract_label_en-US" xlink:label="lab_cah_NarativeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Narative [Abstract]</link:label>
    <link:label id="lab_cah_NarativeAbstract_documentation_en-US" xlink:label="lab_cah_NarativeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Narative [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NarativeAbstract" xlink:href="cah-20220331.xsd#cah_NarativeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NarativeAbstract" xlink:to="lab_cah_NarativeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_46c83fe6-92fd-43e9-947c-5baeea46007e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders&#8217; equity/(deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_ab6593ca-3127-45bd-9825-0356f2ece181_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Loss [Rollforward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_d2c8aba3-296b-4677-a006-bb4fc0874536_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_b393d9e7-c17d-45e0-b883-723c61d69fd0_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOtherShares_76bc9a91-d5d5-4b0e-bd00-38bebcb668f0_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOtherShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other Shares</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOtherShares_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOtherShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOtherShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOtherShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOtherShares" xlink:to="lab_us-gaap_StockholdersEquityOtherShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_78ca7c9b-5d4c-487a-9ef4-d978d643ac75_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in trade receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_c1388f2e-105c-4abc-8b7e-53fa962ad4a2_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_0caa8688-718b-415d-93eb-09710ae2131c_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f2d28335-6fc5-4bd3-9721-2a858277bea1_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_93ca0fd0-87e1-412a-9896-6d5566f6d78c_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of subsidiaries, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_ea7e8e52-7bf4-40eb-9382-2a275789d89c_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Profit by Reportable Segment</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_a77acb96-c2ec-432f-8d07-687476390da9_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_ece2d5d2-2402-4b75-8838-bd532191167a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_6fb18041-5b01-4a77-804d-b4b36b9a6594_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_946f49a8-a0c3-46bc-95c6-b6b2f7c90b7f_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, interest and penalties accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TaxMatterAxis_1815e51a-4fb9-44fa-a946-3576d0e7f81c_terseLabel_en-US" xlink:label="lab_cah_TaxMatterAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matter [Axis]</link:label>
    <link:label id="lab_cah_TaxMatterAxis_label_en-US" xlink:label="lab_cah_TaxMatterAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matter [Axis]</link:label>
    <link:label id="lab_cah_TaxMatterAxis_documentation_en-US" xlink:label="lab_cah_TaxMatterAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matter [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterAxis" xlink:href="cah-20220331.xsd#cah_TaxMatterAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TaxMatterAxis" xlink:to="lab_cah_TaxMatterAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OpioidLawsuitsMember_94340e31-0fc1-4e80-be89-460846997fb6_terseLabel_en-US" xlink:label="lab_cah_OpioidLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Lawsuits [Member]</link:label>
    <link:label id="lab_cah_OpioidLawsuitsMember_label_en-US" xlink:label="lab_cah_OpioidLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Lawsuits [Member]</link:label>
    <link:label id="lab_cah_OpioidLawsuitsMember_documentation_en-US" xlink:label="lab_cah_OpioidLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Lawsuits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember" xlink:href="cah-20220331.xsd#cah_OpioidLawsuitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OpioidLawsuitsMember" xlink:to="lab_cah_OpioidLawsuitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_AlamedaCountyMember_8690ee09-52d3-451a-8383-6b3a02e76631_terseLabel_en-US" xlink:label="lab_cah_AlamedaCountyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alameda County [Member]</link:label>
    <link:label id="lab_cah_AlamedaCountyMember_label_en-US" xlink:label="lab_cah_AlamedaCountyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alameda County [Member]</link:label>
    <link:label id="lab_cah_AlamedaCountyMember_documentation_en-US" xlink:label="lab_cah_AlamedaCountyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alameda County [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AlamedaCountyMember" xlink:href="cah-20220331.xsd#cah_AlamedaCountyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_AlamedaCountyMember" xlink:to="lab_cah_AlamedaCountyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_9da218ca-a07f-46ff-ab31-fa39f9207d28_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Intangible, Total other intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_48cee3a4-c280-4ac7-b214-f6d0ab84a159_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_6d1b0d50-c848-485c-a6e6-27e6a9eca5fc_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_5eda6b7e-19f3-453d-ad65-64c77396d36d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PrivatePartiesMember_157adcf9-b29a-460e-9be7-a3be3925d6a9_terseLabel_en-US" xlink:label="lab_cah_PrivatePartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Parties [Member]</link:label>
    <link:label id="lab_cah_PrivatePartiesMember_label_en-US" xlink:label="lab_cah_PrivatePartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Parties [Member]</link:label>
    <link:label id="lab_cah_PrivatePartiesMember_documentation_en-US" xlink:label="lab_cah_PrivatePartiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Parties [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PrivatePartiesMember" xlink:href="cah-20220331.xsd#cah_PrivatePartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PrivatePartiesMember" xlink:to="lab_cah_PrivatePartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dcbb9262-a385-4c52-9947-fca286644f38_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_139ec096-d2dc-4270-8cfb-b843cab7c699_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_8587207a-fdd8-475b-a43f-10f6cf0f175f_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_1b74f071-c344-4662-868c-4a4f007f37df_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_DiscountRateFairValueInput_278695a1-07a2-4eef-9e2a-df54eae627ad_terseLabel_en-US" xlink:label="lab_cah_DiscountRateFairValueInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount Rate, Fair Value Input</link:label>
    <link:label id="lab_cah_DiscountRateFairValueInput_label_en-US" xlink:label="lab_cah_DiscountRateFairValueInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount Rate, Fair Value Input</link:label>
    <link:label id="lab_cah_DiscountRateFairValueInput_documentation_en-US" xlink:label="lab_cah_DiscountRateFairValueInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount Rate, Fair Value Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DiscountRateFairValueInput" xlink:href="cah-20220331.xsd#cah_DiscountRateFairValueInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_DiscountRateFairValueInput" xlink:to="lab_cah_DiscountRateFairValueInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitDomain_f562e226-a4ac-41b5-bbbe-673345c0871f_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitDomain_label_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitDomain" xlink:to="lab_us-gaap_ReportingUnitDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_42576442-84fa-4af6-ad2f-7122f54e2730_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermPurchaseCommitmentPeriod_dbda8453-3365-41a2-8077-487789e0e6e6_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment, Period</link:label>
    <link:label id="lab_us-gaap_LongtermPurchaseCommitmentPeriod_label_en-US" xlink:label="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Purchase Commitment, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:to="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_bb3c5b4b-1f51-4eb5-8656-73e945a3df13_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_80202831-c978-4cdc-97ce-ff03ac919341_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_aa50fd0d-90e7-4610-aa80-52e2966952b9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Transactions Related to Restricted Share Units Under the Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrentAndNoncurrent_a7601ca6-3e2e-49dd-bff0-3320b7743840_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_b44864d1-a0f8-4426-bb4f-520fd41c1a41_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_090e8ea0-489a-4235-8914-78752d8a9312_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OpioidLitigationAxis_d092d9a0-87dd-40e4-9b77-f15fb0b0123f_terseLabel_en-US" xlink:label="lab_cah_OpioidLitigationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation [Axis]</link:label>
    <link:label id="lab_cah_OpioidLitigationAxis_label_en-US" xlink:label="lab_cah_OpioidLitigationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation [Axis]</link:label>
    <link:label id="lab_cah_OpioidLitigationAxis_documentation_en-US" xlink:label="lab_cah_OpioidLitigationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis" xlink:href="cah-20220331.xsd#cah_OpioidLitigationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OpioidLitigationAxis" xlink:to="lab_cah_OpioidLitigationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_AdditionalStockOptionPlanDataTableTextBlock_1a4989d0-4bb5-48d1-b55c-900d386dfb21_terseLabel_en-US" xlink:label="lab_cah_AdditionalStockOptionPlanDataTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Additional Data Related to Stock Option Activity</link:label>
    <link:label id="lab_cah_AdditionalStockOptionPlanDataTableTextBlock_label_en-US" xlink:label="lab_cah_AdditionalStockOptionPlanDataTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Stock Option Plan Data [Table Text Block]</link:label>
    <link:label id="lab_cah_AdditionalStockOptionPlanDataTableTextBlock_documentation_en-US" xlink:label="lab_cah_AdditionalStockOptionPlanDataTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A disclosure of additional data related to all stock option activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AdditionalStockOptionPlanDataTableTextBlock" xlink:href="cah-20220331.xsd#cah_AdditionalStockOptionPlanDataTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_AdditionalStockOptionPlanDataTableTextBlock" xlink:to="lab_cah_AdditionalStockOptionPlanDataTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_68407e1c-f03a-4323-ab49-07e0b62c7d2b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount_35697516-1b9f-4cd6-a1c9-610285b9be9b_terseLabel_en-US" xlink:label="lab_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount</link:label>
    <link:label id="lab_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount_label_en-US" xlink:label="lab_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount</link:label>
    <link:label id="lab_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount_documentation_en-US" xlink:label="lab_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount" xlink:href="cah-20220331.xsd#cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount" xlink:to="lab_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_AggregateAnnualAssessment_8b717e8d-885d-4ed5-9f55-160391efc78c_terseLabel_en-US" xlink:label="lab_cah_AggregateAnnualAssessment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Annual Assessment</link:label>
    <link:label id="lab_cah_AggregateAnnualAssessment_label_en-US" xlink:label="lab_cah_AggregateAnnualAssessment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Annual Assessment</link:label>
    <link:label id="lab_cah_AggregateAnnualAssessment_documentation_en-US" xlink:label="lab_cah_AggregateAnnualAssessment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Annual Assessment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AggregateAnnualAssessment" xlink:href="cah-20220331.xsd#cah_AggregateAnnualAssessment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_AggregateAnnualAssessment" xlink:to="lab_cah_AggregateAnnualAssessment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_4fadc92b-e8ef-4293-9eb4-650b3329f79c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_01723cd7-a2ea-4a3e-bb2b-6696712f073c_negatedLabel_en-US" xlink:label="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_label_en-US" xlink:label="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of available-for-sale securities and other investments</link:label>
    <link:label id="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_documentation_en-US" xlink:label="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash outflow from purchases of available-for-sale securities and other investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:href="cah-20220331.xsd#cah_Purchaseofavailableforsalesecuritiesandotherinvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:to="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_e81e7ff8-ac5e-45b0-be0d-b1b4a2f7e609_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_39bed44a-0722-4e04-8866-356f2e5f495a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_A200MillionShareRepurchaseProgramMember_64783188-8e27-440e-a317-41d96b0222fa_terseLabel_en-US" xlink:label="lab_cah_A200MillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$200 million share repurchase program</link:label>
    <link:label id="lab_cah_A200MillionShareRepurchaseProgramMember_label_en-US" xlink:label="lab_cah_A200MillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$200 million share repurchase program [Member]</link:label>
    <link:label id="lab_cah_A200MillionShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_cah_A200MillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$200 million share repurchase program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A200MillionShareRepurchaseProgramMember" xlink:href="cah-20220331.xsd#cah_A200MillionShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_A200MillionShareRepurchaseProgramMember" xlink:to="lab_cah_A200MillionShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_561a714e-b223-4302-a8bc-18ae39697aee_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_434bceac-0499-4503-9735-5a45423aab7e_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_6e988934-a19d-43d2-a8f4-d79f1e598c1d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term obligations, less current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_33c307ad-0fd9-43dd-b014-f1363c4488cf_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_LossContingencyLawsuitsNumber_c60339ae-21cd-4270-bea6-e4923d0be950_verboseLabel_en-US" xlink:label="lab_cah_LossContingencyLawsuitsNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Lawsuits, Number</link:label>
    <link:label id="lab_cah_LossContingencyLawsuitsNumber_label_en-US" xlink:label="lab_cah_LossContingencyLawsuitsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Lawsuits, Number</link:label>
    <link:label id="lab_cah_LossContingencyLawsuitsNumber_documentation_en-US" xlink:label="lab_cah_LossContingencyLawsuitsNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Lawsuits, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LossContingencyLawsuitsNumber" xlink:href="cah-20220331.xsd#cah_LossContingencyLawsuitsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_LossContingencyLawsuitsNumber" xlink:to="lab_cah_LossContingencyLawsuitsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_f9deb938-190f-4c68-ad1f-060af57ca854_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_17ca7668-bf64-42c9-8799-79b0e1c99269_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_7634162e-96c3-4f2f-80a4-82f5374d2cb4_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_749ee102-0ea1-4e48-bf4b-4a023b1c24c8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes and other liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax and Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_256da74c-1619-4e7a-9a8a-28c79488a499_terseLabel_en-US" xlink:label="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue from External Customers by Geographic Area [Line Items]</link:label>
    <link:label id="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_label_en-US" xlink:label="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue from External Customers by Geographic Area [Line Items]</link:label>
    <link:label id="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_documentation_en-US" xlink:label="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Segment Revenue from External Customers by Geographic Area [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" xlink:href="cah-20220331.xsd#cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" xlink:to="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_3c68e00f-d700-4e50-8bd9-bd83283bc474_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_WA_b534f0b8-8cb0-4c8d-a6c1-78327c79a58e_terseLabel_en-US" xlink:label="lab_stpr_WA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WASHINGTON</link:label>
    <link:label id="lab_stpr_WA_label_en-US" xlink:label="lab_stpr_WA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WASHINGTON</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WA" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_WA" xlink:to="lab_stpr_WA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_9cc55f42-6f20-4ff5-a41c-df02c0563ff2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual amortization of intangible assets - Remainder of Fiscal Year</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_3eb1e8f8-c7d3-48b8-91e5-1ba540fd6574_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain/(Loss) on Derivatives, net of tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrencySwapMember_dc72c4c8-b35f-46ed-a5e4-2a5f62224588_terseLabel_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency Swap [Member]</link:label>
    <link:label id="lab_us-gaap_CurrencySwapMember_label_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrencySwapMember" xlink:to="lab_us-gaap_CurrencySwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_2cd56554-afbd-43a0-a445-eb030b1bf95a_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_23beb35c-f528-43a0-a933-470027bab57a_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase/(decrease) in cash and equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_0daf5825-2bdb-4903-b0af-cfa6f36202f8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_db413127-7671-4c4e-9af2-53b0e04a47a8_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock options, restricted share units, and performance share units (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_ed7d7982-7144-4b82-bc47-b285b62a0a06_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Restructuring and Employee Severance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_18de5d09-99bb-435b-bf45-7cee4637320a_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_9c244526-64a2-42f9-b614-29fbc06e91af_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_d3747d06-0d54-4722-8fa6-4392fbd597b5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_dcbd8402-1143-4b09-b55c-d4337d2c2208_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_cdcb9f09-4a3b-46cf-830e-365567f7c10a_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6f3cea36-f62e-45d1-8049-35d0500bab82_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3ef43f55-f809-406d-b5c3-badcde489442_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_cd85f313-d76a-4102-b833-8b8df47d58e2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserve_43a1fe30-a3b3-4ffa-a914-5c92a4bd213e_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability</link:label>
    <link:label id="lab_us-gaap_LitigationReserve_label_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserve" xlink:to="lab_us-gaap_LitigationReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_a5219441-8a51-4c8c-824a-e2603eb6a119_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_f9758460-ec8b-469b-bed2-64357f655801_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_904f7acc-71af-4317-8ea8-d7ed5608cef5_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_a94c44f5-dc26-418e-9902-314522e02dd3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities and operating items, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_02b57d5e-e9bd-44cc-8f67-26d21265eab5_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_fb6d36a1-6127-4154-8f16-9f260bd4761c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c078230b-3f21-4164-98cf-3fbdbe18151f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_5a3c8201-2476-4e7f-bd3b-08494a69881b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TaxMattersAgreementDomain_bb030e13-7cab-4eb1-b24e-d5d864c96f53_terseLabel_en-US" xlink:label="lab_cah_TaxMattersAgreementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matters Agreement [Domain]</link:label>
    <link:label id="lab_cah_TaxMattersAgreementDomain_label_en-US" xlink:label="lab_cah_TaxMattersAgreementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matters Agreement [Domain]</link:label>
    <link:label id="lab_cah_TaxMattersAgreementDomain_documentation_en-US" xlink:label="lab_cah_TaxMattersAgreementDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Tax Matters Agreement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementDomain" xlink:href="cah-20220331.xsd#cah_TaxMattersAgreementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TaxMattersAgreementDomain" xlink:to="lab_cah_TaxMattersAgreementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualPayments_8b6e246b-52d6-446b-a1ad-b0ea7d425a60_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual, Payments</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualPayments_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualPayments" xlink:to="lab_us-gaap_LossContingencyAccrualPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TaxMattersAgreementAxis_d7b60a06-58eb-4062-9fa5-472db77337b4_terseLabel_en-US" xlink:label="lab_cah_TaxMattersAgreementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matters Agreement [Axis]</link:label>
    <link:label id="lab_cah_TaxMattersAgreementAxis_label_en-US" xlink:label="lab_cah_TaxMattersAgreementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matters Agreement [Axis]</link:label>
    <link:label id="lab_cah_TaxMattersAgreementAxis_documentation_en-US" xlink:label="lab_cah_TaxMattersAgreementAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matters Agreement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementAxis" xlink:href="cah-20220331.xsd#cah_TaxMattersAgreementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TaxMattersAgreementAxis" xlink:to="lab_cah_TaxMattersAgreementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b9330cd2-b484-41e9-8552-3a179a9ef8c1_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_178cb9f8-5504-4fcf-9860-b4cc7e18de29_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual amortization of intangible assets - Year One</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_45118ea2-3545-44d6-ade2-0b432f7994a8_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>cah-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:5843d3e5-829e-408b-801e-c8a62435530f,g:2e89d43f-ed1a-46fa-9c57-992bbbf67b50-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cardinal.com/role/CoverPage" xlink:type="simple" xlink:href="cah-20220331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_8f0e1c4e-356a-498f-a239-e340f7689874" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_aefcbc16-9e42-4c66-bdbc-ceec91c1fe34" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8f0e1c4e-356a-498f-a239-e340f7689874" xlink:to="loc_dei_DocumentType_aefcbc16-9e42-4c66-bdbc-ceec91c1fe34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_599beeb0-5737-47fa-be44-362f3df1c9b2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8f0e1c4e-356a-498f-a239-e340f7689874" xlink:to="loc_dei_DocumentQuarterlyReport_599beeb0-5737-47fa-be44-362f3df1c9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_d82843c0-11a0-4c45-ac95-e75ac581dd40" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8f0e1c4e-356a-498f-a239-e340f7689874" xlink:to="loc_dei_DocumentPeriodEndDate_d82843c0-11a0-4c45-ac95-e75ac581dd40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_6cf95e98-6583-4212-9abb-e45afcf04208" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8f0e1c4e-356a-498f-a239-e340f7689874" xlink:to="loc_dei_DocumentTransitionReport_6cf95e98-6583-4212-9abb-e45afcf04208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_c9674a9a-6114-465f-b85e-e889e845a37f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8f0e1c4e-356a-498f-a239-e340f7689874" xlink:to="loc_dei_EntityFileNumber_c9674a9a-6114-465f-b85e-e889e845a37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_0465132f-8727-49de-9aa3-2fa0a5cb8384" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8f0e1c4e-356a-498f-a239-e340f7689874" xlink:to="loc_dei_EntityRegistrantName_0465132f-8727-49de-9aa3-2fa0a5cb8384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_76b8dfcb-bbe4-4680-9c96-63cd335d9eb2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8f0e1c4e-356a-498f-a239-e340f7689874" xlink:to="loc_dei_EntityCentralIndexKey_76b8dfcb-bbe4-4680-9c96-63cd335d9eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_424e8f77-f2cd-4b0b-b893-044e43a4e586" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8f0e1c4e-356a-498f-a239-e340f7689874" xlink:to="loc_dei_CurrentFiscalYearEndDate_424e8f77-f2cd-4b0b-b893-044e43a4e586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_81ca395a-819d-4ae3-85ee-7e66a7891afe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8f0e1c4e-356a-498f-a239-e340f7689874" xlink:to="loc_dei_DocumentFiscalYearFocus_81ca395a-819d-4ae3-85ee-7e66a7891afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_afaa70ec-6ef2-4b57-a657-4204a4db7ba8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8f0e1c4e-356a-498f-a239-e340f7689874" xlink:to="loc_dei_DocumentFiscalPeriodFocus_afaa70ec-6ef2-4b57-a657-4204a4db7ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_b432b678-d3f9-45d6-a0d3-accdebb7993d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8f0e1c4e-356a-498f-a239-e340f7689874" xlink:to="loc_dei_AmendmentFlag_b432b678-d3f9-45d6-a0d3-accdebb7993d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_f509fba4-495b-4c14-8e23-8bc21995348f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8f0e1c4e-356a-498f-a239-e340f7689874" xlink:to="loc_dei_EntityIncorporationStateCountryCode_f509fba4-495b-4c14-8e23-8bc21995348f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_3201e826-8851-4995-aa7f-8247f841bbc5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8f0e1c4e-356a-498f-a239-e340f7689874" xlink:to="loc_dei_EntityTaxIdentificationNumber_3201e826-8851-4995-aa7f-8247f841bbc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_a44427b0-5b67-4c91-9600-e221002b2fe9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8f0e1c4e-356a-498f-a239-e340f7689874" xlink:to="loc_dei_EntityAddressAddressLine1_a44427b0-5b67-4c91-9600-e221002b2fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_b9f45fe8-c582-4bd7-8352-6e746c7bfd9c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8f0e1c4e-356a-498f-a239-e340f7689874" xlink:to="loc_dei_EntityAddressCityOrTown_b9f45fe8-c582-4bd7-8352-6e746c7bfd9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_8d53924d-f97c-457e-9bd7-de9e5eb77e72" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8f0e1c4e-356a-498f-a239-e340f7689874" xlink:to="loc_dei_EntityAddressStateOrProvince_8d53924d-f97c-457e-9bd7-de9e5eb77e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_0af2e7ac-990c-45f9-bfd8-6af0a81d9b5f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8f0e1c4e-356a-498f-a239-e340f7689874" xlink:to="loc_dei_EntityAddressPostalZipCode_0af2e7ac-990c-45f9-bfd8-6af0a81d9b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_e60c0da7-fabd-4f1f-952a-7e38bc5e7db8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8f0e1c4e-356a-498f-a239-e340f7689874" xlink:to="loc_dei_CityAreaCode_e60c0da7-fabd-4f1f-952a-7e38bc5e7db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_e66bcb4f-9417-4b6c-bb33-0882318f6c04" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8f0e1c4e-356a-498f-a239-e340f7689874" xlink:to="loc_dei_LocalPhoneNumber_e66bcb4f-9417-4b6c-bb33-0882318f6c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_62b99ac7-af29-465e-ad21-5e0005f30214" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8f0e1c4e-356a-498f-a239-e340f7689874" xlink:to="loc_dei_Security12bTitle_62b99ac7-af29-465e-ad21-5e0005f30214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_3c0f39d1-4d28-400b-8d99-055e53151101" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8f0e1c4e-356a-498f-a239-e340f7689874" xlink:to="loc_dei_TradingSymbol_3c0f39d1-4d28-400b-8d99-055e53151101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_000edc1f-4cd2-47f1-a80c-732701152511" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8f0e1c4e-356a-498f-a239-e340f7689874" xlink:to="loc_dei_SecurityExchangeName_000edc1f-4cd2-47f1-a80c-732701152511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_dfb423e5-8c21-45d9-91b5-19e94eece1c0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8f0e1c4e-356a-498f-a239-e340f7689874" xlink:to="loc_dei_EntityCurrentReportingStatus_dfb423e5-8c21-45d9-91b5-19e94eece1c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_49686d88-0359-4d38-b700-28f5c848552b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8f0e1c4e-356a-498f-a239-e340f7689874" xlink:to="loc_dei_EntityInteractiveDataCurrent_49686d88-0359-4d38-b700-28f5c848552b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_4e0b1dbb-c845-431b-9540-317c0604c15e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8f0e1c4e-356a-498f-a239-e340f7689874" xlink:to="loc_dei_EntityFilerCategory_4e0b1dbb-c845-431b-9540-317c0604c15e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_f93c4afe-6041-4703-9731-2f7572b45d6f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8f0e1c4e-356a-498f-a239-e340f7689874" xlink:to="loc_dei_EntitySmallBusiness_f93c4afe-6041-4703-9731-2f7572b45d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_62dd52c7-81ec-4049-8bba-33179ff0d057" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8f0e1c4e-356a-498f-a239-e340f7689874" xlink:to="loc_dei_EntityEmergingGrowthCompany_62dd52c7-81ec-4049-8bba-33179ff0d057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_ca8b90bb-abbd-4507-af21-ac09defca5d2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8f0e1c4e-356a-498f-a239-e340f7689874" xlink:to="loc_dei_EntityShellCompany_ca8b90bb-abbd-4507-af21-ac09defca5d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_961b3d58-a0a7-4c5e-8e07-2332e24e81eb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8f0e1c4e-356a-498f-a239-e340f7689874" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_961b3d58-a0a7-4c5e-8e07-2332e24e81eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="cah-20220331.xsd#CondensedConsolidatedStatementsofEarnings"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_15063324-7326-41ca-b3b9-a9f6076bc8ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_1b009803-b2e8-45d6-882b-c9b33e10d37d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_15063324-7326-41ca-b3b9-a9f6076bc8ba" xlink:to="loc_us-gaap_Revenues_1b009803-b2e8-45d6-882b-c9b33e10d37d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_a5ee9eb7-086e-4c41-b15f-322c3f695002" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_15063324-7326-41ca-b3b9-a9f6076bc8ba" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_a5ee9eb7-086e-4c41-b15f-322c3f695002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_24f18b56-82c4-4cab-ab52-0e79eec95e34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_15063324-7326-41ca-b3b9-a9f6076bc8ba" xlink:to="loc_us-gaap_GrossProfit_24f18b56-82c4-4cab-ab52-0e79eec95e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_827bc1cb-cbec-4340-99d4-96403527d7a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_15063324-7326-41ca-b3b9-a9f6076bc8ba" xlink:to="loc_us-gaap_OperatingExpensesAbstract_827bc1cb-cbec-4340-99d4-96403527d7a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ba4a8d80-cd61-4997-9b58-5cc8df36c200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_827bc1cb-cbec-4340-99d4-96403527d7a2" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ba4a8d80-cd61-4997-9b58-5cc8df36c200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_671193f7-a371-4237-b1fb-625acc5ad17a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_827bc1cb-cbec-4340-99d4-96403527d7a2" xlink:to="loc_us-gaap_RestructuringCharges_671193f7-a371-4237-b1fb-625acc5ad17a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Amortizationandotheracquisitionrelatedcosts_9e2997fa-94d6-421b-8018-4a5bac0c8df9" xlink:href="cah-20220331.xsd#cah_Amortizationandotheracquisitionrelatedcosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_827bc1cb-cbec-4340-99d4-96403527d7a2" xlink:to="loc_cah_Amortizationandotheracquisitionrelatedcosts_9e2997fa-94d6-421b-8018-4a5bac0c8df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_a5d65280-66bb-4009-b37a-59815cf0467c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_827bc1cb-cbec-4340-99d4-96403527d7a2" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_a5d65280-66bb-4009-b37a-59815cf0467c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_162cfe44-7655-4213-b384-7d169deeac00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_827bc1cb-cbec-4340-99d4-96403527d7a2" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_162cfe44-7655-4213-b384-7d169deeac00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0b99575c-f422-4adb-a130-b540e26b803c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_15063324-7326-41ca-b3b9-a9f6076bc8ba" xlink:to="loc_us-gaap_OperatingIncomeLoss_0b99575c-f422-4adb-a130-b540e26b803c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_5e4c31d2-1ec4-4d5e-bea7-d624a50803e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_15063324-7326-41ca-b3b9-a9f6076bc8ba" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_5e4c31d2-1ec4-4d5e-bea7-d624a50803e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_c0586c7f-ec6a-44ce-ba26-ec1780a42d74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_15063324-7326-41ca-b3b9-a9f6076bc8ba" xlink:to="loc_us-gaap_InterestExpense_c0586c7f-ec6a-44ce-ba26-ec1780a42d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_e1e5ff37-1a50-43e4-9aaa-d864326a261b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_15063324-7326-41ca-b3b9-a9f6076bc8ba" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_e1e5ff37-1a50-43e4-9aaa-d864326a261b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_2a0235fa-563b-48ef-a018-b3e3375b4628" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_15063324-7326-41ca-b3b9-a9f6076bc8ba" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_2a0235fa-563b-48ef-a018-b3e3375b4628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2ef4654b-0dcc-4cda-b4ca-f2be936236b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_15063324-7326-41ca-b3b9-a9f6076bc8ba" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2ef4654b-0dcc-4cda-b4ca-f2be936236b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9694ddf2-86c4-4adc-a56e-f85b4bf0be40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_15063324-7326-41ca-b3b9-a9f6076bc8ba" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9694ddf2-86c4-4adc-a56e-f85b4bf0be40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_64cea5fc-30ae-47e4-9d2c-b27c4591f12d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_15063324-7326-41ca-b3b9-a9f6076bc8ba" xlink:to="loc_us-gaap_ProfitLoss_64cea5fc-30ae-47e4-9d2c-b27c4591f12d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_43c3e6b0-16c7-45dd-aae8-7735e1b30d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_15063324-7326-41ca-b3b9-a9f6076bc8ba" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_43c3e6b0-16c7-45dd-aae8-7735e1b30d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_86f9929f-454f-46c6-b668-b8be1ef4a6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_15063324-7326-41ca-b3b9-a9f6076bc8ba" xlink:to="loc_us-gaap_NetIncomeLoss_86f9929f-454f-46c6-b668-b8be1ef4a6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_146ae525-ffd2-435d-9f69-fab7bcc5a1fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_15063324-7326-41ca-b3b9-a9f6076bc8ba" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_146ae525-ffd2-435d-9f69-fab7bcc5a1fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_67587bff-4a55-4d76-8085-71acc6af93c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_146ae525-ffd2-435d-9f69-fab7bcc5a1fa" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_67587bff-4a55-4d76-8085-71acc6af93c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_4621b568-9d60-4fb0-a4eb-457a9571ed69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_146ae525-ffd2-435d-9f69-fab7bcc5a1fa" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_4621b568-9d60-4fb0-a4eb-457a9571ed69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_aae5716a-b7fd-4efa-9298-d4b6bacd4ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_15063324-7326-41ca-b3b9-a9f6076bc8ba" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_aae5716a-b7fd-4efa-9298-d4b6bacd4ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_b52e89c8-3eb7-4e3c-8d2b-fee65082b640" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_15063324-7326-41ca-b3b9-a9f6076bc8ba" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_b52e89c8-3eb7-4e3c-8d2b-fee65082b640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2e32ee6f-277d-4e62-abe3-0b6870e0d7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_b52e89c8-3eb7-4e3c-8d2b-fee65082b640" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2e32ee6f-277d-4e62-abe3-0b6870e0d7f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3716c998-7f9e-4958-8308-7d7927629bad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_b52e89c8-3eb7-4e3c-8d2b-fee65082b640" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3716c998-7f9e-4958-8308-7d7927629bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_65723e61-3b69-42b8-9f7f-9caff29048c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_15063324-7326-41ca-b3b9-a9f6076bc8ba" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_65723e61-3b69-42b8-9f7f-9caff29048c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="cah-20220331.xsd#CondensedConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8488d06a-35ea-45d0-8e64-9225d0a93d79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d2f67fce-c37c-44ed-877a-2b2b5ca2accd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8488d06a-35ea-45d0-8e64-9225d0a93d79" xlink:to="loc_us-gaap_ProfitLoss_d2f67fce-c37c-44ed-877a-2b2b5ca2accd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a47d13a1-aee2-48e5-b417-536ba616107a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8488d06a-35ea-45d0-8e64-9225d0a93d79" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a47d13a1-aee2-48e5-b417-536ba616107a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_f111a565-2d6e-44dd-8c0a-4c1d5dc6bf8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a47d13a1-aee2-48e5-b417-536ba616107a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_f111a565-2d6e-44dd-8c0a-4c1d5dc6bf8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_64b695e4-68e2-437c-ba49-46013cfc5148" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a47d13a1-aee2-48e5-b417-536ba616107a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_64b695e4-68e2-437c-ba49-46013cfc5148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_91361387-4652-40ae-a4ae-0f9d1b463b05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a47d13a1-aee2-48e5-b417-536ba616107a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_91361387-4652-40ae-a4ae-0f9d1b463b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_72f32f10-bcd8-48bd-aba0-df9b4ca72db8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8488d06a-35ea-45d0-8e64-9225d0a93d79" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_72f32f10-bcd8-48bd-aba0-df9b4ca72db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_ade6741f-0aff-444e-a0f5-f58f5d137b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8488d06a-35ea-45d0-8e64-9225d0a93d79" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_ade6741f-0aff-444e-a0f5-f58f5d137b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_a56b172b-d21c-4367-9602-4b7c2ed12cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8488d06a-35ea-45d0-8e64-9225d0a93d79" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_a56b172b-d21c-4367-9602-4b7c2ed12cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cah-20220331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_9514b689-6a2e-4a01-a470-8f018eda27bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_f5466776-36bf-4f63-81b3-eba6d92bd92a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9514b689-6a2e-4a01-a470-8f018eda27bc" xlink:to="loc_us-gaap_AssetsAbstract_f5466776-36bf-4f63-81b3-eba6d92bd92a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_82f5e3d9-d884-40c5-83bd-1d6e0e6aee27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f5466776-36bf-4f63-81b3-eba6d92bd92a" xlink:to="loc_us-gaap_AssetsCurrentAbstract_82f5e3d9-d884-40c5-83bd-1d6e0e6aee27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0b2470ca-5155-4d48-ba0e-f1e38fabc46b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_82f5e3d9-d884-40c5-83bd-1d6e0e6aee27" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0b2470ca-5155-4d48-ba0e-f1e38fabc46b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_2798ff13-e691-4e0c-a105-3bf9c9ec05dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_82f5e3d9-d884-40c5-83bd-1d6e0e6aee27" xlink:to="loc_us-gaap_ReceivablesNetCurrent_2798ff13-e691-4e0c-a105-3bf9c9ec05dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_ed9c93d1-8b0c-4014-979b-4ff1fbf24c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_82f5e3d9-d884-40c5-83bd-1d6e0e6aee27" xlink:to="loc_us-gaap_InventoryNet_ed9c93d1-8b0c-4014-979b-4ff1fbf24c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_3e3458c6-f36a-4b52-8142-0282684d0067" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_82f5e3d9-d884-40c5-83bd-1d6e0e6aee27" xlink:to="loc_us-gaap_OtherAssetsCurrent_3e3458c6-f36a-4b52-8142-0282684d0067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_8c5ef248-4413-4441-935e-68884b2eb537" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_82f5e3d9-d884-40c5-83bd-1d6e0e6aee27" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_8c5ef248-4413-4441-935e-68884b2eb537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9ae74332-c3cc-44f9-a0d7-a83b8cbb3bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_82f5e3d9-d884-40c5-83bd-1d6e0e6aee27" xlink:to="loc_us-gaap_AssetsCurrent_9ae74332-c3cc-44f9-a0d7-a83b8cbb3bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_cc192140-e7ab-45e0-b3f2-cba57320d4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f5466776-36bf-4f63-81b3-eba6d92bd92a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_cc192140-e7ab-45e0-b3f2-cba57320d4ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_6dc88878-2a6c-46bc-99b0-2beb42044ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f5466776-36bf-4f63-81b3-eba6d92bd92a" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_6dc88878-2a6c-46bc-99b0-2beb42044ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_be7f2350-d17d-4c40-b18b-4e9c37e65a54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f5466776-36bf-4f63-81b3-eba6d92bd92a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_be7f2350-d17d-4c40-b18b-4e9c37e65a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_28d33e1b-dc64-4ad3-85ae-389d08f71e70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f5466776-36bf-4f63-81b3-eba6d92bd92a" xlink:to="loc_us-gaap_Assets_28d33e1b-dc64-4ad3-85ae-389d08f71e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_07913a70-e950-42aa-a737-d1821140001c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9514b689-6a2e-4a01-a470-8f018eda27bc" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_07913a70-e950-42aa-a737-d1821140001c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_9de6ab2d-c9d6-4dd3-af02-07f8fe43fa31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_07913a70-e950-42aa-a737-d1821140001c" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_9de6ab2d-c9d6-4dd3-af02-07f8fe43fa31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_7e66c693-99a9-49e0-8914-2092f1d263a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9de6ab2d-c9d6-4dd3-af02-07f8fe43fa31" xlink:to="loc_us-gaap_AccountsPayableCurrent_7e66c693-99a9-49e0-8914-2092f1d263a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_19382fc3-5d20-456d-af8d-1d6163c836d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9de6ab2d-c9d6-4dd3-af02-07f8fe43fa31" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_19382fc3-5d20-456d-af8d-1d6163c836d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0f3d845d-9716-4ae5-b824-403f09005175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9de6ab2d-c9d6-4dd3-af02-07f8fe43fa31" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0f3d845d-9716-4ae5-b824-403f09005175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_84599b7c-eced-44b5-aafb-9eb4d42eeb2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9de6ab2d-c9d6-4dd3-af02-07f8fe43fa31" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_84599b7c-eced-44b5-aafb-9eb4d42eeb2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7f6f6f56-34cd-4b1c-917d-43370a7c8cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9de6ab2d-c9d6-4dd3-af02-07f8fe43fa31" xlink:to="loc_us-gaap_LiabilitiesCurrent_7f6f6f56-34cd-4b1c-917d-43370a7c8cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_4da3adf3-c82f-4fed-8aca-58e6b85e42b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_07913a70-e950-42aa-a737-d1821140001c" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_4da3adf3-c82f-4fed-8aca-58e6b85e42b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_7ec47c22-cdc0-4fc0-b188-0f4c6eacbf76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_07913a70-e950-42aa-a737-d1821140001c" xlink:to="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_7ec47c22-cdc0-4fc0-b188-0f4c6eacbf76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_96d0b446-38cb-43dd-999f-3b36211553b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_07913a70-e950-42aa-a737-d1821140001c" xlink:to="loc_us-gaap_StockholdersEquityAbstract_96d0b446-38cb-43dd-999f-3b36211553b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_236c2e95-cea5-4977-9c61-5e6b2c4c5cb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_96d0b446-38cb-43dd-999f-3b36211553b7" xlink:to="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_236c2e95-cea5-4977-9c61-5e6b2c4c5cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_33a228aa-964b-4086-a396-d9758699e30d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_236c2e95-cea5-4977-9c61-5e6b2c4c5cb4" xlink:to="loc_us-gaap_PreferredStockValue_33a228aa-964b-4086-a396-d9758699e30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_6a48884b-ed34-43ed-a774-708703cca21d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_96d0b446-38cb-43dd-999f-3b36211553b7" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_6a48884b-ed34-43ed-a774-708703cca21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_af7690f9-3c1d-4233-849e-ba645d9e07dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_6a48884b-ed34-43ed-a774-708703cca21d" xlink:to="loc_us-gaap_CommonStockValue_af7690f9-3c1d-4233-849e-ba645d9e07dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_244877f8-904f-48d8-843b-44e8383d467f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_96d0b446-38cb-43dd-999f-3b36211553b7" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_244877f8-904f-48d8-843b-44e8383d467f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_0d98c811-9ce6-49d7-9608-6531fd63b463" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_96d0b446-38cb-43dd-999f-3b36211553b7" xlink:to="loc_us-gaap_TreasuryStockValue_0d98c811-9ce6-49d7-9608-6531fd63b463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_66c034a9-55e0-4893-9a6b-84b84c53dcb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_96d0b446-38cb-43dd-999f-3b36211553b7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_66c034a9-55e0-4893-9a6b-84b84c53dcb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f21e492d-d6a5-419c-9e07-64b5989b07b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_96d0b446-38cb-43dd-999f-3b36211553b7" xlink:to="loc_us-gaap_StockholdersEquity_f21e492d-d6a5-419c-9e07-64b5989b07b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_7483534b-107c-4cfe-b01c-58b1846dfcf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_96d0b446-38cb-43dd-999f-3b36211553b7" xlink:to="loc_us-gaap_MinorityInterest_7483534b-107c-4cfe-b01c-58b1846dfcf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6125d58c-b0cc-45c0-9ba3-fbd61de1dcfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_96d0b446-38cb-43dd-999f-3b36211553b7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6125d58c-b0cc-45c0-9ba3-fbd61de1dcfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_e1a11d9c-b7d9-4ca0-9f8e-75923ae0c8e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_07913a70-e950-42aa-a737-d1821140001c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_e1a11d9c-b7d9-4ca0-9f8e-75923ae0c8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_575b6c31-b0fb-406a-ac77-8e1d3ff31ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9514b689-6a2e-4a01-a470-8f018eda27bc" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_575b6c31-b0fb-406a-ac77-8e1d3ff31ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_5f958904-6cc7-42c7-8558-15784c42180a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9514b689-6a2e-4a01-a470-8f018eda27bc" xlink:to="loc_us-gaap_PreferredStockSharesIssued_5f958904-6cc7-42c7-8558-15784c42180a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_22047806-e507-40c3-90e1-5bb473f9bf91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9514b689-6a2e-4a01-a470-8f018eda27bc" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_22047806-e507-40c3-90e1-5bb473f9bf91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_f2bb6810-03de-4a82-a412-f9285c7d983d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9514b689-6a2e-4a01-a470-8f018eda27bc" xlink:to="loc_us-gaap_CommonStockSharesIssued_f2bb6810-03de-4a82-a412-f9285c7d983d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_1205bfab-46ed-4342-be2d-a2f451f1fcfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9514b689-6a2e-4a01-a470-8f018eda27bc" xlink:to="loc_us-gaap_TreasuryStockShares_1205bfab-46ed-4342-be2d-a2f451f1fcfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cah-20220331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_61ae58af-e31c-4286-90c0-6df01be42670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_d435b246-4bbf-428a-9f74-59a737e0b966" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_61ae58af-e31c-4286-90c0-6df01be42670" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_d435b246-4bbf-428a-9f74-59a737e0b966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_cafcb0b6-bc93-4c7c-9d69-a1646713fd50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_61ae58af-e31c-4286-90c0-6df01be42670" xlink:to="loc_us-gaap_PreferredStockSharesIssued_cafcb0b6-bc93-4c7c-9d69-a1646713fd50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_e99edcca-2de5-4229-ba4e-2720df7d6129" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_61ae58af-e31c-4286-90c0-6df01be42670" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_e99edcca-2de5-4229-ba4e-2720df7d6129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_0dffe1ee-b195-4e55-85be-1c6e1670d2c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_61ae58af-e31c-4286-90c0-6df01be42670" xlink:to="loc_us-gaap_CommonStockSharesIssued_0dffe1ee-b195-4e55-85be-1c6e1670d2c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_6d296359-305f-412e-972c-789dec022674" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_61ae58af-e31c-4286-90c0-6df01be42670" xlink:to="loc_us-gaap_TreasuryStockShares_6d296359-305f-412e-972c-789dec022674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="cah-20220331.xsd#CondensedConsolidatedStatementsofShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_34b087a3-e760-42dc-a3b2-be5a01dab456" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_920f5301-ab9f-4fd1-92aa-7fab822e55b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_34b087a3-e760-42dc-a3b2-be5a01dab456" xlink:to="loc_us-gaap_StatementTable_920f5301-ab9f-4fd1-92aa-7fab822e55b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f5e15a8c-50b9-4ccf-b2a7-54a946cce68a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_920f5301-ab9f-4fd1-92aa-7fab822e55b8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f5e15a8c-50b9-4ccf-b2a7-54a946cce68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e6cdc23e-d283-42cf-b069-3e484e29df6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f5e15a8c-50b9-4ccf-b2a7-54a946cce68a" xlink:to="loc_us-gaap_EquityComponentDomain_e6cdc23e-d283-42cf-b069-3e484e29df6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1d7c08f8-a2cd-40e9-ba30-787938f6c03f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e6cdc23e-d283-42cf-b069-3e484e29df6b" xlink:to="loc_us-gaap_CommonStockMember_1d7c08f8-a2cd-40e9-ba30-787938f6c03f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_3fca4ba7-fc62-4e11-bde4-ab1401d71a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e6cdc23e-d283-42cf-b069-3e484e29df6b" xlink:to="loc_us-gaap_RetainedEarningsMember_3fca4ba7-fc62-4e11-bde4-ab1401d71a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_f17d25e8-ee43-4810-9a85-0c01fe8cab4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e6cdc23e-d283-42cf-b069-3e484e29df6b" xlink:to="loc_us-gaap_TreasuryStockMember_f17d25e8-ee43-4810-9a85-0c01fe8cab4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a77773c0-9d39-4d07-9235-0356c83152d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e6cdc23e-d283-42cf-b069-3e484e29df6b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a77773c0-9d39-4d07-9235-0356c83152d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_c3ac6677-0302-492b-9c74-9bfe14ff3886" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e6cdc23e-d283-42cf-b069-3e484e29df6b" xlink:to="loc_us-gaap_NoncontrollingInterestMember_c3ac6677-0302-492b-9c74-9bfe14ff3886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4d9ee6af-2306-4826-bf49-1768968daa02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_920f5301-ab9f-4fd1-92aa-7fab822e55b8" xlink:to="loc_us-gaap_StatementLineItems_4d9ee6af-2306-4826-bf49-1768968daa02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_ae96a2d2-3ed3-4cf2-b377-764ebfd127db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4d9ee6af-2306-4826-bf49-1768968daa02" xlink:to="loc_us-gaap_CommonStockSharesIssued_ae96a2d2-3ed3-4cf2-b377-764ebfd127db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1ba7c23b-1741-49bf-98c6-ff3fa80c525b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4d9ee6af-2306-4826-bf49-1768968daa02" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1ba7c23b-1741-49bf-98c6-ff3fa80c525b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_c763019c-6f4d-4f2b-8e30-e4989f96540b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4d9ee6af-2306-4826-bf49-1768968daa02" xlink:to="loc_us-gaap_TreasuryStockShares_c763019c-6f4d-4f2b-8e30-e4989f96540b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_ff0c98c7-654d-42d2-939d-fc817757f3d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4d9ee6af-2306-4826-bf49-1768968daa02" xlink:to="loc_us-gaap_TreasuryStockValue_ff0c98c7-654d-42d2-939d-fc817757f3d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ecebcb6f-c273-43a3-b5fd-e94e58bb87b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4d9ee6af-2306-4826-bf49-1768968daa02" xlink:to="loc_us-gaap_ProfitLoss_ecebcb6f-c273-43a3-b5fd-e94e58bb87b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_53c9320e-6ed0-4d0f-bb0a-cd7f6ed1ea21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4d9ee6af-2306-4826-bf49-1768968daa02" xlink:to="loc_us-gaap_NetIncomeLoss_53c9320e-6ed0-4d0f-bb0a-cd7f6ed1ea21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1859e6c3-f974-44c1-a0f8-3f8493a16c67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4d9ee6af-2306-4826-bf49-1768968daa02" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1859e6c3-f974-44c1-a0f8-3f8493a16c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3e8974c3-1950-48e0-acc3-9d8c65190fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4d9ee6af-2306-4826-bf49-1768968daa02" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3e8974c3-1950-48e0-acc3-9d8c65190fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_78adea2c-3525-497f-ae39-6e495ab14ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4d9ee6af-2306-4826-bf49-1768968daa02" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_78adea2c-3525-497f-ae39-6e495ab14ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_153e9b7d-562d-4e51-8d39-769fe2802f81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4d9ee6af-2306-4826-bf49-1768968daa02" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_153e9b7d-562d-4e51-8d39-769fe2802f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_db671bbc-2a17-4a85-ac33-cd674f2b8f04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4d9ee6af-2306-4826-bf49-1768968daa02" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_db671bbc-2a17-4a85-ac33-cd674f2b8f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_a61c3dd8-8733-4c45-81d1-63bfa22252f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4d9ee6af-2306-4826-bf49-1768968daa02" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_a61c3dd8-8733-4c45-81d1-63bfa22252f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_22084a36-49a7-4376-9e1d-07d53f7f42f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4d9ee6af-2306-4826-bf49-1768968daa02" xlink:to="loc_us-gaap_Dividends_22084a36-49a7-4376-9e1d-07d53f7f42f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOtherShares_da7e73ba-54d9-47ad-9068-ee2f20077cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOtherShares"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4d9ee6af-2306-4826-bf49-1768968daa02" xlink:to="loc_us-gaap_StockholdersEquityOtherShares_da7e73ba-54d9-47ad-9068-ee2f20077cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_b112e525-0bc3-4dfe-8a42-a92c99c5da48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4d9ee6af-2306-4826-bf49-1768968daa02" xlink:to="loc_us-gaap_StockholdersEquityOther_b112e525-0bc3-4dfe-8a42-a92c99c5da48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_e2052b2d-47a5-4a6d-8eb6-2e4e09337443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4d9ee6af-2306-4826-bf49-1768968daa02" xlink:to="loc_us-gaap_CommonStockSharesIssued_e2052b2d-47a5-4a6d-8eb6-2e4e09337443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8f05a75e-3d7f-4afd-9640-cca9a0371a74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4d9ee6af-2306-4826-bf49-1768968daa02" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8f05a75e-3d7f-4afd-9640-cca9a0371a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_049a1603-8c80-4c04-9d93-ea3be87351da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4d9ee6af-2306-4826-bf49-1768968daa02" xlink:to="loc_us-gaap_TreasuryStockShares_049a1603-8c80-4c04-9d93-ea3be87351da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_b5710ca9-17b7-4b84-910e-d37316dc33d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4d9ee6af-2306-4826-bf49-1768968daa02" xlink:to="loc_us-gaap_TreasuryStockValue_b5710ca9-17b7-4b84-910e-d37316dc33d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_34676ea7-e1d5-4541-a108-d0d5cc03781f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4d9ee6af-2306-4826-bf49-1768968daa02" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_34676ea7-e1d5-4541-a108-d0d5cc03781f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cah-20220331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_6eade78a-5ea3-4d39-bd71-dc02bf84ef02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cbfeaa76-08e3-4840-b474-9c08b30c37f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6eade78a-5ea3-4d39-bd71-dc02bf84ef02" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cbfeaa76-08e3-4840-b474-9c08b30c37f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_310b5495-a626-477c-914b-c690eb8692a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cbfeaa76-08e3-4840-b474-9c08b30c37f4" xlink:to="loc_us-gaap_ProfitLoss_310b5495-a626-477c-914b-c690eb8692a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a564406-e783-43b4-b3c4-0c2ffe01b660" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cbfeaa76-08e3-4840-b474-9c08b30c37f4" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a564406-e783-43b4-b3c4-0c2ffe01b660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_37822c9b-b9c9-4a25-93fa-9347eeeaeaf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a564406-e783-43b4-b3c4-0c2ffe01b660" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_37822c9b-b9c9-4a25-93fa-9347eeeaeaf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_af5eed53-c764-4e2c-837f-ae1ce299148d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfOtherInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a564406-e783-43b4-b3c4-0c2ffe01b660" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherInvestments_af5eed53-c764-4e2c-837f-ae1ce299148d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_013731b6-266b-402f-a318-289e6bc99d60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a564406-e783-43b4-b3c4-0c2ffe01b660" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_013731b6-266b-402f-a318-289e6bc99d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_bee78b6b-d9f6-4b6d-839a-5c655419f845" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a564406-e783-43b4-b3c4-0c2ffe01b660" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_bee78b6b-d9f6-4b6d-839a-5c655419f845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6663545c-4e0a-4585-9db0-cb67fa8c79de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a564406-e783-43b4-b3c4-0c2ffe01b660" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6663545c-4e0a-4585-9db0-cb67fa8c79de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e400190e-ba06-465b-a92a-bf234dd078fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a564406-e783-43b4-b3c4-0c2ffe01b660" xlink:to="loc_us-gaap_ShareBasedCompensation_e400190e-ba06-465b-a92a-bf234dd078fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_5afa6e14-0f28-48c1-a18a-55a0a9b5c3b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a564406-e783-43b4-b3c4-0c2ffe01b660" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_5afa6e14-0f28-48c1-a18a-55a0a9b5c3b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fd4fb172-4c3d-4a4d-a455-76e7b0a4a26d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a564406-e783-43b4-b3c4-0c2ffe01b660" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fd4fb172-4c3d-4a4d-a455-76e7b0a4a26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_96bac4ef-c153-404d-9624-42e37497d32e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fd4fb172-4c3d-4a4d-a455-76e7b0a4a26d" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_96bac4ef-c153-404d-9624-42e37497d32e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_5224fb88-303d-45aa-800a-fe6e7aa59c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fd4fb172-4c3d-4a4d-a455-76e7b0a4a26d" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_5224fb88-303d-45aa-800a-fe6e7aa59c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_697304b6-8ad9-4c07-acea-4acb589f5a55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fd4fb172-4c3d-4a4d-a455-76e7b0a4a26d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_697304b6-8ad9-4c07-acea-4acb589f5a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_64052c9b-27b3-4a1a-bb6a-5ab2a910b867" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fd4fb172-4c3d-4a4d-a455-76e7b0a4a26d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_64052c9b-27b3-4a1a-bb6a-5ab2a910b867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_524b482f-f6c6-4122-a3c9-04895b3bf219" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cbfeaa76-08e3-4840-b474-9c08b30c37f4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_524b482f-f6c6-4122-a3c9-04895b3bf219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_df504275-c096-4558-94c2-67612241138e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6eade78a-5ea3-4d39-bd71-dc02bf84ef02" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_df504275-c096-4558-94c2-67612241138e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets_58290b15-34d4-486d-af9c-d97f2511fd8c" xlink:href="cah-20220331.xsd#cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_df504275-c096-4558-94c2-67612241138e" xlink:to="loc_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets_58290b15-34d4-486d-af9c-d97f2511fd8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_e06a3de2-3741-4d76-9515-53937a2b9058" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_df504275-c096-4558-94c2-67612241138e" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_e06a3de2-3741-4d76-9515-53937a2b9058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_033517ad-85a3-4131-a70a-fcb5c7423682" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_df504275-c096-4558-94c2-67612241138e" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_033517ad-85a3-4131-a70a-fcb5c7423682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_c3ac1185-0fab-4c46-9977-3bcd23ab05c0" xlink:href="cah-20220331.xsd#cah_Purchaseofavailableforsalesecuritiesandotherinvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_df504275-c096-4558-94c2-67612241138e" xlink:to="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_c3ac1185-0fab-4c46-9977-3bcd23ab05c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_b0ff709f-98a9-4be1-8995-3974477e9284" xlink:href="cah-20220331.xsd#cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_df504275-c096-4558-94c2-67612241138e" xlink:to="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_b0ff709f-98a9-4be1-8995-3974477e9284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeInvestingActivities_d867a485-78f3-45c5-9e33-f6c97cdf61d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromHedgeInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_df504275-c096-4558-94c2-67612241138e" xlink:to="loc_us-gaap_ProceedsFromHedgeInvestingActivities_d867a485-78f3-45c5-9e33-f6c97cdf61d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c5cda3e3-1312-4142-9b85-4df718aa263f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_df504275-c096-4558-94c2-67612241138e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c5cda3e3-1312-4142-9b85-4df718aa263f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4fc5bbff-e388-4aea-9ff7-dae4ded6aa3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6eade78a-5ea3-4d39-bd71-dc02bf84ef02" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4fc5bbff-e388-4aea-9ff7-dae4ded6aa3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromHedgeFinancingActivities_ce21182a-135a-42eb-9aef-f0d8fad89398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromHedgeFinancingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4fc5bbff-e388-4aea-9ff7-dae4ded6aa3b" xlink:to="loc_us-gaap_PaymentsForProceedsFromHedgeFinancingActivities_ce21182a-135a-42eb-9aef-f0d8fad89398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_d6b379a4-c0e6-4d61-a17c-f4d37e6c240a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4fc5bbff-e388-4aea-9ff7-dae4ded6aa3b" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_d6b379a4-c0e6-4d61-a17c-f4d37e6c240a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_26fb09c0-5fe5-4a3f-8ad0-5a8c5c3e67bd" xlink:href="cah-20220331.xsd#cah_Netproceedstaxwithholdingsfromsharebasedcompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4fc5bbff-e388-4aea-9ff7-dae4ded6aa3b" xlink:to="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_26fb09c0-5fe5-4a3f-8ad0-5a8c5c3e67bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_b91e6c52-6579-4c71-9100-4efe0406fec9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4fc5bbff-e388-4aea-9ff7-dae4ded6aa3b" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_b91e6c52-6579-4c71-9100-4efe0406fec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_ef13602b-9c1d-4db7-b48d-77aee432aa97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4fc5bbff-e388-4aea-9ff7-dae4ded6aa3b" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_ef13602b-9c1d-4db7-b48d-77aee432aa97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1491fbcf-5f87-4d74-a722-4f9cd3fbe30d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4fc5bbff-e388-4aea-9ff7-dae4ded6aa3b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1491fbcf-5f87-4d74-a722-4f9cd3fbe30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_be0762fb-096f-4804-806c-b7ebe281e2d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4fc5bbff-e388-4aea-9ff7-dae4ded6aa3b" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_be0762fb-096f-4804-806c-b7ebe281e2d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CashReclassifiedToAssetHeldForSale_62a53dfa-b6a4-4191-a3e0-07f6b34c4771" xlink:href="cah-20220331.xsd#cah_CashReclassifiedToAssetHeldForSale"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6eade78a-5ea3-4d39-bd71-dc02bf84ef02" xlink:to="loc_cah_CashReclassifiedToAssetHeldForSale_62a53dfa-b6a4-4191-a3e0-07f6b34c4771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e733f0a9-d717-457a-ad98-0c80a7ce5e18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6eade78a-5ea3-4d39-bd71-dc02bf84ef02" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e733f0a9-d717-457a-ad98-0c80a7ce5e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8ac662de-0326-4916-8755-c25a2ed5f06d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6eade78a-5ea3-4d39-bd71-dc02bf84ef02" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8ac662de-0326-4916-8755-c25a2ed5f06d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d8b7ca81-c3a2-48ea-a8ba-df9a7208920d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6eade78a-5ea3-4d39-bd71-dc02bf84ef02" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d8b7ca81-c3a2-48ea-a8ba-df9a7208920d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="cah-20220331.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5cbde806-90cb-4bc9-a089-a8b18f42f021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_0c8be6b4-29e8-48b1-b4db-33900badcb4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5cbde806-90cb-4bc9-a089-a8b18f42f021" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_0c8be6b4-29e8-48b1-b4db-33900badcb4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="cah-20220331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_aa4d104d-c8c7-4401-adaf-23a5c9b02630" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6c4e3d6f-bf9c-433c-aa65-34d8a9678413" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aa4d104d-c8c7-4401-adaf-23a5c9b02630" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6c4e3d6f-bf9c-433c-aa65-34d8a9678413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_86d81933-eda2-4dad-b068-b9858c90a93c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aa4d104d-c8c7-4401-adaf-23a5c9b02630" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_86d81933-eda2-4dad-b068-b9858c90a93c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7273c55d-0294-456a-81e9-885bf9408dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/Divestitures" xlink:type="simple" xlink:href="cah-20220331.xsd#Divestitures"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/Divestitures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_81b68457-0574-4fd5-9d3c-d7573e16fe84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_b40f19c7-d8c8-468b-9fd9-8fd1ea5a909c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_81b68457-0574-4fd5-9d3c-d7573e16fe84" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_b40f19c7-d8c8-468b-9fd9-8fd1ea5a909c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsTables" xlink:type="simple" xlink:href="cah-20220331.xsd#DiscontinuedOperationsandDisposalGroupsTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_29a7b84c-84d4-4e22-bf70-faff8e7eaac7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#DiscontinuedOperationsandDisposalGroupsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_99c1b0ac-f39a-440b-8fb4-679bc56e833b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_bb334688-274f-447e-b1e6-b5fb179fb33d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_99c1b0ac-f39a-440b-8fb4-679bc56e833b" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_bb334688-274f-447e-b1e6-b5fb179fb33d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7f6ddcf4-f00f-4052-8e61-617487635e60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_bb334688-274f-447e-b1e6-b5fb179fb33d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7f6ddcf4-f00f-4052-8e61-617487635e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9f1def4d-b91d-4712-bac8-dae90634ccba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7f6ddcf4-f00f-4052-8e61-617487635e60" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9f1def4d-b91d-4712-bac8-dae90634ccba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_1083c0b8-b7c8-4157-8678-3756f13368ce" xlink:href="cah-20220331.xsd#cah_CordisDivestitureAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_bb334688-274f-447e-b1e6-b5fb179fb33d" xlink:to="loc_cah_CordisDivestitureAxis_1083c0b8-b7c8-4157-8678-3756f13368ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_7f2dcaad-3271-4715-8fdd-5afc7c0c88ef" xlink:href="cah-20220331.xsd#cah_CordisDivestitureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureAxis_1083c0b8-b7c8-4157-8678-3756f13368ce" xlink:to="loc_cah_CordisDivestitureDomain_7f2dcaad-3271-4715-8fdd-5afc7c0c88ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_d8109d45-da6e-47e5-9d46-f63b814ae35a" xlink:href="cah-20220331.xsd#cah_CordisDivestitureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureDomain_7f2dcaad-3271-4715-8fdd-5afc7c0c88ef" xlink:to="loc_cah_CordisDivestitureMember_d8109d45-da6e-47e5-9d46-f63b814ae35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c7fc58af-fa67-464e-bf28-ae8391833979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_bb334688-274f-447e-b1e6-b5fb179fb33d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c7fc58af-fa67-464e-bf28-ae8391833979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_764f2fb8-c819-44cc-8837-9c5b53b53b69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c7fc58af-fa67-464e-bf28-ae8391833979" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_764f2fb8-c819-44cc-8837-9c5b53b53b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeverance" xlink:type="simple" xlink:href="cah-20220331.xsd#RestructuringandEmployeeSeverance"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeverance" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_d0e84cff-d279-4666-b818-e6a3b31ea75b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_50e112d0-d094-414f-8e3d-56998674bb36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_d0e84cff-d279-4666-b818-e6a3b31ea75b" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_50e112d0-d094-414f-8e3d-56998674bb36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables" xlink:type="simple" xlink:href="cah-20220331.xsd#RestructuringandEmployeeSeveranceTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_06f1056f-009e-457a-b169-f90178efb28d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_fa9de103-da40-41f7-9488-d8c35fb87a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_06f1056f-009e-457a-b169-f90178efb28d" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_fa9de103-da40-41f7-9488-d8c35fb87a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_490a77eb-fbdb-4269-9819-6a1a1d8bfaeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_06f1056f-009e-457a-b169-f90178efb28d" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_490a77eb-fbdb-4269-9819-6a1a1d8bfaeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_9abfa4b2-582c-4dee-bfbf-0a63f7046ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_01d84ba7-170f-4586-80e2-c4994a95d6e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_9abfa4b2-582c-4dee-bfbf-0a63f7046ceb" xlink:to="loc_us-gaap_SeveranceCosts1_01d84ba7-170f-4586-80e2-c4994a95d6e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts_65684d5e-995f-4bbc-bc97-1a393c19651e" xlink:href="cah-20220331.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_9abfa4b2-582c-4dee-bfbf-0a63f7046ceb" xlink:to="loc_cah_FacilityExitAndOtherCosts_65684d5e-995f-4bbc-bc97-1a393c19651e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_10a2ab25-2b10-4b3e-9eb8-defbad68e63a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_9abfa4b2-582c-4dee-bfbf-0a63f7046ceb" xlink:to="loc_us-gaap_RestructuringCharges_10a2ab25-2b10-4b3e-9eb8-defbad68e63a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_987f1a25-d45e-448a-9af1-c78b6c5cae83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6dceffaa-39ea-44d1-af45-a5475732d19a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_987f1a25-d45e-448a-9af1-c78b6c5cae83" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6dceffaa-39ea-44d1-af45-a5475732d19a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_2903709f-8d3e-4c34-92b0-ef274fbc745e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6dceffaa-39ea-44d1-af45-a5475732d19a" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_2903709f-8d3e-4c34-92b0-ef274fbc745e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_97011ea7-ea55-45f6-84a9-d0e33027721f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_2903709f-8d3e-4c34-92b0-ef274fbc745e" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_97011ea7-ea55-45f6-84a9-d0e33027721f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_5e906129-72cb-45ff-a42f-c748a7601686" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_97011ea7-ea55-45f6-84a9-d0e33027721f" xlink:to="loc_us-gaap_EmployeeSeveranceMember_5e906129-72cb-45ff-a42f-c748a7601686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember_683cdc91-6c3d-4b7e-b564-3a22cf8a21e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FacilityClosingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_97011ea7-ea55-45f6-84a9-d0e33027721f" xlink:to="loc_us-gaap_FacilityClosingMember_683cdc91-6c3d-4b7e-b564-3a22cf8a21e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_c8777029-1354-429b-a997-e68e99127be5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6dceffaa-39ea-44d1-af45-a5475732d19a" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_c8777029-1354-429b-a997-e68e99127be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_fe126553-615b-45fb-b6fa-89b6834b91fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c8777029-1354-429b-a997-e68e99127be5" xlink:to="loc_us-gaap_RestructuringReserveRollForward_fe126553-615b-45fb-b6fa-89b6834b91fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_8c97a303-36d8-4eeb-a19a-987279d8e276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_fe126553-615b-45fb-b6fa-89b6834b91fd" xlink:to="loc_us-gaap_RestructuringReserve_8c97a303-36d8-4eeb-a19a-987279d8e276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts_b56540aa-5592-4855-9d3b-b170e14d86cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_fe126553-615b-45fb-b6fa-89b6834b91fd" xlink:to="loc_us-gaap_RestructuringCosts_b56540aa-5592-4855-9d3b-b170e14d86cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_58b11da0-0945-4bb3-b935-f2a219d5daab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_fe126553-615b-45fb-b6fa-89b6834b91fd" xlink:to="loc_us-gaap_PaymentsForRestructuring_58b11da0-0945-4bb3-b935-f2a219d5daab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_6e5e5df3-f221-4fa4-b063-cc53b619d17f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_fe126553-615b-45fb-b6fa-89b6834b91fd" xlink:to="loc_us-gaap_RestructuringReserve_6e5e5df3-f221-4fa4-b063-cc53b619d17f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#RestructuringandEmployeeSeveranceNarativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cah_NarativeAbstract_1984b661-b44c-401f-989a-c4453459ba96" xlink:href="cah-20220331.xsd#cah_NarativeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0185f001-532f-4857-8915-8afe571b796a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_NarativeAbstract_1984b661-b44c-401f-989a-c4453459ba96" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0185f001-532f-4857-8915-8afe571b796a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_67a15464-8826-4981-9508-078544f1e5d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0185f001-532f-4857-8915-8afe571b796a" xlink:to="loc_us-gaap_RestructuringPlanAxis_67a15464-8826-4981-9508-078544f1e5d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_c13be742-e221-48c6-80c1-a8ffe439ef2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_67a15464-8826-4981-9508-078544f1e5d5" xlink:to="loc_us-gaap_RestructuringPlanDomain_c13be742-e221-48c6-80c1-a8ffe439ef2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_874efa7c-a14e-4ded-b394-b40b96dbe989" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0185f001-532f-4857-8915-8afe571b796a" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_874efa7c-a14e-4ded-b394-b40b96dbe989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_56541126-7620-468e-8e0a-eb2a49a6307c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_874efa7c-a14e-4ded-b394-b40b96dbe989" xlink:to="loc_us-gaap_SeveranceCosts1_56541126-7620-468e-8e0a-eb2a49a6307c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts_7d0669f7-9217-4de9-8760-bb25d73ada7e" xlink:href="cah-20220331.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_874efa7c-a14e-4ded-b394-b40b96dbe989" xlink:to="loc_cah_FacilityExitAndOtherCosts_7d0669f7-9217-4de9-8760-bb25d73ada7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets" xlink:type="simple" xlink:href="cah-20220331.xsd#GoodwillandOtherIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_39f06377-cbd3-4aa2-8d2b-e6491e1a8341" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_cbe1f62a-60cb-4ae2-b528-2fbfe3452c17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_39f06377-cbd3-4aa2-8d2b-e6491e1a8341" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_cbe1f62a-60cb-4ae2-b528-2fbfe3452c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables" xlink:type="simple" xlink:href="cah-20220331.xsd#GoodwillandOtherIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2bba351b-8c11-4ee2-856b-612bf9838029" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_227e293c-c776-42b8-aad7-56edb4c54355" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2bba351b-8c11-4ee2-856b-612bf9838029" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_227e293c-c776-42b8-aad7-56edb4c54355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_0b96bc00-9d61-49e3-b886-1bac05f1b825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2bba351b-8c11-4ee2-856b-612bf9838029" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_0b96bc00-9d61-49e3-b886-1bac05f1b825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_aa3b2de7-724e-4af4-b3c4-f23cfea60fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_563460a0-d57e-4432-b56d-2557cffdf3e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_aa3b2de7-724e-4af4-b3c4-f23cfea60fe2" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_563460a0-d57e-4432-b56d-2557cffdf3e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_2752f9d3-b17a-4de1-aec0-c5a2a93ab442" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_563460a0-d57e-4432-b56d-2557cffdf3e0" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_2752f9d3-b17a-4de1-aec0-c5a2a93ab442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_bd321051-e9f3-46d3-9916-d6a9566f8f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2752f9d3-b17a-4de1-aec0-c5a2a93ab442" xlink:to="loc_us-gaap_SegmentDomain_bd321051-e9f3-46d3-9916-d6a9566f8f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_5bc8463b-58c1-4d98-981b-a10b24f563c7" xlink:href="cah-20220331.xsd#cah_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_bd321051-e9f3-46d3-9916-d6a9566f8f5b" xlink:to="loc_cah_PharmaceuticalMember_5bc8463b-58c1-4d98-981b-a10b24f563c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_0e37cd23-0a03-4873-9b46-3b069cc24b09" xlink:href="cah-20220331.xsd#cah_MedicalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_bd321051-e9f3-46d3-9916-d6a9566f8f5b" xlink:to="loc_cah_MedicalMember_0e37cd23-0a03-4873-9b46-3b069cc24b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_3298a960-b674-492f-887f-6cc335ea8c34" xlink:href="cah-20220331.xsd#cah_CordisDivestitureAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_563460a0-d57e-4432-b56d-2557cffdf3e0" xlink:to="loc_cah_CordisDivestitureAxis_3298a960-b674-492f-887f-6cc335ea8c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_ea08640f-5a5d-402b-a669-be5494da86ee" xlink:href="cah-20220331.xsd#cah_CordisDivestitureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureAxis_3298a960-b674-492f-887f-6cc335ea8c34" xlink:to="loc_cah_CordisDivestitureDomain_ea08640f-5a5d-402b-a669-be5494da86ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_d7845ac1-341e-4e4c-a79a-d59d4f695d2e" xlink:href="cah-20220331.xsd#cah_CordisDivestitureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureDomain_ea08640f-5a5d-402b-a669-be5494da86ee" xlink:to="loc_cah_CordisDivestitureMember_d7845ac1-341e-4e4c-a79a-d59d4f695d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_41515d92-c7d5-4678-a03e-5244833a6675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_563460a0-d57e-4432-b56d-2557cffdf3e0" xlink:to="loc_us-gaap_GoodwillLineItems_41515d92-c7d5-4678-a03e-5244833a6675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_84438e62-1d41-4732-b8cf-a4447647f523" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_41515d92-c7d5-4678-a03e-5244833a6675" xlink:to="loc_us-gaap_GoodwillRollForward_84438e62-1d41-4732-b8cf-a4447647f523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ac9010a7-793f-47e2-82cc-4b5c0adfa81b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_84438e62-1d41-4732-b8cf-a4447647f523" xlink:to="loc_us-gaap_Goodwill_ac9010a7-793f-47e2-82cc-4b5c0adfa81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_3a1d0af8-3475-43e7-a531-5f017f4e47c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_84438e62-1d41-4732-b8cf-a4447647f523" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_3a1d0af8-3475-43e7-a531-5f017f4e47c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_f7ca7ae7-8fd9-4ac1-8fcc-428a90b79c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_84438e62-1d41-4732-b8cf-a4447647f523" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_f7ca7ae7-8fd9-4ac1-8fcc-428a90b79c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_f828a3a3-1e10-47a7-a09a-dd432301948b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_84438e62-1d41-4732-b8cf-a4447647f523" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_f828a3a3-1e10-47a7-a09a-dd432301948b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_77b55242-831d-4f97-97a4-babb8b537371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_84438e62-1d41-4732-b8cf-a4447647f523" xlink:to="loc_us-gaap_Goodwill_77b55242-831d-4f97-97a4-babb8b537371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_7c089d84-973e-4ad6-8fda-fbdc67380c00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_41515d92-c7d5-4678-a03e-5244833a6675" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_7c089d84-973e-4ad6-8fda-fbdc67380c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e6acd5bc-e266-43cb-b7e6-2ec60fd707a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_9f672a81-5ee1-48e5-bdda-a9582f61b87b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e6acd5bc-e266-43cb-b7e6-2ec60fd707a4" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_9f672a81-5ee1-48e5-bdda-a9582f61b87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8167558a-3849-4088-b6af-db1271fd7e19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_9f672a81-5ee1-48e5-bdda-a9582f61b87b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8167558a-3849-4088-b6af-db1271fd7e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_69ed395e-9d25-40aa-91a0-74bf1dd1b298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8167558a-3849-4088-b6af-db1271fd7e19" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_69ed395e-9d25-40aa-91a0-74bf1dd1b298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IPRDTrademarksandOtherMember_984c6604-7d0b-4f52-ba8b-cce53009e446" xlink:href="cah-20220331.xsd#cah_IPRDTrademarksandOtherMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_69ed395e-9d25-40aa-91a0-74bf1dd1b298" xlink:to="loc_cah_IPRDTrademarksandOtherMember_984c6604-7d0b-4f52-ba8b-cce53009e446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_e0b6a1da-e9de-43a3-8dd7-a5dbf9777217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_9f672a81-5ee1-48e5-bdda-a9582f61b87b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_e0b6a1da-e9de-43a3-8dd7-a5dbf9777217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_d7a26c9b-002e-46f8-9d0b-bae4563d69ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_e0b6a1da-e9de-43a3-8dd7-a5dbf9777217" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_d7a26c9b-002e-46f8-9d0b-bae4563d69ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_690c5562-c8f2-4032-83ff-75d4932f1143" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e6acd5bc-e266-43cb-b7e6-2ec60fd707a4" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_690c5562-c8f2-4032-83ff-75d4932f1143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9c264c54-bbf6-4c90-bae6-744ec5f2194b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_690c5562-c8f2-4032-83ff-75d4932f1143" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9c264c54-bbf6-4c90-bae6-744ec5f2194b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c1844ebe-3021-479c-b995-4e3be19693a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9c264c54-bbf6-4c90-bae6-744ec5f2194b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c1844ebe-3021-479c-b995-4e3be19693a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_ad910104-4d61-42c0-8f9b-2016aac05a58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c1844ebe-3021-479c-b995-4e3be19693a7" xlink:to="loc_us-gaap_CustomerRelationshipsMember_ad910104-4d61-42c0-8f9b-2016aac05a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TrademarksAndPatentsMember_32d31008-b140-49f6-b1a0-0708bf228a04" xlink:href="cah-20220331.xsd#cah_TrademarksAndPatentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c1844ebe-3021-479c-b995-4e3be19693a7" xlink:to="loc_cah_TrademarksAndPatentsMember_32d31008-b140-49f6-b1a0-0708bf228a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_523fbb69-3ac3-4819-b8e6-8bf0575e871f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c1844ebe-3021-479c-b995-4e3be19693a7" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_523fbb69-3ac3-4819-b8e6-8bf0575e871f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2d44ce79-dbf6-4be2-b157-ec9e5c49c54b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_690c5562-c8f2-4032-83ff-75d4932f1143" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2d44ce79-dbf6-4be2-b157-ec9e5c49c54b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_77ca4578-a5a9-4a8e-9e4e-13266a317f37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2d44ce79-dbf6-4be2-b157-ec9e5c49c54b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_77ca4578-a5a9-4a8e-9e4e-13266a317f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0a38602c-7923-4d6a-a566-44ac8d91d3ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2d44ce79-dbf6-4be2-b157-ec9e5c49c54b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0a38602c-7923-4d6a-a566-44ac8d91d3ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2bbf2509-2c54-4ac0-875e-e547cbd65928" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2d44ce79-dbf6-4be2-b157-ec9e5c49c54b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2bbf2509-2c54-4ac0-875e-e547cbd65928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_3b464b69-2873-48f3-9f50-019753105499" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2d44ce79-dbf6-4be2-b157-ec9e5c49c54b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_3b464b69-2873-48f3-9f50-019753105499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_9244e90a-cc01-47e0-9005-eeb9d6a2260d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e6acd5bc-e266-43cb-b7e6-2ec60fd707a4" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_9244e90a-cc01-47e0-9005-eeb9d6a2260d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_e43db3f7-df32-4cfa-88fd-6acdb851d91e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e6acd5bc-e266-43cb-b7e6-2ec60fd707a4" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_e43db3f7-df32-4cfa-88fd-6acdb851d91e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#GoodwillandOtherIntangibleAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_394c3fc7-1b4e-4bd1-8e62-ac93f22308f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_157e708b-91f0-408b-888d-dcd690a3f8bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_394c3fc7-1b4e-4bd1-8e62-ac93f22308f4" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_157e708b-91f0-408b-888d-dcd690a3f8bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_fd87b106-e85f-4a2f-87d4-28a940dbbc41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_394c3fc7-1b4e-4bd1-8e62-ac93f22308f4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_fd87b106-e85f-4a2f-87d4-28a940dbbc41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6d2304df-a2c4-43eb-b0e4-b206c84e1340" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_394c3fc7-1b4e-4bd1-8e62-ac93f22308f4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6d2304df-a2c4-43eb-b0e4-b206c84e1340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_bb279703-668f-46c0-9345-21c21781ec4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_394c3fc7-1b4e-4bd1-8e62-ac93f22308f4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_bb279703-668f-46c0-9345-21c21781ec4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_d4783b33-2848-4318-931d-64c9688fd857" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_394c3fc7-1b4e-4bd1-8e62-ac93f22308f4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_d4783b33-2848-4318-931d-64c9688fd857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_cfcdf280-8559-49c0-b992-9c391b3b1994" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_394c3fc7-1b4e-4bd1-8e62-ac93f22308f4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_cfcdf280-8559-49c0-b992-9c391b3b1994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_c865eb11-f061-4316-9773-dd7a7ef3646d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_394c3fc7-1b4e-4bd1-8e62-ac93f22308f4" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_c865eb11-f061-4316-9773-dd7a7ef3646d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_d8ab273c-2879-4c9a-b674-9a25a73fd5a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_c865eb11-f061-4316-9773-dd7a7ef3646d" xlink:to="loc_us-gaap_ReportingUnitAxis_d8ab273c-2879-4c9a-b674-9a25a73fd5a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_1caf5c1d-cfd6-4e36-8275-d419c9a08d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_d8ab273c-2879-4c9a-b674-9a25a73fd5a6" xlink:to="loc_us-gaap_ReportingUnitDomain_1caf5c1d-cfd6-4e36-8275-d419c9a08d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_408c4d5e-4c18-4be0-964e-5194d8df7fe5" xlink:href="cah-20220331.xsd#cah_MedicalUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_1caf5c1d-cfd6-4e36-8275-d419c9a08d4a" xlink:to="loc_cah_MedicalUnitMember_408c4d5e-4c18-4be0-964e-5194d8df7fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_dd252a5b-96f8-414c-a081-91fde0328a19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_c865eb11-f061-4316-9773-dd7a7ef3646d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_dd252a5b-96f8-414c-a081-91fde0328a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3c7ecaf4-5773-4fb0-87b1-0335a358d853" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_dd252a5b-96f8-414c-a081-91fde0328a19" xlink:to="loc_us-gaap_SegmentDomain_3c7ecaf4-5773-4fb0-87b1-0335a358d853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_5b8a2f68-b831-448f-a563-c6fcb0b6c7cc" xlink:href="cah-20220331.xsd#cah_MedicalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3c7ecaf4-5773-4fb0-87b1-0335a358d853" xlink:to="loc_cah_MedicalMember_5b8a2f68-b831-448f-a563-c6fcb0b6c7cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentAxis_cb9e756a-967d-4d57-a205-1e0883bfdd2b" xlink:href="cah-20220331.xsd#cah_GoodwillImpairmentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_c865eb11-f061-4316-9773-dd7a7ef3646d" xlink:to="loc_cah_GoodwillImpairmentAxis_cb9e756a-967d-4d57-a205-1e0883bfdd2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentDomain_91e6d611-bb90-4899-99c7-b97200011986" xlink:href="cah-20220331.xsd#cah_GoodwillImpairmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_GoodwillImpairmentAxis_cb9e756a-967d-4d57-a205-1e0883bfdd2b" xlink:to="loc_cah_GoodwillImpairmentDomain_91e6d611-bb90-4899-99c7-b97200011986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_c638d509-24e8-427c-b89c-c60ff7738d65" xlink:href="cah-20220331.xsd#cah_MedicalUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_GoodwillImpairmentDomain_91e6d611-bb90-4899-99c7-b97200011986" xlink:to="loc_cah_MedicalUnitMember_c638d509-24e8-427c-b89c-c60ff7738d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_754a524a-800b-46df-8fc9-24e3cbd4fa5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_c865eb11-f061-4316-9773-dd7a7ef3646d" xlink:to="loc_us-gaap_GoodwillLineItems_754a524a-800b-46df-8fc9-24e3cbd4fa5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_70584c31-ee59-43d6-94f9-9c37e818e25d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_754a524a-800b-46df-8fc9-24e3cbd4fa5c" xlink:to="loc_us-gaap_Goodwill_70584c31-ee59-43d6-94f9-9c37e818e25d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_4d44cdad-931e-4939-8072-54e48d650008" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_754a524a-800b-46df-8fc9-24e3cbd4fa5c" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_4d44cdad-931e-4939-8072-54e48d650008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DiscountRateFairValueInput_b2082015-2dc1-43f3-8dfd-38fc36dd0b34" xlink:href="cah-20220331.xsd#cah_DiscountRateFairValueInput"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_754a524a-800b-46df-8fc9-24e3cbd4fa5c" xlink:to="loc_cah_DiscountRateFairValueInput_b2082015-2dc1-43f3-8dfd-38fc36dd0b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TerminalGrowthRateFairValueInput_de797fbc-39e4-4663-9ea8-2b05778bd32b" xlink:href="cah-20220331.xsd#cah_TerminalGrowthRateFairValueInput"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_754a524a-800b-46df-8fc9-24e3cbd4fa5c" xlink:to="loc_cah_TerminalGrowthRateFairValueInput_de797fbc-39e4-4663-9ea8-2b05778bd32b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings" xlink:type="simple" xlink:href="cah-20220331.xsd#LongTermObligationsandOtherShortTermBorrowings"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_8b45a085-d31c-4adc-ac61-c60f544acb2e" xlink:href="cah-20220331.xsd#cah_LongTermObligationsandOtherShortTermBorrowingsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_27889b22-c130-43af-b7d5-fa0bb93d42c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_8b45a085-d31c-4adc-ac61-c60f544acb2e" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_27889b22-c130-43af-b7d5-fa0bb93d42c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsTables" xlink:type="simple" xlink:href="cah-20220331.xsd#LongTermObligationsandOtherShortTermBorrowingsTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_e39728e5-820b-48d6-bee3-815cf43bd12d" xlink:href="cah-20220331.xsd#cah_LongTermObligationsandOtherShortTermBorrowingsAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#LongTermObligationsandOtherShortTermBorrowingsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_09210b55-0304-4be1-b2c2-173d75cf829d" xlink:href="cah-20220331.xsd#cah_LongTermObligationsandOtherShortTermBorrowingsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_f56aeda6-58ea-434b-9c45-cc6a5da82b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_09210b55-0304-4be1-b2c2-173d75cf829d" xlink:to="loc_us-gaap_DebtInstrumentTable_f56aeda6-58ea-434b-9c45-cc6a5da82b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a9dd8439-b5c1-456c-ad55-bde7088a1bae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f56aeda6-58ea-434b-9c45-cc6a5da82b5f" xlink:to="loc_us-gaap_DebtInstrumentAxis_a9dd8439-b5c1-456c-ad55-bde7088a1bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_92fcd9d0-d408-4156-91dc-c4bbe6e5284c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_a9dd8439-b5c1-456c-ad55-bde7088a1bae" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_92fcd9d0-d408-4156-91dc-c4bbe6e5284c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.616Notesdue2022Member_57fa9a9f-9b99-42c7-920f-f5fb50b32d0d" xlink:href="cah-20220331.xsd#cah_A2.616Notesdue2022Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_92fcd9d0-d408-4156-91dc-c4bbe6e5284c" xlink:to="loc_cah_A2.616Notesdue2022Member_57fa9a9f-9b99-42c7-920f-f5fb50b32d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember_5ce7381d-adf0-4ed5-b135-9ece8874ec74" xlink:href="cah-20220331.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_92fcd9d0-d408-4156-91dc-c4bbe6e5284c" xlink:to="loc_cah_CommittedReceivablesSalesFacilityProgramMember_5ce7381d-adf0-4ed5-b135-9ece8874ec74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FloatingRateNotesdue2022Member_3a8eac71-65e4-44ce-90a8-23a3d3ba4a02" xlink:href="cah-20220331.xsd#cah_FloatingRateNotesdue2022Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_92fcd9d0-d408-4156-91dc-c4bbe6e5284c" xlink:to="loc_cah_FloatingRateNotesdue2022Member_3a8eac71-65e4-44ce-90a8-23a3d3ba4a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_e7fdde95-5bf5-4901-9df8-49432db40275" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f56aeda6-58ea-434b-9c45-cc6a5da82b5f" xlink:to="loc_us-gaap_CreditFacilityAxis_e7fdde95-5bf5-4901-9df8-49432db40275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_80766d8c-93a0-4d10-9e9e-e12f0778eedc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_e7fdde95-5bf5-4901-9df8-49432db40275" xlink:to="loc_us-gaap_CreditFacilityDomain_80766d8c-93a0-4d10-9e9e-e12f0778eedc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_244a63fb-461c-4a2b-a544-a020696494ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_80766d8c-93a0-4d10-9e9e-e12f0778eedc" xlink:to="loc_us-gaap_CommercialPaperMember_244a63fb-461c-4a2b-a544-a020696494ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_c6cf4e72-8a1f-4fbc-90bd-22cc8ea4f7f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_80766d8c-93a0-4d10-9e9e-e12f0778eedc" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_c6cf4e72-8a1f-4fbc-90bd-22cc8ea4f7f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShortTermCreditFacilitiesMember_d1aa86fb-2d2e-4b1f-9dce-a0fda512fcee" xlink:href="cah-20220331.xsd#cah_ShortTermCreditFacilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_80766d8c-93a0-4d10-9e9e-e12f0778eedc" xlink:to="loc_cah_ShortTermCreditFacilitiesMember_d1aa86fb-2d2e-4b1f-9dce-a0fda512fcee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember_1d1f8339-f489-489d-8f47-1bf6e93c4de0" xlink:href="cah-20220331.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_80766d8c-93a0-4d10-9e9e-e12f0778eedc" xlink:to="loc_cah_CommittedReceivablesSalesFacilityProgramMember_1d1f8339-f489-489d-8f47-1bf6e93c4de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_059ce8d2-d1fb-4dc8-9ca5-5d76330a6d37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f56aeda6-58ea-434b-9c45-cc6a5da82b5f" xlink:to="loc_us-gaap_DebtInstrumentLineItems_059ce8d2-d1fb-4dc8-9ca5-5d76330a6d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalLongTermandShortTermObligations_094e127c-8d37-4707-95d7-e07f74f571dd" xlink:href="cah-20220331.xsd#cah_TotalLongTermandShortTermObligations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_059ce8d2-d1fb-4dc8-9ca5-5d76330a6d37" xlink:to="loc_cah_TotalLongTermandShortTermObligations_094e127c-8d37-4707-95d7-e07f74f571dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_c6b32cdd-f043-418f-8c57-e3421244a525" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_059ce8d2-d1fb-4dc8-9ca5-5d76330a6d37" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_c6b32cdd-f043-418f-8c57-e3421244a525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a4ef28b5-e5a8-4dda-8f32-467123517e19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_059ce8d2-d1fb-4dc8-9ca5-5d76330a6d37" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a4ef28b5-e5a8-4dda-8f32-467123517e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_b7c69fdf-2877-44dc-8cc0-8a06f7c9f89d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_059ce8d2-d1fb-4dc8-9ca5-5d76330a6d37" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_b7c69fdf-2877-44dc-8cc0-8a06f7c9f89d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_a41b5ce8-7917-49f3-99e9-e45f69c09eca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_059ce8d2-d1fb-4dc8-9ca5-5d76330a6d37" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_a41b5ce8-7917-49f3-99e9-e45f69c09eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermBorrowings_89a38c6f-6252-4dd3-94ec-4387d340e994" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermBorrowings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_059ce8d2-d1fb-4dc8-9ca5-5d76330a6d37" xlink:to="loc_us-gaap_OtherShortTermBorrowings_89a38c6f-6252-4dd3-94ec-4387d340e994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_4afc8cea-287f-4681-8125-c31d8de31965" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_059ce8d2-d1fb-4dc8-9ca5-5d76330a6d37" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_4afc8cea-287f-4681-8125-c31d8de31965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_b35e28d0-7367-4a0a-a008-9c8715af73d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAverageOutstandingAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_059ce8d2-d1fb-4dc8-9ca5-5d76330a6d37" xlink:to="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_b35e28d0-7367-4a0a-a008-9c8715af73d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d4abbae6-b909-4ac0-ad4d-f1ff217fbe7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_d004e6de-7e57-4c17-8b4c-a4d2eca60b58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d4abbae6-b909-4ac0-ad4d-f1ff217fbe7a" xlink:to="loc_us-gaap_DebtInstrumentTable_d004e6de-7e57-4c17-8b4c-a4d2eca60b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_100a7184-c606-4cc7-a45c-cbe3f7d3e314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d004e6de-7e57-4c17-8b4c-a4d2eca60b58" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_100a7184-c606-4cc7-a45c-cbe3f7d3e314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4471fb98-6eca-4cb9-836a-7b4bd4bc4e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_100a7184-c606-4cc7-a45c-cbe3f7d3e314" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4471fb98-6eca-4cb9-836a-7b4bd4bc4e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c67762a4-edbd-438b-9093-7aa12ffec363" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d004e6de-7e57-4c17-8b4c-a4d2eca60b58" xlink:to="loc_us-gaap_DebtInstrumentAxis_c67762a4-edbd-438b-9093-7aa12ffec363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_edb57655-6ef6-4aee-94fa-04eb347e2941" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_c67762a4-edbd-438b-9093-7aa12ffec363" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_edb57655-6ef6-4aee-94fa-04eb347e2941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.616Notesdue2022Member_9f0bf180-6118-4ac1-af0d-a28f940fa43d" xlink:href="cah-20220331.xsd#cah_A2.616Notesdue2022Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_edb57655-6ef6-4aee-94fa-04eb347e2941" xlink:to="loc_cah_A2.616Notesdue2022Member_9f0bf180-6118-4ac1-af0d-a28f940fa43d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FloatingRateNotesdue2022Member_687ff881-21ad-4f36-8a94-50ea651e17e7" xlink:href="cah-20220331.xsd#cah_FloatingRateNotesdue2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_edb57655-6ef6-4aee-94fa-04eb347e2941" xlink:to="loc_cah_FloatingRateNotesdue2022Member_687ff881-21ad-4f36-8a94-50ea651e17e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_865d7cf9-49c6-4f78-a549-9ae1bf1fecc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d004e6de-7e57-4c17-8b4c-a4d2eca60b58" xlink:to="loc_us-gaap_DebtInstrumentLineItems_865d7cf9-49c6-4f78-a549-9ae1bf1fecc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalLongTermandShortTermObligations_f2615682-20ca-45b0-86f0-504ca550ddc9" xlink:href="cah-20220331.xsd#cah_TotalLongTermandShortTermObligations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_865d7cf9-49c6-4f78-a549-9ae1bf1fecc9" xlink:to="loc_cah_TotalLongTermandShortTermObligations_f2615682-20ca-45b0-86f0-504ca550ddc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_39090efd-2f2a-4134-ac03-be4d8fe62d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_865d7cf9-49c6-4f78-a549-9ae1bf1fecc9" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_39090efd-2f2a-4134-ac03-be4d8fe62d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_ea6eee57-548f-450c-9dd3-1d0a4c3799bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_865d7cf9-49c6-4f78-a549-9ae1bf1fecc9" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_ea6eee57-548f-450c-9dd3-1d0a4c3799bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation" xlink:type="simple" xlink:href="cah-20220331.xsd#CommitmentsContingentLiabilitiesandLitigation"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2cb17c81-068d-4974-a699-ddb4c52ea2c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9212f229-852c-4d16-b2d6-c9ac54b13e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2cb17c81-068d-4974-a699-ddb4c52ea2c1" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9212f229-852c-4d16-b2d6-c9ac54b13e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#CommitmentsContingentLiabilitiesandLitigationDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c4e6877e-877a-4086-bf46-f459329427a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_c691539b-ca68-44d9-9c4d-6a5a38c8824a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c4e6877e-877a-4086-bf46-f459329427a5" xlink:to="loc_us-gaap_LossContingenciesTable_c691539b-ca68-44d9-9c4d-6a5a38c8824a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_56edc9ba-9e2c-4453-ad03-d9e586e2f969" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c691539b-ca68-44d9-9c4d-6a5a38c8824a" xlink:to="loc_srt_MajorCustomersAxis_56edc9ba-9e2c-4453-ad03-d9e586e2f969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_4fe7fe13-60d0-4a66-817a-4045d2ccf575" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_56edc9ba-9e2c-4453-ad03-d9e586e2f969" xlink:to="loc_srt_NameOfMajorCustomerDomain_4fe7fe13-60d0-4a66-817a-4045d2ccf575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CVSHealthMember_ee43aa36-b0bf-4aaa-941a-96b7799157ed" xlink:href="cah-20220331.xsd#cah_CVSHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_4fe7fe13-60d0-4a66-817a-4045d2ccf575" xlink:to="loc_cah_CVSHealthMember_ee43aa36-b0bf-4aaa-941a-96b7799157ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_31f4b215-3b17-4f22-b161-116779032b26" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c691539b-ca68-44d9-9c4d-6a5a38c8824a" xlink:to="loc_srt_LitigationCaseAxis_31f4b215-3b17-4f22-b161-116779032b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_1329071c-b758-4f83-b846-90cf4970cfb1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_31f4b215-3b17-4f22-b161-116779032b26" xlink:to="loc_srt_LitigationCaseTypeDomain_1329071c-b758-4f83-b846-90cf4970cfb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NewYorkOpioidStewardshipActMember_240ea4af-5907-475e-ba40-d86451931ac5" xlink:href="cah-20220331.xsd#cah_NewYorkOpioidStewardshipActMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_1329071c-b758-4f83-b846-90cf4970cfb1" xlink:to="loc_cah_NewYorkOpioidStewardshipActMember_240ea4af-5907-475e-ba40-d86451931ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember_a2803e3d-05ce-43bc-9a44-9839ca0abae7" xlink:href="cah-20220331.xsd#cah_OpioidLawsuitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_1329071c-b758-4f83-b846-90cf4970cfb1" xlink:to="loc_cah_OpioidLawsuitsMember_a2803e3d-05ce-43bc-9a44-9839ca0abae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsStateMember_612b0457-613b-4901-966d-1a66a69209c0" xlink:href="cah-20220331.xsd#cah_OpioidLawsuitsStateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_1329071c-b758-4f83-b846-90cf4970cfb1" xlink:to="loc_cah_OpioidLawsuitsStateMember_612b0457-613b-4901-966d-1a66a69209c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_a94191ee-86ec-4df3-bfd6-51b0164d5d06" xlink:href="cah-20220331.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_1329071c-b758-4f83-b846-90cf4970cfb1" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_a94191ee-86ec-4df3-bfd6-51b0164d5d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DOJInvestigationMember_32caba85-7a37-4246-ab65-f14d141ebf65" xlink:href="cah-20220331.xsd#cah_DOJInvestigationMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_1329071c-b758-4f83-b846-90cf4970cfb1" xlink:to="loc_cah_DOJInvestigationMember_32caba85-7a37-4246-ab65-f14d141ebf65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_385d4101-557a-4eb5-9f94-4a93ca2c6293" xlink:href="cah-20220331.xsd#cah_OpioidLitigationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c691539b-ca68-44d9-9c4d-6a5a38c8824a" xlink:to="loc_cah_OpioidLitigationAxis_385d4101-557a-4eb5-9f94-4a93ca2c6293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_a06a5e2f-4a84-4787-8131-bdeb99288d54" xlink:href="cah-20220331.xsd#cah_OpioidLitigationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationAxis_385d4101-557a-4eb5-9f94-4a93ca2c6293" xlink:to="loc_cah_OpioidLitigationDomain_a06a5e2f-4a84-4787-8131-bdeb99288d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_6dc0968b-c7d1-48c7-bba4-4470f1459e6b" xlink:href="cah-20220331.xsd#cah_TotalOpioidLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationDomain_a06a5e2f-4a84-4787-8131-bdeb99288d54" xlink:to="loc_cah_TotalOpioidLitigationMember_6dc0968b-c7d1-48c7-bba4-4470f1459e6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeAxis_a1f9f89c-3b4d-4656-b59d-779801dd65fe" xlink:href="cah-20220331.xsd#cah_LawsuitTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c691539b-ca68-44d9-9c4d-6a5a38c8824a" xlink:to="loc_cah_LawsuitTypeAxis_a1f9f89c-3b4d-4656-b59d-779801dd65fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeDomain_0347b3b3-fff1-47fc-9eb8-ceffbd8dd0eb" xlink:href="cah-20220331.xsd#cah_LawsuitTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_LawsuitTypeAxis_a1f9f89c-3b4d-4656-b59d-779801dd65fe" xlink:to="loc_cah_LawsuitTypeDomain_0347b3b3-fff1-47fc-9eb8-ceffbd8dd0eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ClassActionLawsuitsMember_7d3baafa-9e19-47d7-9008-194bdbac2bd5" xlink:href="cah-20220331.xsd#cah_ClassActionLawsuitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_LawsuitTypeDomain_0347b3b3-fff1-47fc-9eb8-ceffbd8dd0eb" xlink:to="loc_cah_ClassActionLawsuitsMember_7d3baafa-9e19-47d7-9008-194bdbac2bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_58d417ad-a2cf-425c-8eff-b01a04b2a037" xlink:href="cah-20220331.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_LawsuitTypeDomain_0347b3b3-fff1-47fc-9eb8-ceffbd8dd0eb" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_58d417ad-a2cf-425c-8eff-b01a04b2a037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeAxis_8d35c700-3db9-40e7-94b5-dca05dc0cfc8" xlink:href="cah-20220331.xsd#cah_PlaintiffTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c691539b-ca68-44d9-9c4d-6a5a38c8824a" xlink:to="loc_cah_PlaintiffTypeAxis_8d35c700-3db9-40e7-94b5-dca05dc0cfc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeDomain_46aa1b53-bdcd-4bd1-8799-e19f243db6ed" xlink:href="cah-20220331.xsd#cah_PlaintiffTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_PlaintiffTypeAxis_8d35c700-3db9-40e7-94b5-dca05dc0cfc8" xlink:to="loc_cah_PlaintiffTypeDomain_46aa1b53-bdcd-4bd1-8799-e19f243db6ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PrivatePartiesMember_a706e2ee-9284-4230-8c7f-f501402284e2" xlink:href="cah-20220331.xsd#cah_PrivatePartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_PlaintiffTypeDomain_46aa1b53-bdcd-4bd1-8799-e19f243db6ed" xlink:to="loc_cah_PrivatePartiesMember_a706e2ee-9284-4230-8c7f-f501402284e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_1a8b0dbc-f2db-469e-b939-55050db0e092" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c691539b-ca68-44d9-9c4d-6a5a38c8824a" xlink:to="loc_srt_StatementGeographicalAxis_1a8b0dbc-f2db-469e-b939-55050db0e092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_137f4820-e6c7-49e4-9e7a-552be5a8c96b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_1a8b0dbc-f2db-469e-b939-55050db0e092" xlink:to="loc_srt_SegmentGeographicalDomain_137f4820-e6c7-49e4-9e7a-552be5a8c96b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_GA_c91ae4c4-a01a-4d4d-b528-2c1a35f3b316" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_GA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_137f4820-e6c7-49e4-9e7a-552be5a8c96b" xlink:to="loc_stpr_GA_c91ae4c4-a01a-4d4d-b528-2c1a35f3b316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WV_2a7309da-2e2d-4dd7-967b-98d83f6f9fa2" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WV"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_137f4820-e6c7-49e4-9e7a-552be5a8c96b" xlink:to="loc_stpr_WV_2a7309da-2e2d-4dd7-967b-98d83f6f9fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WA_8830074d-8eb7-4193-9ee4-2cb3ce932ca7" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WA"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_137f4820-e6c7-49e4-9e7a-552be5a8c96b" xlink:to="loc_stpr_WA_8830074d-8eb7-4193-9ee4-2cb3ce932ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AlamedaCountyMember_8b18c5bc-0378-41e7-8eec-aea056b0ecc9" xlink:href="cah-20220331.xsd#cah_AlamedaCountyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_137f4820-e6c7-49e4-9e7a-552be5a8c96b" xlink:to="loc_cah_AlamedaCountyMember_8b18c5bc-0378-41e7-8eec-aea056b0ecc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OtherJurisdictionsMember_58a4254e-0f97-46d4-842e-96e3c9e9303f" xlink:href="cah-20220331.xsd#cah_OtherJurisdictionsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_137f4820-e6c7-49e4-9e7a-552be5a8c96b" xlink:to="loc_cah_OtherJurisdictionsMember_58a4254e-0f97-46d4-842e-96e3c9e9303f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7cdedaab-8bf8-4455-b92e-fe9f418b9a06" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c691539b-ca68-44d9-9c4d-6a5a38c8824a" xlink:to="loc_srt_RangeAxis_7cdedaab-8bf8-4455-b92e-fe9f418b9a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b9ad9c3f-869e-4f3e-b5ef-5d13e6e73506" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7cdedaab-8bf8-4455-b92e-fe9f418b9a06" xlink:to="loc_srt_RangeMember_b9ad9c3f-869e-4f3e-b5ef-5d13e6e73506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_59e41b56-7632-42c3-8021-89a642460305" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b9ad9c3f-869e-4f3e-b5ef-5d13e6e73506" xlink:to="loc_srt_MinimumMember_59e41b56-7632-42c3-8021-89a642460305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_aed5dea0-5f93-4715-9940-d1b9a2137eab" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b9ad9c3f-869e-4f3e-b5ef-5d13e6e73506" xlink:to="loc_srt_MaximumMember_aed5dea0-5f93-4715-9940-d1b9a2137eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_f7979af0-60d6-4485-9324-f739ae8dc737" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c691539b-ca68-44d9-9c4d-6a5a38c8824a" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_f7979af0-60d6-4485-9324-f739ae8dc737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_8730f1ba-fd39-4fba-8ab8-6585efa039e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_f7979af0-60d6-4485-9324-f739ae8dc737" xlink:to="loc_us-gaap_LossContingencyNatureDomain_8730f1ba-fd39-4fba-8ab8-6585efa039e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember_0eb6284d-790e-4f7e-a445-c8a4eecd6445" xlink:href="cah-20220331.xsd#cah_OpioidLawsuitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_8730f1ba-fd39-4fba-8ab8-6585efa039e3" xlink:to="loc_cah_OpioidLawsuitsMember_0eb6284d-790e-4f7e-a445-c8a4eecd6445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_0ba8afc8-b43f-40a6-97e9-50718a25807a" xlink:href="cah-20220331.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_8730f1ba-fd39-4fba-8ab8-6585efa039e3" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_0ba8afc8-b43f-40a6-97e9-50718a25807a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1239258a-b982-4ef8-84a5-4205e8958d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c691539b-ca68-44d9-9c4d-6a5a38c8824a" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1239258a-b982-4ef8-84a5-4205e8958d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_47f4d7cb-5e08-44a4-bba0-ba271645cbf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1239258a-b982-4ef8-84a5-4205e8958d1c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_47f4d7cb-5e08-44a4-bba0-ba271645cbf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_d2cd7ff3-82ff-48bd-b367-c56a62cfcd93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_47f4d7cb-5e08-44a4-bba0-ba271645cbf6" xlink:to="loc_us-gaap_SubsequentEventMember_d2cd7ff3-82ff-48bd-b367-c56a62cfcd93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_28278dcb-4714-46ab-a345-d84c5761c0c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c691539b-ca68-44d9-9c4d-6a5a38c8824a" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_28278dcb-4714-46ab-a345-d84c5761c0c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_afe16565-c6bc-4f31-82dd-ce5cd9bab4bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_28278dcb-4714-46ab-a345-d84c5761c0c8" xlink:to="loc_us-gaap_SegmentDomain_afe16565-c6bc-4f31-82dd-ce5cd9bab4bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_c165d777-f907-492e-922f-3bfd09bedd5d" xlink:href="cah-20220331.xsd#cah_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_afe16565-c6bc-4f31-82dd-ce5cd9bab4bf" xlink:to="loc_cah_PharmaceuticalMember_c165d777-f907-492e-922f-3bfd09bedd5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c691539b-ca68-44d9-9c4d-6a5a38c8824a" xlink:to="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod_94df7c5f-79ec-4bba-b53e-a3921eac3610" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:to="loc_us-gaap_LongtermPurchaseCommitmentPeriod_94df7c5f-79ec-4bba-b53e-a3921eac3610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AggregateAnnualAssessment_0b3e2a01-3d85-48dc-b057-6052d6083ba5" xlink:href="cah-20220331.xsd#cah_AggregateAnnualAssessment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:to="loc_cah_AggregateAnnualAssessment_0b3e2a01-3d85-48dc-b057-6052d6083ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_51d9f0c2-61a1-4375-bd4c-455e03b76f32" xlink:href="cah-20220331.xsd#cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:to="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_51d9f0c2-61a1-4375-bd4c-455e03b76f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments_a016a065-b7d3-4944-85ef-70b1547a0201" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:to="loc_us-gaap_LossContingencyAccrualPayments_a016a065-b7d3-4944-85ef-70b1547a0201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_07fad293-111b-482d-954c-5f473f95ad6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_07fad293-111b-482d-954c-5f473f95ad6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LossContingencyLawsuitsNumber_e106aa88-363e-4bcd-a53f-158746de17ca" xlink:href="cah-20220331.xsd#cah_LossContingencyLawsuitsNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:to="loc_cah_LossContingencyLawsuitsNumber_e106aa88-363e-4bcd-a53f-158746de17ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NumberofStateAttorneysGeneralfilinglawsuits_36987a76-0840-4af1-9027-1aa38fdde3e3" xlink:href="cah-20220331.xsd#cah_NumberofStateAttorneysGeneralfilinglawsuits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:to="loc_cah_NumberofStateAttorneysGeneralfilinglawsuits_36987a76-0840-4af1-9027-1aa38fdde3e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_65922a08-9229-401f-bf4d-d7253d4d732b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_65922a08-9229-401f-bf4d-d7253d4d732b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_97eaa1ed-22a4-4238-9f5a-5be12ccc87c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserve"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:to="loc_us-gaap_LitigationReserve_97eaa1ed-22a4-4238-9f5a-5be12ccc87c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_44b335dd-038c-45a9-9d6b-a4ad7e05aaa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:to="loc_us-gaap_LitigationReserveCurrent_44b335dd-038c-45a9-9d6b-a4ad7e05aaa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_8bdd2131-ad42-472e-b065-07efc33bfe36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:to="loc_us-gaap_LitigationSettlementExpense_8bdd2131-ad42-472e-b065-07efc33bfe36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_c00c3749-7525-4e02-8415-d6e871a7fa54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_c00c3749-7525-4e02-8415-d6e871a7fa54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_2309800a-6b9e-4d0e-a027-1b2a323afde9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_2309800a-6b9e-4d0e-a027-1b2a323afde9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsSettledNumber_5c649eb5-e14d-4c25-95b6-75e352b68f02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyClaimsSettledNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:to="loc_us-gaap_LossContingencyClaimsSettledNumber_5c649eb5-e14d-4c25-95b6-75e352b68f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_b353c4fe-04d9-4c36-aeb5-7ad52a0df53c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_b353c4fe-04d9-4c36-aeb5-7ad52a0df53c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_JudgmentForLostProfits_c35cbdeb-040f-408b-8dcc-56f389a0f123" xlink:href="cah-20220331.xsd#cah_JudgmentForLostProfits"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:to="loc_cah_JudgmentForLostProfits_c35cbdeb-040f-408b-8dcc-56f389a0f123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SettlingStates_fa890b43-b79e-4e04-a20c-25d5e4ac5eb1" xlink:href="cah-20220331.xsd#cah_SettlingStates"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:to="loc_cah_SettlingStates_fa890b43-b79e-4e04-a20c-25d5e4ac5eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SettlingUSTerritories_cfbd6092-2724-478e-82ef-9c30f88c157d" xlink:href="cah-20220331.xsd#cah_SettlingUSTerritories"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:to="loc_cah_SettlingUSTerritories_cfbd6092-2724-478e-82ef-9c30f88c157d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_4ccbb706-5ad2-4696-bd8e-b8728df221ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_4ccbb706-5ad2-4696-bd8e-b8728df221ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_e2127a53-5672-40a4-bc90-220ae80e2339" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_e2127a53-5672-40a4-bc90-220ae80e2339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LossContingencyClaimsSettledPercent_1c2aa088-1584-4aa7-a271-9bbc97e588f5" xlink:href="cah-20220331.xsd#cah_LossContingencyClaimsSettledPercent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d7a7fb7-8f75-4480-91fa-05f19e9061c3" xlink:to="loc_cah_LossContingencyClaimsSettledPercent_1c2aa088-1584-4aa7-a271-9bbc97e588f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cah-20220331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_511e06a7-8648-4248-8e04-e3413e3b4541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1741974f-6298-4b46-a4a2-9a259e00572c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_511e06a7-8648-4248-8e04-e3413e3b4541" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1741974f-6298-4b46-a4a2-9a259e00572c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a0bbca56-8eb8-4994-bdfb-d8da8c1c6e39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_40afb215-fc8b-453e-a378-f09db444ebb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a0bbca56-8eb8-4994-bdfb-d8da8c1c6e39" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_40afb215-fc8b-453e-a378-f09db444ebb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_8b13161b-bad9-4328-bb75-6b8a1395434d" xlink:href="cah-20220331.xsd#cah_OpioidLitigationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_40afb215-fc8b-453e-a378-f09db444ebb2" xlink:to="loc_cah_OpioidLitigationAxis_8b13161b-bad9-4328-bb75-6b8a1395434d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_618bd82f-0721-49a0-87d1-cb4438656a1a" xlink:href="cah-20220331.xsd#cah_OpioidLitigationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationAxis_8b13161b-bad9-4328-bb75-6b8a1395434d" xlink:to="loc_cah_OpioidLitigationDomain_618bd82f-0721-49a0-87d1-cb4438656a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_61e557fc-27ba-4307-8b4d-2b8e56e3dc2e" xlink:href="cah-20220331.xsd#cah_TotalOpioidLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationDomain_618bd82f-0721-49a0-87d1-cb4438656a1a" xlink:to="loc_cah_TotalOpioidLitigationMember_61e557fc-27ba-4307-8b4d-2b8e56e3dc2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterAxis_157cffec-f414-4b05-bea6-58923519715c" xlink:href="cah-20220331.xsd#cah_TaxMatterAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_40afb215-fc8b-453e-a378-f09db444ebb2" xlink:to="loc_cah_TaxMatterAxis_157cffec-f414-4b05-bea6-58923519715c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterDomain_67a3535a-38af-4f20-a6a3-d9f569a6dbbd" xlink:href="cah-20220331.xsd#cah_TaxMatterDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMatterAxis_157cffec-f414-4b05-bea6-58923519715c" xlink:to="loc_cah_TaxMatterDomain_67a3535a-38af-4f20-a6a3-d9f569a6dbbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PatientRecoveryBusinessMember_70bba0ce-aa9d-40d1-8f8a-f10139eb9699" xlink:href="cah-20220331.xsd#cah_PatientRecoveryBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMatterDomain_67a3535a-38af-4f20-a6a3-d9f569a6dbbd" xlink:to="loc_cah_PatientRecoveryBusinessMember_70bba0ce-aa9d-40d1-8f8a-f10139eb9699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CareFusionMember_eefdcfa5-78ee-40a8-b5c6-d2313cc31abe" xlink:href="cah-20220331.xsd#cah_CareFusionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMatterDomain_67a3535a-38af-4f20-a6a3-d9f569a6dbbd" xlink:to="loc_cah_CareFusionMember_eefdcfa5-78ee-40a8-b5c6-d2313cc31abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e5da45df-f786-4e56-b81f-c0e748c514ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_40afb215-fc8b-453e-a378-f09db444ebb2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e5da45df-f786-4e56-b81f-c0e748c514ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0c6c6601-e768-409a-827f-2425595ed4f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e5da45df-f786-4e56-b81f-c0e748c514ac" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0c6c6601-e768-409a-827f-2425595ed4f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PatientRecoveryBusinessMember_c8a8b2d4-db52-4a29-939b-408029edb219" xlink:href="cah-20220331.xsd#cah_PatientRecoveryBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0c6c6601-e768-409a-827f-2425595ed4f6" xlink:to="loc_cah_PatientRecoveryBusinessMember_c8a8b2d4-db52-4a29-939b-408029edb219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementAxis_337306ff-91fd-430a-9f39-e176c3913b4b" xlink:href="cah-20220331.xsd#cah_TaxMattersAgreementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_40afb215-fc8b-453e-a378-f09db444ebb2" xlink:to="loc_cah_TaxMattersAgreementAxis_337306ff-91fd-430a-9f39-e176c3913b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementDomain_cebf405f-fb18-4f8a-bd20-f4052ee244ff" xlink:href="cah-20220331.xsd#cah_TaxMattersAgreementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMattersAgreementAxis_337306ff-91fd-430a-9f39-e176c3913b4b" xlink:to="loc_cah_TaxMattersAgreementDomain_cebf405f-fb18-4f8a-bd20-f4052ee244ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CareFusionMember_a5eaf060-32b3-4c4e-81cf-762b9ba63d60" xlink:href="cah-20220331.xsd#cah_CareFusionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMattersAgreementDomain_cebf405f-fb18-4f8a-bd20-f4052ee244ff" xlink:to="loc_cah_CareFusionMember_a5eaf060-32b3-4c4e-81cf-762b9ba63d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_90fa59be-5759-4972-8575-2753e39db5e5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_40afb215-fc8b-453e-a378-f09db444ebb2" xlink:to="loc_srt_RangeAxis_90fa59be-5759-4972-8575-2753e39db5e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_adff6e9d-e4e5-4d8f-a5cd-a154c4839438" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_90fa59be-5759-4972-8575-2753e39db5e5" xlink:to="loc_srt_RangeMember_adff6e9d-e4e5-4d8f-a5cd-a154c4839438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6d7df18c-0e6f-4f97-aed5-66ef0d45e5cb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_adff6e9d-e4e5-4d8f-a5cd-a154c4839438" xlink:to="loc_srt_MinimumMember_6d7df18c-0e6f-4f97-aed5-66ef0d45e5cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cc79d287-d256-4fae-bb86-ebac916a7651" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_adff6e9d-e4e5-4d8f-a5cd-a154c4839438" xlink:to="loc_srt_MaximumMember_cc79d287-d256-4fae-bb86-ebac916a7651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NetOperatingLossCarrybackAxis_0206a96e-aa68-4890-ac14-ba786505a648" xlink:href="cah-20220331.xsd#cah_NetOperatingLossCarrybackAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_40afb215-fc8b-453e-a378-f09db444ebb2" xlink:to="loc_cah_NetOperatingLossCarrybackAxis_0206a96e-aa68-4890-ac14-ba786505a648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CARESActDomain_d99dfc24-6c21-4263-835a-359360d8c4bf" xlink:href="cah-20220331.xsd#cah_CARESActDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_NetOperatingLossCarrybackAxis_0206a96e-aa68-4890-ac14-ba786505a648" xlink:to="loc_cah_CARESActDomain_d99dfc24-6c21-4263-835a-359360d8c4bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NetOperatingLossCarrybackMember_5fb9f0f2-93bf-4339-905b-9ba198dc01d8" xlink:href="cah-20220331.xsd#cah_NetOperatingLossCarrybackMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CARESActDomain_d99dfc24-6c21-4263-835a-359360d8c4bf" xlink:to="loc_cah_NetOperatingLossCarrybackMember_5fb9f0f2-93bf-4339-905b-9ba198dc01d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_3f754502-a867-43c7-ab59-d5b176829f3a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_40afb215-fc8b-453e-a378-f09db444ebb2" xlink:to="loc_srt_StatementScenarioAxis_3f754502-a867-43c7-ab59-d5b176829f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_03492b61-bee3-4e2a-a3a6-20b897c182a9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_3f754502-a867-43c7-ab59-d5b176829f3a" xlink:to="loc_srt_ScenarioUnspecifiedDomain_03492b61-bee3-4e2a-a3a6-20b897c182a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_c78d971e-190b-431e-9720-98f256925816" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_03492b61-bee3-4e2a-a3a6-20b897c182a9" xlink:to="loc_srt_ScenarioForecastMember_c78d971e-190b-431e-9720-98f256925816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentAxis_deaf3252-8aa2-4e75-a1f0-3dfb458c4784" xlink:href="cah-20220331.xsd#cah_GoodwillImpairmentAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_40afb215-fc8b-453e-a378-f09db444ebb2" xlink:to="loc_cah_GoodwillImpairmentAxis_deaf3252-8aa2-4e75-a1f0-3dfb458c4784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentDomain_ff533701-ca6f-444b-924d-0a600ccc0f38" xlink:href="cah-20220331.xsd#cah_GoodwillImpairmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_GoodwillImpairmentAxis_deaf3252-8aa2-4e75-a1f0-3dfb458c4784" xlink:to="loc_cah_GoodwillImpairmentDomain_ff533701-ca6f-444b-924d-0a600ccc0f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_d2c8d128-3d09-4296-9d03-6387cbfb3208" xlink:href="cah-20220331.xsd#cah_MedicalUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_GoodwillImpairmentDomain_ff533701-ca6f-444b-924d-0a600ccc0f38" xlink:to="loc_cah_MedicalUnitMember_d2c8d128-3d09-4296-9d03-6387cbfb3208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitGoodwillImpairmentMember_44978d58-b93f-4b4e-96c3-57abf1fe24f3" xlink:href="cah-20220331.xsd#cah_MedicalUnitGoodwillImpairmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_GoodwillImpairmentDomain_ff533701-ca6f-444b-924d-0a600ccc0f38" xlink:to="loc_cah_MedicalUnitGoodwillImpairmentMember_44978d58-b93f-4b4e-96c3-57abf1fe24f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_560f520a-4aac-4dbd-9af9-b03b36788377" xlink:href="cah-20220331.xsd#cah_CordisDivestitureAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_40afb215-fc8b-453e-a378-f09db444ebb2" xlink:to="loc_cah_CordisDivestitureAxis_560f520a-4aac-4dbd-9af9-b03b36788377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_3ce71296-5591-411e-9955-cd08b3a91a28" xlink:href="cah-20220331.xsd#cah_CordisDivestitureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureAxis_560f520a-4aac-4dbd-9af9-b03b36788377" xlink:to="loc_cah_CordisDivestitureDomain_3ce71296-5591-411e-9955-cd08b3a91a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_22a033ab-d822-40c6-a30a-899d5149a570" xlink:href="cah-20220331.xsd#cah_CordisDivestitureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureDomain_3ce71296-5591-411e-9955-cd08b3a91a28" xlink:to="loc_cah_CordisDivestitureMember_22a033ab-d822-40c6-a30a-899d5149a570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_cc957468-4910-4275-a74b-c0c6ebeee497" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_40afb215-fc8b-453e-a378-f09db444ebb2" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_cc957468-4910-4275-a74b-c0c6ebeee497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7afe013d-3e57-4461-9424-5705055e78d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_cc957468-4910-4275-a74b-c0c6ebeee497" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7afe013d-3e57-4461-9424-5705055e78d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_d64dccda-b38a-4956-8759-7a1ddf2c02c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7afe013d-3e57-4461-9424-5705055e78d2" xlink:to="loc_us-gaap_SubsequentEventMember_d64dccda-b38a-4956-8759-7a1ddf2c02c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_4467267c-e2e6-496d-88e6-577d07a25aae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_40afb215-fc8b-453e-a378-f09db444ebb2" xlink:to="loc_us-gaap_ReportingUnitAxis_4467267c-e2e6-496d-88e6-577d07a25aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_4d47c3b0-8ca9-41ff-b4f3-a6ecba4546fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_4467267c-e2e6-496d-88e6-577d07a25aae" xlink:to="loc_us-gaap_ReportingUnitDomain_4d47c3b0-8ca9-41ff-b4f3-a6ecba4546fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_1f520f09-ed63-450d-a770-6a66e2a1481b" xlink:href="cah-20220331.xsd#cah_MedicalUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_4d47c3b0-8ca9-41ff-b4f3-a6ecba4546fa" xlink:to="loc_cah_MedicalUnitMember_1f520f09-ed63-450d-a770-6a66e2a1481b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_39038186-fb51-48d6-9811-a85d4a2a277e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_40afb215-fc8b-453e-a378-f09db444ebb2" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_39038186-fb51-48d6-9811-a85d4a2a277e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_46f1208b-4b70-47ab-bbbd-273577c53db0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_39038186-fb51-48d6-9811-a85d4a2a277e" xlink:to="loc_us-gaap_LitigationReserve_46f1208b-4b70-47ab-bbbd-273577c53db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e8166959-ce75-4a39-b187-ee514d780e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_39038186-fb51-48d6-9811-a85d4a2a277e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e8166959-ce75-4a39-b187-ee514d780e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_37c93067-4b3d-4d0e-aeee-3c43f0f1b5d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_39038186-fb51-48d6-9811-a85d4a2a277e" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_37c93067-4b3d-4d0e-aeee-3c43f0f1b5d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_575ef562-13ff-44ac-bac0-a42146555984" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_39038186-fb51-48d6-9811-a85d4a2a277e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_575ef562-13ff-44ac-bac0-a42146555984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_aaf06605-4288-4c15-945c-a0ae0b83515f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_39038186-fb51-48d6-9811-a85d4a2a277e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_aaf06605-4288-4c15-945c-a0ae0b83515f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_baa0eb49-3ed2-4517-bbbf-d66f19267cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_39038186-fb51-48d6-9811-a85d4a2a277e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_baa0eb49-3ed2-4517-bbbf-d66f19267cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_621c171c-b931-4faf-8412-d925ef845338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_39038186-fb51-48d6-9811-a85d4a2a277e" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_621c171c-b931-4faf-8412-d925ef845338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IndemnificationReceivable_79760650-3144-4ecb-8f38-99940b964425" xlink:href="cah-20220331.xsd#cah_IndemnificationReceivable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_39038186-fb51-48d6-9811-a85d4a2a277e" xlink:to="loc_cah_IndemnificationReceivable_79760650-3144-4ecb-8f38-99940b964425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8d1de096-adf8-46ad-9e13-733a159f874f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_39038186-fb51-48d6-9811-a85d4a2a277e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8d1de096-adf8-46ad-9e13-733a159f874f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_64bc85ab-5f4d-4fef-aa1c-215383cee44c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_39038186-fb51-48d6-9811-a85d4a2a277e" xlink:to="loc_us-gaap_LitigationSettlementExpense_64bc85ab-5f4d-4fef-aa1c-215383cee44c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_1047adee-3900-4126-b2a7-bc5039590cce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_39038186-fb51-48d6-9811-a85d4a2a277e" xlink:to="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_1047adee-3900-4126-b2a7-bc5039590cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReceivable_fce45cba-04f7-4412-a211-dc110da9122a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReceivable"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_39038186-fb51-48d6-9811-a85d4a2a277e" xlink:to="loc_us-gaap_IncomeTaxReceivable_fce45cba-04f7-4412-a211-dc110da9122a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_3643ef4a-15e4-41bb-98e2-9e02fe9c960a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_39038186-fb51-48d6-9811-a85d4a2a277e" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_3643ef4a-15e4-41bb-98e2-9e02fe9c960a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIncomeTaxRefunds_bef45656-03d2-467d-9ef2-e554a3a2eae8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_39038186-fb51-48d6-9811-a85d4a2a277e" xlink:to="loc_us-gaap_ProceedsFromIncomeTaxRefunds_bef45656-03d2-467d-9ef2-e554a3a2eae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="cah-20220331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b7f4c28f-fd0f-4bf8-8112-11898e686aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_aa58c541-b7ad-4941-9019-2afd42dcf425" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b7f4c28f-fd0f-4bf8-8112-11898e686aaa" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_aa58c541-b7ad-4941-9019-2afd42dcf425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="cah-20220331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1b85f74c-ba09-4051-be4d-d37ab56e74f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_6b734e95-b3a7-44e4-848e-ed0bd40b1af3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1b85f74c-ba09-4051-be4d-d37ab56e74f8" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_6b734e95-b3a7-44e4-848e-ed0bd40b1af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d04bcd7e-56f2-4b08-a779-7ebe6274518f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11dc99ee-0cca-48b9-a7ca-66a07c8b5f64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d04bcd7e-56f2-4b08-a779-7ebe6274518f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11dc99ee-0cca-48b9-a7ca-66a07c8b5f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c6e4794c-d46c-4812-a37e-48ee0a715965" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11dc99ee-0cca-48b9-a7ca-66a07c8b5f64" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c6e4794c-d46c-4812-a37e-48ee0a715965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d432612-1b7f-4202-ba91-1fcf370dbd2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c6e4794c-d46c-4812-a37e-48ee0a715965" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d432612-1b7f-4202-ba91-1fcf370dbd2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_142985a8-a9b8-4d90-ad57-3dd8768b8854" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d432612-1b7f-4202-ba91-1fcf370dbd2b" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_142985a8-a9b8-4d90-ad57-3dd8768b8854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_100ecb3a-f3fc-4a8a-b80a-55df396e4f77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d432612-1b7f-4202-ba91-1fcf370dbd2b" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_100ecb3a-f3fc-4a8a-b80a-55df396e4f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e4e96755-1d5f-4e53-a9d1-ac981326c688" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d432612-1b7f-4202-ba91-1fcf370dbd2b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e4e96755-1d5f-4e53-a9d1-ac981326c688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_80fcd692-33eb-4983-a0a9-748933a1d477" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11dc99ee-0cca-48b9-a7ca-66a07c8b5f64" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_80fcd692-33eb-4983-a0a9-748933a1d477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e90d7c70-2436-4b58-b592-93181ddff2ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_80fcd692-33eb-4983-a0a9-748933a1d477" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e90d7c70-2436-4b58-b592-93181ddff2ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_60233ab8-e725-4385-9011-3879cc450b14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e90d7c70-2436-4b58-b592-93181ddff2ae" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_60233ab8-e725-4385-9011-3879cc450b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_71afe7b8-f483-4be3-b931-f9856853c03f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11dc99ee-0cca-48b9-a7ca-66a07c8b5f64" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_71afe7b8-f483-4be3-b931-f9856853c03f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_0bbe542d-e6ef-4019-9460-ccd06d87ae67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_71afe7b8-f483-4be3-b931-f9856853c03f" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_0bbe542d-e6ef-4019-9460-ccd06d87ae67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_71cc3651-aee1-4950-8603-aa3003e08efc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0bbe542d-e6ef-4019-9460-ccd06d87ae67" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_71cc3651-aee1-4950-8603-aa3003e08efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_4e9ee395-2c7f-4cd6-9479-f9f32b0dcaed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0bbe542d-e6ef-4019-9460-ccd06d87ae67" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_4e9ee395-2c7f-4cd6-9479-f9f32b0dcaed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_a36a31e4-978e-4031-81e4-2ced27b4ec9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0bbe542d-e6ef-4019-9460-ccd06d87ae67" xlink:to="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_a36a31e4-978e-4031-81e4-2ced27b4ec9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_b7d66bcc-c668-4929-83af-80500e7bcbe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_71afe7b8-f483-4be3-b931-f9856853c03f" xlink:to="loc_us-gaap_LiabilitiesAbstract_b7d66bcc-c668-4929-83af-80500e7bcbe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_064b8358-d6ec-4ea8-ad75-76244a1ab3e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_b7d66bcc-c668-4929-83af-80500e7bcbe8" xlink:to="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_064b8358-d6ec-4ea8-ad75-76244a1ab3e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstruments" xlink:type="simple" xlink:href="cah-20220331.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_fd33d6e8-3490-4150-88f3-0ddf1631333c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_81974918-8208-40cb-97da-c17e02ff9d16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_fd33d6e8-3490-4150-88f3-0ddf1631333c" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_81974918-8208-40cb-97da-c17e02ff9d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="cah-20220331.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9e2ae290-fd30-46ec-ba96-cdcb8b5dae26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_e01c9667-bcde-49ae-8954-a11f3524951b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9e2ae290-fd30-46ec-ba96-cdcb8b5dae26" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_e01c9667-bcde-49ae-8954-a11f3524951b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f96dedf4-557e-401d-b36a-9f505e440987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_97c4dcd9-4453-46ff-81fc-3db739cbb703" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f96dedf4-557e-401d-b36a-9f505e440987" xlink:to="loc_us-gaap_DerivativeTable_97c4dcd9-4453-46ff-81fc-3db739cbb703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a5f48065-556e-49f1-97d7-607e4d7f1bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_97c4dcd9-4453-46ff-81fc-3db739cbb703" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a5f48065-556e-49f1-97d7-607e4d7f1bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_83ff1db3-a7b9-447e-b40f-62ececd6b0b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a5f48065-556e-49f1-97d7-607e4d7f1bdb" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_83ff1db3-a7b9-447e-b40f-62ececd6b0b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_85a53948-755f-4979-93fa-c4ec2ac8d8ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_83ff1db3-a7b9-447e-b40f-62ececd6b0b8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_85a53948-755f-4979-93fa-c4ec2ac8d8ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cce14e93-2901-458c-8539-a9ac38d8ace3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_97c4dcd9-4453-46ff-81fc-3db739cbb703" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cce14e93-2901-458c-8539-a9ac38d8ace3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f050fb92-9b41-4b9a-99c5-368134568a18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cce14e93-2901-458c-8539-a9ac38d8ace3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f050fb92-9b41-4b9a-99c5-368134568a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_aeb9e163-09c9-482f-bfc1-d8e8e4e25762" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f050fb92-9b41-4b9a-99c5-368134568a18" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_aeb9e163-09c9-482f-bfc1-d8e8e4e25762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_dec68e4e-2fe3-432d-ad47-55fbb266dc71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_97c4dcd9-4453-46ff-81fc-3db739cbb703" xlink:to="loc_us-gaap_HedgingDesignationAxis_dec68e4e-2fe3-432d-ad47-55fbb266dc71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_890c5000-25ab-42df-8d1a-0b6548689d72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_dec68e4e-2fe3-432d-ad47-55fbb266dc71" xlink:to="loc_us-gaap_HedgingDesignationDomain_890c5000-25ab-42df-8d1a-0b6548689d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_09333417-fe84-4b84-9f33-7cce3409c862" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_890c5000-25ab-42df-8d1a-0b6548689d72" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_09333417-fe84-4b84-9f33-7cce3409c862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_0001e222-8605-4e3b-a719-52560274e1cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_890c5000-25ab-42df-8d1a-0b6548689d72" xlink:to="loc_us-gaap_NondesignatedMember_0001e222-8605-4e3b-a719-52560274e1cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_62eb23a1-acdf-46dd-aeaa-4f8dbcab23b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_97c4dcd9-4453-46ff-81fc-3db739cbb703" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_62eb23a1-acdf-46dd-aeaa-4f8dbcab23b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_ea194233-39bf-4d78-be00-92f7d417b648" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_62eb23a1-acdf-46dd-aeaa-4f8dbcab23b4" xlink:to="loc_us-gaap_HedgingRelationshipDomain_ea194233-39bf-4d78-be00-92f7d417b648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_bcc428f7-f125-4dbc-8fec-fbad1ad196b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_ea194233-39bf-4d78-be00-92f7d417b648" xlink:to="loc_us-gaap_FairValueHedgingMember_bcc428f7-f125-4dbc-8fec-fbad1ad196b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_90fe7ed7-d35d-4591-813b-f8a00522c2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_ea194233-39bf-4d78-be00-92f7d417b648" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_90fe7ed7-d35d-4591-813b-f8a00522c2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_ead3eba8-a690-4c45-9c5b-5b5a57cb728a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_97c4dcd9-4453-46ff-81fc-3db739cbb703" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_ead3eba8-a690-4c45-9c5b-5b5a57cb728a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9940cb68-82e5-4528-9228-5d936b9b4130" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ead3eba8-a690-4c45-9c5b-5b5a57cb728a" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9940cb68-82e5-4528-9228-5d936b9b4130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_a7195dce-c190-4de6-a30f-b527ac51527a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9940cb68-82e5-4528-9228-5d936b9b4130" xlink:to="loc_us-gaap_CashFlowHedgingMember_a7195dce-c190-4de6-a30f-b527ac51527a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_3890b0e1-f8de-4eee-bf1e-86b7d7f90406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9940cb68-82e5-4528-9228-5d936b9b4130" xlink:to="loc_us-gaap_InterestRateSwapMember_3890b0e1-f8de-4eee-bf1e-86b7d7f90406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_f7e3a7a0-dd1f-4efd-81d8-1088a867b852" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9940cb68-82e5-4528-9228-5d936b9b4130" xlink:to="loc_us-gaap_ForeignExchangeContractMember_f7e3a7a0-dd1f-4efd-81d8-1088a867b852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_a555e861-93b1-4083-ba3c-43014aa1ab4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9940cb68-82e5-4528-9228-5d936b9b4130" xlink:to="loc_us-gaap_CurrencySwapMember_a555e861-93b1-4083-ba3c-43014aa1ab4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MaturityDateAxis_da9c2bcf-d03f-4947-a1bd-b0fc131ce176" xlink:href="cah-20220331.xsd#cah_MaturityDateAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_97c4dcd9-4453-46ff-81fc-3db739cbb703" xlink:to="loc_cah_MaturityDateAxis_da9c2bcf-d03f-4947-a1bd-b0fc131ce176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MaturityDateDomain_d891740a-152d-4fdb-a857-2727ec5dd22f" xlink:href="cah-20220331.xsd#cah_MaturityDateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_MaturityDateAxis_da9c2bcf-d03f-4947-a1bd-b0fc131ce176" xlink:to="loc_cah_MaturityDateDomain_d891740a-152d-4fdb-a857-2727ec5dd22f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_September2025Member_5cf89fc5-f68a-43c9-9913-f8dc774e9481" xlink:href="cah-20220331.xsd#cah_September2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_MaturityDateDomain_d891740a-152d-4fdb-a857-2727ec5dd22f" xlink:to="loc_cah_September2025Member_5cf89fc5-f68a-43c9-9913-f8dc774e9481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_June2027Member_266a0569-dfe1-4915-8a96-58b1db741d29" xlink:href="cah-20220331.xsd#cah_June2027Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_MaturityDateDomain_d891740a-152d-4fdb-a857-2727ec5dd22f" xlink:to="loc_cah_June2027Member_266a0569-dfe1-4915-8a96-58b1db741d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_561b956c-c47c-46e6-bbf7-02cd30ce0cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_97c4dcd9-4453-46ff-81fc-3db739cbb703" xlink:to="loc_us-gaap_DerivativeLineItems_561b956c-c47c-46e6-bbf7-02cd30ce0cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_5a8144be-44d6-4f70-b4a3-2c269e926347" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_561b956c-c47c-46e6-bbf7-02cd30ce0cd4" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_5a8144be-44d6-4f70-b4a3-2c269e926347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_fa81eb60-9274-4036-a1de-2b4059379286" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_561b956c-c47c-46e6-bbf7-02cd30ce0cd4" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_fa81eb60-9274-4036-a1de-2b4059379286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_ab1fcaf0-a099-47ed-9cb7-48a40d84ce8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_561b956c-c47c-46e6-bbf7-02cd30ce0cd4" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_ab1fcaf0-a099-47ed-9cb7-48a40d84ce8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_02956f99-c424-418a-9419-c085d84edb31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_561b956c-c47c-46e6-bbf7-02cd30ce0cd4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_02956f99-c424-418a-9419-c085d84edb31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_5511bf92-a2c1-4d24-abea-0aaa9677b33a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_561b956c-c47c-46e6-bbf7-02cd30ce0cd4" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_5511bf92-a2c1-4d24-abea-0aaa9677b33a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_7accfd99-2cc3-4ee7-afad-b6aee1f5cf53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_561b956c-c47c-46e6-bbf7-02cd30ce0cd4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_7accfd99-2cc3-4ee7-afad-b6aee1f5cf53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount_1e977684-75e8-4c61-8b12-e550ddc72d8c" xlink:href="cah-20220331.xsd#cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_561b956c-c47c-46e6-bbf7-02cd30ce0cd4" xlink:to="loc_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount_1e977684-75e8-4c61-8b12-e550ddc72d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeInvestingActivities_4e0a823c-ffba-4f1e-b77e-4adfc1afbe20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromHedgeInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_561b956c-c47c-46e6-bbf7-02cd30ce0cd4" xlink:to="loc_us-gaap_ProceedsFromHedgeInvestingActivities_4e0a823c-ffba-4f1e-b77e-4adfc1afbe20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_776a48ad-bad4-4dbc-bd83-47fbdeacec2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6420cd82-c732-48c9-a9f3-d171372c5a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_776a48ad-bad4-4dbc-bd83-47fbdeacec2e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6420cd82-c732-48c9-a9f3-d171372c5a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_43911dc0-ba38-4fa1-9973-3959994020fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6420cd82-c732-48c9-a9f3-d171372c5a9f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_43911dc0-ba38-4fa1-9973-3959994020fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9480e044-14f8-4cb7-ba6a-6b7655f251c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_43911dc0-ba38-4fa1-9973-3959994020fe" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9480e044-14f8-4cb7-ba6a-6b7655f251c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_abf87f38-8589-44a5-a0ec-7ae1416c227d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9480e044-14f8-4cb7-ba6a-6b7655f251c5" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_abf87f38-8589-44a5-a0ec-7ae1416c227d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3180af18-514e-4652-90b2-93224b6115ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6420cd82-c732-48c9-a9f3-d171372c5a9f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3180af18-514e-4652-90b2-93224b6115ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_ce3f15bc-7b3a-448b-8dbf-1292e0816116" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3180af18-514e-4652-90b2-93224b6115ae" xlink:to="loc_us-gaap_DebtInstrumentFairValue_ce3f15bc-7b3a-448b-8dbf-1292e0816116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings_9369b24f-ecd7-41ee-a169-2462e9e28041" xlink:href="cah-20220331.xsd#cah_CarryingAmountofLongTermandotherShortTermBorrowings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3180af18-514e-4652-90b2-93224b6115ae" xlink:to="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings_9369b24f-ecd7-41ee-a169-2462e9e28041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="cah-20220331.xsd#ShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_cda09323-cbe8-444d-ac87-b1140c47dbb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4bd633ce-731e-49fa-bbc1-f4c3fe77302c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_cda09323-cbe8-444d-ac87-b1140c47dbb1" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4bd633ce-731e-49fa-bbc1-f4c3fe77302c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityTables" xlink:type="simple" xlink:href="cah-20220331.xsd#ShareholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_9546e366-125c-49dd-a1c0-af2d72cfe153" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_6ccc49d1-e16c-448a-babf-57ae272501a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9546e366-125c-49dd-a1c0-af2d72cfe153" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_6ccc49d1-e16c-448a-babf-57ae272501a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#ShareholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_777314da-72e1-4055-b6c8-abe9a4945851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_8827a2e6-2bed-49d3-9fb0-104e2f20129d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_777314da-72e1-4055-b6c8-abe9a4945851" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_8827a2e6-2bed-49d3-9fb0-104e2f20129d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_70f2e179-6f80-4150-9b88-f3d4ea7c2036" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8827a2e6-2bed-49d3-9fb0-104e2f20129d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_70f2e179-6f80-4150-9b88-f3d4ea7c2036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7173d174-fe97-4891-97dc-afdbdbe774d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_70f2e179-6f80-4150-9b88-f3d4ea7c2036" xlink:to="loc_us-gaap_EquityComponentDomain_7173d174-fe97-4891-97dc-afdbdbe774d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_31800238-a1f7-4f08-ad5c-c634a24d51e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7173d174-fe97-4891-97dc-afdbdbe774d9" xlink:to="loc_us-gaap_TreasuryStockMember_31800238-a1f7-4f08-ad5c-c634a24d51e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis_dcb99d25-2cf7-46c6-9005-e7959d6a2135" xlink:href="cah-20220331.xsd#cah_ShareRepurchaseProgramAggregatePurchasePriceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8827a2e6-2bed-49d3-9fb0-104e2f20129d" xlink:to="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis_dcb99d25-2cf7-46c6-9005-e7959d6a2135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain_29f50603-ab11-48cc-9b3a-27162628c34b" xlink:href="cah-20220331.xsd#cah_ShareRepurchaseProgramAggregatePurchasePriceDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis_dcb99d25-2cf7-46c6-9005-e7959d6a2135" xlink:to="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain_29f50603-ab11-48cc-9b3a-27162628c34b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A500MillionShareRepurchaseProgramMember_4aa041a2-8920-45a7-97ad-1d9706eff4bc" xlink:href="cah-20220331.xsd#cah_A500MillionShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain_29f50603-ab11-48cc-9b3a-27162628c34b" xlink:to="loc_cah_A500MillionShareRepurchaseProgramMember_4aa041a2-8920-45a7-97ad-1d9706eff4bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A300MillionShareRepurchaseProgramMember_e813c3ee-d451-4541-b12f-3aba17ed8b17" xlink:href="cah-20220331.xsd#cah_A300MillionShareRepurchaseProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain_29f50603-ab11-48cc-9b3a-27162628c34b" xlink:to="loc_cah_A300MillionShareRepurchaseProgramMember_e813c3ee-d451-4541-b12f-3aba17ed8b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A200MillionShareRepurchaseProgramMember_df4cab39-8b9b-4ece-91f4-712b09631a67" xlink:href="cah-20220331.xsd#cah_A200MillionShareRepurchaseProgramMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain_29f50603-ab11-48cc-9b3a-27162628c34b" xlink:to="loc_cah_A200MillionShareRepurchaseProgramMember_df4cab39-8b9b-4ece-91f4-712b09631a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_d48a2894-1063-40ef-934b-33a4370a2c02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8827a2e6-2bed-49d3-9fb0-104e2f20129d" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_d48a2894-1063-40ef-934b-33a4370a2c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3d0f54a1-7aac-4d71-8df7-2fca10d0db5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d48a2894-1063-40ef-934b-33a4370a2c02" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3d0f54a1-7aac-4d71-8df7-2fca10d0db5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_7dc29d9a-2404-4ce9-b583-d64b71594e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3d0f54a1-7aac-4d71-8df7-2fca10d0db5f" xlink:to="loc_us-gaap_SubsequentEventMember_7dc29d9a-2404-4ce9-b583-d64b71594e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_f32c4b5f-a1cd-4469-9ccd-4f0e1e68fd79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8827a2e6-2bed-49d3-9fb0-104e2f20129d" xlink:to="loc_us-gaap_ClassOfStockLineItems_f32c4b5f-a1cd-4469-9ccd-4f0e1e68fd79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_af725f13-d3bb-490a-9e37-3a24794eb6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f32c4b5f-a1cd-4469-9ccd-4f0e1e68fd79" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_af725f13-d3bb-490a-9e37-3a24794eb6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_27cea91d-16cf-43e3-9841-1966275ad152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f32c4b5f-a1cd-4469-9ccd-4f0e1e68fd79" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_27cea91d-16cf-43e3-9841-1966275ad152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_544714b2-1a80-4554-bfb0-5b6cda8847ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f32c4b5f-a1cd-4469-9ccd-4f0e1e68fd79" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_544714b2-1a80-4554-bfb0-5b6cda8847ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4f746313-9287-49a0-9410-122fca8e31c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_b9790122-6db0-48cd-9e0f-4b69391aae02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4f746313-9287-49a0-9410-122fca8e31c0" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_b9790122-6db0-48cd-9e0f-4b69391aae02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3746ea3b-677a-445d-a103-188400ab2c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_b9790122-6db0-48cd-9e0f-4b69391aae02" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3746ea3b-677a-445d-a103-188400ab2c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_867a83ce-ee43-4222-b652-8d52c54d84ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3746ea3b-677a-445d-a103-188400ab2c6a" xlink:to="loc_us-gaap_EquityComponentDomain_867a83ce-ee43-4222-b652-8d52c54d84ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_84f38134-062d-4fe6-9494-126e6b934cba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_867a83ce-ee43-4222-b652-8d52c54d84ea" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_84f38134-062d-4fe6-9494-126e6b934cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_f8539cb6-17d7-4afb-9486-1aac07aea030" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_867a83ce-ee43-4222-b652-8d52c54d84ea" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_f8539cb6-17d7-4afb-9486-1aac07aea030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_7cbeb081-a451-4e8b-a780-62b130f1b7fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_867a83ce-ee43-4222-b652-8d52c54d84ea" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_7cbeb081-a451-4e8b-a780-62b130f1b7fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b737a379-d8e5-4698-bbdd-da9e7a855c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_867a83ce-ee43-4222-b652-8d52c54d84ea" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b737a379-d8e5-4698-bbdd-da9e7a855c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_30069e80-64df-4148-8305-346a5be50616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_b9790122-6db0-48cd-9e0f-4b69391aae02" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_30069e80-64df-4148-8305-346a5be50616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_4aff9e90-0923-4307-b0c4-f6f8c32aeff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_30069e80-64df-4148-8305-346a5be50616" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_4aff9e90-0923-4307-b0c4-f6f8c32aeff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f93271c7-c519-4673-bf34-179e3dc29a70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_4aff9e90-0923-4307-b0c4-f6f8c32aeff7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f93271c7-c519-4673-bf34-179e3dc29a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_508baac2-7ef5-4109-9242-73703cf9a829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_4aff9e90-0923-4307-b0c4-f6f8c32aeff7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_508baac2-7ef5-4109-9242-73703cf9a829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_9804bc84-3c64-4261-82a0-c41194e8f26a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_4aff9e90-0923-4307-b0c4-f6f8c32aeff7" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_9804bc84-3c64-4261-82a0-c41194e8f26a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0c187688-e59e-4bcc-86dc-112f859a4efa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_4aff9e90-0923-4307-b0c4-f6f8c32aeff7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0c187688-e59e-4bcc-86dc-112f859a4efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_efd26d3e-4dbf-4fb2-b63d-f9bf91224c11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_4aff9e90-0923-4307-b0c4-f6f8c32aeff7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_efd26d3e-4dbf-4fb2-b63d-f9bf91224c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc" xlink:type="simple" xlink:href="cah-20220331.xsd#EarningsPerShareAttributabletoCardinalHealthInc"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_307b9e95-c0c9-4366-b1f2-54dca9112a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_9ee48d0a-a04f-43b9-8406-44224e570f90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_307b9e95-c0c9-4366-b1f2-54dca9112a3c" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_9ee48d0a-a04f-43b9-8406-44224e570f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables" xlink:type="simple" xlink:href="cah-20220331.xsd#EarningsPerShareAttributabletoCardinalHealthIncTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9f5a2f45-904a-409b-a004-c3b1c3ee697c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_efe3e8f1-0513-451b-9ddb-6c2a34f65b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9f5a2f45-904a-409b-a004-c3b1c3ee697c" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_efe3e8f1-0513-451b-9ddb-6c2a34f65b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_497f713e-2e81-4938-8ac6-a6864722a991" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4641909c-8511-463b-b2c0-5ce4d545b0da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_497f713e-2e81-4938-8ac6-a6864722a991" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4641909c-8511-463b-b2c0-5ce4d545b0da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss_4c5de5ff-2f88-4be6-a0e5-d8f7c7102b8e" xlink:href="cah-20220331.xsd#cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_497f713e-2e81-4938-8ac6-a6864722a991" xlink:to="loc_cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss_4c5de5ff-2f88-4be6-a0e5-d8f7c7102b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_171448fc-53ea-4517-abc3-8e7cffe72382" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cc6fd988-6680-42e8-8b17-818a7568ab6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_171448fc-53ea-4517-abc3-8e7cffe72382" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cc6fd988-6680-42e8-8b17-818a7568ab6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_c9d36867-773b-4558-b974-e5638cd0c2f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_171448fc-53ea-4517-abc3-8e7cffe72382" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_c9d36867-773b-4558-b974-e5638cd0c2f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_bd0656bc-78c0-4a5c-bfce-97441b6d37d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_c9d36867-773b-4558-b974-e5638cd0c2f3" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_bd0656bc-78c0-4a5c-bfce-97441b6d37d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8a289f7b-5610-4274-8e2f-316ece60ef50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_171448fc-53ea-4517-abc3-8e7cffe72382" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8a289f7b-5610-4274-8e2f-316ece60ef50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformation" xlink:type="simple" xlink:href="cah-20220331.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_c9e366c6-1469-4526-8ac5-d67a26adaa6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_5ddb4fc9-1c9c-4695-8464-5fb76ea3b279" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c9e366c6-1469-4526-8ac5-d67a26adaa6d" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_5ddb4fc9-1c9c-4695-8464-5fb76ea3b279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="cah-20220331.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_e7449561-5046-4f89-8cc7-7d73a55ff330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_374a8024-a6cc-4212-a23d-53a3fabd2047" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e7449561-5046-4f89-8cc7-7d73a55ff330" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_374a8024-a6cc-4212-a23d-53a3fabd2047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_909deea9-412e-4c95-a577-382b9f515944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e7449561-5046-4f89-8cc7-7d73a55ff330" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_909deea9-412e-4c95-a577-382b9f515944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_80b9dcb8-1507-4bf0-9c03-8a462a1f0b75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e7449561-5046-4f89-8cc7-7d73a55ff330" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_80b9dcb8-1507-4bf0-9c03-8a462a1f0b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_132db758-9f0e-4748-9641-6410abd7898e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e7449561-5046-4f89-8cc7-7d73a55ff330" xlink:to="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_132db758-9f0e-4748-9641-6410abd7898e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#SegmentInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_0803fcd5-3edb-4a9c-bb67-56f0f9580fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f8c2efc4-e532-4c3d-9e18-2522a37b2f87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0803fcd5-3edb-4a9c-bb67-56f0f9580fa7" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f8c2efc4-e532-4c3d-9e18-2522a37b2f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_8ea6a49f-6041-4137-8213-948e11634577" xlink:href="cah-20220331.xsd#cah_OpioidLitigationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f8c2efc4-e532-4c3d-9e18-2522a37b2f87" xlink:to="loc_cah_OpioidLitigationAxis_8ea6a49f-6041-4137-8213-948e11634577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_76f186aa-b90f-4893-b38e-76e05a70c589" xlink:href="cah-20220331.xsd#cah_OpioidLitigationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationAxis_8ea6a49f-6041-4137-8213-948e11634577" xlink:to="loc_cah_OpioidLitigationDomain_76f186aa-b90f-4893-b38e-76e05a70c589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_e7edb98b-faf3-4fc1-bbae-d2adb37325d0" xlink:href="cah-20220331.xsd#cah_TotalOpioidLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationDomain_76f186aa-b90f-4893-b38e-76e05a70c589" xlink:to="loc_cah_TotalOpioidLitigationMember_e7edb98b-faf3-4fc1-bbae-d2adb37325d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_f1aa0f0d-a7e1-487e-a7a7-0921ec40381f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f8c2efc4-e532-4c3d-9e18-2522a37b2f87" xlink:to="loc_srt_LitigationCaseAxis_f1aa0f0d-a7e1-487e-a7a7-0921ec40381f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_287bf6c6-4085-49d4-940e-e1e33cb49b3b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_f1aa0f0d-a7e1-487e-a7a7-0921ec40381f" xlink:to="loc_srt_LitigationCaseTypeDomain_287bf6c6-4085-49d4-940e-e1e33cb49b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NewYorkOpioidStewardshipActMember_aa5b2153-26d5-4166-8882-86dec45c19ed" xlink:href="cah-20220331.xsd#cah_NewYorkOpioidStewardshipActMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_287bf6c6-4085-49d4-940e-e1e33cb49b3b" xlink:to="loc_cah_NewYorkOpioidStewardshipActMember_aa5b2153-26d5-4166-8882-86dec45c19ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_e63df0c7-8d2a-4f53-83ac-f53cb7dc8fe8" xlink:href="cah-20220331.xsd#cah_CordisDivestitureAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f8c2efc4-e532-4c3d-9e18-2522a37b2f87" xlink:to="loc_cah_CordisDivestitureAxis_e63df0c7-8d2a-4f53-83ac-f53cb7dc8fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_34f7e371-c2f7-4e64-9632-a18756da3fb0" xlink:href="cah-20220331.xsd#cah_CordisDivestitureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureAxis_e63df0c7-8d2a-4f53-83ac-f53cb7dc8fe8" xlink:to="loc_cah_CordisDivestitureDomain_34f7e371-c2f7-4e64-9632-a18756da3fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_c4cb91a1-930f-4013-8257-1a78c954631c" xlink:href="cah-20220331.xsd#cah_CordisDivestitureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureDomain_34f7e371-c2f7-4e64-9632-a18756da3fb0" xlink:to="loc_cah_CordisDivestitureMember_c4cb91a1-930f-4013-8257-1a78c954631c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_85496725-7cf3-4d81-ac81-62c6ba9559a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f8c2efc4-e532-4c3d-9e18-2522a37b2f87" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_85496725-7cf3-4d81-ac81-62c6ba9559a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_803e4b42-b951-44ed-a37e-a4cb9e9a659d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_85496725-7cf3-4d81-ac81-62c6ba9559a0" xlink:to="loc_us-gaap_SegmentDomain_803e4b42-b951-44ed-a37e-a4cb9e9a659d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_2dc58bef-1822-4d0d-84b4-c03f8e271349" xlink:href="cah-20220331.xsd#cah_MedicalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_803e4b42-b951-44ed-a37e-a4cb9e9a659d" xlink:to="loc_cah_MedicalMember_2dc58bef-1822-4d0d-84b4-c03f8e271349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_a765de79-f1bb-48e1-b9c6-e296524ffbce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f8c2efc4-e532-4c3d-9e18-2522a37b2f87" xlink:to="loc_us-gaap_ReportingUnitAxis_a765de79-f1bb-48e1-b9c6-e296524ffbce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_c7a5d129-1e1e-43f2-9d29-2eeda38f0a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_a765de79-f1bb-48e1-b9c6-e296524ffbce" xlink:to="loc_us-gaap_ReportingUnitDomain_c7a5d129-1e1e-43f2-9d29-2eeda38f0a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_1578ed15-eeae-4085-9dee-4023f17c8856" xlink:href="cah-20220331.xsd#cah_MedicalUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_c7a5d129-1e1e-43f2-9d29-2eeda38f0a6a" xlink:to="loc_cah_MedicalUnitMember_1578ed15-eeae-4085-9dee-4023f17c8856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_6cb1abd9-be5c-4810-aee6-0d3329d87a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f8c2efc4-e532-4c3d-9e18-2522a37b2f87" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_6cb1abd9-be5c-4810-aee6-0d3329d87a4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_3d85075b-b9e9-4b2b-8d0f-712879cd1645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6cb1abd9-be5c-4810-aee6-0d3329d87a4f" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_3d85075b-b9e9-4b2b-8d0f-712879cd1645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_6780e4cb-50eb-4ea0-802e-053c029044b8" xlink:href="cah-20220331.xsd#cah_ProjectCostsOnInvestmentAndOtherSpending"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6cb1abd9-be5c-4810-aee6-0d3329d87a4f" xlink:to="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_6780e4cb-50eb-4ea0-802e-053c029044b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_447356c7-d2aa-4b62-a5a9-d6ae67f10183" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6cb1abd9-be5c-4810-aee6-0d3329d87a4f" xlink:to="loc_us-gaap_NumberOfReportableSegments_447356c7-d2aa-4b62-a5a9-d6ae67f10183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_24d66495-b487-4c68-9476-42252c0e9396" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6cb1abd9-be5c-4810-aee6-0d3329d87a4f" xlink:to="loc_us-gaap_NumberOfOperatingSegments_24d66495-b487-4c68-9476-42252c0e9396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_1b05d8b8-26dd-447e-8256-81169f9caa07" xlink:href="cah-20220331.xsd#cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6cb1abd9-be5c-4810-aee6-0d3329d87a4f" xlink:to="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_1b05d8b8-26dd-447e-8256-81169f9caa07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_b2eaef7b-0f8f-49ac-ae58-e50be91ae567" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6cb1abd9-be5c-4810-aee6-0d3329d87a4f" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_b2eaef7b-0f8f-49ac-ae58-e50be91ae567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_25ef9f96-bb16-49d6-b3c1-1d8ed3791cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6cb1abd9-be5c-4810-aee6-0d3329d87a4f" xlink:to="loc_us-gaap_LitigationSettlementExpense_25ef9f96-bb16-49d6-b3c1-1d8ed3791cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_e6fde282-a8c5-461c-9027-75d6e574f56f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0803fcd5-3edb-4a9c-bb67-56f0f9580fa7" xlink:to="loc_us-gaap_NumberOfOperatingSegments_e6fde282-a8c5-461c-9027-75d6e574f56f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_be129736-d67c-4d48-92e0-d9bb8290e713" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0803fcd5-3edb-4a9c-bb67-56f0f9580fa7" xlink:to="loc_us-gaap_NumberOfReportableSegments_be129736-d67c-4d48-92e0-d9bb8290e713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_a23f0f58-19bb-4952-9bb1-8fd86094030a" xlink:href="cah-20220331.xsd#cah_ProjectCostsOnInvestmentAndOtherSpending"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0803fcd5-3edb-4a9c-bb67-56f0f9580fa7" xlink:to="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_a23f0f58-19bb-4952-9bb1-8fd86094030a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#SegmentInformationRevenuebyReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_3aee953d-32e2-4b57-a1da-b7e16e616b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_191b761a-4314-4941-9d0a-bfa9fd07f498" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_3aee953d-32e2-4b57-a1da-b7e16e616b7c" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_191b761a-4314-4941-9d0a-bfa9fd07f498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_d29524ff-dd9d-483f-883f-d4fb68d92385" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_191b761a-4314-4941-9d0a-bfa9fd07f498" xlink:to="loc_us-gaap_SubsegmentsAxis_d29524ff-dd9d-483f-883f-d4fb68d92385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_3aabd574-6260-4b18-bdfc-a2cc921dcb00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_d29524ff-dd9d-483f-883f-d4fb68d92385" xlink:to="loc_us-gaap_SubsegmentsDomain_3aabd574-6260-4b18-bdfc-a2cc921dcb00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalDistributionandSpecialtyMember_1224fba2-3b58-4745-bdbc-9892b9494237" xlink:href="cah-20220331.xsd#cah_PharmaceuticalDistributionandSpecialtyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_3aabd574-6260-4b18-bdfc-a2cc921dcb00" xlink:to="loc_cah_PharmaceuticalDistributionandSpecialtyMember_1224fba2-3b58-4745-bdbc-9892b9494237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NuclearPrecisionHealthSolutionsMember_12e7e6a5-ae67-4a38-95a6-9bc7925e41e9" xlink:href="cah-20220331.xsd#cah_NuclearPrecisionHealthSolutionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_3aabd574-6260-4b18-bdfc-a2cc921dcb00" xlink:to="loc_cah_NuclearPrecisionHealthSolutionsMember_12e7e6a5-ae67-4a38-95a6-9bc7925e41e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicaldistributionandproductsMember_3f286595-05f8-4ae5-92bf-c7092cb2182b" xlink:href="cah-20220331.xsd#cah_MedicaldistributionandproductsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_3aabd574-6260-4b18-bdfc-a2cc921dcb00" xlink:to="loc_cah_MedicaldistributionandproductsMember_3f286595-05f8-4ae5-92bf-c7092cb2182b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CardinalHealthAtHomeMember_7ec3798f-3241-4ed4-a870-6984ad5950a8" xlink:href="cah-20220331.xsd#cah_CardinalHealthAtHomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_3aabd574-6260-4b18-bdfc-a2cc921dcb00" xlink:to="loc_cah_CardinalHealthAtHomeMember_7ec3798f-3241-4ed4-a870-6984ad5950a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_12d5560f-6132-4b28-a1ae-db0ba4d149ec" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_191b761a-4314-4941-9d0a-bfa9fd07f498" xlink:to="loc_srt_ConsolidationItemsAxis_12d5560f-6132-4b28-a1ae-db0ba4d149ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_49777c3f-3563-4041-863b-bbedbb346c7e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_12d5560f-6132-4b28-a1ae-db0ba4d149ec" xlink:to="loc_srt_ConsolidationItemsDomain_49777c3f-3563-4041-863b-bbedbb346c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_4d763bb7-763f-4b63-bbe8-82b4b7ddb1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_49777c3f-3563-4041-863b-bbedbb346c7e" xlink:to="loc_us-gaap_OperatingSegmentsMember_4d763bb7-763f-4b63-bbe8-82b4b7ddb1bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_6981c0e7-c9c2-4b63-a82c-ebeb43a8179b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_49777c3f-3563-4041-863b-bbedbb346c7e" xlink:to="loc_us-gaap_CorporateNonSegmentMember_6981c0e7-c9c2-4b63-a82c-ebeb43a8179b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7002c49a-ec5e-49fa-a52d-53c78ba53213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_191b761a-4314-4941-9d0a-bfa9fd07f498" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7002c49a-ec5e-49fa-a52d-53c78ba53213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_25a9fecf-04e7-4540-a1f5-a5c104a1570a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7002c49a-ec5e-49fa-a52d-53c78ba53213" xlink:to="loc_us-gaap_SegmentDomain_25a9fecf-04e7-4540-a1f5-a5c104a1570a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_c90c3298-101a-40c6-8828-0e0ae0f13f3b" xlink:href="cah-20220331.xsd#cah_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_25a9fecf-04e7-4540-a1f5-a5c104a1570a" xlink:to="loc_cah_PharmaceuticalMember_c90c3298-101a-40c6-8828-0e0ae0f13f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_048e3cb2-3b34-49c5-8391-c139d7c224e6" xlink:href="cah-20220331.xsd#cah_MedicalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_25a9fecf-04e7-4540-a1f5-a5c104a1570a" xlink:to="loc_cah_MedicalMember_048e3cb2-3b34-49c5-8391-c139d7c224e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_8a585630-b759-4b15-a151-3fd8a1c31202" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_191b761a-4314-4941-9d0a-bfa9fd07f498" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_8a585630-b759-4b15-a151-3fd8a1c31202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_abd7d2b8-66cb-4832-934b-d5d07f085982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8a585630-b759-4b15-a151-3fd8a1c31202" xlink:to="loc_us-gaap_Revenues_abd7d2b8-66cb-4832-934b-d5d07f085982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#SegmentInformationSegmentProfitbyReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_23cb0d7f-bc5d-4a43-b1d1-39314f7330ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_7e8ff4a0-3ea8-466d-883a-6d6d161b2fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_23cb0d7f-bc5d-4a43-b1d1-39314f7330ac" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_7e8ff4a0-3ea8-466d-883a-6d6d161b2fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_05201d45-5084-4162-b1d5-61a2d9eb517f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_7e8ff4a0-3ea8-466d-883a-6d6d161b2fb2" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_05201d45-5084-4162-b1d5-61a2d9eb517f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_02a5ce0f-f045-4f27-a45b-d6879d26ea37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_05201d45-5084-4162-b1d5-61a2d9eb517f" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_02a5ce0f-f045-4f27-a45b-d6879d26ea37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_a407902e-aabe-4552-b655-73e4aa023c2c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_7e8ff4a0-3ea8-466d-883a-6d6d161b2fb2" xlink:to="loc_srt_ConsolidationItemsAxis_a407902e-aabe-4552-b655-73e4aa023c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_4cac9bdc-7777-4bbf-b0db-cdc173923152" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_a407902e-aabe-4552-b655-73e4aa023c2c" xlink:to="loc_srt_ConsolidationItemsDomain_4cac9bdc-7777-4bbf-b0db-cdc173923152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_ae73d261-12d5-4c0d-83c9-d2b10e26b9ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_4cac9bdc-7777-4bbf-b0db-cdc173923152" xlink:to="loc_us-gaap_OperatingSegmentsMember_ae73d261-12d5-4c0d-83c9-d2b10e26b9ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_59c1e96e-cb63-4dfe-90eb-242731902ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_4cac9bdc-7777-4bbf-b0db-cdc173923152" xlink:to="loc_us-gaap_CorporateNonSegmentMember_59c1e96e-cb63-4dfe-90eb-242731902ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_c1c2048f-c7e6-4411-b82a-ab23bf381b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_7e8ff4a0-3ea8-466d-883a-6d6d161b2fb2" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_c1c2048f-c7e6-4411-b82a-ab23bf381b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0f4e9bca-eddc-4638-8a0e-2e6926db867a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c1c2048f-c7e6-4411-b82a-ab23bf381b8d" xlink:to="loc_us-gaap_SegmentDomain_0f4e9bca-eddc-4638-8a0e-2e6926db867a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_8d3928ef-1206-4891-b812-ede50dc95a8d" xlink:href="cah-20220331.xsd#cah_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_0f4e9bca-eddc-4638-8a0e-2e6926db867a" xlink:to="loc_cah_PharmaceuticalMember_8d3928ef-1206-4891-b812-ede50dc95a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_7aef55da-1322-4a1c-a587-4e1051d2de27" xlink:href="cah-20220331.xsd#cah_MedicalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_0f4e9bca-eddc-4638-8a0e-2e6926db867a" xlink:to="loc_cah_MedicalMember_7aef55da-1322-4a1c-a587-4e1051d2de27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b6664ed3-d32a-49ef-ac36-f53cde210949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_7e8ff4a0-3ea8-466d-883a-6d6d161b2fb2" xlink:to="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b6664ed3-d32a-49ef-ac36-f53cde210949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_306769ad-c3b1-4246-a1c1-24dbbdb456d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b6664ed3-d32a-49ef-ac36-f53cde210949" xlink:to="loc_us-gaap_OperatingIncomeLoss_306769ad-c3b1-4246-a1c1-24dbbdb456d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_JudgmentForLostProfits_9449e8aa-a2c6-4620-be8c-78e1df51c22e" xlink:href="cah-20220331.xsd#cah_JudgmentForLostProfits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b6664ed3-d32a-49ef-ac36-f53cde210949" xlink:to="loc_cah_JudgmentForLostProfits_9449e8aa-a2c6-4620-be8c-78e1df51c22e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ContingentAttorneyFee_0eae6662-d0df-4f06-88f5-52095b2d0a35" xlink:href="cah-20220331.xsd#cah_ContingentAttorneyFee"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b6664ed3-d32a-49ef-ac36-f53cde210949" xlink:to="loc_cah_ContingentAttorneyFee_0eae6662-d0df-4f06-88f5-52095b2d0a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_bc86e93f-2e96-4ce9-9a8a-323114e83b76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_69e591b2-ef36-4d43-8725-0f0b5a93bfa5" xlink:href="cah-20220331.xsd#cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_bc86e93f-2e96-4ce9-9a8a-323114e83b76" xlink:to="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_69e591b2-ef36-4d43-8725-0f0b5a93bfa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_cf3c2524-566f-4e87-96b5-c7ee052f4dab" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_69e591b2-ef36-4d43-8725-0f0b5a93bfa5" xlink:to="loc_srt_ConsolidationItemsAxis_cf3c2524-566f-4e87-96b5-c7ee052f4dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_278bc9fd-525a-4e74-9ff0-ca4d9b53089d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_cf3c2524-566f-4e87-96b5-c7ee052f4dab" xlink:to="loc_srt_ConsolidationItemsDomain_278bc9fd-525a-4e74-9ff0-ca4d9b53089d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_0e37becd-bd02-4ec7-b00d-2b02a28547f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_278bc9fd-525a-4e74-9ff0-ca4d9b53089d" xlink:to="loc_us-gaap_OperatingSegmentsMember_0e37becd-bd02-4ec7-b00d-2b02a28547f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_dfea25e5-495b-41e7-a88a-cfac34558250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_278bc9fd-525a-4e74-9ff0-ca4d9b53089d" xlink:to="loc_us-gaap_CorporateNonSegmentMember_dfea25e5-495b-41e7-a88a-cfac34558250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_fd5a2702-a984-4149-81a4-7d8fb8a29879" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_69e591b2-ef36-4d43-8725-0f0b5a93bfa5" xlink:to="loc_srt_StatementGeographicalAxis_fd5a2702-a984-4149-81a4-7d8fb8a29879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2331aa09-8c10-45fe-956f-dfcee56b46ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_fd5a2702-a984-4149-81a4-7d8fb8a29879" xlink:to="loc_srt_SegmentGeographicalDomain_2331aa09-8c10-45fe-956f-dfcee56b46ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_5a1ce02f-16fe-46bc-85e5-2647b398a0a2" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2331aa09-8c10-45fe-956f-dfcee56b46ad" xlink:to="loc_country_US_5a1ce02f-16fe-46bc-85e5-2647b398a0a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_b53305a7-a608-4ffd-b709-73cef24400fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2331aa09-8c10-45fe-956f-dfcee56b46ad" xlink:to="loc_us-gaap_NonUsMember_b53305a7-a608-4ffd-b709-73cef24400fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_40160d18-8ae5-4411-ab02-9a1e401dd5b9" xlink:href="cah-20220331.xsd#cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_69e591b2-ef36-4d43-8725-0f0b5a93bfa5" xlink:to="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_40160d18-8ae5-4411-ab02-9a1e401dd5b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_4d1bf7b1-08d8-4b0f-8861-efba743b1491" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_40160d18-8ae5-4411-ab02-9a1e401dd5b9" xlink:to="loc_us-gaap_Revenues_4d1bf7b1-08d8-4b0f-8861-efba743b1491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#SegmentInformationAssetsbyReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_62fabeb4-b777-4336-93af-1b58e900c7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0de17507-2c94-4af7-a65a-08334eb5bab7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_62fabeb4-b777-4336-93af-1b58e900c7b3" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0de17507-2c94-4af7-a65a-08334eb5bab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_df7cc149-c90c-4be7-8385-60be78789125" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0de17507-2c94-4af7-a65a-08334eb5bab7" xlink:to="loc_srt_ConsolidationItemsAxis_df7cc149-c90c-4be7-8385-60be78789125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_243debfb-b2f2-486e-907a-278b06bbe619" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_df7cc149-c90c-4be7-8385-60be78789125" xlink:to="loc_srt_ConsolidationItemsDomain_243debfb-b2f2-486e-907a-278b06bbe619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_7090de0f-3963-4464-8ac4-a29b4b298ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_243debfb-b2f2-486e-907a-278b06bbe619" xlink:to="loc_us-gaap_OperatingSegmentsMember_7090de0f-3963-4464-8ac4-a29b4b298ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_706a4fd9-b9d4-490c-b181-dfaabec72927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_243debfb-b2f2-486e-907a-278b06bbe619" xlink:to="loc_us-gaap_CorporateNonSegmentMember_706a4fd9-b9d4-490c-b181-dfaabec72927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_b0ae1041-23df-4dfe-b248-53370f5d03e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0de17507-2c94-4af7-a65a-08334eb5bab7" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_b0ae1041-23df-4dfe-b248-53370f5d03e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8fd2999c-d2a8-48e1-a840-3e88a57146ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b0ae1041-23df-4dfe-b248-53370f5d03e8" xlink:to="loc_us-gaap_SegmentDomain_8fd2999c-d2a8-48e1-a840-3e88a57146ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_93d0afec-7caa-420c-827f-defdefa1774e" xlink:href="cah-20220331.xsd#cah_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8fd2999c-d2a8-48e1-a840-3e88a57146ae" xlink:to="loc_cah_PharmaceuticalMember_93d0afec-7caa-420c-827f-defdefa1774e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_a1016de9-915b-4e66-ba2b-22e1013586e1" xlink:href="cah-20220331.xsd#cah_MedicalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8fd2999c-d2a8-48e1-a840-3e88a57146ae" xlink:to="loc_cah_MedicalMember_a1016de9-915b-4e66-ba2b-22e1013586e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_5e8e0dca-e635-4475-b785-8ffcf42d6332" xlink:href="cah-20220331.xsd#cah_CordisDivestitureAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0de17507-2c94-4af7-a65a-08334eb5bab7" xlink:to="loc_cah_CordisDivestitureAxis_5e8e0dca-e635-4475-b785-8ffcf42d6332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_a3e37009-76b8-462f-b7f2-348b4d8975e8" xlink:href="cah-20220331.xsd#cah_CordisDivestitureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureAxis_5e8e0dca-e635-4475-b785-8ffcf42d6332" xlink:to="loc_cah_CordisDivestitureDomain_a3e37009-76b8-462f-b7f2-348b4d8975e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_f7586dc3-25ab-464f-bdbe-b5682231eaa8" xlink:href="cah-20220331.xsd#cah_CordisDivestitureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureDomain_a3e37009-76b8-462f-b7f2-348b4d8975e8" xlink:to="loc_cah_CordisDivestitureMember_f7586dc3-25ab-464f-bdbe-b5682231eaa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_ff01bac1-ae60-417b-9a2c-bbe1705e101e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0de17507-2c94-4af7-a65a-08334eb5bab7" xlink:to="loc_us-gaap_ReportingUnitAxis_ff01bac1-ae60-417b-9a2c-bbe1705e101e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_a7ec8adf-ec19-4ce9-bf13-515edd377439" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_ff01bac1-ae60-417b-9a2c-bbe1705e101e" xlink:to="loc_us-gaap_ReportingUnitDomain_a7ec8adf-ec19-4ce9-bf13-515edd377439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_3dd20027-f9dd-411c-acb3-9b8b178b69d6" xlink:href="cah-20220331.xsd#cah_MedicalUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_a7ec8adf-ec19-4ce9-bf13-515edd377439" xlink:to="loc_cah_MedicalUnitMember_3dd20027-f9dd-411c-acb3-9b8b178b69d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_cbe60118-8223-4d4c-9f55-2901147aa953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0de17507-2c94-4af7-a65a-08334eb5bab7" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_cbe60118-8223-4d4c-9f55-2901147aa953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_67a81620-143b-4de1-8719-04c0b0a0988e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cbe60118-8223-4d4c-9f55-2901147aa953" xlink:to="loc_us-gaap_Assets_67a81620-143b-4de1-8719-04c0b0a0988e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_c65fb181-30a1-4bfb-bd2e-80a60d246d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cbe60118-8223-4d4c-9f55-2901147aa953" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_c65fb181-30a1-4bfb-bd2e-80a60d246d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_2f80f137-fe8f-4b63-90da-9c70928a2fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cbe60118-8223-4d4c-9f55-2901147aa953" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_2f80f137-fe8f-4b63-90da-9c70928a2fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="cah-20220331.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7549d465-5b79-462e-b8d3-9aaef4fd1b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f82dd061-28ac-4cbd-be96-ca2ad42b9c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7549d465-5b79-462e-b8d3-9aaef4fd1b7a" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f82dd061-28ac-4cbd-be96-ca2ad42b9c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="cah-20220331.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5748128a-4d77-4ce0-8884-fb8f8a6be673" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_c363c813-7881-4688-b8f3-7640666ae9df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5748128a-4d77-4ce0-8884-fb8f8a6be673" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_c363c813-7881-4688-b8f3-7640666ae9df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6867d721-9d07-410d-bf55-2235742ce82f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5748128a-4d77-4ce0-8884-fb8f8a6be673" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6867d721-9d07-410d-bf55-2235742ce82f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AdditionalStockOptionPlanDataTableTextBlock_f55acf0a-ef8b-4bb0-887e-f8011dfef71f" xlink:href="cah-20220331.xsd#cah_AdditionalStockOptionPlanDataTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5748128a-4d77-4ce0-8884-fb8f8a6be673" xlink:to="loc_cah_AdditionalStockOptionPlanDataTableTextBlock_f55acf0a-ef8b-4bb0-887e-f8011dfef71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_e46194f0-1d60-4ac0-b712-04a137be7f92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5748128a-4d77-4ce0-8884-fb8f8a6be673" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_e46194f0-1d60-4ac0-b712-04a137be7f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_c6559014-e9ed-4ecb-bfc4-2c13305bb504" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5748128a-4d77-4ce0-8884-fb8f8a6be673" xlink:to="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_c6559014-e9ed-4ecb-bfc4-2c13305bb504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#ShareBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_937b2e88-175d-46ef-8703-e708dbec8697" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_08196976-4c0e-402e-9df3-1e78294461dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_937b2e88-175d-46ef-8703-e708dbec8697" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_08196976-4c0e-402e-9df3-1e78294461dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1a7980c7-c3e4-46c2-8c44-f27559a415df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_08196976-4c0e-402e-9df3-1e78294461dd" xlink:to="loc_us-gaap_AwardTypeAxis_1a7980c7-c3e4-46c2-8c44-f27559a415df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e952c874-e83e-4c26-8473-1ba4207ae701" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1a7980c7-c3e4-46c2-8c44-f27559a415df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e952c874-e83e-4c26-8473-1ba4207ae701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_412b3363-8867-41ac-92d9-2f1aed723820" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e952c874-e83e-4c26-8473-1ba4207ae701" xlink:to="loc_us-gaap_EmployeeStockOptionMember_412b3363-8867-41ac-92d9-2f1aed723820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6be94425-d973-4990-b733-b9b2b6073bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e952c874-e83e-4c26-8473-1ba4207ae701" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6be94425-d973-4990-b733-b9b2b6073bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_e2c88527-bde0-442d-8f66-7fe3f944fd3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e952c874-e83e-4c26-8473-1ba4207ae701" xlink:to="loc_us-gaap_PerformanceSharesMember_e2c88527-bde0-442d-8f66-7fe3f944fd3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c0b4c040-cda9-40f4-8d11-91ae97907726" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_08196976-4c0e-402e-9df3-1e78294461dd" xlink:to="loc_srt_RangeAxis_c0b4c040-cda9-40f4-8d11-91ae97907726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bd63e62d-d1d6-4fbf-8173-e23c4f4313dd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c0b4c040-cda9-40f4-8d11-91ae97907726" xlink:to="loc_srt_RangeMember_bd63e62d-d1d6-4fbf-8173-e23c4f4313dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cebfa431-16b3-4990-bc36-2231d3b5ddb9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bd63e62d-d1d6-4fbf-8173-e23c4f4313dd" xlink:to="loc_srt_MinimumMember_cebfa431-16b3-4990-bc36-2231d3b5ddb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_51db0901-0423-4c18-b727-2a5d07730012" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bd63e62d-d1d6-4fbf-8173-e23c4f4313dd" xlink:to="loc_srt_MaximumMember_51db0901-0423-4c18-b727-2a5d07730012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b00ef9b-586e-4ce6-a96f-aa3ab6e4ecfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_08196976-4c0e-402e-9df3-1e78294461dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b00ef9b-586e-4ce6-a96f-aa3ab6e4ecfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_VestingPeriodinyearsforShares_1e95f302-1fc9-4bc0-89c5-404a7812a205" xlink:href="cah-20220331.xsd#cah_VestingPeriodinyearsforShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b00ef9b-586e-4ce6-a96f-aa3ab6e4ecfc" xlink:to="loc_cah_VestingPeriodinyearsforShares_1e95f302-1fc9-4bc0-89c5-404a7812a205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_48ea71c5-a07f-46f0-9426-cf7721c3dc93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b00ef9b-586e-4ce6-a96f-aa3ab6e4ecfc" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_48ea71c5-a07f-46f0-9426-cf7721c3dc93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_73d4a297-e623-4013-be72-60317de0f4c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b00ef9b-586e-4ce6-a96f-aa3ab6e4ecfc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_73d4a297-e623-4013-be72-60317de0f4c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_60218e30-79cc-4136-9bb6-ef1469bb0af9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b00ef9b-586e-4ce6-a96f-aa3ab6e4ecfc" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_60218e30-79cc-4136-9bb6-ef1469bb0af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7235367e-ed48-42b1-a6a6-ccdc1b64c5b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b00ef9b-586e-4ce6-a96f-aa3ab6e4ecfc" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7235367e-ed48-42b1-a6a6-ccdc1b64c5b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ExercisablePeriodOfPlansInYears_839b26c4-6b04-4e8c-84ed-331009981c41" xlink:href="cah-20220331.xsd#cah_ExercisablePeriodOfPlansInYears"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b00ef9b-586e-4ce6-a96f-aa3ab6e4ecfc" xlink:to="loc_cah_ExercisablePeriodOfPlansInYears_839b26c4-6b04-4e8c-84ed-331009981c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_9bf3abd9-4815-42ca-af0c-149872c52114" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b00ef9b-586e-4ce6-a96f-aa3ab6e4ecfc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_9bf3abd9-4815-42ca-af0c-149872c52114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d4403977-604e-4d3f-853e-0b6a62bb37e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_429a7b9e-da1f-4cd4-a4d6-ac9a6c5de4cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d4403977-604e-4d3f-853e-0b6a62bb37e1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_429a7b9e-da1f-4cd4-a4d6-ac9a6c5de4cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6e7efaed-8576-4dbe-8cd4-d50cccd03653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_429a7b9e-da1f-4cd4-a4d6-ac9a6c5de4cc" xlink:to="loc_us-gaap_AwardTypeAxis_6e7efaed-8576-4dbe-8cd4-d50cccd03653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abd8e6e0-31e7-441f-83c5-6b95f4f7c099" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6e7efaed-8576-4dbe-8cd4-d50cccd03653" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abd8e6e0-31e7-441f-83c5-6b95f4f7c099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_03c1069e-b297-43e7-947b-adae6d34054e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abd8e6e0-31e7-441f-83c5-6b95f4f7c099" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_03c1069e-b297-43e7-947b-adae6d34054e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1a75cad2-c709-411a-a321-34222e0cb328" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abd8e6e0-31e7-441f-83c5-6b95f4f7c099" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1a75cad2-c709-411a-a321-34222e0cb328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_55cc78a3-c8e2-4043-ae19-81c4665a7532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abd8e6e0-31e7-441f-83c5-6b95f4f7c099" xlink:to="loc_us-gaap_PerformanceSharesMember_55cc78a3-c8e2-4043-ae19-81c4665a7532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_822d68ce-2572-4449-97fb-dd72fd0da8c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_429a7b9e-da1f-4cd4-a4d6-ac9a6c5de4cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_822d68ce-2572-4449-97fb-dd72fd0da8c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_eaaebb88-16fc-4567-9d91-40fde2bd1fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_822d68ce-2572-4449-97fb-dd72fd0da8c9" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_eaaebb88-16fc-4567-9d91-40fde2bd1fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8b5b0bcb-7bf8-4ea1-b7ac-81f0ad0b239c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_05674eb6-99a6-4896-8ac5-209b11ca54b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8b5b0bcb-7bf8-4ea1-b7ac-81f0ad0b239c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_05674eb6-99a6-4896-8ac5-209b11ca54b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c02c309d-8034-41c6-a43d-d049502b3155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_05674eb6-99a6-4896-8ac5-209b11ca54b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c02c309d-8034-41c6-a43d-d049502b3155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2ab592a0-aca5-4860-a3c2-76f4db01ac2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_05674eb6-99a6-4896-8ac5-209b11ca54b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2ab592a0-aca5-4860-a3c2-76f4db01ac2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7b902c9f-453b-47d9-890b-b55515e151d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_05674eb6-99a6-4896-8ac5-209b11ca54b5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7b902c9f-453b-47d9-890b-b55515e151d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_90953a16-b84d-4588-8b70-465f81a6faef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_05674eb6-99a6-4896-8ac5-209b11ca54b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_90953a16-b84d-4588-8b70-465f81a6faef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6e33a5da-e0ae-404e-9fe5-e7261eaed4eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_05674eb6-99a6-4896-8ac5-209b11ca54b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6e33a5da-e0ae-404e-9fe5-e7261eaed4eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_783ca027-1d98-4cc3-a8e9-7c4055e0344e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8b5b0bcb-7bf8-4ea1-b7ac-81f0ad0b239c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_783ca027-1d98-4cc3-a8e9-7c4055e0344e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0d1dc820-29cf-4036-ba67-1516ea2c6765" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8b5b0bcb-7bf8-4ea1-b7ac-81f0ad0b239c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0d1dc820-29cf-4036-ba67-1516ea2c6765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4a1a1d86-6ca4-4588-89b4-03f38129e6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0d1dc820-29cf-4036-ba67-1516ea2c6765" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4a1a1d86-6ca4-4588-89b4-03f38129e6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_b73bd430-f566-4f38-abe1-e324167db672" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0d1dc820-29cf-4036-ba67-1516ea2c6765" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_b73bd430-f566-4f38-abe1-e324167db672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c3512ae0-b810-46c5-9756-3385d77ed711" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0d1dc820-29cf-4036-ba67-1516ea2c6765" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c3512ae0-b810-46c5-9756-3385d77ed711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_942da8d7-5e74-4144-9b09-354cfa4cef6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0d1dc820-29cf-4036-ba67-1516ea2c6765" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_942da8d7-5e74-4144-9b09-354cfa4cef6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6c59a3f2-55bc-40ba-a282-fc789a94448c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0d1dc820-29cf-4036-ba67-1516ea2c6765" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6c59a3f2-55bc-40ba-a282-fc789a94448c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_d432310b-f35d-4e4d-a231-9270b163f7cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0d1dc820-29cf-4036-ba67-1516ea2c6765" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_d432310b-f35d-4e4d-a231-9270b163f7cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_45ebe306-ed5b-4d8f-98b6-9114d5c74a26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bab5de0a-2b3f-40dc-8852-087fc78954f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_45ebe306-ed5b-4d8f-98b6-9114d5c74a26" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bab5de0a-2b3f-40dc-8852-087fc78954f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_41e23038-1149-4486-ba8d-ebb78077ad6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bab5de0a-2b3f-40dc-8852-087fc78954f6" xlink:to="loc_us-gaap_AwardTypeAxis_41e23038-1149-4486-ba8d-ebb78077ad6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_174fbb27-f3e7-4926-80e9-f0005cd37fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_41e23038-1149-4486-ba8d-ebb78077ad6d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_174fbb27-f3e7-4926-80e9-f0005cd37fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f72f4f6d-d55b-4949-a86e-6ee31d78b8e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_174fbb27-f3e7-4926-80e9-f0005cd37fdf" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f72f4f6d-d55b-4949-a86e-6ee31d78b8e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_43dc0f44-9b54-4380-b36c-54e8b4f9c0be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bab5de0a-2b3f-40dc-8852-087fc78954f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_43dc0f44-9b54-4380-b36c-54e8b4f9c0be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_9f8cd815-fc14-4ea2-8b84-03b4e5de2487" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_43dc0f44-9b54-4380-b36c-54e8b4f9c0be" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_9f8cd815-fc14-4ea2-8b84-03b4e5de2487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_76d8f731-3143-4420-ab31-86c957402a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_43dc0f44-9b54-4380-b36c-54e8b4f9c0be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_76d8f731-3143-4420-ab31-86c957402a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_e96edc64-0e1d-4441-98db-cd670c2781f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_43dc0f44-9b54-4380-b36c-54e8b4f9c0be" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_e96edc64-0e1d-4441-98db-cd670c2781f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_00a7c2d5-a824-4e73-b9b5-acc1551c700c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_43dc0f44-9b54-4380-b36c-54e8b4f9c0be" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_00a7c2d5-a824-4e73-b9b5-acc1551c700c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_c19619f3-a29e-4e15-a550-a1e447b4deec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_43dc0f44-9b54-4380-b36c-54e8b4f9c0be" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_c19619f3-a29e-4e15-a550-a1e447b4deec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_40e747d9-4e02-4036-aee2-9c0e1efb6acc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_792ae3b6-0e3e-4c71-9682-dbf9b98a5595" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_40e747d9-4e02-4036-aee2-9c0e1efb6acc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_792ae3b6-0e3e-4c71-9682-dbf9b98a5595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ddbdffc9-9b68-47fb-9ad9-8400aa12416f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_792ae3b6-0e3e-4c71-9682-dbf9b98a5595" xlink:to="loc_us-gaap_AwardTypeAxis_ddbdffc9-9b68-47fb-9ad9-8400aa12416f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3ee1223d-2252-4a3d-b5ed-6946a8451c52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ddbdffc9-9b68-47fb-9ad9-8400aa12416f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3ee1223d-2252-4a3d-b5ed-6946a8451c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1e748fac-c035-4deb-879a-1490131cf278" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3ee1223d-2252-4a3d-b5ed-6946a8451c52" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1e748fac-c035-4deb-879a-1490131cf278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2bcfd2eb-6103-4e94-a160-1402bd569659" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3ee1223d-2252-4a3d-b5ed-6946a8451c52" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2bcfd2eb-6103-4e94-a160-1402bd569659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e2d4ca2b-d88d-4807-be6b-0f3c6cb14d74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_792ae3b6-0e3e-4c71-9682-dbf9b98a5595" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e2d4ca2b-d88d-4807-be6b-0f3c6cb14d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_fa684d46-019b-439b-a0d6-cd0ec233bb88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e2d4ca2b-d88d-4807-be6b-0f3c6cb14d74" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_fa684d46-019b-439b-a0d6-cd0ec233bb88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_bd962c13-dc6c-4a46-992e-8526c9cb8482" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e2d4ca2b-d88d-4807-be6b-0f3c6cb14d74" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_bd962c13-dc6c-4a46-992e-8526c9cb8482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_65a5360d-c8fd-4c5e-aec1-5aff105aedce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e2d4ca2b-d88d-4807-be6b-0f3c6cb14d74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_65a5360d-c8fd-4c5e-aec1-5aff105aedce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_805d3cb0-7ade-46d6-bcdf-cc24cfef672c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_65a5360d-c8fd-4c5e-aec1-5aff105aedce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_805d3cb0-7ade-46d6-bcdf-cc24cfef672c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7d260a0c-d73a-49ee-b78f-12b2f1445c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_65a5360d-c8fd-4c5e-aec1-5aff105aedce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7d260a0c-d73a-49ee-b78f-12b2f1445c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_22549a0b-5a89-4d34-942b-cefaed0792ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_65a5360d-c8fd-4c5e-aec1-5aff105aedce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_22549a0b-5a89-4d34-942b-cefaed0792ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1c3bd42b-36fd-4632-bf11-90bdafe85634" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_65a5360d-c8fd-4c5e-aec1-5aff105aedce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1c3bd42b-36fd-4632-bf11-90bdafe85634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a408129c-29df-489e-8ebe-59aed807e467" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_65a5360d-c8fd-4c5e-aec1-5aff105aedce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a408129c-29df-489e-8ebe-59aed807e467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_498e2703-9536-48e0-9a6f-919b71c5ce62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e2d4ca2b-d88d-4807-be6b-0f3c6cb14d74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_498e2703-9536-48e0-9a6f-919b71c5ce62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ad0b6e12-fe82-4638-8754-71f2939b5e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_498e2703-9536-48e0-9a6f-919b71c5ce62" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ad0b6e12-fe82-4638-8754-71f2939b5e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_61f3f5d7-1f77-4e28-afa2-dfd0a16de11a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_498e2703-9536-48e0-9a6f-919b71c5ce62" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_61f3f5d7-1f77-4e28-afa2-dfd0a16de11a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_bb7fcee1-1921-447a-8304-6e436923e944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_498e2703-9536-48e0-9a6f-919b71c5ce62" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_bb7fcee1-1921-447a-8304-6e436923e944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ba84b913-3d23-4941-8570-b61fa975a569" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_498e2703-9536-48e0-9a6f-919b71c5ce62" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ba84b913-3d23-4941-8570-b61fa975a569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5bfa56da-f0a2-4425-8cca-d8cfed21779c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_498e2703-9536-48e0-9a6f-919b71c5ce62" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5bfa56da-f0a2-4425-8cca-d8cfed21779c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20220331.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a5852f5c-a732-40b4-8995-3fb43c62abb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98ac066f-2103-41c0-89b7-0bcc6f6e4500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a5852f5c-a732-40b4-8995-3fb43c62abb3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98ac066f-2103-41c0-89b7-0bcc6f6e4500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cc9d86c9-1e64-49fa-905c-467131ef697f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98ac066f-2103-41c0-89b7-0bcc6f6e4500" xlink:to="loc_us-gaap_AwardTypeAxis_cc9d86c9-1e64-49fa-905c-467131ef697f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_05bf7c84-a4f8-42fd-a955-4359da95fa1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_cc9d86c9-1e64-49fa-905c-467131ef697f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_05bf7c84-a4f8-42fd-a955-4359da95fa1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_bb9e03e5-1ee9-4052-80ef-218f17160abc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_05bf7c84-a4f8-42fd-a955-4359da95fa1c" xlink:to="loc_us-gaap_PerformanceSharesMember_bb9e03e5-1ee9-4052-80ef-218f17160abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f5cb980a-682d-4191-ae8d-6456a6bd7a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98ac066f-2103-41c0-89b7-0bcc6f6e4500" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f5cb980a-682d-4191-ae8d-6456a6bd7a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2cb76339-ef4c-4dd5-99ef-caec6cc535f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f5cb980a-682d-4191-ae8d-6456a6bd7a4e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2cb76339-ef4c-4dd5-99ef-caec6cc535f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_dba04b4d-b27f-47b8-8b35-732f0f2814b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f5cb980a-682d-4191-ae8d-6456a6bd7a4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_dba04b4d-b27f-47b8-8b35-732f0f2814b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_76012fe7-4757-4eda-bf19-505a6b9dd954" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_dba04b4d-b27f-47b8-8b35-732f0f2814b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_76012fe7-4757-4eda-bf19-505a6b9dd954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2e1ac68f-5bf9-4d42-a7f8-6ceb8c9cc1c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_dba04b4d-b27f-47b8-8b35-732f0f2814b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2e1ac68f-5bf9-4d42-a7f8-6ceb8c9cc1c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_48b3b26c-b88d-4d1e-82f2-f58c1f25b5bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_dba04b4d-b27f-47b8-8b35-732f0f2814b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_48b3b26c-b88d-4d1e-82f2-f58c1f25b5bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_737645d9-9fba-4c72-b86f-d8949395095b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_dba04b4d-b27f-47b8-8b35-732f0f2814b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_737645d9-9fba-4c72-b86f-d8949395095b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_33b4d35c-d979-414e-894e-d7095dcaac87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_dba04b4d-b27f-47b8-8b35-732f0f2814b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_33b4d35c-d979-414e-894e-d7095dcaac87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c9251145-970a-4b67-8730-6ba52fda3775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f5cb980a-682d-4191-ae8d-6456a6bd7a4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c9251145-970a-4b67-8730-6ba52fda3775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_df4be35c-6cae-4399-b48e-b48d30a361b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c9251145-970a-4b67-8730-6ba52fda3775" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_df4be35c-6cae-4399-b48e-b48d30a361b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_316a67d5-d901-4f82-95d3-a839cb3b9b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c9251145-970a-4b67-8730-6ba52fda3775" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_316a67d5-d901-4f82-95d3-a839cb3b9b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3fad475c-43a1-451c-b5cc-74c91edb60af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c9251145-970a-4b67-8730-6ba52fda3775" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3fad475c-43a1-451c-b5cc-74c91edb60af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ab1fd0d4-c811-45fa-b4d0-25f8ef268852" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c9251145-970a-4b67-8730-6ba52fda3775" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ab1fd0d4-c811-45fa-b4d0-25f8ef268852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_812c982e-72ad-4b40-9c46-f0ccab1e9484" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c9251145-970a-4b67-8730-6ba52fda3775" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_812c982e-72ad-4b40-9c46-f0ccab1e9484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5a7d34d5-4a7f-41ca-be71-76159fb5a1e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f5cb980a-682d-4191-ae8d-6456a6bd7a4e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5a7d34d5-4a7f-41ca-be71-76159fb5a1e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f184cc0d-68fc-4073-b76f-ae926e616eda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f5cb980a-682d-4191-ae8d-6456a6bd7a4e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f184cc0d-68fc-4073-b76f-ae926e616eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7e1fbae3-3602-4417-bda2-11dd740391e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f5cb980a-682d-4191-ae8d-6456a6bd7a4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7e1fbae3-3602-4417-bda2-11dd740391e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>cah-20220331_g1.jpg
<TEXT>
begin 644 cah-20220331_g1.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$]_CU\+M3?0-=\>Z#<Z_X=O+60AM.N[X>'KBWD1NH,;RH0>ORUYC_P '!_\
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M (5KH_A6QLY-!O,:U<FW^W/+&TJYN3(K[&7Y I&#S7UG_P %'_\ @K;^Q/\
M\$L/!^F>)/VJ_B!=0ZCKI?\ X1_PIH%C]LU74E3&]XX=RJD:Y ,DKHF3M#%N
M* /I>BOBO_@FS_P7U_X)Y?\ !4?QM<_"GX!^+-?T+QG#:/=P>#_'6E1V5[>P
M(,R26YBFFAFV#ED60N%!;;M!8;'[2?\ P7"_X)__ +(?[6E[^QS^T/X^U7PU
MXBTWPJ_B&_U>[TG.EPV:VLER!YRL7>5EC*)$D;,\C(B@EA0!]>45\#_L$_\
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M)))]S7H'_!R)^S]J?[17_!&CXS>'_#]BT^I>'-)MO%%FJ+DA--NHKJY.._\
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M;?#<:%_PFGB3_A(]-MO[.^SZW<W4W^CSW"7$VV&1'_=1OG.!D@BN7_X+1?\
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M(HKG7S&,K"WV2YN(<GH"+G7+3WX([< '[.4444 %%%% !1110 4444 %%%%
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MW3_T(5!4^E_\A*W_ .NZ?^A"@#Z)HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "O,_VRO^36?'7_ &+T_P#(5Z97F?[9
M7_)K/CK_ +%Z?^0H _)>BBB@ HHHH **** "OTF_X):?\FLI_P!C#>?RCK\V
M:_2;_@EI_P FLI_V,-Y_*.@#Z.HHHH **** /,/C_P#\A+3O^N$G_H0KSZO0
M?C__ ,A+3O\ KA)_Z$*\^H **** "BBB@ J?2_\ D)6__7=/_0A4%3Z7_P A
M*W_Z[I_Z$* /HFBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %W3_P!"% 'T31110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXU#QS\:=6M_L>J_L6^,+F'<&\JXL2Z[@<@X,9&0>:G_X69\>_P#HSWQO_P"
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MW2?&O[.7B#P9!:V@FAOM7D)2=]P7RUS&G."3WX!KU"@ HHHH **** "BBB@
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M3;?M%?#/Q!JWQ-LO&.J?VOJ6CRZ/-;M87T=[,#<Q6LK7=Q;+;ES &3*J"HP
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M(W@3XL_$7P=_:/B#X::M<ZGX)U#^T+B'^S;JXM7M9I-D4BI-NAD=-LJNHW9
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MUQ\0M"U7P9^TE_P34C_9ST?PM8:?:>"]/MOB9H^OV^H0;94>&*/3 !9I;I%
M K##"8!?N&@#YU_X(W?LR^"_V0?V\?VR?@-X&\2>(-;MM,U?P)=7NO\ BO5G
MOM3U:^NM"DNKN]NIV^_+-<32R-@!07PH   _1&OF?]E?]GWXO?#?_@H=^U3\
M<_&GA'[%X5^)%]X+D\%ZI]OMY/[16PT,6MV?*CD:2'9-\G[U4W=5W+S7TQ0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
>4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>cah-20220331_g2.jpg
<TEXT>
begin 644 cah-20220331_g2.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-?&+XB^*]>\517_[-?CO3Y_ "6.HP)%<L;S4X?\ 30T#&4;;2+_5F+DMZ@
M_4O_ ()R_!W]M[P7_P %4OVB?'WQV_;\\-_$/X<:S?:NW@;X7Z9\5+K5KOPH
MCZNLD*3:;(@CL3%!F A"=C'8.*^S?C%^U/\ LQ?L[W5E8_M ?M&^ _ L^I#.
MG0^,?%]EICW0SMS&+F5"_/'RYYXK\8/^"(7B/3_!W_!P_P#\% /%VK;OLNE7
M'BZ\N=@Y\N+Q*KMCWPIKQ/\ X(R_\$R_A_\ \'$WQ!^/?[?_ /P4;^(OB_4+
MVY\5)INBV/A_65M_L<TL33'#/&^(K>)[>*"( (JAMP;@  _H\T#Q!H/BO1+7
MQ+X7UNTU+3KZ!9[+4+"Y6:"XB895T="5=2.002#7FNO_ +=?[$/A3XA/\(_%
M'[8_PJTWQ7'<&W?PQ?\ Q#TV'45E! \LVSSB0-D@;=N<D5\2?\$L_P#@D%^W
M5_P3]_87^-W[&OCK]N?0[/2O%L=Y_P *N\3:%9W-W-X($\4\5Q>8G-N S(8)
MA%&RI%,DCAV+EC^-O[9?['?_  0,_9)_8A\2_#O1?V\-2^,?[3T%S-)I?B#P
M$L\NB2R_:_DB?"O:B+R.'87$DOF%F4[<+0!^W7_!SO\ '?XT?LZ?\$F?$GQ1
M_9_^+/B'P7XC@\6:)#;Z]X6UB:QNXXI+H*Z++"RL%9>" <$5]"_\$G?'?C7X
MG_\ !,GX"?$7XC^+-1UW7];^$^AWNLZUJ]X]Q=7US)91M)-+*Y+2.S$DLQ))
M.37XV_M,?$SQE\6_^#*_X:^+O'NNW.I:C%KUKI@N[N8R.;>Q\2WME;(6/)"0
M6\2#V05^OO\ P1B_Y1+_ +.'_9&/#W_I!%0!],4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5^#O\ P6'_ .5M']D7_L!^$O\ T^ZO
M7[Q44 %?AG_P? ?\D ^ ?_8Y:S_Z26]?N910!^3'_!YC_P HF-!_[+1H_P#Z
M0:G7Q=_P< >&O'NB_LK?\$\/CU\1/AWJOBSX'>%OASH"^,]&LG=+>2X:UTJ2
M2WF=<")[FUB>*)R1]R0 @YS_ $<5!JFE:9K>GS:1K6FP7EI<(4N+6ZA62.53
MU5E8$,/8T ?RQ_\ !53]O7]F7]K'XN_LR?&G]C3]C'5/A3^SY\+?&ZVD'B2\
M\'6FC6>I:G+=6%Q=PQQVA:(^1!91$MO+$LV0HVEOM7_@IVT5Q_P=X?LI2(RN
MC>#-#964Y!'VS6R"*_<?3=,TW1K"+2M'T^"TM8$"06UM$(XXU'1550 !["IZ
M /QZ_P"#UK_E&'\//^R\Z=_Z9=9KE?\ @YQ_Y5XO@9_V,G@S_P!1^]K]KZ*
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MR6+H2T31%2C-N5/Z8ZS?$7@WPAXO6W3Q9X5TW5!:R^;:C4;&.<0O_>3>#M/
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*=%\6:58O?1>'_&VCQ6<^H6B.JR3VS0SS1R!2R$H660!MVS 8@ ^UJ*^)?\
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ML]&NE.'@FFFN(0\B'AUA$I1@4;#JRCZB\+?\%"_V5?B#^Q!JO_!0WX9?$/\
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M_&&HI'+XG\-6U]:074%XMN+:6:..\*V]W;W$"KYL+'?YFY@K[QL /A7]H?\
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MDC8'S/ECDDFOHR7_ ()L_MJ-_P '347_  4<7X,?\687PS]D/C+_ (2/3?\
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M5>,-8NSKGQ=U.[MKQM(LKJ-+>[FTMXKH.YFA3*Q/;F1';.;<EG7Z(_X(C_\
M!$O]I#P'_P $G/V@_P!@/_@H/\+7\!W/Q7U^<Z88M<T[4WAC;3[9(+U397$J
M;HKF%7".RDF(9&#F@#\_/V3/BCJVK_\ !%F]_8N\'?\ !O1\5_B/=^-M#U6:
M#XZ^'_!5W>)>:O)-/]CU.":+3)"PM&$,01)L$6[H2-[Y_8K_ (-C?#W[2_@'
M_@DWX7^$G[4_PH\7^#=>\'^)M6TS3=(\;Z!=:;??V<TXN86\JZ1)#&#<2(C8
MQB/:.%P/SF^'G[,/_!U?^QW^R_JW_!)'X$_!;1+WP-=7]S;^'/BOH?B&VANM
M*L9[@S3_ &*^-["UK$[O*_[Z#[0GFR"/!V;?VR_X)V_L]_&_]EW]CGP5\&/V
ME/C]K7Q.\?:;I[2>*_&6NZK/>RW=Y+(TCQI-.?,>&(,(49\,RQAF +$  ]LH
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\K?^"M/_
M  ;M_$S]K[]M.R_X*._L*?M;/\)/BTEO;+J<]Q'<)%<7%O;BVBNX;JV;S;>3
M[.J0.FQUD11]WY@_ZI44 ?E1_P $R?\ @WG^.OP)_;@MO^"CG_!2/]M*X^-'
MQ-T6SDA\,1J]U<0VDKPO )Y+F[(>01Q22+'"L:)&S;P20 /U7I&944N[  #)
M)/2OC7X+?\%N/V9/CE^S-\=OVR?"/@+QC)\-/@3KM]IE_P"(XK6UD_X24VD8
MDFFTY//&]/+>%U,IC)$R]#D  ^RZ*\8_8"_;I^#G_!1[]F+1OVL?@-I&OV/A
MG7;R\MK.V\3V45O>*]M</;R%TAEE0 O&Q&'.1C..E>ST %%%?/7_  4L_P""
MEOP _P""5GP#T_\ :-_:0T+Q3J&@ZEXJM] MX/".G07-R+J:WN)T9DGGA41[
M+60$[B<E>#DD 'T+17/_  E^).@?&;X5>&?C!X4@NHM+\5^'[+6--BOHU29+
M>Z@2>,2*K,%<*XR Q .<$]:\C_X*._\ !1CX$_\ !+W]GA/VF/VB-$\3:AX?
MD\06VCB#PI807-U]HG25T.R::%=F(FR=V>1P>P![Y17QU^V5_P %OOV0OV&_
MV2_A3^V9\8?"GCR[\*?&&QLKOPM:Z!HUK-?0I=6"WT8N8Y+J-(R(F .QWPV0
M,CFM?]O#_@L5^RQ_P3P\8?"+P1\<_#/C6]O/C3<R0>$W\-:3;7$<#))9QG[2
M9;F(QC-[#]P/P']!D ^KJ*^6OVH_^"NO[,/[(_[<?PN_X)__ !.\-^,KGQM\
M6Q8_\(Q>:-I5M+IT/VJ]DLX_M$LERDB8DB8MMC?"X(R>*^I: "BBB@ HHHH
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MK4EM;Q6DEQ%<Q/Y-I')+$Z1L\$R%L+O9B5'V'_P6#_X*B_L_ZI_P1=\#?\%
M?"'[,W@3XR^#O''B72&T[PA\5-'6[L[:26*[$ADB!(%U;RPRPD@D!A( 2.2W
M]L'QK\#-0_X-0I==LM0TQO"]Q^S/X?L]'"NGEK?"VLH;>$#_ )ZI>*B%?O+(
MA!Y!K\S/C%8>(['_ (,TOA6^NI*L%Q\=)Y=)$F?^/8ZAJXROL95E/XDT >V_
M\'1GC?3_ (F_\$7OV-_B1I/@?2?#%IXA@TC4K7PWH,'E6.DQS^'$E6TMT_@A
MB#B-%[*@%=!_P=-_\G#_ /!/W_L,W?\ Z5^'J\__ .#C+_E 3^PC_P!BQX;_
M /45AKT#_@Z;_P"3A_\ @G[_ -AF[_\ 2OP]0!]-_P#!47]MSX?_  2_X+B_
MLO?LT>(/V(OA3XVU;QL-#_L_XF>*M"$^O>&_.UJY@7[#/C]UY;(94]'=C70?
M\%IO^"^VK_\ !//XP^&?V+/V1/@$?BQ\<_%D$-Q!H!2>:WTV.9BMO&T%K^^N
MKB8JQ6!&0A,.6PRAOE[_ (+B_P#*SO\ L/\ ^[X9_P#4DO*Q_@Q=:#X5_P"#
MU;X@?\+PN(8]0U+1)$\#SZB0 T\GARR^SK$S<;C:"XC&.2=R]3B@#W#_ ()N
M_P#!QE^T7XZ_;:TS_@G?_P %8_V0H/@U\0?%!BB\):A96-Y8V]Q=2@F"WEM;
MV25U6<@I%.DKJTFV/;\VX;7_  4>_P"#B?XJ?L!_\%1C^PQ8?LLP>/-'N/"E
MM<Z';: ;EM<U?6;RVD^Q6,2KN0+)=>2A81NP1F*J[ *?G;_@ZZGTCQ'_ ,%+
M?V+?!?PBDAD^*"Z\2T=F0;M8IM7TU=+SM^8#[1'>E/??CO5[]I/2=/UK_@]4
M^$=GJ=JDT:>%89U1UR!)%X<U.6-OJ'16'H0* /1OV+/^#BW]NF;_ (*8^'/^
M">W_  5#_8<T?X67GCZ>*#PK)I<-Y;W=C)<!_L;3"XFF2[BED0P^9%Y>V0G(
M.UE'H/\ P4A_X+G_ +9O@7]OR_\ ^"9'_!*;]C32_BM\3/#.A1ZGXOO?$<TA
MM+02013^6D4<]N-J17%N7F>=1OF$87<,GY]_X+RP0Q?\'*O["M['&!+)J7A6
M-W Y*CQ3+@?3YF_,T_\ X*W?\$G_ !'^U)_P5&\0_M,_\$C/^"C7@S0OVBH]
M%CN_&_PPT[X@G3];LVLXK>R>XAFLW9[<O']E22WN%C4DEBY$FT 'U1_P1T_X
M+6_M(?MH_M+^/?V#_P!O+]D0_"WXM^!+$WMS_9$%R-/G13%OMY$F:0P2[)HI
MHV\Z1)HF9E("C?X1X9U^3]AC_@[^UGP#I4IL_#?[3GPUCO+NR!Q"+U;.219\
M=W:ZTFY /K>2#O6#_P $6O\ @K!_P59^'_\ P4ZB_P""/?\ P5AT9-6\1ZGI
M5U+I6L7D-F=2T^>#3WU",R7-B3!>V\MM#)ASND#E,R<,M2_\%:8I;_\ X.O?
MV,[/0LF_C\':7)<[/O?9UU36V;/ML6;\,T ?MI1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\M_\ !:S]
ME?4_VSO^"6?QH^ 7AS36N]9O?"+ZEX?M8TS)/J&GRQW]O"G^U));+$/^NF#P
M37S#_P $E=$T_P#X*J?\&U6A?LP1?$5?#]_J'@/4?AWJVLC3_MITF2UF>"%C
M!YL7F'[+]FDV;TXD'(K]0J\+_8F_X)Y?L_\ _!/Z7XAVO[.;ZY9:1\1_&L_B
MG4O#E]J"2V&FW\PQ*+*-8U,$;*(UV%GPL,8!&WD ^7M/_P""!/V#_@A_??\
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MVIM7^.7Q0TW+>'+O5;65+;39O+\H74CW$\TUW.L?RQLQ18LY",RHZ>R>/_\
M@B__ ,)S_P %K_"7_!8?_AI+[+_PBVC?8/\ A77_  AV_P"U?\2N[L-_V_[8
M-G_'UYF/L[?<VY^;</N:B@#X9_;T_P""+W_#;O\ P4E^!/\ P4*_X:3_ .$8
M_P"%*7>ES_\ "(?\(=]M_MG['JC7^/M7VR+[/OW>7GRI-N-W/W:\O_X*8_\
M!NLW[5W[7 _X*!?L4?MA^(?@)\7KB%$US5=#MYFAU&1(1 )U>WG@FM96A CD
M*ETE51E Q=F_3:B@#\Y_^"4O_! .T_82_:1UK]N?]J/]J[Q#\=/C5K-A)9P^
M*M>AE1-.CD18Y'#3SSS7$QB01"5W4+$614 .:\)^#/AJ3]N+_@[A^(7QMTZ/
M[7X8_9C^'<.C)J &Z(:I-9M;?9SZ.);_ %0C/>T8]<5^QU>%_L1_\$\OV?\
M]@>/Q_=_!I]<U#5_B?XUN?%/C7Q'XGU!+J_U&_F))#2)'&!&K-(RIMX::0Y.
MXT >Z4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%9GC/QCX<^'W
MA:_\:^+]1^R:9IENT][<^2\GEQCJ=J L?H 30!IT5XE_P\7_ &-O^BQ?^6]J
M/_R/1_P\7_8V_P"BQ?\ EO:C_P#(] 'MM%>)?\/%_P!C;_HL7_EO:C_\CT?\
M/%_V-O\ HL7_ );VH_\ R/0![;17B7_#Q?\ 8V_Z+%_Y;VH__(]'_#Q?]C;_
M *+%_P"6]J/_ ,CT >VT5XE_P\7_ &-O^BQ?^6]J/_R/7I7PL^+?P]^-7A8>
M-?AEX@_M/3#</ +G[)+#^\3&X;945N,CG&* .CHHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "O,_VRO^36?'7_8O3_R%>F5YG^V5_P FL^.O^Q>G_D* /R7H
MHHH **** "BBB@ K])O^"6G_ ":RG_8PWG\HZ_-FOTF_X):?\FLI_P!C#>?R
MCH ^CJ*** "BBB@#F/'_ ,2/^$&N;:W_ +&^U?:(V;/VC9MP0/[ISUKGO^&@
M_P#J4?\ R?\ _M=0?'__ )"6G?\ 7"3_ -"%>?4 >D?\-!_]2C_Y/_\ VNC_
M (:#_P"I1_\ )_\ ^UUYO10!Z1_PT'_U*/\ Y/\ _P!KH_X:#_ZE'_R?_P#M
M=>;T4 >D?\-!_P#4H_\ D_\ _:ZDM?CY]IN8[?\ X1/;YD@7/V_.,G'_ #SK
MS.I]+_Y"5O\ ]=T_]"% 'T31110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %>9_ME?\FL^.O\ L7I_Y"O3*\S_ &RO^36?
M'7_8O3_R% 'Y+T444 %%%% !1110 5^DW_!+3_DUE/\ L8;S^4=?FS7Z3?\
M!+3_ )-93_L8;S^4= 'T=1110 4444 >8?'_ /Y"6G?]<)/_ $(5Y]7H/Q__
M .0EIW_7"3_T(5Y]0 4444 %%%% !4^E_P#(2M_^NZ?^A"H*GTO_ )"5O_UW
M3_T(4 ?1-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ME?\ )K/CK_L7I_Y"O3*\S_;*_P"36?'7_8O3_P A0!^2]%%% !1110 4444
M%?I-_P $M/\ DUE/^QAO/Y1U^;-?I-_P2T_Y-93_ +&&\_E'0!]'4444 %%%
M% 'F'Q__ .0EIW_7"3_T(5Y]7H/Q_P#^0EIW_7"3_P!"%>?4 %%%% !1110
M5/I?_(2M_P#KNG_H0J"I]+_Y"5O_ -=T_P#0A0!]$T444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7S7_ ,%=/VJ_@_\
ML;_\$_\ Q_\ &3XTZO-;Z;_9ZZ=86MI$)+F_O;APD-M"A(#.QR>2 JHS$@*3
M7TI7P;_P<=_L9?$G]M'_ ()HZIHWP=U&VC\5?#[Q7I_C30[*\=4BU"6S6:)[
M<LWRJ3%<R,N[Y2Z(K%02P /RG_8@_P""CW@O]K;7[_X;:YX2O_#'BZS6ZNX-
M,OK<I'=V4=R\0:-BQ)E0!5D0@8</MR%;;W?QC_;+^%/P9^.7@C]GK5ENM0\2
M>-[Y8+>VT]HV_L]&8(DUQN8%59B0N 2=C<<5\R?\$P/VI/!/B+X@0_ ?XR?
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M^";WPL^+?QIUF74_$FHZ/<P7VK7"%9-12VOKBU@NWSR6FAABE+'[QD)[U?\
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M1)?A%8?%KPW-XIASYOAV+6H&O4(&64PAM^X#DKC(')&*ZNOR$U+X,^%_ ?\
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MPI_V,,G_ *(:OSD\6_#'PAXV\4>&_&/B"P>6_P#">HRWNBRK*5$4TEO);N6
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M$OPYHO[5&J7'QE^+%W-J?BGXU3^'X3,FI-$L,$D%B) D=O;QJ$BM_,PHW?,
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M6G_)K*?]C#>?RCH ^CJ*** "BBB@#S#X_P#_ "$M._ZX2?\ H0KSZO0?C_\
M\A+3O^N$G_H0KSZ@ HHHH **** "I]+_ .0E;_\ 7=/_ $(5!4^E_P#(2M_^
MNZ?^A"@#Z)HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **\2U3P+^WI+J=S+I'QW\$0VC3N;6*7PO(S)&6.U2=W) P":@_P"$!_X*
M"?\ 1?\ P)_X2DG_ ,50!YU_P5Y_Y)3X4_[&&3_T0U? E?HC\7OV2_VK_CSI
M-IH?Q7^*O@35;6QN#/:Q?V%=P;)"I4G,,J$\$C!)%<#_ ,.JO'?_ $'? G_@
M+JG_ ,E4 ?%E%?:?_#JKQW_T'? G_@+JG_R51_PZJ\=_]!WP)_X"ZI_\E4 ?
M%E%?:?\ PZJ\=_\ 0=\"?^ NJ?\ R51_PZJ\=_\ 0=\"?^ NJ?\ R50!\645
M]I_\.JO'?_0=\"?^ NJ?_)5'_#JKQW_T'? G_@+JG_R50!]@?"/_ ))3X8_[
M%ZR_]$)70UX%I'PL_;UT+2;70]*^._@2*UL[=(+:+_A%Y6V1HH51DN2<  9)
M)JS_ ,(#_P %!/\ HO\ X$_\)23_ .*H ]THKPO_ (0'_@H)_P!%_P# G_A*
M2?\ Q5'_  @/_!03_HO_ ($_\)23_P"*H ]TKPSXF?\ (]ZE_P!=Q_Z"*3_A
M ?\ @H)_T7_P)_X2DG_Q586I_L[_ +9^L7\NIZE\9? DD\S;I'_X1VX&3TZ"
M0"@!:*K_ /#,O[87_17O G_A/W/_ ,=H_P"&9?VPO^BO>!/_  G[G_X[0!8H
MJO\ \,R_MA?]%>\"?^$_<_\ QVC_ (9E_;"_Z*]X$_\ "?N?_CM %BBJ_P#P
MS+^V%_T5[P)_X3]S_P#':/\ AF7]L+_HKW@3_P )^Y_^.T =G\&/^1[@_P"N
M$G_H->RU\XZ+\ /VU?#U^NIZ/\:/ D,ZJ55_^$<N&P#P>&D(K:_X0'_@H)_T
M7_P)_P"$I)_\50![I17A?_" _P#!03_HO_@3_P )23_XJC_A ?\ @H)_T7_P
M)_X2DG_Q5 'NE>9_ME?\FL^.O^Q>G_D*Y?\ X0'_ (*"?]%_\"?^$I)_\569
MXS^"'[</Q!\+7_@KQ?\ &[P)=Z9J=NT%[;?\(U/'YD9ZC<CAA]00: /S2HK[
M3_X=5>._^@[X$_\  75/_DJC_AU5X[_Z#O@3_P !=4_^2J /BRBOM/\ X=5>
M._\ H.^!/_ 75/\ Y*H_X=5>._\ H.^!/_ 75/\ Y*H ^+**^T_^'57CO_H.
M^!/_  %U3_Y*H_X=5>._^@[X$_\  75/_DJ@#XLK])O^"6G_ ":RG_8PWG\H
MZ\L_X=5>._\ H.^!/_ 75/\ Y*KTGX6?LS?MA?!7PL/!7PR^+_@33-,%P\XM
MO^$?N9OWCXW'=+*S<X'&<4 ?3%%>%_\ " _\%!/^B_\ @3_PE)/_ (JC_A ?
M^"@G_1?_  )_X2DG_P 50![I17A?_" _\%!/^B_^!/\ PE)/_BJ/^$!_X*"?
M]%_\"?\ A*2?_%4 =+\?_P#D):=_UPD_]"%>?58\0? []N#Q3+'-KOQM\"3M
M"I6,_P#"-3K@'K]UQ6?_ ,,R_MA?]%>\"?\ A/W/_P =H L457_X9E_;"_Z*
M]X$_\)^Y_P#CM'_#,O[87_17O G_ (3]S_\ ': +%%5_^&9?VPO^BO>!/_"?
MN?\ X[1_PS+^V%_T5[P)_P"$_<__ !V@"Q4^E_\ (2M_^NZ?^A"J'_#,O[87
M_17O G_A/W/_ ,=I8OV:?VQ895FB^,'@0,C!E/\ PC]SP1_VTH ^EZ*\+_X0
M'_@H)_T7_P "?^$I)_\ %4?\(#_P4$_Z+_X$_P#"4D_^*H ]THKS[X,^'/VD
MM$U.]E^./Q'\/:Y:/ HL8M%T=K9HI-W+,23N&.,5Z#0 4444 %%%% !1110
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MRXM=<UB\M]5C$<U]<A"ERX6=EW-'NVJ@! '/27?P[_:!_P""+?[97P0_L_\
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M]W-'#;^#=2\9V4.I-+)CRXO(>0.)'W+L0@,^1M!S7J] !1110 4444 %%%%
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MBR!OEED(1%R0,DCD@=ZXGXR?MN_L=?L[^$]"\=?'C]J+P%X.TCQ1"DWAN_\
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M#%AXU\">)].UK1M5M4N=,U?2;V.YM;R!QE)8I8R4D1@00RD@CH:T: "BBB@
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M[ PH 'R=KG_!M#_P1'\2^,+WQYKW[$D=WJFHZC+?WL\WQ"\1E)IY)#([&/\
MM'R\%F)V[=O.,8XKZFA_; _91G^$^L?'F/\ :4\"_P#"#^']0FL-<\8-XJM!
MIEA=1.$D@ENC)Y22*[*I4MD,0.IQ5[X"_M,?L[_M3>#Y/'_[-GQP\*>/-%AN
M3;W&I>$]>@OXH)@ 3%(86;RWP0=K8."#C!% &I\(O@_\+?@%\-])^#_P5\ :
M3X6\+Z%:_9](T+1+)+>VM8\EB%10!DL69F/+,Q8DDDUTE86J_$_X=:'\0-(^
M%&L>-M+MO$VOV-W>Z)H,UXBW=];VIB%Q-%$3N=(S-$&8#"^8N>M;M !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?FC_P<
M2>.OV<_AGXT_9&\>_M<Q:._PUTOX]O-XP7Q!HAU*R-F-)N@?.MA'*9EW%?EV
M-]*_2ZO@W_@L-IVGZM^UC^P[INJV,-S;S?M'E98+B(.CC^Q[S@J>"/K0 _\
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M>!_V+?AGH'AW6_!?PM\4W/Q^_P"$,TF&RMXO#UU:PQ:+9WJVZJAD-\J311L
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M$FVVD?!(B*(H+2&K_P#P3C^!OQ*_;3LOC'_P58^(FKZAX/\ &7[07AVZ\._
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
#'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>cah-20220331_g3.jpg
<TEXT>
begin 644 cah-20220331_g3.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M85"I(T29;.:^)/\ @GW^VU^U[_P;1?M$?%G_ ()[_%W]BGQ+\3(O%GB-;KP
MFB22VKZQ=(&A@N[1A!,+J"ZB\C<J O$\6TC>'0?TMV5E9Z;:1:?IUI%;P0H$
MA@AC")&H& J@< #T%?A'8_$__@Z:_P""5OQ^\;?#^T^#7B3]J;P+?W#P^"M?
MUX7&M(ENLCF"Y#VLRW,$A1@LT4_&Y?E. KL <A_P;%:K\<_$/_!>3]J/Q+^T
MQH$>D_$'4O"6MWGC/28&!2PU*;Q!82SVRX+ +&[-& "0 F,G&:]%_P"#)_\
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MV!\G&<\?LY5#1/"OA?PR]S+X;\-V&GM>S&6\:QLTB,\ASEWV@;FY/)R>:OT
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!S/Q8^-?P:^ OA=?''QS^+?ACP7HKW:6J:QXLUZWTZU:=PQ6(2W#HA<A&(
M7.2%/'!KS>/_ (*8_P#!.":188?^"@?P1=W8!57XK:.22>@ ^TU\&_\ !Y-_
MRB1TO_LL.C?^D>H5X3^QC_P:)?\ !.[]IS]ASX4_M$>(_CO\:=-\3?$#X5Z'
MXBOX[+7-(:PM;Z^TZ"YD$<+:9YAA624@(92VT %R?FH _<?PQXI\,>-M M?%
M?@SQ'8:OI=]%YMCJ6EWB7%O<)TW))&2KC@\@D5?K\%_^#.;XD?$[P#\=/VC_
M -AR;QX_B/P-X0O([[1[J*0M:17L=[/9R3VXR0BW4:(Y )!\A2.Y/VA^US_P
M='_\$K?V/?V@M1_9P\5^(O&?BO6=#U!K#Q'J7@?P_#>:?I5TC;989)I;B(R/
M&00X@67:P*GYE90 ?HQ17RY\;_\ @L-^Q+\$_P!A;1?^"CH\7:MXM^$^O7UM
M:VFN^#=)-W)"TS21@S0R-&\.V6,PNK@.DK!&4'./2M*_;7^ &L?L4I_P4 M/
M$\H^&S?#UO&;:B]OB=--6T-TP,6>)E0%#%G/F IUH ]9HKY;^ '_  6'_8F^
M/_[#WB+_ (**6OBS5_"GPI\,7]S::CK_ (STDVC.T/E!C#$C2-,&DF6%%0%W
ME!15)QGPC]E#_@Z9_P""4_[6WQ]T_P#9X\.^)?&?A+5=;U%;#P]JOCGP]#::
M=J=R[;8XDFBN)3$SD@+YZQ DA<[B 0#]&Z*^:_VZO^"K?[)7_!.KXE?#'X6_
MM+ZMK5C??%G5)K'PS=V&G)+:0O%-:PR/=2O(@@C5KR(ESD!0Q/W:^<_!/_!U
M7_P2,\>_M/6O[,VC?$+Q7$M_K"Z98>/[WPXL7AZXN&?RTQ,9O/2-G( E>!8P
M#N+!?FH _2"BOFC]N[_@J_\ LH_\$ZOB3\-/A5^T3)XD75?BOJ,UEX4_L/1A
M=1F6.:VA;SF,B^6-]W%S@\;O2K?_  4@_P""HW[+W_!+#X<>'_BE^U-)XA72
M_$NMMI6F_P#".Z0+R3[0(6F.]2Z;5VH><GF@#Z,HKPK]M?\ X*/_ +)W_!/K
M]G6W_:;_ &G/'TFCZ!J)ACT2RMK0SW^JW$L?F);V\"G+R; 6))"( 2S*.:\1
M_P""<7_!PM_P3G_X*<_%&3X'?!'Q)XE\.>-&MY9],\,^/-(BLKC58HE+2M:O
M#/-%*R*"YCWB3:K,$*HY4 ^XZ*** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MRQ,FG7/ER([R3L5D5]UPC$ JAK[]_P""$/\ P2W_ ."EO_!-7]ISXR_L@_M
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M?%FQ?X%^'? &I6YU[XP^&_$\=AJ&H1PQ& 374UEJ$C7[")GQ#;I'%+(P:7&
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MG3/@A^VG^P;=VMK\=_@9!9K::1<W\$#:C%!)'<PB&:8^1YUO<H[!)&6.1)Y
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M6/\ PC%YHVE6TNG0_:KV2SC^T2R7*2)B2)BVV-\+@C)XKZEH **** "BBB@
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M(*13I*ZM)MCV_-N&U_P4>_X.)_BI^P'_ ,%1C^PQ8?LLP>/-'N/"EM<Z';:
M;EM<U?6;RVD^Q6,2KN0+)=>2A81NP1F*J[ *?G;_ (.NI](\1_\ !2W]BWP7
M\(I(9/B@NO$M'9D&[6*;5]-72\[?F ^T1WI3WWX[U>_:3TG3]:_X/5/A'9ZG
M:I-&GA6&=4=<@21>'-3EC;ZAT5AZ$"@#T;]BS_@XM_;IF_X*8^'/^">W_!4/
M]AS1_A9>>/IXH/"LFEPWEO=V,EP'^QM,+B:9+N*61##YD7E[9"<@[64>@_\
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MF4@*-_A'AG7Y/V&/^#O[6? .E2FS\-_M.?#6.\N[('$(O5LY)%GQW=KK2;D
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M_P +'_X03&S&N1ZKL_L_[=S_ *OR<_:!UWXXV5[%X>_X)=_V#_P1ZD_X)/\
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M;^8DD-(D<8$:LTC*FWAII#D[C0![I1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1169XS\8^'/A]X6O_&OB_4?LFF:9;M/>W/DO)Y<8ZG:@+'Z
M $T :=%>)?\ #Q?]C;_HL7_EO:C_ /(]'_#Q?]C;_HL7_EO:C_\ (] 'MM%>
M)?\ #Q?]C;_HL7_EO:C_ /(]'_#Q?]C;_HL7_EO:C_\ (] 'MM%>)?\ #Q?]
MC;_HL7_EO:C_ /(]'_#Q?]C;_HL7_EO:C_\ (] 'MM%>)?\ #Q?]C;_HL7_E
MO:C_ /(]>E?"SXM_#WXU>%AXU^&7B#^T],-P\ N?LDL/[Q,;AME16XR.<8H
MZ.BBB@ HHHH **X3XO\ C/Q+X6OK*'0M2\A9HG:0>2C9((Q]X&N._P"%N?$/
M_H8/_)2'_P"(H ]LHKQ/_A;GQ#_Z&#_R4A_^(H_X6Y\0_P#H8/\ R4A_^(H
M]LHKQ/\ X6Y\0_\ H8/_ "4A_P#B*/\ A;GQ#_Z&#_R4A_\ B* /;**\3_X6
MY\0_^A@_\E(?_B*EL/BQX_FOH89=?RKRJK#[+%R"?]R@#V>BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\S_;*_Y-9\
M=?\ 8O3_ ,A7IE>9_ME?\FL^.O\ L7I_Y"@#\EZ*** "BBB@ HHHH *_2;_@
MEI_R:RG_ &,-Y_*.OS9K])O^"6G_ ":RG_8PWG\HZ /HZBBB@ HHHH \P^/_
M /R$M._ZX2?^A"O/J]!^/_\ R$M._P"N$G_H0KSZ@ HHHH **** "I]+_P"0
ME;_]=T_]"%05/I?_ "$K?_KNG_H0H ^B:*** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ KS/\ ;*_Y-9\=?]B]/_(5Z97F
M?[97_)K/CK_L7I_Y"@#\EZ*** "BBB@ HHHH *_2;_@EI_R:RG_8PWG\HZ_-
MFOTF_P""6G_)K*?]C#>?RCH ^CJ*** "BBB@#S#X_P#_ "$M._ZX2?\ H0KS
MZO0?C_\ \A+3O^N$G_H0KSZ@ HHHH **** "I]+_ .0E;_\ 7=/_ $(5!4^E
M_P#(2M_^NZ?^A"@#Z)HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "O,_VRO^36?'7_8O3_R%>F5YG^V5_P FL^.O^Q>G
M_D* /R7HHHH **** "BBB@ K])O^"6G_ ":RG_8PWG\HZ_-FOTF_X):?\FLI
M_P!C#>?RCH ^CJ*** "BBB@#S#X__P#(2T[_ *X2?^A"O/J]!^/_ /R$M._Z
MX2?^A"O,]=UW0_"^BW?B3Q-K-IIVG6%N\]]?WUPL,-O$@+-)([D*B@ DL2
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M>?#_ .&$=U<)X#O+:WN]8)C-K?M*9EW6[*Q+*&@<;B #P1D'-?L#_P $M/\
MDUE/^QAO/Y1U_/Q_P2N^'?A;X2?M3_M'_#+P39O;Z3H6M:19:?%)*9&6)#?@
M;F/+'N3ZFOZ!_P#@EI_R:RG_ &,-Y_*.@#Z.HHHH **** /,/C__ ,A+3O\
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MLZ?^SWX.^!_Q"^*OQ!OM$.M7'A'X;:+'=S:;I@D,8N[N2:6*.%'=61!N+,P
MP,@GN?V2?VL_A3^V?\(4^,'PF35;6"'5+G2M:T/Q#IYM-2T34K=MMQ8WD!)\
MF>,D97)&&4@D$&@#WCX,?\CW!_UPD_\ 0:]EKQKX,?\ (]P?]<)/_0:]EH *
M*** "O,_VRO^36?'7_8O3_R%>F5YG^V5_P FL^.O^Q>G_D* /R7HHHH ****
M "BBB@ K])O^"6G_ ":RG_8PWG\HZ_-FOTF_X):?\FLI_P!C#>?RCH ^CJ**
M* "BBB@#S#X__P#(2T[_ *X2?^A"O/J]!^/_ /R$M._ZX2?^A"O/J "BBB@
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M/X_U#PIK?B#PS>V&C>)M*NI(;C2KN6!TANHWC(=6C<J^5(/R\$5^5.J_#/\
MX*4_MF>+/&?[ 'QK_9E@T'5M>\!?#G1/BU\2KGQE:W=G!I.E:IK%P=6ME4F6
MXGORK".(@-&\<OF;!A@ ?0'_  4)E_X;L\3_ !3^&=J?M'PM_9U\!ZQJOBF1
M>8-<\;OI4[V-CD<.FGPN+J0 \7$UNK#,=?2__!,W_E'!^S]_V1+PK_Z:+6O%
M?VP_^"''_!/KXV^'/B;\6=(_91M=4^*/B?2]7U&PU(^*M1A:YUR:&5XI-K7:
MP(3<,IPP6,9Y 7-:G[*/[-OQ4_X)Q?\ !-/P7X"_94_90LM3^)-Q9:#?>/\
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M L&C6MW,)KZ7SI)I[IP, R2R,SM@$X&<+DX R:[VOM/_ (=5>._^@[X$_P#
M75/_ )*H_P"'57CO_H.^!/\ P%U3_P"2J /L#X1_\DI\,?\ 8O67_HA*Z&O
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MXQ7H- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV<_VP/BUJ4.E^ O'?PZUWX67GB:^<1V>D:O)<1:C8)/(WRQ?:622)">,HV2
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M>.I[<13^(O#^IVGVS2;RY4<?:3"LBR$$YV+N9WW.WVM7Y]_\$D/$FD?M(_\
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MTC,T09@,+YBYZUNT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?#RNY=E#%BWZMU\1_'G_ )3[_L^?]D"\;_\ I9IE?;E !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
40 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>cah-20220331_g4.jpg
<TEXT>
begin 644 cah-20220331_g4.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:7P?!?:A'=26R0)I\C7#>?9-'=++-(\4;-(LO.?+6O5?^")^IP:/_P &^_\
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MV ?^#F[]H/\ 8/BF-OX)_: TS_A.O"MCG"+J_D?;YC&O1%(;54(7J+>'LH
M/V*HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH _,3_ (.[/$.J:+_P1I\0:;I\C"+5_'F@VE\%/#1+<-.
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_A\7_P!6Z?\ EW?_ ')0!]M45\2_\/B_^K=/_+N_^Y*/^'Q?_5NG_EW?_<E
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MHZ_-FOTF_P""6G_)K*?]C#>?RCH ^CJ*** "BBB@#S#X_P#_ "$M._ZX2?\
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M]"% 'T31110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3*)/^QSO_P#T7!7T[\;OB78_!KX/>*/BQJ,:R1>'=!NM0\ICCS6BB9UC^K,
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M"_!?ACXBZ^FK>(=.\):=:Z[JD<WF+>7D=K&D\P<_>#R!FW=\YK\P/@'^UO\
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M3_T5G0?_  8I_C7U-_PJ[X9_]$[T+_P40_\ Q-'_  J[X9_]$[T+_P %$/\
M\30!\\_#+]J;]G7P]XLBU/6/C'H,,"Q.K/\ ;0V"1@<+DUZ9_P -S_LC_P#1
M>M!_[_/_ /$UW7_"KOAG_P!$[T+_ ,%$/_Q-'_"KOAG_ -$[T+_P40__ !-
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MCN(MP!.&V2+D>M '3T444 %%%% !1110 45^;#?M6_\ !;O]IK]LSX^_!O\
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M_3_W5YIJQR'<)'GV"&-CO9;B$'EJ /KRBOSP_P"'@W_!32']F/X!>%Y?@CX
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M=T^^XN[BYN[R6>>1SCEW.  HP  /TD^%'A[QUX1^%OAKPI\4/B)_PE_B;2]
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:1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>cah-20220331_g5.jpg
<TEXT>
begin 644 cah-20220331_g5.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@!
MD (4 P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%ZAIWA[5]<N/-NSHYTJSFT^"1@ "8K26"'@!1Y>%55 4>O?\$!_^5C;]O/\
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M7QII/B'1-1C\S3]9T/48KNUN4R1NCEB9D<9!&03TK^:?]J/XV_L._P#!1?\
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M)S_\%-_BN/@1\%-=\5>&_&L]K+<Z7X:\>:+%9SZG'$A>7[.\$\\,CH@+F/S
M^U68*51B/NB@#R_Q%^V_^Q;X/^(DGP@\6_M>_"_2_%L5]'92^%]1\?Z=!J*7
M,A4) ;9YA*)&W+A-NX[A@<BNS^)/Q/\ AI\&O!EY\1OB_P#$/0O"GA[3S&+_
M %[Q)JT-C96WF2+''YD\[*B;I'1!DC+,H') K^1+_@NEX=\97?\ P6?_ &FO
MB)X+G>";P+XBM-=N+J/[UNH?2[2.0'L1/=P?G7ZQ_P#!S_\ M?2?'C_@CQ\
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MNF7EF9(8UEMIPY\T,9XR,JO!/3&* /=?A/\ M%_L^?'JYU:R^!GQV\&^-)M
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M)?L\EO//$[HBLYC+ARJLP4A&( /NNBBB@ HHHH **** "BBB@ HHHH ****
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M":KJ&X6POHXY(FMK@H"RPS12NA902C>6^UMFT@'S=_P62_X)!_\ !/SX2?\
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M^#)SXDPW,S,EO\1H(X%)^XA\5:4V![;F8_B:^Y_^""_[#?[+7P$_X(X?#O\
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M\46GC+1=1MM#MF:0VK7<$S22+<VZR2();>.42JH8J3^[36_X-=?@WXD^!?\
MP6Z_:N^$GB;QY/XMU#P=HFKZ+K7BN<'?JE]%K\$<MR^YF(:22*5R"2<YR2<F
M@"Q_P:U_\B9_P4)_W;/_ -%^(ZU_^#-S]C+]F?XO?LG_ !D^,GQ?^"?AGQ7J
M^H^-!X7:;Q'HL-[Y6FI80S/!&)E8(LC73;]N-^Q,YVC'M/\ P00_X);_ +=G
M[%?AG]L?3_VF/@9_PC4WQ5%M_P ($G_"3:7>?VIL36@W-I<RB#!N[?\ UVS_
M %G^RV/3O^#73_@GU^UY_P $Z?V-O'OPI_;(^$?_  AVOZU\39=6TRP_M_3]
M0\ZS.G64(EWV,\R+^\BD7:S!OESC!!(!\N?\&8FG1^%/B)^V)\.M+D<:7HGB
MGPU#86[.2$ FUZ+//<K#&">^T5^O7[>=]^R_IO[&OQ)O/VT[@)\*5\)W0\=K
M]LN8#-IY7$D*M:NDQ:3(C5(V#NSA!DM@_ /_  ;8?\$V/VU?V OB_P#M2^*?
MVMO@O_PB=A\1O$NBW?@R?_A(]-O_ .T(8+C6GE;;97$S0[5N[<XE"$^9P#M;
M'V9_P5P_8R\4?\%!O^"<WQ2_9#\#:_;:9KGBW18#HEU>N5@-Y:7EO?01RLH)
M2.22V2-F .U7)P<8(!^#W[1W[5/PE^+O_!)SQ]\#/^"9/_!#76=(^ VEI<7E
MY\>?B$(VN;,K?"1[B*=T8S7*/B(8O)G1,1E2HQ7L"?L _M*_\%'O^#2']GSP
M?^S7ILFO>*?!/C+5O$0\,BZ6.35[2'6->LVBAWD*TT:7"NBDC<L;JN695-+X
M;?L3_P#!R[\5_P#@F=JO_!(#7/V8O!7@3X>^%]&OL^*-4U6S&J>(DBFDO[;1
M8)8KUX3Y]ULC^T>7&@3'F3 !O,]^\&?\$D_^"K6N_P#!O?\ #S]CCP!XY\3?
M _XX?"_Q)K-R-!TGXCQVUKXJTZYU"\NOLLUUI5S)$-RW2&/S&(62W*N$63S%
M /AF;_@L;\&_$-UX%_9._P""\_\ P1KT:6T\ W<*V.J>'-$O?"NKZ8B1>07E
MT_,7VF,K@O LL,+%$81DH@'],_PP\2^!_&?PU\/>,/AEJ<5[X;U;0[2\\/7L
M#,8[BQEA1X)%+?,5:-D()YP>:_!#]J7]G+_@YG_X+&_#/P7^PI^U[^QK\/\
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M&0!X95#*<$8*NKJ65E8^M4 %%%% !1110 4444 %%%% !1110 45\Y?LU?\
M!2WX/?M'_MH?&/\ 8-@\(Z[X:^('P;GMY-2L->6$)K.GSA3'?V9CD8M#MDMV
M.\*P%U%P<G'T;0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Y#_\ !Z;_ ,HJ
M_!/_ &7K2?\ TSZU7Z\5^0__  >F_P#**OP3_P!EZTG_ -,^M4 9OC_X _\
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M^%T^GZ%X5\+0:GH_A>;5QG3M-DMWT6*$W'R,/*2*.(ME&RB/A3R*@_X*J_\
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M78NPEB1#%ECL%>Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !7#>)OC1_PCNO7.B?\(UYWV>3;YOVS;NX!Z;#CKZUW->&?$S_D>]2_
MZ[C_ -!% '5_\-!_]2C_ .3_ /\ :Z/^&@_^I1_\G_\ [77F]% 'I'_#0?\
MU*/_ )/_ /VNC_AH/_J4?_)__P"UUYO10!Z1_P -!_\ 4H_^3_\ ]KH_X:#_
M .I1_P#)_P#^UUYO10!Z]X+^+G_"7Z\FB?\ "/\ V??&S>;]KWXP,]-@_G79
M5XU\&/\ D>X/^N$G_H->RT %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 45YA\?_P#D):=_UPD_]"%>?4 ?2%%?-]% 'TA17S?10!](45\WU/I?
M_(2M_P#KNG_H0H ^B:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8_[%ZR_]$)70USWPC_Y)3X8_[%ZR_P#1"5T- !1110 5X9\3/^1[U+_KN/\
MT$5[G7PM_P %3/VC?&/P+\.2^#?@G!#>?%3XE:_'X7^&&G2C<HU*>/+WTJX/
M^CVD"RW4K$;=L(4XWB@"I\!OVY?@G^TA^T=\6/V:/A=+?7FK?!RXTVU\5:H8
MX_L4EU=K<$P0.KEG>%K:2.7<JA7&T%L''<?'/XW_  Q_9M^$6O\ QT^,OBB+
M1O#'AG3VO-7U&92WEQ@@!5506=V8JB(H+,[JH!) KXM_X)7_ +._@[]E+_@H
M+^TE\!?!%Q/<VN@^!OARMUJ=V<W&IWDEIJDMU>S,22TT\[RS.<_>D/;%;?\
MP7N\<ZEX(_9G^%QL_ ]QXI@U+]HGPC;WWA2VF6-M<CCGFNDL2S_*HFFMH4R<
M@;@<'% 'I'[-W_!4'X>_'OXUZ;\ ?&7[/?Q2^%?B+Q-HT^K^!8/B;X;CL4\2
MV4(#3&V:.:3$T:,)'A?:ZH0WJ!W/[1W[<7P/_9E^*OPS^"'C?5)+KQ9\5?%4
M.B^&]"T]D:=%?(>]E5F&RW1@J%N26<!0<-M^>O"7QQ_:\\!_MM_";X>?\%,/
M@'\&+\>-Y-57X1>.?AW!=S3^$]82R9[C3YGO@6#3VH=!/!L#E2I!4X3E?^"@
M?['/P0^#W[5_P$_:7T'2+V_\=^/_ -K7P^-;\2ZW?M=7$-FNG:D8]/MMW%O:
M(44B) ,E5+%BJX /IK]K;]N2R_9D\7:%\,?"/P*\7?$OQ?K6BZAKK^&O!IM5
MGLM%L3$+J^E:ZFB3 ::-(XP2\LC;%&:O^)?VW_A=;_!CX8?&7X>6-WXGM_C#
MK>BZ=X#T^T(AFO#J"^<97W_ZM8+5)[B7()5;=QC.*X3]L/X)?M5:3^TQX<_:
M\_9#\#^&?%NMQ_#C5_ NM^'?%'B%M,CA@O+JUN[;4(Y1#*'$,]L?,B(#.CX4
MY''SQ\#M=^$W['_C3PE8?&'Q5?ZUX6_9>\)Z=\+O!Z^'M$N=0NO$WQ!U2TCN
M-4-A:VZ-+-)#9K#"J $HMS=!B-K4 ?JK\&/^1[@_ZX2?^@U[+7S9^Q%\=/AA
M^TGHVA_&?X.^(_[4\/ZQ:W!M+EK:2"1'C9XI898I55XI8Y4>-XW4,K(P(XKZ
M3H **** "O,_VRO^36?'7_8O3_R%>F5YG^V5_P FL^.O^Q>G_D* /R7HKQ?]
MK3]N?X2?LA-H^D>,=)UO7-=U\N=*\/>'+-9[J2-,;I6#,H5,\#DEB#@':Q'2
M_LR?M._"W]K/X8Q_%/X4WET;3[4]K>V6H0B.YLKA0"T4JJS -M96!5B"&!!H
M ]#HKS+]J7]K/X3?LB^![?QG\4)[V9]0NQ:Z/H^DVXFO-0FQDI$A91@#!+,0
M!D#.64'G_P!GW]OOX#_M!?#+Q1\2[&?4?#L?@A'?Q=IGB*U$5SIB*COYC*C,
M&4B.3&#NRC J#Q0![;17S#\#?^"KO[/'QS^*FE_"VR\*>+M!?Q%+)'X7U?Q#
MI4<-IJKH2"D;I(Q!)&%R,$X4D,0IW/$'_!1/X7>'OCZWP6N/ _B*33H/%5MX
M8OO&L=O'_9MMK-PA>.T8E]_8JS8PI!XQ\U 'T%7Z3?\ !+3_ )-93_L8;S^4
M=?DW+\?-(E_:2B_9LT?0+F\OXO"S:[K.I1RJ(-.A,WE0QOW,DC9(48(4;NE?
MK)_P2T_Y-93_ +&&\_E'0!]'4444 %%%% 'F'Q__ .0EIW_7"3_T(5Y'XA^)
M7P\\)^+-!\!^*/'.DZ=K?BF:XB\-:1>ZA'%<ZJ\$1FF6WC8AIC'&"[!0=J\G
M KU?]HR^LM,EL]2U*[BM[>WLYI;B>>0(D2+@LS,>   22> !7XTZ?XI\:_M/
M_P#!6K]F+]O/7=1O(/"/B[Q9XQT'X0:'*"B#PY8^'[S_ (FK(<$27]R\LPR
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M^&/^Q>LO_1"5T-<]\(_^24^&/^Q>LO\ T0E=#0 4444 %?%?_!0/]@7]D?\
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M/^N$G_H->RT %%%% !7F?[97_)K/CK_L7I_Y"O3*\S_;*_Y-9\=?]B]/_(4
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M'_Z+UH/_ '^?_P")KO)?AI\.)Y6GG^'^B.[L6=WTJ$EB>I)V\FF_\*N^&?\
MT3O0O_!1#_\ $T ?'7_!1OXX?!SX\_#[P]H?PH^*&@ZK=6.LO/=1?VI%!LC,
M3*#F8H#R0, DU\A_\(=J/_08T'_PI['_ ./5^P/_  J[X9_]$[T+_P %$/\
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M,@$'!!&02*V?^&Y_V1_^B]:#_P!_G_\ B:[K_A5WPS_Z)WH7_@HA_P#B:/\
MA5WPS_Z)WH7_ (*(?_B: .%_X;G_ &1_^B]:#_W^?_XFC_AN?]D?_HO6@_\
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M\*N^&?\ T3O0O_!1#_\ $T <+_PW/^R/_P!%ZT'_ +_/_P#$T?\ #<_[(_\
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MS:=T19><'C.:^I?^%7?#/_HG>A?^"B'_ .)H_P"%7?#/_HG>A?\ @HA_^)H
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M\-%? G_HK.@_^#%/\:/^&BO@3_T5G0?_  8I_C7U-_PJ[X9_]$[T+_P40_\
MQ-'_  J[X9_]$[T+_P %$/\ \30!\L_\-%? G_HK.@_^#%/\:/\ AHKX$_\
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MX!_\$^_@VGQE^/6H:G+'?:I#I/AKPWX=TXWNK>(=3FSY-A8VRD&:=\' )50
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M74M OYY;6X@O;5K>\TV]A(6:SNH&^:&>,D94Y!#*REE96/JM !1110 4444
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M"[7WG!#!B4 /T0HHHH **** "BBB@ ILT,5Q$T$\2NCJ5='7(8'@@@]13J*
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ML/VR;'P_X*^+/P)\3:CH?QITNP+P:=8B#S)H-3A\YW=;*>U7S$D9B"8I2"5
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MK4KB&*VOS>22?9[FZ1;F"26#RD&TD#8=Q3VOX_?M4_\ !1;XW?MJ>-/V-?\
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M_A75AX8^R6+00(EC]EL7>.39)'-)YQ.YO/VD81:]?H **** "BBB@ K\OO\
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K 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>cah-20220331_g6.jpg
<TEXT>
begin 644 cah-20220331_g6.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?!'Q \+/H/BOPW^T9HOQ#T4ZAXHE-M]I:XEC(BF=9I&2XCBEE9K<1*B@ ,"
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M(^(/QHLK/6;OPOJ@^SZYIDK6A5&="5EA=)"002"'R#S7Z?5_.=^U7J%_J?\
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MA>)J-G-I%W:V46M;8YYC;LIAO-.23STE^[*HWD(BKA5\GO\ _@IW^W?\0_\
M@@9^V%^S+^TG\1;GQ%X\^"_CC1/!&J>/8[PSSWFEW^JM:7,$MP /M/-G<PF=
MOFDBNU#9/S$ _;3]GW_@K?\ \$U_VJOC)/\ L^_L^?MC^#/%'C"(RB+1;"^9
M7O/+!+_97D58[O:JLQ\AG^52WW0370?M;_\ !1K]A[]A";1K/]KC]I3PWX'N
M?$+-_8UCJD[O<7*J=K2B&%7D$0) ,I4(#P6!K\$=6_8W_;-^(/[,?[,?B3]A
MC_@A#-\-/'?PVO\ 0?$ND_&S1OB+HLEYXSA2U%Q)+<(!#+,;B417*F61S"BO
M&H",0/JGX5_ KX)_MT?\'8'[1GA7]M#X=Z+XXT_X>?"VQ'@?P=XPT^.]L(HQ
M;:0OF_9IPT<H O;B4*RE0]V9 -P4@ _4CP5_P43_ &'OB1J/C'2_A]^T[X3U
MN7X?^%T\1^,6TK4//CTS27MQ<I>O(@*-$T++(&4ME2"*X/5?^"V7_!*#1+GP
MA::K^W?X!A;QU%YOAEGU)MD\7GO;B65PFVUC,L<B!YS&I*-@D#-?D7^Q3\&_
MA+^SY^V5_P %6_@Q\"K.&U\)^'O@GXEM=&T^VE+Q6"?9[IFM$))(6%V>$ DE
M1& >E>/Q?L-_LLZ?_P &ADW[8W_"E?#\WQ/U'QJMZWCF?38WU2%4\3_V4+>.
MY(\Q+?[,F#"I"%F+%2W- '[_ &E_\%0_^"?&M_M2O^Q3I/[6O@ZX^*$=T]J?
M"<6HDRFZ4$M:B7'DM<#!!@#F0$$%<@BKO[7O_!1_]AO]@HZ3%^UW^TIX=\$7
M&NAFTBPU&226ZND4X:58($>7RP>#(5V \9SQ7X@_\%!OV,?V;_V2/V6?^"9O
MQD^ WPFT3PYXUU7Q;X6NO$?B[2M/2'4=:NKB#3KZ6>[G4![AQ<%G0N6\L.53
M:O%7_BEK?Q$^.'_!QK^TOK7BG_@EU;_M;2^#- M-#T'P%KGB33[.S\.Z>L-H
MJ7BQ:A%+'+N+2%<+E'NWD&&8$ '[FZI^VE^RCH_[,I_;,O/C[X:;X5K91W9\
M=VVHK/IXA>98%;S(]W_+9A&1U5\J0""!YRW_  6)_P""8"_%[PU\"#^VSX&/
MBOQ=:6-QH&EKJ+$7"WL22VBM*%\J&25)(V2.5T=A(F%^89_'&P_9K_;#_90_
MX-\_VYOAA^T/^SIJOPR\%:CXTTK7_A7X8U3Q):ZI]@M+K6K1)[1)X)'W"$06
MRLS!-SEFV@LU<S_P4V_8 _9,^!__  ;(_LZ?M)_#;X):#I7Q&U.;PMJ^K>/+
M2P1-7U"34].N+BXCGN@/-EB#LA2-F*Q^4FP+CD _0W_@I'_P7B\-_L@_\%9_
M@[^P]_PMKPCX=\!QN]_\=?$&H1-)=:6)+*6:SL6)!6!)%>UF+*K.PE0!D&X-
M^FNF:E8ZSIMOJ^EW*SVUU DUO,G22-@&5A[$$&OPT_X*5_LO_L[_ !G_ .#B
M/]CO3_BG\'="URV^*_P_%Y\1H-0L@Z>(9X;&ZBADN1_RT*1V\"#/01*.U?N9
MIVG6.D:?!I.F6J06UK"L-O#&,+&B@!5 ]  !0!-1110 4444 %%%% !1110
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MX2_'W]E_2_\ @HWK.I_"CXN>!=;T#PWX.NO"DC0Z!=Z@8$&K2Q_;1'<7$4$
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "L+XI:A>Z3\,O$>JZ9=/!<VNA7DMO-&<-&ZPN58'U! -;M<Y\8_^21>
M*O\ L6[[_P!)WH _GJ_X)@?"3_@X5_X*C?LB:K^UM\"?^"P6N:3+I?B:]T:T
M\,^)M7N@UW<6UO!-DRI&Z*K^>JC<I ()/%?>7_!"W_@MK=?'/_@F;XI^/O\
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M0/QKM?A;H\?BWP[\8]2\.Z'KZVH^TV.E-%"YLXW_ (8BR@[?45^U5 !1110
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M=[$I,@AE66".= 2X1T7.X#G\XO '_!J?\0;_ %CPE\'?VI?^"I'COXD?L^>
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_D)6_P#UW3_T(4 ?1-%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@E\5M7O= ^&7Q<\-^(+[3N;ZTT;6H+F2 9QN98V)"YXSTSQG-?JE_P $M/\
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MP3X*779K2"ZL1J.L:K]FF988 7N;. SLP=@1&N[D#ZR_X)!V/[*L?[-;Z_\
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M:[9@-[N8?W04G:H+$#+$UULEA8RW<=_+91-/$"(IFC!= >H!ZC-2T4 %%%%
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M^)H_X5=\,_\ HG>A?^"B'_XF@#A?^&Y_V1_^B]:#_P!_G_\ B:/^&Y_V1_\
MHO6@_P#?Y_\ XFNZ_P"%7?#/_HG>A?\ @HA_^)H_X5=\,_\ HG>A?^"B'_XF
M@#A?^&Y_V1_^B]:#_P!_G_\ B:X;]I?]K;]FKX@_ /Q9X*\(?&G0;O4]3T:6
M"RMOM?E^9(>@W. H^I(%>Y_\*N^&?_1.]"_\%$/_ ,31_P *N^&?_1.]"_\
M!1#_ /$T ?C]_P (=J/_ $&-!_\ "GL?_CU'_"':C_T&-!_\*>Q_^/5^P/\
MPJ[X9_\ 1.]"_P#!1#_\31_PJ[X9_P#1.]"_\%$/_P 30!^/W_"':C_T&-!_
M\*>Q_P#CU'_"':C_ -!C0?\ PI['_P"/5^P/_"KOAG_T3O0O_!1#_P#$T?\
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MMY?"[X]?M1?%C]CN'PIX@\->.OA'=6AU73/$<,$8U;3KI"]MJ=BT4K^=:N,
MDA61F57520* /<**^9/C?_P5 ^'_ ,*_VA_&G[,'P^_9_P#B5\4?%GP\^'4/
MB[Q=8_#C18+XV,=Q,(K73]KSH[WTZGSD@53F(%R0 <?/7_$1GI'_  M?_A1'
M_#HO]L7_ (34^'O[>'A/_A5MM_:/]E^?]G^W?9_MOF>1YW[KS<;=_P N<\4
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M&2#MD7=N5L<,H/:OR]\?1_\ !Q/\!OV:_#_[!_PD_9TN_$_B;X?ZG8P?#O\
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M$!@& ."1GN: /T8HKY$^%?[<OQP\(?\ !4OQ5_P3R_:QTGPY:V/B;PE#XK^
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MX"M?!FC:^7F\0HT3VL5T+N6-/LKJLT;LKAU:2-AD*P.Y^R[_ ,%;/A%\4O\
M@EM=_P#!1;XU(GAA_ ^AWL7Q7\.A2DVBZ_I_[J\TU8Y#N$CS[!#&QWLMQ"#R
MU 'UY17YX?\ #P;_ (*:0_LQ_ +PO+\$? $'[1G[3&NW\_A?0]6L[ZWT#P3H
M,%LU\TVI[96GN+B&S\DM&K1%I9B@4&+:_I7[%/[7O[9-G^V=XI_X)T_\%!=&
M\ W?C?3_ (>P>//!?C7X9P75OIVN:&U[]AG6>VNG=[>YAN3&I 8JZR @#&7
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MKJ_@W]GO_@O2N@V?B#Q)>>(->DE_98T*^NM2U.Z??<7=Q<W=Y+//(YQR[G
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M G2XI;G2%2"233Q=CYT9H 8O.'S G=UK[(_;G_9B_P"&T?V/_B+^RC_PF_\
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MSPAX3\ _\%T_V</!O@3POIVBZ/IW[/GC:'3]*TFRCMK:VC%[IF$CBC 5%Y/
M %?=U>(^/?V-_P#A-_V^_A[^W)_PL;[+_P ('X!USPS_ ,(O_9&_[=_:,UK+
M]H^T^</*\O[-C9Y3;M^=RXP?;J "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
&BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>cah-20220331_g7.jpg
<TEXT>
begin 644 cah-20220331_g7.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHW9)WF.GV2O\QW"=A_&0>]\:_LK_ +,W[)W_  >"_LZ^$OV7OAWH/A#2]?\
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MM?\ "\?^%@_:_&5YKW]N_P#",_V3L\^"VB\GR?M-QG;]GSOW\[\;1C)^L:*
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MB&TC*3ZM':(8[83X.)#&A*JQ&0O&<5V5 'R)^WS_ ,$K/^&XOVS?V;OVNO\
MA>__  B__#/?BF;6?^$>_P"$7^V_V_YES93^5Y_VJ+[+C['MW>7+GS,X^7!^
MF?B]X!_X6M\)O%'PN_M;[!_PDGAV]TK[=Y'F_9OM$#P^9LW+OV[\[=PSC&1U
MKHJ* /SP\!?\$%/^$(_X(F^)?^".O_#5GVK_ (2+4'NO^%B_\(+L^S[M5@U#
M;]@^W'?_ *CR\_:!][=CC:=#]L;_ ((8_P##6?\ P3^_9W_86_X:B_L#_A0E
MSH$O_"4_\(3]K_MW^S-,:QQ]F^VQ_9?,W>9_K9=F-OS?>K[_ ** /D75O^"5
MO]J?\%C=+_X*T?\ "]_+_LWX=-X5_P"$ _X1?/F929?M/V[[5Q_K<^7Y!^[]
M[GCQ_P"$?_! #_A5G[(?[4W[*O\ PUG]O_X:6\27.K?V]_P@?E?\(YYTC/Y7
MD?;V^V8SC=OASCH*_1JB@#\Z?BY_P0(_X6I^R[^RA^S9_P -8_8/^&8?$%IJ
MG]M?\()YO_"2^0\3^7Y/VY?L>[R\;M\V-W0XYN_\%./^"%6H_MB?M/Z-^WE^
MR!^U[XA^ ?QJTW3%TS4O%.@V;SQ:Q:*IC02K'-"Z2",^67W,KQHB,GRAA^A-
M% 'P9_P3]_X(7>!_V(_V??C#X5\1?'_6?B#\6/CKH]]9^/\ XM^(; O<2-<0
M3QKY<#S.Y17G>5]\Q>9^6< (J.^"W_!$K_A4'_!%[Q%_P2&_X:9_M'^W['5+
M?_A87_"&>3Y'VR]-UN^P?;&W;,[,?:!NZ\=*^\:* /S5^.W_  ;L:-\3?V2/
MV?/A7\._VNM9\%_%W]FS35M? GQAT3P_Y9G =9&$UD+G*KO1&7$Y*'?]\.RG
MK/\ @G=_P14^(O[-O[8&J_\ !0G]MW]MC6?CS\8+KPZ="T/5[S0DTVTT:Q;A
MQ'$LLFYRNY1CRT42R_(S/O'W]4&I:=9ZOIUQI.H1%[>Z@>&= Y7<C JPR"".
M">0<T ?F)_P0%\,R_'K]KK]LW_@IPT1ET7XE_&*3PSX"OV'_ !]:3I#2Q_:(
MS_%'(LELN1P&MV'8U^H5<G\#_@7\(/V:OA;I/P2^ OP]TSPKX3T*.1-)T'2(
M/+M[822O*^T>K2.[DG)+,2>M=90 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !17,>/_B1_P@US
M;6_]C?:OM$;-G[1LVX(']TYZUSW_  T'_P!2C_Y/_P#VN@#TBBO-_P#AH/\
MZE'_ ,G_ /[71_PT'_U*/_D__P#:Z /2**\W_P"&@_\ J4?_ "?_ /M='_#0
M?_4H_P#D_P#_ &N@#TBBO-_^&@_^I1_\G_\ [74EK\?/M-S';_\ ")[?,D"Y
M^WYQDX_YYT >B4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YA\?_\
MD):=_P!<)/\ T(5Y]7H/Q_\ ^0EIW_7"3_T(5Y]0 4444 %%%% !4^E_\A*W
M_P"NZ?\ H0J"I]+_ .0E;_\ 7=/_ $(4 ?1-%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO,_VRO\ DUGQU_V+T_\ (5Z97F?[97_)K/CK_L7I_P"0H _)>OSZ_:-_;O\
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M_P#ML?LI:7?3Z9J'QRT.*XMIFBGB>5LHZDAE/R]00147_#<_[(__ $7K0?\
MO\__ ,37>2_#3X<3RM//\/\ 1'=V+.[Z5"2Q/4D[>33?^%7?#/\ Z)WH7_@H
MA_\ B: /CK_@HW\</@Y\>?A]X>T/X4?%#0=5NK'67GNHO[4B@V1F)E!S,4!Y
M(& 2:^0_^$.U'_H,:#_X4]C_ /'J_8'_ (5=\,_^B=Z%_P""B'_XFC_A5WPS
M_P"B=Z%_X*(?_B: /YE_^"O'BO\ 9FU33K_]GGXR^& WC6S\!WOB7P-XD34+
M4V<<JK(/LR7,5P2TKF!LP,I#83@L4K@/V9I?AW\-?@1^TC\$OCAX[OO'7P8^
M'VK:5:V5WIVKK-.\=S(RR0VS03 RK'(D&_R3Y:_.Y 5S7]!W_!4K_@C]^RS_
M ,%,/V=-2^&7BGX9>'-,\966G7/_  @'C5;!XIM!OI$ $I^S-&TT60I:%R4;
M:"5R 1Z%\!O^":7["W[.'[.K_LL?"_\ 9A\(VO@J[M)H=7TB[TP7G]IF9-DS
MW,MR9);AG7"EI'8[0J@@*  #^:?X\_#?]F#P9\5/V5?%?[$<'AJRUGQ!XJLC
M"F@ZW;27,NG.]ON.H[)6:)@'=':<AL><K'",%SOVD_A-\$X[+]HCQ9\$?VWG
M\.:)9W5V?B!\,'6&!]2UP&54AM6GD1Y89+D88P1R*5W ,4*[?Z(?V3O^"$/_
M  2L_8H^+MS\=/V?_P!E33['Q+-'+%:7VLZO>ZHNG1R9#K;1WDTJ0DJ2N]1O
MVDKNVL08OCG_ ,$%/^"3W[1W[1J?M3_%S]D72-1\6--%-?\ D:C=VUAJ,L0
M1[FRAE2WF.%&[<F),8D#CB@#\I_^"8'PJ\1^%?V"?AIINJWFDP2SZ))?+%<Z
M_9Q2+'=7,US'N1Y0RG9*IP0#S7O?_"':C_T&-!_\*>Q_^/5^OUM\)OA79V\=
MG9_#/P_%%$@2**/1H%5% P% "8  XQ3_ /A5WPS_ .B=Z%_X*(?_ (F@#RSX
M=?MH_LK:%\/M"T/5?CEH,5U9Z-:P7,7V@MLD2)589 (."",@D5L_\-S_ +(_
M_1>M!_[_ #__ !-=U_PJ[X9_]$[T+_P40_\ Q-'_  J[X9_]$[T+_P %$/\
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M $3O0O\ P40__$T?\*N^&?\ T3O0O_!1#_\ $T ?C]_PAVH_]!C0?_"GL?\
MX]7VY^P/^T9\"/@K\ U\%?$WXM:#IFIC6;F<VW]H)-^[?9M.Z(LO.#QG-?4O
M_"KOAG_T3O0O_!1#_P#$T?\ "KOAG_T3O0O_  40_P#Q- '"_P##<_[(_P#T
M7K0?^_S_ /Q-'_#<_P"R/_T7K0?^_P __P 37=?\*N^&?_1.]"_\%$/_ ,31
M_P *N^&?_1.]"_\ !1#_ /$T <+_ ,-S_LC_ /1>M!_[_/\ _$T?\-S_ +(_
M_1>M!_[_ #__ !-=U_PJ[X9_]$[T+_P40_\ Q-'_  J[X9_]$[T+_P %$/\
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MSQ-HT^M67@#X7:)%>7UKI,,@BDU&Z::6*.WM_,S$C,V7D&U0>2 #Z2HKRO\
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MN']AF[T4?&OX)W]\VCZ%XCG,&G>+=%OHEBO]'N)1_JF=41X96^6.0'.W=YB
M#/\ @OC\._!_Q'_X) _'>W\801_\2/P//KVCW1^62TU&Q9;JUEB<<H_FQ*H*
MD'#D=&(/0^'%\?V_[+/A[]O+X)_LKZ)\0?V@_$WPA\-V<]O?Z_%HLNJ0RB">
M6WFOI(Y%BBA:XN+@)L.YDV#!<,/S?_;RT#_@O5^W/-XQL_&?[%'Q$\$? '78
M-#;XM_":'Q[X>UO5KVVLKNW>\@\--;+%-OEBA+NDCLLS%PO+"(_;'QC\:_\
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M\#?AK\$-6N/$7A+X7Z=X[M_$FIZ[XC>%H;:\N[JU40)#;*SR1A=K[S@A@Q*
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M1=7^-7QP\9MXG^(DWAS>=/TQ4B$%CI-JS_-)#:P#:&;)R[#+ !C]6T %%%%
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M\)/V)/\ @GR_P?M=2\?>"-=U_4M1^+6FZE-;Q#3Y(%V1M82AE)64\%&R1U%
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MX4O\2/\ A+/L']C?:O[8_P!#FMOLV_SH_L_^NW>9MD^[C;SD '$?L1?LW?\
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M('QW^)D\FG?"7X:V39>^N0/GOKM@1]GT^W!\R:9BHPI4,OS.GS'^SC_P1?\
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DH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780947424344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-11373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cardinal Health, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000721371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">OH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">31-0958666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7000 Cardinal Place<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Dublin<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">OH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">43017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(614)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">757-5000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common shares (without par value)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CAH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">272,427,362<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780947127288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Earnings - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 44,836<span></span>
</td>
<td class="nump">$ 39,275<span></span>
</td>
<td class="nump">$ 134,261<span></span>
</td>
<td class="nump">$ 119,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">43,154<span></span>
</td>
<td class="nump">37,463<span></span>
</td>
<td class="nump">129,321<span></span>
</td>
<td class="nump">114,578<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="nump">1,682<span></span>
</td>
<td class="nump">1,812<span></span>
</td>
<td class="nump">4,940<span></span>
</td>
<td class="nump">5,303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Distribution, selling, general and administrative expenses</a></td>
<td class="nump">1,137<span></span>
</td>
<td class="nump">1,120<span></span>
</td>
<td class="nump">3,402<span></span>
</td>
<td class="nump">3,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring and employee severance</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_Amortizationandotheracquisitionrelatedcosts', window );">Amortization and other acquisition-related costs</a></td>
<td class="nump">79<span></span>
</td>
<td class="nump">111<span></span>
</td>
<td class="nump">237<span></span>
</td>
<td class="nump">345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">Impairments and (gain)/loss on disposal of assets, net</a></td>
<td class="nump">471<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="nump">1,764<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Litigation (recoveries)/charges, net</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="nump">1,085<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating earnings/(loss)</a></td>
<td class="num">(97)<span></span>
</td>
<td class="nump">473<span></span>
</td>
<td class="num">(632)<span></span>
</td>
<td class="nump">310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income)/expense, net</a></td>
<td class="nump">3<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on Extinguishment of Debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">(Gain)/Loss on sale of equity interest in naviHealth</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings/(loss) before income taxes</a></td>
<td class="num">(137)<span></span>
</td>
<td class="nump">440<span></span>
</td>
<td class="num">(741)<span></span>
</td>
<td class="nump">204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for/(benefit from) income taxes</a></td>
<td class="nump">1,253<span></span>
</td>
<td class="nump">320<span></span>
</td>
<td class="nump">328<span></span>
</td>
<td class="num">(293)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net earnings/(loss)</a></td>
<td class="num">(1,390)<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="num">(1,069)<span></span>
</td>
<td class="nump">497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net earnings attributable to noncontrolling interests</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings/(loss) attributable to Cardinal Health, Inc.</a></td>
<td class="num">$ (1,391)<span></span>
</td>
<td class="nump">$ 119<span></span>
</td>
<td class="num">$ (1,071)<span></span>
</td>
<td class="nump">$ 495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Earnings/(Loss) per common share attributable to Cardinal Health, Inc.:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Basic (in shares)</a></td>
<td class="num">$ (5.05)<span></span>
</td>
<td class="nump">$ 0.41<span></span>
</td>
<td class="num">$ (3.82)<span></span>
</td>
<td class="nump">$ 1.69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Income (Loss) from Continuing Operations, Per Diluted Share</a></td>
<td class="num">$ (5.05)<span></span>
</td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="num">$ (3.82)<span></span>
</td>
<td class="nump">$ 1.68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted-average number of common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">292<span></span>
</td>
<td class="nump">281<span></span>
</td>
<td class="nump">293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">294<span></span>
</td>
<td class="nump">281<span></span>
</td>
<td class="nump">294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Cash dividends declared per common share</a></td>
<td class="nump">$ 0.4908<span></span>
</td>
<td class="nump">$ 0.4859<span></span>
</td>
<td class="nump">$ 1.4724<span></span>
</td>
<td class="nump">$ 1.4577<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Amortizationandotheracquisitionrelatedcosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of acquired intangible assets and changes in the fair value of contingent consideration obligations. This also represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Amortizationandotheracquisitionrelatedcosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780947358360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net earnings/(loss)</a></td>
<td class="num">$ (1,390)<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
<td class="num">$ (1,069)<span></span>
</td>
<td class="nump">$ 497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income/(loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments and other</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Net unrealized gain/(loss) on derivative instruments, net of tax</a></td>
<td class="nump">12<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income/(loss), net of tax</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Total comprehensive income/(loss)</a></td>
<td class="num">(1,382)<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="num">(1,112)<span></span>
</td>
<td class="nump">553<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net earnings attributable to noncontrolling interests</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive income attributable to Cardinal Health, Inc.</a></td>
<td class="num">$ (1,383)<span></span>
</td>
<td class="nump">$ 124<span></span>
</td>
<td class="num">$ (1,114)<span></span>
</td>
<td class="nump">$ 551<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780947127064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and equivalents</a></td>
<td class="nump">$ 2,356<span></span>
</td>
<td class="nump">$ 3,407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">10,250<span></span>
</td>
<td class="nump">9,103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">15,493<span></span>
</td>
<td class="nump">14,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">2,785<span></span>
</td>
<td class="nump">2,843<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Total assets held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,101<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">30,884<span></span>
</td>
<td class="nump">31,048<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,298<span></span>
</td>
<td class="nump">2,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Goodwill and other intangibles, net</a></td>
<td class="nump">8,022<span></span>
</td>
<td class="nump">10,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">907<span></span>
</td>
<td class="nump">951<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">42,111<span></span>
</td>
<td class="nump">44,453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">24,821<span></span>
</td>
<td class="nump">23,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term obligations and other short-term borrowings</a></td>
<td class="nump">861<span></span>
</td>
<td class="nump">871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">3,033<span></span>
</td>
<td class="nump">2,957<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation', window );">Disposal Group, Including Discontinued Operation, Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">28,715<span></span>
</td>
<td class="nump">27,624<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term obligations, less current portion</a></td>
<td class="nump">4,751<span></span>
</td>
<td class="nump">5,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent', window );">Deferred income taxes and other liabilities</a></td>
<td class="nump">9,338<span></span>
</td>
<td class="nump">9,670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred shares, without par value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Authorized&#8212;500 thousand shares, Issued&#8212;none</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common shares, without par value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Authorized&#8212;755 million shares, Issued&#8212;327 million shares at March&#160;31, 2022 and June 30, 2021</a></td>
<td class="nump">2,761<span></span>
</td>
<td class="nump">2,806<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings/(accumulated deficit)</a></td>
<td class="num">(281)<span></span>
</td>
<td class="nump">1,205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Common shares in treasury, at cost: 54 million shares and 36 million shares at March&#160;31, 2022 and June 30, 2021, respectively</a></td>
<td class="num">(3,100)<span></span>
</td>
<td class="num">(2,186)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(77)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Cardinal Health, Inc. shareholders' equity</a></td>
<td class="num">(697)<span></span>
</td>
<td class="nump">1,791<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders&#8217; equity/(deficit)</a></td>
<td class="num">(693)<span></span>
</td>
<td class="nump">1,794<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity/(deficit)</a></td>
<td class="nump">$ 42,111<span></span>
</td>
<td class="nump">$ 44,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares, authorized</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred shares, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, authorized</a></td>
<td class="nump">755,000<span></span>
</td>
<td class="nump">755,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, issued</a></td>
<td class="nump">327,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Common shares in treasury</a></td>
<td class="nump">54,000<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780947280120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares, authorized</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred shares, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, authorized</a></td>
<td class="nump">755,000<span></span>
</td>
<td class="nump">755,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, issued</a></td>
<td class="nump">327,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Common shares in treasury</a></td>
<td class="nump">54,000<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780944634120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Shareholders' Equity - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income/(Loss)</div></th>
<th class="th"><div>Noncontrolling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at beginning of period (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Jun. 30, 2020</a></td>
<td class="nump">$ 1,792<span></span>
</td>
<td class="nump">$ 2,789<span></span>
</td>
<td class="nump">$ 1,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (104)<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at beginning of period (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at beginning of period at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,066)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</a></td>
<td class="nump">497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="nump">495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other Comprehensive Income (Loss), Net of Tax</a></td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</a></td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares</a></td>
<td class="num">(200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury shares acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="num">(432)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(432)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOtherShares', window );">Stockholders' Equity, Other Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at end of period (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Mar. 31, 2021</a></td>
<td class="nump">1,794<span></span>
</td>
<td class="nump">$ 2,807<span></span>
</td>
<td class="nump">1,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at end of period (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at end of period at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,202)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury Stock, Value, Acquired, Cost Method</a></td>
<td class="num">(200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at beginning of period (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Dec. 31, 2020</a></td>
<td class="nump">1,975<span></span>
</td>
<td class="nump">$ 2,778<span></span>
</td>
<td class="nump">1,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at beginning of period (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at beginning of period at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,009)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</a></td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other Comprehensive Income (Loss), Net of Tax</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares</a></td>
<td class="num">(200)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury shares acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="num">(143)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(143)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOtherShares', window );">Stockholders' Equity, Other Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at end of period (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Mar. 31, 2021</a></td>
<td class="nump">1,794<span></span>
</td>
<td class="nump">$ 2,807<span></span>
</td>
<td class="nump">1,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at end of period (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at end of period at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,202)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury Stock, Value, Acquired, Cost Method</a></td>
<td class="num">$ (200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at beginning of period (in shares) at Jun. 30, 2021</a></td>
<td class="nump">327,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Jun. 30, 2021</a></td>
<td class="nump">$ 1,794<span></span>
</td>
<td class="nump">$ 2,806<span></span>
</td>
<td class="nump">1,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at beginning of period (in shares) at Jun. 30, 2021</a></td>
<td class="num">(36,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at beginning of period at Jun. 30, 2021</a></td>
<td class="num">$ (2,186)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</a></td>
<td class="num">(1,069)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="num">(1,071)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other Comprehensive Income (Loss), Net of Tax</a></td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</a></td>
<td class="num">$ (43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="nump">$ 41<span></span>
</td>
<td class="num">$ (5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury shares acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="num">(415)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(415)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOtherShares', window );">Stockholders' Equity, Other Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at end of period (in shares) at Mar. 31, 2022</a></td>
<td class="nump">327,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Mar. 31, 2022</a></td>
<td class="num">$ (693)<span></span>
</td>
<td class="nump">$ 2,761<span></span>
</td>
<td class="num">(281)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(77)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at end of period (in shares) at Mar. 31, 2022</a></td>
<td class="num">(54,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at end of period at Mar. 31, 2022</a></td>
<td class="num">$ (3,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury Stock, Value, Acquired, Cost Method</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (960)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at beginning of period (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Dec. 31, 2021</a></td>
<td class="nump">1,002<span></span>
</td>
<td class="nump">$ 2,721<span></span>
</td>
<td class="nump">1,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(85)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at beginning of period (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at beginning of period at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</a></td>
<td class="num">(1,390)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="num">(1,391)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other Comprehensive Income (Loss), Net of Tax</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury shares acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="num">(135)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(135)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOtherShares', window );">Stockholders' Equity, Other Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at end of period (in shares) at Mar. 31, 2022</a></td>
<td class="nump">327,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Mar. 31, 2022</a></td>
<td class="num">$ (693)<span></span>
</td>
<td class="nump">$ 2,761<span></span>
</td>
<td class="num">$ (281)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (77)<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at end of period (in shares) at Mar. 31, 2022</a></td>
<td class="num">(54,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at end of period at Mar. 31, 2022</a></td>
<td class="num">$ (3,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury Stock, Value, Acquired, Cost Method</a></td>
<td class="num">$ (200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (220)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOtherShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of increase (decrease) in shares of stock classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOtherShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780950242328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net earnings/(loss)</a></td>
<td class="num">$ (1,069)<span></span>
</td>
<td class="nump">$ 497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">513<span></span>
</td>
<td class="nump">603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherInvestments', window );">Impairments and Loss on Sale of Other Investments</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">(Gain)/Loss on sale of equity interest in naviHealth</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">Impairments and (gain)/loss on disposal of assets, net</a></td>
<td class="nump">1,764<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on Extinguishment of Debt</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for bad debts</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities, net of effects from acquisitions and divestitures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Increase in trade receivables</a></td>
<td class="num">(1,193)<span></span>
</td>
<td class="num">(511)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in inventories</a></td>
<td class="num">(922)<span></span>
</td>
<td class="num">(1,323)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Increase in accounts payable</a></td>
<td class="nump">1,121<span></span>
</td>
<td class="nump">1,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other accrued liabilities and operating items, net</a></td>
<td class="num">(206)<span></span>
</td>
<td class="nump">1,019<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">1,764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets', window );">Proceeds from divestitures and disposal of property and equipment and held for sale assets</a></td>
<td class="nump">934<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition of subsidiaries, net of cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property and equipment</a></td>
<td class="num">(223)<span></span>
</td>
<td class="num">(274)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_Purchaseofavailableforsalesecuritiesandotherinvestments', window );">Purchases of investments</a></td>
<td class="num">(38)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments', window );">Proceeds from investments</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromHedgeInvestingActivities', window );">Proceeds from Hedge, Investing Activities</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by/(used in) investing activities</a></td>
<td class="nump">771<span></span>
</td>
<td class="num">(290)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromHedgeFinancingActivities', window );">Proceeds from interest rate swap terminations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Reduction of long-term obligations</a></td>
<td class="num">(597)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_Netproceedstaxwithholdingsfromsharebasedcompensation', window );">Net proceeds/(tax withholdings) from share-based compensation</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Dividends on common shares</a></td>
<td class="num">(425)<span></span>
</td>
<td class="num">(432)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="num">(200)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(2,048)<span></span>
</td>
<td class="num">(668)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</a></td>
<td class="num">(13)<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_CashReclassifiedToAssetHeldForSale', window );">Cash and equivalents reclassified from/(to) assets held for sale</a></td>
<td class="nump">109<span></span>
</td>
<td class="num">(86)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase/(decrease) in cash and equivalents</a></td>
<td class="num">(1,051)<span></span>
</td>
<td class="nump">728<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and equivalents at beginning of period</a></td>
<td class="nump">3,407<span></span>
</td>
<td class="nump">2,771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and equivalents at end of period</a></td>
<td class="nump">$ 2,356<span></span>
</td>
<td class="nump">$ 3,499<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_CashReclassifiedToAssetHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Reclassified to Asset Held for Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_CashReclassifiedToAssetHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Netproceedstaxwithholdingsfromsharebasedcompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow/(outflow) associated with the amount received from holders exercising their stock options and paid by the company to satisfy an employee's income tax withholding obligation when shares are withheld from settlement of a share-based award to cover taxes. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Netproceedstaxwithholdingsfromsharebasedcompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from divestitures and disposal of property and equipment and held for sale assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of available-for-sale securities and other investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Purchaseofavailableforsalesecuritiesandotherinvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from purchases of available-for-sale securities and other investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Purchaseofavailableforsalesecuritiesandotherinvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) included in earnings for investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromHedgeFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash outflow or inflow for a financial contract that meets the hedge criteria as either cash flow hedge, fair value hedge or hedge of net investment in foreign operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromHedgeFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromHedgeInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 27<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3581-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromHedgeInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780946414664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">1. Basis of Presentation and Summary of Significant Accounting Policies </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2022 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fiscal year ends on June 30. References to fiscal 2022 and  2021 in these condensed consolidated financial statements are to the fiscal years ending or ended June&#160;30, 2022 and June&#160;30, 2021, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic ("COVID-19") continues to affect the U.S. and global economies, and as previously disclosed, the pandemic began to materially affect our businesses during the third quarter of fiscal 2020. The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2022 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2022. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2021 (the "2021 Form 10-K").</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Issued Financial Accounting Standards</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Not Yet Adopted</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2021 Form 10-K. There were no accounting standards issued in fiscal 2022 that will have a material impact on our condensed consolidated financial statements.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Adopted Financial Accounting Standards</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted in the nine months ended March 31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780946403800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestitures<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Disposal Groups, Including Discontinued Operations, Disclosure</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">2. Divestitures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we sold the Cordis business to Hellman &amp; Friedman for proceeds of $923 million, net of cash transferred, and we retained certain working capital accounts and certain liabilities. The purchase price is subject to adjustments based on working capital requirements as set forth in the agreement. Cardinal Health will retain product liability associated with lawsuits and claims related to inferior vena cava ("IVC") filters in the U.S. and Canada, as well as authority for these matters discussed in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iaf3733bf892b435689161c61a06da348_103" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Cordis business operated within our Medical segment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780946290104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring and Employee Severance</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">3. Restructuring and Employee Severance</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restructuring and employee severance:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">19</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">31</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">22</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">34</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">56</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of accelerated depreciation, lease costs associated with vacant facilities, professional, project management and other service fees to support divestitures, vendor transition fees, project consulting fees, and certain other divestiture-related costs.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring costs during both the three and nine months ended March&#160;31, 2022 and 2021 were primarily related to the implementation of certain enterprise-wide cost-savings measures, which includes facility exit costs related to decreasing our overall office space, and the divestiture of the Cordis business. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity related to liabilities associated with restructuring and employee severance:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.237%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.237%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.241%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-<br/>Related Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility Exit<br/>and Other Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">79</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(48)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">49</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">66</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI https://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780949975736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Other Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">4. Goodwill and Other Intangible Assets</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill by segment and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.640%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.556%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical (2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,659&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,330&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,989</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill acquired, net of purchase price adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(41)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,781)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,781)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,659</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,508</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,167</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">At March 31, 2022 and June 30, 2021, the Pharmaceutical segment accumulated goodwill impairment loss was $829&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">At March 31, 2022 and June 30, 2021, the Medical segment accumulated goodwill impairment loss was $3.2&#160;billion and $1.4&#160;billion, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended March&#160;31, 2022, the Medical Unit, which is our Medical operating segment excluding our Cardinal Health at-Home Solutions division, continued to experience adverse financial results related to inflationary impacts and the adverse impact of global supply chain constraints. Due to the risks and uncertainties related to these impacts, we elected to bypass the qualitative assessment in the second and third quarters of fiscal 2022 and perform interim goodwill impairment testing for the Medical Unit. This quantitative testing resulted in the carrying amount of the Medical Unit exceeding the fair value, resulting in pre-tax impairment charges of $474&#160;million and $1.3&#160;billion, which were recognized during the three months ended March&#160;31, 2022 and&#160;December 31, 2021, respectively, and are included in impairments and (gain)/loss on disposal of assets in our condensed consolidated statements of earnings/(loss). The goodwill balance of the Medical Unit, after recognizing the impairment, was $2.3&#160;billion at March&#160;31, 2022.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our determination of the estimated fair value of the Medical Unit is based on a combination of the income-based approach (using a terminal growth rate of 2 percent), and the market-based approach. For the income-based approach, we also used discount rates of 9.5 percent and 9 percent for the interim testing at March&#160;31, 2022 and&#160;December 31, 2021, respectively. The increase in the discount rate was primarily due to an increase in the risk-free interest rate. Our fair value estimates utilize significant unobservable inputs and thus represent Level 3 fair value measurements.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Intangible Assets</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize other intangible assets by class at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:24.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.409%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted- Average Remaining Amortization Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,293</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,130</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,163</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">552</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">352</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">200</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,036</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">557</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">479</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,881</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,039</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,842</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,894</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,039</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,855</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:42.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.308%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.643%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.312%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,035&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,916&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,823&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,093&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,928&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,823&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,105&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amortization of intangible assets was $78 million and $109 million for the three months ended March 31, 2022 and 2021, respectively, and $235 million and $337 million for the nine months ended March&#160;31, 2022 and 2021, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2022 through 2026 is as follows: $78 million, $284 million, $260 million, $235 million, and $208 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780950255096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Obligations and Other Short-Term Borrowings<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract', window );"><strong>Long-Term Obligations and Other Short-Term Borrowings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-Term Obligations and Other Short-Term Borrowings</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">5. Long-Term Obligations and Other Short-Term Borrowings</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Long-Term Debt and Other Short-Term Borrowings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had total long-term obligations, including the current portion and other short-term borrowings, of $5.6 billion and $6.2 billion at March&#160;31, 2022 and June&#160;30, 2021, respectively. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $24.8 billion and $23.7 billion at March&#160;31, 2022 and June&#160;30, 2021, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2022, we redeemed all outstanding $572 million principal amount of 2.616% Notes due June 2022 at a redemption price equal to 100% of the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes. In connection with this redemption, we recorded a $10&#160;million loss on early extinguishment of debt. The early redemption was funded with available cash.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2021, we early repurchased a total of $40 million of the Floating Rate Notes due 2022 and $2 million of the 2.616% Notes due June 2022. The repurchases were funded with available cash. In connection with the early debt repurchases, we recorded a $1 million loss on early extinguishment of debt during the nine months ended March&#160;31, 2021.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Financing Arrangements</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to cash and equivalents and operating cash flow, other sources of liquidity include a&#160;$2.0 billion&#160;commercial paper program backed by a $2.0 billion&#160;revolving credit facility. We also have a&#160;$1.0 billion&#160;committed receivables sales facility. At&#160;March&#160;31, 2022, we had no amounts outstanding under our commercial paper program, revolving credit facility, or our committed receivables sales facility. During the nine months ended March&#160;31, 2022, we had a daily maximum amount outstanding under our commercial paper and committed receivables programs of $1.2&#160;billion and an average daily amount outstanding of $25&#160;million.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (&#8220;CHF&#8221;) through September 30, 2022. CHF was organized for</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, CHF is a separate legal entity from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF. CHF is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its creditors. </span></div>Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. As of March&#160;31, 2022, we were in compliance with this financial covenant.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-Term Obligations and Other Short-Term Borrowings [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_LongTermObligationsandOtherShortTermBorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780946396856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments, Contingent Liabilities and Litigation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments, Contingent Liabilities and Litigation</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">6. Commitments, Contingent Liabilities and Litigation</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commitments</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Generic Sourcing Venture with CVS Health Corporation ("CVS Health")</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of 10 years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. In August 2021, we amended our agreement to extend the term through June 2029. We are required to make quarterly payments to CVS Health for the term of the arrangement.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New York Opioid Stewardship Act</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $100&#160;million annual assessment on all manufacturers and distributors licensed to sell or distribute opioids in New York. Under the OSA, each licensed manufacturer and distributor would be required to pay a portion of the assessment based on its share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The constitutionality of portions of the OSA has been challenged in court. In December 2018, the OSA was ruled unconstitutional by the U.S. district court for the Southern District of New York. Subsequently, New York passed a new statute that modified the assessment going forward and limited the OSA to two years (2017 and 2018). The U.S. Court of Appeals for the Second Circuit reversed the district court's decision on procedural grounds. In February 2021, the Second Circuit stayed the effect of the ruling pending a petition to the U.S. Supreme Court to review the Second Circuit's opinion. In October 2021, the U.S. Supreme Court declined to review the decision. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. Because of the Second Circuit ruling, we recorded an aggregate accrual of $41&#160;million for calendar year 2017 and 2018 during the nine months ended March 31, 2021 based on the probable estimated payment amount. In the three months ended December 31, 2021, we paid the State of New York $20&#160;million, our portion of the assessment for calendar year 2017. As a result, as of March 31, 2022, we had an accrual of $20&#160;million, which reflects our best estimate of the portion of the assessment that we may owe for sales during calendar year 2018.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We become involved from time to time in disputes, litigation and regulatory matters.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we determine that products we source, manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, product liability claims and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we become aware through employees, internal audits or other parties of possible compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.</span></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges in our condensed consolidated statements of earnings/(loss); however, losses and recoveries of lost profits from disputes that occur in the ordinary course of business are included within segment profit. For example, in the second quarter of fiscal year 2022, our Pharmaceutical segment profit was positively impacted by a $16&#160;million judgment for lost profits related to an ordinary course intellectual property rights claim.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opioid Lawsuits and Investigations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 2022, pharmaceutical wholesale distributors, including us, were defendants in approximately 3,400 lawsuits relating to the distribution of prescription opioid pain medications. The lawsuits sought equitable relief and monetary damages based on a variety of legal theories including various common law claims, such as public nuisance, negligence and unjust enrichment as well as violations of controlled substance laws, the Racketeer Influenced and Corrupt Organizations Act and various other statutes. These lawsuits also name pharmaceutical manufacturers, retail pharmacy chains and other entities as defendants.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">States &amp; Political Subdivisions</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 2,700 of these lawsuits were filed by counties, municipalities, cities and political subdivisions in various federal, state, and other courts. The vast majority of these lawsuits were filed in U.S. federal court and were transferred for consolidated pre-trial proceedings in a Multi-District Litigation proceeding in the U.S. District Court for the Northern District of Ohio (the &#8220;MDL&#8221;).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, 25 state attorneys general filed lawsuits against distributors, including us, in various state courts. We have also received requests, civil investigative demands, subpoenas or requests for information from additional state attorneys general offices and governmental authorities. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we determined that there was sufficient participation to proceed with a settlement agreement (the "Settlement Agreement") to settle the vast majority of opioid lawsuits filed by state attorneys general and political subdivisions. This Settlement Agreement became effective on April 2, 2022. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to us and two other national distributors, parties to the Settlement Agreement include 46 states, the District of Columbia and 5 U.S. territories. As of April 28, 2022, over 98 percent of political subdivisions (by population as calculated under the Settlement Agreement) that had brought opioid-related suits against us as calculated under the Settlement Agreement had chosen to join the Settlement Agreement or have had their claims addressed by state legislation. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this Settlement Agreement, we will pay up to approximately $6.0&#160;billion, the majority of which will be paid over 18 years. The exact payment amount will depend on several factors, including the extent to which states take action to foreclose opioid lawsuits by political subdivisions (e.g., by passing laws barring or limiting opioid lawsuits by political subdivisions), and the extent to which </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional political subdivisions in participating states file additional opioid lawsuits against us. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Settlement Agreement also includes injunctive relief terms related to distributors&#8217; controlled substance anti-diversion programs, including with respect to: (1) governance; (2) independence and training of the personnel operating controlled substances monitoring programs; (3) due diligence for new and existing customers; (4) ordering limits for certain products; and (5) suspicious order monitoring. A monitor will be selected to oversee compliance with these provisions for a period of five years. In addition, we and the two other settling distributors will engage a third-party vendor to act as a clearinghouse for data aggregation and reporting, which distributors will fund the for ten years.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The participating states and the distributors are cooperating to obtain consent judgments embodying the terms of the Settlement Agreement in each participating state and the participating states and subdivisions are dismissing their lawsuits. As a result, as of April 28, 2022, approximately 2,000 lawsuits against us have been dismissed. We expect additional lawsuits to be dismissed over the coming months. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, we had separately negotiated settlements with each of Florida, New York, Ohio, Rhode Island, Texas and their participating subdivisions; however, as contemplated, these states and their participating subdivisions are now participating in the Settlement Agreement.  </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2022, we paid into escrow the majority of our first annual payment under the Settlement Agreement, which is reflected in prepaid expenses and other assets in our condensed consolidated balance sheets. We also made certain payments under the separate New York, Ohio and Rhode Island settlements, as well as certain payments under Cherokee Nation settlement and Native American term sheet. During the nine months ended March 31, 2022, we paid $348&#160;million in connection with these matters. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, we and two other national distributors reached an agreement with the Washington Attorney General, under which we will pay up to approximately $160&#160;million to the State of Washington and its participating subdivisions to resolve opioid-related claims. This amount is consistent with the amount that would have been allocated to Washington under the Settlement Agreement, had Washington agreed to participate, plus certain attorneys' fees and costs. The terms of this agreement in principle are substantially consistent with the Settlement Agreement. This agreement is subject to certain contingencies, including the rate of subdivision participation. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">West Virginia subdivisions and Native American tribes were not a part of the broader settlement process and we have been involved in separate negotiations with these groups. In September 2021 we announced that we, along with two other national distributors, had reached an agreement with the Cherokee Nation in connection with ongoing negotiations toward a broader agreement with Native American tribes. In January 2022, we, along with two other </span></div></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">national distributors, entered into a term sheet with the Native American tribes.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first phase of a bench trial in West Virginia State Court for a consolidated case brought by 63 West Virginia subdivisions against the Company and two other national distributors is scheduled to begin July 5, 2022. A bench trial before a federal judge in West Virginia brought by Cabell County and City of Huntington against us and two other national distributors concluded in July 2021. The judge has not yet issued a decision. Trials are inherently unpredictable and it is possible that the outcome of these trials could materially negatively impact our financial results, cash flows or results of operations.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Settlement Agreement did not resolve all opioid lawsuits and claims brought by states and political subdivisions. The Attorney General of Oklahoma filed a lawsuit against us in January 2020, and did not agree to join the Settlement Agreement. As of April 28, 2022, we are still defendants in approximately 700 lawsuits brought by counties, municipalities and other political subdivisions; however, we expect this number to decline as additional cases are dismissed as a result of the Settlement Agreement.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In total, we have $6.70&#160;billion accrued at March&#160;31, 2022, of which $738&#160;million is included in other accrued liabilities and the remainder is included in deferred income taxes and other liabilities in our condensed consolidated balance sheets. During the nine months ended March 31, 2021, we recorded total pre-tax charges of $1.02&#160;billion in litigation (recoveries)/charges, net in our condensed consolidated statements of earnings/(loss). </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual, whether as a result of settlement discussions, a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters. We continue to strongly dispute the allegations made in these lawsuits none of these agreements is an admission of liability or wrongdoing.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Justice Investigations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). We have also received civil requests for information from other DOJ offices. We believe that these investigations concern operation of our anti-diversion program, our anti-diversion policies and procedures, and distribution of certain controlled substances. We are cooperating with these investigations. We are unable to predict the outcome of any of these investigations. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Private Plaintiffs</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Settlement Agreement does not address claims by private parties, which includes unions and other health and welfare funds, </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hospital systems and other healthcare providers, businesses and individuals alleging personal injury. Private parties had brought approximately 453 lawsuits as of May 4, 2022. Of these, 141 are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A trial in a case involving 21 plaintiffs is scheduled to begin in state court in Georgia in July 2022. We are vigorously defending ourselves in all of these matters; however, trials are inherently unpredictable and it is possible that an unfavorable outcome in these matters, individually or in the aggregate, could have a negative impact on our financial results.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Insurance Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in legal proceedings with two insurers related to the availability of insurance coverage for the lawsuits described above. In October 2020, we filed a complaint for declaratory judgment against National Union Fire Insurance Company of Pittsburgh, PA (&#8220;National Union&#8221;) seeking a declaration that National Union is obligated to reimburse us for defense costs incurred in connection with the lawsuits described above. In January 2021, Swiss Re International SE commenced an arbitration in London seeking a determination that it does not have an obligation to reimburse us for defense and indemnity expenses incurred in connection with the lawsuits described above. We have not recorded a receivable for any recoveries related to these insurance litigation matters as of</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cordis IVC Filter Matters </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Liability Lawsuits</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April 29, 2022, we are named as a defendant in 457 product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately 5,872 plaintiffs that allege personal injuries associated with the use of Cordis OptEase and TrapEase inferior vena cava ("IVC") filter products. Another 26 lawsuits involving similar claims by approximately 30 plaintiffs are pending in other jurisdictions. These lawsuits seek a variety of remedies, including unspecified monetary damages. In July 2021, we entered into an agreement to settle approximately 1,300 claims. We continue to vigorously defend ourselves in these lawsuits and are engaged in ongoing resolution discussions with certain plaintiffs.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2022, we had a total of $494&#160;million net of estimated insurance recoveries, accrued for losses and legal defense costs, related to the Cordis IVC filter lawsuits in our condensed consolidated balance sheets. We believe there is a range of estimated losses with respect to these matters. Because no amount within the range is a better estimate than any other amount within the range, we have accrued the minimum amount in the range. We estimate the high end of the range to be approximately $1.05&#160;billion, net of estimated insurance recoveries. The sale of the Cordis disposal group does not include product liability related to the IVC filters in the U.S. and Canada, which we retained.</span></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Mexico Attorney General Action </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Attorney General for the State of New Mexico filed an action against certain IVC filter manufacturers, including us, alleging claims under New Mexico's Unfair Practices Act, Medicaid Fraud Act and Fraud Against Taxpayers Act. The allegations made are similar to those made in the product liability lawsuits, described above. We intend to vigorously defend ourselves against these claims.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SEC Investigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we received a subpoena from the U.S. Securities and Exchange Commission ("SEC") requesting the production of documents from 2015 through 2019 relating to inventory in the Cordis business, analysis of goodwill of the Medical segment and other matters. In March 2022, the SEC informed us that it had concluded its investigation and did not intend to recommend an enforcement action. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholder Securities Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Louisiana Sheriffs' Pension &amp; Relief Fund filed a purported class action complaint against Cardinal Health and certain current and former officers and employees in the United States District Court for the Southern District of Ohio purportedly on behalf of all purchasers of our common shares between March 2015 and May 2018. In June 2020, the court appointed 1199 SEIU Health Care Employees Pension Fund as lead plaintiff and a consolidated amended complaint was filed in September 2020. The amended complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 by making misrepresentations and omissions related to the acquisition and integration of the Cordis business and inventory and supply chain problems within the Cordis business, and seeks to recover unspecified damages and equitable relief for the alleged misstatements and omissions. The complaint also alleges that one of the individual defendants violated Section 20A of the Exchange Act because he sold shares of Cardinal Health stock during the time period. In September 2021, the court denied our motion to dismiss. We are vigorously defending ourselves against these claims. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Specialty Solutions DOJ Investigation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the United States Attorney&#8217;s Office for the District of Massachusetts (the "USAO") commenced an investigation of Cardinal Health regarding possible violations of the U.S. healthcare fraud and abuse laws. The USAO sought, among other things, documents and information relating to discounts and rebates offered or provided to certain Specialty Solutions customers. In January 2022, without admitting liability, we settled this matter with the DOJ for approximately $13 million, which was recorded as expense within litigation (recoveries)/charges net in our consolidated statement of earnings/(loss) during the fiscal year ended June 30, 2021. Additionally, our Specialty Pharmaceutical Distribution business entered into a five-year corporate integrity agreement with the Department of Health and Human Services, Office of Inspector General, under which it agreed to certain remedial measures, including no longer offering term-based up-front discounts.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Civil Litigation </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Pharmaceutical Pricing Antitrust Litigation </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and improperly engaged in customer allocation. We have filed a motion to dismiss the complaints and we intend to vigorously defend ourselves. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Active Pharmaceutical Ingredient Impurity Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many participants in the pharmaceutical supply chain, including active pharmaceutical ingredient ("API") manufacturers, finished dose manufacturers, repackagers, distributors, and retailers have been named as defendants in lawsuits arising out of recalls of certain medications due to alleged impurities in the active pharmaceutical ingredients or finished product. </span></div>In February 2019, a Multidistrict Litigation was created in the U.S. District Court for the District of New Jersey (the &#8220;Sartan MDL&#8221;) alleging API impurities in certain generic blood pressure medications. We have been named as a defendant in the Sartan MDL. We are vigorously defending ourselves in this matter.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780950271240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">7. Income Taxes</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in our benefit from income taxes as a percentage of pretax earnings/(loss) (&#8220;effective tax rate&#8221;) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items. </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effective Tax Rate</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended&#160;March&#160;31, 2022, the effective tax rate was&#160;(916.5) percent and&#160;(44.4) percent, </span></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively, and reflects the impact of the tax effect of the year-to-date goodwill impairment charges recognized during the nine months ended March&#160;31, 2022. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended&#160;March&#160;31, 2021, the effective tax rate was 72.8 percent and (143.3) percent, respectively, and included the impact related to the treatment of the tax effect of opioid litigation charges, the resolution of certain transfer pricing matters with the U.S. Internal Revenue Service ("IRS") and withholding taxes for planned distributions from foreign subsidiaries. During the nine months ended&#160;March&#160;31, 2021, the effective tax rate included the benefit from a net operating loss carryback primarily related to a self-insurance pre-tax loss.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Goodwill Impairment Charge</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2022, we recognized year-to-date pre-tax charges of $1.8&#160;billion for goodwill impairments related to the Medical Unit. The net tax benefit related to these charges is $126&#160;million for fiscal 2022. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings/(loss) before income taxes for the year-to-date period to compute our benefit from income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effect of the goodwill impairment charges during the nine months ended March 31, 2022 was included in our estimated annual effective tax rate because it was not considered unusual or infrequent, given that we recorded goodwill impairment in prior fiscal years. The impact of the non-deductible goodwill significantly decreased the estimated annual effective tax rate for fiscal 2022. Applying the lower tax rate to the year-to-date loss resulted in recognizing an interim tax expense of approximately $1.2&#160;billion, which impacted the provision for income taxes in the condensed consolidated statements of earnings/(loss) during the three and nine months ended March&#160;31, 2022 and prepaid expenses and other assets in the condensed consolidated balance sheet at March&#160;31, 2022. Approximately $180&#160;million of this interim tax expense will reverse in the fourth quarter of fiscal 2022.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cordis Divestiture</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2022, we completed the divestiture of the Cordis business. In connection with the closing, we recorded net tax expense of $9&#160;million and $29&#160;million during the three and nine months ended March&#160;31, 2022, respectively. The tax effects of these matters during the nine months ended March 31, 2022 were included in our full year effective tax rate forecast. We currently estimate the tax expense associated with this matter for the full fiscal 2022 will be $38&#160;million.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Self-Insurance Pre-tax Loss</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2021, our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fiscal 2020 statutory financial statements primarily related to opioid litigation. This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes. The net operating loss was carried back and applied to adjust our taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security ("CARES") Act enacted by the United States Congress in March 2020.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, our provision for income taxes during the nine months ended March&#160;31, 2021 included a $419&#160;million benefit from the net operating loss carryback primarily to reflect the difference between the federal statutory income tax rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In fiscal 2021, we filed for a refund of $974&#160;million, which we expect to receive within 12 months. Accordingly, we had a current asset for this amounts on our condensed consolidated balance sheets at both March 31, 2022  and June 30, 2021. In April 2022, we received a payment for $966&#160;million, which is net of certain adjustments. We also increased our non-current deferred tax liability by approximately $700&#160;million during the nine months ended March&#160;31, 2021 related to this matter.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of tax law; however, it is possible that the tax authorities could challenge these tax benefits. The actual amount of the tax benefit may differ materially from these estimates.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Opioid Litigation Charges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the $1.02&#160;billion pre-tax charges for the opioid litigation recorded during the nine months ended March&#160;31, 2021, the net tax benefits were approximately $180 million for the nine months ended March&#160;31, 2021 and $228 million for fiscal 2021. Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $35 million during the nine months ended March&#160;31, 2021, and $219 million for fiscal 2021. We have recognized no tax benefit associated with Opioid accruals made in fiscal 2022. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the U.S. Tax Cuts and Jobs Act ("Tax Act"); however, these estimates require significant judgment since the U.S. tax law governing deductibility was changed by the Tax Act. Further, it is possible Congress or the tax authorities could challenge our interpretation of the Tax Act or the estimates and assumptions used to assess the future deductibility of these benefits. The actual amount of the tax benefit may differ materially from these estimates.</span></div></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrecognized Tax Benefits</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $938 million and $932 million of unrecognized tax benefits, at March&#160;31, 2022 and June&#160;30, 2021 respectively. The March&#160;31, 2022 and June&#160;30, 2021 balances include $856 million and $849 million of unrecognized tax benefits, respectively, that if recognized, would have an impact on the effective tax rate. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2022 and June&#160;30, 2021, we had $46 million and $49 million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for/(benefit from) income taxes in the condensed consolidated statements of earnings/(loss). These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the IRS or other taxing authorities, possible settlement of IRS and other audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between zero and a net decrease of up to $5 million, exclusive of penalties and interest.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Tax Matters</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions, and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through 2020.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expiring or unusable loss and credit carryforwards and the required valuation allowances are adjusted quarterly based on available information. This information may support either an increase or a decrease in the required valuation allowance. After applying the valuation allowances, we do not anticipate any limitations on our use of any of the other net deferred income tax assets described above. We operate in a complex multinational tax environment and are subject to tax treaty arrangements and transfer pricing guidelines for intercompany transactions that are subject to interpretation. Uncertainty in a tax position may arise as tax laws are subject to interpretation.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), a subsidiary of Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $73 million at March&#160;31, 2022 and $72&#160;million at June&#160;30, 2021, and is included in other assets in the condensed consolidated balance sheets.</span></div>As a result of the acquisition of the Patient Recovery Business, Medtronic plc is obligated to indemnify us for certain tax exposures and transaction taxes related to periods prior to the acquisition under the purchase agreement. The indemnification receivable was zero at March&#160;31, 2022 and $12&#160;million at June&#160;30, 2021, respectively, and is included in other assets in the condensed consolidated balance sheets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780946290104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Disclosures</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">8. Fair Value Measurements</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">671</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">671</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">112</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">112</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(12)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(12)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780946240024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">9. Financial Instruments </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative </span></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Interest Rate Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities along with both fixed-rate and variable-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Currency Exchange Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commodity Price Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of earnings/(loss). For the three and nine months ended March&#160;31, 2022 and 2021, there was no gain or loss recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the nine months ended March 31, 2022, we entered into pay-floating interest rate swaps with notional amounts of $100 million and $200 million. These swaps have been designated as fair value hedges of our fixed rate debt and are included in </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">deferred income taxes and other liabilities in the condensed consolidated balance sheets.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cash Flow Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax gains recognized in other comprehensive loss were $1&#160;million and $13&#160;million for the three months ended March&#160;31, 2022 and 2021, respectively, and $4&#160;million and $20&#160;million for the nine months ended March&#160;31, 2022 and 2021, respectively. Gains and losses recognized in accumulated other comprehensive loss and reclassified into earnings were immaterial for the three and nine months ended March&#160;31, 2022 and 2021. All gains and losses currently included within accumulated other comprehensive loss associated with our cash flow hedges to be reclassified into net earnings within the next 12 months are immaterial.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net Investment Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended&#160;March&#160;31, 2022, we entered into a &#165;24 billion ($200 million) cross-currency swap maturing in September 2025 and a &#165;24&#160;billion ($200&#160;million) cross-currency swap maturing in June 2027.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended&#160;March&#160;31, 2022, we terminated the &#165;64 billion ($600 million) cross-currency swap entered into in August 2019 and received a net settlement of $71 million in cash recorded in proceeds from net investment hedge terminations in our condensed consolidated statements of cash flows. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax gain and loss from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive loss was a $22&#160;million gain and a $49&#160;million gain during the three months ended March&#160;31, 2022 and 2021, respectively, and a $44&#160;million gain and a $3&#160;million loss during the nine months ended March&#160;31, 2022 and 2021, respectively. Gains </span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognized in interest expense, net in the condensed consolidated statements of earnings/(loss) for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were $5&#160;million during both the three months ended March&#160;31, 2022 and 2021 and $16&#160;million and $14&#160;million during the nine months ended March&#160;31, 2022 and 2021, respectively. </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Economic (Non-Designated) Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. We recorded a $4 million loss and a $1 million gain during the three months ended March 31, 2022 and 2021, respectively, and an immaterial loss and $4 million loss during the nine months ended March&#160;31, 2022 and 2021, respectively. The principal currencies managed through foreign currency contracts are Euro, Chinese renminbi, Canadian dollar.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and equivalents, trade receivables, accounts payable, and other accrued liabilities at March&#160;31, 2022 and June&#160;30, 2021 approximate fair value due to their short-term maturities.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.109%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.986%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated fair value</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,645</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,751&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying amount</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,612</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,236&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780950252808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">10. Shareholders' Equity/(Deficit)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We repurchased $1.0&#160;billion of our common shares, in the aggregate, through share repurchase programs during the nine months ended March&#160;31, 2022. We funded the repurchases with available cash. The common shares repurchased are held in treasury to be used for general corporate purposes.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022, we entered into an accelerated share repurchase ("ASR") program to repurchase common shares for an aggregate purchase price of $200 million. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received an initial delivery of 3.0 million common shares using a reference price of $54.01. The program concluded on April 18, 2022 at a volume weighted average price per common share of $56.02 resulting in a final delivery of 0.6 million common shares.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December 31, 2021, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $300&#160;million. We received an initial delivery of 4.8 million common shares using a reference price of $50.30. The program concluded on January 31, 2022 at a volume weighted average price per common share of $49.39 resulting in a final delivery of 1.3 million common shares.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2021, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $500&#160;million. We received an initial delivery of 7.8 million common shares using a reference price of $51.53. The program concluded on October 4, 2021 at a volume weighted average price per common share of $51.10 resulting in a final delivery of 2.0 million common shares. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $200&#160;million. The program began on February 9, 2021 and concluded on March 31, 2021. The average price paid per common share was $54.40, resulting in a total delivery of 3.7 million common shares.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(34)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive loss attributable to Cardinal Health, Inc. net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(43)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(93)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(77)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780946412440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share Attributable to Cardinal Health, Inc.<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share [Text Block]</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">11. Earnings/(Loss) Per Share Attributable to Cardinal Health, Inc.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the number of common shares used to compute basic and diluted loss per share attributable to Cardinal Health, Inc.:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">275</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">275</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">281</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">281</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive were 5 million for both the three and nine months March&#160;31, 2022. For the three and nine months ended March&#160;31, 2022, there were 2 million and 1 million potentially dilutive employee stock options, restricted share units and performance share units, respectively, not included in the computation of diluted loss per common share attributable to Cardinal Health, Inc. because their effect would have been anti-dilutive as a result of the net loss during those periods.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive were 3 million for the three months ended March 31, 2021 and 4 million for the nine months ended March 31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780946287944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">12. Segment Information</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; provides pharmacy management services to hospitals as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers and payers; and repackages generic pharmaceuticals and over-the-counter healthcare products. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present revenue for each reportable segment and disaggregated revenue within our two reportable segments and Corporate:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.593%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">40,723</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,903&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">234</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">40,957</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,104&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,283</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">601</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">536&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,884</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,174&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">44,841</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,278&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">44,836</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,275&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.593%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">121,501</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106,859&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">653</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">122,154</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107,452&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,296</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,822</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,636&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12,118</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,441&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">134,272</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119,893&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">134,261</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119,881&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Products and services offered by our Specialty Solutions division are referred to as &#8220;specialty pharmaceutical products and services."</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present revenue by geographic area:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.482%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.215%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.217%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43,710</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,089&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,131</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">44,841</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,278&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">44,836</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,275&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.906%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.217%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">130,933</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116,425&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,339</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">134,272</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119,893&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">134,261</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119,881&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Profit</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&amp;A") expenses. Segment SG&amp;A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology, and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">methodologies. The results attributable to noncontrolling interests are recorded within segment profit.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not allocate the following items to our segments: </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">last-in first-out, or ("LIFO"), inventory charges/(credits); </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">surgical gown recall costs/(income);</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">restructuring and employee severance;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">amortization and other acquisition-related costs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">impairments and (gain)/loss on disposal of assets;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">litigation (recoveries)/charges, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">state opioid assessment related to prior fiscal years;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">other (income)/expense, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">interest expense, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">loss on early extinguishment of debt; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">(gain)/loss on sale of equity interest in naviHealth; or</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">provision for income taxes </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $20 million and $4 million for the three months ended March&#160;31, 2022 and 2021, and $38 million and $15 million for the nine months ended March&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the interim goodwill impairment testing for the Medical Unit as discussed further in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iaf3733bf892b435689161c61a06da348_91" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we recognized goodwill impairment charges of $474&#160;million and $1.8&#160;billion during the three and nine months ended March&#160;31, 2022, respectively, which were retained at Corporate. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the opioid litigation as discussed further in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iaf3733bf892b435689161c61a06da348_103" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we recognized a pre-tax charge of $1.02&#160;billion</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the nine months ended March&#160;31, 2021 which was retained at Corporate.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present segment profit by reportable segment and Corporate:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:50.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.429%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.122%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical (1)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">487</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">59</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">546</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">685&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(643)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(212)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings/(loss)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(97)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical (1)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,319</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,326&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">232</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,551</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,966&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2,183)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,656)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings/(loss)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(632)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Pharmaceutical segment profit includes opioid-related litigation defense and compliance costs, but does not include a one-time contingent attorney fee of $18&#160;million incurred during the three and nine months ended March&#160;31, 2022 related to the finalization of the Settlement Agreement. Due to the unique nature and significance of the Settlement Agreement, and the one-time, contingent nature of the fee, this related fee was included in litigation (recoveries)/charges, net in the condensed consolidated statements of earnings/(loss). Additionally, pharmaceutical segment profit during nine months ended March 31, 2022 was positively impacted by a $16&#160;million judgment for lost profits related to an ordinary course intellectual property rights claim.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total assets for each reportable segment and Corporate at: </span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:52.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.503%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">25,470</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,624&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical (1) (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12,166</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate </span></td><td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,475</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/><td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,421&#160;</span></td><td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">42,111</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,453&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Assets of $1.1 billion classified as held for sale related to the Cordis divestiture were included within Medical at June 30, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div>(2)Medical reflects $1.8&#160;billion of goodwill impairment charges recorded in connection with interim goodwill impairment testing for the Medical Unit at March 31, 2022, and December 31, 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780950274056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">13. Share-Based Compensation</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain stock incentive plans (collectively, the &#8220;Plans&#8221;) for the benefit of certain of our officers, directors and employees. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides total share-based compensation expense by type of award:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">53</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">65</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total tax benefit related to share-based compensation was $3 million and $5 million for the three months ended March&#160;31, 2022 and 2021, respectively, and $9 million and $12 million for the nine months ended March&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted share units granted under the Plans generally vest in equal annual installments over three years. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to restricted share units under the Plans:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.218%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.05&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.61&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at March 31, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45.99</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2022, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $89 million, which is expected to be recognized over a weighted-average period of two years.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee stock options granted under the Plans generally vest in equal annual installments over three years and are exercisable for ten years from the grant date. All stock options are exercisable at a price equal to the market value of the common shares underlying the option on the grant date.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all stock option transactions under the Plans:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.616%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.480%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.061%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price per<br/>Common Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at June 30, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.46&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding at March 31, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">69.41</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercisable at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">69.58</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2022, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested stock options not yet recognized was $0.2 million, which is expected to be recognized over a weighted-average period of two years.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide additional detail related to stock options:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate intrinsic value of outstanding options at period end</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate intrinsic value of exercisable options at period end</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining contractual life of outstanding options</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining contractual life of exercisable options</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Performance Share Units</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance share units vest over a 3-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from zero to 240 percent of the target award amount for the fiscal 2020 and 2021 grants and zero to 234 percent for the fiscal 2022 grant. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:49.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.023%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.147%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance<br/>Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.89&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.00&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at March 31, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">57.27</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2022, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $25 million, which is expected to be recognized over a weighted-average period of two years if performance goals are achieved.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780944868456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Financial Accounting Standards</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Issued Financial Accounting Standards</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Not Yet Adopted</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2021 Form 10-K. There were no accounting standards issued in fiscal 2022 that will have a material impact on our condensed consolidated financial statements.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Adopted Financial Accounting Standards</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted in the nine months ended March 31, 2022.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2022 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fiscal year ends on June 30. References to fiscal 2022 and  2021 in these condensed consolidated financial statements are to the fiscal years ending or ended June&#160;30, 2022 and June&#160;30, 2021, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic ("COVID-19") continues to affect the U.S. and global economies, and as previously disclosed, the pandemic began to materially affect our businesses during the third quarter of fiscal 2020. The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2022 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2022. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2021 (the "2021 Form 10-K").</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Issued Financial Accounting Standards</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Not Yet Adopted</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2021 Form 10-K. There were no accounting standards issued in fiscal 2022 that will have a material impact on our condensed consolidated financial statements.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Adopted Financial Accounting Standards</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted in the nine months ended March 31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780950987080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Summary of Restructuring and Employee Severance</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restructuring and employee severance:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">19</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">31</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">22</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">34</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">56</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity related to liabilities associated with restructuring and employee severance:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.237%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.237%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.241%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-<br/>Related Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility Exit<br/>and Other Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">79</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(48)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">49</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">66</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780950648616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill by Reportable Segment</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill by segment and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.640%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.556%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical (2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,659&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,330&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,989</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill acquired, net of purchase price adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(41)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,781)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,781)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,659</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,508</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,167</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">At March 31, 2022 and June 30, 2021, the Pharmaceutical segment accumulated goodwill impairment loss was $829&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">At March 31, 2022 and June 30, 2021, the Medical segment accumulated goodwill impairment loss was $3.2&#160;billion and $1.4&#160;billion, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize other intangible assets by class at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:24.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.409%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted- Average Remaining Amortization Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,293</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,130</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,163</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">552</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">352</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">200</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,036</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">557</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">479</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,881</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,039</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,842</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,894</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,039</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,855</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:42.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.308%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.643%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.312%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,035&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,916&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,823&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,093&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,928&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,823&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,105&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780946290104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">671</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">671</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">112</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">112</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(12)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(12)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780946260024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.109%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.986%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated fair value</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,645</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,751&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying amount</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,612</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,236&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780946266184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(34)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive loss attributable to Cardinal Health, Inc. net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(43)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(93)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(77)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780946236264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the number of common shares used to compute basic and diluted loss per share attributable to Cardinal Health, Inc.:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">275</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">275</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">281</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">281</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780944564456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue [Table Text Block]</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.593%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">40,723</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,903&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">234</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">40,957</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,104&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,283</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">601</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">536&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,884</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,174&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">44,841</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,278&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">44,836</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,275&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.593%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">121,501</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106,859&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">653</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">122,154</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107,452&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,296</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,822</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,636&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12,118</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,441&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">134,272</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119,893&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">134,261</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119,881&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Products and services offered by our Specialty Solutions division are referred to as &#8220;specialty pharmaceutical products and services."</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Revenue from External Customers by Geographic Areas [Table Text Block]</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present revenue by geographic area:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.482%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.215%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.217%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43,710</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,089&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,131</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">44,841</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,278&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">44,836</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,275&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.906%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.217%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">130,933</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116,425&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,339</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">134,272</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119,893&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">134,261</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119,881&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Segment Profit by Reportable Segment</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present segment profit by reportable segment and Corporate:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:50.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.429%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.122%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical (1)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">487</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">59</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">546</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">685&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(643)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(212)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings/(loss)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(97)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical (1)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,319</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,326&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">232</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,551</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,966&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2,183)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,656)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings/(loss)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(632)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Pharmaceutical segment profit includes opioid-related litigation defense and compliance costs, but does not include a one-time contingent attorney fee of $18&#160;million incurred during the three and nine months ended March&#160;31, 2022 related to the finalization of the Settlement Agreement. Due to the unique nature and significance of the Settlement Agreement, and the one-time, contingent nature of the fee, this related fee was included in litigation (recoveries)/charges, net in the condensed consolidated statements of earnings/(loss). Additionally, pharmaceutical segment profit during nine months ended March 31, 2022 was positively impacted by a $16&#160;million judgment for lost profits related to an ordinary course intellectual property rights claim.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock', window );">Assets by Reportable Segment</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total assets for each reportable segment and Corporate at: </span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:52.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.503%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">25,470</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,624&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical (1) (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12,166</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate </span></td><td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,475</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/><td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,421&#160;</span></td><td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">42,111</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,453&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Assets of $1.1 billion classified as held for sale related to the Cordis divestiture were included within Medical at June 30, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div>(2)Medical reflects $1.8&#160;billion of goodwill impairment charges recorded in connection with interim goodwill impairment testing for the Medical Unit at March 31, 2022, and December 31, 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780950027976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Total Share-based Compensation Expense by Type of Award</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides total share-based compensation expense by type of award:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">53</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">65</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Transactions Under the Plans</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all stock option transactions under the Plans:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.616%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.480%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.061%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price per<br/>Common Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at June 30, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.46&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding at March 31, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">69.41</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercisable at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">69.58</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_AdditionalStockOptionPlanDataTableTextBlock', window );">Schedule of Additional Data Related to Stock Option Activity</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide additional detail related to stock options:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate intrinsic value of outstanding options at period end</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate intrinsic value of exercisable options at period end</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining contractual life of outstanding options</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining contractual life of exercisable options</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Transactions Related to Restricted Share Units Under the Plans</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to restricted share units under the Plans:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.218%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.05&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.61&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at March 31, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45.99</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock', window );">Schedule of Transactions Related to Performance Share Units Under the Plans</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:49.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.023%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.147%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance<br/>Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.89&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.00&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at March 31, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">57.27</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_AdditionalStockOptionPlanDataTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A disclosure of additional data related to all stock option activity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_AdditionalStockOptionPlanDataTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested performance-based units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780949993656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations and Disposal Groups (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_CordisDivestitureAxis=cah_CordisDivestitureMember', window );">Cordis Divestiture</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from Divestiture of Businesses</a></td>
<td class="nump">$ 923<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_CordisDivestitureAxis=cah_CordisDivestitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_CordisDivestitureAxis=cah_CordisDivestitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780944835784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Employee-related costs</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_FacilityExitAndOtherCosts', window );">Facility Exit and Other Costs</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total restructuring and employee severance</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_FacilityExitAndOtherCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_FacilityExitAndOtherCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139781042112472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning Balance</a></td>
<td class="nump">$ 79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Additions</a></td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments and other adjustments</a></td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending Balance</a></td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee- Related Costs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning Balance</a></td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Additions</a></td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments and other adjustments</a></td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending Balance</a></td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember', window );">Facility Exit and Other Costs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning Balance</a></td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Additions</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments and other adjustments</a></td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending Balance</a></td>
<td class="nump">$ 17<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139781042101304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance Narative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Employee-related costs</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_FacilityExitAndOtherCosts', window );">Facility Exit and Other Costs</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_FacilityExitAndOtherCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_FacilityExitAndOtherCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780947158296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">$ 7,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, Transfers</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments and other</a></td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="nump">1,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">6,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember', window );">Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">2,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, Transfers</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">2,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Goodwill, Impaired, Accumulated Impairment Loss</a></td>
<td class="nump">829<span></span>
</td>
<td class="nump">$ 829<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember', window );">Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">5,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, Transfers</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments and other</a></td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="nump">1,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">3,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Goodwill, Impaired, Accumulated Impairment Loss</a></td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780944817624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Intangible</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Intangible</a></td>
<td class="nump">4,881<span></span>
</td>
<td class="nump">4,916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">3,039<span></span>
</td>
<td class="nump">2,823<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangible</a></td>
<td class="nump">$ 1,842<span></span>
</td>
<td class="nump">2,093<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted- Average Remaining Amortization Period (Years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Intangible, Total other intangible assets</a></td>
<td class="nump">$ 4,894<span></span>
</td>
<td class="nump">4,928<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Intangible, Total other intangible assets</a></td>
<td class="nump">1,855<span></span>
</td>
<td class="nump">2,105<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=cah_IPRDTrademarksandOtherMember', window );">Trademarks and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Intangible</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Intangible</a></td>
<td class="nump">3,293<span></span>
</td>
<td class="nump">3,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">2,130<span></span>
</td>
<td class="nump">1,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangible</a></td>
<td class="nump">$ 1,163<span></span>
</td>
<td class="nump">1,341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted- Average Remaining Amortization Period (Years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cah_TrademarksAndPatentsMember', window );">Trademarks, trade names and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Intangible</a></td>
<td class="nump">$ 552<span></span>
</td>
<td class="nump">551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">352<span></span>
</td>
<td class="nump">328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangible</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted- Average Remaining Amortization Period (Years)</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Intangible</a></td>
<td class="nump">$ 1,036<span></span>
</td>
<td class="nump">1,035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">557<span></span>
</td>
<td class="nump">506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangible</a></td>
<td class="nump">$ 479<span></span>
</td>
<td class="nump">$ 529<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted- Average Remaining Amortization Period (Years)</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=cah_IPRDTrademarksandOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=cah_IPRDTrademarksandOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cah_TrademarksAndPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cah_TrademarksAndPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780947216184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109<span></span>
</td>
<td class="nump">$ 235<span></span>
</td>
<td class="nump">$ 337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Estimated annual amortization of intangible assets - Remainder of Fiscal Year</a></td>
<td class="nump">78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Estimated annual amortization of intangible assets - Year One</a></td>
<td class="nump">284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Estimated annual amortization of intangible assets - Year Two</a></td>
<td class="nump">260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Estimated annual amortization of intangible assets - Year Three</a></td>
<td class="nump">235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Estimated annual amortization of intangible assets - Year Four</a></td>
<td class="nump">208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">6,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember', window );">Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">3,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=cah_MedicalUnitMember', window );">Medical Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="nump">$ 474<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_DiscountRateFairValueInput', window );">Discount Rate, Fair Value Input</a></td>
<td class="nump">9.50%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_TerminalGrowthRateFairValueInput', window );">Terminal Growth Rate, Fair Value Input</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_DiscountRateFairValueInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount Rate, Fair Value Input</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_DiscountRateFairValueInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_TerminalGrowthRateFairValueInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Terminal Growth Rate, Fair Value Input</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_TerminalGrowthRateFairValueInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=cah_MedicalUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=cah_MedicalUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780943450728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Obligations and Other Short-Term Borrowings (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_TotalLongTermandShortTermObligations', window );">Total Long-Term and Short-Term Obligations</a></td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts Payable</a></td>
<td class="nump">24,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod', window );">Line of Credit Facility, Maximum Amount Outstanding During Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAverageOutstandingAmount', window );">Line of Credit Facility, Average Outstanding Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=cah_ShortTermCreditFacilitiesMember', window );">Short Term Credit Facilities Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherShortTermBorrowings', window );">Other Short-term Borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cah_A2.616Notesdue2022Member', window );">2.616% Notes due 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">572<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cah_CommittedReceivablesSalesFacilityProgramMember', window );">Committed Receivables Sales Facility Program [Member] | Short Term Credit Facilities Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cah_FloatingRateNotesdue2022Member', window );">Floating Rate Notes due 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_TotalLongTermandShortTermObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total Long-Term and Short-Term Obligations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_TotalLongTermandShortTermObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAverageOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average amount borrowed under the credit facility during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAverageOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount borrowed under the credit facility at any time during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=cah_ShortTermCreditFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=cah_ShortTermCreditFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cah_A2.616Notesdue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cah_A2.616Notesdue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cah_CommittedReceivablesSalesFacilityProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cah_CommittedReceivablesSalesFacilityProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cah_FloatingRateNotesdue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cah_FloatingRateNotesdue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780950926328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_TotalLongTermandShortTermObligations', window );">Total Long-Term and Short-Term Obligations</a></td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="nump">$ 6,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Long-term Debt and Lease Obligation, Current</a></td>
<td class="nump">861<span></span>
</td>
<td class="nump">871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term Debt and Lease Obligation</a></td>
<td class="nump">$ 4,751<span></span>
</td>
<td class="nump">$ 5,365<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_TotalLongTermandShortTermObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total Long-Term and Short-Term Obligations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_TotalLongTermandShortTermObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780937709336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments, Contingent Liabilities and Litigation (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 29, 2022 </div>
<div>lawsuit </div>
<div>plaintiff</div>
</th>
<th class="th">
<div>Apr. 28, 2022 </div>
<div>numberOfUSTerritories </div>
<div>StateAG </div>
<div>lawsuit </div>
<div>plaintiff </div>
<div>states</div>
</th>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>lawsuit</div>
</th>
<th class="th"><div>Jul. 31, 2014</div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 04, 2022 </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>May 02, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2022 </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Loss Related to Litigation Settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 113<span></span>
</td>
<td class="nump">$ 1,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember', window );">Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_JudgmentForLostProfits', window );">Judgment for lost profits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss Contingency, New Claims Filed, Number | lawsuit</a></td>
<td class="nump">457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LawsuitTypeAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyClaimsSettledNumber', window );">Loss Contingency, Claims Settled, Number | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LawsuitTypeAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss Contingency Accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LawsuitTypeAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss Contingency Accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember', window );">Total Opioid Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss Contingency, Estimate of Possible Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">Estimated Litigation Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Estimated Litigation Liability, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation Settlement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for Legal Settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember', window );">Total Opioid Litigation [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_SettlingStates', window );">Settling States | states</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_SettlingUSTerritories', window );">Settling U.S Territories | numberOfUSTerritories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LossContingencyClaimsSettledPercent', window );">Loss Contingency Claims Settled Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_NewYorkOpioidStewardshipActMember', window );">New York Opioid Stewardship Act [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_AggregateAnnualAssessment', window );">Aggregate Annual Assessment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct', window );">Estimated Liability for New York Opioid Stewardship Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualPayments', window );">Loss Contingency Accrual, Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss Contingency Accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember', window );">Opioid Lawsuits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LossContingencyLawsuitsNumber', window );">Loss Contingency, Lawsuits, Number | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember', window );">Opioid Lawsuits [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_NumberofStateAttorneysGeneralfilinglawsuits', window );">Number of State Attorneys General filing lawsuits | StateAG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember', window );">Opioid Lawsuits [Member] | WEST VIRGINIA | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Loss Contingency, Number of Plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember', window );">Opioid Lawsuits [Member] | WASHINGTON | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss Contingency, Estimate of Possible Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember', window );">Opioid Lawsuits [Member] | Private Parties [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LossContingencyLawsuitsNumber', window );">Loss Contingency, Lawsuits, Number | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember', window );">Opioid Lawsuits [Member] | Private Parties [Member] | GEORGIA | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Loss Contingency, Number of Plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember', window );">Opioid Lawsuits [Member] | Class Action Lawsuits [Member] | Private Parties [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LossContingencyLawsuitsNumber', window );">Loss Contingency, Lawsuits, Number | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsStateMember', window );">Opioid Lawsuits State [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LossContingencyLawsuitsNumber', window );">Loss Contingency, Lawsuits, Number | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyClaimsSettledNumber', window );">Loss Contingency, Claims Settled, Number | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss Contingency, Pending Claims, Number | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss Contingency, New Claims Filed, Number | lawsuit</a></td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits | Alameda County [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Loss Contingency, Number of Plaintiffs | plaintiff</a></td>
<td class="nump">5,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits | Other Jurisdictions [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Loss Contingency, Number of Plaintiffs | plaintiff</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_DOJInvestigationMember', window );">DOJ Investigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Loss Related to Litigation Settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=cah_CVSHealthMember', window );">CVS Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermPurchaseCommitmentPeriod', window );">Long-term Purchase Commitment, Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_AggregateAnnualAssessment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Annual Assessment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_AggregateAnnualAssessment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated Liability for New York Opioid Stewardship Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_JudgmentForLostProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Judgment for lost profits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_JudgmentForLostProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_LossContingencyClaimsSettledPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency Claims Settled Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_LossContingencyClaimsSettledPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_LossContingencyLawsuitsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Lawsuits, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_LossContingencyLawsuitsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_NumberofStateAttorneysGeneralfilinglawsuits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of State Attorneys General filing lawsuits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_NumberofStateAttorneysGeneralfilinglawsuits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_SettlingStates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Settling States</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_SettlingStates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_SettlingUSTerritories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Settling U.S Territories</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_SettlingUSTerritories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermPurchaseCommitmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermPurchaseCommitmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14615-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow reducing loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyClaimsSettledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of claims settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyClaimsSettledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfPlaintiffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of plaintiffs that have filed claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfPlaintiffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=cah_ProductLiabilityLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=cah_ProductLiabilityLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_LawsuitTypeAxis=cah_ProductLiabilityLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_LawsuitTypeAxis=cah_ProductLiabilityLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_NewYorkOpioidStewardshipActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_NewYorkOpioidStewardshipActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_OpioidLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_WV">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_WV</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_WA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_WA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_PlaintiffTypeAxis=cah_PrivatePartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_PlaintiffTypeAxis=cah_PrivatePartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_GA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_GA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_LawsuitTypeAxis=cah_ClassActionLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_LawsuitTypeAxis=cah_ClassActionLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsStateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_OpioidLawsuitsStateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_ProductLiabilityLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_ProductLiabilityLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=cah_AlamedaCountyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=cah_AlamedaCountyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=cah_OtherJurisdictionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=cah_OtherJurisdictionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_DOJInvestigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_DOJInvestigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cah_CVSHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cah_CVSHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780940468920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 320<span></span>
</td>
<td class="nump">$ 328<span></span>
</td>
<td class="num">$ (293)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">849<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized tax benefits, interest and penalties accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective Income Tax Rate Reconciliation, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(916.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.80%<span></span>
</td>
<td class="num">(44.40%)<span></span>
</td>
<td class="num">(143.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent', window );">Deferred income taxes and other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,670<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=cah_MedicalUnitMember', window );">Medical Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">474<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_CordisDivestitureAxis=cah_CordisDivestitureMember', window );">Cordis Divestiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation', window );">Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_GoodwillImpairmentAxis=cah_MedicalUnitGoodwillImpairmentMember', window );">Medical Unit Goodwill Impairment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_GoodwillImpairmentAxis=cah_MedicalUnitGoodwillImpairmentMember', window );">Medical Unit Goodwill Impairment [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="num">$ (180)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | Cordis Divestiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation', window );">Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | Medical Unit Goodwill Impairment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (126)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_NetOperatingLossCarrybackAxis=cah_NetOperatingLossCarrybackMember', window );">Net Operating Loss Carryback [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (419)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent', window );">Deferred income taxes and other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReceivable', window );">Income Taxes Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">974<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_NetOperatingLossCarrybackAxis=cah_NetOperatingLossCarrybackMember', window );">Net Operating Loss Carryback [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIncomeTaxRefunds', window );">Proceeds from Income Tax Refunds</a></td>
<td class="nump">$ 966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Estimated range of decrease in unrecognized tax benefits within the next 12 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Estimated range of decrease in unrecognized tax benefits within the next 12 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_TaxMatterAxis=cah_PatientRecoveryBusinessMember', window );">Patient Recovery Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_IndemnificationReceivable', window );">Indemnification Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_TaxMatterAxis=cah_CareFusionMember', window );">CareFusion [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_IndemnificationReceivable', window );">Indemnification Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember', window );">Total Opioid Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">Estimated Litigation Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(180)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(228)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 219<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation Settlement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_IndemnificationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indemnification receivable from Patient recovery related to certain pre-acquisition tax exposures and transaction taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_IndemnificationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) on gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIncomeTaxRefunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash received during the period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIncomeTaxRefunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=cah_MedicalUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=cah_MedicalUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_CordisDivestitureAxis=cah_CordisDivestitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_CordisDivestitureAxis=cah_CordisDivestitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_GoodwillImpairmentAxis=cah_MedicalUnitGoodwillImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_GoodwillImpairmentAxis=cah_MedicalUnitGoodwillImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_NetOperatingLossCarrybackAxis=cah_NetOperatingLossCarrybackMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_NetOperatingLossCarrybackAxis=cah_NetOperatingLossCarrybackMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_TaxMatterAxis=cah_PatientRecoveryBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_TaxMatterAxis=cah_PatientRecoveryBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_TaxMatterAxis=cah_CareFusionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_TaxMatterAxis=cah_CareFusionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780937682712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details) - Recurring - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 671<span></span>
</td>
<td class="nump">$ 1,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Other investments</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Forward Contract</a></td>
<td class="num">(12)<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Forward Contract</a></td>
<td class="num">(12)<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">671<span></span>
</td>
<td class="nump">1,883<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Other investments</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Forward Contract</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Forward Contract</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Other investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Forward Contract</a></td>
<td class="num">(12)<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Forward Contract</a></td>
<td class="num">(12)<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Other investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Forward Contract</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Forward Contract</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126966630&amp;loc=d3e41228-113958<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780944640008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Narrative) (Details)<br> &#165; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>JPY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1', window );">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromHedgeInvestingActivities', window );">Proceeds from Hedge, Investing Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</a></td>
<td class="nump">22<span></span>
</td>
<td class="num">(49)<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest Income (Expense), Nonoperating, Net</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Fair Value Hedging | Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative Liability, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Net Investment Hedging [Member] | Currency Swap [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount', window );">Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 64,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Net Investment Hedging [Member] | Currency Swap [Member] | September 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative Liability, Notional Amount</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Net Investment Hedging [Member] | Currency Swap [Member] | June 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative Liability, Notional Amount</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other Nonoperating Income (Expense) [Member] | Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</a></td>
<td class="num">$ (4)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromHedgeInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 27<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3581-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromHedgeInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_MaturityDateAxis=cah_September2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_MaturityDateAxis=cah_September2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_MaturityDateAxis=cah_June2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_MaturityDateAxis=cah_June2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780950601592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_CarryingAmountofLongTermandotherShortTermBorrowings', window );">Carrying Amount of Long-Term and other Short-Term Borrowings</a></td>
<td class="nump">$ 5,612<span></span>
</td>
<td class="nump">$ 6,236<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Estimated fair value</a></td>
<td class="nump">$ 5,645<span></span>
</td>
<td class="nump">$ 6,751<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_CarryingAmountofLongTermandotherShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying Amount of Long-Term and other Short-Term Borrowings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_CarryingAmountofLongTermandotherShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780939532632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Narrative) (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis=cah_A500MillionShareRepurchaseProgramMember', window );">$500 million share repurchase program [Domain]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis=cah_A300MillionShareRepurchaseProgramMember', window );">$300 million share repurchase program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis=cah_A200MillionShareRepurchaseProgramMember', window );">$200 million share repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember', window );">Treasury Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury Stock, Shares, Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.7)<span></span>
</td>
<td class="num">(19.0)<span></span>
</td>
<td class="num">(4.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury shares acquired, average price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember', window );">Treasury Shares | $500 million share repurchase program [Domain]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury Stock, Shares, Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.0)<span></span>
</td>
<td class="num">(7.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury shares acquired, average price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51.10<span></span>
</td>
<td class="nump">$ 51.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember', window );">Treasury Shares | $300 million share repurchase program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury Stock, Shares, Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
<td class="num">(4.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury shares acquired, average price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49.39<span></span>
</td>
<td class="nump">$ 50.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember', window );">Treasury Shares | $200 million share repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury Stock, Shares, Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury shares acquired, average price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember', window );">Treasury Shares | $200 million share repurchase program | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury Stock, Shares, Acquired</a></td>
<td class="num">(0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury shares acquired, average price per share (in usd per share)</a></td>
<td class="nump">$ 56.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis=cah_A500MillionShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_ShareRepurchaseProgramAggregatePurchasePriceAxis=cah_A500MillionShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis=cah_A300MillionShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_ShareRepurchaseProgramAggregatePurchasePriceAxis=cah_A300MillionShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis=cah_A200MillionShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_ShareRepurchaseProgramAggregatePurchasePriceAxis=cah_A200MillionShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780947242168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="nump">$ 1,002<span></span>
</td>
<td class="nump">$ 1,975<span></span>
</td>
<td class="nump">$ 1,794<span></span>
</td>
<td class="nump">$ 1,792<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income/(loss), net of tax</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="num">(693)<span></span>
</td>
<td class="nump">1,794<span></span>
</td>
<td class="num">(693)<span></span>
</td>
<td class="nump">1,794<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Foreign Currency Translation Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(46)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income/(loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="num">(93)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(93)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember', window );">Unrealized Gain/(Loss) on Derivatives, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income/(loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income/(loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="num">(77)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(77)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">AOCI Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="num">(85)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="num">(104)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="num">$ (77)<span></span>
</td>
<td class="num">$ (48)<span></span>
</td>
<td class="num">$ (77)<span></span>
</td>
<td class="num">$ (48)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780950003352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive (in shares)</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss', window );">Shares that would be antidilutive as a result of net loss</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares that would be antidilutive as a result of net loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780947216504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares&#8211;basic (in shares)</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">292<span></span>
</td>
<td class="nump">281<span></span>
</td>
<td class="nump">293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Employee stock options, restricted share units, and performance share units (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares&#8211;diluted (in shares)</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">294<span></span>
</td>
<td class="nump">281<span></span>
</td>
<td class="nump">294<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780947159240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Narrative) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Loss Related to Litigation Settlement</a></td>
<td class="nump">$ 61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 113<span></span>
</td>
<td class="nump">$ 1,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_ProjectCostsOnInvestmentAndOtherSpending', window );">Project costs on investment and other spending</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_ProjectCostsOnInvestmentAndOtherSpending', window );">Project costs on investment and other spending</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=cah_MedicalUnitMember', window );">Medical Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="nump">$ 474<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember', window );">Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_NewYorkOpioidStewardshipActMember', window );">New York Opioid Stewardship Act [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct', window );">Estimated Liability for New York Opioid Stewardship Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember', window );">Total Opioid Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation Settlement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,020<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated Liability for New York Opioid Stewardship Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_ProjectCostsOnInvestmentAndOtherSpending">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment spending at the Corporate level. Investment spending generally includes the first year spend for certain projects that require incremental investments in the form of additional operating expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_ProjectCostsOnInvestmentAndOtherSpending</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=cah_MedicalUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=cah_MedicalUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_NewYorkOpioidStewardshipActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_NewYorkOpioidStewardshipActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780940402776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Revenue by Reportable Segment) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 44,836<span></span>
</td>
<td class="nump">$ 39,275<span></span>
</td>
<td class="nump">$ 134,261<span></span>
</td>
<td class="nump">$ 119,881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">44,841<span></span>
</td>
<td class="nump">39,278<span></span>
</td>
<td class="nump">134,272<span></span>
</td>
<td class="nump">119,893<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">40,957<span></span>
</td>
<td class="nump">35,104<span></span>
</td>
<td class="nump">122,154<span></span>
</td>
<td class="nump">107,452<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">3,884<span></span>
</td>
<td class="nump">4,174<span></span>
</td>
<td class="nump">12,118<span></span>
</td>
<td class="nump">12,441<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=cah_PharmaceuticalDistributionandSpecialtyMember', window );">Pharmaceutical Distribution and Specialty [Member] | Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">40,723<span></span>
</td>
<td class="nump">34,903<span></span>
</td>
<td class="nump">121,501<span></span>
</td>
<td class="nump">106,859<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=cah_NuclearPrecisionHealthSolutionsMember', window );">Nuclear Precision Health Services [Member] | Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">234<span></span>
</td>
<td class="nump">201<span></span>
</td>
<td class="nump">653<span></span>
</td>
<td class="nump">593<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=cah_MedicaldistributionandproductsMember', window );">Medical distribution and products [Member] | Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">3,283<span></span>
</td>
<td class="nump">3,638<span></span>
</td>
<td class="nump">10,296<span></span>
</td>
<td class="nump">10,805<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=cah_CardinalHealthAtHomeMember', window );">Cardinal Health At Home [Member] | Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 601<span></span>
</td>
<td class="nump">$ 536<span></span>
</td>
<td class="nump">$ 1,822<span></span>
</td>
<td class="nump">$ 1,636<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_PharmaceuticalDistributionandSpecialtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_PharmaceuticalDistributionandSpecialtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_NuclearPrecisionHealthSolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_NuclearPrecisionHealthSolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_MedicaldistributionandproductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_MedicaldistributionandproductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_CardinalHealthAtHomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_CardinalHealthAtHomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780947466728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Segment Profit by Reportable Segment) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="num">$ (97)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 473<span></span>
</td>
<td class="num">$ (632)<span></span>
</td>
<td class="nump">$ 310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_ContingentAttorneyFee', window );">Contingent Attorney Fee</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember', window );">Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_JudgmentForLostProfits', window );">Judgment for lost profits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="nump">546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">685<span></span>
</td>
<td class="nump">1,551<span></span>
</td>
<td class="nump">1,966<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="nump">487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">511<span></span>
</td>
<td class="nump">1,319<span></span>
</td>
<td class="nump">1,326<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174<span></span>
</td>
<td class="nump">232<span></span>
</td>
<td class="nump">640<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="num">$ (643)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (212)<span></span>
</td>
<td class="num">$ (2,183)<span></span>
</td>
<td class="num">$ (1,656)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_ContingentAttorneyFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Attorney Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_ContingentAttorneyFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_JudgmentForLostProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Judgment for lost profits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_JudgmentForLostProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780947595016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information Revenue From External Customers By Geographic Areas (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems', window );"><strong>Segment Revenue from External Customers by Geographic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 44,836<span></span>
</td>
<td class="nump">$ 39,275<span></span>
</td>
<td class="nump">$ 134,261<span></span>
</td>
<td class="nump">$ 119,881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems', window );"><strong>Segment Revenue from External Customers by Geographic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">43,710<span></span>
</td>
<td class="nump">38,089<span></span>
</td>
<td class="nump">130,933<span></span>
</td>
<td class="nump">116,425<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems', window );"><strong>Segment Revenue from External Customers by Geographic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,131<span></span>
</td>
<td class="nump">1,189<span></span>
</td>
<td class="nump">3,339<span></span>
</td>
<td class="nump">3,468<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems', window );"><strong>Segment Revenue from External Customers by Geographic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">44,841<span></span>
</td>
<td class="nump">39,278<span></span>
</td>
<td class="nump">134,272<span></span>
</td>
<td class="nump">119,893<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems', window );"><strong>Segment Revenue from External Customers by Geographic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="num">$ (5)<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
<td class="num">$ (11)<span></span>
</td>
<td class="num">$ (12)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Segment Revenue from External Customers by Geographic Area [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780937697000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Assets by Reportable Segment) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 42,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,111<span></span>
</td>
<td class="nump">$ 44,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Total assets held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=cah_MedicalUnitMember', window );">Medical Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="nump">474<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember', window );">Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember', window );">Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember', window );">Medical | Cordis Divestiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Total assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">25,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,470<span></span>
</td>
<td class="nump">23,624<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">12,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,166<span></span>
</td>
<td class="nump">15,408<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 4,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,475<span></span>
</td>
<td class="nump">$ 5,421<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=cah_MedicalUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=cah_MedicalUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_CordisDivestitureAxis=cah_CordisDivestitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_CordisDivestitureAxis=cah_CordisDivestitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780944555144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Tax benefit related to share-based compensation</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_ExercisablePeriodOfPlansInYears', window );">Exercisable period of plans (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Share Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="nump">89,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_VestingPeriodinyearsforShares', window );">Vesting Period in years for Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Units | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Target performance goal (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Units | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Target performance goal (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234.00%<span></span>
</td>
<td class="nump">240.00%<span></span>
</td>
<td class="nump">240.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_ExercisablePeriodOfPlansInYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The instrument's contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_ExercisablePeriodOfPlansInYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_VestingPeriodinyearsforShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vesting Period in years for Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_VestingPeriodinyearsforShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780947463880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">$ 84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Share Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780947179064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period (in shares) | shares</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Canceled and forfeited (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period (in shares) | shares</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (in shares) | shares</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price per Common Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 68.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Canceled and forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (in usd per share) | $ / shares</a></td>
<td class="nump">69.41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 69.58<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780940435832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details) - Stock Options - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of outstanding options at period end</a></td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of exercisable options at period end</a></td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780947377960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)<br> $ / shares in Units, shares in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Share Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $</a></td>
<td class="nump">$ 89,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Share Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at beginning of period (in shares) | shares</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled and forfeited (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at end of period (in shares) | shares</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at beginning of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 49.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">51.78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in usd per share) | $ / shares</a></td>
<td class="nump">49.61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled and forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at end of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 45.99<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $</a></td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139780937695368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details) - Performance Share Units<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Performance Share Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at beginning of period (in shares) | shares</a></td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled and forfeited (in shares) | shares</a></td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at end of period (in shares) | shares</a></td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at beginning of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 54.89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">51.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in usd per share) | $ / shares</a></td>
<td class="nump">52.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled and forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">52.36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at end of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 57.27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $</a></td>
<td class="nump">$ 25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>cah-20220331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cah="http://www.cardinal.com/20220331"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cah-20220331.xsd" xlink:type="simple"/>
    <context id="i21939e337a964eb182b2e0d93b533226_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8a49f4b92dd448488ec3ce2514a9b527_I20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="i79f0c6d48d9042059a71690df0625736_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePriceAxis">cah:A300MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id0bcebad12fc4c40a4b459a431f9432e_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePriceAxis">cah:A300MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idb40345a5fe44f68828da6e24128f448_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePriceAxis">cah:A300MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4a80329f29594c698d9ee74e1eaacbbe_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePriceAxis">cah:A200MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3bd39d7063da4c278767bc202d3ccfc3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePriceAxis">cah:A200MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i88bcf45d478a46e4b22b402f4b7f54c3_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePriceAxis">cah:A200MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if9374cb6cebc440eabca82aeeccf1677_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if22adf094ce443b8a6d548e13f36c294_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia92405f06fae4c4cb90f702005b8b2a7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7c93d4e78a8c4d04b6c310720c3be878_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2a93b5354aeb44f8b3cc0d0d850b2501_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id1d5a08085294befb4f0b438a66e23de_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i75e8b16bb97541c8bd805031f5452617_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if883c9a37b644835bbe659371a267a15_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ide0abb91cd8d4383a017830f5ef299ff_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8232a7a263294a17a4f15379d0173ba2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5f9edcb7c954465280f497a367eed0d4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i56eb96c92b484bcaa4f9f5c171ad239f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i52413ad34f00440b833f5b75a8dd4627_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iaff4ed7f966c47e4962d2bf39a55b561_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4a915a1a243e410f9ec96b9ace3e80d6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ieed2c03cd42a4857909b008f32e31e33_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4ee4d69320c340dcb7f8fca3e33c99e1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6addc7f27a0049d9963b698b876c52cf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id578e6daf1574d8eb480d856c73bbcda_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i443356fbbe284138a0f49faa34b3208e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id981bf2219e54d3eb7348670fb74ec8c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iee675ac2f5dd4bb5a80f01c9e1535b8b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2703e84aa6d447f29d3aac9d09f5f094_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5214de7195b64409b6762f36bf235b55_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i22fec11876c34d5ebd2c18f6a35aa182_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i12146da7d33541d09f9ef291e388a502_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i359769217d5441bc9c97571164783ca2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i74e91c5fe50846e4abcf66f67c9b72da_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i89dbe704562b4ba5ac39a63d65dbff5a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic83e16a32c7b450083b893267a9ccda4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib6ce5f003d8e47b7ac0d61aa5df61b12_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i021442adc8e24489b12297c43e3fabda_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i43de0647ce12490ab30c52d836774dce_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i07511c4beddc431e9241b971549f9ad5_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3ec660a67cd04983b32b8b4fe7d9870a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i644e369be5f6420aa49654a4323fa93d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6a430c2a1ae64753ae7b549dfc1f69c7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic3c75fe6e5544a349f30d33c4e68a2ac_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie8151fa2583d44a688b40d92d9d83b78_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i77aa86d8f8f8485ab211b681b5f58fb3_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2ed02a1c09cd4d529605f81979cbf648_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iaeff0c865a8a4369ab8c5fdca6cee729_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idb593644726c4c428ed6ceb42a31ff8f_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i090402a139834d23aa8e6c3a5b7f46f8_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie6dfd6eb1a2c4315afc3207155a386d9_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i42e7af7d759c4fa5bfb0b98fa27e974f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i9744506513214bcc9e61087cf55e047e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i307f69a4e1d24b7f8e2b9180075e87b8_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i69e2c38f6f454bfa9b9fece718b91fbe_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i8e0fd895201d4863a312198f691a8d0b_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic358c286737245819556816b3a0a5db5_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia4b35350391644c2a0bdf28917ce2828_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7afc2ffa017e47fe877f56fa2b3a45d4_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6ca3ba0c73594ed7bbc82421ddc8eb83_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i32f5ee07df944be68a4ca171d08f3c89_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:CordisDivestitureAxis">cah:CordisDivestitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i45240633cec7475d96b338fa98ea6450_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i21b9f08e069e407899537ccf182d99fb_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i739eec2ece12431aa16063ab41067d2c_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8e58575430c249979ddd28860b77d7ea_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8754e705bb17409ca30ddb1af53bfd62_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i75ec9e64c1d7453ca7736eb6d2cd74b4_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ifbcce5e048774bd281968e39fa6fd1d5_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i1cf7100a49b8462b95d20252b5ae23fc_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie8dd1990825346198258de24f42bdfab_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i41161f1b8d3943d8bd64b5d48963474e_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i51a8695f54ef4860b74b13f3c337f04d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idb7f73d87fb74abbb28799bf351ad2cf_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2473dfc0495e42aeb265fd377f6c1a00_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">cah:MedicalUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8c4e40c1def448fcb66e1d0cc8122850_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">cah:MedicalUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2843d7b87d1544cf87e968d6d3ae3124_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">cah:MedicalUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id1a80ba5335a434499eb18f05cfe77bd_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cah:IPRDTrademarksandOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i04b1540e67e14f1491c2bcf9e8c40937_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1e32d2dbae964ed2b9f89a485ba2d9f2_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ica172f3bed03490b81be7777d6520978_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i51a8e1fc38aa4e9fa1cbb316ac661cf2_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id70764894a9a471186543cece23c0235_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3ac7d4f29a95405f9301d56ef3d96f7d_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i58dd95f7f9f14ed4a4314c6690da932a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cah:IPRDTrademarksandOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i95eee9fd908844ee899640d22db70870_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i602bf6f83c0542c597ac5984f1a805f8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6be348f5aeaf4eb1a576923d8e90234e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if590433d5a9845a7a608dab6a0c258f3_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A2.616Notesdue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9cb2151ddcdc4fc59c0b79ed2096beec_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:FloatingRateNotesdue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i13e48b0505964bf68353a1b6f9547f38_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A2.616Notesdue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iaf3cd5065e6243ffbbc71550c25ca7f8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i993a04a28da74821b93ee616926e595e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id353836da7934ebb8d1cb8a20ca4a576_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cah:ShortTermCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:CommittedReceivablesSalesFacilityProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iea2152d45a954937a5a92441521a45ff_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cah:ShortTermCreditFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0ab6a9c65c7e4470950a3a5d6dc31d86_D20140731-20140731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cah:CVSHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-07-31</startDate>
            <endDate>2014-07-31</endDate>
        </period>
    </context>
    <context id="i23ebd145540743d0ab7dda2a643e03b3_I20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="i5255724c8ed4493ca93e7bf150c7f600_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5ee03b4ae5f340a187f4bc77f729452b_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i491c71d0bbb64a989ca7c5c82a284488_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9215c78d739b4b399eaa5fb71927062e_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i882c87a069664d07be3f57a3c4880673_I20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="ib8066d95edcd4276b92e5941e9cf1675_I20220428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsStateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-28</instant>
        </period>
    </context>
    <context id="i3f3f37b2e6a246ca91a14261f83072a8_I20220428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-28</instant>
        </period>
    </context>
    <context id="i56ecddadc331422e91dd1962e9bd826a_I20220428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-28</instant>
        </period>
    </context>
    <context id="i8d6bdce912f94701b4d5c146cec19721_D20220428-20220428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-28</startDate>
            <endDate>2022-04-28</endDate>
        </period>
    </context>
    <context id="i66875ebb8eef4db4b014c5f748452b43_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic882bf829b3c4091beef8438bdf4b296_D20220428-20220428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsStateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-28</startDate>
            <endDate>2022-04-28</endDate>
        </period>
    </context>
    <context id="i0247bbb36fd244a09bc9d98fe2b16dcb_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4ff29a3a90e442dd8c5616657406a603_I20220502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-02</instant>
        </period>
    </context>
    <context id="i0bc140f1011640a682a782f1cae16cad_D20220428-20220428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WV</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-28</startDate>
            <endDate>2022-04-28</endDate>
        </period>
    </context>
    <context id="i7cfeb36a6e0d45f8aa734c1879638433_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ifc7fdc5fa1c84d5aa2af19ed52614364_I20220504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-04</instant>
        </period>
    </context>
    <context id="i5118cc3369704619a0d6f9362d7b4be6_I20220504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ClassActionLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-04</instant>
        </period>
    </context>
    <context id="i9ba9d001296a4abc99e1e8dbda30b7a3_D20220428-20220428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:GA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-28</startDate>
            <endDate>2022-04-28</endDate>
        </period>
    </context>
    <context id="icbd0825dbe564a209ad97999fd39b901_D20220429-20220429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-29</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="i967e05473aad4bdab16324a714471629_D20220429-20220429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cah:AlamedaCountyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-29</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="i9dfeb8260c1c4f43b4a0668f4c5957f8_D20220429-20220429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-29</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="ia501b89dcc1041d69e1b5309d5f9f944_D20220429-20220429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cah:OtherJurisdictionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-29</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="i989aea95b6504bd0b4aa8ccb22169319_D20210731-20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-31</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="ic2ae902498a44131a91a5bebbbda2131_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9e7f4d19047348f89f56bfebceea170d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie60f8b5fae944fc6a15c2435abf6b955_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:DOJInvestigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i579fe90cd44b45029f6ce1e6fd52d06e_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">cah:MedicalUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7a1ee29c629542f28c59d5fc1aa744bc_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:GoodwillImpairmentAxis">cah:MedicalUnitGoodwillImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i733aa2f887dc40399537d2978ea4fed6_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:GoodwillImpairmentAxis">cah:MedicalUnitGoodwillImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia07b2306645b4f5b9983cc7a043e7f14_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:GoodwillImpairmentAxis">cah:MedicalUnitGoodwillImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if20d9caabe284cddb92eb75707c2d485_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:CordisDivestitureAxis">cah:CordisDivestitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i55ae6d66a0154f618e5ff8b55c474990_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:CordisDivestitureAxis">cah:CordisDivestitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8498a443311b4f6ea73d7b6ae59ff884_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:NetOperatingLossCarrybackAxis">cah:NetOperatingLossCarrybackMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7b95fd8ae52348c2a406851e857bf380_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:NetOperatingLossCarrybackAxis">cah:NetOperatingLossCarrybackMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4a43d062c10d4b5dbe47ed5927846f46_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:NetOperatingLossCarrybackAxis">cah:NetOperatingLossCarrybackMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i08ae81a7c49448f6a2bf594f079b609d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:NetOperatingLossCarrybackAxis">cah:NetOperatingLossCarrybackMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4c3e04c844a0448ba87bfb01fae49ef6_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6880faa0fa0e4239896a55f349c38f00_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i469fd276126b4ef2a0a27b313a8c926f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i34b741e645b547cba1a09aef122491a7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i19311f0a545a45fabf7564bb3e12fa8f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i97ee2fe5350d48a8a6d2429ec7ce8ba3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:CareFusionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i97c5d03ddc3b4285af82f4a8cdd73077_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:CareFusionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib619e74f426d4144819daac0dcea199d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:PatientRecoveryBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iabd8bb008ac74a12a6602b75f99f57be_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:PatientRecoveryBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7a166264477c46fab57fcf607e059c5e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3682e4eb8a05493a929d3c71c120ed44_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic39a5057fc6f46779de6e92cbbdcda7a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="icac6fea690094cec98b24894f11a9dc5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia6a713b79a1b4db391a01b08a7955833_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8dd0cc9f485540cfba812a2f569e0eec_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if6b241993ad04feca1177de9a32b41d8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic8196f6a78b04b869ddf71567a35ba1e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ied79b20d51d24a52ac6760b96c790928_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id3ce5b3abcbd46bd97aab3629e9beed9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3c0359ac173741d1a3e87605773843bb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9364c217c27b48f7b6d55997d6363b7d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia89d064616e44ff0bc7a6c819fa695aa_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibb3a9b89882f4cad85e3415fe62bbe64_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic064a2bc08564367b783b55fd00e3a4c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:MaturityDateAxis">cah:September2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id24201ce4b9a45b3984c1578539f4366_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:MaturityDateAxis">cah:June2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5481aab2ab274715b2e24d13110e9131_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia6a258e1b3d647dab58b5794f710d928_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5c5d8170ec134e538d16a98b7645242a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie780eda2dbfa43b5ba1886064e5bee88_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8b561ae116c44487bc2d0b64415c487c_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id3d6a7b343d84263bcfd5f6081c9080a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5f6a2249983a48ba948782ea8ac398ae_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ida3f04fa5227480f833bb171bc91c08c_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0faba6dab9bb45eba4532f90d44b6e37_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iddd5f86516724f048fca712cc799eb64_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ice6d3b2a080d44b5b66bace596c4726a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePriceAxis">cah:A500MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i493db659fb0e48c29fa86341836956fb_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePriceAxis">cah:A500MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id7b83872d6a44abb948f2abd62a0d67d_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePriceAxis">cah:A500MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1bc04df5c22d4ac594b0f37e4348fad8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if1d975e32208495384d3c3f118607978_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib919fba7df9a4af5a962444ad795f36e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i85dc1b14fefe4551abd5390650b6c712_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6973b5f7f08f491a99b32b3361d5234a_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i88939d79b6fc434586eae883166fc9d8_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i96f98f7a3c2b4137aadf18cea504d375_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5ebf444915254c15b3d63cf748c3515a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if466229061cc43eda2992e495763f330_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i271748b8420f4075b02360857adce1b3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6c47eb93c86c45f18852a7d4732bcc2b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i55a8895770e74654bb814d7570d0be67_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic20d148712384093a21beaae9dbb11ae_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i50ba23949f524ee39edd3981f77140d5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i84520ad8572840ff8aebaffcf2fc874b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i35c8403b7fd7460d84fabd0ac9bdf6b9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i69525c4e29b84ce794f19067c425c73f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ida0bf17cdf17411ab1c3212847b430cb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i74d2de9e32a34ab5b7753b90bdd5d03f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i76a973b7ccb648908c98bf838383a489_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i968b05c553634c7a8ef37ffb3b2c9491_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9b6fce6427cc4db58e97a1124f989059_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i940747d1739c452b84105fc820e21d0f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia2b4c786f4bf4513b3347b942f655efd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i50f9973da9d3455e928bdbe756cb6f44_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6fc7d8e372df4069be7ed7b9e033f09f_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2178f9d823184a19a7be4b97a98bbfcd_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie832c8853e2a4345938d5c0300e49149_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i995eb07521ae4433bdc8160df2f79810_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4a8fa6b7c4c04392ad18e36a04760533_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib25907ae15fa44dcb0802c504cec1c88_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5b0d22bf281f4584bad7e62de864bf75_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i77648cd7d3a34814beda9dcd87e2f35d_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic7bcf27f7221414f96fbedd5799f6902_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i479768cce42840d6807b6cf8e3d09439_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6afdf5f1340d41c6941f5cc19ff2ef71_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i203ccf6041354aa887510c9903970c43_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib7205a1910584e49b66107f75befc03d_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic84e3ea0e4fb4425b6174e7655ba01f1_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic1865dd177bf446bb0808b03a8c0b8b6_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8b1b3f0e63094c6ba80ba1a031e52c86_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i70d8b7dbb46a4e8fa9f3548d4edd3460_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6b6b3238d8dc4c6094d322879432c3a3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibe5bb815566842549cff77434b3664c5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i625a7e6298c541f0ab5627a25b81a35f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic282070c0abd4da7b2e98ef29dabe2a4_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibe9bf4e4c9f04b558b3d275631d67107_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i60837aa8922b471583b5179248715cc5_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icadf953dd78648ce88457a23b39ed9b3_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2dc2bc03fca7468582ef192514e3bfd5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iab9fb6c03f2c41b09eab97067568553e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id1b44ed725e04cc79bd011f2ce6f6445_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2054ef93e9f6497bb4e5e5e8c06c5afa_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3a7244a5c088444480543d7621bd8890_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5fa86c22fb664c2d85324c8fa396e444_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i25b4b6630ae44ef28341784008cfd847_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:CordisDivestitureAxis">cah:CordisDivestitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i59ac145c43e84d588b95df88a14fdc55_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7d746fa13a56425188cf694ad9491c8b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7fc6f93a9a324e02934d0435deab460b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i12af8121f223485cbae6b363fb276e76_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7587b0e2335a4976aed28934df90543d_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i884f8a089566407ab080d0ebb229f552_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iec8a7050443b4a1cb54f2dc25501b78f_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic70067800d5143aea0895bee00acddf8_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iaa16d72f5cb94c3dae8ef889f5cf1b73_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i429695d6f4bd42f3954b0d838fa9cbea_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i72e703868e904b989107e7bea5f5c25a_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i81916c52c3fd4ebfbcb9cb988adcf939_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i563a2c8d36a84c8890168f4f9a86e549_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if6804c7cefdb418480ee13a51907f380_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5833a4aca61e4135963e45569b6980df_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i160dc3f384644e66812cbec2a46665b2_D20190701-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i766ebcafc487484896f01112fb4d75ea_D20190701-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i3b9a407d237d4399ad21e36831394a4a_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8b1fc63c210f45c4b87728a4957e3834_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i971a6ca11d6d4f408c6af2dc52b79810_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id38ff405ba8f4f46b884a396366a86de_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="lawsuit">
        <measure>cah:lawsuit</measure>
    </unit>
    <unit id="stateag">
        <measure>cah:StateAG</measure>
    </unit>
    <unit id="states">
        <measure>cah:states</measure>
    </unit>
    <unit id="numberofusterritories">
        <measure>cah:numberOfUSTerritories</measure>
    </unit>
    <unit id="plaintiff">
        <measure>cah:plaintiff</measure>
    </unit>
    <unit id="jpy">
        <measure>iso4217:JPY</measure>
    </unit>
    <unit id="segment">
        <measure>cah:segment</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF80L2ZyYWc6YWZiNzY4NGVjYjIxNGRlYjkzNWY2OTdjMDBiNTNmY2EvdGFibGU6MzFkMDFlZjJkOTE4NDZjMzlmZTVjMmEwYzYxMDFiYTIvdGFibGVyYW5nZTozMWQwMWVmMmQ5MTg0NmMzOWZlNWMyYTBjNjEwMWJhMl8yLTEtMS0xLTk4Njk0_ae1b5646-8f98-4f64-86cb-8d898d37f87c">0000721371</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF80L2ZyYWc6YWZiNzY4NGVjYjIxNGRlYjkzNWY2OTdjMDBiNTNmY2EvdGFibGU6MzFkMDFlZjJkOTE4NDZjMzlmZTVjMmEwYzYxMDFiYTIvdGFibGVyYW5nZTozMWQwMWVmMmQ5MTg0NmMzOWZlNWMyYTBjNjEwMWJhMl8zLTEtMS0xLTk4Njk0_0ac62204-bfc1-4172-8c01-3dfd8b5fa2b6">--06-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF80L2ZyYWc6YWZiNzY4NGVjYjIxNGRlYjkzNWY2OTdjMDBiNTNmY2EvdGFibGU6MzFkMDFlZjJkOTE4NDZjMzlmZTVjMmEwYzYxMDFiYTIvdGFibGVyYW5nZTozMWQwMWVmMmQ5MTg0NmMzOWZlNWMyYTBjNjEwMWJhMl80LTEtMS0xLTk4Njk0_3cd89fe6-c544-48ff-a4c2-2f6e4d6adf64">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF80L2ZyYWc6YWZiNzY4NGVjYjIxNGRlYjkzNWY2OTdjMDBiNTNmY2EvdGFibGU6MzFkMDFlZjJkOTE4NDZjMzlmZTVjMmEwYzYxMDFiYTIvdGFibGVyYW5nZTozMWQwMWVmMmQ5MTg0NmMzOWZlNWMyYTBjNjEwMWJhMl81LTEtMS0xLTk4Njk0_31a27cc1-469a-4f7e-8d65-c43ec8f678c4">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF80L2ZyYWc6YWZiNzY4NGVjYjIxNGRlYjkzNWY2OTdjMDBiNTNmY2EvdGFibGU6MzFkMDFlZjJkOTE4NDZjMzlmZTVjMmEwYzYxMDFiYTIvdGFibGVyYW5nZTozMWQwMWVmMmQ5MTg0NmMzOWZlNWMyYTBjNjEwMWJhMl82LTEtMS0xLTk4Njk0_756335cf-733d-4ddd-a646-f96b1dd99b14">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGV4dHJlZ2lvbjo2YzU2MDdiYzc2YmI0NjRkOGVjMTVjM2QyNDQyZTQyOV84NA_ae82131e-251e-4ad0-bab5-8fe0f77c769e">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGFibGU6Zjg4YmM3YWY1NTJkNDA0NDlmZWQ0ODk0MzVjMGVhY2QvdGFibGVyYW5nZTpmODhiYzdhZjU1MmQ0MDQ0OWZlZDQ4OTQzNWMwZWFjZF8wLTAtMS0xLTk4Njk0_f14cc45f-bb1b-4e6c-903a-620ec6805c12">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGV4dHJlZ2lvbjo2YzU2MDdiYzc2YmI0NjRkOGVjMTVjM2QyNDQyZTQyOV8xMjE_5829fa59-a25a-4e23-83a1-facd88888787">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGFibGU6N2QxMjgxODdiZTQ3NDRhYzkzNGU2NjJhM2IyN2VhM2EvdGFibGVyYW5nZTo3ZDEyODE4N2JlNDc0NGFjOTM0ZTY2MmEzYjI3ZWEzYV8wLTAtMS0xLTk4Njk0_9cbeff0b-b037-46dd-a4f9-c620ee66113c">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGV4dHJlZ2lvbjo2YzU2MDdiYzc2YmI0NjRkOGVjMTVjM2QyNDQyZTQyOV8xNTc4_092a5abf-fbb4-4e11-8846-320d1d9b792b">1-11373</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGV4dHJlZ2lvbjo2YzU2MDdiYzc2YmI0NjRkOGVjMTVjM2QyNDQyZTQyOV8xNTc5_137799e4-4713-41aa-a7ad-904d90146fe2">Cardinal Health, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGFibGU6YjBlOTk4NTZhMzI0NDk4NmJkZjA0ZjNmNmI1NTZlY2QvdGFibGVyYW5nZTpiMGU5OTg1NmEzMjQ0OTg2YmRmMDRmM2Y2YjU1NmVjZF8wLTAtMS0xLTk4Njk0_54f36145-d561-4f1c-8238-a5cfb5a4b741">OH</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGFibGU6YjBlOTk4NTZhMzI0NDk4NmJkZjA0ZjNmNmI1NTZlY2QvdGFibGVyYW5nZTpiMGU5OTg1NmEzMjQ0OTg2YmRmMDRmM2Y2YjU1NmVjZF8wLTYtMS0xLTk4Njk0_ba697469-6f9f-4985-8b98-91d7f000c454">31-0958666</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGFibGU6YjBlOTk4NTZhMzI0NDk4NmJkZjA0ZjNmNmI1NTZlY2QvdGFibGVyYW5nZTpiMGU5OTg1NmEzMjQ0OTg2YmRmMDRmM2Y2YjU1NmVjZF8zLTAtMS0xLTk4Njk0_8694ce50-53dd-498d-84bf-670b27fdbe0c">7000 Cardinal Place</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGFibGU6YjBlOTk4NTZhMzI0NDk4NmJkZjA0ZjNmNmI1NTZlY2QvdGFibGVyYW5nZTpiMGU5OTg1NmEzMjQ0OTg2YmRmMDRmM2Y2YjU1NmVjZF8zLTItMS0xLTk4Njk0_f7b9ee7a-5434-4a9d-bf7e-78c76ec1bc58">Dublin</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGFibGU6YjBlOTk4NTZhMzI0NDk4NmJkZjA0ZjNmNmI1NTZlY2QvdGFibGVyYW5nZTpiMGU5OTg1NmEzMjQ0OTg2YmRmMDRmM2Y2YjU1NmVjZF8zLTQtMS0xLTk4Njk0_d9b9f01e-b5d2-449a-a53c-5e5f849c67fe">OH</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGFibGU6YjBlOTk4NTZhMzI0NDk4NmJkZjA0ZjNmNmI1NTZlY2QvdGFibGVyYW5nZTpiMGU5OTg1NmEzMjQ0OTg2YmRmMDRmM2Y2YjU1NmVjZF8zLTYtMS0xLTk4Njk0_06fbdef0-f2c6-4eeb-b3a1-da125a367b54">43017</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGFibGU6YjBlOTk4NTZhMzI0NDk4NmJkZjA0ZjNmNmI1NTZlY2QvdGFibGVyYW5nZTpiMGU5OTg1NmEzMjQ0OTg2YmRmMDRmM2Y2YjU1NmVjZF82LTQtMS0xLTk4Njk0_dc36385e-cf04-43ec-811b-16448df18160">(614)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGFibGU6YjBlOTk4NTZhMzI0NDk4NmJkZjA0ZjNmNmI1NTZlY2QvdGFibGVyYW5nZTpiMGU5OTg1NmEzMjQ0OTg2YmRmMDRmM2Y2YjU1NmVjZF82LTYtMS0xLTk4Njk0_0f031ca0-7638-462a-a852-bb177cfafa7d">757-5000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGFibGU6NzkxOTY0MTgwMDE4NDNhMDg4Y2ExY2Q3ZTkzMjJhYzUvdGFibGVyYW5nZTo3OTE5NjQxODAwMTg0M2EwODhjYTFjZDdlOTMyMmFjNV8yLTAtMS0xLTk4Njk0_b8a259dd-2222-4f98-b0d9-43ccc7fe114f">Common shares (without par value)</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGFibGU6NzkxOTY0MTgwMDE4NDNhMDg4Y2ExY2Q3ZTkzMjJhYzUvdGFibGVyYW5nZTo3OTE5NjQxODAwMTg0M2EwODhjYTFjZDdlOTMyMmFjNV8yLTEtMS0xLTk4Njk0_625bf864-7909-4b48-8984-896e0be35738">CAH</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGFibGU6NzkxOTY0MTgwMDE4NDNhMDg4Y2ExY2Q3ZTkzMjJhYzUvdGFibGVyYW5nZTo3OTE5NjQxODAwMTg0M2EwODhjYTFjZDdlOTMyMmFjNV8yLTItMS0xLTk4Njk0_5116038e-2518-4136-9518-034a5ac50d13">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGV4dHJlZ2lvbjo2YzU2MDdiYzc2YmI0NjRkOGVjMTVjM2QyNDQyZTQyOV8xNTgw_81d9aab3-80c5-47c9-9686-8207920882b8">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGV4dHJlZ2lvbjo2YzU2MDdiYzc2YmI0NjRkOGVjMTVjM2QyNDQyZTQyOV8xNTgx_0e71d48b-167a-4dfc-8ae1-3c24dfc572ea">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGFibGU6MGJiMWI5YmQ2YzNjNGEwZWI5NzFhYWQ4Y2I3NzUyMDEvdGFibGVyYW5nZTowYmIxYjliZDZjM2M0YTBlYjk3MWFhZDhjYjc3NTIwMV8wLTAtMS0xLTk4Njk0_1a1591f9-78ce-428e-b019-5c73242b3ef9">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGFibGU6MGJiMWI5YmQ2YzNjNGEwZWI5NzFhYWQ4Y2I3NzUyMDEvdGFibGVyYW5nZTowYmIxYjliZDZjM2M0YTBlYjk3MWFhZDhjYjc3NTIwMV8xLTQtMS0xLTk4Njk0_4dffbdda-f4bc-4ad8-80e5-840d2d5f4668">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGFibGU6MGJiMWI5YmQ2YzNjNGEwZWI5NzFhYWQ4Y2I3NzUyMDEvdGFibGVyYW5nZTowYmIxYjliZDZjM2M0YTBlYjk3MWFhZDhjYjc3NTIwMV8yLTQtMS0xLTk4Njk0_513e9ded-2549-41fb-acea-5c6ec35f0f35">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGV4dHJlZ2lvbjo2YzU2MDdiYzc2YmI0NjRkOGVjMTVjM2QyNDQyZTQyOV8xNTgy_f924a048-2ba6-4816-adf1-68e62d4be050">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i8a49f4b92dd448488ec3ce2514a9b527_I20220430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xL2ZyYWc6NmM1NjA3YmM3NmJiNDY0ZDhlYzE1YzNkMjQ0MmU0MjkvdGV4dHJlZ2lvbjo2YzU2MDdiYzc2YmI0NjRkOGVjMTVjM2QyNDQyZTQyOV8xNTc2_3eb14a10-7332-45a1-bc47-bfd7a11aa2a1"
      unitRef="shares">272427362</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i79f0c6d48d9042059a71690df0625736_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF81OC9mcmFnOjMxNThiZTMxNGJiMTRjODBiOWViZWNjM2NhYjg2ZDkxL3RleHRyZWdpb246MzE1OGJlMzE0YmIxNGM4MGI5ZWJlY2MzY2FiODZkOTFfODc2_64a9fece-fd6e-420f-91b2-8b4dc583125a"
      unitRef="usd">300000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="id0bcebad12fc4c40a4b459a431f9432e_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF81OC9mcmFnOjMxNThiZTMxNGJiMTRjODBiOWViZWNjM2NhYjg2ZDkxL3RleHRyZWdpb246MzE1OGJlMzE0YmIxNGM4MGI5ZWJlY2MzY2FiODZkOTFfOTE1_b1cf531b-f8bc-4212-ab03-44fa4f994195"
      unitRef="shares">4800000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="id0bcebad12fc4c40a4b459a431f9432e_D20211001-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF81OC9mcmFnOjMxNThiZTMxNGJiMTRjODBiOWViZWNjM2NhYjg2ZDkxL3RleHRyZWdpb246MzE1OGJlMzE0YmIxNGM4MGI5ZWJlY2MzY2FiODZkOTFfOTU5_a7d816fb-c1e0-4e73-a781-d7c74b11c87d"
      unitRef="usdPerShare">50.30</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="idb40345a5fe44f68828da6e24128f448_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF81OC9mcmFnOjMxNThiZTMxNGJiMTRjODBiOWViZWNjM2NhYjg2ZDkxL3RleHRyZWdpb246MzE1OGJlMzE0YmIxNGM4MGI5ZWJlY2MzY2FiODZkOTFfMTA0Ng_d303f17c-6e71-4a62-9522-cf6d9d5308f9"
      unitRef="usdPerShare">49.39</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="idb40345a5fe44f68828da6e24128f448_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF81OC9mcmFnOjMxNThiZTMxNGJiMTRjODBiOWViZWNjM2NhYjg2ZDkxL3RleHRyZWdpb246MzE1OGJlMzE0YmIxNGM4MGI5ZWJlY2MzY2FiODZkOTFfMTA4Mg_19162380-0d76-414b-b32b-1d9379a729d0"
      unitRef="shares">1300000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i4a80329f29594c698d9ee74e1eaacbbe_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF81OC9mcmFnOjMxNThiZTMxNGJiMTRjODBiOWViZWNjM2NhYjg2ZDkxL3RleHRyZWdpb246MzE1OGJlMzE0YmIxNGM4MGI5ZWJlY2MzY2FiODZkOTFfNzE0NjgyNTU4MjY0Mw_491620b1-1c8a-4cd6-bca1-8635a37d6660"
      unitRef="usd">200000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i3bd39d7063da4c278767bc202d3ccfc3_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF81OC9mcmFnOjMxNThiZTMxNGJiMTRjODBiOWViZWNjM2NhYjg2ZDkxL3RleHRyZWdpb246MzE1OGJlMzE0YmIxNGM4MGI5ZWJlY2MzY2FiODZkOTFfNzE0NjgyNTU4MjY1NA_b60ce76f-c995-46ab-8e84-c2532dc8056b"
      unitRef="shares">3000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i3bd39d7063da4c278767bc202d3ccfc3_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF81OC9mcmFnOjMxNThiZTMxNGJiMTRjODBiOWViZWNjM2NhYjg2ZDkxL3RleHRyZWdpb246MzE1OGJlMzE0YmIxNGM4MGI5ZWJlY2MzY2FiODZkOTFfNzE0NjgyNTU4MjY1OQ_ffa1ff47-afaa-4f28-b5a0-97e6926b03fa"
      unitRef="usdPerShare">54.01</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i88bcf45d478a46e4b22b402f4b7f54c3_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF81OC9mcmFnOjMxNThiZTMxNGJiMTRjODBiOWViZWNjM2NhYjg2ZDkxL3RleHRyZWdpb246MzE1OGJlMzE0YmIxNGM4MGI5ZWJlY2MzY2FiODZkOTFfNzE0NjgyNTU4MjcxMw_05ee8c00-a37f-44f1-b1cd-d2b715cb8a1c"
      unitRef="usdPerShare">56.02</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i88bcf45d478a46e4b22b402f4b7f54c3_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF81OC9mcmFnOjMxNThiZTMxNGJiMTRjODBiOWViZWNjM2NhYjg2ZDkxL3RleHRyZWdpb246MzE1OGJlMzE0YmIxNGM4MGI5ZWJlY2MzY2FiODZkOTFfNzE0NjgyNTU4MjY4Nw_e7f5a586-e334-4067-a9aa-34ade3f5ad82"
      unitRef="shares">600000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i4a80329f29594c698d9ee74e1eaacbbe_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF81OC9mcmFnOjMxNThiZTMxNGJiMTRjODBiOWViZWNjM2NhYjg2ZDkxL3RleHRyZWdpb246MzE1OGJlMzE0YmIxNGM4MGI5ZWJlY2MzY2FiODZkOTFfMzI5ODUzNDg4NjQwMw_491620b1-1c8a-4cd6-bca1-8635a37d6660"
      unitRef="usd">200000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:Revenues
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMi0xLTEtMS05ODY5NA_e2b16488-d85c-48b6-a187-17bcff475651"
      unitRef="usd">44836000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMi0zLTEtMS05ODY5NA_e055d9ca-61e9-48e6-a640-fd6c6d9e84ac"
      unitRef="usd">39275000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMi01LTEtMS05ODY5NA_a62a8b08-a175-4441-80c1-dff36364843b"
      unitRef="usd">134261000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMi03LTEtMS05ODY5NA_16796090-e505-4e42-b4a9-5b1d538f520b"
      unitRef="usd">119881000000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMy0xLTEtMS05ODY5NA_4fce27fa-66d0-4a92-a6a9-4b01003cfc6f"
      unitRef="usd">43154000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMy0zLTEtMS05ODY5NA_4f86cc2b-f8fb-4e5f-b5ad-a765a839ccaa"
      unitRef="usd">37463000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMy01LTEtMS05ODY5NA_49d0050a-fab8-4769-a49e-992a4cedf2f0"
      unitRef="usd">129321000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMy03LTEtMS05ODY5NA_ba84819b-a30c-48be-9ca8-d4c683478185"
      unitRef="usd">114578000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfNC0xLTEtMS05ODY5NA_2c672e37-0063-4cb4-89ec-ca4d9a295983"
      unitRef="usd">1682000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfNC0zLTEtMS05ODY5NA_24eb8305-21b2-428b-81ed-4f9822bccf79"
      unitRef="usd">1812000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfNC01LTEtMS05ODY5NA_74aa8e0d-26e0-4a58-9f8b-14cff8793914"
      unitRef="usd">4940000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfNC03LTEtMS05ODY5NA_36e1254b-a9d4-4dfd-acfc-02d00b7ee417"
      unitRef="usd">5303000000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfNy0xLTEtMS05ODY5NA_a4e631df-64c5-497b-965f-239f7922cc91"
      unitRef="usd">1137000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfNy0zLTEtMS05ODY5NA_62c920bb-2fe4-4eb0-8247-302245d244b0"
      unitRef="usd">1120000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfNy01LTEtMS05ODY5NA_2498b4f5-c8ad-468a-9c41-b350f37ed9cf"
      unitRef="usd">3402000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfNy03LTEtMS05ODY5NA_aa539fa4-2244-4d6f-9d04-4817cde462cb"
      unitRef="usd">3404000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:RestructuringCharges
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfOC0xLTEtMS05ODY5NA_25a5286a-61cb-412f-a85a-9f27faf257e4"
      unitRef="usd">31000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfOC0zLTEtMS05ODY5NA_2bade189-99ff-407f-bc36-18fbafb6b806"
      unitRef="usd">24000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfOC01LTEtMS05ODY5NA_c8875dc2-a69b-4277-9269-4fbd073200f1"
      unitRef="usd">56000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfOC03LTEtMS05ODY5NA_4c14253c-bc25-41ba-a964-1ff5e9a02a1c"
      unitRef="usd">81000000</us-gaap:RestructuringCharges>
    <cah:Amortizationandotheracquisitionrelatedcosts
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfOS0xLTEtMS05ODY5NA_d719c4f7-0257-4204-bde2-97f83877bfe7"
      unitRef="usd">79000000</cah:Amortizationandotheracquisitionrelatedcosts>
    <cah:Amortizationandotheracquisitionrelatedcosts
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfOS0zLTEtMS05ODY5NA_172dbb98-c675-433e-b62b-d18dceab734a"
      unitRef="usd">111000000</cah:Amortizationandotheracquisitionrelatedcosts>
    <cah:Amortizationandotheracquisitionrelatedcosts
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfOS01LTEtMS05ODY5NA_7c6e4a84-cfd2-46a9-87cd-b01b5423402c"
      unitRef="usd">237000000</cah:Amortizationandotheracquisitionrelatedcosts>
    <cah:Amortizationandotheracquisitionrelatedcosts
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfOS03LTEtMS05ODY5NA_e2b585ef-8e06-4fd2-9024-c5b9aee2034d"
      unitRef="usd">345000000</cah:Amortizationandotheracquisitionrelatedcosts>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTAtMS0xLTEtOTg2OTQ_e5385782-163e-4d46-aa92-1be60dde9905"
      unitRef="usd">-471000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTAtMy0xLTEtOTg2OTQ_28d60dc6-edc6-48d7-8245-a9b7d2308bca"
      unitRef="usd">-69000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTAtNS0xLTEtOTg2OTQ_b45481df-6def-48da-9ddc-4feb562e4200"
      unitRef="usd">-1764000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTAtNy0xLTEtOTg2OTQ_d6d7a77a-b911-4645-b354-e66b2031fdc5"
      unitRef="usd">-78000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTEtMS0xLTEtOTg2OTQ_7a1b7567-824e-4817-b100-1d93da2205d4"
      unitRef="usd">-61000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTEtMy0xLTEtOTg2OTQ_b4ca148c-8924-4846-a83b-7eb030edeff4"
      unitRef="usd">-15000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTEtNS0xLTEtOTg2OTQ_f43644b1-d95b-43a2-bce1-4a6b662c2a95"
      unitRef="usd">-113000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTEtNy0xLTEtOTg2OTQ_2ca814bd-8989-4d9c-b68e-770b5e01e964"
      unitRef="usd">-1085000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTItMS0xLTEtOTg2OTQ_63b9a3a5-21d1-4bf1-89ce-1fc2c1709ec2"
      unitRef="usd">-97000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTItMy0xLTEtOTg2OTQ_c0f01cb6-f1d1-4dae-a71f-2dea53357ab9"
      unitRef="usd">473000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTItNS0xLTEtOTg2OTQ_37c77578-dfc6-41c2-856a-8bddfeda9b4b"
      unitRef="usd">-632000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTItNy0xLTEtOTg2OTQ_c6372f64-8e29-414c-acb4-be97380386b7"
      unitRef="usd">310000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTQtMS0xLTEtOTg2OTQ_87591de2-f6e9-4c5a-8dea-d2be2ffc4b5b"
      unitRef="usd">-3000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTQtMy0xLTEtOTg2OTQ_bb4cde22-6bf2-4eb6-bf3d-516545224a38"
      unitRef="usd">12000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTQtNS0xLTEtOTg2OTQ_f1a30c38-e1c2-4b5d-94e0-2b1e21808bb3"
      unitRef="usd">14000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTQtNy0xLTEtOTg2OTQ_655e890f-9b47-43f3-87df-edd2531a798c"
      unitRef="usd">31000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestExpense
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTUtMS0xLTEtOTg2OTQ_ff76ebbe-0cd3-4280-9a76-a59bd971900b"
      unitRef="usd">38000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTUtMy0xLTEtOTg2OTQ_7ad9ccda-346b-4f94-bbe1-917157d39dfb"
      unitRef="usd">45000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTUtNS0xLTEtOTg2OTQ_dfb16510-fb43-4619-872d-3c2528fd949f"
      unitRef="usd">115000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTUtNy0xLTEtOTg2OTQ_ec378f60-771f-4c9f-9c1d-0c46ffa1fe09"
      unitRef="usd">136000000</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTYtMS0xLTEtOTg2OTQ_55e45728-22d3-4627-8501-3a187bc1932b"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTYtMy0xLTEtOTg2OTQ_605cb7e8-6bb2-4449-8658-c932114670f0"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTYtMy0xLTEtOTg2OTQ_cde64219-3c78-4ee5-b3bf-7ff3809a309c"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTYtNS0xLTEtOTg2OTQ_1666657b-8fea-480e-8819-db4b3bb7b043"
      unitRef="usd">-10000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTYtNy0xLTEtOTg2OTQ_7959ed66-aca2-47f1-9b29-071ae7996abd"
      unitRef="usd">-1000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTctMS0xLTEtOTg2OTQ_a15cb902-e258-4de4-a3a5-2607ff699eac"
      unitRef="usd">1000000</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTctMy0xLTEtOTg2OTQ_af825b88-a98b-4fc0-adee-35747efb7236"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTctNS0xLTEtOTg2OTQ_ffeda087-8804-49cc-99d1-dad1365d02c6"
      unitRef="usd">2000000</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTctNy0xLTEtOTg2OTQ_87db69d9-006b-48d6-8ccc-70d91cc48e49"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTgtMS0xLTEtOTg2OTQ_4f9a96fc-3f45-457f-acf6-dfd92247cc53"
      unitRef="usd">-137000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTgtMy0xLTEtOTg2OTQ_c207d938-7cd3-44d8-9961-5762928709d5"
      unitRef="usd">440000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTgtNS0xLTEtOTg2OTQ_c1541ae7-276a-45b9-8a22-2d5ad4225a79"
      unitRef="usd">-741000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMTgtNy0xLTEtOTg2OTQ_a0fb6641-fab4-461b-8a5e-243128cc3f5c"
      unitRef="usd">204000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMjAtMS0xLTEtOTg2OTQ_44fe0585-91c0-4005-acd0-86e1ef855cdd"
      unitRef="usd">1253000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMjAtMy0xLTEtOTg2OTQ_fdd499b7-f611-4f75-bc86-9d4e6f3886e0"
      unitRef="usd">320000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMjAtNS0xLTEtOTg2OTQ_c9fe8f3e-b91b-4e69-acec-ba76a751c8da"
      unitRef="usd">328000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMjAtNy0xLTEtOTg2OTQ_1d2ab9e2-f124-45fa-bffd-3d9723d04971"
      unitRef="usd">-293000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMjEtMS0xLTEtOTg2OTQ_df6683a1-140c-46e0-b64c-5af884cfaf9b"
      unitRef="usd">-1390000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMjEtMy0xLTEtOTg2OTQ_7b252768-b694-4883-9bad-0d98bc7807e7"
      unitRef="usd">120000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMjEtNS0xLTEtOTg2OTQ_f26bb9a6-6e1f-4232-973d-2f8424033a46"
      unitRef="usd">-1069000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMjEtNy0xLTEtOTg2OTQ_6e8d05c9-f155-4842-a0e4-7f82076b53d3"
      unitRef="usd">497000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMjYtMS0xLTEtOTg2OTQ_23dcc8bb-3ba9-49b6-8688-62731112dbe5"
      unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMjYtMy0xLTEtOTg2OTQ_1de159ce-ab99-4e1a-abca-5be63fe1eaf0"
      unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMjYtNS0xLTEtOTg2OTQ_419d2378-a222-4f10-9d0a-c03e805366eb"
      unitRef="usd">2000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMjYtNy0xLTEtOTg2OTQ_ea8aa778-2b3e-4223-9f1b-3d65b1632125"
      unitRef="usd">2000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMjctMS0xLTEtOTg2OTQ_44f97a0c-f528-4ea4-90dd-7ed82bd91459"
      unitRef="usd">-1391000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMjctMy0xLTEtOTg2OTQ_496e0e89-9521-47c2-b9f7-3ec2203923ab"
      unitRef="usd">119000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMjctNS0xLTEtOTg2OTQ_48717c83-5726-47b1-bf64-f060fbd222f6"
      unitRef="usd">-1071000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMjctNy0xLTEtOTg2OTQ_5e66f6e3-ccb3-4dd9-9ac9-b725e7089a71"
      unitRef="usd">495000000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMzAtMS0xLTEtOTg2OTQ_883a99a1-e952-42e8-8295-7d87eaf44c1e"
      unitRef="usdPerShare">-5.05</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMzAtMy0xLTEtOTg2OTQ_a1cc1388-8759-4050-afea-45841fbd3eb9"
      unitRef="usdPerShare">0.41</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMzAtNS0xLTEtOTg2OTQ_7f348c47-e13a-4629-94b5-dcaf5eb7293f"
      unitRef="usdPerShare">-3.82</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMzAtNy0xLTEtOTg2OTQ_099b9ff6-9e42-46be-a421-93a2859fad8e"
      unitRef="usdPerShare">1.69</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMzEtMS0xLTEtOTg2OTQ_3c7b5805-80ba-4dc8-9981-0f7da3865e8c"
      unitRef="usdPerShare">-5.05</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMzEtMy0xLTEtOTg2OTQ_e6407440-ffc3-4699-9685-e36133cb9ad7"
      unitRef="usdPerShare">0.40</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMzEtNS0xLTEtOTg2OTQ_b7980380-f13c-443d-8c0a-3e554e50a77e"
      unitRef="usdPerShare">-3.82</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMzEtNy0xLTEtOTg2OTQ_e9d07d6c-c23d-4da3-bb25-aae629dbe4dd"
      unitRef="usdPerShare">1.68</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMzQtMS0xLTEtOTg2OTQ_e9e8bf03-cb64-4976-8707-8f6129cd082b"
      unitRef="shares">275000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMzQtMy0xLTEtOTg2OTQ_4f1df5bc-2f09-4190-bd07-5ebef1144e6c"
      unitRef="shares">292000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMzQtNS0xLTEtOTg2OTQ_e063b0d3-d8f4-46cb-b97c-ab9fb46e4e26"
      unitRef="shares">281000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMzQtNy0xLTEtOTg2OTQ_92fd0fbe-05d2-4526-b292-02d4e9d7c7d4"
      unitRef="shares">293000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMzUtMS0xLTEtOTg2OTQ_b1d20440-b5bc-4355-9a6d-ba264d115d97"
      unitRef="shares">275000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMzUtMy0xLTEtOTg2OTQ_a7007c79-fc7f-41ae-912c-bdb92301d7f3"
      unitRef="shares">294000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMzUtNS0xLTEtOTg2OTQ_86cf409c-b548-4310-b3aa-54a4152c8d4e"
      unitRef="shares">281000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMzUtNy0xLTEtOTg2OTQ_bdb19207-be4e-4632-af6f-96b7615d64a3"
      unitRef="shares">294000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMzctMS0xLTEtOTg2OTQ_188d0ac9-3ad5-4c49-95d5-8f73748de47a"
      unitRef="usdPerShare">0.4908</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMzctMy0xLTEtOTg2OTQ_b8e408a1-ec1d-4ad6-9abf-2be981435b08"
      unitRef="usdPerShare">0.4859</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMzctNS0xLTEtOTg2OTQ_22a8ec7f-0e03-4aa6-857f-df94e5a56b10"
      unitRef="usdPerShare">1.4724</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82NC9mcmFnOmZkZTYwNjMxZDM2ZjQ2M2FiN2Y5MzI3ZDk5ZTQ2M2YyL3RhYmxlOmYzMjdmYmVhOGU5YTQyY2RhODUwMWMwOTNiZTYyODI4L3RhYmxlcmFuZ2U6ZjMyN2ZiZWE4ZTlhNDJjZGE4NTAxYzA5M2JlNjI4MjhfMzctNy0xLTEtOTg2OTQ_0b7b0c55-6eca-4d36-b262-7cde6f5e0809"
      unitRef="usdPerShare">1.4577</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:ProfitLoss
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfMi0xLTEtMS05ODY5NA_fadcaf21-d261-4711-975b-184bb4c6ba15"
      unitRef="usd">-1390000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfMi0zLTEtMS05ODY5NA_26362b9c-4913-4190-b385-3026cf4f757c"
      unitRef="usd">120000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfMi01LTEtMS05ODY5NA_2343395a-70b8-453d-8a88-3dc7daaaa40c"
      unitRef="usd">-1069000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfMi03LTEtMS05ODY5NA_c8c48aa8-5d4f-4537-b777-0caf53ea5a97"
      unitRef="usd">497000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfNS0xLTEtMS05ODY5NA_1d22d645-03f5-46af-a5e2-b900d7abfe0f"
      unitRef="usd">-4000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfNS0zLTEtMS05ODY5NA_511a052c-a5c3-439e-9380-5dbbcf2b33ad"
      unitRef="usd">9000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfNS01LTEtMS05ODY5NA_84316675-f8d4-4d6e-84fc-e86dfda58312"
      unitRef="usd">-47000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfNS03LTEtMS05ODY5NA_a0a7e718-d2a3-4bb4-80dd-d166d97040a0"
      unitRef="usd">42000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfNy0xLTEtMS05ODY5NA_bb060f62-cae6-457a-a47c-5e436cad9dd5"
      unitRef="usd">12000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfNy0zLTEtMS05ODY5NA_fe851769-14f9-4ed0-abf9-e0de82a32003"
      unitRef="usd">-4000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfNy01LTEtMS05ODY5NA_7a42bf40-d590-4344-ba82-358c549242a5"
      unitRef="usd">4000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfNy03LTEtMS05ODY5NA_99aa46e6-48b2-447d-b350-c9b6763e0919"
      unitRef="usd">14000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfOC0xLTEtMS05ODY5NA_f6334d1f-2946-4064-a168-c7787ea297d3"
      unitRef="usd">8000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfOC0zLTEtMS05ODY5NA_49aa837a-bd41-4b2b-963f-37330090e67a"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfOC01LTEtMS05ODY5NA_3659b7d2-8ff9-4127-9f7d-2149ff77a07e"
      unitRef="usd">-43000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfOC03LTEtMS05ODY5NA_276e1f7e-c8f0-4ccf-8b6b-b24e6a652cdb"
      unitRef="usd">56000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfMTAtMS0xLTEtOTg2OTQ_c6377cc0-8c61-4fba-b74f-5f8b0e49d875"
      unitRef="usd">-1382000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfMTAtMy0xLTEtOTg2OTQ_7104c298-811e-42a1-a1f8-aee2a0879d1c"
      unitRef="usd">125000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfMTAtNS0xLTEtOTg2OTQ_7ab93797-c983-4bc0-bcee-16738ed695a4"
      unitRef="usd">-1112000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfMTAtNy0xLTEtOTg2OTQ_c236c0ec-c556-4a1c-aef5-70be4ea395ca"
      unitRef="usd">553000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfMTItMS0xLTEtOTg2OTQ_9ca7f7ff-268e-4148-9092-665b9c321bb8"
      unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfMTItMy0xLTEtOTg2OTQ_ec7a8b84-b6d5-463e-8da3-f284eed123b4"
      unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfMTItNS0xLTEtOTg2OTQ_38659b39-a512-436c-a227-92890f224c1a"
      unitRef="usd">2000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfMTItNy0xLTEtOTg2OTQ_a2224f23-9b36-4bb4-91c5-7fbaa1838dad"
      unitRef="usd">2000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfMTQtMS0xLTEtOTg2OTQ_f97b539b-c9ef-431c-bbb2-c7210b1e0001"
      unitRef="usd">-1383000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfMTQtMy0xLTEtOTg2OTQ_a021119f-1e1c-4d8d-94c2-ffc750d457c4"
      unitRef="usd">124000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfMTQtNS0xLTEtOTg2OTQ_ac3d4811-6212-4bcb-8ec8-698b03da950e"
      unitRef="usd">-1114000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF82Ny9mcmFnOmQzMTY4YTEyMmE3ZDRlNDU5MzRkZjZjNDNjMTM5NGRiL3RhYmxlOmFjYzQ0YWQyNDZiNDQzNmM4YzJiMWUzMTgxOThjOGNjL3RhYmxlcmFuZ2U6YWNjNDRhZDI0NmI0NDM2YzhjMmIxZTMxODE5OGM4Y2NfMTQtNy0xLTEtOTg2OTQ_ae4c537f-6350-46ae-b222-048132a660a8"
      unitRef="usd">551000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfNC0xLTEtMS05ODY5NA_aae6b31e-7b4d-4644-949a-32d133d207ca"
      unitRef="usd">2356000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfNC0zLTEtMS05ODY5NA_b7043949-cd9e-4094-99b8-c1e719d042db"
      unitRef="usd">3407000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ReceivablesNetCurrent
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfNS0xLTEtMS05ODY5NA_a70c83a1-1001-4e78-97ab-174718cfd1ff"
      unitRef="usd">10250000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfNS0zLTEtMS05ODY5NA_dd2a97d1-a265-4a93-a642-7e0104d58274"
      unitRef="usd">9103000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfNi0xLTEtMS05ODY5NA_1a4ce09a-d129-4bdb-82da-44bd55863832"
      unitRef="usd">15493000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfNi0zLTEtMS05ODY5NA_4debe60d-0656-4833-bcf7-889d509fa165"
      unitRef="usd">14594000000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfNy0xLTEtMS05ODY5NA_984bce2e-7347-4dba-a1c2-b2af3d5f85e9"
      unitRef="usd">2785000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfNy0zLTEtMS05ODY5NA_52f6023e-b700-485d-bbbc-033e835da3f9"
      unitRef="usd">2843000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfOC0xLTEtMS05ODY5NA_1c43747d-ae59-445f-b03a-f20b9024a719"
      unitRef="usd">0</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfOC0zLTEtMS05ODY5NA_8ffabeb5-d194-4c7e-b3ad-5c5e0bba8e51"
      unitRef="usd">1101000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:AssetsCurrent
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfOS0xLTEtMS05ODY5NA_6c41228b-f23d-4b1b-bd4e-ff35a1c58276"
      unitRef="usd">30884000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfOS0zLTEtMS05ODY5NA_dfc444ea-b377-449d-9c84-d69558fe4a45"
      unitRef="usd">31048000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMTEtMS0xLTEtOTg2OTQ_c82142e1-f9f1-4390-8f6f-a2acba4f4193"
      unitRef="usd">2298000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMTEtMy0xLTEtOTg2OTQ_ae8b95d0-722a-4b81-b992-24de2f5d18de"
      unitRef="usd">2360000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMTItMS0xLTEtOTg2OTQ_c12722b8-b2cd-40cd-9e2e-1820e485b104"
      unitRef="usd">8022000000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMTItMy0xLTEtOTg2OTQ_4664cf13-06d3-4c1a-a01d-f03944a4b140"
      unitRef="usd">10094000000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMTQtMS0xLTEtOTg2OTQ_9247706a-e3cc-4593-8484-5ad1d02b1e32"
      unitRef="usd">907000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMTQtMy0xLTEtOTg2OTQ_a7ba91d0-0cd2-4c48-a7f0-27fa9209cbe8"
      unitRef="usd">951000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMTUtMS0xLTEtOTg2OTQ_0a043dc1-f234-4e75-b6c5-04ab90b84cd9"
      unitRef="usd">42111000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMTUtMy0xLTEtOTg2OTQ_6ed72fbc-c1b1-4154-a969-e42ce86806c0"
      unitRef="usd">44453000000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMTktMS0xLTEtOTg2OTQ_d907a166-ab7c-458f-b5ae-bd5ab1383bc9"
      unitRef="usd">24821000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMTktMy0xLTEtOTg2OTQ_557e3b88-064c-4d4b-bdd2-422d369fa074"
      unitRef="usd">23700000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMjAtMS0xLTEtOTg2OTQ_808f18d0-8dc2-426a-abf7-8602a3ff4a12"
      unitRef="usd">861000000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMjAtMy0xLTEtOTg2OTQ_43881be3-c836-4a70-b4d7-0739a03128e7"
      unitRef="usd">871000000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMjEtMS0xLTEtOTg2OTQ_84d25d06-ef96-4892-93bd-3c89efc4cddd"
      unitRef="usd">3033000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMjEtMy0xLTEtOTg2OTQ_d2bc0ff6-b49f-4ab5-b7c3-88675a103752"
      unitRef="usd">2957000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMjItMS0xLTEtOTg2OTQ_c310b535-50dd-4a3b-ab0e-61021e0de41b"
      unitRef="usd">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMjItMy0xLTEtOTg2OTQ_b6754526-24f9-4fb7-a2f3-fd6554cab19d"
      unitRef="usd">96000000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:LiabilitiesCurrent
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMjMtMS0xLTEtOTg2OTQ_f6d40c49-0ee5-4338-b603-49af9df8b05f"
      unitRef="usd">28715000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMjMtMy0xLTEtOTg2OTQ_cea04f59-f374-4652-b7e0-b953b277c815"
      unitRef="usd">27624000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMjUtMS0xLTEtOTg2OTQ_3ee5e22a-1110-4cf4-a3de-3ba679b2cdd2"
      unitRef="usd">4751000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMjUtMy0xLTEtOTg2OTQ_d46970cf-0839-4d6b-9c60-84ccd7ac4694"
      unitRef="usd">5365000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMjYtMS0xLTEtOTg2OTQ_f1060e6e-a014-4680-b375-ed1b774d7a18"
      unitRef="usd">9338000000</us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent>
    <us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMjYtMy0xLTEtOTg2OTQ_026600e1-20b2-4456-b37f-95264447e359"
      unitRef="usd">9670000000</us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzAtMC0xLTEtOTg2OTQvdGV4dHJlZ2lvbjoxNDFlMmUzZjkzY2Q0OWQxYTMzZDZiZjdkZmFiYTY5Yl8xNQ_b979d46f-d304-4cec-b6fd-e303a59b431e"
      unitRef="shares">500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzAtMC0xLTEtOTg2OTQvdGV4dHJlZ2lvbjoxNDFlMmUzZjkzY2Q0OWQxYTMzZDZiZjdkZmFiYTY5Yl8xNQ_f9edd006-5ac8-4a9e-a718-8026cebe7a72"
      unitRef="shares">500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzAtMC0xLTEtOTg2OTQvdGV4dHJlZ2lvbjoxNDFlMmUzZjkzY2Q0OWQxYTMzZDZiZjdkZmFiYTY5Yl8zMw_b6fe99cc-4c4b-474b-a863-75ac7b5b99a4"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzAtMC0xLTEtOTg2OTQvdGV4dHJlZ2lvbjoxNDFlMmUzZjkzY2Q0OWQxYTMzZDZiZjdkZmFiYTY5Yl8zMw_c890aa9a-0ed7-465f-9621-87454f0ae14c"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzAtMS0xLTEtOTg2OTQ_42060602-7a5c-4a1f-8f51-51bfcb45df13"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzAtMy0xLTEtOTg2OTQ_3f79a0c3-3732-4b09-a73f-1356edbebf19"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzItMC0xLTEtOTg2OTQvdGV4dHJlZ2lvbjo0ZDgxYWFmMGIyYmU0MTUyODA0NmE3MjExY2M1MjQxZV8xNg_6cb60285-2627-4d03-b506-2fd38817c365"
      unitRef="shares">755000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzItMC0xLTEtOTg2OTQvdGV4dHJlZ2lvbjo0ZDgxYWFmMGIyYmU0MTUyODA0NmE3MjExY2M1MjQxZV8xNg_d35572f0-a3e3-4252-b9fa-25f9dfc11792"
      unitRef="shares">755000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzItMC0xLTEtOTg2OTQvdGV4dHJlZ2lvbjo0ZDgxYWFmMGIyYmU0MTUyODA0NmE3MjExY2M1MjQxZV8zNA_56632999-55a3-41e5-b4b2-973f3d444672"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzItMC0xLTEtOTg2OTQvdGV4dHJlZ2lvbjo0ZDgxYWFmMGIyYmU0MTUyODA0NmE3MjExY2M1MjQxZV8zNA_a0af6484-35e6-44bf-bafd-1f17a46d3cc0"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzItMS0xLTEtOTg2OTQ_e04af131-e194-48eb-8e82-cc2aaea75f54"
      unitRef="usd">2761000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzItMy0xLTEtOTg2OTQ_452a67ee-9b8b-4aa8-b208-eb1257aa6aad"
      unitRef="usd">2806000000</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzMtMS0xLTEtOTg2OTQ_dafed80f-6cb8-4c49-bbd9-89f26241853c"
      unitRef="usd">-281000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzMtMy0xLTEtOTg2OTQ_6d204eb5-e973-456c-9f29-e2806d670096"
      unitRef="usd">1205000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockShares
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzQtMC0xLTEtOTg2OTQvdGV4dHJlZ2lvbjoyM2ZjNTFkZjJjODc0MDY0Yjg3OTQ4YmYxYzI0NWExNl80MQ_dc3dcae0-ccf5-447d-93e0-bd8794f2d00f"
      unitRef="shares">54000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzQtMC0xLTEtOTg2OTQvdGV4dHJlZ2lvbjoyM2ZjNTFkZjJjODc0MDY0Yjg3OTQ4YmYxYzI0NWExNl81NQ_e062c988-f34e-44f7-b855-2081c900db92"
      unitRef="shares">36000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzQtMS0xLTEtOTg2OTQ_d388c913-b137-408b-8b29-025736e38046"
      unitRef="usd">3100000000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzQtMy0xLTEtOTg2OTQ_eb0124df-d842-4dbe-8e34-8d37937ae72b"
      unitRef="usd">2186000000</us-gaap:TreasuryStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzUtMS0xLTEtOTg2OTQ_48b37887-302c-4856-9fde-5f476442d961"
      unitRef="usd">-77000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzUtMy0xLTEtOTg2OTQ_cb99d7db-012e-4840-85a4-de12808463bd"
      unitRef="usd">-34000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzYtMS0xLTEtOTg2OTQ_8a8e6893-cdc7-44b7-b58a-91f9ab76beaf"
      unitRef="usd">-697000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzYtMy0xLTEtOTg2OTQ_9e4dea9b-ee01-45e1-9a5b-40dd57701e71"
      unitRef="usd">1791000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzctMS0xLTEtOTg2OTQ_353b3d9e-1ef3-46f6-af04-6ad1eb87bc1a"
      unitRef="usd">4000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzctMy0xLTEtOTg2OTQ_266482e9-5b12-4e44-a32a-8897ac0d21cc"
      unitRef="usd">3000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzgtMS0xLTEtOTg2OTQ_cda16a44-3b84-4cc7-a7ef-14ecf156bb91"
      unitRef="usd">-693000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzgtMy0xLTEtOTg2OTQ_588a557c-2dfb-4b26-962f-c5f7329ba8df"
      unitRef="usd">1794000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzktMS0xLTEtOTg2OTQ_de9c511b-8363-4d40-b89b-29b2f509410f"
      unitRef="usd">42111000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83MC9mcmFnOjBmMDUxOGE3NThjOTQ3NjlhNGZlNDA2NmIwY2U4NzFjL3RhYmxlOjAwMzU3Mjk2YTZjNjRlYmJiYzJjZGMyZTA1MTk5ZGM2L3RhYmxlcmFuZ2U6MDAzNTcyOTZhNmM2NGViYmJjMmNkYzJlMDUxOTlkYzZfMzktMy0xLTEtOTg2OTQ_a6af76fc-551b-4191-b271-50013eac62ac"
      unitRef="usd">44453000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="if22adf094ce443b8a6d548e13f36c294_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfMy0xLTEtMS05ODY5NA_0a9e9a6f-5b0c-4b43-a118-ff051392cd44"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if22adf094ce443b8a6d548e13f36c294_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfMy0zLTEtMS05ODY5NA_76528e3a-d30e-4393-848a-d7fc9ceca49f"
      unitRef="usd">2721000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia92405f06fae4c4cb90f702005b8b2a7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfMy01LTEtMS05ODY5NA_b56855d1-1ae8-41e3-a342-652c5492dab4"
      unitRef="usd">1245000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="i7c93d4e78a8c4d04b6c310720c3be878_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfMy03LTEtMS05ODY5NA_cdd59d00-d7b6-4d15-a7f8-4bc3e5521994"
      unitRef="shares">-50000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i7c93d4e78a8c4d04b6c310720c3be878_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfMy05LTEtMS05ODY5NA_f529854f-461b-479f-bda1-44ddff5cea5d"
      unitRef="usd">-2883000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2a93b5354aeb44f8b3cc0d0d850b2501_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfMy0xMS0xLTEtOTg2OTQ_5e447634-162a-4e26-bfcf-e303a52bb317"
      unitRef="usd">-85000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id1d5a08085294befb4f0b438a66e23de_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfMy0xMy0xLTEtOTg2OTQ_1bf54f9f-df50-4928-b08f-9c7f2378f5b8"
      unitRef="usd">4000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i75e8b16bb97541c8bd805031f5452617_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfMy0xNS0xLTEtOTg2OTQ_ffce4ff3-81cb-4351-b12f-31678e695e41"
      unitRef="usd">1002000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfNC01LTEtMS05ODY5NA_44f97a0c-f528-4ea4-90dd-7ed82bd91459"
      unitRef="usd">-1391000000</us-gaap:NetIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="if883c9a37b644835bbe659371a267a15_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfNC0xMy0xLTEtOTg2OTQ_2268543c-d249-4230-8c25-1219de94f28a"
      unitRef="usd">1000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfNC0xNS0xLTEtOTg2OTQ_03540a09-f903-48ea-8429-f9827eb1d1ee"
      unitRef="usd">-1390000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfNS0xMS0xLTEtOTg2OTQ_f6334d1f-2946-4064-a168-c7787ea297d3"
      unitRef="usd">8000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfNS0xNS0xLTEtOTg2OTQ_4c51f96c-b82a-4a58-9756-6da0cb5b52ba"
      unitRef="usd">8000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ide0abb91cd8d4383a017830f5ef299ff_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfNy0xLTEtMS05ODY5NA_ad037230-e8e4-49a1-ae74-b1d2f85157ba"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ide0abb91cd8d4383a017830f5ef299ff_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfNy0zLTEtMS05ODY5NA_9ad306d3-9650-4ca9-b7fa-e508a5d14006"
      unitRef="usd">20000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i8232a7a263294a17a4f15379d0173ba2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfNy03LTEtMS05ODY5NA_51acd8cc-0f61-4ee9-b784-b9210d5bbed4"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8232a7a263294a17a4f15379d0173ba2_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfNy05LTEtMS05ODY5NA_e0a4caf9-6b25-4cad-acba-1fbc129161b0"
      unitRef="usd">3000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfNy0xNS0xLTEtOTg2OTQ_23067795-3263-4610-af55-25b9d1a8db7b"
      unitRef="usd">23000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ide0abb91cd8d4383a017830f5ef299ff_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfOC0zLTEtMS05ODY5NA_d48772b4-6e65-49d9-bb80-99df9cb5f55d"
      unitRef="usd">20000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i8232a7a263294a17a4f15379d0173ba2_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfOC03LTEtMS05ODY5NA_ef45fff2-45d7-4239-97c2-912c3d2796ce"
      unitRef="shares">4000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i8232a7a263294a17a4f15379d0173ba2_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfOC05LTEtMS05ODY5NA_92a71149-f11d-4b3f-a868-15651a946737"
      unitRef="usd">220000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfOC0xNS0xLTEtOTg2OTQ_ab5ac632-5870-4ac4-9c68-4debc33ac13f"
      unitRef="usd">200000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:Dividends
      contextRef="i5f9edcb7c954465280f497a367eed0d4_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfOS01LTEtMS05ODY5NA_987c2064-d387-4af0-b148-38b9ba9c5df5"
      unitRef="usd">135000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfOS0xNS0xLTEtOTg2OTQ_82a8cf2b-7961-4fe2-9757-bfc02ccaaa37"
      unitRef="usd">135000000</us-gaap:Dividends>
    <us-gaap:StockholdersEquityOther
      contextRef="ide0abb91cd8d4383a017830f5ef299ff_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfMTAtMy0xLTEtOTg2OTQ_e13f1622-f4ae-4cff-9997-01fbfa3bf5c1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityOther
      contextRef="i5f9edcb7c954465280f497a367eed0d4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfMTAtNS0xLTEtOTg2OTQ_e65262f9-7cd7-48d2-9251-87ba4a3e8143"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="i8232a7a263294a17a4f15379d0173ba2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfMTAtNy0xLTEtOTg2OTQ_57ebf3e3-3c74-4d8c-b750-42ef88d35294"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityOther
      contextRef="if883c9a37b644835bbe659371a267a15_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfMTAtMTMtMS0xLTk4Njk0_93a9c9e0-3027-4547-941b-732495010366"
      unitRef="usd">1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfMTAtMTUtMS0xLTk4Njk0_96b27278-8bd2-4fb3-aea6-171c4a4fa9be"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesIssued
      contextRef="i56eb96c92b484bcaa4f9f5c171ad239f_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfMTItMS0xLTEtOTg2OTQ_1301f506-a6b9-4025-8179-46eeea80789a"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i56eb96c92b484bcaa4f9f5c171ad239f_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfMTItMy0xLTEtOTg2OTQ_fc637a8b-2fe2-4cb3-8692-1a67704032f4"
      unitRef="usd">2761000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i52413ad34f00440b833f5b75a8dd4627_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfMTItNS0xLTEtOTg2OTQ_233c2dbc-8f3a-4e98-bd68-b56dc0559706"
      unitRef="usd">-281000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="iaff4ed7f966c47e4962d2bf39a55b561_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfMTItNy0xLTEtOTg2OTQ_54554288-a069-402f-8555-100f193cb180"
      unitRef="shares">54000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="iaff4ed7f966c47e4962d2bf39a55b561_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfMTItOS0xLTEtOTg2OTQ_55a4db5a-c4d2-420f-89ef-5bd505c284f8"
      unitRef="usd">3100000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4a915a1a243e410f9ec96b9ace3e80d6_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfMTItMTEtMS0xLTk4Njk0_82b7560d-ce6b-4b68-9a74-be462dbe0dc5"
      unitRef="usd">-77000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieed2c03cd42a4857909b008f32e31e33_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfMTItMTMtMS0xLTk4Njk0_9623bd78-39ef-4652-b945-af19d76d74ba"
      unitRef="usd">4000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjkyY2FkMmUwNDU2MDRkOWI5NmNjMGJmOTIyNmUwN2UxL3RhYmxlcmFuZ2U6OTJjYWQyZTA0NTYwNGQ5Yjk2Y2MwYmY5MjI2ZTA3ZTFfMTItMTUtMS0xLTk4Njk0_bdc79150-9eed-4c42-a01a-4c91d175afe4"
      unitRef="usd">-693000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="i4ee4d69320c340dcb7f8fca3e33c99e1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfMS0xLTEtMS05ODY5NA_68ed12fb-8c5b-4862-a9ad-18efa9aab5b7"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4ee4d69320c340dcb7f8fca3e33c99e1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfMS0zLTEtMS05ODY5NA_dbf1d512-5883-451a-858b-ebf1341711ba"
      unitRef="usd">2778000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6addc7f27a0049d9963b698b876c52cf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfMS01LTEtMS05ODY5NA_16c8fb81-35d4-4177-91a0-eb25353b6f14"
      unitRef="usd">1255000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="id578e6daf1574d8eb480d856c73bbcda_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfMS03LTEtMS05ODY5NA_4a41763d-0dfb-42af-a293-6bc2c477ed06"
      unitRef="shares">33000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="id578e6daf1574d8eb480d856c73bbcda_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfMS05LTEtMS05ODY5NA_3c7f7ae3-70d1-4457-9efb-e372c432f458"
      unitRef="usd">2009000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i443356fbbe284138a0f49faa34b3208e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfMS0xMS0xLTEtOTg2OTQ_620a585d-adba-4c4a-bf25-d363ae998af8"
      unitRef="usd">-53000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id981bf2219e54d3eb7348670fb74ec8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfMS0xMy0xLTEtOTg2OTQ_12ced7b1-6bcf-4f5c-9927-2f09fe3f8409"
      unitRef="usd">4000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iee675ac2f5dd4bb5a80f01c9e1535b8b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfMS0xNS0xLTEtOTg2OTQ_b2533ddf-99e8-4992-ad48-ef06f92e6b56"
      unitRef="usd">1975000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfMi01LTEtMS05ODY5NA_763bd76d-645c-4a48-86a2-bb1a2f5146a4"
      unitRef="usd">119000000</us-gaap:NetIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="i2703e84aa6d447f29d3aac9d09f5f094_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfMi0xMy0xLTEtOTg2OTQ_4541ba7a-55db-4891-9e3e-1c7e4e271276"
      unitRef="usd">1000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfMi0xNS0xLTEtOTg2OTQ_6a300478-56ac-4c50-8a3b-acb550aab0e9"
      unitRef="usd">120000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i5214de7195b64409b6762f36bf235b55_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfMy0xMS0xLTEtOTg2OTQ_8c55e23c-39a1-406f-a2f7-fbe6a7fed6a0"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfMy0xNS0xLTEtOTg2OTQ_3112e970-9f0a-4e9a-9e32-791c500c4c2b"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i22fec11876c34d5ebd2c18f6a35aa182_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfNS0xLTEtMS05ODY5NA_8252486b-a8d4-4010-91f6-c7a6e4bfa168"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i22fec11876c34d5ebd2c18f6a35aa182_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfNS0zLTEtMS05ODY5NA_40a1ef45-4f8a-49d4-8f3a-c45e9b8d68a5"
      unitRef="usd">29000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i12146da7d33541d09f9ef291e388a502_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfNS03LTEtMS05ODY5NA_5a9bda85-0ba2-412b-960b-c21b53f8385c"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i12146da7d33541d09f9ef291e388a502_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfNS05LTEtMS05ODY5NA_9bd23fcd-cbb7-4b5c-ad34-5cf89b6f4cea"
      unitRef="usd">7000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfNS0xNS0xLTEtOTg2OTQ_9b759009-8b9f-4841-b99e-102a35a62140"
      unitRef="usd">36000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i22fec11876c34d5ebd2c18f6a35aa182_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfNi0zLTEtMS05ODY5NA_158ac71b-92d0-4abf-89fc-7dc5c8923fe1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i12146da7d33541d09f9ef291e388a502_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfNi03LTEtMS05ODY5NA_8623a11d-f4a3-47fb-8f14-2ec11610ec54"
      unitRef="shares">4000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i12146da7d33541d09f9ef291e388a502_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfNi05LTEtMS05ODY5NA_96f55bf8-57cc-4be2-8e4d-e2c6f0c224ec"
      unitRef="usd">200000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfNi0xNS0xLTEtOTg2OTQ_100480bc-b335-4e9e-9245-92437b302693"
      unitRef="usd">200000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:Dividends
      contextRef="i359769217d5441bc9c97571164783ca2_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfNy01LTEtMS05ODY5NA_c82cfd1d-633e-4cb7-9040-d949f628136b"
      unitRef="usd">143000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfNy0xNS0xLTEtOTg2OTQ_b25bcc0a-ece1-44d5-8b40-a00e0d17cb15"
      unitRef="usd">143000000</us-gaap:Dividends>
    <us-gaap:StockholdersEquityOther
      contextRef="i22fec11876c34d5ebd2c18f6a35aa182_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfOC0zLTEtMS05ODY5NA_62057991-5727-4bed-a5c4-a53645e968f4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityOther
      contextRef="i359769217d5441bc9c97571164783ca2_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfOC01LTEtMS05ODY5NA_23c3d0c0-bc54-4d59-bf0a-ba27368bcc70"
      unitRef="usd">-2000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="i12146da7d33541d09f9ef291e388a502_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfOC03LTEtMS0xMzAxNzU_9b154764-4918-46c5-9902-28a839a4cf20"
      unitRef="shares">-1000000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOther
      contextRef="i2703e84aa6d447f29d3aac9d09f5f094_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfOC0xMy0xLTEtOTg2OTQ_1e0f5c76-ce94-46d7-ae1b-c67cb997db40"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfOC0xNS0xLTEtOTg2OTQ_9d85929e-1bdc-4c70-b396-2cba7366afc5"
      unitRef="usd">1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesIssued
      contextRef="i74e91c5fe50846e4abcf66f67c9b72da_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfMTAtMS0xLTEtOTg2OTQ_4dc29e2e-fbaa-4d2e-bc82-063cfce282b9"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i74e91c5fe50846e4abcf66f67c9b72da_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfMTAtMy0xLTEtOTg2OTQ_4ec365a1-dd7e-4863-8584-5e1dade83d1a"
      unitRef="usd">2807000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i89dbe704562b4ba5ac39a63d65dbff5a_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfMTAtNS0xLTEtOTg2OTQ_b2cff4cd-914a-4a83-b25d-e638ef5321c2"
      unitRef="usd">1233000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="ic83e16a32c7b450083b893267a9ccda4_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfMTAtNy0xLTEtOTg2OTQ_07091de0-eadd-47d7-9d37-d2c4d7da6810"
      unitRef="shares">36000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="ic83e16a32c7b450083b893267a9ccda4_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfMTAtOS0xLTEtOTg2OTQ_b7981f5a-a1d1-4ec1-aa1b-50932557ef77"
      unitRef="usd">2202000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib6ce5f003d8e47b7ac0d61aa5df61b12_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfMTAtMTEtMS0xLTk4Njk0_1ceca789-afb0-4cbd-8234-81aa254ffca0"
      unitRef="usd">-48000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i021442adc8e24489b12297c43e3fabda_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfMTAtMTMtMS0xLTk4Njk0_e71ac74a-0560-40f8-a399-4a4900581038"
      unitRef="usd">4000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i43de0647ce12490ab30c52d836774dce_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOmJjNmVlMjkwZDkxNjRjMDNiMmFlOGZiMmZiMmYyMjI1L3RhYmxlcmFuZ2U6YmM2ZWUyOTBkOTE2NGMwM2IyYWU4ZmIyZmIyZjIyMjVfMTAtMTUtMS0xLTk4Njk0_aff886f6-7391-40fa-93fd-6d33a61bb35b"
      unitRef="usd">1794000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="i07511c4beddc431e9241b971549f9ad5_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfMy0xLTEtMS05ODY5NA_52b1da83-baae-40b9-8ff0-f4a51af13897"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i07511c4beddc431e9241b971549f9ad5_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfMy0zLTEtMS05ODY5NA_53f3865d-54ad-4da6-bd25-0eb1b67bb0a9"
      unitRef="usd">2806000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3ec660a67cd04983b32b8b4fe7d9870a_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfMy01LTEtMS05ODY5NA_930a121b-b3fb-433e-a16c-6c09b8b3e730"
      unitRef="usd">1205000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="i644e369be5f6420aa49654a4323fa93d_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfMy03LTEtMS05ODY5NA_c16a8851-47b5-457f-907e-e53b4c15ff53"
      unitRef="shares">-36000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i644e369be5f6420aa49654a4323fa93d_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfMy05LTEtMS05ODY5NA_e5e38451-98e3-4799-8952-3906e501ee81"
      unitRef="usd">-2186000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6a430c2a1ae64753ae7b549dfc1f69c7_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfMy0xMS0xLTEtOTg2OTQ_cf5eac75-7053-40e5-b867-6562a4aa1dc1"
      unitRef="usd">-34000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic3c75fe6e5544a349f30d33c4e68a2ac_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfMy0xMy0xLTEtOTg2OTQ_f3cbccbf-e474-451b-be5b-128260b14515"
      unitRef="usd">3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfMy0xNS0xLTEtOTg2OTQ_d04898d1-cfb4-4814-bd08-5f643ad05a6e"
      unitRef="usd">1794000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfNC01LTEtMS05ODY5NA_3ff0a8f8-b2df-46e3-a519-cb5e81cb793d"
      unitRef="usd">-1071000000</us-gaap:NetIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="ie8151fa2583d44a688b40d92d9d83b78_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfNC0xMy0xLTEtOTg2OTQ_8667d47e-bc0d-4dae-bfd4-f7fc4c964c20"
      unitRef="usd">2000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfNC0xNS0xLTEtOTg2OTQ_6deb16a9-ae08-4702-9455-ea699ef3b16b"
      unitRef="usd">-1069000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i77aa86d8f8f8485ab211b681b5f58fb3_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfNS0xMS0xLTEtOTg2OTQ_06992a6d-0540-4505-bf96-265ea7971691"
      unitRef="usd">-43000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfNS0xNS0xLTEtOTg2OTQ_d3fed633-eec6-460f-bfca-d8dc88c12456"
      unitRef="usd">-43000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i2ed02a1c09cd4d529605f81979cbf648_D20210701-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfNy0xLTEtMS05ODY5NA_aa4ce2a1-5d1d-47cd-9004-f500dc3745c7"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i2ed02a1c09cd4d529605f81979cbf648_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfNy0zLTEtMS05ODY5NA_1c15d0e7-f825-49ac-bb2a-47a07d231a55"
      unitRef="usd">-5000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfNy03LTEtMS05ODY5NA_61a17171-f9aa-4aa3-a444-90b7d9b49dac"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iaeff0c865a8a4369ab8c5fdca6cee729_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfNy05LTEtMS05ODY5NA_2219c901-852a-4b40-b810-25a19e4e435e"
      unitRef="usd">46000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfNy0xNS0xLTEtOTg2OTQ_a6e0db59-509c-41a4-a616-b52c5337d52b"
      unitRef="usd">41000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i2ed02a1c09cd4d529605f81979cbf648_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfOC0zLTEtMS05ODY5NA_c411dae0-74c8-4e77-98ed-d628f29016bd"
      unitRef="usd">-40000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="iaeff0c865a8a4369ab8c5fdca6cee729_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfOC03LTEtMS05ODY5NA_cc87aa3d-c58c-456e-bcda-a7867d713fce"
      unitRef="shares">19000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="iaeff0c865a8a4369ab8c5fdca6cee729_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfOC05LTEtMS05ODY5NA_8f80a017-489c-403a-a551-c4522fa40020"
      unitRef="usd">960000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfOC0xNS0xLTEtOTg2OTQ_f2f00b7d-1096-453b-9caa-26e4c4f012cf"
      unitRef="usd">1000000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:Dividends
      contextRef="idb593644726c4c428ed6ceb42a31ff8f_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfOS01LTEtMS05ODY5NA_58f2aa70-8b6c-45ef-acfc-99a40d82a2c4"
      unitRef="usd">415000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfOS0xNS0xLTEtOTg2OTQ_c506ace3-936d-435a-8fe1-46a515d8f4bb"
      unitRef="usd">415000000</us-gaap:Dividends>
    <us-gaap:StockholdersEquityOther
      contextRef="idb593644726c4c428ed6ceb42a31ff8f_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfMTAtNS0xLTEtOTg2OTQ_1c5b69ce-1f31-46b3-8327-d7fc74c0ccdc"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="iaeff0c865a8a4369ab8c5fdca6cee729_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfMTAtNy0xLTEtOTg2OTQ_575bc1be-f3e1-43ec-b438-53dd7a33555d"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityOther
      contextRef="ie8151fa2583d44a688b40d92d9d83b78_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfMTAtMTMtMS0xLTk4Njk0_d890be05-0d9f-4f7c-bf02-4589c6041fe5"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfMTAtMTUtMS0xLTk4Njk0_bde4dce7-5041-45f6-8ea4-6117410a0b56"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesIssued
      contextRef="i56eb96c92b484bcaa4f9f5c171ad239f_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfMTItMS0xLTEtOTg2OTQ_2a5e74ab-c691-4d4c-92d6-91416694843e"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i56eb96c92b484bcaa4f9f5c171ad239f_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfMTItMy0xLTEtOTg2OTQ_4a7362d7-888f-4a26-8e12-fb9e55b131c8"
      unitRef="usd">2761000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i52413ad34f00440b833f5b75a8dd4627_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfMTItNS0xLTEtOTg2OTQ_be9f0c37-310a-4771-86f0-bc9432d1bf7e"
      unitRef="usd">-281000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="iaff4ed7f966c47e4962d2bf39a55b561_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfMTItNy0xLTEtOTg2OTQ_dfd8ea08-f335-4ecb-9e11-ecbe43a9d0cd"
      unitRef="shares">54000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="iaff4ed7f966c47e4962d2bf39a55b561_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfMTItOS0xLTEtOTg2OTQ_68b236eb-3551-481d-bc65-9ae2638ce710"
      unitRef="usd">3100000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4a915a1a243e410f9ec96b9ace3e80d6_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfMTItMTEtMS0xLTk4Njk0_d232bf8c-a427-4270-a4fb-950354e20807"
      unitRef="usd">-77000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieed2c03cd42a4857909b008f32e31e33_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfMTItMTMtMS0xLTk4Njk0_8c0a6b62-15e2-40c4-8b49-527f227b4e1a"
      unitRef="usd">4000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjRkN2M0NWMzZDI4NzQzNTk5NWYxOGQ4MzBiYzY1OWY2L3RhYmxlcmFuZ2U6NGQ3YzQ1YzNkMjg3NDM1OTk1ZjE4ZDgzMGJjNjU5ZjZfMTItMTUtMS0xLTk4Njk0_7a5f2195-33be-48b5-a57f-47911795c909"
      unitRef="usd">-693000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="i090402a139834d23aa8e6c3a5b7f46f8_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfMS0xLTEtMS05ODY5NA_265cf6db-9345-47db-82c8-6aff5890421b"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i090402a139834d23aa8e6c3a5b7f46f8_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfMS0zLTEtMS05ODY5NA_822a6a7b-b5cf-4f76-81d3-20e006d669b8"
      unitRef="usd">2789000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie6dfd6eb1a2c4315afc3207155a386d9_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfMS01LTEtMS05ODY5NA_be009a12-6722-4480-b0b7-f07e68cb2b11"
      unitRef="usd">1170000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="i42e7af7d759c4fa5bfb0b98fa27e974f_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfMS03LTEtMS05ODY5NA_b47cb329-d45d-48e1-bd9c-8c279a12cdcd"
      unitRef="shares">35000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i42e7af7d759c4fa5bfb0b98fa27e974f_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfMS05LTEtMS05ODY5NA_b27da814-5492-497e-808f-c1eb61d6d5b8"
      unitRef="usd">2066000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9744506513214bcc9e61087cf55e047e_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfMS0xMS0xLTEtOTg2OTQ_9f7ea8a6-2362-435b-bef4-e06da66cb6ab"
      unitRef="usd">-104000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i307f69a4e1d24b7f8e2b9180075e87b8_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfMS0xMy0xLTEtOTg2OTQ_a396dbae-307d-49e7-bfa1-eb645b41afef"
      unitRef="usd">3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i69e2c38f6f454bfa9b9fece718b91fbe_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfMS0xNS0xLTEtOTg2OTQ_1f531491-0287-475f-ace9-5215f1a17118"
      unitRef="usd">1792000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfMi01LTEtMS05ODY5NA_844ee0d8-e2b3-4cfc-964e-73323b864f89"
      unitRef="usd">495000000</us-gaap:NetIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="i8e0fd895201d4863a312198f691a8d0b_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfMi0xMy0xLTEtOTg2OTQ_11840138-befb-4878-ba36-aac643e7b22b"
      unitRef="usd">2000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfMi0xNS0xLTEtOTg2OTQ_8b9fd812-4522-4b1a-9e4a-c12758e2fc31"
      unitRef="usd">497000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ic358c286737245819556816b3a0a5db5_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfMy0xMS0xLTEtOTg2OTQ_db187cbb-f9cc-4ea9-9b35-16020a06dd74"
      unitRef="usd">56000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfMy0xNS0xLTEtOTg2OTQ_419e0835-5348-44fc-a14a-8edcd1ae7c42"
      unitRef="usd">56000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ia4b35350391644c2a0bdf28917ce2828_D20200701-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfNS0xLTEtMS05ODY5NA_8a691f61-3172-4c59-a437-4387f597cb97"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia4b35350391644c2a0bdf28917ce2828_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfNS0zLTEtMS05ODY5NA_23bbbea3-1b23-4b20-a5b2-682c07ddfcf0"
      unitRef="usd">18000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i7afc2ffa017e47fe877f56fa2b3a45d4_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfNS03LTEtMS05ODY5NA_da814726-12bc-479e-a466-e4115d52271c"
      unitRef="shares">2000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7afc2ffa017e47fe877f56fa2b3a45d4_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfNS05LTEtMS05ODY5NA_f54e33fb-82ff-4e1a-97d9-d94ef32381c1"
      unitRef="usd">64000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfNS0xNS0xLTEtOTg2OTQ_b1820ff1-c72b-4a4d-8bc5-98b6b446e267"
      unitRef="usd">82000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i7afc2ffa017e47fe877f56fa2b3a45d4_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfNi03LTEtMS05ODY5NA_d0e51c66-2bcc-4cc5-b74e-5703dadca69e"
      unitRef="shares">4000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i7afc2ffa017e47fe877f56fa2b3a45d4_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfNi05LTEtMS05ODY5NA_169a4347-ea9a-46f0-8bab-dbd1246a0bcf"
      unitRef="usd">200000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfNi0xNS0xLTEtOTg2OTQ_be134a88-a82d-4ee7-9b4b-00008653da7d"
      unitRef="usd">200000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:Dividends
      contextRef="i6ca3ba0c73594ed7bbc82421ddc8eb83_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfNy01LTEtMS05ODY5NA_ecef678f-2859-487d-a6e0-5a98eea8bae5"
      unitRef="usd">432000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfNy0xNS0xLTEtOTg2OTQ_598df841-cb56-46f4-bbf9-9197153fd5eb"
      unitRef="usd">432000000</us-gaap:Dividends>
    <us-gaap:StockholdersEquityOther
      contextRef="i6ca3ba0c73594ed7bbc82421ddc8eb83_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfOC01LTEtMS05ODY5NA_296a6599-ebe4-467a-a11f-1a441391544b"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="i7afc2ffa017e47fe877f56fa2b3a45d4_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfOC03LTEtMS0xNDQ2ODk_83a7b859-5862-4336-92bb-301fe3cf8118"
      unitRef="shares">-1000000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOther
      contextRef="i8e0fd895201d4863a312198f691a8d0b_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfOC0xMy0xLTEtOTg2OTQ_fe4351f7-a187-42c1-a5cd-ae4e62f687e5"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfOC0xNS0xLTEtOTg2OTQ_424c8d09-ece6-48e3-8e84-12bf21cf926b"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesIssued
      contextRef="i74e91c5fe50846e4abcf66f67c9b72da_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfOS0xLTEtMS05ODY5NA_42a9f217-33f4-49df-abea-d20b09262cad"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i74e91c5fe50846e4abcf66f67c9b72da_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfOS0zLTEtMS05ODY5NA_d0d63631-31f0-4f05-b66e-0b7726390621"
      unitRef="usd">2807000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i89dbe704562b4ba5ac39a63d65dbff5a_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfOS01LTEtMS05ODY5NA_e2f8faf1-38a9-42d1-a5ba-80038d9c45c3"
      unitRef="usd">1233000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="ic83e16a32c7b450083b893267a9ccda4_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfOS03LTEtMS05ODY5NA_c71d63e2-34aa-49ed-bef7-44a458d907c7"
      unitRef="shares">36000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="ic83e16a32c7b450083b893267a9ccda4_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfOS05LTEtMS05ODY5NA_20daeb92-2fc9-4eb1-8855-382094796959"
      unitRef="usd">2202000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib6ce5f003d8e47b7ac0d61aa5df61b12_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfOS0xMS0xLTEtOTg2OTQ_ffc07249-4d7f-4236-8cdb-f3ba32fb95e8"
      unitRef="usd">-48000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i021442adc8e24489b12297c43e3fabda_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfOS0xMy0xLTEtOTg2OTQ_3b5ce89c-c47d-456c-9c71-df0e7183b715"
      unitRef="usd">4000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i43de0647ce12490ab30c52d836774dce_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83My9mcmFnOjIwMDNmOWZhNTcyMDQ4ZThhY2ZmODc0YmRhNmZkMWFjL3RhYmxlOjBlN2Y3ODVmYTEwOTQxM2E5MWE2YTVlMzk4MWNjNjIxL3RhYmxlcmFuZ2U6MGU3Zjc4NWZhMTA5NDEzYTkxYTZhNWUzOTgxY2M2MjFfOS0xNS0xLTEtOTg2OTQ_f2922bc0-bacc-4cfc-bca2-487b17fbb9d4"
      unitRef="usd">1794000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMy0xLTEtMS05ODY5NA_4f3f8626-7418-471d-a2d9-e7a7b91d40c2"
      unitRef="usd">-1069000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMy0zLTEtMS05ODY5NA_21c2cb23-8b4b-4467-82ce-d9277b0fb28b"
      unitRef="usd">497000000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfNi0xLTEtMS05ODY5NA_19fee9cb-1a1b-4c72-9f52-84106502c8e1"
      unitRef="usd">513000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfNi0zLTEtMS05ODY5NA_d01d0e95-6cf6-44ab-a0cf-279b96c888a7"
      unitRef="usd">603000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GainLossOnSaleOfOtherInvestments
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfNy0xLTEtMS05ODY5NA_0d79cb47-4437-4a80-93ff-5c16b712ae32"
      unitRef="usd">-3000000</us-gaap:GainLossOnSaleOfOtherInvestments>
    <us-gaap:GainLossOnSaleOfOtherInvestments
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfNy0zLTEtMS05ODY5NA_210b8585-1669-4992-955d-c2edf79bcd91"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfOtherInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfOC0xLTEtMS05ODY5NA_3b625f38-b0c8-4eba-af16-042660ad637e"
      unitRef="usd">2000000</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfOC0zLTEtMS05ODY5NA_f9419ef3-a032-4631-8ccf-d1f0f914f96d"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfOS0xLTEtMS05ODY5NA_4f7dbd8e-464f-4288-9978-9763e722806a"
      unitRef="usd">-1764000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfOS0zLTEtMS05ODY5NA_2ee224ea-655b-4eaf-828a-09f9e0e613b6"
      unitRef="usd">-78000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMTAtMS0xLTEtOTg2OTQ_633079c5-6e2a-4c72-afa7-eed91e2706a8"
      unitRef="usd">-10000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMTAtMy0xLTEtOTg2OTQ_597d4a88-d811-4dcb-8f9e-42497645dccb"
      unitRef="usd">-1000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ShareBasedCompensation
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMTEtMS0xLTEtOTg2OTQ_e44b7855-1d54-4bc6-880a-e74a6c089d08"
      unitRef="usd">65000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMTEtMy0xLTEtOTg2OTQ_dea43c98-d624-4c2f-a4c1-17f6ced91293"
      unitRef="usd">84000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMTMtMS0xLTEtOTg2OTQ_656c4124-3062-471d-af3a-f91198ddc1e6"
      unitRef="usd">46000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMTMtMy0xLTEtOTg2OTQ_2a71a518-56c4-4d16-bdb0-3df5083f356e"
      unitRef="usd">49000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMTUtMS0xLTEtOTg2OTQ_4e9e680f-ce81-447f-8883-73473766e9d9"
      unitRef="usd">1193000000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMTUtMy0xLTEtOTg2OTQ_e856c73d-5c4b-4093-a6ae-f3e948a4dfa8"
      unitRef="usd">511000000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMTYtMS0xLTEtOTg2OTQ_6e91829e-cdf6-48f9-8237-e4f77416fa8a"
      unitRef="usd">922000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMTYtMy0xLTEtOTg2OTQ_db9dd9cd-fa8f-49d1-94bd-c5e01cfb5083"
      unitRef="usd">1323000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMTctMS0xLTEtOTg2OTQ_bf6f029f-3016-40b6-ab57-a2701bb07ff7"
      unitRef="usd">1121000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMTctMy0xLTEtOTg2OTQ_f418bce3-9652-4c29-b163-5c099f9301e7"
      unitRef="usd">1267000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMTgtMS0xLTEtOTg2OTQ_3e4f1bbd-3468-4a21-9843-0345597b2f70"
      unitRef="usd">206000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMTgtMy0xLTEtOTg2OTQ_b9cb5e92-987b-462c-99fd-e0b4e8010644"
      unitRef="usd">-1019000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMTktMS0xLTEtOTg2OTQ_805976db-1a46-45be-a226-086e73cf730a"
      unitRef="usd">130000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMTktMy0xLTEtOTg2OTQ_5e57c01a-abfb-41fa-a122-dfbd714d232b"
      unitRef="usd">1764000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <cah:Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMjItMS0xLTEtOTg2OTQ_0a9746a4-28f0-4b97-80ba-324b7a5b81cc"
      unitRef="usd">934000000</cah:Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets>
    <cah:Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMjItMy0xLTEtOTg2OTQ_adac57dd-8c6a-406e-b8f1-51d6428967ec"
      unitRef="usd">0</cah:Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMjMtMS0xLTEtOTg2OTQ_245bfac0-ba90-4f69-a2c4-8f4cfa233f25"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMjMtMy0xLTEtOTg2OTQ_58de76bb-7475-4224-a8db-bf7e35e6f53b"
      unitRef="usd">3000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMjQtMS0xLTEtOTg2OTQ_06ec19f0-2741-4eb7-8ef3-3691a47ee46f"
      unitRef="usd">223000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMjQtMy0xLTEtOTg2OTQ_f6448451-3ec2-49dc-b8c4-f70e48647c5b"
      unitRef="usd">274000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <cah:Purchaseofavailableforsalesecuritiesandotherinvestments
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMjUtMS0xLTEtOTg2OTQ_367f2a5b-3a33-4643-ab57-ba45552aed7d"
      unitRef="usd">38000000</cah:Purchaseofavailableforsalesecuritiesandotherinvestments>
    <cah:Purchaseofavailableforsalesecuritiesandotherinvestments
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMjUtMy0xLTEtOTg2OTQ_4108271a-07fb-43e3-9dbe-175fc0fca88e"
      unitRef="usd">18000000</cah:Purchaseofavailableforsalesecuritiesandotherinvestments>
    <cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMjYtMS0xLTEtOTg2OTQ_19b97990-a120-43af-b71f-d8994ea12914"
      unitRef="usd">27000000</cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments>
    <cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMjYtMy0xLTEtOTg2OTQ_d24a41b5-77c1-4851-91b8-99b5a80f2028"
      unitRef="usd">5000000</cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments>
    <us-gaap:ProceedsFromHedgeInvestingActivities
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMjctMS0xLTEtOTg2OTQ_b6e607d6-ec65-4a70-b66d-80e96e2e90ba"
      unitRef="usd">71000000</us-gaap:ProceedsFromHedgeInvestingActivities>
    <us-gaap:ProceedsFromHedgeInvestingActivities
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMjctMy0xLTEtOTg2OTQ_f1ff3fff-af39-4790-bb9e-014e993450ff"
      unitRef="usd">0</us-gaap:ProceedsFromHedgeInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMjgtMS0xLTEtOTg2OTQ_98bc3bb0-32da-4873-ac13-6a27c13ff9c7"
      unitRef="usd">771000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMjgtMy0xLTEtOTg2OTQ_d973c37b-eb26-47c8-8c8b-66febee0a128"
      unitRef="usd">-290000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsForProceedsFromHedgeFinancingActivities
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMzItMS0xLTEtOTg2OTQ_fcf04c07-1333-417e-be0a-5efe6b08c859"
      unitRef="usd">0</us-gaap:PaymentsForProceedsFromHedgeFinancingActivities>
    <us-gaap:PaymentsForProceedsFromHedgeFinancingActivities
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMzItMy0xLTEtOTg2OTQ_8d0d466b-3b73-4f60-acec-3b3dbaf619ea"
      unitRef="usd">-18000000</us-gaap:PaymentsForProceedsFromHedgeFinancingActivities>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMzMtMS0xLTEtOTg2OTQ_b026b888-9c1b-46de-a7f6-688a6bdb4cd1"
      unitRef="usd">597000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMzMtMy0xLTEtOTg2OTQ_d349954e-f495-4d90-9be7-71c32b07b702"
      unitRef="usd">53000000</us-gaap:RepaymentsOfLongTermDebt>
    <cah:Netproceedstaxwithholdingsfromsharebasedcompensation
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMzQtMS0xLTEtOTg2OTQ_d5df1f44-3cee-4e36-864b-5df1edf3b533"
      unitRef="usd">-26000000</cah:Netproceedstaxwithholdingsfromsharebasedcompensation>
    <cah:Netproceedstaxwithholdingsfromsharebasedcompensation
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMzQtMy0xLTEtOTg2OTQ_392a2986-c32c-4f58-87a5-5378a6f52f1e"
      unitRef="usd">-1000000</cah:Netproceedstaxwithholdingsfromsharebasedcompensation>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMzYtMS0xLTEtOTg2OTQ_bd354a72-eacd-4e1c-a142-7d0c6a471710"
      unitRef="usd">425000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMzYtMy0xLTEtOTg2OTQ_3e0073dd-a8b9-469f-9f0f-32a25eef10ea"
      unitRef="usd">432000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMzctMS0xLTEtOTg2OTQ_aea7c5f2-b0db-4b3c-9184-24f5dc037b38"
      unitRef="usd">1000000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMzctMy0xLTEtOTg2OTQ_928b5cd3-8a2e-4f50-a084-db32633ba6fd"
      unitRef="usd">200000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMzgtMS0xLTEtOTg2OTQ_68d646e9-52e0-4527-adb8-9a3fd69bd2dc"
      unitRef="usd">-2048000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfMzgtMy0xLTEtOTg2OTQ_f8c34efa-ac79-4a16-bd28-cdd536110d31"
      unitRef="usd">-668000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfNDAtMS0xLTEtOTg2OTQ_06693036-ba23-4984-b605-3c01fd3ddef3"
      unitRef="usd">-13000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfNDAtMy0xLTEtOTg2OTQ_f7c93750-c630-460a-9369-a1591c9be4dc"
      unitRef="usd">8000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <cah:CashReclassifiedToAssetHeldForSale
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfNDEtMS0xLTEtOTg2OTQ_8ae6891f-f3be-4a38-b629-828eb050ec30"
      unitRef="usd">109000000</cah:CashReclassifiedToAssetHeldForSale>
    <cah:CashReclassifiedToAssetHeldForSale
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfNDEtMy0xLTEtOTg2OTQ_531e378d-5079-48e0-a6c1-bed10c4c92a4"
      unitRef="usd">-86000000</cah:CashReclassifiedToAssetHeldForSale>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfNDMtMS0xLTEtOTg2OTQ_5705c031-db9d-4b90-987b-d4b4a84ba31e"
      unitRef="usd">-1051000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfNDMtMy0xLTEtOTg2OTQ_06ea5326-f498-4086-809c-905491c2ec7c"
      unitRef="usd">728000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfNDQtMS0xLTEtOTg2OTQ_825eb851-f3ed-436f-8c39-5e5f7c12f341"
      unitRef="usd">3407000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i69e2c38f6f454bfa9b9fece718b91fbe_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfNDQtMy0xLTEtOTg2OTQ_95a7dedf-b9bc-4114-a799-e124160259c1"
      unitRef="usd">2771000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfNDUtMS0xLTEtOTg2OTQ_897bc6c1-22db-4232-a1f2-13e294bdf53e"
      unitRef="usd">2356000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i43de0647ce12490ab30c52d836774dce_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF83Ni9mcmFnOjllOWNkNzkwZGEwMDRmNzNhNjEyMjAyOWMyY2Y1YjY1L3RhYmxlOjVhNWM3NjAzOWJkZTQ0ODI5MWUxNjgxZThiYmZkMzI4L3RhYmxlcmFuZ2U6NWE1Yzc2MDM5YmRlNDQ4MjkxZTE2ODFlOGJiZmQzMjhfNDUtMy0xLTEtOTg2OTQ_ea4ce765-b36d-4a41-bb85-7074bdf86877"
      unitRef="usd">3499000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84Mi9mcmFnOjI5ZDUxNGQwOGU4MDQ2YWI5YzhlMTI5Yzg4MDgwODkxL3RleHRyZWdpb246MjlkNTE0ZDA4ZTgwNDZhYjljOGUxMjljODgwODA4OTFfMzEwNQ_174069d5-adaa-4d5c-92d8-da97db342566">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;1. Basis of Presentation and Summary of Significant Accounting Policies &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2022 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our fiscal year ends on June 30. References to fiscal 2022 and  2021 in these condensed consolidated financial statements are to the fiscal years ending or ended June&#160;30, 2022 and June&#160;30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The COVID-19 pandemic ("COVID-19") continues to affect the U.S. and global economies, and as previously disclosed, the pandemic began to materially affect our businesses during the third quarter of fiscal 2020. The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2022 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2022. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2021 (the "2021 Form 10-K").&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Recently Issued Financial Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2021 Form 10-K. There were no accounting standards issued in fiscal 2022 that will have a material impact on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Recently Adopted Financial Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new material accounting standards adopted in the nine months ended March 31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84Mi9mcmFnOjI5ZDUxNGQwOGU4MDQ2YWI5YzhlMTI5Yzg4MDgwODkxL3RleHRyZWdpb246MjlkNTE0ZDA4ZTgwNDZhYjljOGUxMjljODgwODA4OTFfMzExMA_423c995f-d075-45ef-93f6-674c1cb7e811">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2022 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our fiscal year ends on June 30. References to fiscal 2022 and  2021 in these condensed consolidated financial statements are to the fiscal years ending or ended June&#160;30, 2022 and June&#160;30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The COVID-19 pandemic ("COVID-19") continues to affect the U.S. and global economies, and as previously disclosed, the pandemic began to materially affect our businesses during the third quarter of fiscal 2020. The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2022 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2022. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2021 (the "2021 Form 10-K").&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Recently Issued Financial Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2021 Form 10-K. There were no accounting standards issued in fiscal 2022 that will have a material impact on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Recently Adopted Financial Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new material accounting standards adopted in the nine months ended March 31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84Mi9mcmFnOjI5ZDUxNGQwOGU4MDQ2YWI5YzhlMTI5Yzg4MDgwODkxL3RleHRyZWdpb246MjlkNTE0ZDA4ZTgwNDZhYjljOGUxMjljODgwODA4OTFfMzExMg_ad24c5a1-0348-4a67-8fe1-71c47ca4448b">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Recently Issued Financial Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2021 Form 10-K. There were no accounting standards issued in fiscal 2022 that will have a material impact on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Recently Adopted Financial Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new material accounting standards adopted in the nine months ended March 31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84NS9mcmFnOjdiODg5MGQ4MGM5ZDRmYjQ4MTQ5NDMwYTgyOTI2NjlhL3RleHRyZWdpb246N2I4ODkwZDgwYzlkNGZiNDgxNDk0MzBhODI5MjY2OWFfNTc3_5a18986b-7691-42fa-9812-eb55ccc76dcd">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;2. Divestitures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, we sold the Cordis business to Hellman &amp;amp; Friedman for proceeds of $923 million, net of cash transferred, and we retained certain working capital accounts and certain liabilities. The purchase price is subject to adjustments based on working capital requirements as set forth in the agreement. Cardinal Health will retain product liability associated with lawsuits and claims related to inferior vena cava ("IVC") filters in the U.S. and Canada, as well as authority for these matters discussed in &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#iaf3733bf892b435689161c61a06da348_103" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 6&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Cordis business operated within our Medical segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i32f5ee07df944be68a4ca171d08f3c89_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84NS9mcmFnOjdiODg5MGQ4MGM5ZDRmYjQ4MTQ5NDMwYTgyOTI2NjlhL3RleHRyZWdpb246N2I4ODkwZDgwYzlkNGZiNDgxNDk0MzBhODI5MjY2OWFfOTA_b3d3abb5-600e-416f-b14f-98498fbcb11a"
      unitRef="usd">923000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RleHRyZWdpb246MDQ5MzM5OGZjMjc3NGY4NWIyZGRkODVmYTM2ODQyOWJfMTAwMg_c6407174-893e-4ca2-942c-6cbd4bd5232e">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;3. Restructuring and Employee Severance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes restructuring and employee severance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-related&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility exit and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total restructuring and employee severance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-related&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;22&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility exit and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;34&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total restructuring and employee severance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;56&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of accelerated depreciation, lease costs associated with vacant facilities, professional, project management and other service fees to support divestitures, vendor transition fees, project consulting fees, and certain other divestiture-related costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restructuring costs during both the three and nine months ended March&#160;31, 2022 and 2021 were primarily related to the implementation of certain enterprise-wide cost-savings measures, which includes facility exit costs related to decreasing our overall office space, and the divestiture of the Cordis business. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes activity related to liabilities associated with restructuring and employee severance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.237%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.237%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.241%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-&lt;br/&gt;Related Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility Exit&lt;br/&gt;and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;79&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;35&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;49&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;66&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RleHRyZWdpb246MDQ5MzM5OGZjMjc3NGY4NWIyZGRkODVmYTM2ODQyOWJfOTgz_f2c6ef5d-aa44-4d73-bc79-3ed517dbda76">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes restructuring and employee severance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-related&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility exit and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total restructuring and employee severance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-related&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;22&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility exit and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;34&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total restructuring and employee severance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;56&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:SeveranceCosts1
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOjk3OGZlZjEwZDlkZDQwMzk4YWM4MzM0MWEyMDc2ODAzL3RhYmxlcmFuZ2U6OTc4ZmVmMTBkOWRkNDAzOThhYzgzMzQxYTIwNzY4MDNfMi0xLTEtMS05ODY5NA_bd7cf314-6765-4615-a963-cf2548b2bc56"
      unitRef="usd">12000000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOjk3OGZlZjEwZDlkZDQwMzk4YWM4MzM0MWEyMDc2ODAzL3RhYmxlcmFuZ2U6OTc4ZmVmMTBkOWRkNDAzOThhYzgzMzQxYTIwNzY4MDNfMi0zLTEtMS05ODY5NA_7784d9ac-84b6-40c1-bd37-ac591f04a540"
      unitRef="usd">13000000</us-gaap:SeveranceCosts1>
    <cah:FacilityExitAndOtherCosts
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOjk3OGZlZjEwZDlkZDQwMzk4YWM4MzM0MWEyMDc2ODAzL3RhYmxlcmFuZ2U6OTc4ZmVmMTBkOWRkNDAzOThhYzgzMzQxYTIwNzY4MDNfMy0xLTEtMS05ODY5NA_a5888658-3080-4d61-add4-fed726d40904"
      unitRef="usd">19000000</cah:FacilityExitAndOtherCosts>
    <cah:FacilityExitAndOtherCosts
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOjk3OGZlZjEwZDlkZDQwMzk4YWM4MzM0MWEyMDc2ODAzL3RhYmxlcmFuZ2U6OTc4ZmVmMTBkOWRkNDAzOThhYzgzMzQxYTIwNzY4MDNfMy0zLTEtMS05ODY5NA_ab8dfc37-3994-4e71-9b34-88b19a1a26bc"
      unitRef="usd">11000000</cah:FacilityExitAndOtherCosts>
    <us-gaap:RestructuringCharges
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOjk3OGZlZjEwZDlkZDQwMzk4YWM4MzM0MWEyMDc2ODAzL3RhYmxlcmFuZ2U6OTc4ZmVmMTBkOWRkNDAzOThhYzgzMzQxYTIwNzY4MDNfNC0xLTEtMS05ODY5NA_cea0e59e-f24c-4152-89e8-050464c212af"
      unitRef="usd">31000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOjk3OGZlZjEwZDlkZDQwMzk4YWM4MzM0MWEyMDc2ODAzL3RhYmxlcmFuZ2U6OTc4ZmVmMTBkOWRkNDAzOThhYzgzMzQxYTIwNzY4MDNfNC0zLTEtMS05ODY5NA_fc246d48-3d22-4574-a787-a0fc2723f0e1"
      unitRef="usd">24000000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOmQzOTY0MzhiNmQ2NjQ0OGQ4MzNhODNkZTdjYzFiZDg5L3RhYmxlcmFuZ2U6ZDM5NjQzOGI2ZDY2NDQ4ZDgzM2E4M2RlN2NjMWJkODlfMi0xLTEtMS05ODY5NA_6a3e7347-a3dc-4e40-ba26-793cb8a47a1d"
      unitRef="usd">22000000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOmQzOTY0MzhiNmQ2NjQ0OGQ4MzNhODNkZTdjYzFiZDg5L3RhYmxlcmFuZ2U6ZDM5NjQzOGI2ZDY2NDQ4ZDgzM2E4M2RlN2NjMWJkODlfMi0zLTEtMS05ODY5NA_63cb8db2-5bcf-467e-a9d6-21f517b9e5b6"
      unitRef="usd">45000000</us-gaap:SeveranceCosts1>
    <cah:FacilityExitAndOtherCosts
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOmQzOTY0MzhiNmQ2NjQ0OGQ4MzNhODNkZTdjYzFiZDg5L3RhYmxlcmFuZ2U6ZDM5NjQzOGI2ZDY2NDQ4ZDgzM2E4M2RlN2NjMWJkODlfMy0xLTEtMS05ODY5NA_4e5cab96-7ab7-4041-af9c-ee7c17b81f2b"
      unitRef="usd">34000000</cah:FacilityExitAndOtherCosts>
    <cah:FacilityExitAndOtherCosts
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOmQzOTY0MzhiNmQ2NjQ0OGQ4MzNhODNkZTdjYzFiZDg5L3RhYmxlcmFuZ2U6ZDM5NjQzOGI2ZDY2NDQ4ZDgzM2E4M2RlN2NjMWJkODlfMy0zLTEtMS05ODY5NA_5049a2fc-b1c3-499e-b7e0-20625e66fb52"
      unitRef="usd">36000000</cah:FacilityExitAndOtherCosts>
    <us-gaap:RestructuringCharges
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOmQzOTY0MzhiNmQ2NjQ0OGQ4MzNhODNkZTdjYzFiZDg5L3RhYmxlcmFuZ2U6ZDM5NjQzOGI2ZDY2NDQ4ZDgzM2E4M2RlN2NjMWJkODlfNC0xLTEtMS05ODY5NA_303453b5-b265-461b-89f6-0b5f56de6f69"
      unitRef="usd">56000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOmQzOTY0MzhiNmQ2NjQ0OGQ4MzNhODNkZTdjYzFiZDg5L3RhYmxlcmFuZ2U6ZDM5NjQzOGI2ZDY2NDQ4ZDgzM2E4M2RlN2NjMWJkODlfNC0zLTEtMS05ODY5NA_e257053e-00b3-406e-ad27-5d586b23256e"
      unitRef="usd">81000000</us-gaap:RestructuringCharges>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RleHRyZWdpb246MDQ5MzM5OGZjMjc3NGY4NWIyZGRkODVmYTM2ODQyOWJfOTky_dc5651da-d76b-42ac-a564-1a6cf13c9d17">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes activity related to liabilities associated with restructuring and employee severance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.237%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.237%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.241%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-&lt;br/&gt;Related Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility Exit&lt;br/&gt;and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;79&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;35&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;49&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;66&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="i45240633cec7475d96b338fa98ea6450_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOjAzYmFhOTdhNDg3ZTQxN2FiYTQ1NzY3YjQ4MzBhOTNiL3RhYmxlcmFuZ2U6MDNiYWE5N2E0ODdlNDE3YWJhNDU3NjdiNDgzMGE5M2JfMS0xLTEtMS05ODY5NA_6b31c735-8fea-4cac-b564-6a2ca28360a2"
      unitRef="usd">53000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i21b9f08e069e407899537ccf182d99fb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOjAzYmFhOTdhNDg3ZTQxN2FiYTQ1NzY3YjQ4MzBhOTNiL3RhYmxlcmFuZ2U6MDNiYWE5N2E0ODdlNDE3YWJhNDU3NjdiNDgzMGE5M2JfMS0zLTEtMS05ODY5NA_456a957d-ed27-4f97-abfa-988754f1b7f3"
      unitRef="usd">26000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOjAzYmFhOTdhNDg3ZTQxN2FiYTQ1NzY3YjQ4MzBhOTNiL3RhYmxlcmFuZ2U6MDNiYWE5N2E0ODdlNDE3YWJhNDU3NjdiNDgzMGE5M2JfMS01LTEtMS05ODY5NA_0a36f1ce-6e7f-4e74-a244-b9fb5bf06eec"
      unitRef="usd">79000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCosts
      contextRef="i739eec2ece12431aa16063ab41067d2c_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOjAzYmFhOTdhNDg3ZTQxN2FiYTQ1NzY3YjQ4MzBhOTNiL3RhYmxlcmFuZ2U6MDNiYWE5N2E0ODdlNDE3YWJhNDU3NjdiNDgzMGE5M2JfMi0xLTEtMS05ODY5NA_961cd696-8481-416e-897c-338549e81d14"
      unitRef="usd">34000000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="i8e58575430c249979ddd28860b77d7ea_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOjAzYmFhOTdhNDg3ZTQxN2FiYTQ1NzY3YjQ4MzBhOTNiL3RhYmxlcmFuZ2U6MDNiYWE5N2E0ODdlNDE3YWJhNDU3NjdiNDgzMGE5M2JfMi0zLTEtMS05ODY5NA_1e86f3fa-72a6-4e84-8a6d-5c7ca3b710b0"
      unitRef="usd">1000000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOjAzYmFhOTdhNDg3ZTQxN2FiYTQ1NzY3YjQ4MzBhOTNiL3RhYmxlcmFuZ2U6MDNiYWE5N2E0ODdlNDE3YWJhNDU3NjdiNDgzMGE5M2JfMi01LTEtMS05ODY5NA_02e6bd91-8d05-4d33-bfca-ea94975cfc81"
      unitRef="usd">35000000</us-gaap:RestructuringCosts>
    <us-gaap:PaymentsForRestructuring
      contextRef="i739eec2ece12431aa16063ab41067d2c_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOjAzYmFhOTdhNDg3ZTQxN2FiYTQ1NzY3YjQ4MzBhOTNiL3RhYmxlcmFuZ2U6MDNiYWE5N2E0ODdlNDE3YWJhNDU3NjdiNDgzMGE5M2JfMy0xLTEtMS05ODY5NA_d8bed1e9-cde8-44c3-af5b-2fe1e917e461"
      unitRef="usd">38000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i8e58575430c249979ddd28860b77d7ea_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOjAzYmFhOTdhNDg3ZTQxN2FiYTQ1NzY3YjQ4MzBhOTNiL3RhYmxlcmFuZ2U6MDNiYWE5N2E0ODdlNDE3YWJhNDU3NjdiNDgzMGE5M2JfMy0zLTEtMS05ODY5NA_5856110c-fb0b-42b0-9600-037174037093"
      unitRef="usd">10000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOjAzYmFhOTdhNDg3ZTQxN2FiYTQ1NzY3YjQ4MzBhOTNiL3RhYmxlcmFuZ2U6MDNiYWE5N2E0ODdlNDE3YWJhNDU3NjdiNDgzMGE5M2JfMy01LTEtMS05ODY5NA_34848bb8-eb57-4264-9989-a17839f6b1d8"
      unitRef="usd">48000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve
      contextRef="i8754e705bb17409ca30ddb1af53bfd62_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOjAzYmFhOTdhNDg3ZTQxN2FiYTQ1NzY3YjQ4MzBhOTNiL3RhYmxlcmFuZ2U6MDNiYWE5N2E0ODdlNDE3YWJhNDU3NjdiNDgzMGE5M2JfNC0xLTEtMS05ODY5NA_86cdb893-f2a5-4f22-a984-7cbc5c6eedde"
      unitRef="usd">49000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i75ec9e64c1d7453ca7736eb6d2cd74b4_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOjAzYmFhOTdhNDg3ZTQxN2FiYTQ1NzY3YjQ4MzBhOTNiL3RhYmxlcmFuZ2U6MDNiYWE5N2E0ODdlNDE3YWJhNDU3NjdiNDgzMGE5M2JfNC0zLTEtMS05ODY5NA_e2f546d6-2b38-402b-870f-f625bda0431d"
      unitRef="usd">17000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF84OC9mcmFnOjA0OTMzOThmYzI3NzRmODViMmRkZDg1ZmEzNjg0MjliL3RhYmxlOjAzYmFhOTdhNDg3ZTQxN2FiYTQ1NzY3YjQ4MzBhOTNiL3RhYmxlcmFuZ2U6MDNiYWE5N2E0ODdlNDE3YWJhNDU3NjdiNDgzMGE5M2JfNC01LTEtMS05ODY5NA_8e6dd30a-ec3a-4f9e-a9e3-d6262e119f27"
      unitRef="usd">66000000</us-gaap:RestructuringReserve>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfMTg1Mw_397fd644-c359-43ed-8f4a-1ebb768b7af1">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;4. Goodwill and Other Intangible Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill by segment and in total:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.801%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,989&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill acquired, net of purchase price adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,781)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,781)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,659&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,508&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,167&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;At March 31, 2022 and June 30, 2021, the Pharmaceutical segment accumulated goodwill impairment loss was $829&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;At March 31, 2022 and June 30, 2021, the Medical segment accumulated goodwill impairment loss was $3.2&#160;billion and $1.4&#160;billion, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended March&#160;31, 2022, the Medical Unit, which is our Medical operating segment excluding our Cardinal Health at-Home Solutions division, continued to experience adverse financial results related to inflationary impacts and the adverse impact of global supply chain constraints. Due to the risks and uncertainties related to these impacts, we elected to bypass the qualitative assessment in the second and third quarters of fiscal 2022 and perform interim goodwill impairment testing for the Medical Unit. This quantitative testing resulted in the carrying amount of the Medical Unit exceeding the fair value, resulting in pre-tax impairment charges of $474&#160;million and $1.3&#160;billion, which were recognized during the three months ended March&#160;31, 2022 and&#160;December 31, 2021, respectively, and are included in impairments and (gain)/loss on disposal of assets in our condensed consolidated statements of earnings/(loss). The goodwill balance of the Medical Unit, after recognizing the impairment, was $2.3&#160;billion at March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our determination of the estimated fair value of the Medical Unit is based on a combination of the income-based approach (using a terminal growth rate of 2 percent), and the market-based approach. For the income-based approach, we also used discount rates of 9.5 percent and 9 percent for the interim testing at March&#160;31, 2022 and&#160;December 31, 2021, respectively. The increase in the discount rate was primarily due to an increase in the risk-free interest rate. Our fair value estimates utilize significant unobservable inputs and thus represent Level 3 fair value measurements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Other Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize other intangible assets by class at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted- Average Remaining Amortization Period (Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Indefinite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks and patents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total indefinite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Definite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,293&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,130&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,163&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks, trade names and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;552&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;352&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;200&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,036&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;557&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;479&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total definite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,881&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,039&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,842&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,894&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,039&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,855&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.308%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.643%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.312%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Indefinite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks and patents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total indefinite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Definite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks, trade names and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total definite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total amortization of intangible assets was $78 million and $109 million for the three months ended March 31, 2022 and 2021, respectively, and $235 million and $337 million for the nine months ended March&#160;31, 2022 and 2021, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2022 through 2026 is as follows: $78 million, $284 million, $260 million, $235 million, and $208 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfMTg4Mg_9cc5b7f3-a030-4d33-badc-9d9ad5037043">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill by segment and in total:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.801%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,989&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill acquired, net of purchase price adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,781)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,781)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,659&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,508&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,167&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;At March 31, 2022 and June 30, 2021, the Pharmaceutical segment accumulated goodwill impairment loss was $829&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;At March 31, 2022 and June 30, 2021, the Medical segment accumulated goodwill impairment loss was $3.2&#160;billion and $1.4&#160;billion, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="ifbcce5e048774bd281968e39fa6fd1d5_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjU2NDVhNTIzM2EyYTQ1MGViNzgwNGZkYmFmYjBmODQ0L3RhYmxlcmFuZ2U6NTY0NWE1MjMzYTJhNDUwZWI3ODA0ZmRiYWZiMGY4NDRfMS0xLTEtMS05ODY5NA_49de33cb-f080-4190-a8d2-b8efdc355d68"
      unitRef="usd">2659000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i1cf7100a49b8462b95d20252b5ae23fc_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjU2NDVhNTIzM2EyYTQ1MGViNzgwNGZkYmFmYjBmODQ0L3RhYmxlcmFuZ2U6NTY0NWE1MjMzYTJhNDUwZWI3ODA0ZmRiYWZiMGY4NDRfMS0zLTEtMS05ODY5NA_36d5efa9-05ee-4424-8429-4520df8c090e"
      unitRef="usd">5330000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjU2NDVhNTIzM2EyYTQ1MGViNzgwNGZkYmFmYjBmODQ0L3RhYmxlcmFuZ2U6NTY0NWE1MjMzYTJhNDUwZWI3ODA0ZmRiYWZiMGY4NDRfMS01LTEtMS05ODY5NA_84dc6b2f-f461-417b-bc18-48039919fbb5"
      unitRef="usd">7989000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ie8dd1990825346198258de24f42bdfab_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjU2NDVhNTIzM2EyYTQ1MGViNzgwNGZkYmFmYjBmODQ0L3RhYmxlcmFuZ2U6NTY0NWE1MjMzYTJhNDUwZWI3ODA0ZmRiYWZiMGY4NDRfMi0xLTEtMS05ODY5NA_5ece25a7-56b2-4e8d-bfda-8415c70bee66"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i41161f1b8d3943d8bd64b5d48963474e_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjU2NDVhNTIzM2EyYTQ1MGViNzgwNGZkYmFmYjBmODQ0L3RhYmxlcmFuZ2U6NTY0NWE1MjMzYTJhNDUwZWI3ODA0ZmRiYWZiMGY4NDRfMi0zLTEtMS05ODY5NA_1f3490ab-64ff-4f30-81bc-c8c979fa34be"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjU2NDVhNTIzM2EyYTQ1MGViNzgwNGZkYmFmYjBmODQ0L3RhYmxlcmFuZ2U6NTY0NWE1MjMzYTJhNDUwZWI3ODA0ZmRiYWZiMGY4NDRfMi01LTEtMS05ODY5NA_d3def9cb-76dc-4668-a9a4-64b6fc999998"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ie8dd1990825346198258de24f42bdfab_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjU2NDVhNTIzM2EyYTQ1MGViNzgwNGZkYmFmYjBmODQ0L3RhYmxlcmFuZ2U6NTY0NWE1MjMzYTJhNDUwZWI3ODA0ZmRiYWZiMGY4NDRfMy0xLTEtMS05ODY5NA_59d70690-2bdd-4a90-b36a-c84c71ed677b"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i41161f1b8d3943d8bd64b5d48963474e_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjU2NDVhNTIzM2EyYTQ1MGViNzgwNGZkYmFmYjBmODQ0L3RhYmxlcmFuZ2U6NTY0NWE1MjMzYTJhNDUwZWI3ODA0ZmRiYWZiMGY4NDRfMy0zLTEtMS05ODY5NA_7519ee4c-8aad-47e1-acf8-723b98fe20f9"
      unitRef="usd">-41000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjU2NDVhNTIzM2EyYTQ1MGViNzgwNGZkYmFmYjBmODQ0L3RhYmxlcmFuZ2U6NTY0NWE1MjMzYTJhNDUwZWI3ODA0ZmRiYWZiMGY4NDRfMy01LTEtMS05ODY5NA_a83ea62b-214f-48ea-8cd6-62ad180cfcbf"
      unitRef="usd">-41000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ie8dd1990825346198258de24f42bdfab_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjU2NDVhNTIzM2EyYTQ1MGViNzgwNGZkYmFmYjBmODQ0L3RhYmxlcmFuZ2U6NTY0NWE1MjMzYTJhNDUwZWI3ODA0ZmRiYWZiMGY4NDRfNC0xLTEtMS05ODY5NA_ba101fe0-eac5-4068-b782-8a6f0dd71ba2"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i41161f1b8d3943d8bd64b5d48963474e_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjU2NDVhNTIzM2EyYTQ1MGViNzgwNGZkYmFmYjBmODQ0L3RhYmxlcmFuZ2U6NTY0NWE1MjMzYTJhNDUwZWI3ODA0ZmRiYWZiMGY4NDRfNC0zLTEtMS05ODY5NA_ffba26d8-c8a2-4c2c-babf-1ece72ff739a"
      unitRef="usd">1781000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjU2NDVhNTIzM2EyYTQ1MGViNzgwNGZkYmFmYjBmODQ0L3RhYmxlcmFuZ2U6NTY0NWE1MjMzYTJhNDUwZWI3ODA0ZmRiYWZiMGY4NDRfNC01LTEtMS05ODY5NA_cc2897f0-6540-4430-aea9-0189bd009fa3"
      unitRef="usd">1781000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:Goodwill
      contextRef="i51a8695f54ef4860b74b13f3c337f04d_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjU2NDVhNTIzM2EyYTQ1MGViNzgwNGZkYmFmYjBmODQ0L3RhYmxlcmFuZ2U6NTY0NWE1MjMzYTJhNDUwZWI3ODA0ZmRiYWZiMGY4NDRfNS0xLTEtMS05ODY5NA_f969a31d-f40a-4948-bff7-bba06ae55df2"
      unitRef="usd">2659000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="idb7f73d87fb74abbb28799bf351ad2cf_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjU2NDVhNTIzM2EyYTQ1MGViNzgwNGZkYmFmYjBmODQ0L3RhYmxlcmFuZ2U6NTY0NWE1MjMzYTJhNDUwZWI3ODA0ZmRiYWZiMGY4NDRfNS0zLTEtMS05ODY5NA_12f6ad2a-56a8-4695-ab1a-264095064e7f"
      unitRef="usd">3508000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjU2NDVhNTIzM2EyYTQ1MGViNzgwNGZkYmFmYjBmODQ0L3RhYmxlcmFuZ2U6NTY0NWE1MjMzYTJhNDUwZWI3ODA0ZmRiYWZiMGY4NDRfNS01LTEtMS05ODY5NA_e19dc664-e613-4fd9-a298-6d198ba2bc31"
      unitRef="usd">6167000000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="ifbcce5e048774bd281968e39fa6fd1d5_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfMjMy_64209b03-fd34-4758-91c0-22f65a1eeff6"
      unitRef="usd">829000000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i51a8695f54ef4860b74b13f3c337f04d_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfMjMy_c5e1e651-945f-4163-a523-ae3f72bc63d8"
      unitRef="usd">829000000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="idb7f73d87fb74abbb28799bf351ad2cf_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfMzM3_891fedb9-ecdd-48ae-a85b-ca0a26fe27dc"
      unitRef="usd">3200000000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i1cf7100a49b8462b95d20252b5ae23fc_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfMzQ0_32525e9a-0dd7-4154-a8c6-30183e03a48e"
      unitRef="usd">1400000000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i2473dfc0495e42aeb265fd377f6c1a00_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfNzE0NjgyNTU4NTE4MQ_c7e51357-5524-44a3-9a05-2d4ebe1fb89e"
      unitRef="usd">474000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i8c4e40c1def448fcb66e1d0cc8122850_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfNzE0NjgyNTU4NjYwMA_c8fea723-0b81-4792-801b-8881053de36e"
      unitRef="usd">1300000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:Goodwill
      contextRef="i2843d7b87d1544cf87e968d6d3ae3124_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfNzE0NjgyNTU4NDAyMQ_f818626a-67b5-488c-8bfa-085c47c72a77"
      unitRef="usd">2300000000</us-gaap:Goodwill>
    <cah:TerminalGrowthRateFairValueInput
      contextRef="i8c4e40c1def448fcb66e1d0cc8122850_D20211001-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfMzI5ODUzNDg5MDUwMw_80a59695-66bc-4503-bda7-558de15faf02"
      unitRef="number">0.02</cah:TerminalGrowthRateFairValueInput>
    <cah:TerminalGrowthRateFairValueInput
      contextRef="i2473dfc0495e42aeb265fd377f6c1a00_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfMzI5ODUzNDg5MDUwMw_85492539-6c2a-4f2e-9fd2-cd445119ee5d"
      unitRef="number">0.02</cah:TerminalGrowthRateFairValueInput>
    <cah:DiscountRateFairValueInput
      contextRef="i2473dfc0495e42aeb265fd377f6c1a00_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfMzI5ODUzNDg5MDQ3NA_7686170d-8d23-48e4-8940-0ba6bfefd059"
      unitRef="number">0.095</cah:DiscountRateFairValueInput>
    <cah:DiscountRateFairValueInput
      contextRef="i8c4e40c1def448fcb66e1d0cc8122850_D20211001-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfMzI5ODUzNDg5MDQ4NQ_0e48a5e1-9e79-465f-9d00-f5864272c2db"
      unitRef="number">0.09</cah:DiscountRateFairValueInput>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfMTg1OQ_46aaffda-5afa-4b30-8428-4fa46fa8d4d2">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize other intangible assets by class at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted- Average Remaining Amortization Period (Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Indefinite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks and patents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total indefinite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Definite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,293&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,130&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,163&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks, trade names and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;552&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;352&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;200&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,036&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;557&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;479&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total definite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,881&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,039&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,842&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,894&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,039&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,855&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.308%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.643%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.312%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Indefinite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks and patents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total indefinite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Definite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks, trade names and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total definite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="id1a80ba5335a434499eb18f05cfe77bd_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfMy0xLTEtMS05ODY5NA_fa936c18-53d0-4307-b32c-9712d4e500f6"
      unitRef="usd">13000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="id1a80ba5335a434499eb18f05cfe77bd_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfMy01LTEtMS05ODY5NA_3c6f5987-952f-4496-b69d-3bb3ec57b785"
      unitRef="usd">13000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfNC0xLTEtMS05ODY5NA_3f2672e1-7771-428d-bbda-20680345fdd6"
      unitRef="usd">13000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfNC01LTEtMS05ODY5NA_84103872-4578-414d-aeae-28d9f84799bd"
      unitRef="usd">13000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i04b1540e67e14f1491c2bcf9e8c40937_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfNy0xLTEtMS05ODY5NA_66b4708b-a923-49d6-b180-6419f7321bdf"
      unitRef="usd">3293000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i04b1540e67e14f1491c2bcf9e8c40937_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfNy0zLTEtMS05ODY5NA_2a8f8431-e9e6-4414-b8c9-0672206d18e2"
      unitRef="usd">2130000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i04b1540e67e14f1491c2bcf9e8c40937_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfNy01LTEtMS05ODY5NA_20320af7-bcc5-462d-ac36-cebb766ee73f"
      unitRef="usd">1163000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i1e32d2dbae964ed2b9f89a485ba2d9f2_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfNy03LTEtMS05ODY5NA_a9a81e3a-af5d-49f1-a520-a2ae3cec456c">P10Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ica172f3bed03490b81be7777d6520978_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfOC0xLTEtMS05ODY5NA_7fe02b79-a5c5-4724-aeb6-473d1443625a"
      unitRef="usd">552000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ica172f3bed03490b81be7777d6520978_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfOC0zLTEtMS05ODY5NA_66911105-a46f-4181-90ba-b9b474998293"
      unitRef="usd">352000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ica172f3bed03490b81be7777d6520978_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfOC01LTEtMS05ODY5NA_2eb75f14-40c1-413e-b5d5-bcbd9b623b90"
      unitRef="usd">200000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i51a8e1fc38aa4e9fa1cbb316ac661cf2_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfOC03LTEtMS05ODY5NA_2a0c7b79-6ced-47cc-aa96-40e265773bfa">P9Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id70764894a9a471186543cece23c0235_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfOS0xLTEtMS05ODY5NA_9a0691a0-cd3d-44b9-ade8-8145a0c155c4"
      unitRef="usd">1036000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id70764894a9a471186543cece23c0235_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfOS0zLTEtMS05ODY5NA_308ff19f-5334-4cf6-8d84-353a09dccd91"
      unitRef="usd">557000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id70764894a9a471186543cece23c0235_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfOS01LTEtMS05ODY5NA_92b06ac1-cf34-4fc8-b029-f3f0e6434d03"
      unitRef="usd">479000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i3ac7d4f29a95405f9301d56ef3d96f7d_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfOS03LTEtMS05ODY5NA_b8ebcd8b-0ca6-44c1-bdfd-c7320fa2786a">P9Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfMTAtMS0xLTEtOTg2OTQ_d726eb3e-3bd0-450b-8386-e5cb733f7d52"
      unitRef="usd">4881000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfMTAtMy0xLTEtOTg2OTQ_6ecca467-9dc0-49d8-bb33-f3abf0995e8e"
      unitRef="usd">3039000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfMTAtNS0xLTEtOTg2OTQ_3ea5ee82-fb73-42d5-b870-ca92a31e8363"
      unitRef="usd">1842000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfMTAtNy0xLTEtOTg2OTQ_76e9a307-5694-48bc-8b90-bf5a2fca139f">P10Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfMTEtMS0xLTEtOTg2OTQ_f4b56a86-7d5c-4e45-bad7-7723a3d62bea"
      unitRef="usd">4894000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfMTEtMy0xLTEtOTg2OTQ_ed2a85f1-63d9-42f5-a694-93bbacc111ea"
      unitRef="usd">3039000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOjc3NWYwM2ZlZTU5YTRmMjU4OGIxNmJjZjU5MTcxYTFhL3RhYmxlcmFuZ2U6Nzc1ZjAzZmVlNTlhNGYyNTg4YjE2YmNmNTkxNzFhMWFfMTEtNS0xLTEtOTg2OTQ_749eebc3-14db-44aa-a0d4-9b7cb9a67094"
      unitRef="usd">1855000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i58dd95f7f9f14ed4a4314c6690da932a_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOmI1MDk3OTkzMTFmNjQ1MTViNWVmNzU0ODQ1MjgxMjQ2L3RhYmxlcmFuZ2U6YjUwOTc5OTMxMWY2NDUxNWI1ZWY3NTQ4NDUyODEyNDZfMy0xLTEtMS05ODY5NA_69c1d985-347e-4868-b4ca-c645986e3592"
      unitRef="usd">12000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i58dd95f7f9f14ed4a4314c6690da932a_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOmI1MDk3OTkzMTFmNjQ1MTViNWVmNzU0ODQ1MjgxMjQ2L3RhYmxlcmFuZ2U6YjUwOTc5OTMxMWY2NDUxNWI1ZWY3NTQ4NDUyODEyNDZfMy01LTEtMS05ODY5NA_a280a94d-b5a7-47e7-8d62-e1f86c6c6453"
      unitRef="usd">12000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOmI1MDk3OTkzMTFmNjQ1MTViNWVmNzU0ODQ1MjgxMjQ2L3RhYmxlcmFuZ2U6YjUwOTc5OTMxMWY2NDUxNWI1ZWY3NTQ4NDUyODEyNDZfNC0xLTEtMS05ODY5NA_f4181567-91f5-49cc-9a7a-80bb150c38b0"
      unitRef="usd">12000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOmI1MDk3OTkzMTFmNjQ1MTViNWVmNzU0ODQ1MjgxMjQ2L3RhYmxlcmFuZ2U6YjUwOTc5OTMxMWY2NDUxNWI1ZWY3NTQ4NDUyODEyNDZfNC01LTEtMS05ODY5NA_36dfbb89-5c3e-4240-83e6-d28ae8519ad2"
      unitRef="usd">12000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i95eee9fd908844ee899640d22db70870_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOmI1MDk3OTkzMTFmNjQ1MTViNWVmNzU0ODQ1MjgxMjQ2L3RhYmxlcmFuZ2U6YjUwOTc5OTMxMWY2NDUxNWI1ZWY3NTQ4NDUyODEyNDZfNy0xLTEtMS05ODY5NA_b4279286-944a-4b1a-b44e-bcfd3e833138"
      unitRef="usd">3330000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i95eee9fd908844ee899640d22db70870_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOmI1MDk3OTkzMTFmNjQ1MTViNWVmNzU0ODQ1MjgxMjQ2L3RhYmxlcmFuZ2U6YjUwOTc5OTMxMWY2NDUxNWI1ZWY3NTQ4NDUyODEyNDZfNy0zLTEtMS05ODY5NA_342acc55-ab75-46d0-8783-e0dacc263ab3"
      unitRef="usd">1989000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i95eee9fd908844ee899640d22db70870_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOmI1MDk3OTkzMTFmNjQ1MTViNWVmNzU0ODQ1MjgxMjQ2L3RhYmxlcmFuZ2U6YjUwOTc5OTMxMWY2NDUxNWI1ZWY3NTQ4NDUyODEyNDZfNy01LTEtMS05ODY5NA_178a9a0d-1894-4b7a-975c-7c817db97341"
      unitRef="usd">1341000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i602bf6f83c0542c597ac5984f1a805f8_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOmI1MDk3OTkzMTFmNjQ1MTViNWVmNzU0ODQ1MjgxMjQ2L3RhYmxlcmFuZ2U6YjUwOTc5OTMxMWY2NDUxNWI1ZWY3NTQ4NDUyODEyNDZfOC0xLTEtMS05ODY5NA_280d9b75-ad81-46a1-9357-6a0a5cb4075f"
      unitRef="usd">551000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i602bf6f83c0542c597ac5984f1a805f8_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOmI1MDk3OTkzMTFmNjQ1MTViNWVmNzU0ODQ1MjgxMjQ2L3RhYmxlcmFuZ2U6YjUwOTc5OTMxMWY2NDUxNWI1ZWY3NTQ4NDUyODEyNDZfOC0zLTEtMS05ODY5NA_daeceb27-d97c-4e88-8971-68957abdda16"
      unitRef="usd">328000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i602bf6f83c0542c597ac5984f1a805f8_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOmI1MDk3OTkzMTFmNjQ1MTViNWVmNzU0ODQ1MjgxMjQ2L3RhYmxlcmFuZ2U6YjUwOTc5OTMxMWY2NDUxNWI1ZWY3NTQ4NDUyODEyNDZfOC01LTEtMS05ODY5NA_10c7b3b9-9e42-4e02-a8ca-94622163bb06"
      unitRef="usd">223000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6be348f5aeaf4eb1a576923d8e90234e_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOmI1MDk3OTkzMTFmNjQ1MTViNWVmNzU0ODQ1MjgxMjQ2L3RhYmxlcmFuZ2U6YjUwOTc5OTMxMWY2NDUxNWI1ZWY3NTQ4NDUyODEyNDZfOS0xLTEtMS05ODY5NA_2809b151-1578-43dd-a569-8ba4f9dd8e33"
      unitRef="usd">1035000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6be348f5aeaf4eb1a576923d8e90234e_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOmI1MDk3OTkzMTFmNjQ1MTViNWVmNzU0ODQ1MjgxMjQ2L3RhYmxlcmFuZ2U6YjUwOTc5OTMxMWY2NDUxNWI1ZWY3NTQ4NDUyODEyNDZfOS0zLTEtMS05ODY5NA_58305d76-c625-4b51-9b81-ffc5f5bd7f4e"
      unitRef="usd">506000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6be348f5aeaf4eb1a576923d8e90234e_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOmI1MDk3OTkzMTFmNjQ1MTViNWVmNzU0ODQ1MjgxMjQ2L3RhYmxlcmFuZ2U6YjUwOTc5OTMxMWY2NDUxNWI1ZWY3NTQ4NDUyODEyNDZfOS01LTEtMS05ODY5NA_48f85f70-1299-4fa7-a821-4ffaad92da74"
      unitRef="usd">529000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOmI1MDk3OTkzMTFmNjQ1MTViNWVmNzU0ODQ1MjgxMjQ2L3RhYmxlcmFuZ2U6YjUwOTc5OTMxMWY2NDUxNWI1ZWY3NTQ4NDUyODEyNDZfMTAtMS0xLTEtOTg2OTQ_18d829df-0ed1-4728-a3e7-1418a4ea7107"
      unitRef="usd">4916000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOmI1MDk3OTkzMTFmNjQ1MTViNWVmNzU0ODQ1MjgxMjQ2L3RhYmxlcmFuZ2U6YjUwOTc5OTMxMWY2NDUxNWI1ZWY3NTQ4NDUyODEyNDZfMTAtMy0xLTEtOTg2OTQ_fbc98ebd-2d19-4a8e-9bc2-811502a62cb9"
      unitRef="usd">2823000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOmI1MDk3OTkzMTFmNjQ1MTViNWVmNzU0ODQ1MjgxMjQ2L3RhYmxlcmFuZ2U6YjUwOTc5OTMxMWY2NDUxNWI1ZWY3NTQ4NDUyODEyNDZfMTAtNS0xLTEtOTg2OTQ_9e4cc332-93ab-4dc7-a71a-7d786e19f455"
      unitRef="usd">2093000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOmI1MDk3OTkzMTFmNjQ1MTViNWVmNzU0ODQ1MjgxMjQ2L3RhYmxlcmFuZ2U6YjUwOTc5OTMxMWY2NDUxNWI1ZWY3NTQ4NDUyODEyNDZfMTEtMS0xLTEtOTg2OTQ_053890bd-1521-4ec0-9497-0c5403a690c0"
      unitRef="usd">4928000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOmI1MDk3OTkzMTFmNjQ1MTViNWVmNzU0ODQ1MjgxMjQ2L3RhYmxlcmFuZ2U6YjUwOTc5OTMxMWY2NDUxNWI1ZWY3NTQ4NDUyODEyNDZfMTEtMy0xLTEtOTg2OTQ_2957d35d-4ec7-4433-9910-25f616cc07b7"
      unitRef="usd">2823000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RhYmxlOmI1MDk3OTkzMTFmNjQ1MTViNWVmNzU0ODQ1MjgxMjQ2L3RhYmxlcmFuZ2U6YjUwOTc5OTMxMWY2NDUxNWI1ZWY3NTQ4NDUyODEyNDZfMTEtNS0xLTEtOTg2OTQ_2dd0c81c-af63-462a-a6e1-5e30e96564f6"
      unitRef="usd">2105000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfMTYxMA_b535b9e3-92bc-48b2-888c-203ebeb85de0"
      unitRef="usd">78000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfMTYxNw_019cc769-61cd-43a9-854e-ffc1a6b3c125"
      unitRef="usd">109000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfMTY3Ng_633b202a-17d7-4d9e-8ee4-541de091afd2"
      unitRef="usd">235000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfMTY4Mw_9dfe52ce-6043-430f-8efd-a39ea38239c3"
      unitRef="usd">337000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfMTgzMA_99d99713-a76b-4e16-8db7-4269b515a6b9"
      unitRef="usd">78000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfMTgzNA_7cc9fd94-8e5c-4632-97e8-2e729ef8a50a"
      unitRef="usd">284000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfMTgzOA_966d478f-5c02-4d54-987e-1a7933f9c8c3"
      unitRef="usd">260000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfMTg0Mg_8d4df3b0-1f40-4fb4-831c-334774d58e00"
      unitRef="usd">235000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF85MS9mcmFnOmZjMmJiNGQ4NzJlMzRiZDhiMTUwMjY3YzY5MmUyNmE0L3RleHRyZWdpb246ZmMyYmI0ZDg3MmUzNGJkOGIxNTAyNjdjNjkyZTI2YTRfMTg1MA_119cdbed-123a-4ff0-9079-ee359d97c298"
      unitRef="usd">208000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDAvZnJhZzpkNDRjYzYwN2MzM2Y0ZDhjOTNkNGEzNGRkYmZlMGZhYy90ZXh0cmVnaW9uOmQ0NGNjNjA3YzMzZjRkOGM5M2Q0YTM0ZGRiZmUwZmFjXzIzMTA_644a011e-cbe6-4df2-9ba1-803bd0d497d2">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;5. Long-Term Obligations and Other Short-Term Borrowings&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Long-Term Debt and Other Short-Term Borrowings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had total long-term obligations, including the current portion and other short-term borrowings, of $5.6 billion and $6.2 billion at March&#160;31, 2022 and June&#160;30, 2021, respectively. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $24.8 billion and $23.7 billion at March&#160;31, 2022 and June&#160;30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended March&#160;31, 2022, we redeemed all outstanding $572 million principal amount of 2.616% Notes due June 2022 at a redemption price equal to 100% of the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes. In connection with this redemption, we recorded a $10&#160;million loss on early extinguishment of debt. The early redemption was funded with available cash.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended March&#160;31, 2021, we early repurchased a total of $40 million of the Floating Rate Notes due 2022 and $2 million of the 2.616% Notes due June 2022. The repurchases were funded with available cash. In connection with the early debt repurchases, we recorded a $1 million loss on early extinguishment of debt during the nine months ended March&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Other Financing Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to cash and equivalents and operating cash flow, other sources of liquidity include a&#160;$2.0 billion&#160;commercial paper program backed by a $2.0 billion&#160;revolving credit facility. We also have a&#160;$1.0 billion&#160;committed receivables sales facility. At&#160;March&#160;31, 2022, we had no amounts outstanding under our commercial paper program, revolving credit facility, or our committed receivables sales facility. During the nine months ended March&#160;31, 2022, we had a daily maximum amount outstanding under our commercial paper and committed receivables programs of $1.2&#160;billion and an average daily amount outstanding of $25&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (&#x201c;CHF&#x201d;) through September 30, 2022. CHF was organized for&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, CHF is a separate legal entity from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF. CHF is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its creditors. &lt;/span&gt;&lt;/div&gt;Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. As of March&#160;31, 2022, we were in compliance with this financial covenant.</us-gaap:DebtDisclosureTextBlock>
    <cah:TotalLongTermandShortTermObligations
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDAvZnJhZzpkNDRjYzYwN2MzM2Y0ZDhjOTNkNGEzNGRkYmZlMGZhYy90ZXh0cmVnaW9uOmQ0NGNjNjA3YzMzZjRkOGM5M2Q0YTM0ZGRiZmUwZmFjXzE1Nw_e5714bb0-bfea-4dc3-a4b0-87c0902d8b8b"
      unitRef="usd">5600000000</cah:TotalLongTermandShortTermObligations>
    <cah:TotalLongTermandShortTermObligations
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDAvZnJhZzpkNDRjYzYwN2MzM2Y0ZDhjOTNkNGEzNGRkYmZlMGZhYy90ZXh0cmVnaW9uOmQ0NGNjNjA3YzMzZjRkOGM5M2Q0YTM0ZGRiZmUwZmFjXzE2NA_4d2c15f6-336c-43be-85c5-f0fb4e7de1ca"
      unitRef="usd">6200000000</cah:TotalLongTermandShortTermObligations>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDAvZnJhZzpkNDRjYzYwN2MzM2Y0ZDhjOTNkNGEzNGRkYmZlMGZhYy90ZXh0cmVnaW9uOmQ0NGNjNjA3YzMzZjRkOGM5M2Q0YTM0ZGRiZmUwZmFjXzU1MA_e4da3a41-afcf-4461-a1ff-fd7513f28d01"
      unitRef="usd">24800000000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDAvZnJhZzpkNDRjYzYwN2MzM2Y0ZDhjOTNkNGEzNGRkYmZlMGZhYy90ZXh0cmVnaW9uOmQ0NGNjNjA3YzMzZjRkOGM5M2Q0YTM0ZGRiZmUwZmFjXzU1Nw_e11036b0-9c1c-4b4f-a5b1-bc868ca400b0"
      unitRef="usd">23700000000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="if590433d5a9845a7a608dab6a0c258f3_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDAvZnJhZzpkNDRjYzYwN2MzM2Y0ZDhjOTNkNGEzNGRkYmZlMGZhYy90ZXh0cmVnaW9uOmQ0NGNjNjA3YzMzZjRkOGM5M2Q0YTM0ZGRiZmUwZmFjXzYzNA_57d17b3c-177b-4eba-ae50-4568e0a82c8d"
      unitRef="usd">572000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="if590433d5a9845a7a608dab6a0c258f3_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDAvZnJhZzpkNDRjYzYwN2MzM2Y0ZDhjOTNkNGEzNGRkYmZlMGZhYy90ZXh0cmVnaW9uOmQ0NGNjNjA3YzMzZjRkOGM5M2Q0YTM0ZGRiZmUwZmFjXzg4MA_0655dcb4-6b6d-4a3d-bd26-1dafafa50233"
      unitRef="usd">-10000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i9cb2151ddcdc4fc59c0b79ed2096beec_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDAvZnJhZzpkNDRjYzYwN2MzM2Y0ZDhjOTNkNGEzNGRkYmZlMGZhYy90ZXh0cmVnaW9uOmQ0NGNjNjA3YzMzZjRkOGM5M2Q0YTM0ZGRiZmUwZmFjXzEwMjQ_7ed045d0-d421-4f4a-93fe-4e111acdd4ed"
      unitRef="usd">40000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i13e48b0505964bf68353a1b6f9547f38_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDAvZnJhZzpkNDRjYzYwN2MzM2Y0ZDhjOTNkNGEzNGRkYmZlMGZhYy90ZXh0cmVnaW9uOmQ0NGNjNjA3YzMzZjRkOGM5M2Q0YTM0ZGRiZmUwZmFjXzEwNjc_e8c2b314-ec65-46eb-b7fc-5f6d0ca7e618"
      unitRef="usd">2000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDAvZnJhZzpkNDRjYzYwN2MzM2Y0ZDhjOTNkNGEzNGRkYmZlMGZhYy90ZXh0cmVnaW9uOmQ0NGNjNjA3YzMzZjRkOGM5M2Q0YTM0ZGRiZmUwZmFjXzEyMTA_7959ed66-aca2-47f1-9b29-071ae7996abd"
      unitRef="usd">-1000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="iaf3cd5065e6243ffbbc71550c25ca7f8_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDAvZnJhZzpkNDRjYzYwN2MzM2Y0ZDhjOTNkNGEzNGRkYmZlMGZhYy90ZXh0cmVnaW9uOmQ0NGNjNjA3YzMzZjRkOGM5M2Q0YTM0ZGRiZmUwZmFjXzE0MDk_3f7c319f-a156-4898-9f64-8aa8ce6eeef2"
      unitRef="usd">2000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i993a04a28da74821b93ee616926e595e_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDAvZnJhZzpkNDRjYzYwN2MzM2Y0ZDhjOTNkNGEzNGRkYmZlMGZhYy90ZXh0cmVnaW9uOmQ0NGNjNjA3YzMzZjRkOGM5M2Q0YTM0ZGRiZmUwZmFjXzE0NDk_f4621f1c-af61-4042-b262-d7ad144eb3ec"
      unitRef="usd">2000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="id353836da7934ebb8d1cb8a20ca4a576_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDAvZnJhZzpkNDRjYzYwN2MzM2Y0ZDhjOTNkNGEzNGRkYmZlMGZhYy90ZXh0cmVnaW9uOmQ0NGNjNjA3YzMzZjRkOGM5M2Q0YTM0ZGRiZmUwZmFjXzE0OTQ_34c92881-694c-4746-8d5b-3df9623d3304"
      unitRef="usd">1000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:OtherShortTermBorrowings
      contextRef="iea2152d45a954937a5a92441521a45ff_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDAvZnJhZzpkNDRjYzYwN2MzM2Y0ZDhjOTNkNGEzNGRkYmZlMGZhYy90ZXh0cmVnaW9uOmQ0NGNjNjA3YzMzZjRkOGM5M2Q0YTM0ZGRiZmUwZmFjXzE1NDk_c2f39945-216d-406d-a83b-30b82be51d78"
      unitRef="usd">0</us-gaap:OtherShortTermBorrowings>
    <us-gaap:LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDAvZnJhZzpkNDRjYzYwN2MzM2Y0ZDhjOTNkNGEzNGRkYmZlMGZhYy90ZXh0cmVnaW9uOmQ0NGNjNjA3YzMzZjRkOGM5M2Q0YTM0ZGRiZmUwZmFjXzMyOTg1MzQ4ODU5ODQ_c7ddb1b2-36e5-490e-9100-289453d62322"
      unitRef="usd">1200000000</us-gaap:LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod>
    <us-gaap:LineOfCreditFacilityAverageOutstandingAmount
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDAvZnJhZzpkNDRjYzYwN2MzM2Y0ZDhjOTNkNGEzNGRkYmZlMGZhYy90ZXh0cmVnaW9uOmQ0NGNjNjA3YzMzZjRkOGM5M2Q0YTM0ZGRiZmUwZmFjXzMyOTg1MzQ4ODU5OTg_a0cc265f-59e0-40f0-93a5-4c77b1dd4045"
      unitRef="usd">25000000</us-gaap:LineOfCreditFacilityAverageOutstandingAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzIyNzIy_55f34d5d-5f48-495d-a50b-f205172c2d0e">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;6. Commitments, Contingent Liabilities and Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Generic Sourcing Venture with CVS Health Corporation ("CVS Health")&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of 10 years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. In August 2021, we amended our agreement to extend the term through June 2029. We are required to make quarterly payments to CVS Health for the term of the arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;New York Opioid Stewardship Act&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $100&#160;million annual assessment on all manufacturers and distributors licensed to sell or distribute opioids in New York. Under the OSA, each licensed manufacturer and distributor would be required to pay a portion of the assessment based on its share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The constitutionality of portions of the OSA has been challenged in court. In December 2018, the OSA was ruled unconstitutional by the U.S. district court for the Southern District of New York. Subsequently, New York passed a new statute that modified the assessment going forward and limited the OSA to two years (2017 and 2018). The U.S. Court of Appeals for the Second Circuit reversed the district court's decision on procedural grounds. In February 2021, the Second Circuit stayed the effect of the ruling pending a petition to the U.S. Supreme Court to review the Second Circuit's opinion. In October 2021, the U.S. Supreme Court declined to review the decision. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. Because of the Second Circuit ruling, we recorded an aggregate accrual of $41&#160;million for calendar year 2017 and 2018 during the nine months ended March 31, 2021 based on the probable estimated payment amount. In the three months ended December 31, 2021, we paid the State of New York $20&#160;million, our portion of the assessment for calendar year 2017. As a result, as of March 31, 2022, we had an accrual of $20&#160;million, which reflects our best estimate of the portion of the assessment that we may owe for sales during calendar year 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We become involved from time to time in disputes, litigation and regulatory matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we determine that products we source, manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, product liability claims and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we become aware through employees, internal audits or other parties of possible compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges in our condensed consolidated statements of earnings/(loss); however, losses and recoveries of lost profits from disputes that occur in the ordinary course of business are included within segment profit. For example, in the second quarter of fiscal year 2022, our Pharmaceutical segment profit was positively impacted by a $16&#160;million judgment for lost profits related to an ordinary course intellectual property rights claim.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Opioid Lawsuits and Investigations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of February 2022, pharmaceutical wholesale distributors, including us, were defendants in approximately 3,400 lawsuits relating to the distribution of prescription opioid pain medications. The lawsuits sought equitable relief and monetary damages based on a variety of legal theories including various common law claims, such as public nuisance, negligence and unjust enrichment as well as violations of controlled substance laws, the Racketeer Influenced and Corrupt Organizations Act and various other statutes. These lawsuits also name pharmaceutical manufacturers, retail pharmacy chains and other entities as defendants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;States &amp;amp; Political Subdivisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Approximately 2,700 of these lawsuits were filed by counties, municipalities, cities and political subdivisions in various federal, state, and other courts. The vast majority of these lawsuits were filed in U.S. federal court and were transferred for consolidated pre-trial proceedings in a Multi-District Litigation proceeding in the U.S. District Court for the Northern District of Ohio (the &#x201c;MDL&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, 25 state attorneys general filed lawsuits against distributors, including us, in various state courts. We have also received requests, civil investigative demands, subpoenas or requests for information from additional state attorneys general offices and governmental authorities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2022, we determined that there was sufficient participation to proceed with a settlement agreement (the "Settlement Agreement") to settle the vast majority of opioid lawsuits filed by state attorneys general and political subdivisions. This Settlement Agreement became effective on April 2, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to us and two other national distributors, parties to the Settlement Agreement include 46 states, the District of Columbia and 5 U.S. territories. As of April 28, 2022, over 98 percent of political subdivisions (by population as calculated under the Settlement Agreement) that had brought opioid-related suits against us as calculated under the Settlement Agreement had chosen to join the Settlement Agreement or have had their claims addressed by state legislation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under this Settlement Agreement, we will pay up to approximately $6.0&#160;billion, the majority of which will be paid over 18 years. The exact payment amount will depend on several factors, including the extent to which states take action to foreclose opioid lawsuits by political subdivisions (e.g., by passing laws barring or limiting opioid lawsuits by political subdivisions), and the extent to which &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;additional political subdivisions in participating states file additional opioid lawsuits against us. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Settlement Agreement also includes injunctive relief terms related to distributors&#x2019; controlled substance anti-diversion programs, including with respect to: (1) governance; (2) independence and training of the personnel operating controlled substances monitoring programs; (3) due diligence for new and existing customers; (4) ordering limits for certain products; and (5) suspicious order monitoring. A monitor will be selected to oversee compliance with these provisions for a period of five years. In addition, we and the two other settling distributors will engage a third-party vendor to act as a clearinghouse for data aggregation and reporting, which distributors will fund the for ten years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The participating states and the distributors are cooperating to obtain consent judgments embodying the terms of the Settlement Agreement in each participating state and the participating states and subdivisions are dismissing their lawsuits. As a result, as of April 28, 2022, approximately 2,000 lawsuits against us have been dismissed. We expect additional lawsuits to be dismissed over the coming months. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, we had separately negotiated settlements with each of Florida, New York, Ohio, Rhode Island, Texas and their participating subdivisions; however, as contemplated, these states and their participating subdivisions are now participating in the Settlement Agreement.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended March&#160;31, 2022, we paid into escrow the majority of our first annual payment under the Settlement Agreement, which is reflected in prepaid expenses and other assets in our condensed consolidated balance sheets. We also made certain payments under the separate New York, Ohio and Rhode Island settlements, as well as certain payments under Cherokee Nation settlement and Native American term sheet. During the nine months ended March 31, 2022, we paid $348&#160;million in connection with these matters. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, we and two other national distributors reached an agreement with the Washington Attorney General, under which we will pay up to approximately $160&#160;million to the State of Washington and its participating subdivisions to resolve opioid-related claims. This amount is consistent with the amount that would have been allocated to Washington under the Settlement Agreement, had Washington agreed to participate, plus certain attorneys' fees and costs. The terms of this agreement in principle are substantially consistent with the Settlement Agreement. This agreement is subject to certain contingencies, including the rate of subdivision participation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;West Virginia subdivisions and Native American tribes were not a part of the broader settlement process and we have been involved in separate negotiations with these groups. In September 2021 we announced that we, along with two other national distributors, had reached an agreement with the Cherokee Nation in connection with ongoing negotiations toward a broader agreement with Native American tribes. In January 2022, we, along with two other &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;national distributors, entered into a term sheet with the Native American tribes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The first phase of a bench trial in West Virginia State Court for a consolidated case brought by 63 West Virginia subdivisions against the Company and two other national distributors is scheduled to begin July 5, 2022. A bench trial before a federal judge in West Virginia brought by Cabell County and City of Huntington against us and two other national distributors concluded in July 2021. The judge has not yet issued a decision. Trials are inherently unpredictable and it is possible that the outcome of these trials could materially negatively impact our financial results, cash flows or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Settlement Agreement did not resolve all opioid lawsuits and claims brought by states and political subdivisions. The Attorney General of Oklahoma filed a lawsuit against us in January 2020, and did not agree to join the Settlement Agreement. As of April 28, 2022, we are still defendants in approximately 700 lawsuits brought by counties, municipalities and other political subdivisions; however, we expect this number to decline as additional cases are dismissed as a result of the Settlement Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In total, we have $6.70&#160;billion accrued at March&#160;31, 2022, of which $738&#160;million is included in other accrued liabilities and the remainder is included in deferred income taxes and other liabilities in our condensed consolidated balance sheets. During the nine months ended March 31, 2021, we recorded total pre-tax charges of $1.02&#160;billion in litigation (recoveries)/charges, net in our condensed consolidated statements of earnings/(loss). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual, whether as a result of settlement discussions, a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters. We continue to strongly dispute the allegations made in these lawsuits none of these agreements is an admission of liability or wrongdoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Department of Justice Investigations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). We have also received civil requests for information from other DOJ offices. We believe that these investigations concern operation of our anti-diversion program, our anti-diversion policies and procedures, and distribution of certain controlled substances. We are cooperating with these investigations. We are unable to predict the outcome of any of these investigations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Private Plaintiffs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Settlement Agreement does not address claims by private parties, which includes unions and other health and welfare funds, &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;hospital systems and other healthcare providers, businesses and individuals alleging personal injury. Private parties had brought approximately 453 lawsuits as of May 4, 2022. Of these, 141 are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A trial in a case involving 21 plaintiffs is scheduled to begin in state court in Georgia in July 2022. We are vigorously defending ourselves in all of these matters; however, trials are inherently unpredictable and it is possible that an unfavorable outcome in these matters, individually or in the aggregate, could have a negative impact on our financial results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Insurance Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are involved in legal proceedings with two insurers related to the availability of insurance coverage for the lawsuits described above. In October 2020, we filed a complaint for declaratory judgment against National Union Fire Insurance Company of Pittsburgh, PA (&#x201c;National Union&#x201d;) seeking a declaration that National Union is obligated to reimburse us for defense costs incurred in connection with the lawsuits described above. In January 2021, Swiss Re International SE commenced an arbitration in London seeking a determination that it does not have an obligation to reimburse us for defense and indemnity expenses incurred in connection with the lawsuits described above. We have not recorded a receivable for any recoveries related to these insurance litigation matters as of&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cordis IVC Filter Matters &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Liability Lawsuits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of April 29, 2022, we are named as a defendant in 457 product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately 5,872 plaintiffs that allege personal injuries associated with the use of Cordis OptEase and TrapEase inferior vena cava ("IVC") filter products. Another 26 lawsuits involving similar claims by approximately 30 plaintiffs are pending in other jurisdictions. These lawsuits seek a variety of remedies, including unspecified monetary damages. In July 2021, we entered into an agreement to settle approximately 1,300 claims. We continue to vigorously defend ourselves in these lawsuits and are engaged in ongoing resolution discussions with certain plaintiffs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2022, we had a total of $494&#160;million net of estimated insurance recoveries, accrued for losses and legal defense costs, related to the Cordis IVC filter lawsuits in our condensed consolidated balance sheets. We believe there is a range of estimated losses with respect to these matters. Because no amount within the range is a better estimate than any other amount within the range, we have accrued the minimum amount in the range. We estimate the high end of the range to be approximately $1.05&#160;billion, net of estimated insurance recoveries. The sale of the Cordis disposal group does not include product liability related to the IVC filters in the U.S. and Canada, which we retained.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;New Mexico Attorney General Action &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, the Attorney General for the State of New Mexico filed an action against certain IVC filter manufacturers, including us, alleging claims under New Mexico's Unfair Practices Act, Medicaid Fraud Act and Fraud Against Taxpayers Act. The allegations made are similar to those made in the product liability lawsuits, described above. We intend to vigorously defend ourselves against these claims.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;SEC Investigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, we received a subpoena from the U.S. Securities and Exchange Commission ("SEC") requesting the production of documents from 2015 through 2019 relating to inventory in the Cordis business, analysis of goodwill of the Medical segment and other matters. In March 2022, the SEC informed us that it had concluded its investigation and did not intend to recommend an enforcement action. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shareholder Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, the Louisiana Sheriffs' Pension &amp;amp; Relief Fund filed a purported class action complaint against Cardinal Health and certain current and former officers and employees in the United States District Court for the Southern District of Ohio purportedly on behalf of all purchasers of our common shares between March 2015 and May 2018. In June 2020, the court appointed 1199 SEIU Health Care Employees Pension Fund as lead plaintiff and a consolidated amended complaint was filed in September 2020. The amended complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 by making misrepresentations and omissions related to the acquisition and integration of the Cordis business and inventory and supply chain problems within the Cordis business, and seeks to recover unspecified damages and equitable relief for the alleged misstatements and omissions. The complaint also alleges that one of the individual defendants violated Section 20A of the Exchange Act because he sold shares of Cardinal Health stock during the time period. In September 2021, the court denied our motion to dismiss. We are vigorously defending ourselves against these claims. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Specialty Solutions DOJ Investigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, the United States Attorney&#x2019;s Office for the District of Massachusetts (the "USAO") commenced an investigation of Cardinal Health regarding possible violations of the U.S. healthcare fraud and abuse laws. The USAO sought, among other things, documents and information relating to discounts and rebates offered or provided to certain Specialty Solutions customers. In January 2022, without admitting liability, we settled this matter with the DOJ for approximately $13 million, which was recorded as expense within litigation (recoveries)/charges net in our consolidated statement of earnings/(loss) during the fiscal year ended June 30, 2021. Additionally, our Specialty Pharmaceutical Distribution business entered into a five-year corporate integrity agreement with the Department of Health and Human Services, Office of Inspector General, under which it agreed to certain remedial measures, including no longer offering term-based up-front discounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Civil Litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Generic Pharmaceutical Pricing Antitrust Litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and improperly engaged in customer allocation. We have filed a motion to dismiss the complaints and we intend to vigorously defend ourselves. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Active Pharmaceutical Ingredient Impurity Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Many participants in the pharmaceutical supply chain, including active pharmaceutical ingredient ("API") manufacturers, finished dose manufacturers, repackagers, distributors, and retailers have been named as defendants in lawsuits arising out of recalls of certain medications due to alleged impurities in the active pharmaceutical ingredients or finished product. &lt;/span&gt;&lt;/div&gt;In February 2019, a Multidistrict Litigation was created in the U.S. District Court for the District of New Jersey (the &#x201c;Sartan MDL&#x201d;) alleging API impurities in certain generic blood pressure medications. We have been named as a defendant in the Sartan MDL. We are vigorously defending ourselves in this matter.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LongtermPurchaseCommitmentPeriod
      contextRef="i0ab6a9c65c7e4470950a3a5d6dc31d86_D20140731-20140731"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzI1NA_9ed2ee31-dfbd-49ac-8095-fc019d76bc0b">P10Y</us-gaap:LongtermPurchaseCommitmentPeriod>
    <cah:AggregateAnnualAssessment
      contextRef="i23ebd145540743d0ab7dda2a643e03b3_I20180430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzcwOQ_e0a8744c-a4cb-4788-b3bf-e79ecf8c2a80"
      unitRef="usd">100000000</cah:AggregateAnnualAssessment>
    <cah:EstimatedLiabilityForNewYorkOpioidStewardshipAct
      contextRef="i5255724c8ed4493ca93e7bf150c7f600_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzE5MzY_95606654-26e1-471c-9464-54da04c6d3f7"
      unitRef="usd">41000000</cah:EstimatedLiabilityForNewYorkOpioidStewardshipAct>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="i5ee03b4ae5f340a187f4bc77f729452b_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzIxMjU_9c534a15-bbab-44d7-abc0-27e1648e92d8"
      unitRef="usd">20000000</us-gaap:LossContingencyAccrualPayments>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i491c71d0bbb64a989ca7c5c82a284488_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzIyNDI_ee579d95-e86c-4b3a-b461-477f1457cbcc"
      unitRef="usd">20000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <cah:JudgmentForLostProfits
      contextRef="i9215c78d739b4b399eaa5fb71927062e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzU5MzM_d231b28d-ffe5-451b-966b-a98e78bf5dca"
      unitRef="usd">16000000</cah:JudgmentForLostProfits>
    <cah:LossContingencyLawsuitsNumber
      contextRef="i882c87a069664d07be3f57a3c4880673_I20220228"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzYxNjM_6dfc12d5-ed30-4175-ba40-90d3b41de5a6"
      unitRef="lawsuit">3400</cah:LossContingencyLawsuitsNumber>
    <cah:LossContingencyLawsuitsNumber
      contextRef="ib8066d95edcd4276b92e5941e9cf1675_I20220428"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzY3MjY_77b34ea9-4830-4e03-9c9d-5db382200915"
      unitRef="lawsuit">2700</cah:LossContingencyLawsuitsNumber>
    <cah:NumberofStateAttorneysGeneralfilinglawsuits
      contextRef="i3f3f37b2e6a246ca91a14261f83072a8_I20220428"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzcxMzQ_b2155dee-bc34-49dc-852b-70523c14d818"
      unitRef="stateag">25</cah:NumberofStateAttorneysGeneralfilinglawsuits>
    <cah:SettlingStates
      contextRef="i56ecddadc331422e91dd1962e9bd826a_I20220428"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzMyOTg1MzQ5MjE5NDA_97ca6e15-0936-4058-ae55-d46cdc387f91"
      unitRef="states">46</cah:SettlingStates>
    <cah:SettlingUSTerritories
      contextRef="i56ecddadc331422e91dd1962e9bd826a_I20220428"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzMyOTg1MzQ5MjE5NDE_c4b9fd20-9ee7-448f-839f-45c47a4534f4"
      unitRef="numberofusterritories">5</cah:SettlingUSTerritories>
    <cah:LossContingencyClaimsSettledPercent
      contextRef="i8d6bdce912f94701b4d5c146cec19721_D20220428-20220428"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzMyOTg1MzQ5MjQ5OTk_afa36aac-163b-46e0-84c2-ca2dc5887b92"
      unitRef="number">0.98</cah:LossContingencyClaimsSettledPercent>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i66875ebb8eef4db4b014c5f748452b43_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzMyOTg1MzQ5MjE5NjU_34940a89-27b7-4ec4-8a82-88d1f097d3dc"
      unitRef="usd">6000000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyClaimsSettledNumber
      contextRef="ic882bf829b3c4091beef8438bdf4b296_D20220428-20220428"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzMyOTg1MzQ5MjE5NDM_b8cc1bbf-9bcb-4d1f-b769-ff57399f3ece"
      unitRef="lawsuit">2000</us-gaap:LossContingencyClaimsSettledNumber>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="i0247bbb36fd244a09bc9d98fe2b16dcb_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzMyOTg1MzQ5MjIyMTY_d76d65d4-3e9e-4b65-90fe-8a6ebce93e8b"
      unitRef="usd">348000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i4ff29a3a90e442dd8c5616657406a603_I20220502"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzMyOTg1MzQ5MjE5NTA_69ee2d04-6399-4a44-9899-d63d131f2094"
      unitRef="usd">160000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i0bc140f1011640a682a782f1cae16cad_D20220428-20220428"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzMyOTg1MzQ5MjUwMDc_20b8770d-46c7-48a1-912f-5a8771306bd2"
      unitRef="plaintiff">63</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ib8066d95edcd4276b92e5941e9cf1675_I20220428"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzMyOTg1MzQ5MjE5Nzg_3d75a19a-4f68-4dbb-8f3e-d316c2dae094"
      unitRef="lawsuit">700</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LitigationReserve
      contextRef="i66875ebb8eef4db4b014c5f748452b43_I20220331"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzE4MTQxOTQxODkzMDM3_0a475714-64fa-45cf-b1df-2ebf9d7fb753"
      unitRef="usd">6700000000</us-gaap:LitigationReserve>
    <us-gaap:LitigationReserveCurrent
      contextRef="i66875ebb8eef4db4b014c5f748452b43_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzE4MTQxOTQxODkzMDY4_41f1cef0-f392-43c6-b835-e1da61e1593e"
      unitRef="usd">738000000</us-gaap:LitigationReserveCurrent>
    <us-gaap:LitigationSettlementExpense
      contextRef="i7cfeb36a6e0d45f8aa734c1879638433_D20200701-20210331"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzE4MTQxOTQxODkzMzE5_a3f7e46d-9941-4c9b-9a80-f9745ce1b3c5"
      unitRef="usd">1020000000.00</us-gaap:LitigationSettlementExpense>
    <cah:LossContingencyLawsuitsNumber
      contextRef="ifc7fdc5fa1c84d5aa2af19ed52614364_I20220504"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzE1MjAx_dfcfb3dc-b884-4cc8-9566-4e098861ecad"
      unitRef="lawsuit">453</cah:LossContingencyLawsuitsNumber>
    <cah:LossContingencyLawsuitsNumber
      contextRef="i5118cc3369704619a0d6f9362d7b4be6_I20220504"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzE1MjQ3_e9549b11-0350-4250-bc23-5c2644c8a98a"
      unitRef="lawsuit">141</cah:LossContingencyLawsuitsNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i9ba9d001296a4abc99e1e8dbda30b7a3_D20220428-20220428"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzE1NDEw_925b5cda-744b-4a8b-b6cd-6bfbaf4fb8b1"
      unitRef="plaintiff">21</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="icbd0825dbe564a209ad97999fd39b901_D20220429-20220429"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzE2NjY3_9f42f656-c31c-4c31-af1b-ee820d84a9ca"
      unitRef="lawsuit">457</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i967e05473aad4bdab16324a714471629_D20220429-20220429"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzE2Nzkw_0ee76c62-3aa3-40df-b2fb-cffa59100be6"
      unitRef="plaintiff">5872</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i9dfeb8260c1c4f43b4a0668f4c5957f8_D20220429-20220429"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzE2OTQx_77ab065c-5845-414d-809d-1422e1aa92ed"
      unitRef="lawsuit">26</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="ia501b89dcc1041d69e1b5309d5f9f944_D20220429-20220429"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzE2OTk1_4638e099-9095-4691-9c76-dedc902dd49c"
      unitRef="plaintiff">30</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyClaimsSettledNumber
      contextRef="i989aea95b6504bd0b4aa8ccb22169319_D20210731-20210731"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzE3MTk1_2e706ee1-6a9f-48bd-a642-dd109b2c66fd"
      unitRef="lawsuit">1300</us-gaap:LossContingencyClaimsSettledNumber>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="ic2ae902498a44131a91a5bebbbda2131_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzE3NDE5_da01f7a2-d510-4f84-87f6-3ad5a5e83ec7"
      unitRef="usd">494000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i9e7f4d19047348f89f56bfebceea170d_I20220331"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzE3ODc1_a367b38f-6c4e-427d-9dfb-aaa521a0f62e"
      unitRef="usd">1050000000.00</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="ie60f8b5fae944fc6a15c2435abf6b955_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDMvZnJhZzphMTkxMjE2ZjIzMjA0Y2U4YmMyMDFlYmE5MWMwYTIxOS90ZXh0cmVnaW9uOmExOTEyMTZmMjMyMDRjZThiYzIwMWViYTkxYzBhMjE5XzIwNzMx_65cfd2e7-eb20-4c50-98d8-10e97d31da9a"
      unitRef="usd">-13000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzg3NTg_abfec452-f7f9-406f-a448-8c746b625c74">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;7. Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fluctuations in our benefit from income taxes as a percentage of pretax earnings/(loss) (&#x201c;effective tax rate&#x201d;) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Effective Tax Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended&#160;March&#160;31, 2022, the effective tax rate was&#160;(916.5) percent and&#160;(44.4) percent, &lt;/span&gt;&lt;/div&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;respectively, and reflects the impact of the tax effect of the year-to-date goodwill impairment charges recognized during the nine months ended March&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended&#160;March&#160;31, 2021, the effective tax rate was 72.8 percent and (143.3) percent, respectively, and included the impact related to the treatment of the tax effect of opioid litigation charges, the resolution of certain transfer pricing matters with the U.S. Internal Revenue Service ("IRS") and withholding taxes for planned distributions from foreign subsidiaries. During the nine months ended&#160;March&#160;31, 2021, the effective tax rate included the benefit from a net operating loss carryback primarily related to a self-insurance pre-tax loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Tax Effects of Goodwill Impairment Charge&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended March&#160;31, 2022, we recognized year-to-date pre-tax charges of $1.8&#160;billion for goodwill impairments related to the Medical Unit. The net tax benefit related to these charges is $126&#160;million for fiscal 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings/(loss) before income taxes for the year-to-date period to compute our benefit from income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax effect of the goodwill impairment charges during the nine months ended March 31, 2022 was included in our estimated annual effective tax rate because it was not considered unusual or infrequent, given that we recorded goodwill impairment in prior fiscal years. The impact of the non-deductible goodwill significantly decreased the estimated annual effective tax rate for fiscal 2022. Applying the lower tax rate to the year-to-date loss resulted in recognizing an interim tax expense of approximately $1.2&#160;billion, which impacted the provision for income taxes in the condensed consolidated statements of earnings/(loss) during the three and nine months ended March&#160;31, 2022 and prepaid expenses and other assets in the condensed consolidated balance sheet at March&#160;31, 2022. Approximately $180&#160;million of this interim tax expense will reverse in the fourth quarter of fiscal 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cordis Divestiture&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended March&#160;31, 2022, we completed the divestiture of the Cordis business. In connection with the closing, we recorded net tax expense of $9&#160;million and $29&#160;million during the three and nine months ended March&#160;31, 2022, respectively. The tax effects of these matters during the nine months ended March 31, 2022 were included in our full year effective tax rate forecast. We currently estimate the tax expense associated with this matter for the full fiscal 2022 will be $38&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Tax Effects of Self-Insurance Pre-tax Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended March&#160;31, 2021, our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;fiscal 2020 statutory financial statements primarily related to opioid litigation. This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes. The net operating loss was carried back and applied to adjust our taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security ("CARES") Act enacted by the United States Congress in March 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accordingly, our provision for income taxes during the nine months ended March&#160;31, 2021 included a $419&#160;million benefit from the net operating loss carryback primarily to reflect the difference between the federal statutory income tax rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In fiscal 2021, we filed for a refund of $974&#160;million, which we expect to receive within 12 months. Accordingly, we had a current asset for this amounts on our condensed consolidated balance sheets at both March 31, 2022  and June 30, 2021. In April 2022, we received a payment for $966&#160;million, which is net of certain adjustments. We also increased our non-current deferred tax liability by approximately $700&#160;million during the nine months ended March&#160;31, 2021 related to this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of tax law; however, it is possible that the tax authorities could challenge these tax benefits. The actual amount of the tax benefit may differ materially from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Tax Effects of Opioid Litigation Charges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the $1.02&#160;billion pre-tax charges for the opioid litigation recorded during the nine months ended March&#160;31, 2021, the net tax benefits were approximately $180 million for the nine months ended March&#160;31, 2021 and $228 million for fiscal 2021. Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $35 million during the nine months ended March&#160;31, 2021, and $219 million for fiscal 2021. We have recognized no tax benefit associated with Opioid accruals made in fiscal 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the U.S. Tax Cuts and Jobs Act ("Tax Act"); however, these estimates require significant judgment since the U.S. tax law governing deductibility was changed by the Tax Act. Further, it is possible Congress or the tax authorities could challenge our interpretation of the Tax Act or the estimates and assumptions used to assess the future deductibility of these benefits. The actual amount of the tax benefit may differ materially from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Unrecognized Tax Benefits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had $938 million and $932 million of unrecognized tax benefits, at March&#160;31, 2022 and June&#160;30, 2021 respectively. The March&#160;31, 2022 and June&#160;30, 2021 balances include $856 million and $849 million of unrecognized tax benefits, respectively, that if recognized, would have an impact on the effective tax rate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2022 and June&#160;30, 2021, we had $46 million and $49 million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for/(benefit from) income taxes in the condensed consolidated statements of earnings/(loss). These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the IRS or other taxing authorities, possible settlement of IRS and other audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between zero and a net decrease of up to $5 million, exclusive of penalties and interest.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Tax Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions, and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expiring or unusable loss and credit carryforwards and the required valuation allowances are adjusted quarterly based on available information. This information may support either an increase or a decrease in the required valuation allowance. After applying the valuation allowances, we do not anticipate any limitations on our use of any of the other net deferred income tax assets described above. We operate in a complex multinational tax environment and are subject to tax treaty arrangements and transfer pricing guidelines for intercompany transactions that are subject to interpretation. Uncertainty in a tax position may arise as tax laws are subject to interpretation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), a subsidiary of Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $73 million at March&#160;31, 2022 and $72&#160;million at June&#160;30, 2021, and is included in other assets in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;As a result of the acquisition of the Patient Recovery Business, Medtronic plc is obligated to indemnify us for certain tax exposures and transaction taxes related to periods prior to the acquisition under the purchase agreement. The indemnification receivable was zero at March&#160;31, 2022 and $12&#160;million at June&#160;30, 2021, respectively, and is included in other assets in the condensed consolidated balance sheets.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzMyOTg1MzQ5MTY3OTE_27fd1242-5c09-42d4-8c6a-f486e831cc4f"
      unitRef="number">-9.165</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzMyOTg1MzQ5MTg4ODc_c1fd9c1e-d79c-4c85-bc1a-28bcf64af988"
      unitRef="number">-0.444</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzMyOTg1MzQ5MTkwOTk_042b08ae-1fc5-4f42-b2ee-f10c32942465"
      unitRef="number">0.728</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzMyOTg1MzQ5MTczNDk_b7982b2e-59e3-459e-9b3b-41db72983a48"
      unitRef="number">-1.433</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i579fe90cd44b45029f6ce1e6fd52d06e_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzMyOTg1MzQ5MjA1MDU_763bb6ac-9d1d-427a-afce-ec39ac0de8bb"
      unitRef="usd">1800000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7a1ee29c629542f28c59d5fc1aa744bc_D20210701-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzMyOTg1MzQ5MjAyNzM_28048dfa-68a1-4e6d-8ebd-a6190b155fc7"
      unitRef="usd">-126000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i733aa2f887dc40399537d2978ea4fed6_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzMyOTg1MzQ5MjAzMDE_f10660e7-eb4a-49d2-a8cf-f3daaa7ad9b6"
      unitRef="usd">1200000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia07b2306645b4f5b9983cc7a043e7f14_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzMyOTg1MzQ5MjAyODc_6a0a637a-bb4f-4297-970c-b8f1c7764486"
      unitRef="usd">-180000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation
      contextRef="if20d9caabe284cddb92eb75707c2d485_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzIwMjg_b6d01f49-6d87-4ffd-9f32-6caae84671bd"
      unitRef="usd">9000000</us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation
      contextRef="i32f5ee07df944be68a4ca171d08f3c89_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzE0ODQzNDA2OTg1ODkx_3b26dd24-57f7-4cda-a667-cc274bc0a5ea"
      unitRef="usd">29000000</us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation
      contextRef="i55ae6d66a0154f618e5ff8b55c474990_D20210701-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzMyOTg1MzQ5MjA0Mzk_3456aae0-f4bd-42c8-b58c-aa59e86732e0"
      unitRef="usd">38000000</us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8498a443311b4f6ea73d7b6ae59ff884_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzMxNTQ_11b346b8-8136-43b0-b334-44ff3d983abc"
      unitRef="usd">-419000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxReceivable
      contextRef="i7b95fd8ae52348c2a406851e857bf380_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzE1MzkzMTYyNzk4NDY0_e115854f-d3a7-40b2-b4ff-00782deb9b59"
      unitRef="usd">974000000</us-gaap:IncomeTaxReceivable>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="i4a43d062c10d4b5dbe47ed5927846f46_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzMyOTg1MzQ5MjA0NTQ_35d7dbdd-6d17-47a3-8018-9c2008a0f62e"
      unitRef="usd">966000000</us-gaap:ProceedsFromIncomeTaxRefunds>
    <us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent
      contextRef="i08ae81a7c49448f6a2bf594f079b609d_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzM4MDM_2f50d8c6-80f4-43cf-83be-0d757fa56f10"
      unitRef="usd">700000000</us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent>
    <us-gaap:LitigationSettlementExpense
      contextRef="i7cfeb36a6e0d45f8aa734c1879638433_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzQyMTk_edd60dcc-f530-4718-a7b4-a3f66549c5f2"
      unitRef="usd">1020000000.00</us-gaap:LitigationSettlementExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7cfeb36a6e0d45f8aa734c1879638433_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzQzMzE_983cae9a-c436-447f-b47d-33107b1335e8"
      unitRef="usd">-180000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4c3e04c844a0448ba87bfb01fae49ef6_D20200701-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzQzNTI_b7b49c3b-0c4a-4364-989f-abb255618e4f"
      unitRef="usd">-228000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i6880faa0fa0e4239896a55f349c38f00_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzQ2MTk_08206bcb-e406-42a9-99d1-e28d1e37682b"
      unitRef="usd">35000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i469fd276126b4ef2a0a27b313a8c926f_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzQ2NDQ_ec67321f-bf5c-41ea-a10b-95581ce091dd"
      unitRef="usd">219000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0247bbb36fd244a09bc9d98fe2b16dcb_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzQ2ODM_ade3f799-a3a8-4a20-b183-6ca9c8535603"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzY0OTA_c3c61e95-6a4f-4b4e-b29e-b3325bba9fe2"
      unitRef="usd">938000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzY0OTc_2be0e674-5706-48d0-8989-328427251521"
      unitRef="usd">932000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzY1ODg_5ef1a189-18b8-43f6-bde7-51e36bafc40d"
      unitRef="usd">856000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzY1OTU_c84a43f3-92fd-49c4-95ac-af063e62c195"
      unitRef="usd">849000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzY3MzI_ac53703a-edb5-4dce-ae43-a07506d7c75c"
      unitRef="usd">46000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzY3Mzk_68b9bbae-11e2-433e-b0af-b45941403445"
      unitRef="usd">49000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="i34b741e645b547cba1a09aef122491a7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzc2MTU_13b92bcf-0963-4c3d-a6a6-7004ac761e0d"
      unitRef="usd">0</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="i19311f0a545a45fabf7564bb3e12fa8f_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzc2NDY_056cc14f-6b69-41e6-abf8-24196e072c94"
      unitRef="usd">5000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <cah:IndemnificationReceivable
      contextRef="i97ee2fe5350d48a8a6d2429ec7ce8ba3_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzgyNzQ_b31d66f7-704f-4ddb-ae7e-0b55ae3dd6df"
      unitRef="usd">73000000</cah:IndemnificationReceivable>
    <cah:IndemnificationReceivable
      contextRef="i97c5d03ddc3b4285af82f4a8cdd73077_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzMyOTg1MzQ5MjA0Njg_cc8b9bd4-33cd-4da0-bb89-89d2bf7ca03f"
      unitRef="usd">72000000</cah:IndemnificationReceivable>
    <cah:IndemnificationReceivable
      contextRef="ib619e74f426d4144819daac0dcea199d_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzMyOTg1MzQ5MjA0ODg_a1b81f33-01e4-4d2a-858f-8262a3b8abba"
      unitRef="usd">0</cah:IndemnificationReceivable>
    <cah:IndemnificationReceivable
      contextRef="iabd8bb008ac74a12a6602b75f99f57be_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDYvZnJhZzoyYWMyZTAxODdiYmY0NTFjYTc0MDVjMzFkNzZlZDQ1MS90ZXh0cmVnaW9uOjJhYzJlMDE4N2JiZjQ1MWNhNzQwNWMzMWQ3NmVkNDUxXzg2NTI_835ea7f6-7b50-4039-8c7e-86101c2feeb6"
      unitRef="usd">12000000</cah:IndemnificationReceivable>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90ZXh0cmVnaW9uOmFmNzhiYmNhOWQ2NTRjZjRhYTkyZGZmYWYyNDYwMTI5XzEyMTU_f74047b3-e58b-44e3-93d0-f37eb4d94797">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;8. Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;671&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;671&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;112&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;112&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contracts (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contracts (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90ZXh0cmVnaW9uOmFmNzhiYmNhOWQ2NTRjZjRhYTkyZGZmYWYyNDYwMTI5XzEyMjI_bed1497a-76d7-4c2d-ae9f-8c59aeda9b50">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;671&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;671&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;112&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;112&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contracts (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contracts (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7a166264477c46fab57fcf607e059c5e_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZTo1ZDI4MzY4MzExNTk0NGU0YTAxNjBkOTBjMTRjOTY4NS90YWJsZXJhbmdlOjVkMjgzNjgzMTE1OTQ0ZTRhMDE2MGQ5MGMxNGM5Njg1XzMtMS0xLTEtOTg2OTQ_5a6bc57f-7974-4edf-99de-f0c4d9966945"
      unitRef="usd">671000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3682e4eb8a05493a929d3c71c120ed44_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZTo1ZDI4MzY4MzExNTk0NGU0YTAxNjBkOTBjMTRjOTY4NS90YWJsZXJhbmdlOjVkMjgzNjgzMTE1OTQ0ZTRhMDE2MGQ5MGMxNGM5Njg1XzMtMy0xLTEtOTg2OTQ_c336dac7-c8d7-4af6-abcb-bbab21116289"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic39a5057fc6f46779de6e92cbbdcda7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZTo1ZDI4MzY4MzExNTk0NGU0YTAxNjBkOTBjMTRjOTY4NS90YWJsZXJhbmdlOjVkMjgzNjgzMTE1OTQ0ZTRhMDE2MGQ5MGMxNGM5Njg1XzMtNS0xLTEtOTg2OTQ_57755524-a029-4fbf-8a3f-c0a1cac5984a"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="icac6fea690094cec98b24894f11a9dc5_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZTo1ZDI4MzY4MzExNTk0NGU0YTAxNjBkOTBjMTRjOTY4NS90YWJsZXJhbmdlOjVkMjgzNjgzMTE1OTQ0ZTRhMDE2MGQ5MGMxNGM5Njg1XzMtNy0xLTEtOTg2OTQ_8729ff9e-7506-4131-a43d-b9367a2a2022"
      unitRef="usd">671000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i7a166264477c46fab57fcf607e059c5e_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZTo1ZDI4MzY4MzExNTk0NGU0YTAxNjBkOTBjMTRjOTY4NS90YWJsZXJhbmdlOjVkMjgzNjgzMTE1OTQ0ZTRhMDE2MGQ5MGMxNGM5Njg1XzUtMS0xLTEtOTg2OTQ_45247b22-25d4-4345-b823-16dfc619bda9"
      unitRef="usd">112000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i3682e4eb8a05493a929d3c71c120ed44_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZTo1ZDI4MzY4MzExNTk0NGU0YTAxNjBkOTBjMTRjOTY4NS90YWJsZXJhbmdlOjVkMjgzNjgzMTE1OTQ0ZTRhMDE2MGQ5MGMxNGM5Njg1XzUtMy0xLTEtOTg2OTQ_9d506670-f399-42f8-9ea0-243bb3eca78c"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ic39a5057fc6f46779de6e92cbbdcda7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZTo1ZDI4MzY4MzExNTk0NGU0YTAxNjBkOTBjMTRjOTY4NS90YWJsZXJhbmdlOjVkMjgzNjgzMTE1OTQ0ZTRhMDE2MGQ5MGMxNGM5Njg1XzUtNS0xLTEtOTg2OTQ_3d063113-7483-4cd8-88c7-1b82573fa947"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="icac6fea690094cec98b24894f11a9dc5_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZTo1ZDI4MzY4MzExNTk0NGU0YTAxNjBkOTBjMTRjOTY4NS90YWJsZXJhbmdlOjVkMjgzNjgzMTE1OTQ0ZTRhMDE2MGQ5MGMxNGM5Njg1XzUtNy0xLTEtOTg2OTQ_44449764-84b0-449a-a095-586dc67f3b86"
      unitRef="usd">112000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="i7a166264477c46fab57fcf607e059c5e_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZTo1ZDI4MzY4MzExNTk0NGU0YTAxNjBkOTBjMTRjOTY4NS90YWJsZXJhbmdlOjVkMjgzNjgzMTE1OTQ0ZTRhMDE2MGQ5MGMxNGM5Njg1XzgtMS0xLTEtMTM4OTMx_5d4ae2fd-818b-4cac-b789-f2d0086a9d97"
      unitRef="usd">0</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="i3682e4eb8a05493a929d3c71c120ed44_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZTo1ZDI4MzY4MzExNTk0NGU0YTAxNjBkOTBjMTRjOTY4NS90YWJsZXJhbmdlOjVkMjgzNjgzMTE1OTQ0ZTRhMDE2MGQ5MGMxNGM5Njg1XzgtMy0xLTEtMTM4OTM0_5565fd4c-801a-4ba5-81fc-fa8389d297e1"
      unitRef="usd">-12000000</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="ic39a5057fc6f46779de6e92cbbdcda7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZTo1ZDI4MzY4MzExNTk0NGU0YTAxNjBkOTBjMTRjOTY4NS90YWJsZXJhbmdlOjVkMjgzNjgzMTE1OTQ0ZTRhMDE2MGQ5MGMxNGM5Njg1XzgtNS0xLTEtMTM4OTM3_df8a4f14-107b-4412-a8d6-1f2edfb7d96e"
      unitRef="usd">0</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="icac6fea690094cec98b24894f11a9dc5_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZTo1ZDI4MzY4MzExNTk0NGU0YTAxNjBkOTBjMTRjOTY4NS90YWJsZXJhbmdlOjVkMjgzNjgzMTE1OTQ0ZTRhMDE2MGQ5MGMxNGM5Njg1XzgtNy0xLTEtMTM4OTQw_7b3bdcc2-b68c-4290-8087-0d1f3862e9ee"
      unitRef="usd">-12000000</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia6a713b79a1b4db391a01b08a7955833_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZToyYzMwNWU2ZWUyMDc0YTM2YWY3YjljNThhMjM5YTE1Ni90YWJsZXJhbmdlOjJjMzA1ZTZlZTIwNzRhMzZhZjdiOWM1OGEyMzlhMTU2XzMtMS0xLTEtOTg2OTQ_07a3b8a3-9489-4b62-aeeb-2d503f9e797d"
      unitRef="usd">1883000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8dd0cc9f485540cfba812a2f569e0eec_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZToyYzMwNWU2ZWUyMDc0YTM2YWY3YjljNThhMjM5YTE1Ni90YWJsZXJhbmdlOjJjMzA1ZTZlZTIwNzRhMzZhZjdiOWM1OGEyMzlhMTU2XzMtMy0xLTEtOTg2OTQ_a09fbbfe-8d51-4daa-8d61-3c703c02c293"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if6b241993ad04feca1177de9a32b41d8_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZToyYzMwNWU2ZWUyMDc0YTM2YWY3YjljNThhMjM5YTE1Ni90YWJsZXJhbmdlOjJjMzA1ZTZlZTIwNzRhMzZhZjdiOWM1OGEyMzlhMTU2XzMtNS0xLTEtOTg2OTQ_25dee99e-6e56-4d8c-9bd1-f2edc4c58865"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic8196f6a78b04b869ddf71567a35ba1e_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZToyYzMwNWU2ZWUyMDc0YTM2YWY3YjljNThhMjM5YTE1Ni90YWJsZXJhbmdlOjJjMzA1ZTZlZTIwNzRhMzZhZjdiOWM1OGEyMzlhMTU2XzMtNy0xLTEtOTg2OTQ_8e6b1801-17b3-4829-8da9-5fc0b65b36fa"
      unitRef="usd">1883000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ia6a713b79a1b4db391a01b08a7955833_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZToyYzMwNWU2ZWUyMDc0YTM2YWY3YjljNThhMjM5YTE1Ni90YWJsZXJhbmdlOjJjMzA1ZTZlZTIwNzRhMzZhZjdiOWM1OGEyMzlhMTU2XzUtMS0xLTEtOTg2OTQ_29ce876b-18ae-4ee5-bf13-e4d246b178a7"
      unitRef="usd">126000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i8dd0cc9f485540cfba812a2f569e0eec_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZToyYzMwNWU2ZWUyMDc0YTM2YWY3YjljNThhMjM5YTE1Ni90YWJsZXJhbmdlOjJjMzA1ZTZlZTIwNzRhMzZhZjdiOWM1OGEyMzlhMTU2XzUtMy0xLTEtOTg2OTQ_ea75c283-6b99-411f-a594-a626454c6327"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="if6b241993ad04feca1177de9a32b41d8_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZToyYzMwNWU2ZWUyMDc0YTM2YWY3YjljNThhMjM5YTE1Ni90YWJsZXJhbmdlOjJjMzA1ZTZlZTIwNzRhMzZhZjdiOWM1OGEyMzlhMTU2XzUtNS0xLTEtOTg2OTQ_599e53a3-a27d-4d95-aca1-ee0ed1c1c21e"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ic8196f6a78b04b869ddf71567a35ba1e_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZToyYzMwNWU2ZWUyMDc0YTM2YWY3YjljNThhMjM5YTE1Ni90YWJsZXJhbmdlOjJjMzA1ZTZlZTIwNzRhMzZhZjdiOWM1OGEyMzlhMTU2XzUtNy0xLTEtOTg2OTQ_e94b23af-99ca-4093-88d8-a8fa98230a1f"
      unitRef="usd">126000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="ia6a713b79a1b4db391a01b08a7955833_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZToyYzMwNWU2ZWUyMDc0YTM2YWY3YjljNThhMjM5YTE1Ni90YWJsZXJhbmdlOjJjMzA1ZTZlZTIwNzRhMzZhZjdiOWM1OGEyMzlhMTU2XzYtMS0xLTEtOTg2OTQ_bfa7a210-9075-4f6d-8a83-3d60f64f01d9"
      unitRef="usd">0</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="i8dd0cc9f485540cfba812a2f569e0eec_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZToyYzMwNWU2ZWUyMDc0YTM2YWY3YjljNThhMjM5YTE1Ni90YWJsZXJhbmdlOjJjMzA1ZTZlZTIwNzRhMzZhZjdiOWM1OGEyMzlhMTU2XzYtMy0xLTEtOTg2OTQ_822afb06-66c9-4cbb-a4ae-62d8a6da689a"
      unitRef="usd">42000000</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="if6b241993ad04feca1177de9a32b41d8_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZToyYzMwNWU2ZWUyMDc0YTM2YWY3YjljNThhMjM5YTE1Ni90YWJsZXJhbmdlOjJjMzA1ZTZlZTIwNzRhMzZhZjdiOWM1OGEyMzlhMTU2XzYtNS0xLTEtOTg2OTQ_a4dcee88-4081-47ac-bfab-d850f4c18ff3"
      unitRef="usd">0</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="ic8196f6a78b04b869ddf71567a35ba1e_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMDkvZnJhZzphZjc4YmJjYTlkNjU0Y2Y0YWE5MmRmZmFmMjQ2MDEyOS90YWJsZToyYzMwNWU2ZWUyMDc0YTM2YWY3YjljNThhMjM5YTE1Ni90YWJsZXJhbmdlOjJjMzA1ZTZlZTIwNzRhMzZhZjdiOWM1OGEyMzlhMTU2XzYtNy0xLTEtOTg2OTQ_d177cdc3-a260-4640-a604-77c6cad73e57"
      unitRef="usd">42000000</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzc5MDY_b61595a5-6be4-4992-be29-aeeb0aa86aed">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;9. Financial Instruments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative &lt;/span&gt;&lt;/div&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Interest Rate Risk Management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities along with both fixed-rate and variable-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Currency Exchange Risk Management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Commodity Price Risk Management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Fair Value Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of earnings/(loss). For the three and nine months ended March&#160;31, 2022 and 2021, there was no gain or loss recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the nine months ended March 31, 2022, we entered into pay-floating interest rate swaps with notional amounts of $100 million and $200 million. These swaps have been designated as fair value hedges of our fixed rate debt and are included in &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;deferred income taxes and other liabilities in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Cash Flow Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pre-tax gains recognized in other comprehensive loss were $1&#160;million and $13&#160;million for the three months ended March&#160;31, 2022 and 2021, respectively, and $4&#160;million and $20&#160;million for the nine months ended March&#160;31, 2022 and 2021, respectively. Gains and losses recognized in accumulated other comprehensive loss and reclassified into earnings were immaterial for the three and nine months ended March&#160;31, 2022 and 2021. All gains and losses currently included within accumulated other comprehensive loss associated with our cash flow hedges to be reclassified into net earnings within the next 12 months are immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Net Investment Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended&#160;March&#160;31, 2022, we entered into a &#xa5;24 billion ($200 million) cross-currency swap maturing in September 2025 and a &#xa5;24&#160;billion ($200&#160;million) cross-currency swap maturing in June 2027.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended&#160;March&#160;31, 2022, we terminated the &#xa5;64 billion ($600 million) cross-currency swap entered into in August 2019 and received a net settlement of $71 million in cash recorded in proceeds from net investment hedge terminations in our condensed consolidated statements of cash flows. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pre-tax gain and loss from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive loss was a $22&#160;million gain and a $49&#160;million gain during the three months ended March&#160;31, 2022 and 2021, respectively, and a $44&#160;million gain and a $3&#160;million loss during the nine months ended March&#160;31, 2022 and 2021, respectively. Gains &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;recognized in interest expense, net in the condensed consolidated statements of earnings/(loss) for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were $5&#160;million during both the three months ended March&#160;31, 2022 and 2021 and $16&#160;million and $14&#160;million during the nine months ended March&#160;31, 2022 and 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Economic (Non-Designated) Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. We recorded a $4 million loss and a $1 million gain during the three months ended March 31, 2022 and 2021, respectively, and an immaterial loss and $4 million loss during the nine months ended March&#160;31, 2022 and 2021, respectively. The principal currencies managed through foreign currency contracts are Euro, Chinese renminbi, Canadian dollar.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of cash and equivalents, trade receivables, accounts payable, and other accrued liabilities at March&#160;31, 2022 and June&#160;30, 2021 approximate fair value due to their short-term maturities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,645&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,612&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.&lt;/span&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzMyNzM_2166a6d4-1d4f-4c11-990b-01c2ef8e3f6b"
      unitRef="usd">0</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzMyNzM_8557b0d3-fc96-41de-9c2a-1e3aee3a4579"
      unitRef="usd">0</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzMyNzM_a3e318fa-1484-4094-8503-2ffff8317b14"
      unitRef="usd">0</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzMyNzM_b0bc40f6-9b7a-43bc-992b-57240c074402"
      unitRef="usd">0</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="ied79b20d51d24a52ac6760b96c790928_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzM1MzA_98ad61f4-693a-45e3-ad65-8d61e0fab5ac"
      unitRef="usd">100000000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="id3ce5b3abcbd46bd97aab3629e9beed9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzM1Mzc_dad4f46b-1424-4f2e-91e6-cbdeba51fd4f"
      unitRef="usd">200000000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i3c0359ac173741d1a3e87605773843bb_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzQ0MDI_21c61452-9b83-45f4-89a2-2053e2d7b2c6"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i9364c217c27b48f7b6d55997d6363b7d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzQ0MDk_86aa8d61-dfae-4ce5-a0a5-1a0a4bbb9c81"
      unitRef="usd">13000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ia89d064616e44ff0bc7a6c819fa695aa_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzQ0NzA_22da46cd-f97e-4b5c-988f-aeeaadc9fe73"
      unitRef="usd">4000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ibb3a9b89882f4cad85e3415fe62bbe64_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzQ0Nzc_65f181e9-2765-4f6d-913a-ec90da0324c1"
      unitRef="usd">20000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="ic064a2bc08564367b783b55fd00e3a4c_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzcxNDY4MjU1ODg2MTA_ed84531b-84f5-4b79-aed4-727b84949cbb"
      unitRef="jpy">24000000000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="ic064a2bc08564367b783b55fd00e3a4c_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzcxNDY4MjU1ODg2MzE_a8c0eb08-e28b-4281-bad6-8d1c6cd38725"
      unitRef="usd">200000000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="id24201ce4b9a45b3984c1578539f4366_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzMyOTg1MzQ4OTIyNDU_470dc0e2-31bb-442c-8e48-29973e6bc681"
      unitRef="jpy">24000000000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="id24201ce4b9a45b3984c1578539f4366_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzMyOTg1MzQ4OTIyMTk_36d3864c-3e25-4f50-88a4-1d3495651dcc"
      unitRef="usd">200000000</us-gaap:DerivativeLiabilityNotionalAmount>
    <cah:DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount
      contextRef="i5481aab2ab274715b2e24d13110e9131_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzcxNDY4MjU1ODg5MzI_23a464ca-7ae1-4090-bb2d-84c7d178ec05"
      unitRef="jpy">64000000000</cah:DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount>
    <cah:DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount
      contextRef="i5481aab2ab274715b2e24d13110e9131_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzcxNDY4MjU1ODg5NDg_b8f4315b-41d0-4a28-bea4-1505629516cb"
      unitRef="usd">600000000</cah:DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount>
    <us-gaap:ProceedsFromHedgeInvestingActivities
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzcxNDY4MjU1ODkwODU_4286d028-1846-46c9-a8e2-0694cc29cba2"
      unitRef="usd">71000000</us-gaap:ProceedsFromHedgeInvestingActivities>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ia6a258e1b3d647dab58b5794f710d928_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzU3ODM_5d3c39d8-e08b-4dd1-bd05-b97a43390310"
      unitRef="usd">22000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i5c5d8170ec134e538d16a98b7645242a_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzU3OTc_ab3efc38-f266-4447-82a4-b53e12218fd0"
      unitRef="usd">-49000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ie780eda2dbfa43b5ba1886064e5bee88_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzU4NjY_664ee8b3-460c-4d0c-b757-6546b2fad0c5"
      unitRef="usd">44000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i8b561ae116c44487bc2d0b64415c487c_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzU4ODA_22810f98-77d3-441a-a15b-f4840de80079"
      unitRef="usd">-3000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ia6a258e1b3d647dab58b5794f710d928_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzIxOTkwMjMyNjM1MjE_c5b57aff-2d23-4b19-8b3a-0ab86c8e9f8a"
      unitRef="usd">5000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i5c5d8170ec134e538d16a98b7645242a_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzIxOTkwMjMyNjM1MjE_e36de2fb-73c4-4696-a3f7-3f00b596cb98"
      unitRef="usd">5000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ie780eda2dbfa43b5ba1886064e5bee88_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzYxNzY_7be7a33a-0f5a-4f8a-931f-20396f1a48d8"
      unitRef="usd">16000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i8b561ae116c44487bc2d0b64415c487c_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzYxODM_adf0db81-0fdc-4d93-9aed-f80fdd0b7a26"
      unitRef="usd">14000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="id3d6a7b343d84263bcfd5f6081c9080a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzcwMDQ_b5bc943c-7811-4af3-83cf-ef161fc0672a"
      unitRef="usd">-4000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i5f6a2249983a48ba948782ea8ac398ae_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzcwMTg_8addda90-88ba-41bb-ba48-d846096c8918"
      unitRef="usd">1000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="ida3f04fa5227480f833bb171bc91c08c_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzcwOTk_493642fb-c46d-4135-9470-7e211d4a6e18"
      unitRef="usd">-4000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90ZXh0cmVnaW9uOmY0MmE5YjE0NzI5MjQ0NDA4N2YzMTk1OTJiMDJiYTIwXzc5MTU_4bb0662f-ccca-4a3c-8736-8c40d1699b38">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,645&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,612&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i0faba6dab9bb45eba4532f90d44b6e37_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90YWJsZTo5YTliZTJmMDk0MDk0MDExODUxYWI0Mjk5MTFkMDA4Mi90YWJsZXJhbmdlOjlhOWJlMmYwOTQwOTQwMTE4NTFhYjQyOTkxMWQwMDgyXzEtMS0xLTEtOTg2OTQ_b4d1bbac-02ae-4e54-80d7-bd236ca7f490"
      unitRef="usd">5645000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="iddd5f86516724f048fca712cc799eb64_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90YWJsZTo5YTliZTJmMDk0MDk0MDExODUxYWI0Mjk5MTFkMDA4Mi90YWJsZXJhbmdlOjlhOWJlMmYwOTQwOTQwMTE4NTFhYjQyOTkxMWQwMDgyXzEtMy0xLTEtOTg2OTQ_40079c2b-70b3-461a-8f8c-ddc9ee8a0b3a"
      unitRef="usd">6751000000</us-gaap:DebtInstrumentFairValue>
    <cah:CarryingAmountofLongTermandotherShortTermBorrowings
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90YWJsZTo5YTliZTJmMDk0MDk0MDExODUxYWI0Mjk5MTFkMDA4Mi90YWJsZXJhbmdlOjlhOWJlMmYwOTQwOTQwMTE4NTFhYjQyOTkxMWQwMDgyXzItMS0xLTEtOTg2OTQ_83371a17-6407-4372-baff-ccccb0c36050"
      unitRef="usd">5612000000</cah:CarryingAmountofLongTermandotherShortTermBorrowings>
    <cah:CarryingAmountofLongTermandotherShortTermBorrowings
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTIvZnJhZzpmNDJhOWIxNDcyOTI0NDQwODdmMzE5NTkyYjAyYmEyMC90YWJsZTo5YTliZTJmMDk0MDk0MDExODUxYWI0Mjk5MTFkMDA4Mi90YWJsZXJhbmdlOjlhOWJlMmYwOTQwOTQwMTE4NTFhYjQyOTkxMWQwMDgyXzItMy0xLTEtOTg2OTQ_ed61e05c-e062-4ece-a3a9-5b1658fa9dd3"
      unitRef="usd">6236000000</cah:CarryingAmountofLongTermandotherShortTermBorrowings>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90ZXh0cmVnaW9uOmUzYmJiNmRhNjY3NTRhZTliNzFiNmRkYzU4Y2QwYjYwXzEyMTY_637e27ed-0794-4522-91ea-365f34f2445b">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;10. Shareholders' Equity/(Deficit)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We repurchased $1.0&#160;billion of our common shares, in the aggregate, through share repurchase programs during the nine months ended March&#160;31, 2022. We funded the repurchases with available cash. The common shares repurchased are held in treasury to be used for general corporate purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2022, we entered into an accelerated share repurchase ("ASR") program to repurchase common shares for an aggregate purchase price of $200 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We received an initial delivery of 3.0 million common shares using a reference price of $54.01. The program concluded on April 18, 2022 at a volume weighted average price per common share of $56.02 resulting in a final delivery of 0.6 million common shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended December 31, 2021, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $300&#160;million. We received an initial delivery of 4.8 million common shares using a reference price of $50.30. The program concluded on January 31, 2022 at a volume weighted average price per common share of $49.39 resulting in a final delivery of 1.3 million common shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September 30, 2021, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $500&#160;million. We received an initial delivery of 7.8 million common shares using a reference price of $51.53. The program concluded on October 4, 2021 at a volume weighted average price per common share of $51.10 resulting in a final delivery of 2.0 million common shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2021, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $200&#160;million. The program began on February 9, 2021 and concluded on March 31, 2021. The average price paid per common share was $54.40, resulting in a total delivery of 3.7 million common shares.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.050%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign&lt;br/&gt;Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized&lt;br/&gt;Gain/(Loss) on&lt;br/&gt;Derivatives,&lt;br/&gt;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated Other&lt;br/&gt;Comprehensive&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss, before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other comprehensive loss attributable to Cardinal Health, Inc. net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;16&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90ZXh0cmVnaW9uOmUzYmJiNmRhNjY3NTRhZTliNzFiNmRkYzU4Y2QwYjYwXzI0_3831f46b-75b8-4b65-a1ee-3c2dabca1049"
      unitRef="usd">1000000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i4a80329f29594c698d9ee74e1eaacbbe_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90ZXh0cmVnaW9uOmUzYmJiNmRhNjY3NTRhZTliNzFiNmRkYzU4Y2QwYjYwXzc2OTY1ODEzOTYxMDQ_491620b1-1c8a-4cd6-bca1-8635a37d6660"
      unitRef="usd">200000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i3bd39d7063da4c278767bc202d3ccfc3_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90ZXh0cmVnaW9uOmUzYmJiNmRhNjY3NTRhZTliNzFiNmRkYzU4Y2QwYjYwXzc2OTY1ODEzOTYxMDk_b60ce76f-c995-46ab-8e84-c2532dc8056b"
      unitRef="shares">3000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i3bd39d7063da4c278767bc202d3ccfc3_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90ZXh0cmVnaW9uOmUzYmJiNmRhNjY3NTRhZTliNzFiNmRkYzU4Y2QwYjYwXzc2OTY1ODEzOTYxMTQ_ffa1ff47-afaa-4f28-b5a0-97e6926b03fa"
      unitRef="usdPerShare">54.01</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i88bcf45d478a46e4b22b402f4b7f54c3_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90ZXh0cmVnaW9uOmUzYmJiNmRhNjY3NTRhZTliNzFiNmRkYzU4Y2QwYjYwXzc2OTY1ODEzOTYxNjU_05ee8c00-a37f-44f1-b1cd-d2b715cb8a1c"
      unitRef="usdPerShare">56.02</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i88bcf45d478a46e4b22b402f4b7f54c3_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90ZXh0cmVnaW9uOmUzYmJiNmRhNjY3NTRhZTliNzFiNmRkYzU4Y2QwYjYwXzc2OTY1ODEzOTYxNjk_e7f5a586-e334-4067-a9aa-34ade3f5ad82"
      unitRef="shares">600000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i79f0c6d48d9042059a71690df0625736_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90ZXh0cmVnaW9uOmUzYmJiNmRhNjY3NTRhZTliNzFiNmRkYzU4Y2QwYjYwXzQzNQ_64a9fece-fd6e-420f-91b2-8b4dc583125a"
      unitRef="usd">300000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="id0bcebad12fc4c40a4b459a431f9432e_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90ZXh0cmVnaW9uOmUzYmJiNmRhNjY3NTRhZTliNzFiNmRkYzU4Y2QwYjYwXzQ3NA_b1cf531b-f8bc-4212-ab03-44fa4f994195"
      unitRef="shares">4800000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="id0bcebad12fc4c40a4b459a431f9432e_D20211001-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90ZXh0cmVnaW9uOmUzYmJiNmRhNjY3NTRhZTliNzFiNmRkYzU4Y2QwYjYwXzUxOA_a7d816fb-c1e0-4e73-a781-d7c74b11c87d"
      unitRef="usdPerShare">50.30</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="idb40345a5fe44f68828da6e24128f448_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90ZXh0cmVnaW9uOmUzYmJiNmRhNjY3NTRhZTliNzFiNmRkYzU4Y2QwYjYwXzYwNQ_d303f17c-6e71-4a62-9522-cf6d9d5308f9"
      unitRef="usdPerShare">49.39</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="idb40345a5fe44f68828da6e24128f448_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90ZXh0cmVnaW9uOmUzYmJiNmRhNjY3NTRhZTliNzFiNmRkYzU4Y2QwYjYwXzY0MQ_19162380-0d76-414b-b32b-1d9379a729d0"
      unitRef="shares">1300000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ice6d3b2a080d44b5b66bace596c4726a_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90ZXh0cmVnaW9uOmUzYmJiNmRhNjY3NTRhZTliNzFiNmRkYzU4Y2QwYjYwXzgwMw_2aecc427-6ef6-40e8-a4d6-fda8c514ed76"
      unitRef="usd">500000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i493db659fb0e48c29fa86341836956fb_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90ZXh0cmVnaW9uOmUzYmJiNmRhNjY3NTRhZTliNzFiNmRkYzU4Y2QwYjYwXzg0Mg_49b94844-7ee9-441f-add8-9694ec9fe8d3"
      unitRef="shares">7800000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i493db659fb0e48c29fa86341836956fb_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90ZXh0cmVnaW9uOmUzYmJiNmRhNjY3NTRhZTliNzFiNmRkYzU4Y2QwYjYwXzg4Ng_75671f0a-824c-4bf3-b777-ad5cbb12f598"
      unitRef="usdPerShare">51.53</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="id7b83872d6a44abb948f2abd62a0d67d_D20211001-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90ZXh0cmVnaW9uOmUzYmJiNmRhNjY3NTRhZTliNzFiNmRkYzU4Y2QwYjYwXzk4Ng_1e8726ca-60b5-41bb-ab61-7e7b7a2a3e6f"
      unitRef="usdPerShare">51.10</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="id7b83872d6a44abb948f2abd62a0d67d_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90ZXh0cmVnaW9uOmUzYmJiNmRhNjY3NTRhZTliNzFiNmRkYzU4Y2QwYjYwXzEwMjI_6be65f9b-32e9-4e17-850e-e356f5ed3ed3"
      unitRef="shares">2000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90ZXh0cmVnaW9uOmUzYmJiNmRhNjY3NTRhZTliNzFiNmRkYzU4Y2QwYjYwXzEwNDQ1MzYwNDY5MzA3_ab749c49-3050-41ad-9f0c-fcd9c2eb219d"
      unitRef="usd">200000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i12146da7d33541d09f9ef291e388a502_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90ZXh0cmVnaW9uOmUzYmJiNmRhNjY3NTRhZTliNzFiNmRkYzU4Y2QwYjYwXzEwNDQ1MzYwNDY5MzIw_8b09ed22-0dc4-4bba-aa41-b7cd61b77b3a"
      unitRef="usdPerShare">54.40</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i12146da7d33541d09f9ef291e388a502_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90ZXh0cmVnaW9uOmUzYmJiNmRhNjY3NTRhZTliNzFiNmRkYzU4Y2QwYjYwXzEwNDQ1MzYwNDY5MzM0_8e484754-ab8a-4b38-b361-512f024a44a9"
      unitRef="shares">3700000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90ZXh0cmVnaW9uOmUzYmJiNmRhNjY3NTRhZTliNzFiNmRkYzU4Y2QwYjYwXzEyMTA_6629bc2f-16ac-4edc-a478-2d20658c706c">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.050%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign&lt;br/&gt;Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized&lt;br/&gt;Gain/(Loss) on&lt;br/&gt;Derivatives,&lt;br/&gt;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated Other&lt;br/&gt;Comprehensive&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss, before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other comprehensive loss attributable to Cardinal Health, Inc. net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;16&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1bc04df5c22d4ac594b0f37e4348fad8_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90YWJsZToyYWYzMGFkOWEwYTU0YjdmYjE3OGNlMDQ3MGU0MzFmOS90YWJsZXJhbmdlOjJhZjMwYWQ5YTBhNTRiN2ZiMTc4Y2UwNDcwZTQzMWY5XzEtMS0xLTEtOTg2OTQ_42638427-7673-45ae-be5c-f9ce4f162a00"
      unitRef="usd">-46000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if1d975e32208495384d3c3f118607978_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90YWJsZToyYWYzMGFkOWEwYTU0YjdmYjE3OGNlMDQ3MGU0MzFmOS90YWJsZXJhbmdlOjJhZjMwYWQ5YTBhNTRiN2ZiMTc4Y2UwNDcwZTQzMWY5XzEtMy0xLTEtOTg2OTQ_fa24d933-a4fc-40ed-9f3b-909c54a1e0aa"
      unitRef="usd">12000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib919fba7df9a4af5a962444ad795f36e_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90YWJsZToyYWYzMGFkOWEwYTU0YjdmYjE3OGNlMDQ3MGU0MzFmOS90YWJsZXJhbmdlOjJhZjMwYWQ5YTBhNTRiN2ZiMTc4Y2UwNDcwZTQzMWY5XzEtNS0xLTEtOTg2OTQ_cccd7ad7-e5ee-4133-9280-eec976acf769"
      unitRef="usd">-34000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i85dc1b14fefe4551abd5390650b6c712_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90YWJsZToyYWYzMGFkOWEwYTU0YjdmYjE3OGNlMDQ3MGU0MzFmOS90YWJsZXJhbmdlOjJhZjMwYWQ5YTBhNTRiN2ZiMTc4Y2UwNDcwZTQzMWY5XzItMS0xLTEtOTg2OTQ_faff0914-1c26-4c02-ba14-47839877fd4b"
      unitRef="usd">-47000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i6973b5f7f08f491a99b32b3361d5234a_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90YWJsZToyYWYzMGFkOWEwYTU0YjdmYjE3OGNlMDQ3MGU0MzFmOS90YWJsZXJhbmdlOjJhZjMwYWQ5YTBhNTRiN2ZiMTc4Y2UwNDcwZTQzMWY5XzItMy0xLTEtOTg2OTQ_0c195b1d-74ed-4aa8-8ac6-a6e3adcf3b5c"
      unitRef="usd">9000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i77aa86d8f8f8485ab211b681b5f58fb3_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90YWJsZToyYWYzMGFkOWEwYTU0YjdmYjE3OGNlMDQ3MGU0MzFmOS90YWJsZXJhbmdlOjJhZjMwYWQ5YTBhNTRiN2ZiMTc4Y2UwNDcwZTQzMWY5XzItNS0xLTEtOTg2OTQ_01f713c2-3b27-4010-8ae2-288edb9e05fc"
      unitRef="usd">-38000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i85dc1b14fefe4551abd5390650b6c712_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90YWJsZToyYWYzMGFkOWEwYTU0YjdmYjE3OGNlMDQ3MGU0MzFmOS90YWJsZXJhbmdlOjJhZjMwYWQ5YTBhNTRiN2ZiMTc4Y2UwNDcwZTQzMWY5XzMtMS0xLTEtOTg2OTQ_fe4cf154-d696-44a6-ab12-3d9cf992c6a9"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i6973b5f7f08f491a99b32b3361d5234a_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90YWJsZToyYWYzMGFkOWEwYTU0YjdmYjE3OGNlMDQ3MGU0MzFmOS90YWJsZXJhbmdlOjJhZjMwYWQ5YTBhNTRiN2ZiMTc4Y2UwNDcwZTQzMWY5XzMtMy0xLTEtOTg2OTQ_222ddf8f-b14a-42d7-8c64-045e257c15f1"
      unitRef="usd">5000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i77aa86d8f8f8485ab211b681b5f58fb3_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90YWJsZToyYWYzMGFkOWEwYTU0YjdmYjE3OGNlMDQ3MGU0MzFmOS90YWJsZXJhbmdlOjJhZjMwYWQ5YTBhNTRiN2ZiMTc4Y2UwNDcwZTQzMWY5XzMtNS0xLTEtOTg2OTQ_0cecb22f-487c-4539-9306-ea317a0e8071"
      unitRef="usd">5000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i85dc1b14fefe4551abd5390650b6c712_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90YWJsZToyYWYzMGFkOWEwYTU0YjdmYjE3OGNlMDQ3MGU0MzFmOS90YWJsZXJhbmdlOjJhZjMwYWQ5YTBhNTRiN2ZiMTc4Y2UwNDcwZTQzMWY5XzQtMS0xLTEtOTg2OTQ_93299643-763a-48ce-a6d1-ce30b4778f40"
      unitRef="usd">-47000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6973b5f7f08f491a99b32b3361d5234a_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90YWJsZToyYWYzMGFkOWEwYTU0YjdmYjE3OGNlMDQ3MGU0MzFmOS90YWJsZXJhbmdlOjJhZjMwYWQ5YTBhNTRiN2ZiMTc4Y2UwNDcwZTQzMWY5XzQtMy0xLTEtOTg2OTQ_19fefaaa-8ee0-404f-ae1e-272cb89c26f4"
      unitRef="usd">4000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i88939d79b6fc434586eae883166fc9d8_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90YWJsZToyYWYzMGFkOWEwYTU0YjdmYjE3OGNlMDQ3MGU0MzFmOS90YWJsZXJhbmdlOjJhZjMwYWQ5YTBhNTRiN2ZiMTc4Y2UwNDcwZTQzMWY5XzQtNS0xLTEtOTg2OTQ_16e60841-a588-4902-989b-533de36a6dde"
      unitRef="usd">-43000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i96f98f7a3c2b4137aadf18cea504d375_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90YWJsZToyYWYzMGFkOWEwYTU0YjdmYjE3OGNlMDQ3MGU0MzFmOS90YWJsZXJhbmdlOjJhZjMwYWQ5YTBhNTRiN2ZiMTc4Y2UwNDcwZTQzMWY5XzUtMS0xLTEtOTg2OTQ_1146a9d1-cd37-4556-8e6d-3e326fc8b391"
      unitRef="usd">-93000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5ebf444915254c15b3d63cf748c3515a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90YWJsZToyYWYzMGFkOWEwYTU0YjdmYjE3OGNlMDQ3MGU0MzFmOS90YWJsZXJhbmdlOjJhZjMwYWQ5YTBhNTRiN2ZiMTc4Y2UwNDcwZTQzMWY5XzUtMy0xLTEtOTg2OTQ_797415de-c390-49e9-8cbc-6825a434cb49"
      unitRef="usd">16000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if466229061cc43eda2992e495763f330_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTUvZnJhZzplM2JiYjZkYTY2NzU0YWU5YjcxYjZkZGM1OGNkMGI2MC90YWJsZToyYWYzMGFkOWEwYTU0YjdmYjE3OGNlMDQ3MGU0MzFmOS90YWJsZXJhbmdlOjJhZjMwYWQ5YTBhNTRiN2ZiMTc4Y2UwNDcwZTQzMWY5XzUtNS0xLTEtOTg2OTQ_b185dbac-18cb-4a0e-913a-65c1088cbc0c"
      unitRef="usd">-77000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTgvZnJhZzpiYjNjZWZiMjU2YzE0NDk0YjQ1OWYwY2FhMTJjNDFmYy90ZXh0cmVnaW9uOmJiM2NlZmIyNTZjMTQ0OTRiNDU5ZjBjYWExMmM0MWZjXzQxNw_49482284-4356-4980-805c-893a4da432e3">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;11. Earnings/(Loss) Per Share Attributable to Cardinal Health, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the number of common shares used to compute basic and diluted loss per share attributable to Cardinal Health, Inc.:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares&#x2013;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;275&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock options, restricted share units and performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average common shares&#x2013;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;275&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares&#x2013;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;281&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock options, restricted share units and performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average common shares&#x2013;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;281&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive were 5 million for both the three and nine months March&#160;31, 2022. For the three and nine months ended March&#160;31, 2022, there were 2 million and 1 million potentially dilutive employee stock options, restricted share units and performance share units, respectively, not included in the computation of diluted loss per common share attributable to Cardinal Health, Inc. because their effect would have been anti-dilutive as a result of the net loss during those periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive were 3 million for the three months ended March 31, 2021 and 4 million for the nine months ended March 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTgvZnJhZzpiYjNjZWZiMjU2YzE0NDk0YjQ1OWYwY2FhMTJjNDFmYy90ZXh0cmVnaW9uOmJiM2NlZmIyNTZjMTQ0OTRiNDU5ZjBjYWExMmM0MWZjXzQyNg_cdeb6fdb-082c-4929-86c7-b1122e13053a">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the number of common shares used to compute basic and diluted loss per share attributable to Cardinal Health, Inc.:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares&#x2013;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;275&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock options, restricted share units and performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average common shares&#x2013;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;275&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares&#x2013;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;281&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock options, restricted share units and performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average common shares&#x2013;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;281&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTgvZnJhZzpiYjNjZWZiMjU2YzE0NDk0YjQ1OWYwY2FhMTJjNDFmYy90YWJsZToxOGJhOGM3Mjk2M2Y0M2U0ODVlYmZjMzk4NzUyOThlYS90YWJsZXJhbmdlOjE4YmE4YzcyOTYzZjQzZTQ4NWViZmMzOTg3NTI5OGVhXzItMS0xLTEtOTg2OTQ_32981608-9e4d-4347-8745-2f29da10505a"
      unitRef="shares">275000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTgvZnJhZzpiYjNjZWZiMjU2YzE0NDk0YjQ1OWYwY2FhMTJjNDFmYy90YWJsZToxOGJhOGM3Mjk2M2Y0M2U0ODVlYmZjMzk4NzUyOThlYS90YWJsZXJhbmdlOjE4YmE4YzcyOTYzZjQzZTQ4NWViZmMzOTg3NTI5OGVhXzItMy0xLTEtOTg2OTQ_6e3c9f7f-190c-41cd-9312-5f3ad2af10bf"
      unitRef="shares">292000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTgvZnJhZzpiYjNjZWZiMjU2YzE0NDk0YjQ1OWYwY2FhMTJjNDFmYy90YWJsZToxOGJhOGM3Mjk2M2Y0M2U0ODVlYmZjMzk4NzUyOThlYS90YWJsZXJhbmdlOjE4YmE4YzcyOTYzZjQzZTQ4NWViZmMzOTg3NTI5OGVhXzQtMS0xLTEtOTg2OTQ_76da29bc-55ab-4dca-a2e6-e2ea5cb3c4f2"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTgvZnJhZzpiYjNjZWZiMjU2YzE0NDk0YjQ1OWYwY2FhMTJjNDFmYy90YWJsZToxOGJhOGM3Mjk2M2Y0M2U0ODVlYmZjMzk4NzUyOThlYS90YWJsZXJhbmdlOjE4YmE4YzcyOTYzZjQzZTQ4NWViZmMzOTg3NTI5OGVhXzQtMy0xLTEtOTg2OTQ_137b565e-cc7e-47d5-91f4-9938bd3172cb"
      unitRef="shares">2000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTgvZnJhZzpiYjNjZWZiMjU2YzE0NDk0YjQ1OWYwY2FhMTJjNDFmYy90YWJsZToxOGJhOGM3Mjk2M2Y0M2U0ODVlYmZjMzk4NzUyOThlYS90YWJsZXJhbmdlOjE4YmE4YzcyOTYzZjQzZTQ4NWViZmMzOTg3NTI5OGVhXzUtMS0xLTEtOTg2OTQ_dd8ef7c6-a8ed-438f-b14f-93e819ed457d"
      unitRef="shares">275000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTgvZnJhZzpiYjNjZWZiMjU2YzE0NDk0YjQ1OWYwY2FhMTJjNDFmYy90YWJsZToxOGJhOGM3Mjk2M2Y0M2U0ODVlYmZjMzk4NzUyOThlYS90YWJsZXJhbmdlOjE4YmE4YzcyOTYzZjQzZTQ4NWViZmMzOTg3NTI5OGVhXzUtMy0xLTEtOTg2OTQ_fb4b52d9-4b07-4beb-be61-34860f4bba99"
      unitRef="shares">294000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTgvZnJhZzpiYjNjZWZiMjU2YzE0NDk0YjQ1OWYwY2FhMTJjNDFmYy90YWJsZTo2ZmVjNDUyZmJlMzE0ZmFjOTVlZTVkNjIwNmEwY2U4MC90YWJsZXJhbmdlOjZmZWM0NTJmYmUzMTRmYWM5NWVlNWQ2MjA2YTBjZTgwXzItMS0xLTEtOTg2OTQ_d64f0b49-f12e-4ac9-9f7a-2ecb6198b8a1"
      unitRef="shares">281000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTgvZnJhZzpiYjNjZWZiMjU2YzE0NDk0YjQ1OWYwY2FhMTJjNDFmYy90YWJsZTo2ZmVjNDUyZmJlMzE0ZmFjOTVlZTVkNjIwNmEwY2U4MC90YWJsZXJhbmdlOjZmZWM0NTJmYmUzMTRmYWM5NWVlNWQ2MjA2YTBjZTgwXzItMy0xLTEtOTg2OTQ_d4034d3a-7e80-44da-b208-bdb83246c777"
      unitRef="shares">293000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTgvZnJhZzpiYjNjZWZiMjU2YzE0NDk0YjQ1OWYwY2FhMTJjNDFmYy90YWJsZTo2ZmVjNDUyZmJlMzE0ZmFjOTVlZTVkNjIwNmEwY2U4MC90YWJsZXJhbmdlOjZmZWM0NTJmYmUzMTRmYWM5NWVlNWQ2MjA2YTBjZTgwXzQtMS0xLTEtOTg2OTQ_08d959cf-d67b-438f-919d-a69c67c3925f"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTgvZnJhZzpiYjNjZWZiMjU2YzE0NDk0YjQ1OWYwY2FhMTJjNDFmYy90YWJsZTo2ZmVjNDUyZmJlMzE0ZmFjOTVlZTVkNjIwNmEwY2U4MC90YWJsZXJhbmdlOjZmZWM0NTJmYmUzMTRmYWM5NWVlNWQ2MjA2YTBjZTgwXzQtMy0xLTEtOTg2OTQ_26195f0d-307f-4979-be85-ae3f3b09c1d0"
      unitRef="shares">1000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTgvZnJhZzpiYjNjZWZiMjU2YzE0NDk0YjQ1OWYwY2FhMTJjNDFmYy90YWJsZTo2ZmVjNDUyZmJlMzE0ZmFjOTVlZTVkNjIwNmEwY2U4MC90YWJsZXJhbmdlOjZmZWM0NTJmYmUzMTRmYWM5NWVlNWQ2MjA2YTBjZTgwXzUtMS0xLTEtOTg2OTQ_93643ef7-4f0b-4cd2-85ae-46315c73e661"
      unitRef="shares">281000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTgvZnJhZzpiYjNjZWZiMjU2YzE0NDk0YjQ1OWYwY2FhMTJjNDFmYy90YWJsZTo2ZmVjNDUyZmJlMzE0ZmFjOTVlZTVkNjIwNmEwY2U4MC90YWJsZXJhbmdlOjZmZWM0NTJmYmUzMTRmYWM5NWVlNWQ2MjA2YTBjZTgwXzUtMy0xLTEtOTg2OTQ_35453892-0c6e-48c1-9c1c-352d4f741258"
      unitRef="shares">294000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTgvZnJhZzpiYjNjZWZiMjU2YzE0NDk0YjQ1OWYwY2FhMTJjNDFmYy90ZXh0cmVnaW9uOmJiM2NlZmIyNTZjMTQ0OTRiNDU5ZjBjYWExMmM0MWZjXzI5Mg_2530b25d-8d74-4c5b-9444-2842ee4d1253"
      unitRef="shares">5000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTgvZnJhZzpiYjNjZWZiMjU2YzE0NDk0YjQ1OWYwY2FhMTJjNDFmYy90ZXh0cmVnaW9uOmJiM2NlZmIyNTZjMTQ0OTRiNDU5ZjBjYWExMmM0MWZjXzI5Mg_339402ef-ae97-4240-9bdc-f99a6557315c"
      unitRef="shares">5000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <cah:SharesThatWouldBeAntidilutiveAsAResultOfNetLoss
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTgvZnJhZzpiYjNjZWZiMjU2YzE0NDk0YjQ1OWYwY2FhMTJjNDFmYy90ZXh0cmVnaW9uOmJiM2NlZmIyNTZjMTQ0OTRiNDU5ZjBjYWExMmM0MWZjXzEwNDQ1MzYwNDY2OTM0_d7c7ea75-565d-4402-bd4d-b2c9e7027e7c"
      unitRef="shares">2000000</cah:SharesThatWouldBeAntidilutiveAsAResultOfNetLoss>
    <cah:SharesThatWouldBeAntidilutiveAsAResultOfNetLoss
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTgvZnJhZzpiYjNjZWZiMjU2YzE0NDk0YjQ1OWYwY2FhMTJjNDFmYy90ZXh0cmVnaW9uOmJiM2NlZmIyNTZjMTQ0OTRiNDU5ZjBjYWExMmM0MWZjXzEwNDQ1MzYwNDY2OTQy_5daeb057-e44d-4c1d-85c4-f0286cf8923c"
      unitRef="shares">1000000</cah:SharesThatWouldBeAntidilutiveAsAResultOfNetLoss>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTgvZnJhZzpiYjNjZWZiMjU2YzE0NDk0YjQ1OWYwY2FhMTJjNDFmYy90ZXh0cmVnaW9uOmJiM2NlZmIyNTZjMTQ0OTRiNDU5ZjBjYWExMmM0MWZjXzIxOTkwMjMyNTgzODM_a7acd22f-a4ea-41b4-8920-a47851e00f5c"
      unitRef="shares">3000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMTgvZnJhZzpiYjNjZWZiMjU2YzE0NDk0YjQ1OWYwY2FhMTJjNDFmYy90ZXh0cmVnaW9uOmJiM2NlZmIyNTZjMTQ0OTRiNDU5ZjBjYWExMmM0MWZjXzIxOTkwMjMyNTg0MzE_9e22decb-f62a-4a77-8615-f72a81c26336"
      unitRef="shares">4000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90ZXh0cmVnaW9uOmVkNzE0MTJiOTQ5MjRlZDQ5ZDUyZDE3ZjYxYjcyYWM1XzU1NDY_ff191fac-43db-43f9-8bf8-c35fe1c5f528">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;12. Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; provides pharmacy management services to hospitals as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers and payers; and repackages generic pharmaceuticals and over-the-counter healthcare products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present revenue for each reportable segment and disaggregated revenue within our two reportable segments and Corporate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical Distribution and Specialty Solutions (1) (2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;40,723&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nuclear and Precision Health Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;234&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;40,957&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical distribution and products (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,283&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cardinal Health at-Home Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;601&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,884&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;44,841&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;44,836&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical Distribution and Specialty Solutions (1) (2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;121,501&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;106,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nuclear and Precision Health Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;653&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;122,154&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;107,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical distribution and products (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10,296&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cardinal Health at-Home Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,822&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12,118&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;134,272&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;119,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;134,261&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;119,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Products and services offered by our Specialty Solutions division are referred to as &#x201c;specialty pharmaceutical products and services."&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present revenue by geographic area:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.482%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;43,710&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,131&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;44,841&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;44,836&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.906%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;130,933&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;116,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,339&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;134,272&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;119,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;134,261&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;119,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Profit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&amp;amp;A") expenses. Segment SG&amp;amp;A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology, and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;methodologies. The results attributable to noncontrolling interests are recorded within segment profit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not allocate the following items to our segments: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;last-in first-out, or ("LIFO"), inventory charges/(credits); &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;surgical gown recall costs/(income);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;restructuring and employee severance;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;amortization and other acquisition-related costs;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;impairments and (gain)/loss on disposal of assets;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;litigation (recoveries)/charges, net;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;state opioid assessment related to prior fiscal years;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;other (income)/expense, net;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;interest expense, net;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;loss on early extinguishment of debt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;(gain)/loss on sale of equity interest in naviHealth; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;provision for income taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $20 million and $4 million for the three months ended March&#160;31, 2022 and 2021, and $38 million and $15 million for the nine months ended March&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the interim goodwill impairment testing for the Medical Unit as discussed further in &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#iaf3733bf892b435689161c61a06da348_91" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 4&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we recognized goodwill impairment charges of $474&#160;million and $1.8&#160;billion during the three and nine months ended March&#160;31, 2022, respectively, which were retained at Corporate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the opioid litigation as discussed further in &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#iaf3733bf892b435689161c61a06da348_103" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 6&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we recognized a pre-tax charge of $1.02&#160;billion&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;during the nine months ended March&#160;31, 2021 which was retained at Corporate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present segment profit by reportable segment and Corporate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.429%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;487&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;59&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total segment profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;546&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(643)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(212)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total operating earnings/(loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(97)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,319&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;232&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total segment profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,551&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2,183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,656)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total operating earnings/(loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(632)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Pharmaceutical segment profit includes opioid-related litigation defense and compliance costs, but does not include a one-time contingent attorney fee of $18&#160;million incurred during the three and nine months ended March&#160;31, 2022 related to the finalization of the Settlement Agreement. Due to the unique nature and significance of the Settlement Agreement, and the one-time, contingent nature of the fee, this related fee was included in litigation (recoveries)/charges, net in the condensed consolidated statements of earnings/(loss). Additionally, pharmaceutical segment profit during nine months ended March 31, 2022 was positively impacted by a $16&#160;million judgment for lost profits related to an ordinary course intellectual property rights claim.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents total assets for each reportable segment and Corporate at: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;25,470&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical (1) (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12,166&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,475&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;42,111&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Assets of $1.1 billion classified as held for sale related to the Cordis divestiture were included within Medical at June 30, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;(2)Medical reflects $1.8&#160;billion of goodwill impairment charges recorded in connection with interim goodwill impairment testing for the Medical Unit at March 31, 2022, and December 31, 2021.</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90ZXh0cmVnaW9uOmVkNzE0MTJiOTQ5MjRlZDQ5ZDUyZDE3ZjYxYjcyYWM1XzEwMQ_c757bf8a-ff5d-4b36-b8f9-ec93ee053b26"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90ZXh0cmVnaW9uOmVkNzE0MTJiOTQ5MjRlZDQ5ZDUyZDE3ZjYxYjcyYWM1XzEwMQ_ca3994f2-bd23-449d-8506-935ebcdddabf"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90ZXh0cmVnaW9uOmVkNzE0MTJiOTQ5MjRlZDQ5ZDUyZDE3ZjYxYjcyYWM1XzE4NDc_c757bf8a-ff5d-4b36-b8f9-ec93ee053b26"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90ZXh0cmVnaW9uOmVkNzE0MTJiOTQ5MjRlZDQ5ZDUyZDE3ZjYxYjcyYWM1XzE4NDc_ca3994f2-bd23-449d-8506-935ebcdddabf"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90ZXh0cmVnaW9uOmVkNzE0MTJiOTQ5MjRlZDQ5ZDUyZDE3ZjYxYjcyYWM1XzU1NTI_6ce6f0de-6d25-4f9b-b838-f9ddc79275cb">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical Distribution and Specialty Solutions (1) (2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;40,723&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nuclear and Precision Health Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;234&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;40,957&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical distribution and products (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,283&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cardinal Health at-Home Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;601&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,884&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;44,841&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;44,836&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical Distribution and Specialty Solutions (1) (2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;121,501&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;106,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nuclear and Precision Health Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;653&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;122,154&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;107,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical distribution and products (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10,296&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cardinal Health at-Home Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,822&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12,118&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;134,272&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;119,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;134,261&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;119,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Products and services offered by our Specialty Solutions division are referred to as &#x201c;specialty pharmaceutical products and services."&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="i271748b8420f4075b02360857adce1b3_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo4ZmRiZDg0NmI2NWI0OThmOThmNDQwN2M4ZjhjOGMwZC90YWJsZXJhbmdlOjhmZGJkODQ2YjY1YjQ5OGY5OGY0NDA3YzhmOGM4YzBkXzItMS0xLTEtOTg2OTQ_a9092969-0e66-4d9f-9894-48e6bdda2b46"
      unitRef="usd">40723000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6c47eb93c86c45f18852a7d4732bcc2b_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo4ZmRiZDg0NmI2NWI0OThmOThmNDQwN2M4ZjhjOGMwZC90YWJsZXJhbmdlOjhmZGJkODQ2YjY1YjQ5OGY5OGY0NDA3YzhmOGM4YzBkXzItMy0xLTEtOTg2OTQ_3dd40769-71de-4d5a-a7ee-7dc1ebbbe87f"
      unitRef="usd">34903000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i55a8895770e74654bb814d7570d0be67_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo4ZmRiZDg0NmI2NWI0OThmOThmNDQwN2M4ZjhjOGMwZC90YWJsZXJhbmdlOjhmZGJkODQ2YjY1YjQ5OGY5OGY0NDA3YzhmOGM4YzBkXzMtMS0xLTEtOTg2OTQ_da0a76cd-b9da-4367-bbe9-6b3a3ff5fe60"
      unitRef="usd">234000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic20d148712384093a21beaae9dbb11ae_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo4ZmRiZDg0NmI2NWI0OThmOThmNDQwN2M4ZjhjOGMwZC90YWJsZXJhbmdlOjhmZGJkODQ2YjY1YjQ5OGY5OGY0NDA3YzhmOGM4YzBkXzMtMy0xLTEtOTg2OTQ_e252e51a-933b-4a76-aa7b-920cae4a65dd"
      unitRef="usd">201000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i50ba23949f524ee39edd3981f77140d5_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo4ZmRiZDg0NmI2NWI0OThmOThmNDQwN2M4ZjhjOGMwZC90YWJsZXJhbmdlOjhmZGJkODQ2YjY1YjQ5OGY5OGY0NDA3YzhmOGM4YzBkXzQtMS0xLTEtOTg2OTQ_2f009fae-f6e6-40d2-b875-9256e49571bf"
      unitRef="usd">40957000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i84520ad8572840ff8aebaffcf2fc874b_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo4ZmRiZDg0NmI2NWI0OThmOThmNDQwN2M4ZjhjOGMwZC90YWJsZXJhbmdlOjhmZGJkODQ2YjY1YjQ5OGY5OGY0NDA3YzhmOGM4YzBkXzQtMy0xLTEtOTg2OTQ_e241e0b4-850b-4109-808d-d3d7eece00ab"
      unitRef="usd">35104000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i35c8403b7fd7460d84fabd0ac9bdf6b9_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo4ZmRiZDg0NmI2NWI0OThmOThmNDQwN2M4ZjhjOGMwZC90YWJsZXJhbmdlOjhmZGJkODQ2YjY1YjQ5OGY5OGY0NDA3YzhmOGM4YzBkXzUtMS0xLTEtOTg2OTQ_e2693c79-c148-49d1-a944-9a92ada4de44"
      unitRef="usd">3283000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i69525c4e29b84ce794f19067c425c73f_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo4ZmRiZDg0NmI2NWI0OThmOThmNDQwN2M4ZjhjOGMwZC90YWJsZXJhbmdlOjhmZGJkODQ2YjY1YjQ5OGY5OGY0NDA3YzhmOGM4YzBkXzUtMy0xLTEtOTg2OTQ_ede28ba8-3a09-4351-985a-b666ad81ca3a"
      unitRef="usd">3638000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ida0bf17cdf17411ab1c3212847b430cb_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo4ZmRiZDg0NmI2NWI0OThmOThmNDQwN2M4ZjhjOGMwZC90YWJsZXJhbmdlOjhmZGJkODQ2YjY1YjQ5OGY5OGY0NDA3YzhmOGM4YzBkXzYtMS0xLTEtOTg2OTQ_325857b2-e59d-465f-9e64-1c1802b2dfc3"
      unitRef="usd">601000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i74d2de9e32a34ab5b7753b90bdd5d03f_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo4ZmRiZDg0NmI2NWI0OThmOThmNDQwN2M4ZjhjOGMwZC90YWJsZXJhbmdlOjhmZGJkODQ2YjY1YjQ5OGY5OGY0NDA3YzhmOGM4YzBkXzYtMy0xLTEtOTg2OTQ_1fc1c6ad-35e0-455a-bc8c-c86f5a3f8f97"
      unitRef="usd">536000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i76a973b7ccb648908c98bf838383a489_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo4ZmRiZDg0NmI2NWI0OThmOThmNDQwN2M4ZjhjOGMwZC90YWJsZXJhbmdlOjhmZGJkODQ2YjY1YjQ5OGY5OGY0NDA3YzhmOGM4YzBkXzctMS0xLTEtOTg2OTQ_5ad6d88b-fdcd-408f-a826-a0673e61663d"
      unitRef="usd">3884000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i968b05c553634c7a8ef37ffb3b2c9491_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo4ZmRiZDg0NmI2NWI0OThmOThmNDQwN2M4ZjhjOGMwZC90YWJsZXJhbmdlOjhmZGJkODQ2YjY1YjQ5OGY5OGY0NDA3YzhmOGM4YzBkXzctMy0xLTEtOTg2OTQ_2ce18b14-2cac-42b2-99e5-059cece0fab4"
      unitRef="usd">4174000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9b6fce6427cc4db58e97a1124f989059_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo4ZmRiZDg0NmI2NWI0OThmOThmNDQwN2M4ZjhjOGMwZC90YWJsZXJhbmdlOjhmZGJkODQ2YjY1YjQ5OGY5OGY0NDA3YzhmOGM4YzBkXzgtMS0xLTEtOTg2OTQ_3604869e-ac76-4506-8baa-1de6f3213ca8"
      unitRef="usd">44841000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i940747d1739c452b84105fc820e21d0f_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo4ZmRiZDg0NmI2NWI0OThmOThmNDQwN2M4ZjhjOGMwZC90YWJsZXJhbmdlOjhmZGJkODQ2YjY1YjQ5OGY5OGY0NDA3YzhmOGM4YzBkXzgtMy0xLTEtOTg2OTQ_0a11c800-5cf1-4f68-a7df-1f2e1338dca1"
      unitRef="usd">39278000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia2b4c786f4bf4513b3347b942f655efd_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo4ZmRiZDg0NmI2NWI0OThmOThmNDQwN2M4ZjhjOGMwZC90YWJsZXJhbmdlOjhmZGJkODQ2YjY1YjQ5OGY5OGY0NDA3YzhmOGM4YzBkXzktMS0xLTEtOTg2OTQ_857886d0-59fa-4628-95a4-76fbc4538792"
      unitRef="usd">-5000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i50f9973da9d3455e928bdbe756cb6f44_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo4ZmRiZDg0NmI2NWI0OThmOThmNDQwN2M4ZjhjOGMwZC90YWJsZXJhbmdlOjhmZGJkODQ2YjY1YjQ5OGY5OGY0NDA3YzhmOGM4YzBkXzktMy0xLTEtOTg2OTQ_f64e4950-7e39-4b75-bed9-7f8259cd7d32"
      unitRef="usd">-3000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo4ZmRiZDg0NmI2NWI0OThmOThmNDQwN2M4ZjhjOGMwZC90YWJsZXJhbmdlOjhmZGJkODQ2YjY1YjQ5OGY5OGY0NDA3YzhmOGM4YzBkXzEwLTEtMS0xLTk4Njk0_0b894353-4c3c-4676-af91-2ae5f55918a4"
      unitRef="usd">44836000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo4ZmRiZDg0NmI2NWI0OThmOThmNDQwN2M4ZjhjOGMwZC90YWJsZXJhbmdlOjhmZGJkODQ2YjY1YjQ5OGY5OGY0NDA3YzhmOGM4YzBkXzEwLTMtMS0xLTk4Njk0_61b7b56a-48b4-4f56-ae1b-014d2d4d0cd4"
      unitRef="usd">39275000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6fc7d8e372df4069be7ed7b9e033f09f_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkMDEzNDUwYjZjNzM0N2M2OGJhMjQyMjI5YzJhMmVmNi90YWJsZXJhbmdlOmQwMTM0NTBiNmM3MzQ3YzY4YmEyNDIyMjljMmEyZWY2XzItMS0xLTEtOTg2OTQ_cbe07802-aee7-4a4f-98f2-15e01a663c71"
      unitRef="usd">121501000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2178f9d823184a19a7be4b97a98bbfcd_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkMDEzNDUwYjZjNzM0N2M2OGJhMjQyMjI5YzJhMmVmNi90YWJsZXJhbmdlOmQwMTM0NTBiNmM3MzQ3YzY4YmEyNDIyMjljMmEyZWY2XzItMy0xLTEtOTg2OTQ_65858fe2-6393-4768-8650-174a791bfe4f"
      unitRef="usd">106859000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie832c8853e2a4345938d5c0300e49149_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkMDEzNDUwYjZjNzM0N2M2OGJhMjQyMjI5YzJhMmVmNi90YWJsZXJhbmdlOmQwMTM0NTBiNmM3MzQ3YzY4YmEyNDIyMjljMmEyZWY2XzMtMS0xLTEtOTg2OTQ_b86e91b6-981c-4fd5-9571-9a02bc9ebc96"
      unitRef="usd">653000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i995eb07521ae4433bdc8160df2f79810_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkMDEzNDUwYjZjNzM0N2M2OGJhMjQyMjI5YzJhMmVmNi90YWJsZXJhbmdlOmQwMTM0NTBiNmM3MzQ3YzY4YmEyNDIyMjljMmEyZWY2XzMtMy0xLTEtOTg2OTQ_b82130d6-1e91-454a-b9e5-d501cddfc873"
      unitRef="usd">593000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4a8fa6b7c4c04392ad18e36a04760533_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkMDEzNDUwYjZjNzM0N2M2OGJhMjQyMjI5YzJhMmVmNi90YWJsZXJhbmdlOmQwMTM0NTBiNmM3MzQ3YzY4YmEyNDIyMjljMmEyZWY2XzQtMS0xLTEtOTg2OTQ_01f0deb1-acb4-4eed-9ce0-ae0fcdc0714a"
      unitRef="usd">122154000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib25907ae15fa44dcb0802c504cec1c88_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkMDEzNDUwYjZjNzM0N2M2OGJhMjQyMjI5YzJhMmVmNi90YWJsZXJhbmdlOmQwMTM0NTBiNmM3MzQ3YzY4YmEyNDIyMjljMmEyZWY2XzQtMy0xLTEtOTg2OTQ_1b0dc512-d3cf-400a-aa30-908a3e4a806a"
      unitRef="usd">107452000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5b0d22bf281f4584bad7e62de864bf75_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkMDEzNDUwYjZjNzM0N2M2OGJhMjQyMjI5YzJhMmVmNi90YWJsZXJhbmdlOmQwMTM0NTBiNmM3MzQ3YzY4YmEyNDIyMjljMmEyZWY2XzUtMS0xLTEtOTg2OTQ_3ff7cd59-23ac-434a-83a8-b578f6c8aadd"
      unitRef="usd">10296000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i77648cd7d3a34814beda9dcd87e2f35d_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkMDEzNDUwYjZjNzM0N2M2OGJhMjQyMjI5YzJhMmVmNi90YWJsZXJhbmdlOmQwMTM0NTBiNmM3MzQ3YzY4YmEyNDIyMjljMmEyZWY2XzUtMy0xLTEtOTg2OTQ_79206474-81ce-4bbd-b46e-56eee5eec15c"
      unitRef="usd">10805000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic7bcf27f7221414f96fbedd5799f6902_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkMDEzNDUwYjZjNzM0N2M2OGJhMjQyMjI5YzJhMmVmNi90YWJsZXJhbmdlOmQwMTM0NTBiNmM3MzQ3YzY4YmEyNDIyMjljMmEyZWY2XzYtMS0xLTEtOTg2OTQ_428123cb-9e84-4fd9-acc4-3eac5acbe027"
      unitRef="usd">1822000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i479768cce42840d6807b6cf8e3d09439_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkMDEzNDUwYjZjNzM0N2M2OGJhMjQyMjI5YzJhMmVmNi90YWJsZXJhbmdlOmQwMTM0NTBiNmM3MzQ3YzY4YmEyNDIyMjljMmEyZWY2XzYtMy0xLTEtOTg2OTQ_05d5127c-5ba7-435a-b2b0-9967dd7d7f91"
      unitRef="usd">1636000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6afdf5f1340d41c6941f5cc19ff2ef71_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkMDEzNDUwYjZjNzM0N2M2OGJhMjQyMjI5YzJhMmVmNi90YWJsZXJhbmdlOmQwMTM0NTBiNmM3MzQ3YzY4YmEyNDIyMjljMmEyZWY2XzctMS0xLTEtOTg2OTQ_537f5729-6f8a-4acc-b9a5-815914678c7a"
      unitRef="usd">12118000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i203ccf6041354aa887510c9903970c43_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkMDEzNDUwYjZjNzM0N2M2OGJhMjQyMjI5YzJhMmVmNi90YWJsZXJhbmdlOmQwMTM0NTBiNmM3MzQ3YzY4YmEyNDIyMjljMmEyZWY2XzctMy0xLTEtOTg2OTQ_cc57f125-b83a-4e12-8943-72fb9060f12a"
      unitRef="usd">12441000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib7205a1910584e49b66107f75befc03d_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkMDEzNDUwYjZjNzM0N2M2OGJhMjQyMjI5YzJhMmVmNi90YWJsZXJhbmdlOmQwMTM0NTBiNmM3MzQ3YzY4YmEyNDIyMjljMmEyZWY2XzgtMS0xLTEtOTg2OTQ_c3a4e330-fe0f-4c77-bddd-f516b7aefcbf"
      unitRef="usd">134272000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic84e3ea0e4fb4425b6174e7655ba01f1_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkMDEzNDUwYjZjNzM0N2M2OGJhMjQyMjI5YzJhMmVmNi90YWJsZXJhbmdlOmQwMTM0NTBiNmM3MzQ3YzY4YmEyNDIyMjljMmEyZWY2XzgtMy0xLTEtOTg2OTQ_56e7a76c-7daa-41b4-bf09-20fba60fe548"
      unitRef="usd">119893000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic1865dd177bf446bb0808b03a8c0b8b6_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkMDEzNDUwYjZjNzM0N2M2OGJhMjQyMjI5YzJhMmVmNi90YWJsZXJhbmdlOmQwMTM0NTBiNmM3MzQ3YzY4YmEyNDIyMjljMmEyZWY2XzktMS0xLTEtOTg2OTQ_39f37f84-e866-4077-a00a-eac5387d1b2b"
      unitRef="usd">-11000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8b1b3f0e63094c6ba80ba1a031e52c86_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkMDEzNDUwYjZjNzM0N2M2OGJhMjQyMjI5YzJhMmVmNi90YWJsZXJhbmdlOmQwMTM0NTBiNmM3MzQ3YzY4YmEyNDIyMjljMmEyZWY2XzktMy0xLTEtOTg2OTQ_432d444c-f050-4f15-8b4a-37af5237c206"
      unitRef="usd">-12000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkMDEzNDUwYjZjNzM0N2M2OGJhMjQyMjI5YzJhMmVmNi90YWJsZXJhbmdlOmQwMTM0NTBiNmM3MzQ3YzY4YmEyNDIyMjljMmEyZWY2XzEwLTEtMS0xLTk4Njk0_1cc0d5bb-5924-4d36-a9c6-460664397c60"
      unitRef="usd">134261000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkMDEzNDUwYjZjNzM0N2M2OGJhMjQyMjI5YzJhMmVmNi90YWJsZXJhbmdlOmQwMTM0NTBiNmM3MzQ3YzY4YmEyNDIyMjljMmEyZWY2XzEwLTMtMS0xLTk4Njk0_16796090-e505-4e42-b4a9-5b1d538f520b"
      unitRef="usd">119881000000</us-gaap:Revenues>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90ZXh0cmVnaW9uOmVkNzE0MTJiOTQ5MjRlZDQ5ZDUyZDE3ZjYxYjcyYWM1XzU1NTQ_6e9bd9b7-c1e5-4782-9b02-577b0ee18fa8">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present revenue by geographic area:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.482%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;43,710&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,131&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;44,841&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;44,836&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.906%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;130,933&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;116,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,339&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;134,272&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;119,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;134,261&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;119,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:Revenues
      contextRef="i70d8b7dbb46a4e8fa9f3548d4edd3460_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTplMjRlMDA5MmQzNjc0NGMzODA0M2M1Y2NjOWY1ZjNjYy90YWJsZXJhbmdlOmUyNGUwMDkyZDM2NzQ0YzM4MDQzYzVjY2M5ZjVmM2NjXzItMS0xLTEtOTg2OTQ_62fb6e96-4171-4663-9d60-41a34254bf81"
      unitRef="usd">43710000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6b6b3238d8dc4c6094d322879432c3a3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTplMjRlMDA5MmQzNjc0NGMzODA0M2M1Y2NjOWY1ZjNjYy90YWJsZXJhbmdlOmUyNGUwMDkyZDM2NzQ0YzM4MDQzYzVjY2M5ZjVmM2NjXzItMy0xLTEtOTg2OTQ_0f35a960-df7e-4a42-b9fb-b82b32b5c5d3"
      unitRef="usd">38089000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibe5bb815566842549cff77434b3664c5_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTplMjRlMDA5MmQzNjc0NGMzODA0M2M1Y2NjOWY1ZjNjYy90YWJsZXJhbmdlOmUyNGUwMDkyZDM2NzQ0YzM4MDQzYzVjY2M5ZjVmM2NjXzMtMS0xLTEtOTg2OTQ_9e152cc2-2b9c-4678-a1ff-abded710f0a5"
      unitRef="usd">1131000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i625a7e6298c541f0ab5627a25b81a35f_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTplMjRlMDA5MmQzNjc0NGMzODA0M2M1Y2NjOWY1ZjNjYy90YWJsZXJhbmdlOmUyNGUwMDkyZDM2NzQ0YzM4MDQzYzVjY2M5ZjVmM2NjXzMtMy0xLTEtOTg2OTQ_83cdb456-75bc-4c9b-960d-dca3d4811a08"
      unitRef="usd">1189000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9b6fce6427cc4db58e97a1124f989059_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTplMjRlMDA5MmQzNjc0NGMzODA0M2M1Y2NjOWY1ZjNjYy90YWJsZXJhbmdlOmUyNGUwMDkyZDM2NzQ0YzM4MDQzYzVjY2M5ZjVmM2NjXzQtMS0xLTEtOTg2OTQ_380861eb-57d5-445e-a18f-c2f21f21717d"
      unitRef="usd">44841000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i940747d1739c452b84105fc820e21d0f_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTplMjRlMDA5MmQzNjc0NGMzODA0M2M1Y2NjOWY1ZjNjYy90YWJsZXJhbmdlOmUyNGUwMDkyZDM2NzQ0YzM4MDQzYzVjY2M5ZjVmM2NjXzQtMy0xLTEtOTg2OTQ_3062b02f-a4ed-4836-8121-7225eb68243b"
      unitRef="usd">39278000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia2b4c786f4bf4513b3347b942f655efd_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTplMjRlMDA5MmQzNjc0NGMzODA0M2M1Y2NjOWY1ZjNjYy90YWJsZXJhbmdlOmUyNGUwMDkyZDM2NzQ0YzM4MDQzYzVjY2M5ZjVmM2NjXzUtMS0xLTEtOTg2OTQ_466c1ac5-2b02-4c02-8d89-e9ff2ee25e2a"
      unitRef="usd">-5000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i50f9973da9d3455e928bdbe756cb6f44_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTplMjRlMDA5MmQzNjc0NGMzODA0M2M1Y2NjOWY1ZjNjYy90YWJsZXJhbmdlOmUyNGUwMDkyZDM2NzQ0YzM4MDQzYzVjY2M5ZjVmM2NjXzUtMy0xLTEtOTg2OTQ_8f0a0d12-4bdd-4136-8b27-c0341faefbd9"
      unitRef="usd">-3000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTplMjRlMDA5MmQzNjc0NGMzODA0M2M1Y2NjOWY1ZjNjYy90YWJsZXJhbmdlOmUyNGUwMDkyZDM2NzQ0YzM4MDQzYzVjY2M5ZjVmM2NjXzYtMS0xLTEtOTg2OTQ_8f97f7f1-c619-4b01-800a-be4f5b12b4b8"
      unitRef="usd">44836000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTplMjRlMDA5MmQzNjc0NGMzODA0M2M1Y2NjOWY1ZjNjYy90YWJsZXJhbmdlOmUyNGUwMDkyZDM2NzQ0YzM4MDQzYzVjY2M5ZjVmM2NjXzYtMy0xLTEtOTg2OTQ_98e2972f-a74f-4b01-816b-ee47eb771dcb"
      unitRef="usd">39275000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic282070c0abd4da7b2e98ef29dabe2a4_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpjZjlkZjBhYmIxNGU0YzU5ODU4MDdmNjUzYzNmMGQ2Ni90YWJsZXJhbmdlOmNmOWRmMGFiYjE0ZTRjNTk4NTgwN2Y2NTNjM2YwZDY2XzItMS0xLTEtOTg2OTQ_ec18bc17-28da-4021-ad77-b349c7e09849"
      unitRef="usd">130933000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibe9bf4e4c9f04b558b3d275631d67107_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpjZjlkZjBhYmIxNGU0YzU5ODU4MDdmNjUzYzNmMGQ2Ni90YWJsZXJhbmdlOmNmOWRmMGFiYjE0ZTRjNTk4NTgwN2Y2NTNjM2YwZDY2XzItMy0xLTEtOTg2OTQ_477d1a7f-11d0-469c-8f88-715ae9c5acab"
      unitRef="usd">116425000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i60837aa8922b471583b5179248715cc5_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpjZjlkZjBhYmIxNGU0YzU5ODU4MDdmNjUzYzNmMGQ2Ni90YWJsZXJhbmdlOmNmOWRmMGFiYjE0ZTRjNTk4NTgwN2Y2NTNjM2YwZDY2XzMtMS0xLTEtOTg2OTQ_bf4f0ed4-9ac9-4385-a247-fe130c661e22"
      unitRef="usd">3339000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icadf953dd78648ce88457a23b39ed9b3_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpjZjlkZjBhYmIxNGU0YzU5ODU4MDdmNjUzYzNmMGQ2Ni90YWJsZXJhbmdlOmNmOWRmMGFiYjE0ZTRjNTk4NTgwN2Y2NTNjM2YwZDY2XzMtMy0xLTEtOTg2OTQ_69e1eda8-2f55-4d8d-93c2-0e86a18faac9"
      unitRef="usd">3468000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib7205a1910584e49b66107f75befc03d_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpjZjlkZjBhYmIxNGU0YzU5ODU4MDdmNjUzYzNmMGQ2Ni90YWJsZXJhbmdlOmNmOWRmMGFiYjE0ZTRjNTk4NTgwN2Y2NTNjM2YwZDY2XzQtMS0xLTEtOTg2OTQ_6a014bc4-c856-437b-8854-a09a33e72225"
      unitRef="usd">134272000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic84e3ea0e4fb4425b6174e7655ba01f1_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpjZjlkZjBhYmIxNGU0YzU5ODU4MDdmNjUzYzNmMGQ2Ni90YWJsZXJhbmdlOmNmOWRmMGFiYjE0ZTRjNTk4NTgwN2Y2NTNjM2YwZDY2XzQtMy0xLTEtOTg2OTQ_e58c1bb0-b9e7-407e-b91c-b9959ee106f5"
      unitRef="usd">119893000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic1865dd177bf446bb0808b03a8c0b8b6_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpjZjlkZjBhYmIxNGU0YzU5ODU4MDdmNjUzYzNmMGQ2Ni90YWJsZXJhbmdlOmNmOWRmMGFiYjE0ZTRjNTk4NTgwN2Y2NTNjM2YwZDY2XzUtMS0xLTEtOTg2OTQ_353a2b1b-bf8c-429d-8163-1c5b07f5edc7"
      unitRef="usd">-11000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8b1b3f0e63094c6ba80ba1a031e52c86_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpjZjlkZjBhYmIxNGU0YzU5ODU4MDdmNjUzYzNmMGQ2Ni90YWJsZXJhbmdlOmNmOWRmMGFiYjE0ZTRjNTk4NTgwN2Y2NTNjM2YwZDY2XzUtMy0xLTEtOTg2OTQ_a0c4db4f-874c-4b55-9b17-2403e7ab6b47"
      unitRef="usd">-12000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpjZjlkZjBhYmIxNGU0YzU5ODU4MDdmNjUzYzNmMGQ2Ni90YWJsZXJhbmdlOmNmOWRmMGFiYjE0ZTRjNTk4NTgwN2Y2NTNjM2YwZDY2XzYtMS0xLTEtOTg2OTQ_b9d20cc1-c116-4ae2-8600-19c0b3d6b2fb"
      unitRef="usd">134261000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpjZjlkZjBhYmIxNGU0YzU5ODU4MDdmNjUzYzNmMGQ2Ni90YWJsZXJhbmdlOmNmOWRmMGFiYjE0ZTRjNTk4NTgwN2Y2NTNjM2YwZDY2XzYtMy0xLTEtOTg2OTQ_c0055819-8766-4fd9-b86c-dd839eeedcab"
      unitRef="usd">119881000000</us-gaap:Revenues>
    <cah:ProjectCostsOnInvestmentAndOtherSpending
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90ZXh0cmVnaW9uOmVkNzE0MTJiOTQ5MjRlZDQ5ZDUyZDE3ZjYxYjcyYWM1XzQzODE_ce7f7523-cc9c-4a3f-b6c5-9f6029260952"
      unitRef="usd">20000000</cah:ProjectCostsOnInvestmentAndOtherSpending>
    <cah:ProjectCostsOnInvestmentAndOtherSpending
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90ZXh0cmVnaW9uOmVkNzE0MTJiOTQ5MjRlZDQ5ZDUyZDE3ZjYxYjcyYWM1XzQzODg_7796d2af-c0ae-48dc-a35b-f5380d7bcae9"
      unitRef="usd">4000000</cah:ProjectCostsOnInvestmentAndOtherSpending>
    <cah:ProjectCostsOnInvestmentAndOtherSpending
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90ZXh0cmVnaW9uOmVkNzE0MTJiOTQ5MjRlZDQ5ZDUyZDE3ZjYxYjcyYWM1XzQ0MzM_96364cf7-673f-4397-a183-c5dcf3c35fd0"
      unitRef="usd">38000000</cah:ProjectCostsOnInvestmentAndOtherSpending>
    <cah:ProjectCostsOnInvestmentAndOtherSpending
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90ZXh0cmVnaW9uOmVkNzE0MTJiOTQ5MjRlZDQ5ZDUyZDE3ZjYxYjcyYWM1XzQ0NDA_cc9ded5a-2bc2-45fa-b0ac-49a3633b7714"
      unitRef="usd">15000000</cah:ProjectCostsOnInvestmentAndOtherSpending>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i2473dfc0495e42aeb265fd377f6c1a00_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90ZXh0cmVnaW9uOmVkNzE0MTJiOTQ5MjRlZDQ5ZDUyZDE3ZjYxYjcyYWM1XzcxNDY4MjU1ODYxODA_45c80bc3-ace0-4335-ae56-d25daa119b13"
      unitRef="usd">474000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i579fe90cd44b45029f6ce1e6fd52d06e_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90ZXh0cmVnaW9uOmVkNzE0MTJiOTQ5MjRlZDQ5ZDUyZDE3ZjYxYjcyYWM1XzMyOTg1MzQ4OTU3NjM_763bb6ac-9d1d-427a-afce-ec39ac0de8bb"
      unitRef="usd">1800000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:LitigationSettlementExpense
      contextRef="i7cfeb36a6e0d45f8aa734c1879638433_D20200701-20210331"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90ZXh0cmVnaW9uOmVkNzE0MTJiOTQ5MjRlZDQ5ZDUyZDE3ZjYxYjcyYWM1XzQ4MTk_a3f7e46d-9941-4c9b-9a80-f9745ce1b3c5"
      unitRef="usd">1020000000.00</us-gaap:LitigationSettlementExpense>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90ZXh0cmVnaW9uOmVkNzE0MTJiOTQ5MjRlZDQ5ZDUyZDE3ZjYxYjcyYWM1XzU1NjE_1ba37bc8-354e-48b9-ba7a-de0b54ab1cc7">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present segment profit by reportable segment and Corporate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.429%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;487&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;59&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total segment profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;546&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(643)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(212)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total operating earnings/(loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(97)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,319&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;232&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total segment profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,551&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2,183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,656)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total operating earnings/(loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(632)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Pharmaceutical segment profit includes opioid-related litigation defense and compliance costs, but does not include a one-time contingent attorney fee of $18&#160;million incurred during the three and nine months ended March&#160;31, 2022 related to the finalization of the Settlement Agreement. Due to the unique nature and significance of the Settlement Agreement, and the one-time, contingent nature of the fee, this related fee was included in litigation (recoveries)/charges, net in the condensed consolidated statements of earnings/(loss). Additionally, pharmaceutical segment profit during nine months ended March 31, 2022 was positively impacted by a $16&#160;million judgment for lost profits related to an ordinary course intellectual property rights claim.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:OperatingIncomeLoss
      contextRef="i50ba23949f524ee39edd3981f77140d5_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo1Mjc1NjgyZTE5YjY0NzNiODUzMDRhYjE5NWEzZTM5MC90YWJsZXJhbmdlOjUyNzU2ODJlMTliNjQ3M2I4NTMwNGFiMTk1YTNlMzkwXzItMS0xLTEtOTg2OTQ_622804fd-591f-46d1-be6d-7b4456217b3c"
      unitRef="usd">487000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i84520ad8572840ff8aebaffcf2fc874b_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo1Mjc1NjgyZTE5YjY0NzNiODUzMDRhYjE5NWEzZTM5MC90YWJsZXJhbmdlOjUyNzU2ODJlMTliNjQ3M2I4NTMwNGFiMTk1YTNlMzkwXzItMy0xLTEtOTg2OTQ_e170ddb4-aaee-4083-bd1f-96815342846f"
      unitRef="usd">511000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i76a973b7ccb648908c98bf838383a489_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo1Mjc1NjgyZTE5YjY0NzNiODUzMDRhYjE5NWEzZTM5MC90YWJsZXJhbmdlOjUyNzU2ODJlMTliNjQ3M2I4NTMwNGFiMTk1YTNlMzkwXzMtMS0xLTEtOTg2OTQ_79db3d73-94a2-41cb-8f6b-dc598d6e82c4"
      unitRef="usd">59000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i968b05c553634c7a8ef37ffb3b2c9491_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo1Mjc1NjgyZTE5YjY0NzNiODUzMDRhYjE5NWEzZTM5MC90YWJsZXJhbmdlOjUyNzU2ODJlMTliNjQ3M2I4NTMwNGFiMTk1YTNlMzkwXzMtMy0xLTEtOTg2OTQ_17c08b1a-e2e8-4cc8-8bf0-7160816505e5"
      unitRef="usd">174000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9b6fce6427cc4db58e97a1124f989059_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo1Mjc1NjgyZTE5YjY0NzNiODUzMDRhYjE5NWEzZTM5MC90YWJsZXJhbmdlOjUyNzU2ODJlMTliNjQ3M2I4NTMwNGFiMTk1YTNlMzkwXzQtMS0xLTEtOTg2OTQ_fa883a9f-c02d-4a82-b716-28ba7ab03059"
      unitRef="usd">546000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i940747d1739c452b84105fc820e21d0f_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo1Mjc1NjgyZTE5YjY0NzNiODUzMDRhYjE5NWEzZTM5MC90YWJsZXJhbmdlOjUyNzU2ODJlMTliNjQ3M2I4NTMwNGFiMTk1YTNlMzkwXzQtMy0xLTEtOTg2OTQ_241f8d7b-6bea-4a37-9647-a20e1467ff98"
      unitRef="usd">685000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia2b4c786f4bf4513b3347b942f655efd_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo1Mjc1NjgyZTE5YjY0NzNiODUzMDRhYjE5NWEzZTM5MC90YWJsZXJhbmdlOjUyNzU2ODJlMTliNjQ3M2I4NTMwNGFiMTk1YTNlMzkwXzUtMS0xLTEtOTg2OTQ_3611b00b-5330-4274-8bf0-ff8fc6d88186"
      unitRef="usd">-643000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i50f9973da9d3455e928bdbe756cb6f44_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo1Mjc1NjgyZTE5YjY0NzNiODUzMDRhYjE5NWEzZTM5MC90YWJsZXJhbmdlOjUyNzU2ODJlMTliNjQ3M2I4NTMwNGFiMTk1YTNlMzkwXzUtMy0xLTEtOTg2OTQ_6b60f439-03dd-48d8-9b56-27d3bfaf62ec"
      unitRef="usd">-212000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo1Mjc1NjgyZTE5YjY0NzNiODUzMDRhYjE5NWEzZTM5MC90YWJsZXJhbmdlOjUyNzU2ODJlMTliNjQ3M2I4NTMwNGFiMTk1YTNlMzkwXzYtMS0xLTEtOTg2OTQ_3cf54a40-f57c-4f73-b8d5-323f35ad7c98"
      unitRef="usd">-97000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTo1Mjc1NjgyZTE5YjY0NzNiODUzMDRhYjE5NWEzZTM5MC90YWJsZXJhbmdlOjUyNzU2ODJlMTliNjQ3M2I4NTMwNGFiMTk1YTNlMzkwXzYtMy0xLTEtOTg2OTQ_c2084606-45bf-47be-8fd3-1cc5927174d5"
      unitRef="usd">473000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4a8fa6b7c4c04392ad18e36a04760533_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpiMDY2YWEyMzQzYTU0Mzc1YWFmZWYwOWZiNmM0YjhhYy90YWJsZXJhbmdlOmIwNjZhYTIzNDNhNTQzNzVhYWZlZjA5ZmI2YzRiOGFjXzItMS0xLTEtOTg2OTQ_ec9464a4-7db4-482a-afeb-5efb7b6f2dca"
      unitRef="usd">1319000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib25907ae15fa44dcb0802c504cec1c88_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpiMDY2YWEyMzQzYTU0Mzc1YWFmZWYwOWZiNmM0YjhhYy90YWJsZXJhbmdlOmIwNjZhYTIzNDNhNTQzNzVhYWZlZjA5ZmI2YzRiOGFjXzItMy0xLTEtOTg2OTQ_bd31cc84-8cf9-4145-b22c-2ff08732f3f2"
      unitRef="usd">1326000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6afdf5f1340d41c6941f5cc19ff2ef71_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpiMDY2YWEyMzQzYTU0Mzc1YWFmZWYwOWZiNmM0YjhhYy90YWJsZXJhbmdlOmIwNjZhYTIzNDNhNTQzNzVhYWZlZjA5ZmI2YzRiOGFjXzMtMS0xLTEtOTg2OTQ_b12ae61c-9127-4b69-95cc-b7b7b5bdc19b"
      unitRef="usd">232000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i203ccf6041354aa887510c9903970c43_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpiMDY2YWEyMzQzYTU0Mzc1YWFmZWYwOWZiNmM0YjhhYy90YWJsZXJhbmdlOmIwNjZhYTIzNDNhNTQzNzVhYWZlZjA5ZmI2YzRiOGFjXzMtMy0xLTEtOTg2OTQ_b0f1a0e9-f32f-4f8e-8d55-78659f570965"
      unitRef="usd">640000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib7205a1910584e49b66107f75befc03d_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpiMDY2YWEyMzQzYTU0Mzc1YWFmZWYwOWZiNmM0YjhhYy90YWJsZXJhbmdlOmIwNjZhYTIzNDNhNTQzNzVhYWZlZjA5ZmI2YzRiOGFjXzQtMS0xLTEtOTg2OTQ_cb1e10f7-b523-419e-9ff8-e46056f29475"
      unitRef="usd">1551000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic84e3ea0e4fb4425b6174e7655ba01f1_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpiMDY2YWEyMzQzYTU0Mzc1YWFmZWYwOWZiNmM0YjhhYy90YWJsZXJhbmdlOmIwNjZhYTIzNDNhNTQzNzVhYWZlZjA5ZmI2YzRiOGFjXzQtMy0xLTEtOTg2OTQ_8cb0f77d-eedb-49e7-bc3c-91f9994d05e9"
      unitRef="usd">1966000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic1865dd177bf446bb0808b03a8c0b8b6_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpiMDY2YWEyMzQzYTU0Mzc1YWFmZWYwOWZiNmM0YjhhYy90YWJsZXJhbmdlOmIwNjZhYTIzNDNhNTQzNzVhYWZlZjA5ZmI2YzRiOGFjXzUtMS0xLTEtOTg2OTQ_6976d3f1-ba19-4c77-aab3-e2bd8eb9531b"
      unitRef="usd">-2183000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8b1b3f0e63094c6ba80ba1a031e52c86_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpiMDY2YWEyMzQzYTU0Mzc1YWFmZWYwOWZiNmM0YjhhYy90YWJsZXJhbmdlOmIwNjZhYTIzNDNhNTQzNzVhYWZlZjA5ZmI2YzRiOGFjXzUtMy0xLTEtOTg2OTQ_089b27cd-7a85-49bc-a4d3-dd09c7d049b1"
      unitRef="usd">-1656000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpiMDY2YWEyMzQzYTU0Mzc1YWFmZWYwOWZiNmM0YjhhYy90YWJsZXJhbmdlOmIwNjZhYTIzNDNhNTQzNzVhYWZlZjA5ZmI2YzRiOGFjXzYtMS0xLTEtOTg2OTQ_65467ab8-e438-4181-8de8-db9f79520f00"
      unitRef="usd">-632000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpiMDY2YWEyMzQzYTU0Mzc1YWFmZWYwOWZiNmM0YjhhYy90YWJsZXJhbmdlOmIwNjZhYTIzNDNhNTQzNzVhYWZlZjA5ZmI2YzRiOGFjXzYtMy0xLTEtOTg2OTQ_67494005-0267-4a0c-afad-3a064646e38a"
      unitRef="usd">310000000</us-gaap:OperatingIncomeLoss>
    <cah:ContingentAttorneyFee
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90ZXh0cmVnaW9uOmVkNzE0MTJiOTQ5MjRlZDQ5ZDUyZDE3ZjYxYjcyYWM1XzMyOTg1MzQ4OTU3NDg_4657fb9e-7543-4874-b8a4-4012408dd76d"
      unitRef="usd">18000000</cah:ContingentAttorneyFee>
    <cah:JudgmentForLostProfits
      contextRef="i9215c78d739b4b399eaa5fb71927062e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90ZXh0cmVnaW9uOmVkNzE0MTJiOTQ5MjRlZDQ5ZDUyZDE3ZjYxYjcyYWM1XzUwNzQ_d231b28d-ffe5-451b-966b-a98e78bf5dca"
      unitRef="usd">16000000</cah:JudgmentForLostProfits>
    <us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90ZXh0cmVnaW9uOmVkNzE0MTJiOTQ5MjRlZDQ5ZDUyZDE3ZjYxYjcyYWM1XzU1NjI_f0599fa6-5a84-4e12-9988-e73583e9941f">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents total assets for each reportable segment and Corporate at: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;25,470&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical (1) (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12,166&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,475&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;42,111&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Assets of $1.1 billion classified as held for sale related to the Cordis divestiture were included within Medical at June 30, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;(2)Medical reflects $1.8&#160;billion of goodwill impairment charges recorded in connection with interim goodwill impairment testing for the Medical Unit at March 31, 2022, and December 31, 2021.</us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock>
    <us-gaap:Assets
      contextRef="i2dc2bc03fca7468582ef192514e3bfd5_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkOGMzOWNiNjNjMzc0ZmJmOWYwM2I3NDJjNmE4YmZkZi90YWJsZXJhbmdlOmQ4YzM5Y2I2M2MzNzRmYmY5ZjAzYjc0MmM2YThiZmRmXzEtMS0xLTEtOTg2OTQ_70326003-5480-4bd5-bc74-7cd7cc89fff1"
      unitRef="usd">25470000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="iab9fb6c03f2c41b09eab97067568553e_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkOGMzOWNiNjNjMzc0ZmJmOWYwM2I3NDJjNmE4YmZkZi90YWJsZXJhbmdlOmQ4YzM5Y2I2M2MzNzRmYmY5ZjAzYjc0MmM2YThiZmRmXzEtMy0xLTEtOTg2OTQ_eabaab82-4894-4e32-8174-77ef1da0a1f2"
      unitRef="usd">23624000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="id1b44ed725e04cc79bd011f2ce6f6445_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkOGMzOWNiNjNjMzc0ZmJmOWYwM2I3NDJjNmE4YmZkZi90YWJsZXJhbmdlOmQ4YzM5Y2I2M2MzNzRmYmY5ZjAzYjc0MmM2YThiZmRmXzItMS0xLTEtOTg2OTQ_9897a988-fada-484b-9206-21e6e65a7934"
      unitRef="usd">12166000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i2054ef93e9f6497bb4e5e5e8c06c5afa_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkOGMzOWNiNjNjMzc0ZmJmOWYwM2I3NDJjNmE4YmZkZi90YWJsZXJhbmdlOmQ4YzM5Y2I2M2MzNzRmYmY5ZjAzYjc0MmM2YThiZmRmXzItMy0xLTEtOTg2OTQ_973e8af5-4b4b-4be1-8963-5c39e8f58ac7"
      unitRef="usd">15408000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i3a7244a5c088444480543d7621bd8890_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkOGMzOWNiNjNjMzc0ZmJmOWYwM2I3NDJjNmE4YmZkZi90YWJsZXJhbmdlOmQ4YzM5Y2I2M2MzNzRmYmY5ZjAzYjc0MmM2YThiZmRmXzMtMS0xLTEtOTg2OTQ_c93911e1-747b-4b74-a2eb-b30512415f78"
      unitRef="usd">4475000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i5fa86c22fb664c2d85324c8fa396e444_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkOGMzOWNiNjNjMzc0ZmJmOWYwM2I3NDJjNmE4YmZkZi90YWJsZXJhbmdlOmQ4YzM5Y2I2M2MzNzRmYmY5ZjAzYjc0MmM2YThiZmRmXzMtMy0xLTEtOTg2OTQ_509214e3-db10-4034-b694-0fb237a125f7"
      unitRef="usd">5421000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkOGMzOWNiNjNjMzc0ZmJmOWYwM2I3NDJjNmE4YmZkZi90YWJsZXJhbmdlOmQ4YzM5Y2I2M2MzNzRmYmY5ZjAzYjc0MmM2YThiZmRmXzQtMS0xLTEtOTg2OTQ_ae690cbf-b351-4e8a-bb9b-b65bb98fa12c"
      unitRef="usd">42111000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90YWJsZTpkOGMzOWNiNjNjMzc0ZmJmOWYwM2I3NDJjNmE4YmZkZi90YWJsZXJhbmdlOmQ4YzM5Y2I2M2MzNzRmYmY5ZjAzYjc0MmM2YThiZmRmXzQtMy0xLTEtOTg2OTQ_83f3deed-124a-4c14-9560-778362bd81c1"
      unitRef="usd">44453000000</us-gaap:Assets>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="i25b4b6630ae44ef28341784008cfd847_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90ZXh0cmVnaW9uOmVkNzE0MTJiOTQ5MjRlZDQ5ZDUyZDE3ZjYxYjcyYWM1XzUyNzE_55ae735d-501e-4785-9cf4-ec49822c81e7"
      unitRef="usd">1100000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i579fe90cd44b45029f6ce1e6fd52d06e_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjEvZnJhZzplZDcxNDEyYjk0OTI0ZWQ0OWQ1MmQxN2Y2MWI3MmFjNS90ZXh0cmVnaW9uOmVkNzE0MTJiOTQ5MjRlZDQ5ZDUyZDE3ZjYxYjcyYWM1XzMyOTg1MzQ4OTU4NDI_2e674973-267c-4563-a406-242c84b0c40a"
      unitRef="usd">1800000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzI0Njk_fe68d5da-7def-4ed8-b4bb-70830a1d6c73">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;13. Share-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain stock incentive plans (collectively, the &#x201c;Plans&#x201d;) for the benefit of certain of our officers, directors and employees. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides total share-based compensation expense by type of award:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;23&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;53&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;65&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total tax benefit related to share-based compensation was $3 million and $5 million for the three months ended March&#160;31, 2022 and 2021, respectively, and $9 million and $12 million for the nine months ended March&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted share units granted under the Plans generally vest in equal annual installments over three years. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all transactions related to restricted share units under the Plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nonvested at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;45.99&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2022, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $89 million, which is expected to be recognized over a weighted-average period of two years.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee stock options granted under the Plans generally vest in equal annual installments over three years and are exercisable for ten years from the grant date. All stock options are exercisable at a price equal to the market value of the common shares underlying the option on the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all stock option transactions under the Plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.480%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.061%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price per&lt;br/&gt;Common Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;69.41&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercisable at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;69.58&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2022, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested stock options not yet recognized was $0.2 million, which is expected to be recognized over a weighted-average period of two years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables provide additional detail related to stock options:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Aggregate intrinsic value of outstanding options at period end&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Aggregate intrinsic value of exercisable options at period end&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining contractual life of outstanding options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining contractual life of exercisable options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Performance Share Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Performance share units vest over a 3-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from zero to 240 percent of the target award amount for the fiscal 2020 and 2021 grants and zero to 234 percent for the fiscal 2022 grant. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Performance&lt;br/&gt;Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nonvested at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;57.27&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2022, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $25 million, which is expected to be recognized over a weighted-average period of two years if performance goals are achieved.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzI0NTE_4fe48fb1-057c-43fd-a8a0-c36365db794d">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides total share-based compensation expense by type of award:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;23&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;53&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;65&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i59ac145c43e84d588b95df88a14fdc55_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTozMzc0YWYwZWZjNzI0MDI4YTQ0OTE0MGI1Y2QwYzE3MS90YWJsZXJhbmdlOjMzNzRhZjBlZmM3MjQwMjhhNDQ5MTQwYjVjZDBjMTcxXzItMS0xLTEtOTg2OTQ_7ac2e562-ddec-41f7-8c2e-070695b46516"
      unitRef="usd">18000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7d746fa13a56425188cf694ad9491c8b_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTozMzc0YWYwZWZjNzI0MDI4YTQ0OTE0MGI1Y2QwYzE3MS90YWJsZXJhbmdlOjMzNzRhZjBlZmM3MjQwMjhhNDQ5MTQwYjVjZDBjMTcxXzItMy0xLTEtOTg2OTQ_adf5cf9e-5a42-4883-80a3-150e6b722749"
      unitRef="usd">20000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7fc6f93a9a324e02934d0435deab460b_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTozMzc0YWYwZWZjNzI0MDI4YTQ0OTE0MGI1Y2QwYzE3MS90YWJsZXJhbmdlOjMzNzRhZjBlZmM3MjQwMjhhNDQ5MTQwYjVjZDBjMTcxXzQtMS0xLTEtOTg2OTQ_bd7846d0-a846-4932-aa5b-12add703b466"
      unitRef="usd">5000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i12af8121f223485cbae6b363fb276e76_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTozMzc0YWYwZWZjNzI0MDI4YTQ0OTE0MGI1Y2QwYzE3MS90YWJsZXJhbmdlOjMzNzRhZjBlZmM3MjQwMjhhNDQ5MTQwYjVjZDBjMTcxXzQtMy0xLTEtOTg2OTQ_47cc5379-1b2d-45c2-a88a-2d299242ca51"
      unitRef="usd">13000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTozMzc0YWYwZWZjNzI0MDI4YTQ0OTE0MGI1Y2QwYzE3MS90YWJsZXJhbmdlOjMzNzRhZjBlZmM3MjQwMjhhNDQ5MTQwYjVjZDBjMTcxXzUtMS0xLTEtOTg2OTQ_4e80e6e8-b2a0-4052-a503-d281189b4880"
      unitRef="usd">23000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTozMzc0YWYwZWZjNzI0MDI4YTQ0OTE0MGI1Y2QwYzE3MS90YWJsZXJhbmdlOjMzNzRhZjBlZmM3MjQwMjhhNDQ5MTQwYjVjZDBjMTcxXzUtMy0xLTEtOTg2OTQ_3d13f886-3929-479a-aebb-ccf7ae3f9b5f"
      unitRef="usd">33000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7587b0e2335a4976aed28934df90543d_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTpjNzliMTQ1MzA4NDM0YWNhOTkyNzFmNWQyYWI2NWJhNS90YWJsZXJhbmdlOmM3OWIxNDUzMDg0MzRhY2E5OTI3MWY1ZDJhYjY1YmE1XzItMS0xLTEtOTg2OTQ_0dafac9c-5e77-4247-84c6-ff582c421f61"
      unitRef="usd">53000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i884f8a089566407ab080d0ebb229f552_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTpjNzliMTQ1MzA4NDM0YWNhOTkyNzFmNWQyYWI2NWJhNS90YWJsZXJhbmdlOmM3OWIxNDUzMDg0MzRhY2E5OTI3MWY1ZDJhYjY1YmE1XzItMy0xLTEtOTg2OTQ_021b034b-9984-4de1-915e-23991a6a325a"
      unitRef="usd">56000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iec8a7050443b4a1cb54f2dc25501b78f_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTpjNzliMTQ1MzA4NDM0YWNhOTkyNzFmNWQyYWI2NWJhNS90YWJsZXJhbmdlOmM3OWIxNDUzMDg0MzRhY2E5OTI3MWY1ZDJhYjY1YmE1XzQtMS0xLTEtOTg2OTQ_00d0ce7d-6891-4b8c-8d3e-3a4512e1942b"
      unitRef="usd">12000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic70067800d5143aea0895bee00acddf8_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTpjNzliMTQ1MzA4NDM0YWNhOTkyNzFmNWQyYWI2NWJhNS90YWJsZXJhbmdlOmM3OWIxNDUzMDg0MzRhY2E5OTI3MWY1ZDJhYjY1YmE1XzQtMy0xLTEtOTg2OTQ_230416b4-dca9-4c8a-95c6-c249cdef7e6d"
      unitRef="usd">28000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTpjNzliMTQ1MzA4NDM0YWNhOTkyNzFmNWQyYWI2NWJhNS90YWJsZXJhbmdlOmM3OWIxNDUzMDg0MzRhY2E5OTI3MWY1ZDJhYjY1YmE1XzUtMS0xLTEtOTg2OTQ_4716e75b-f53b-4a3b-9a23-e81b3c8e5414"
      unitRef="usd">65000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTpjNzliMTQ1MzA4NDM0YWNhOTkyNzFmNWQyYWI2NWJhNS90YWJsZXJhbmdlOmM3OWIxNDUzMDg0MzRhY2E5OTI3MWY1ZDJhYjY1YmE1XzUtMy0xLTEtOTg2OTQ_874a1f0d-a011-416d-80c5-21b589c0f83e"
      unitRef="usd">84000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzI5Mw_7fefb17e-3da4-4006-a8df-06d7d756979c"
      unitRef="usd">3000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzMwMA_55a3e022-915f-4577-aae0-181af55ac7fb"
      unitRef="usd">5000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzM0NQ_3542c9a7-8fc2-4efd-9c2c-284643496372"
      unitRef="usd">9000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzM1Mg_de5ac30c-e4b3-4bd7-b1b5-fcc5ea9c675d"
      unitRef="usd">12000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i7587b0e2335a4976aed28934df90543d_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzQ4Nw_ab6335ae-d6b5-46ed-b6a2-f475aeb36a58">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzI0MTc_b250c6dd-1311-458b-af3c-1e6621311049">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all transactions related to restricted share units under the Plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nonvested at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;45.99&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="iaa16d72f5cb94c3dae8ef889f5cf1b73_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTozMzY1ZjZmNGI0YjQ0YmYxOWMwZTAzNGJlZDY2Yzk0MS90YWJsZXJhbmdlOjMzNjVmNmY0YjRiNDRiZjE5YzBlMDM0YmVkNjZjOTQxXzEtMS0xLTEtOTg2OTQ_7d5920e9-840c-4ff4-97c7-0501e18a1eaf"
      unitRef="shares">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="iaa16d72f5cb94c3dae8ef889f5cf1b73_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTozMzY1ZjZmNGI0YjQ0YmYxOWMwZTAzNGJlZDY2Yzk0MS90YWJsZXJhbmdlOjMzNjVmNmY0YjRiNDRiZjE5YzBlMDM0YmVkNjZjOTQxXzEtMy0xLTEtOTg2OTQ_8f8a8fb4-72d1-47af-9aad-03a7e1306a08"
      unitRef="usdPerShare">49.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i7587b0e2335a4976aed28934df90543d_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTozMzY1ZjZmNGI0YjQ0YmYxOWMwZTAzNGJlZDY2Yzk0MS90YWJsZXJhbmdlOjMzNjVmNmY0YjRiNDRiZjE5YzBlMDM0YmVkNjZjOTQxXzItMS0xLTEtOTg2OTQ_3e2a09d4-8169-4b43-9199-4c42ba5c2140"
      unitRef="shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7587b0e2335a4976aed28934df90543d_D20210701-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTozMzY1ZjZmNGI0YjQ0YmYxOWMwZTAzNGJlZDY2Yzk0MS90YWJsZXJhbmdlOjMzNjVmNmY0YjRiNDRiZjE5YzBlMDM0YmVkNjZjOTQxXzItMy0xLTEtOTg2OTQ_91448682-aa44-4ec9-8c79-5cd606c73a22"
      unitRef="usdPerShare">51.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i7587b0e2335a4976aed28934df90543d_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTozMzY1ZjZmNGI0YjQ0YmYxOWMwZTAzNGJlZDY2Yzk0MS90YWJsZXJhbmdlOjMzNjVmNmY0YjRiNDRiZjE5YzBlMDM0YmVkNjZjOTQxXzMtMS0xLTEtOTg2OTQ_45219d79-f50b-4888-ad26-aa08b9796e2c"
      unitRef="shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7587b0e2335a4976aed28934df90543d_D20210701-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTozMzY1ZjZmNGI0YjQ0YmYxOWMwZTAzNGJlZDY2Yzk0MS90YWJsZXJhbmdlOjMzNjVmNmY0YjRiNDRiZjE5YzBlMDM0YmVkNjZjOTQxXzMtMy0xLTEtOTg2OTQ_f3b38bb4-9ef4-414c-b433-912b13fa6ee9"
      unitRef="usdPerShare">49.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i7587b0e2335a4976aed28934df90543d_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTozMzY1ZjZmNGI0YjQ0YmYxOWMwZTAzNGJlZDY2Yzk0MS90YWJsZXJhbmdlOjMzNjVmNmY0YjRiNDRiZjE5YzBlMDM0YmVkNjZjOTQxXzQtMS0xLTEtOTg2OTQ_d8a9d472-36a7-4dad-ab2d-ccbd07a889de"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i7587b0e2335a4976aed28934df90543d_D20210701-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTozMzY1ZjZmNGI0YjQ0YmYxOWMwZTAzNGJlZDY2Yzk0MS90YWJsZXJhbmdlOjMzNjVmNmY0YjRiNDRiZjE5YzBlMDM0YmVkNjZjOTQxXzQtMy0xLTEtOTg2OTQ_7c0fa659-8942-4152-b185-aef95320e559"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i429695d6f4bd42f3954b0d838fa9cbea_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTozMzY1ZjZmNGI0YjQ0YmYxOWMwZTAzNGJlZDY2Yzk0MS90YWJsZXJhbmdlOjMzNjVmNmY0YjRiNDRiZjE5YzBlMDM0YmVkNjZjOTQxXzUtMS0xLTEtOTg2OTQ_c971563b-9d6a-4451-833a-a951a352af71"
      unitRef="shares">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i429695d6f4bd42f3954b0d838fa9cbea_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTozMzY1ZjZmNGI0YjQ0YmYxOWMwZTAzNGJlZDY2Yzk0MS90YWJsZXJhbmdlOjMzNjVmNmY0YjRiNDRiZjE5YzBlMDM0YmVkNjZjOTQxXzUtMy0xLTEtOTg2OTQ_fb4af8c5-c6ab-4880-95af-48fffb11333a"
      unitRef="usdPerShare">45.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i429695d6f4bd42f3954b0d838fa9cbea_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzgzNA_2ee2cf29-2e82-48e8-a7f8-f312e85883b6"
      unitRef="usd">89000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i7587b0e2335a4976aed28934df90543d_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzkwNw_d70daecd-4a0b-45cb-b722-a0d166237bc0">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i72e703868e904b989107e7bea5f5c25a_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzEwMjE_9d3d2a80-13b4-42c5-af07-79782b439a91">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <cah:ExercisablePeriodOfPlansInYears
      contextRef="i72e703868e904b989107e7bea5f5c25a_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzEwNDg_b7650d6e-a3b1-4218-ae60-083fe0e1c58f">P10Y</cah:ExercisablePeriodOfPlansInYears>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzI0Mzg_06d55ee5-2f90-41ba-9ec3-cbb0ef9cdfd9">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all stock option transactions under the Plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.480%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.061%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price per&lt;br/&gt;Common Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;69.41&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercisable at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;69.58&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTo1NTU4NDIyNDg0MGU0ZTkzYjU0M2FjOGM2YmMxM2RlZC90YWJsZXJhbmdlOjU1NTg0MjI0ODQwZTRlOTNiNTQzYWM4YzZiYzEzZGVkXzEtMS0xLTEtOTg2OTQ_8074e00e-4bd5-4012-89c6-7984dccbc691"
      unitRef="shares">4000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTo1NTU4NDIyNDg0MGU0ZTkzYjU0M2FjOGM2YmMxM2RlZC90YWJsZXJhbmdlOjU1NTg0MjI0ODQwZTRlOTNiNTQzYWM4YzZiYzEzZGVkXzEtMy0xLTEtOTg2OTQ_5da3d60d-376e-4146-9a1e-761ec381c345"
      unitRef="usdPerShare">68.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTo1NTU4NDIyNDg0MGU0ZTkzYjU0M2FjOGM2YmMxM2RlZC90YWJsZXJhbmdlOjU1NTg0MjI0ODQwZTRlOTNiNTQzYWM4YzZiYzEzZGVkXzItMS0xLTEtOTg2OTQ_bad6a345-a573-45a4-82ad-23c5033436de"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTo1NTU4NDIyNDg0MGU0ZTkzYjU0M2FjOGM2YmMxM2RlZC90YWJsZXJhbmdlOjU1NTg0MjI0ODQwZTRlOTNiNTQzYWM4YzZiYzEzZGVkXzItMy0xLTEtOTg2OTQ_c90b67fa-ef7f-450c-8c1a-f3f8aedae419"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTo1NTU4NDIyNDg0MGU0ZTkzYjU0M2FjOGM2YmMxM2RlZC90YWJsZXJhbmdlOjU1NTg0MjI0ODQwZTRlOTNiNTQzYWM4YzZiYzEzZGVkXzMtMS0xLTEtOTg2OTQ_01c4dcd2-07f6-44d1-bd23-8dabf4363c02"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTo1NTU4NDIyNDg0MGU0ZTkzYjU0M2FjOGM2YmMxM2RlZC90YWJsZXJhbmdlOjU1NTg0MjI0ODQwZTRlOTNiNTQzYWM4YzZiYzEzZGVkXzMtMy0xLTEtOTg2OTQ_20af5b29-e7a2-4325-96a7-9bd7ba1eb3ea"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTo1NTU4NDIyNDg0MGU0ZTkzYjU0M2FjOGM2YmMxM2RlZC90YWJsZXJhbmdlOjU1NTg0MjI0ODQwZTRlOTNiNTQzYWM4YzZiYzEzZGVkXzQtMS0xLTEtOTg2OTQ_712dcbee-bb55-4626-a845-c8e991ac589e"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTo1NTU4NDIyNDg0MGU0ZTkzYjU0M2FjOGM2YmMxM2RlZC90YWJsZXJhbmdlOjU1NTg0MjI0ODQwZTRlOTNiNTQzYWM4YzZiYzEzZGVkXzQtMy0xLTEtOTg2OTQ_8ddc2965-962c-4163-a5dd-5920e45f68a0"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTo1NTU4NDIyNDg0MGU0ZTkzYjU0M2FjOGM2YmMxM2RlZC90YWJsZXJhbmdlOjU1NTg0MjI0ODQwZTRlOTNiNTQzYWM4YzZiYzEzZGVkXzUtMS0xLTEtOTg2OTQ_7704ebb0-3f32-4a3f-9bcc-fc9e66ca94c8"
      unitRef="shares">4000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTo1NTU4NDIyNDg0MGU0ZTkzYjU0M2FjOGM2YmMxM2RlZC90YWJsZXJhbmdlOjU1NTg0MjI0ODQwZTRlOTNiNTQzYWM4YzZiYzEzZGVkXzUtMy0xLTEtOTg2OTQ_de58241d-34ef-406d-95c5-1474066593b3"
      unitRef="usdPerShare">69.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTo1NTU4NDIyNDg0MGU0ZTkzYjU0M2FjOGM2YmMxM2RlZC90YWJsZXJhbmdlOjU1NTg0MjI0ODQwZTRlOTNiNTQzYWM4YzZiYzEzZGVkXzYtMS0xLTEtOTg2OTQ_ecf47edc-e426-4f5a-a754-c32e62a684a0"
      unitRef="shares">4000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="if9374cb6cebc440eabca82aeeccf1677_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTo1NTU4NDIyNDg0MGU0ZTkzYjU0M2FjOGM2YmMxM2RlZC90YWJsZXJhbmdlOjU1NTg0MjI0ODQwZTRlOTNiNTQzYWM4YzZiYzEzZGVkXzYtMy0xLTEtOTg2OTQ_cb5eeb1f-d969-48fd-b407-bdf0ef631c59"
      unitRef="usdPerShare">69.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i81916c52c3fd4ebfbcb9cb988adcf939_I20220331"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzE0MTc_54d8c077-505c-46af-97a1-978dfd4d0b50"
      unitRef="usd">200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i72e703868e904b989107e7bea5f5c25a_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzE0OTA_d99f2ea8-c7ac-45cb-a801-95c7523f22b8">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <cah:AdditionalStockOptionPlanDataTableTextBlock
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzIzOTc_a4f4197b-7523-4f41-9583-358d626ed464">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables provide additional detail related to stock options:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Aggregate intrinsic value of outstanding options at period end&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Aggregate intrinsic value of exercisable options at period end&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining contractual life of outstanding options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining contractual life of exercisable options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</cah:AdditionalStockOptionPlanDataTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i81916c52c3fd4ebfbcb9cb988adcf939_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTowNjZmMGQ5YTQ3MGQ0OTJkODAzMzI1NGQ5YTg4YjAxZC90YWJsZXJhbmdlOjA2NmYwZDlhNDcwZDQ5MmQ4MDMzMjU0ZDlhODhiMDFkXzEtMS0xLTEtOTg2OTQ_e31042e6-add3-40f8-b1de-8ef46accc49d"
      unitRef="usd">8000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i563a2c8d36a84c8890168f4f9a86e549_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTowNjZmMGQ5YTQ3MGQ0OTJkODAzMzI1NGQ5YTg4YjAxZC90YWJsZXJhbmdlOjA2NmYwZDlhNDcwZDQ5MmQ4MDMzMjU0ZDlhODhiMDFkXzEtMy0xLTEtOTg2OTQ_7477af0f-a334-44df-9ec4-18125b55990a"
      unitRef="usd">11000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i81916c52c3fd4ebfbcb9cb988adcf939_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTowNjZmMGQ5YTQ3MGQ0OTJkODAzMzI1NGQ5YTg4YjAxZC90YWJsZXJhbmdlOjA2NmYwZDlhNDcwZDQ5MmQ4MDMzMjU0ZDlhODhiMDFkXzItMS0xLTEtOTg2OTQ_f99d8755-7680-4116-8e85-b20dcb6c3070"
      unitRef="usd">7000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i563a2c8d36a84c8890168f4f9a86e549_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTowNjZmMGQ5YTQ3MGQ0OTJkODAzMzI1NGQ5YTg4YjAxZC90YWJsZXJhbmdlOjA2NmYwZDlhNDcwZDQ5MmQ4MDMzMjU0ZDlhODhiMDFkXzItMy0xLTEtOTg2OTQ_c9a0bdc5-43e2-40ff-95f7-3487746efddd"
      unitRef="usd">11000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i72e703868e904b989107e7bea5f5c25a_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTowNWFlOTg0Y2UwYzA0NjRmYjBkZWJkODkxOTY3MWVlMi90YWJsZXJhbmdlOjA1YWU5ODRjZTBjMDQ2NGZiMGRlYmQ4OTE5NjcxZWUyXzEtMS0xLTEtOTg2OTQ_f72a76d2-bdea-4ebe-ad90-4e9578e8d69b">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="if6804c7cefdb418480ee13a51907f380_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTowNWFlOTg0Y2UwYzA0NjRmYjBkZWJkODkxOTY3MWVlMi90YWJsZXJhbmdlOjA1YWU5ODRjZTBjMDQ2NGZiMGRlYmQ4OTE5NjcxZWUyXzEtMy0xLTEtOTg2OTQ_0717d0ac-82fb-41aa-9acf-bb7b8e6e515d">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i72e703868e904b989107e7bea5f5c25a_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTowNWFlOTg0Y2UwYzA0NjRmYjBkZWJkODkxOTY3MWVlMi90YWJsZXJhbmdlOjA1YWU5ODRjZTBjMDQ2NGZiMGRlYmQ4OTE5NjcxZWUyXzItMS0xLTEtOTg2OTQ_05b9ec33-282e-4ee1-bed6-a53376d5f29d">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="if6804c7cefdb418480ee13a51907f380_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTowNWFlOTg0Y2UwYzA0NjRmYjBkZWJkODkxOTY3MWVlMi90YWJsZXJhbmdlOjA1YWU5ODRjZTBjMDQ2NGZiMGRlYmQ4OTE5NjcxZWUyXzItMy0xLTEtOTg2OTQ_47f1c45f-84d5-4f77-b909-21064ef0f7d5">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <cah:VestingPeriodinyearsforShares
      contextRef="iec8a7050443b4a1cb54f2dc25501b78f_D20210701-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzE2MzM_60b0f886-e752-42dd-ad87-22091cfe4902"
      unitRef="number">3</cah:VestingPeriodinyearsforShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i5833a4aca61e4135963e45569b6980df_D20210701-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzE3OTY_29f7dd63-6961-48ba-954e-245f99c6c0f0"
      unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i160dc3f384644e66812cbec2a46665b2_D20190701-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzE3OTY_7ed9587e-6632-4a79-a98b-d2d90bbf4b20"
      unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i766ebcafc487484896f01112fb4d75ea_D20190701-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzE4MDI_0165a295-6057-4ae9-8e79-48401d89fbb1"
      unitRef="number">2.40</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i3b9a407d237d4399ad21e36831394a4a_D20200701-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzE4MDI_260d97aa-669b-4560-8b07-ea43f058c03c"
      unitRef="number">2.40</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i5833a4aca61e4135963e45569b6980df_D20210701-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzE4NzI_62a91cf6-621e-438f-873b-cb2b985518f4"
      unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i8b1fc63c210f45c4b87728a4957e3834_D20210701-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzE4Nzg_2c178b22-67cb-4de7-9a5f-d0a8abbfd5c2"
      unitRef="number">2.34</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock
      contextRef="i21939e337a964eb182b2e0d93b533226_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzI0NjQ_7f3b4175-f85d-4b95-833c-83d34b17024c">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Performance&lt;br/&gt;Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nonvested at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;57.27&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i971a6ca11d6d4f408c6af2dc52b79810_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTo3NzAxMzRlNDQzNzE0YjFiYjU1MTcyNGZjNDU0NWFmMC90YWJsZXJhbmdlOjc3MDEzNGU0NDM3MTRiMWJiNTUxNzI0ZmM0NTQ1YWYwXzEtMS0xLTEtOTg2OTQ_87357c7c-6d4a-44b7-a472-cbaf9eed9aeb"
      unitRef="shares">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i971a6ca11d6d4f408c6af2dc52b79810_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTo3NzAxMzRlNDQzNzE0YjFiYjU1MTcyNGZjNDU0NWFmMC90YWJsZXJhbmdlOjc3MDEzNGU0NDM3MTRiMWJiNTUxNzI0ZmM0NTQ1YWYwXzEtMy0xLTEtOTg2OTQ_fc85264b-7b4e-4d01-92ac-d159fca7681a"
      unitRef="usdPerShare">54.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="iec8a7050443b4a1cb54f2dc25501b78f_D20210701-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTo3NzAxMzRlNDQzNzE0YjFiYjU1MTcyNGZjNDU0NWFmMC90YWJsZXJhbmdlOjc3MDEzNGU0NDM3MTRiMWJiNTUxNzI0ZmM0NTQ1YWYwXzItMS0xLTEtOTg2OTQ_a78198ba-649e-4eff-b181-5a31526a9fef"
      unitRef="shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iec8a7050443b4a1cb54f2dc25501b78f_D20210701-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTo3NzAxMzRlNDQzNzE0YjFiYjU1MTcyNGZjNDU0NWFmMC90YWJsZXJhbmdlOjc3MDEzNGU0NDM3MTRiMWJiNTUxNzI0ZmM0NTQ1YWYwXzItMy0xLTEtOTg2OTQ_90543cdf-4346-4188-9e4d-16f35cc3a41f"
      unitRef="usdPerShare">51.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="iec8a7050443b4a1cb54f2dc25501b78f_D20210701-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTo3NzAxMzRlNDQzNzE0YjFiYjU1MTcyNGZjNDU0NWFmMC90YWJsZXJhbmdlOjc3MDEzNGU0NDM3MTRiMWJiNTUxNzI0ZmM0NTQ1YWYwXzMtMS0xLTEtOTg2OTQ_e549b20a-3543-4fd1-9c43-4d3df5b6fc86"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="iec8a7050443b4a1cb54f2dc25501b78f_D20210701-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTo3NzAxMzRlNDQzNzE0YjFiYjU1MTcyNGZjNDU0NWFmMC90YWJsZXJhbmdlOjc3MDEzNGU0NDM3MTRiMWJiNTUxNzI0ZmM0NTQ1YWYwXzMtMy0xLTEtOTg2OTQ_ba5c3c67-5160-4236-8b06-42dd011dbdb4"
      unitRef="usdPerShare">52.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="iec8a7050443b4a1cb54f2dc25501b78f_D20210701-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTo3NzAxMzRlNDQzNzE0YjFiYjU1MTcyNGZjNDU0NWFmMC90YWJsZXJhbmdlOjc3MDEzNGU0NDM3MTRiMWJiNTUxNzI0ZmM0NTQ1YWYwXzQtMS0xLTEtOTg2OTQ_39575636-8d0e-46ac-b8e5-31a6c92e300b"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="iec8a7050443b4a1cb54f2dc25501b78f_D20210701-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTo3NzAxMzRlNDQzNzE0YjFiYjU1MTcyNGZjNDU0NWFmMC90YWJsZXJhbmdlOjc3MDEzNGU0NDM3MTRiMWJiNTUxNzI0ZmM0NTQ1YWYwXzQtMy0xLTEtOTg2OTQ_67796469-b0f9-495d-bab5-883a0b7293ef"
      unitRef="usdPerShare">52.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="id38ff405ba8f4f46b884a396366a86de_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTo3NzAxMzRlNDQzNzE0YjFiYjU1MTcyNGZjNDU0NWFmMC90YWJsZXJhbmdlOjc3MDEzNGU0NDM3MTRiMWJiNTUxNzI0ZmM0NTQ1YWYwXzUtMS0xLTEtOTg2OTQ_d5c5a657-6f67-47ae-9fdc-8adae2c3457d"
      unitRef="shares">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="id38ff405ba8f4f46b884a396366a86de_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90YWJsZTo3NzAxMzRlNDQzNzE0YjFiYjU1MTcyNGZjNDU0NWFmMC90YWJsZXJhbmdlOjc3MDEzNGU0NDM3MTRiMWJiNTUxNzI0ZmM0NTQ1YWYwXzUtMy0xLTEtOTg2OTQ_b2435d4a-f85a-4ffd-bf23-550e0ccbcd3e"
      unitRef="usdPerShare">57.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="id38ff405ba8f4f46b884a396366a86de_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzIyODY_90210966-916c-41cc-8175-27caaa8a5977"
      unitRef="usd">25000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="iec8a7050443b4a1cb54f2dc25501b78f_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFmMzczM2JmODkyYjQzNTY4OTE2MWM2MWEwNmRhMzQ4L3NlYzphZjM3MzNiZjg5MmI0MzU2ODkxNjFjNjFhMDZkYTM0OF8xMjQvZnJhZzo0MmIzNjk2ZDE4NmQ0OTQwYTU5YjkyOTEwMDgyMmVhMS90ZXh0cmVnaW9uOjQyYjM2OTZkMTg2ZDQ5NDBhNTliOTI5MTAwODIyZWExXzIzNTk_2cf9e642-986f-4c65-9864-5b151cfddd5b">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>78
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MFFV7]:K'\UU'^.:'04U((%80:IV-X/=5OI&7GV@99WMA2ZFU#+-#3W!7*/,
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M_)J]_"[JA&C9WBQ+BNJO]U)C_8$W6Q4R6];!BL$R3M>OT8^Z([8" NP(0'4
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M"5 $[KD,Q\GL&"C-<[$SF6M+7XU=O6A=HL*8X"%:CQ29!8H"W!,:CC-:RU@
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M5(0.[1J313Z"MTB#CS5"9105(A-YL5385Z/\A\RWWV#@#L/M,"X(Q-+%,+Y
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MQPG8. /%@S=MF#LHJ6F*"=N:QD:T3$#?*V/\[L "]H/HXE]02P,$%     @
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M\7N[\0$50_%#-REE451'&=[J-+XQI7#NWJ8'@W6U6O/A@B>LM$TG12[U/!;
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MO+?%ZQ: M@D^A!'".KBL%5"PC?P9%X3- , FE=R B%Y"2# .)A)-=QW%D?A
M0+H3[PZS'LU91UDM2XC.:J@!.58]X[?)JA0;KEPMT<&4<8OYS%L&_KF>S7ET
M"^ KDVN4F#SUS<:*?()OHIHP\;)123F#I2HXEXPZP@,));Q-FZE+9S(7\1.#
M5@^[0R14VSUZ,;3G1OM$2QCRU6K^;(#??D+COA3<ROQ-VW!!-952P?@@ @CY
MH#.:+H!B0A*PJ>1!>]-$.4IF?"9*4])RY+]25Y"A?[$?ZN[_!KCZ?PD: J5U
M2RYH -%9XQ')+F$8#L02O6QD)('BZ1JP1()5;":BH0HQGU##J89F9:X!0/BY
M0G18MSO-!:E]:.M!)8)SMR5H7 1D&WU?%B-!T=QZ@VD"#E#%J2+2\\6?0[4.
MZ=4E0NQB-0A\M,S&J>E1+C(I%<*SZ13<@#V!EZ28@G<?YM/MJE+&5AEA*A""
M7S1P'AD,(ZA(7KA,V4.XOL+(:OB$H9'3D<RR73?N?\A<<:/QR6+D)A8H/]$0
MCZ)R$]QO-"S!I+>EVL[2^(TX;O"XG\\UAETJ#A/6B-3",U!G/RZ:_#HG?21[
MW/09Y=-Q'Y L: ^F/GY8;DRWM@):N1F,8C6IQ=1+6[M*B!:+'81K52#285[(
M/WS Q1Q_56P0&EW3Y?*SC3L9)Q%B@*RI2RMB/B$[:J,JEL@GB2!3$2_#$G6W
MDMW0&#OY>-6*D%,DR*(+M"*:87P@4_#3?C" 0781Q_0:H(?,J3@DB!@L8XC;
M&%"2 >]F">#)T)*; M!RU \(NMON3!G\IBD^.WN: OFH+K*WD\5G!HEZ.5LJ
M36O-:'50][^SM*D="U/!=9S$+.KK/&YX-4$NC)ZQPCSC@^7-<MLWFQ8&VM1V
MDAU=!.[21@R"'#M:EQ6#7&X_O1*1X@<19_#@T>+QZ>D8Q.1X;<Q4+9-4LH91
M=B[ 7%W)CH*_I7$S <E0R=.0GC%$+PG./L@Y8-U*'3T]#9=8F:VA'*>LAQ%P
M:34_J7 *]+0BD.,2(P E_L)+F#.@@S'0D-BV+)K!$6I!HAJ[KAUU-YKA/^GW
M;=.Y<J,(A-%VS<QT<>W:VJ34:'#C!!.PLPR52UVG.M)?3(E W$(\7S6K>N ,
M5:AF2610O.W6!N8D;G*I8">N03%NR%[ZB O&\++VK:#"N2!,TN6,\V&(ZOC0
M+=.W )XR4PB"FCZ4EWPF&2>:!_+%/Z!X7Q7O6EH<#G\U+"MW+4DZSR1G)COG
MBV>0'?63.:DB= JZEJ(:#>=; & U@MJUO(5X?2QS[=)\/I\/@C6+,19JS!;9
M@B2)&J3NVG@"HS\A*"HZ=Y.&L25/&9&M)J(YK#S4=Z;Q<$5=0*P3@PHU^ )Z
M,</X5*[B#7W:%RE]G=7OQD>C59/YTZ.7DTSXST!0>YGPMQO7:KWE'__Q_/S\
M]*LWW[^6O\Z^.IX%>>=/8BS6PS T]C94R4"SKG^4K!":W&='LHW042/38] B
MXAE<:Y6"+>[QM9M$9M>T1Y#9ZI,#-/$W<6&4D#N6U:Y6K@SR-.)+R57T&PI$
MC(1FAC7/NE7JS\AY*^["#QS5B1.)46=,G8<-U62!@;/I^UI#P+%2J,6QJ_&G
MB_C3T;%6L/B+[/B>[ ;[FC8JJ=1='+A;DZ@=0(F'Z& ^@F9%:P;<GS;5"S57
M.Y$L$CTHDUD?4174P -S3F4H!I;!F1R</:"!XO%3758PIKG47P(6;9?.R*1/
M5&N8L7.]^(.3X"\#S<]C@EFBK1?/"SCA,L3E=YB9!PR<V]U0!^1&T%V7@WKZ
M(=4.#]%_K +#3/:R4T^GV_9%1 I3)1O\WQI>!BXWK;?"^#_;8#D./LL0C+K(
M=Z:A<E7!;_M<>.!2G:]#O!C+HW=(B*C(#:"1%#Z'G8"?B2?X[.G):;&,>7L2
MF,NQYO%E@&4H/,C>G#V/M7V:;D"^LI^5-?2ERK)T1;'TQ*FT8'AT9J6D[,6:
MO.0O=$H5J) @*Z/TPK)81B=V3\%$# Y+B#U9GRSD :,1F"0'EZ:3,@)1(NN'
M\O>G#GJ\2"'GG/#,VMWM&3-[A&G#6FDC\M?GU(QRJ%P_*$ABS(-B<JH_AT8M
M0X!N-);SV#RI/?W1V;.O#J,E28MB%8 JP26R^CW92+&F$->=YK._+!Z<'0=[
MSB&^*AZ<'S-%)T*18!S<M9-J=ZP)88:V:2PY8#N3)XPG%'EB4#$DK) &<C#'
MH^.B&HA_(U:D5V)YF9/9#UBOC!BRE7SC\3'# 2L#B3!,(\-8>/A*1GCPY!@T
M^!WV3[ ?7\PH@4F+GY+>:".=\KN58K+=RU@KVL%444RDJX;,<&VE41-V,2C=
M!"[<V"2,HUD7Y\3U3!HPA"#;K '8,;8D&K_0Y-$U=D03NU1EPQI@66,R#+%I
MF2(A.4!0)I52QT YY>U5 _9G7 V!/D%(L(>9[3BH"G$]DZ$8@);M*!-DYE(V
MB "/PC^F2NQVV5:WT;BHT*>"\4%7IITE!ZA)Q-Q)Z42[227(WCJU-6K,Q]K-
M@>KJW/F9&5(_S:.\S!F-"=HP'S-:?] BB?YEEB2]#98M[?CXF-6$-)):+3X+
ME3OFDK#S]6U,"=DJ57Z]!3.4OM3*564HRJM,"TL9#M=0C<J,;1\+@<.+XI=-
M"_SP"MZLP>"_PH^DO7?=G.$9E[/$A]&<#@M=)&(1%&DJ2/<.)EO6M#>S1^YQ
MUT#^G]P.<#Z6[%W#YC,$X>W-GJ-E!F3E.M_'YJKH3>\'&5'GG(_%=@V/=E)'
MK406FI@84LN@6;*/I)V6IA;3),VQ&BN(9]D:[%>RB[$%;J0Q"L9LIV7Z?+-S
M65GD8?L=8U^"\O8]S.;/:GARP([1?M;HY&++5D+3:/>=T/XO;M5GCQX_3RDE
MM3!-Z(7.K'5J"( ]?F.RH.03(#8STN4F=J=$.Q0'+_XP?@.R>P+Z$"QHYRCC
M:.5)P&8?PW=G3\?&O8CF8]](-HLD-_.VRGT]D?*\9Q/%'"@K6 V12L!_3A33
M8\F3A85?M;U#ZG>C'3-UW981F&2T?4P':)+RI?"7T.T7%V,1TM3#*%\I ON\
M6-F@']*$H%XI\QA<4>XG8*T;#%G;4,82-,(6"FU7W5OP80/RZVQ<G_<!1"(G
MR>HY8N["'F9;-(USJ;6P)[^[;@U\968V[Y#6L.8=$BUL2#$R7O2;B)%,%9&%
MC;G94E+#DGG)-C+UVDB..)B$Z"ED_DR+V"JW4R6ZLKL^=B:>GZDF-9"7,D;W
M-TP?U6W$FA\-8RD9]RO:W+(<4'9,U^9=RT$9M/\P\64V]F'FRBI_,LTDA_'W
MEF19 [3!FYC,U(UKNFMN2K8ZF=W&:'H?]$.\-H6FQ+#XJ<RHI1C36V;J)DJ.
M$H-G1$M/']TK<P&["-L!?TUS^TF6DLK!'1Q"]Y#TQVH#_).8YKB8K&-I&2F"
MVI@A)#*T^\O+2+\T2[J@2UHG)>LRN.8?M6E%+<N8"O@$PMD;H_42EQKVS\]T
M'Y0BEC*I:K>VUWXA2M386?DK5_,)!<E0,8V-*#$1EI?35-=Z'5 ;)^@A.C5<
MC=4$7RJM!$ R-N<0L3(IR%K;JFYOLF8(KQDOV^5%A(,PNX)KY7*C&V'/^%Z8
MVT1_DF]/AN?N3I/9/5\IF=?WM=FT6Y.:"<)4^6ZZB5:>+D(SN5(KFOW1',Y=
MN:R;X"AZS8?<7<]YEN/\;.EW9>$S3'>8)1E*ODEA@3BT9A C*Y5AZ2Z0B&\,
M&*C7DU"&?!LCE_M"*6UG9:_\(OF$SYZ>/$M)IM Q@ '[/?B5,DZ?/7N4X:]8
M-U)%"C VC%+/3MV(:Y0N#!KEV:MD?Z?&4_2B-Q\F?,P'^WL ^=-1YMFT.5F/
M%4A5PGPH8E&8_;1G)Z?GB6D?+R2S/-;_7ZK)8SO$@4KYOZ,G8M;Q^V]IA5"S
M%VW,R,%8T_]8<P2I^MLM$)EA#3T.'$4'7*199@J5X2H&W(/WVNYEN&PG5G@\
M:] 5V/U*DNRAQ>[&L9T1CB<:'+%<X@W:L>T:$_(H$N?+.F*2X\AS!MI0$&I:
M>;#S1^SSU]8B^#N %TT3[(;0>R5=92;V154V1--Y/8^M2J-C2NA)W#VA6B4I
ME-A1$7M_F%7C?%4KN;;O"2[[V+OWTX!U0BEG-?E8Z$HUKH@*UAW%Z\^AN\WJ
M6<$-'\"!TR9%@(R0F61R4!/TJ3(8_=#GOG@KM:U4''QI?'_7*9EDP'Z0-M6K
M,'FPMEIR/+C@!T??O_V)9[@.U_2TDG=_E4X-((:)Q;@3[9VOG;T>$86W<RZ$
M_M_1_\=LQN%\\>+@;S!09:HGAT,TM&B3(UVQ?3,+CO92PNGD7IXHS&*-*?'I
MZ:&)FA+,VAP]$:HF69T/\BZTX;V3KFB8 '\/ FJM(KY0V$E0YW;>T[F8GN-C
M)B1%;KI9VM<<HJ]Z)?W-@U1G-ZW?.?H5?PMIV^Z_),W0DFRNI/4@=OG8V.5$
M$%%I<QA560\A,2\O40)59EQWK!7FE;0IM'G\Y%$&\,*9$GP=T?O;P-I%<?;X
M3'8D-")J;H$A9IEA2_%2VG4<SJ=+?V_202;2Q[T0].4 )DQH7&;]*'\C])F,
MKS"<2 &1T2A'0UKR 8%I-OKAX(1Q[UALY\=_VA9!A\DC@?,D?]=NW78AV2H(
M4<HA[$L"2E:H6->C  93G.&[_O\0*)AFXKRCU">+G7K91ZF(S=9JZ^/9JD6(
M*]0"I9@B113-X:""B-$/G<"IK.<BL"9/)>SW9J>0V7$(VTU*6T+<M<'&1^>Q
MTN=D*@%0+(1$RYP$M))&J24AZA(/S4_*G0J B\%$.@VA%1+ :68[V#:8.M%B
MG/%S#!)_HR87/P#39$N/$3&(?.?ZWB^';KU9%.\NB@>A8V3Z?FP> 7"P[_5P
M8)Q=4GW<VMF,[/6%J*\C@SKKMDOI?AM\(']%U!B.XZ3VVL,)T/L9EH530+Q7
M@">^^,7&CO] UM7+U'^O^9ENZ?HN)6)>P[=*LG=<8-8LK4MTF4U5P6OB(D/&
M\\Y5!DMGMPV%(Z7*__5E1^^K(6X\?1C\L"B7'I6_S7LTIP(KEB:*Q &\>NA
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MO<*%.%N]:.Y:G]"<U&@8Y3K,^56/;JO'IGG%PIB^B>8N-G>&QD3-!T2<O.<
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M+<#O,VM#_D 7-.\OOOH/4$L#!!0    ( %B"I53.$;Q-C@0  ,L*   9
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;+5::V_;.!;]*T2V6+2
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M5S39(BX, 7U!:#[<;723-JI4C05)*#LW4)P,>)K0!)^H[(K))OYKO9)VRR&
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MM>]31)NPXG58Y_%!P(],!Y!$/8C#.#Z EVS23#Q>L@>O20S^F*?&:CH)?Q[
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M<VAE970Q."YX;6S%5FUOVS80_BL'#1@ZP+4LV5[2U#809QE:H!V"IEL_#/U
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M6":ZM]1KHW.=2A/$(DUM8X(V:W%F2YUJY<5>=_3D8!( BDQ/TA; <00POP7
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M-^EVX&P/5M5^R)LK2U'WVX)F=-2.@/Y?*&4W!Z>@F_I/_P502P,$%     @
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M=V]R:W-H965T<R]S:&5E=#(U+GAM;(U5WT_;,!#^5T[1'D!BI$U_L%5MI;:
M8!H"4<8>ICVXR26Q<.S,=EK87[^SDZ8%0;67VF????=]SMUUO%'ZR>2(%IX+
M(<TDR*TM1V%HXAP+9DY5B9)N4J4+9LG466A*C2SQ084(HTYG&!:,RV Z]F=W
M>CI6E15<XIT&4Q4%TR]S%&HS";K!]N">9[EU!^%T7+(,EVA_E'>:K+!%27B!
MTG E06,Z"6;=T;SO_+W#(\>-V=N#4[)2ZLD9U\DDZ#A"*#"V#H'1LL8%"N&
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M02SY2X#6*_#]PAC:;+R#[MLR^0-02P,$%     @ 6(*E5 T\[:3[ @  ? <
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M LD94L"AKQ5;I-+[O8+TC,3?&J"$YKN?^2<L3()X1J-%B+U?^+Q;[/<\M ]
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M'7S0'/G?_BDE,&21[;*894<!'YF]@,GX'+)1ECTOYW!Z<G8$=C(49Q)A+P_
MWAO+A:,Z;-!YX5N+1T O!]#+"#HY /J@2Z,0EIYYI-?MSV'&)-,EJ>(4ALK?
M<2Y"'ZCVH4'2.(KM8/7V;T_.@>!DRX5>PZ%6_OA"#."!HKF?1_A?#?ROCA9E
M84V)R!U4UJC]VH"I8-8Z,G<.__LJ.N#K"!RVQ::XR29YNMEGD^Z]985V'2?6
M06E:[;MG/6B'I7#7S<(?\VZCT*M8"RJ Q(I<1Q?O*+[MIK03O&GB9*R,ISF+
MQYH6&]I@0/>5,7XGA ##JBQ^ U!+ P04    " !8@J540A'66N$"  "]"
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M(8.01=D_^9X7X@  ?MH!5@ZPZH#N$8"= ^Q3 =T<T#TU)2<'.*=&Z.6 WJD
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M-S?PM?%JFPV7[A1GI.TNMSHJKI0L3^Y1UW S%[QDKK8&F%S"#56H858I34W
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MZO<9Y_+U2SK ]A6>R_\!4$L#!!0    ( %B"I50<+^@3H0,  -D0   9
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M:<;UHSA]AE+0U.)M!%?Y)SJ5M8&'-IG2(BF;#8.$I<4W_55.1*,!3P8:2-E
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M0M PO=P2O"(LF2"?KRD5AYO$07Z6/OX/4$L#!!0    ( %B"I53^FH3O[00
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M#TL4$7$./H.G!P^<?3H'GQ);MQ$AJCK$V)(*>@+ \G.8LPPF;(#I@EM&92C
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MV25P]B+9)KWE7#(I69P^AA@%F"<"ZO<58_+M)7%07,5/_@%02P,$%     @
M6(*E5'J?6QG< @  X <  !D   !X;"]W;W)K<VAE971S+W-H965T-#8N>&UL
MI57;;MLP#/T5PD\MT,6)G>Q2) %R&]J'#D&#;0_#'A2;B87*DB?)3?OWHV3'
MRZU9L+W$NO <'C(4V=\H_60R1 LON9!F$&36%K=A:)(,<V9:JD!)-RNE<V9I
MJ]>A*32RU(-R$4;M]OLP9UP&P[X_F^MA7Y56<(ES#:;,<Z9?QRC49A!T@NW!
M(U]GUAV$PW[!UKA ^[68:]J%#4O*<Y2&*PD:5X-@U+F=]9R]-_C&<6-VUN B
M62KUY#;WZ2!H.T$H,+&.@='G&2<HA",B&;]JSJ!QZ8"[ZRW[9Q\[Q;)D!B=*
M?.>IS0;!QP!27+%2V$>UN<,Z'B\P4<+X7]C4MNT DM)8E==@4I!S67W92YV'
M'0#QG 9$-2 Z!'3? ,0U(+[40[<&="_UT*L!/O2PBMTG;LHL&_:UVH!VUL3F
M%C[['DWYXM+5R<)JNN6$L\,9TY++M8$Y:EAD3".,K-5\65JV% A6P83IE$LF
MX Z9L-D-W,ND!5=?F-;,_<O7<#5%R[@PU_ .C.,PVP^7\,"%H)(P_="27N<U
M3&IMXTI;](:V&!Z4M)F!F4PQ/8&?GL=_.H,/*4]-LJ)MLL;16<('IEL0=VX@
M:D?1"3V3R^&=4^'\G_?9/WO?2T;<5$[L^>++*^?':&FLIK?_\PQ_M^'O>O[N
M&_QS95%:SH1XA92+TI4:8%X(]8H(]#"2)U"%ZS;FACH6.>:)Q;2J/"@EMP:8
M3*% [=NI3'#OSF;,P@9IS\A-X^&*2K8JWNM3%5MI[GG-K@<_#WO]\'FW!HXM
MXGV+Z5\Y9L<6W<9B+YF])IF]L\E<5,^QBEF5(H7E0=R,LN722 T6U HDC2BA
MS,E7VSM2%QU$>&S1.= ?[K2L'/7:SPH#B2JEK6JP.6W&T<AWX8/S<>=VTCEQ
M/J7Q54V;/_35[*.'L.;2@, 5N6JW/I!.7<V3:F-5X1OF4EEJOWZ9T0A&[0SH
M?J6H-.N-<] ,]>%O4$L#!!0    ( %B"I5186J4H-P,  *8)   9    >&PO
M=V]R:W-H965T<R]S:&5E=#0W+GAM;*5636_;, S]*X0'#"W0U;&3-&V7!&@^
MANU0(&BQ[3#LH-A,+%26/$ENNG\_2G:\-'738+O8$LWW*#[1E(8;I1],AFCA
M*1?2C(+,VN(Z#$V28<[,N2I0TI>5TCFS--7KT!0:6>I!N0CC3N<BS!F7P7CH
M;0L]'JK2"BYQH<&4><[T[PD*M1D%4; UW/%U9ITA' \+ML9[M%^+A:99V+"D
M/$=IN)*@<34*;J+K^<#Y>X=O'#=F9PPNDZ52#V[R)1T%';<@%)A8Q\#H]8A3
M%,(1T3)^U9Q!$](!=\=;]D\^=\IER0Q.E?C.4YN-@LL 4ERQ4M@[M?F,=3Y]
MQY<H8?P3-K5O)X"D-%;E-9A6D'-9O=E3K<,.@'C: 7$-B/<!O5< W1K0/39"
MKP;TCHW0KP$^];#*W0LW8Y:-AUIM0#MO8G,#K[Y'DUY<NCJYMYJ^<L+9\9QI
MR>7:P (UW&=,(]Q8J_FRM&PI$*R"*=,IETS 9V3"9F?P12;G<'*'B9()%YSY
M'5<KF*H\IY%G,?#58.KA*B]*BS!AAB? 9 HS+LB0PGQQ?PHG,[2,"W,*'\!4
MR/K%)=QR(8C<#$-+N;H5ATF=UZ3**WXEKR[<*FDS W.98MJ"GQW&7QW AZ1Q
M(W2\%7H2'R2\9?H<NM$9Q)TX;EG/]'AXU);._T6?_W/T9V)TFZKK>K[N\57W
MXV9IK*:^\?, ?Z_A[WG^WBO\WWU_P/0#>T1-[0Z2JC2KRGK_[C*.HH]+7Y G
M?&L^;:NR*D[?QW$]]W$<#_K#\'%WYUI\KN+G/K,6G\OHN<^\C:?;^#P3HM\(
MT3\L]&I%'=G]G*G[Z:@G@\&DU-QR--<'E+YH EP<5'J>%T+]1J*U*GD 5;AF
M8,[H"*'=Y(G[S;VZ4$INR>[^_P*U/^!D@KL?W]J*BQ?R=/8VXJ7'_C:\R3%_
MZ1&U;\&@46CP_[68UBWQ#0D&1U1CB\]5;T^&%I\7U7B8IY(BW#EX<M1K?^(;
MRK"4MNH&C;6Y5-SXLW3//HFNIU&+?4:7D.K.\)>^NL%02UIS:4#@BD)US@>T
M4EW="JJ)584_]I;*TB'JAQE=I% [!_J^4LIN)RY <S4;_P%02P,$%     @
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M0$!6>!?*![;_F:0!M36?ST)A_H-]:NLV@+\3DD4I6'D0T3CYQ(<T$04 @A4
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MHRQU>7Z84U^-VFV@YUNE['GB E2=^N(G4$L#!!0    ( %B"I50+A5^#1P,
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M_T\8W7*I"S5U15TI&W=Q],HT@#:L]28,A)65F@RNW%9Y,9,KU5P4_,MMN;O
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M4')O<',O8V]R92YX;6Q02P$"% ,4    " !8@J54F5R<(Q &  "<)P  $P
M            @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (
M %B"I53=V8(^)04  %H5   8              " @0X(  !X;"]W;W)K<VAE
M971S+W-H965T,2YX;6Q02P$"% ,4    " !8@J54MZ8XDQX'  "X'0  &
M            @(%I#0  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#
M%     @ 6(*E5$-I"A#1 P  3@T  !@              ("!O10  'AL+W=O
M<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( %B"I52,G?=0B08  /(:
M   8              " @<08  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q0
M2P$"% ,4    " !8@J54<<T&?(,"   J!P  &               @(&#'P
M>&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ 6(*E5._U#8I;
M"0  VT(  !@              ("!/"(  'AL+W=O<FMS:&5E=',O<VAE970V
M+GAM;%!+ 0(4 Q0    ( %B"I50%ME[P1 <  .\<   8              "
M@<TK  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " !8@J54
M9W]/E(P&  !-$0  &               @(%',P  >&PO=V]R:W-H965T<R]S
M:&5E=#@N>&UL4$L! A0#%     @ 6(*E5/)0NL9* P  UP8  !@
M     ("!"3H  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    (
M %B"I52KIA403@0  )0*   9              " @8D]  !X;"]W;W)K<VAE
M971S+W-H965T,3 N>&UL4$L! A0#%     @ 6(*E5'H(Z"II!P  F1,  !D
M             ("!#D(  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"
M% ,4    " !8@J54IUII3B0&  #,#P  &0              @(&N20  >&PO
M=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( %B"I52[#7!+ 1\
M /5;   9              " @0E0  !X;"]W;W)K<VAE971S+W-H965T,3,N
M>&UL4$L! A0#%     @ 6(*E5([;/!=E#0  RR@  !D              ("!
M06\  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " !8@J54
MSA&\38X$  #+"@  &0              @('=?   >&PO=V]R:W-H965T<R]S
M:&5E=#$U+GAM;%!+ 0(4 Q0    ( %B"I51^_X03\@L  (\G   9
M      " @:*!  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%
M  @ 6(*E5*HV*H#&!   Q@T  !D              ("!RXT  'AL+W=O<FMS
M:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " !8@J54>\A9$Z@#  "G"@
M&0              @('(D@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+
M 0(4 Q0    ( %B"I50H+7WQ9 P  .DC   9              " @:>6  !X
M;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ 6(*E5%DRXO=>
M!@  ,A0  !D              ("!0J,  'AL+W=O<FMS:&5E=',O<VAE970R
M,"YX;6Q02P$"% ,4    " !8@J54Y)?91Z8&  #D$P  &0
M@('7J0  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( %B"
MI50Y:H#&( ,  #@(   9              " @;2P  !X;"]W;W)K<VAE971S
M+W-H965T,C(N>&UL4$L! A0#%     @ 6(*E5 Z[ER6@!    0P  !D
M         ("!"[0  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
M    " !8@J545CWVDYX$  #A"@  &0              @('BN   >&PO=V]R
M:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( %B"I51U(M5 S (   P&
M   9              " @;>]  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL
M4$L! A0#%     @ 6(*E5')HU3_U @  9P8  !D              ("!NL
M 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " !8@J54#3SM
MI/L"  !\!P  &0              @('FPP  >&PO=V]R:W-H965T<R]S:&5E
M=#(W+GAM;%!+ 0(4 Q0    ( %B"I50)MR'9  <  $T4   9
M  " @1C'  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @
M6(*E5*WS>(^P!   'P\  !D              ("!3\X  'AL+W=O<FMS:&5E
M=',O<VAE970R.2YX;6Q02P$"% ,4    " !8@J54I9E@4F8"   V!0  &0
M            @($VTP  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4
M Q0    ( %B"I51"$=9:X0(  +T(   9              " @=/5  !X;"]W
M;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ 6(*E5/([8VX[ P
M@@L  !D              ("!Z]@  'AL+W=O<FMS:&5E=',O<VAE970S,BYX
M;6Q02P$"% ,4    " !8@J54KF)TN:8"  "7!P  &0              @(%=
MW   >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( %B"I51L
MNV3.Q0,  /@.   9              " @3K?  !X;"]W;W)K<VAE971S+W-H
M965T,S0N>&UL4$L! A0#%     @ 6(*E5)ME66"U!   6A4  !D
M     ("!-N,  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %B"I50M)S,8.P<  ,XC   9              "
M@9C\  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ 6(*E
M5!POZ!.A P  V1   !D              ("!"@0! 'AL+W=O<FMS:&5E=',O
M<VAE970T,2YX;6Q02P$"% ,4    " !8@J54-B)053X%  !F%P  &0
M        @('B!P$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0
M   ( %B"I52J0R\.IP(  *\&   9              " @5<- 0!X;"]W;W)K
M<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ 6(*E5"_/(K.T!   5Q<
M !D              ("!-1 ! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q0
M2P$"% ,4    " !8@J54_IJ$[^T$  "6%P  &0              @($@%0$
M>&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( %B"I51ZGUL9
MW (  . '   9              " @40: 0!X;"]W;W)K<VAE971S+W-H965T
M-#8N>&UL4$L! A0#%     @ 6(*E5%A:I2@W P  I@D  !D
M ("!5QT! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    " !8
M@J54$2UC,SP$  "6$0  &0              @('%( $ >&PO=V]R:W-H965T
M<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( %B"I50_&S(9D@0  "P5   9
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M970U,RYX;6Q02P$"% ,4    " !8@J54DH9T"PH#  "Z"@  &0
M    @(&S.@$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    (
M %B"I53I=&=Y00,  +4+   9              " @?0] 0!X;"]W;W)K<VAE
M971S+W-H965T-34N>&UL4$L! A0#%     @ 6(*E5 N%7X-' P  %@H  !D
M             ("!;$$! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"
M% ,4    " !8@J54@-R]FQ,$  #!#P  &0              @('J1 $ >&PO
M=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( %B"I53"%=V?L ,
M 'D,   9              " @31) 0!X;"]W;W)K<VAE971S+W-H965T-3@N
M>&UL4$L! A0#%     @ 6(*E5&:CO7,R P  #!,   T              ( !
M&TT! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !8@J54EXJ[',     3 @
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8;6Q02P4&     $( 0@ %$@  8EH!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>253</ContextCount>
  <ElementCount>268</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>77</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Statements of Earnings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings</Role>
      <ShortName>Condensed Consolidated Statements of Earnings</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Divestitures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/Divestitures</Role>
      <ShortName>Divestitures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2107103 - Disclosure - Restructuring and Employee Severance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeverance</Role>
      <ShortName>Restructuring and Employee Severance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2112104 - Disclosure - Goodwill and Other Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets</Role>
      <ShortName>Goodwill and Other Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2117105 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings</Role>
      <ShortName>Long-Term Obligations and Other Short-Term Borrowings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2121106 - Disclosure - Commitments, Contingent Liabilities and Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation</Role>
      <ShortName>Commitments, Contingent Liabilities and Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2123107 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2125108 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2128109 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2132110 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2136111 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc</Role>
      <ShortName>Earnings Per Share Attributable to Cardinal Health, Inc.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2140112 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2147113 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2308302 - Disclosure - Restructuring and Employee Severance (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables</Role>
      <ShortName>Restructuring and Employee Severance (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/RestructuringandEmployeeSeverance</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2313303 - Disclosure - Goodwill and Other Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Other Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2326305 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/FairValueMeasurements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2329306 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/FinancialInstruments</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2333307 - Disclosure - Shareholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareholdersEquityTables</Role>
      <ShortName>Shareholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareholdersEquity</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2337308 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables</Role>
      <ShortName>Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2341309 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformation</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2348310 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Discontinued Operations and Disposal Groups (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails</Role>
      <ShortName>Discontinued Operations and Disposal Groups (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails</Role>
      <ShortName>Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails</Role>
      <ShortName>Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Restructuring and Employee Severance Narative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails</Role>
      <ShortName>Restructuring and Employee Severance Narative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - Goodwill and Other Intangible Assets (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails</Role>
      <ShortName>Long-Term Obligations and Other Short-Term Borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails</Role>
      <ShortName>Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2422411 - Disclosure - Commitments, Contingent Liabilities and Litigation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails</Role>
      <ShortName>Commitments, Contingent Liabilities and Litigation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2424412 - Disclosure - Income Taxes (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/IncomeTaxes</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2427413 - Disclosure - Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2430414 - Disclosure - Financial Instruments (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Financial Instruments (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2431415 - Disclosure - Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails</Role>
      <ShortName>Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2434416 - Disclosure - Shareholders' Equity (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails</Role>
      <ShortName>Shareholders' Equity (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareholdersEquityTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2435417 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareholdersEquityTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2438418 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails</Role>
      <ShortName>Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2439419 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails</Role>
      <ShortName>Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2442420 - Disclosure - Segment Information (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationNarrativeDetails</Role>
      <ShortName>Segment Information (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformationTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2443421 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails</Role>
      <ShortName>Segment Information (Revenue by Reportable Segment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformationTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2444422 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails</Role>
      <ShortName>Segment Information (Segment Profit by Reportable Segment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformationTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2445423 - Disclosure - Segment Information Revenue From External Customers By Geographic Areas (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails</Role>
      <ShortName>Segment Information Revenue From External Customers By Geographic Areas (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2446424 - Disclosure - Segment Information (Assets by Reportable Segment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails</Role>
      <ShortName>Segment Information (Assets by Reportable Segment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformationTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2449425 - Disclosure - Share-Based Compensation (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails</Role>
      <ShortName>Share-Based Compensation (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2450426 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails</Role>
      <ShortName>Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2451427 - Disclosure - Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails</Role>
      <ShortName>Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2452428 - Disclosure - Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails</Role>
      <ShortName>Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2453429 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails</Role>
      <ShortName>Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="cah-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2454430 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails</Role>
      <ShortName>Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="cah-20220331.htm">cah-20220331.htm</File>
    <File>a22q3_10qx033122xexhibit102.htm</File>
    <File>a22q3_10qx033122xexhibit311.htm</File>
    <File>a22q3_10qx033122xexhibit312.htm</File>
    <File>a22q3_10qx033122xexhibit321.htm</File>
    <File>a22q3_10qx033122xexhibit991.htm</File>
    <File>cah-20220331.xsd</File>
    <File>cah-20220331_cal.xml</File>
    <File>cah-20220331_def.xml</File>
    <File>cah-20220331_lab.xml</File>
    <File>cah-20220331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cah-20220331_g1.jpg</File>
    <File>cah-20220331_g2.jpg</File>
    <File>cah-20220331_g3.jpg</File>
    <File>cah-20220331_g4.jpg</File>
    <File>cah-20220331_g5.jpg</File>
    <File>cah-20220331_g6.jpg</File>
    <File>cah-20220331_g7.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="840">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>83
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cah-20220331.htm": {
   "axisCustom": 9,
   "axisStandard": 24,
   "contextCount": 253,
   "dts": {
    "calculationLink": {
     "local": [
      "cah-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cah-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "cah-20220331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cah-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cah-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cah-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 502,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 5
   },
   "keyCustom": 27,
   "keyStandard": 241,
   "memberCustom": 34,
   "memberStandard": 41,
   "nsprefix": "cah",
   "nsuri": "http://www.cardinal.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i21939e337a964eb182b2e0d93b533226_D20210701-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.cardinal.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i21939e337a964eb182b2e0d93b533226_D20210701-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i21939e337a964eb182b2e0d93b533226_D20210701-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107103 - Disclosure - Restructuring and Employee Severance",
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeverance",
     "shortName": "Restructuring and Employee Severance",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i21939e337a964eb182b2e0d93b533226_D20210701-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i21939e337a964eb182b2e0d93b533226_D20210701-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112104 - Disclosure - Goodwill and Other Intangible Assets",
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets",
     "shortName": "Goodwill and Other Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i21939e337a964eb182b2e0d93b533226_D20210701-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i21939e337a964eb182b2e0d93b533226_D20210701-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117105 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings",
     "role": "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings",
     "shortName": "Long-Term Obligations and Other Short-Term Borrowings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i21939e337a964eb182b2e0d93b533226_D20210701-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i21939e337a964eb182b2e0d93b533226_D20210701-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121106 - Disclosure - Commitments, Contingent Liabilities and Litigation",
     "role": "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation",
     "shortName": "Commitments, Contingent Liabilities and Litigation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i21939e337a964eb182b2e0d93b533226_D20210701-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i21939e337a964eb182b2e0d93b533226_D20210701-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123107 - Disclosure - Income Taxes",
     "role": "http://www.cardinal.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i21939e337a964eb182b2e0d93b533226_D20210701-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i21939e337a964eb182b2e0d93b533226_D20210701-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125108 - Disclosure - Fair Value Measurements",
     "role": "http://www.cardinal.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i21939e337a964eb182b2e0d93b533226_D20210701-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128109 - Disclosure - Financial Instruments",
     "role": "http://www.cardinal.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i26a0d4c581b14b77bdddca64a58d5a16_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i21939e337a964eb182b2e0d93b533226_D20210701-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132110 - Disclosure - Shareholders' Equity",
     "role": "http://www.cardinal.com/role/ShareholdersEquity",
     "shortName": "Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i21939e337a964eb182b2e0d93b533226_D20210701-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i21939e337a964eb182b2e0d93b533226_D20210701-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136111 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc.",
     "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc",
     "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc.",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i21939e337a964eb182b2e0d93b533226_D20210701-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i21939e337a964eb182b2e0d93b533226_D20210701-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140112 - Disclosure - Segment Information",
     "role": "http://www.cardinal.com/role/SegmentInformation",
     "shortName": "Segment Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i21939e337a964eb182b2e0d93b533226_D20210701-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Statements of Earnings",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
     "shortName": "Condensed Consolidated Statements of Earnings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147113 - Disclosure - Share-Based Compensation",
     "role": "http://www.cardinal.com/role/ShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i21939e337a964eb182b2e0d93b533226_D20210701-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i21939e337a964eb182b2e0d93b533226_D20210701-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i21939e337a964eb182b2e0d93b533226_D20210701-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308302 - Disclosure - Restructuring and Employee Severance (Tables)",
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables",
     "shortName": "Restructuring and Employee Severance (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i21939e337a964eb182b2e0d93b533226_D20210701-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i21939e337a964eb182b2e0d93b533226_D20210701-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313303 - Disclosure - Goodwill and Other Intangible Assets (Tables)",
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables",
     "shortName": "Goodwill and Other Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i21939e337a964eb182b2e0d93b533226_D20210701-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i21939e337a964eb182b2e0d93b533226_D20210701-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2326305 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.cardinal.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i21939e337a964eb182b2e0d93b533226_D20210701-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i21939e337a964eb182b2e0d93b533226_D20210701-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2329306 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.cardinal.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i21939e337a964eb182b2e0d93b533226_D20210701-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i21939e337a964eb182b2e0d93b533226_D20210701-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333307 - Disclosure - Shareholders' Equity (Tables)",
     "role": "http://www.cardinal.com/role/ShareholdersEquityTables",
     "shortName": "Shareholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i21939e337a964eb182b2e0d93b533226_D20210701-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i21939e337a964eb182b2e0d93b533226_D20210701-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2337308 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)",
     "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables",
     "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i21939e337a964eb182b2e0d93b533226_D20210701-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i21939e337a964eb182b2e0d93b533226_D20210701-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2341309 - Disclosure - Segment Information (Tables)",
     "role": "http://www.cardinal.com/role/SegmentInformationTables",
     "shortName": "Segment Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i21939e337a964eb182b2e0d93b533226_D20210701-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i21939e337a964eb182b2e0d93b533226_D20210701-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2348310 - Disclosure - Share-Based Compensation (Tables)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i21939e337a964eb182b2e0d93b533226_D20210701-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i32f5ee07df944be68a4ca171d08f3c89_D20210701-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromDivestitureOfBusinesses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Discontinued Operations and Disposal Groups (Details)",
     "role": "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails",
     "shortName": "Discontinued Operations and Disposal Groups (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i32f5ee07df944be68a4ca171d08f3c89_D20210701-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromDivestitureOfBusinesses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)",
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails",
     "shortName": "Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)",
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails",
     "shortName": "Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Restructuring and Employee Severance Narative (Details)",
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails",
     "shortName": "Restructuring and Employee Severance Narative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)",
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
     "shortName": "Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i21939e337a964eb182b2e0d93b533226_D20210701-20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "if9374cb6cebc440eabca82aeeccf1677_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)",
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails",
     "shortName": "Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "if9374cb6cebc440eabca82aeeccf1677_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - Goodwill and Other Intangible Assets (Narrative) (Details)",
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
     "shortName": "Goodwill and Other Intangible Assets (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "if9374cb6cebc440eabca82aeeccf1677_I20220331",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "cah:TotalLongTermandShortTermObligations",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings (Details)",
     "role": "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
     "shortName": "Long-Term Obligations and Other Short-Term Borrowings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "if9374cb6cebc440eabca82aeeccf1677_I20220331",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "cah:TotalLongTermandShortTermObligations",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details)",
     "role": "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails",
     "shortName": "Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossRelatedToLitigationSettlement",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422411 - Disclosure - Commitments, Contingent Liabilities and Litigation (Details)",
     "role": "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
     "shortName": "Commitments, Contingent Liabilities and Litigation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "icbd0825dbe564a209ad97999fd39b901_D20220429-20220429",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:LossContingencyNewClaimsFiledNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "lawsuit",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "if9374cb6cebc440eabca82aeeccf1677_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "if9374cb6cebc440eabca82aeeccf1677_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424412 - Disclosure - Income Taxes (Narrative) (Details)",
     "role": "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "icac6fea690094cec98b24894f11a9dc5_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427413 - Disclosure - Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details)",
     "role": "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
     "shortName": "Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "icac6fea690094cec98b24894f11a9dc5_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
       "span",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430414 - Disclosure - Financial Instruments (Narrative) (Details)",
     "role": "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
     "shortName": "Financial Instruments (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
       "span",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "if9374cb6cebc440eabca82aeeccf1677_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "cah:CarryingAmountofLongTermandotherShortTermBorrowings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431415 - Disclosure - Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details)",
     "role": "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails",
     "shortName": "Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "if9374cb6cebc440eabca82aeeccf1677_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "cah:CarryingAmountofLongTermandotherShortTermBorrowings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "ib9fbfb0a0ab7487db3de84763b7fc3b0_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434416 - Disclosure - Shareholders' Equity (Narrative) (Details)",
     "role": "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails",
     "shortName": "Shareholders' Equity (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "ice6d3b2a080d44b5b66bace596c4726a_D20210701-20210930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i75e8b16bb97541c8bd805031f5452617_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435417 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)",
     "role": "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i1bc04df5c22d4ac594b0f37e4348fad8_I20210630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438418 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details)",
     "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails",
     "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439419 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)",
     "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails",
     "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossRelatedToLitigationSettlement",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442420 - Disclosure - Segment Information (Narrative) (Details)",
     "role": "http://www.cardinal.com/role/SegmentInformationNarrativeDetails",
     "shortName": "Segment Information (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443421 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details)",
     "role": "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
     "shortName": "Segment Information (Revenue by Reportable Segment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i50ba23949f524ee39edd3981f77140d5_D20220101-20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "if9374cb6cebc440eabca82aeeccf1677_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444422 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details)",
     "role": "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails",
     "shortName": "Segment Information (Segment Profit by Reportable Segment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "cah:ContingentAttorneyFee",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445423 - Disclosure - Segment Information Revenue From External Customers By Geographic Areas (Details)",
     "role": "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails",
     "shortName": "Segment Information Revenue From External Customers By Geographic Areas (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i70d8b7dbb46a4e8fa9f3548d4edd3460_D20220101-20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "if9374cb6cebc440eabca82aeeccf1677_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446424 - Disclosure - Segment Information (Assets by Reportable Segment) (Details)",
     "role": "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
     "shortName": "Segment Information (Assets by Reportable Segment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i25b4b6630ae44ef28341784008cfd847_I20210630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449425 - Disclosure - Share-Based Compensation (Narrative) (Details)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
     "shortName": "Share-Based Compensation (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450426 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails",
     "shortName": "Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i8371c1f57d5342cb99add0a3ce02e46e_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451427 - Disclosure - Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails",
     "shortName": "Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i3b4fbaa97a974c38af5e2e1e2e23cd58_I20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i81916c52c3fd4ebfbcb9cb988adcf939_I20220331",
      "decimals": "5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452428 - Disclosure - Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
     "shortName": "Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cah:AdditionalStockOptionPlanDataTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i81916c52c3fd4ebfbcb9cb988adcf939_I20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i7587b0e2335a4976aed28934df90543d_D20210701-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453429 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
     "shortName": "Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "iaa16d72f5cb94c3dae8ef889f5cf1b73_I20210630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i971a6ca11d6d4f408c6af2dc52b79810_I20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454430 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
     "shortName": "Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i971a6ca11d6d4f408c6af2dc52b79810_I20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i090402a139834d23aa8e6c3a5b7f46f8_I20200630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Shareholders' Equity",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
     "shortName": "Condensed Consolidated Statements of Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i090402a139834d23aa8e6c3a5b7f46f8_I20200630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i21939e337a964eb182b2e0d93b533226_D20210701-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i21939e337a964eb182b2e0d93b533226_D20210701-20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i21939e337a964eb182b2e0d93b533226_D20210701-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "role": "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i21939e337a964eb182b2e0d93b533226_D20210701-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i21939e337a964eb182b2e0d93b533226_D20210701-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Divestitures",
     "role": "http://www.cardinal.com/role/Divestitures",
     "shortName": "Divestitures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220331.htm",
      "contextRef": "i21939e337a964eb182b2e0d93b533226_D20210701-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 77,
   "tag": {
    "cah_A2.616Notesdue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.616% Notes due 2022",
        "label": "2.616% Notes due 2022 [Member]",
        "terseLabel": "2.616% Notes due 2022 [Member]"
       }
      }
     },
     "localname": "A2.616Notesdue2022Member",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_A200MillionShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "$200 million share repurchase program",
        "label": "$200 million share repurchase program [Member]",
        "terseLabel": "$200 million share repurchase program"
       }
      }
     },
     "localname": "A200MillionShareRepurchaseProgramMember",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_A300MillionShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "$300 million share repurchase program",
        "label": "$300 million share repurchase program [Member]",
        "terseLabel": "$300 million share repurchase program [Member]"
       }
      }
     },
     "localname": "A300MillionShareRepurchaseProgramMember",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_A500MillionShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "$500 million share repurchase program [Domain]",
        "label": "$500 million share repurchase program [Member]",
        "terseLabel": "$500 million share repurchase program [Domain]"
       }
      }
     },
     "localname": "A500MillionShareRepurchaseProgramMember",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_AdditionalStockOptionPlanDataTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A disclosure of additional data related to all stock option activity",
        "label": "Additional Stock Option Plan Data [Table Text Block]",
        "terseLabel": "Schedule of Additional Data Related to Stock Option Activity"
       }
      }
     },
     "localname": "AdditionalStockOptionPlanDataTableTextBlock",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cah_AggregateAnnualAssessment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Annual Assessment",
        "label": "Aggregate Annual Assessment",
        "terseLabel": "Aggregate Annual Assessment"
       }
      }
     },
     "localname": "AggregateAnnualAssessment",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_AlamedaCountyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alameda County [Member]",
        "label": "Alameda County [Member]",
        "terseLabel": "Alameda County [Member]"
       }
      }
     },
     "localname": "AlamedaCountyMember",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_Amortizationandotheracquisitionrelatedcosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of acquired intangible assets and changes in the fair value of contingent consideration obligations. This also represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Amortization and other acquisition-related costs",
        "terseLabel": "Amortization and other acquisition-related costs"
       }
      }
     },
     "localname": "Amortizationandotheracquisitionrelatedcosts",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_CARESActDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CARES Act",
        "label": "CARES Act [Domain]",
        "terseLabel": "Net Operating Loss Carryback [Domain]"
       }
      }
     },
     "localname": "CARESActDomain",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CVSHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CVS Health [Member]",
        "label": "CVS Health [Member]",
        "terseLabel": "CVS Health"
       }
      }
     },
     "localname": "CVSHealthMember",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CardinalHealthAtHomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cardinal Health At Home [Member]",
        "label": "Cardinal Health At Home [Member]",
        "terseLabel": "Cardinal Health At Home [Member]"
       }
      }
     },
     "localname": "CardinalHealthAtHomeMember",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CareFusionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CareFusion [Member]",
        "label": "CareFusion [Member]",
        "terseLabel": "CareFusion [Member]"
       }
      }
     },
     "localname": "CareFusionMember",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CarryingAmountofLongTermandotherShortTermBorrowings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying Amount of Long-Term and other Short-Term Borrowings",
        "label": "Carrying Amount of Long-Term and other Short-Term Borrowings",
        "terseLabel": "Carrying Amount of Long-Term and other Short-Term Borrowings"
       }
      }
     },
     "localname": "CarryingAmountofLongTermandotherShortTermBorrowings",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_CashReclassifiedToAssetHeldForSale": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Reclassified to Asset Held for Sale",
        "label": "Cash Reclassified to Asset Held for Sale",
        "terseLabel": "Cash and equivalents reclassified from/(to) assets held for sale"
       }
      }
     },
     "localname": "CashReclassifiedToAssetHeldForSale",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_ClassActionLawsuitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Action Lawsuits [Member]",
        "label": "Class Action Lawsuits [Member]",
        "terseLabel": "Class Action Lawsuits [Member]"
       }
      }
     },
     "localname": "ClassActionLawsuitsMember",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CommittedReceivablesSalesFacilityProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Committed receivables sales facility program that exists largely to provide liquidity by selling interests in trade receivables.",
        "label": "Committed Receivables Sales Facility Program [Member]",
        "terseLabel": "Committed Receivables Sales Facility Program [Member]"
       }
      }
     },
     "localname": "CommittedReceivablesSalesFacilityProgramMember",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_ContingentAttorneyFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Attorney Fee",
        "label": "Contingent Attorney Fee",
        "terseLabel": "Contingent Attorney Fee"
       }
      }
     },
     "localname": "ContingentAttorneyFee",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_CordisDivestitureAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cordis Divestiture",
        "label": "Cordis Divestiture [Axis]",
        "terseLabel": "Cordis Divestiture [Axis]"
       }
      }
     },
     "localname": "CordisDivestitureAxis",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_CordisDivestitureDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cordis Divestiture [Domain]",
        "label": "Cordis Divestiture [Domain]",
        "terseLabel": "Cordis Divestiture [Domain]"
       }
      }
     },
     "localname": "CordisDivestitureDomain",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CordisDivestitureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cordis Divestiture",
        "label": "Cordis Divestiture [Member]",
        "terseLabel": "Cordis Divestiture"
       }
      }
     },
     "localname": "CordisDivestitureMember",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_DOJInvestigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DOJ Investigation",
        "label": "DOJ Investigation [Member]",
        "terseLabel": "DOJ Investigation [Member]"
       }
      }
     },
     "localname": "DOJInvestigationMember",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount",
        "label": "Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount",
        "terseLabel": "Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount"
       }
      }
     },
     "localname": "DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_DiscountRateFairValueInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount Rate, Fair Value Input",
        "label": "Discount Rate, Fair Value Input",
        "terseLabel": "Discount Rate, Fair Value Input"
       }
      }
     },
     "localname": "DiscountRateFairValueInput",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated Liability for New York Opioid Stewardship Act",
        "label": "Estimated Liability for New York Opioid Stewardship Act",
        "terseLabel": "Estimated Liability for New York Opioid Stewardship Act"
       }
      }
     },
     "localname": "EstimatedLiabilityForNewYorkOpioidStewardshipAct",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_ExercisablePeriodOfPlansInYears": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The instrument's contractual term.",
        "label": "Exercisable period of plans, in years",
        "terseLabel": "Exercisable period of plans (in years)"
       }
      }
     },
     "localname": "ExercisablePeriodOfPlansInYears",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cah_FacilityExitAndOtherCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services.",
        "label": "Facility Exit and Other Costs",
        "terseLabel": "Facility Exit and Other Costs"
       }
      }
     },
     "localname": "FacilityExitAndOtherCosts",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_FloatingRateNotesdue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Floating Rate Notes due 2022",
        "label": "Floating Rate Notes due 2022 [Member]",
        "terseLabel": "Floating Rate Notes due 2022 [Member]"
       }
      }
     },
     "localname": "FloatingRateNotesdue2022Member",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_GoodwillImpairmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill Impairment",
        "label": "Goodwill Impairment [Axis]",
        "terseLabel": "Goodwill Impairment [Axis]"
       }
      }
     },
     "localname": "GoodwillImpairmentAxis",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_GoodwillImpairmentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill Impairment [Domain]",
        "label": "Goodwill Impairment [Domain]",
        "terseLabel": "Goodwill Impairment [Domain]"
       }
      }
     },
     "localname": "GoodwillImpairmentDomain",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_IPRDTrademarksandOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Includes in process investigation of new knowledge useful in developing new product or service or new process or techniques or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for the improvements to existing product or process and rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "IPR&amp;D,TrademarksandOther [Member]",
        "terseLabel": "Trademarks and patents"
       }
      }
     },
     "localname": "IPRDTrademarksandOtherMember",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_IndemnificationReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indemnification receivable from Patient recovery related to certain pre-acquisition tax exposures and transaction taxes.",
        "label": "Indemnification Receivable",
        "terseLabel": "Indemnification Receivable"
       }
      }
     },
     "localname": "IndemnificationReceivable",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_JudgmentForLostProfits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Judgment for lost profits",
        "label": "Judgment for lost profits",
        "terseLabel": "Judgment for lost profits"
       }
      }
     },
     "localname": "JudgmentForLostProfits",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_June2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "June 2027",
        "label": "June 2027 [Member]",
        "terseLabel": "June 2027"
       }
      }
     },
     "localname": "June2027Member",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_LawsuitTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lawsuit Type [Axis]",
        "label": "Lawsuit Type [Axis]",
        "terseLabel": "Lawsuit Type [Axis]"
       }
      }
     },
     "localname": "LawsuitTypeAxis",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_LawsuitTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Lawsuit Type [Axis]",
        "label": "Lawsuit Type [Domain]",
        "terseLabel": "Lawsuit Type [Domain]"
       }
      }
     },
     "localname": "LawsuitTypeDomain",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_LongTermObligationsandOtherShortTermBorrowingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Obligations and Other Short-Term Borrowings [Abstract]",
        "label": "Long-Term Obligations and Other Short-Term Borrowings [Abstract]",
        "terseLabel": "Long-Term Obligations and Other Short-Term Borrowings [Abstract]"
       }
      }
     },
     "localname": "LongTermObligationsandOtherShortTermBorrowingsAbstract",
     "nsuri": "http://www.cardinal.com/20220331",
     "xbrltype": "stringItemType"
    },
    "cah_LossContingencyClaimsSettledPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency Claims Settled Percent",
        "label": "Loss Contingency Claims Settled Percent",
        "terseLabel": "Loss Contingency Claims Settled Percent"
       }
      }
     },
     "localname": "LossContingencyClaimsSettledPercent",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cah_LossContingencyLawsuitsNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Lawsuits, Number",
        "label": "Loss Contingency, Lawsuits, Number",
        "verboseLabel": "Loss Contingency, Lawsuits, Number"
       }
      }
     },
     "localname": "LossContingencyLawsuitsNumber",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cah_MaturityDateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maturity Date",
        "label": "Maturity Date [Axis]",
        "terseLabel": "Maturity Date"
       }
      }
     },
     "localname": "MaturityDateAxis",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_MaturityDateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maturity Date [Domain]",
        "label": "Maturity Date [Domain]",
        "terseLabel": "Maturity Date [Domain]"
       }
      }
     },
     "localname": "MaturityDateDomain",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_MedicalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical [Member]",
        "label": "Medical Member",
        "terseLabel": "Medical"
       }
      }
     },
     "localname": "MedicalMember",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_MedicalUnitGoodwillImpairmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Unit Goodwill Impairment",
        "label": "Medical Unit Goodwill Impairment [Member]",
        "terseLabel": "Medical Unit Goodwill Impairment [Member]"
       }
      }
     },
     "localname": "MedicalUnitGoodwillImpairmentMember",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_MedicalUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Unit",
        "label": "Medical Unit [Member]",
        "terseLabel": "Medical Unit"
       }
      }
     },
     "localname": "MedicalUnitMember",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_MedicaldistributionandproductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical distribution and products [Member]",
        "label": "Medical distribution and products [Member]",
        "terseLabel": "Medical distribution and products [Member]"
       }
      }
     },
     "localname": "MedicaldistributionandproductsMember",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_NarativeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Narative [Abstract]",
        "label": "Narative [Abstract]",
        "terseLabel": "Narative [Abstract]"
       }
      }
     },
     "localname": "NarativeAbstract",
     "nsuri": "http://www.cardinal.com/20220331",
     "xbrltype": "stringItemType"
    },
    "cah_NetOperatingLossCarrybackAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Operating Loss Carryback",
        "label": "Net Operating Loss Carryback [Axis]",
        "terseLabel": "Net Operating Loss Carryback [Axis]"
       }
      }
     },
     "localname": "NetOperatingLossCarrybackAxis",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_NetOperatingLossCarrybackMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Operating Loss Carryback",
        "label": "Net Operating Loss Carryback [Member]",
        "terseLabel": "Net Operating Loss Carryback [Member]"
       }
      }
     },
     "localname": "NetOperatingLossCarrybackMember",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_Netproceedstaxwithholdingsfromsharebasedcompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow/(outflow) associated with the amount received from holders exercising their stock options and paid by the company to satisfy an employee's income tax withholding obligation when shares are withheld from settlement of a share-based award to cover taxes. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.",
        "label": "Net proceeds/(tax withholdings) from share-based compensation",
        "terseLabel": "Net proceeds/(tax withholdings) from share-based compensation"
       }
      }
     },
     "localname": "Netproceedstaxwithholdingsfromsharebasedcompensation",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_NewYorkOpioidStewardshipActMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New York Opioid Stewardship Act",
        "label": "New York Opioid Stewardship Act [Member]",
        "terseLabel": "New York Opioid Stewardship Act [Member]"
       }
      }
     },
     "localname": "NewYorkOpioidStewardshipActMember",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_NuclearPrecisionHealthSolutionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nuclear Precision Health Solutions",
        "label": "Nuclear Precision Health Solutions [Member]",
        "terseLabel": "Nuclear Precision Health Services [Member]"
       }
      }
     },
     "localname": "NuclearPrecisionHealthSolutionsMember",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_NumberofStateAttorneysGeneralfilinglawsuits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of State Attorneys General filing lawsuits",
        "label": "Number of State Attorneys General filing lawsuits",
        "terseLabel": "Number of State Attorneys General filing lawsuits"
       }
      }
     },
     "localname": "NumberofStateAttorneysGeneralfilinglawsuits",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cah_OpioidLawsuitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opioid Lawsuits [Member]",
        "label": "Opioid Lawsuits [Member]",
        "terseLabel": "Opioid Lawsuits [Member]"
       }
      }
     },
     "localname": "OpioidLawsuitsMember",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_OpioidLawsuitsStateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opioid Lawsuits State and Political Subdivisions [Domain]",
        "label": "Opioid Lawsuits State [Member]",
        "terseLabel": "Opioid Lawsuits State [Member]"
       }
      }
     },
     "localname": "OpioidLawsuitsStateMember",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_OpioidLitigationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opioid Litigation",
        "label": "Opioid Litigation [Axis]",
        "terseLabel": "Opioid Litigation [Axis]"
       }
      }
     },
     "localname": "OpioidLitigationAxis",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_OpioidLitigationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opioid Litigation [Domain]",
        "label": "Opioid Litigation [Domain]",
        "terseLabel": "Opioid Litigation [Domain]"
       }
      }
     },
     "localname": "OpioidLitigationDomain",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_OtherJurisdictionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Jurisdictions [Member]",
        "label": "Other Jurisdictions [Member]",
        "terseLabel": "Other Jurisdictions [Member]"
       }
      }
     },
     "localname": "OtherJurisdictionsMember",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_PatientRecoveryBusinessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patient Recovery Business [Member]",
        "label": "Patient Recovery Business [Member]",
        "terseLabel": "Patient Recovery Business"
       }
      }
     },
     "localname": "PatientRecoveryBusinessMember",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_PharmaceuticalDistributionandSpecialtyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical Distribution and Specialty [Member]",
        "label": "Pharmaceutical Distribution and Specialty [Member]",
        "terseLabel": "Pharmaceutical Distribution and Specialty [Member]"
       }
      }
     },
     "localname": "PharmaceuticalDistributionandSpecialtyMember",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_PharmaceuticalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical [Member]",
        "label": "Pharmaceutical Member",
        "terseLabel": "Pharmaceutical"
       }
      }
     },
     "localname": "PharmaceuticalMember",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_PlaintiffTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plaintiff Type [Axis]",
        "label": "Plaintiff Type [Axis]",
        "terseLabel": "Plaintiff Type [Axis]"
       }
      }
     },
     "localname": "PlaintiffTypeAxis",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_PlaintiffTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Plaintiff Type [Axis]",
        "label": "Plaintiff Type [Domain]",
        "terseLabel": "Plaintiff Type [Domain]"
       }
      }
     },
     "localname": "PlaintiffTypeDomain",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_PrivatePartiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private Parties [Member]",
        "label": "Private Parties [Member]",
        "terseLabel": "Private Parties [Member]"
       }
      }
     },
     "localname": "PrivatePartiesMember",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from divestitures and disposal of property and equipment and held for sale assets",
        "label": "Proceeds from divestitures and disposal of property and equipment and held for sale assets",
        "terseLabel": "Proceeds from divestitures and disposal of property and equipment and held for sale assets"
       }
      }
     },
     "localname": "Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales of available-for-sale securities and other investments.",
        "label": "Proceeds from sale of available-for-sale securities and other investments",
        "terseLabel": "Proceeds from investments"
       }
      }
     },
     "localname": "Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_ProductLiabilityLawsuitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Liability Lawsuits [Member]",
        "label": "Product Liability Lawsuits [Member]",
        "terseLabel": "Product Liability Lawsuits"
       }
      }
     },
     "localname": "ProductLiabilityLawsuitsMember",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_ProjectCostsOnInvestmentAndOtherSpending": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment spending at the Corporate level. Investment spending generally includes the first year spend for certain projects that require incremental investments in the form of additional operating expenses.",
        "label": "Project Costs On Investment And Other Spending",
        "terseLabel": "Project costs on investment and other spending"
       }
      }
     },
     "localname": "ProjectCostsOnInvestmentAndOtherSpending",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_Purchaseofavailableforsalesecuritiesandotherinvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from purchases of available-for-sale securities and other investments.",
        "label": "Purchase of available-for-sale securities and other investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "Purchaseofavailableforsalesecuritiesandotherinvestments",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Segment Revenue from External Customers by Geographic Area [Table]",
        "label": "Segment Revenue from External Customers by Geographic Area [Line Items]",
        "terseLabel": "Segment Revenue from External Customers by Geographic Area [Line Items]"
       }
      }
     },
     "localname": "SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Segment Revenue from External Customers by Geographic Area [Table]",
        "label": "Segment Revenue from External Customers by Geographic Area [Table]",
        "terseLabel": "Segment Revenue from External Customers by Geographic Area [Table]"
       }
      }
     },
     "localname": "SegmentRevenuefromExternalCustomersbyGeographicAreaTable",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_September2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "September 2025",
        "label": "September 2025 [Member]",
        "terseLabel": "September 2025"
       }
      }
     },
     "localname": "September2025Member",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_SettlingStates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settling States",
        "label": "Settling States",
        "terseLabel": "Settling States"
       }
      }
     },
     "localname": "SettlingStates",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cah_SettlingUSTerritories": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settling U.S Territories",
        "label": "Settling U.S Territories",
        "terseLabel": "Settling U.S Territories"
       }
      }
     },
     "localname": "SettlingUSTerritories",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cah_ShareRepurchaseProgramAggregatePurchasePriceAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share repurchase program aggregate purchase price",
        "label": "Share repurchase program aggregate purchase price [Axis]",
        "terseLabel": "Share repurchase program aggregate purchase price [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAggregatePurchasePriceAxis",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_ShareRepurchaseProgramAggregatePurchasePriceDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share repurchase program aggregate purchase price [Domain]",
        "label": "Share repurchase program aggregate purchase price [Domain]",
        "terseLabel": "Share repurchase program aggregate purchase price [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAggregatePurchasePriceDomain",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares that would be antidilutive as a result of net loss",
        "label": "Shares that would be antidilutive as a result of net loss",
        "terseLabel": "Shares that would be antidilutive as a result of net loss"
       }
      }
     },
     "localname": "SharesThatWouldBeAntidilutiveAsAResultOfNetLoss",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cah_ShortTermCreditFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other short-term credit facilities and an unsecured line of credit",
        "label": "Short Term Credit Facilities Member",
        "terseLabel": "Short Term Credit Facilities Member"
       }
      }
     },
     "localname": "ShortTermCreditFacilitiesMember",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_TaxMatterAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Matter [Axis]",
        "label": "Tax Matter [Axis]",
        "terseLabel": "Tax Matter [Axis]"
       }
      }
     },
     "localname": "TaxMatterAxis",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_TaxMatterDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Tax Matter [Axis]",
        "label": "Tax Matter [Domain]",
        "terseLabel": "Tax Matter [Domain]"
       }
      }
     },
     "localname": "TaxMatterDomain",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_TaxMattersAgreementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Matters Agreement [Axis]",
        "label": "Tax Matters Agreement [Axis]",
        "terseLabel": "Tax Matters Agreement [Axis]"
       }
      }
     },
     "localname": "TaxMattersAgreementAxis",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_TaxMattersAgreementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Tax Matters Agreement [Axis]",
        "label": "Tax Matters Agreement [Domain]",
        "terseLabel": "Tax Matters Agreement [Domain]"
       }
      }
     },
     "localname": "TaxMattersAgreementDomain",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_TerminalGrowthRateFairValueInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terminal Growth Rate, Fair Value Input",
        "label": "Terminal Growth Rate, Fair Value Input",
        "terseLabel": "Terminal Growth Rate, Fair Value Input"
       }
      }
     },
     "localname": "TerminalGrowthRateFairValueInput",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cah_TotalLongTermandShortTermObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Long-Term and Short-Term Obligations",
        "label": "Total Long-Term and Short-Term Obligations",
        "terseLabel": "Total Long-Term and Short-Term Obligations"
       }
      }
     },
     "localname": "TotalLongTermandShortTermObligations",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_TotalOpioidLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Opioid Litigation",
        "label": "Total Opioid Litigation [Member]",
        "terseLabel": "Total Opioid Litigation [Member]"
       }
      }
     },
     "localname": "TotalOpioidLitigationMember",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_TrademarksAndPatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, and the exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Trademarks And Patents Member",
        "terseLabel": "Trademarks, trade names and patents"
       }
      }
     },
     "localname": "TrademarksAndPatentsMember",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_VestingPeriodinyearsforShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting Period in years for Shares",
        "label": "Vesting Period in years for Shares",
        "terseLabel": "Vesting Period in years for Shares"
       }
      }
     },
     "localname": "VestingPeriodinyearsforShares",
     "nsuri": "http://www.cardinal.com/20220331",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "UNITED STATES"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r112",
      "r147",
      "r160",
      "r161",
      "r162",
      "r163",
      "r165",
      "r167",
      "r171",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r261",
      "r262",
      "r264",
      "r266",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r112",
      "r147",
      "r160",
      "r161",
      "r162",
      "r163",
      "r165",
      "r167",
      "r171",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r261",
      "r262",
      "r264",
      "r266",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r179",
      "r334",
      "r336",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r244",
      "r246",
      "r247",
      "r248",
      "r272",
      "r309",
      "r347",
      "r350",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r553",
      "r556",
      "r575",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r244",
      "r246",
      "r247",
      "r248",
      "r272",
      "r309",
      "r347",
      "r350",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r553",
      "r556",
      "r575",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r179",
      "r334",
      "r336",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r220",
      "r244",
      "r246",
      "r247",
      "r248",
      "r272",
      "r309",
      "r337",
      "r347",
      "r350",
      "r380",
      "r381",
      "r382",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r553",
      "r556",
      "r575",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r220",
      "r244",
      "r246",
      "r247",
      "r248",
      "r272",
      "r309",
      "r337",
      "r347",
      "r350",
      "r380",
      "r381",
      "r382",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r553",
      "r556",
      "r575",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r122",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast [Member]"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r122",
      "r126",
      "r242",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r175",
      "r176",
      "r334",
      "r335",
      "r554",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r175",
      "r176",
      "r334",
      "r335",
      "r554",
      "r564",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r122",
      "r126",
      "r242",
      "r348",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_GA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GEORGIA",
        "terseLabel": "GEORGIA"
       }
      }
     },
     "localname": "GA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_WA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WASHINGTON",
        "terseLabel": "WASHINGTON"
       }
      }
     },
     "localname": "WA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_WV": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WEST VIRGINIA",
        "terseLabel": "WEST VIRGINIA"
       }
      }
     },
     "localname": "WV",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r46",
      "r497"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r520",
      "r543"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Accounts Payable",
        "terseLabel": "Accounts Payable"
       }
      }
     },
     "localname": "AccountsPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r57",
      "r62",
      "r69",
      "r70",
      "r71",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Foreign Currency Translation Adjustments"
       }
      }
     },
     "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r58",
      "r62",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges, including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Unrealized Gain/(Loss) on Derivatives, net of tax"
       }
      }
     },
     "localname": "AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r38",
      "r60",
      "r61",
      "r62",
      "r537",
      "r561",
      "r562"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r59",
      "r62",
      "r69",
      "r70",
      "r71",
      "r114",
      "r115",
      "r116",
      "r431",
      "r494",
      "r557",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income/(Loss)",
        "verboseLabel": "AOCI Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r385"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total share-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r100",
      "r200",
      "r207"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r59",
      "r62",
      "r69",
      "r70",
      "r71",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r29",
      "r109",
      "r155",
      "r162",
      "r169",
      "r182",
      "r254",
      "r255",
      "r256",
      "r258",
      "r259",
      "r260",
      "r261",
      "r263",
      "r265",
      "r267",
      "r268",
      "r425",
      "r432",
      "r478",
      "r495",
      "r497",
      "r515",
      "r536"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Total assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r23",
      "r44",
      "r109",
      "r182",
      "r254",
      "r255",
      "r256",
      "r258",
      "r259",
      "r260",
      "r261",
      "r263",
      "r265",
      "r267",
      "r268",
      "r425",
      "r432",
      "r478",
      "r495",
      "r497"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": {
     "auth_ref": [
      "r2",
      "r3",
      "r13",
      "r15",
      "r19",
      "r215"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Assets",
        "terseLabel": "Total assets held for sale",
        "verboseLabel": "Total assets held for sale"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r354",
      "r355",
      "r356",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r375",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "verboseLabel": "Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r346",
      "r349",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r346",
      "r349",
      "r416",
      "r417",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r21",
      "r25",
      "r102"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r95",
      "r102",
      "r104"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and equivalents at end of period",
        "periodStartLabel": "Cash and equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r95",
      "r479"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase/(decrease) in cash and equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging [Member]"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": {
     "auth_ref": [
      "r464"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments",
        "terseLabel": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper [Member]"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r238",
      "r239",
      "r240",
      "r249",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments, Contingent Liabilities and Litigation"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Cash dividends declared per common share"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r114",
      "r115",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]",
        "terseLabel": "Common shares, without par value:"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common shares, authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Balance at end of period (in shares)",
        "periodStartLabel": "Balance at beginning of period (in shares)",
        "terseLabel": "Common shares, issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r35",
      "r497"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Authorized\u2014755 million shares, Issued\u2014327 million shares at March\u00a031, 2022 and June 30, 2021"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r65",
      "r67",
      "r68",
      "r80",
      "r527",
      "r548"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive income attributable to Cardinal Health, Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r65",
      "r67",
      "r79",
      "r423",
      "r436",
      "r526",
      "r547"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Total comprehensive income/(loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r160",
      "r161",
      "r162",
      "r163",
      "r165",
      "r171",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r84",
      "r510"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of products sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrencySwapMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Swap involving the exchange of principal and interest in one currency for another currency.",
        "label": "Currency Swap [Member]",
        "terseLabel": "Currency Swap [Member]"
       }
      }
     },
     "localname": "CurrencySwapMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r105",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r286",
      "r293",
      "r294",
      "r296",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Long-Term Obligations and Other Short-Term Borrowings"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r108",
      "r112",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r276",
      "r282",
      "r283",
      "r284",
      "r285",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r297",
      "r298",
      "r299",
      "r300",
      "r492",
      "r516",
      "r517",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r284",
      "r297",
      "r298",
      "r477"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Estimated fair value"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r50",
      "r108",
      "r112",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r276",
      "r282",
      "r283",
      "r284",
      "r285",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r297",
      "r298",
      "r299",
      "r300",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r50",
      "r108",
      "r112",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r276",
      "r282",
      "r283",
      "r284",
      "r285",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r295",
      "r297",
      "r298",
      "r299",
      "r300",
      "r324",
      "r327",
      "r328",
      "r329",
      "r489",
      "r490",
      "r492",
      "r493",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "auth_ref": [
      "r400"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "terseLabel": "Estimated range of decrease in unrecognized tax benefits within the next 12 months"
       }
      }
     },
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other.",
        "label": "Deferred Tax and Other Liabilities, Noncurrent",
        "terseLabel": "Deferred income taxes and other liabilities"
       }
      }
     },
     "localname": "DeferredTaxAndOtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r100",
      "r150"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet": {
     "auth_ref": [
      "r437"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.",
        "label": "Derivative Assets (Liabilities), at Fair Value, Net",
        "terseLabel": "Forward Contract"
       }
      }
     },
     "localname": "DerivativeAssetsLiabilitiesAtFairValueNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative, Name [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r55",
      "r448",
      "r450",
      "r454",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r446",
      "r448",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "auth_ref": [
      "r453",
      "r455"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "terseLabel": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityNotionalAmount": {
     "auth_ref": [
      "r439",
      "r440",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payments on the derivative liability.",
        "label": "Derivative Liability, Notional Amount",
        "terseLabel": "Derivative Liability, Notional Amount"
       }
      }
     },
     "localname": "DerivativeLiabilityNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r438",
      "r441",
      "r442",
      "r446",
      "r447",
      "r451",
      "r454",
      "r461",
      "r462",
      "r465",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "verboseLabel": "Developed technology and other"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of Revenue [Table Text Block]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r353",
      "r354",
      "r386",
      "r387",
      "r389",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "verboseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation": {
     "auth_ref": [
      "r4",
      "r5",
      "r16",
      "r412"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) on gain (loss) not previously recognized resulting from the disposal of a discontinued operation.",
        "label": "Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation",
        "terseLabel": "Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation"
       }
      }
     },
     "localname": "DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r20",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations, Disclosure"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/Divestitures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r346",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Dividends": {
     "auth_ref": [
      "r330",
      "r532"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.",
        "label": "Dividends",
        "negatedTerseLabel": "Dividends"
       }
      }
     },
     "localname": "Dividends",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Earnings/(Loss) per common share attributable to Cardinal Health, Inc.:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r134",
      "r136",
      "r137",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings Per Share [Text Block]"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r479"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r388"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r385"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Expense, Tax Benefit",
        "terseLabel": "Tax benefit related to share-based compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Employee- Related Costs"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options",
        "verboseLabel": "Employee Stock Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r69",
      "r70",
      "r71",
      "r114",
      "r115",
      "r116",
      "r118",
      "r123",
      "r125",
      "r139",
      "r183",
      "r323",
      "r330",
      "r391",
      "r392",
      "r393",
      "r406",
      "r407",
      "r468",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r486",
      "r494",
      "r557",
      "r558",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FacilityClosingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Closing of a facility associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Facility Closing [Member]",
        "terseLabel": "Facility Exit and Other Costs"
       }
      }
     },
     "localname": "FacilityClosingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r470",
      "r471",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring",
        "verboseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r284",
      "r297",
      "r298",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r471",
      "r500",
      "r501",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r470",
      "r471",
      "r472",
      "r473",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Disclosures"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueHedgingMember": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.",
        "label": "Fair Value Hedging [Member]",
        "terseLabel": "Fair Value Hedging"
       }
      }
     },
     "localname": "FairValueHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r284",
      "r338",
      "r339",
      "r344",
      "r345",
      "r471",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level\u00a01"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r284",
      "r297",
      "r298",
      "r338",
      "r339",
      "r344",
      "r345",
      "r471",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2",
        "verboseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r284",
      "r297",
      "r298",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r471",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r284",
      "r297",
      "r298",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r500",
      "r501",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r474",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r27",
      "r206"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r208"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "Estimated annual amortization of intangible assets - Year One"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "Estimated annual amortization of intangible assets - Remainder of Fiscal Year"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r208"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "Estimated annual amortization of intangible assets - Year Four"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r208"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "Estimated annual amortization of intangible assets - Year Three"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r208"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "Estimated annual amortization of intangible assets - Year Two"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r201",
      "r203",
      "r206",
      "r210",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r206",
      "r512"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Intangible"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r201",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "verboseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r206",
      "r511"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Net Intangible"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "auth_ref": [
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "terseLabel": "Weighted- Average Remaining Amortization Period (Years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r55",
      "r338",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign Exchange Contract [Member]"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfInvestments": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.",
        "label": "Gain (Loss) on Sale of Investments",
        "negatedTerseLabel": "(Gain)/Loss on sale of equity interest in naviHealth"
       }
      }
     },
     "localname": "GainLossOnSaleOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfOtherInvestments": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) included in earnings for investments classified as other.",
        "label": "Gain (Loss) on Sale of Other Investments",
        "negatedTerseLabel": "Impairments and Loss on Sale of Other Investments"
       }
      }
     },
     "localname": "GainLossOnSaleOfOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.",
        "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges",
        "negatedTerseLabel": "Impairments and (gain)/loss on disposal of assets, net"
       }
      }
     },
     "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r241"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "negatedLabel": "Loss Related to Litigation Settlement",
        "negatedTerseLabel": "Litigation (recoveries)/charges, net"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r100",
      "r301",
      "r302"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Loss on Extinguishment of Debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r26",
      "r185",
      "r187",
      "r194",
      "r198",
      "r497",
      "r514"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r188",
      "r198"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill, Transfers"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Other Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r192"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "negatedTerseLabel": "Foreign currency translation adjustments and other"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r187",
      "r194",
      "r198"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Goodwill, Impaired, Accumulated Impairment Loss"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r100",
      "r186",
      "r191",
      "r197",
      "r198"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill, Impairment Loss"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r83",
      "r109",
      "r155",
      "r161",
      "r165",
      "r168",
      "r171",
      "r182",
      "r254",
      "r255",
      "r256",
      "r259",
      "r260",
      "r261",
      "r263",
      "r265",
      "r267",
      "r268",
      "r478"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross margin"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r446",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r76",
      "r155",
      "r161",
      "r165",
      "r168",
      "r171",
      "r513",
      "r522",
      "r530",
      "r550"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Earnings/(loss) before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r73",
      "r81",
      "r117",
      "r119",
      "r120",
      "r121",
      "r122",
      "r129",
      "r131",
      "r132",
      "r469",
      "r521",
      "r523",
      "r528",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r73",
      "r81",
      "r117",
      "r119",
      "r120",
      "r121",
      "r122",
      "r129",
      "r131",
      "r132",
      "r133",
      "r469",
      "r528",
      "r544",
      "r546",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Income (Loss) from Continuing Operations, Per Diluted Share"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r346",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r3",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r12",
      "r14",
      "r17",
      "r18",
      "r19",
      "r217",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Schedule of Assets and Liabilities Held for Sale [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r214",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r110",
      "r398",
      "r403",
      "r404",
      "r408",
      "r410",
      "r413",
      "r414",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r111",
      "r124",
      "r125",
      "r153",
      "r396",
      "r409",
      "r411",
      "r551"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income Tax Expense (Benefit)",
        "verboseLabel": "Provision for/(benefit from) income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReceivable": {
     "auth_ref": [
      "r36",
      "r534"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable.",
        "label": "Income Taxes Receivable",
        "terseLabel": "Income Taxes Receivable"
       }
      }
     },
     "localname": "IncomeTaxReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Increase in accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Increase in inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Change in operating assets and liabilities, net of effects from acquisitions and divestitures:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedTerseLabel": "Other accrued liabilities and operating items, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Receivables",
        "negatedTerseLabel": "Increase in trade receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r202",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Indefinite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Indefinite-lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r209"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Net Intangible"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r202",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [
      "r26"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "terseLabel": "Gross Intangible, Total other intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r199",
      "r204"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Net Intangible, Total other intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "terseLabel": "Goodwill and other intangibles, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r74",
      "r149",
      "r488",
      "r491",
      "r529"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense, net"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest Income (Expense), Nonoperating, Net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest Rate Swap"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r22",
      "r42",
      "r497"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r470"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Other investments"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r41",
      "r109",
      "r182",
      "r478",
      "r497",
      "r519",
      "r540"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders\u2019 equity/(deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Shareholders\u2019 Equity/(Deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r24",
      "r49",
      "r109",
      "r182",
      "r254",
      "r255",
      "r256",
      "r259",
      "r260",
      "r261",
      "r263",
      "r265",
      "r267",
      "r268",
      "r426",
      "r432",
      "r433",
      "r478",
      "r495",
      "r496",
      "r497"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": {
     "auth_ref": [
      "r2",
      "r3",
      "r13",
      "r15",
      "r19",
      "r215"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities",
        "terseLabel": "Disposal Group, Including Discontinued Operation, Liabilities"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityAverageOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average amount borrowed under the credit facility during the period.",
        "label": "Line of Credit Facility, Average Outstanding Amount",
        "terseLabel": "Line of Credit Facility, Average Outstanding Amount"
       }
      }
     },
     "localname": "LineOfCreditFacilityAverageOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount borrowed under the credit facility at any time during the period.",
        "label": "Line of Credit Facility, Maximum Amount Outstanding During Period",
        "terseLabel": "Line of Credit Facility, Maximum Amount Outstanding During Period"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationReserve": {
     "auth_ref": [
      "r51",
      "r241"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.",
        "label": "Estimated Litigation Liability",
        "terseLabel": "Estimated Litigation Liability"
       }
      }
     },
     "localname": "LitigationReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationReserveCurrent": {
     "auth_ref": [
      "r51",
      "r241"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.",
        "label": "Estimated Litigation Liability, Current",
        "terseLabel": "Estimated Litigation Liability, Current"
       }
      }
     },
     "localname": "LitigationReserveCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Litigation Settlement, Expense"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.",
        "label": "Long-Term Debt and Lease Obligation",
        "terseLabel": "Long-term obligations, less current portion",
        "verboseLabel": "Long-term Debt and Lease Obligation"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as current.",
        "label": "Long-Term Debt and Lease Obligation, Current",
        "terseLabel": "Current portion of long-term obligations and other short-term borrowings",
        "verboseLabel": "Long-term Debt and Lease Obligation, Current"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r50",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongtermPurchaseCommitmentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Long-Term Purchase Commitment, Period",
        "terseLabel": "Long-term Purchase Commitment, Period"
       }
      }
     },
     "localname": "LongtermPurchaseCommitmentPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r241",
      "r243",
      "r244",
      "r245",
      "r246",
      "r250",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r241",
      "r243",
      "r244",
      "r245",
      "r246",
      "r250",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r241",
      "r242"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Loss Contingency Accrual"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyAccrualPayments": {
     "auth_ref": [
      "r241"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow reducing loss contingency liability.",
        "label": "Loss Contingency Accrual, Payments",
        "terseLabel": "Loss Contingency Accrual, Payments"
       }
      }
     },
     "localname": "LossContingencyAccrualPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyClaimsSettledNumber": {
     "auth_ref": [
      "r243",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of claims settled.",
        "label": "Loss Contingency, Claims Settled, Number",
        "terseLabel": "Loss Contingency, Claims Settled, Number"
       }
      }
     },
     "localname": "LossContingencyClaimsSettledNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "auth_ref": [
      "r244",
      "r246",
      "r250"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "terseLabel": "Loss Contingency, Estimate of Possible Loss"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r241",
      "r243",
      "r244",
      "r245",
      "r246",
      "r250",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r243",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "Loss Contingency, New Claims Filed, Number"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyNumberOfPlaintiffs": {
     "auth_ref": [
      "r243",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Number of Plaintiffs",
        "terseLabel": "Loss Contingency, Number of Plaintiffs"
       }
      }
     },
     "localname": "LossContingencyNumberOfPlaintiffs",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r243",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Loss Contingency, Pending Claims, Number"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r54",
      "r109",
      "r182",
      "r254",
      "r259",
      "r260",
      "r261",
      "r267",
      "r268",
      "r478",
      "r518",
      "r539"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by/(used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r95",
      "r97",
      "r101"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r19",
      "r63",
      "r66",
      "r71",
      "r77",
      "r101",
      "r109",
      "r117",
      "r119",
      "r120",
      "r121",
      "r122",
      "r124",
      "r125",
      "r130",
      "r155",
      "r161",
      "r165",
      "r168",
      "r171",
      "r182",
      "r254",
      "r255",
      "r256",
      "r259",
      "r260",
      "r261",
      "r263",
      "r265",
      "r267",
      "r268",
      "r469",
      "r478",
      "r524",
      "r545"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net earnings/(loss) attributable to Cardinal Health, Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r63",
      "r66",
      "r71",
      "r124",
      "r125",
      "r428",
      "r435"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Less: Net earnings attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net Investment Hedging [Member]"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Financial Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Non-US [Member]"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r330",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument [Member]"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r155",
      "r161",
      "r165",
      "r168",
      "r171"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Total operating earnings",
        "totalLabel": "Operating earnings/(loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r160",
      "r161",
      "r162",
      "r163",
      "r165",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r43",
      "r497"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r62",
      "r69",
      "r70",
      "r72",
      "r480",
      "r482",
      "r486"
     ],
     "calculation": {
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "verboseLabel": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r58",
      "r60"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "terseLabel": "Net unrealized gain/(loss) on derivative instruments, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r58",
      "r60",
      "r449",
      "r452",
      "r463"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustments and other"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r456"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r64",
      "r67",
      "r69",
      "r70",
      "r72",
      "r78",
      "r323",
      "r480",
      "r485",
      "r486",
      "r525",
      "r546"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Total other comprehensive income/(loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income/(loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r64",
      "r67",
      "r423",
      "r424",
      "r430"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other (income)/expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other Nonoperating Income (Expense) [Member]"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherShortTermBorrowings": {
     "auth_ref": [
      "r45"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer.",
        "label": "Other Short-Term Borrowings",
        "terseLabel": "Other Short-term Borrowings"
       }
      }
     },
     "localname": "OtherShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "auth_ref": [
      "r96"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
        "label": "Payments for Legal Settlements",
        "terseLabel": "Payments for Legal Settlements"
       }
      }
     },
     "localname": "PaymentsForLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromHedgeFinancingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash outflow or inflow for a financial contract that meets the hedge criteria as either cash flow hedge, fair value hedge or hedge of net investment in foreign operations.",
        "label": "Payments for (Proceeds from) Hedge, Financing Activities",
        "negatedTerseLabel": "Proceeds from interest rate swap terminations"
       }
      }
     },
     "localname": "PaymentsForProceedsFromHedgeFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Purchase of treasury shares",
        "terseLabel": "Purchase of treasury shares"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r93",
      "r224"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "negatedLabel": "Payments and other adjustments"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividendsCommonStock": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.",
        "label": "Payments of Ordinary Dividends, Common Stock",
        "negatedLabel": "Dividends on common shares"
       }
      }
     },
     "localname": "PaymentsOfDividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisition of subsidiaries, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Additions to property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Share Units",
        "verboseLabel": "Performance Share Unit"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]",
        "terseLabel": "Preferred shares, without par value:"
       }
      }
     },
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred shares, authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r34",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred shares, issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r34",
      "r497"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Authorized\u2014500 thousand shares, Issued\u2014none"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r87"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "terseLabel": "Proceeds from Divestiture of Businesses"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromHedgeInvestingActivities": {
     "auth_ref": [
      "r88",
      "r98"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.",
        "label": "Proceeds from Hedge, Investing Activities",
        "terseLabel": "Proceeds from Hedge, Investing Activities"
       }
      }
     },
     "localname": "ProceedsFromHedgeInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIncomeTaxRefunds": {
     "auth_ref": [
      "r97",
      "r103"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash received during the period as refunds for the overpayment of taxes.",
        "label": "Proceeds from Income Tax Refunds",
        "terseLabel": "Proceeds from Income Tax Refunds"
       }
      }
     },
     "localname": "ProceedsFromIncomeTaxRefunds",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r19",
      "r63",
      "r66",
      "r71",
      "r94",
      "r109",
      "r117",
      "r124",
      "r125",
      "r155",
      "r161",
      "r165",
      "r168",
      "r171",
      "r182",
      "r254",
      "r255",
      "r256",
      "r259",
      "r260",
      "r261",
      "r263",
      "r265",
      "r267",
      "r268",
      "r423",
      "r427",
      "r429",
      "r435",
      "r436",
      "r469",
      "r478",
      "r530"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net earnings/(loss)",
        "totalLabel": "Net earnings/(loss)",
        "verboseLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r213",
      "r497",
      "r531",
      "r542"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r82",
      "r184"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Provision for bad debts"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r497",
      "r541",
      "r563"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]",
        "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Loss [Rollforward]"
       }
      }
     },
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r62",
      "r69",
      "r70",
      "r72",
      "r480",
      "r484",
      "r486"
     ],
     "calculation": {
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "negatedTerseLabel": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Loss [Table]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": {
     "auth_ref": [
      "r162",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.",
        "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]",
        "terseLabel": "Assets by Reportable Segment"
       }
      }
     },
     "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": {
     "auth_ref": [
      "r161",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
        "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r161",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Segment Profit by Reportable Segment"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": {
     "auth_ref": [
      "r160",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.",
        "label": "Reconciliation of Revenue from Segments to Consolidated [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedTerseLabel": "Reduction of long-term obligations"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r92"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "terseLabel": "Repayments of Notes Payable"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReportingUnitAxis": {
     "auth_ref": [
      "r196",
      "r197",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by reporting unit.",
        "label": "Reporting Unit [Axis]",
        "terseLabel": "Reporting Unit [Axis]"
       }
      }
     },
     "localname": "ReportingUnitAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReportingUnitDomain": {
     "auth_ref": [
      "r196",
      "r197",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Level of reporting at which goodwill is tested for impairment.",
        "label": "Reporting Unit [Domain]",
        "terseLabel": "Reporting Unit [Domain]"
       }
      }
     },
     "localname": "ReportingUnitDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Share Units",
        "verboseLabel": "Restricted Share Unit"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r222",
      "r224",
      "r227",
      "r236",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring and Employee Severance"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeverance"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r100",
      "r221",
      "r230",
      "r233"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      },
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring and employee severance",
        "totalLabel": "Total restructuring and employee severance"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringChargesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Charges [Abstract]",
        "terseLabel": "Restructuring Charges [Abstract]"
       }
      }
     },
     "localname": "RestructuringChargesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r223",
      "r224",
      "r233",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCosts": {
     "auth_ref": [
      "r100"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Costs",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "RestructuringCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by individual restructuring plan.",
        "label": "Restructuring Plan [Axis]",
        "terseLabel": "Restructuring Plan [Axis]"
       }
      }
     },
     "localname": "RestructuringPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the individual restructuring plans.",
        "label": "Restructuring Plan [Domain]",
        "terseLabel": "Restructuring Plan [Domain]"
       }
      }
     },
     "localname": "RestructuringPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r224",
      "r231"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r37",
      "r330",
      "r497",
      "r538",
      "r560",
      "r562"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings/(accumulated deficit)"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r114",
      "r115",
      "r116",
      "r118",
      "r123",
      "r125",
      "r183",
      "r391",
      "r392",
      "r393",
      "r406",
      "r407",
      "r468",
      "r557",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Revenue from External Customers by Geographic Areas [Table Text Block]"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r75",
      "r109",
      "r146",
      "r147",
      "r160",
      "r166",
      "r167",
      "r174",
      "r175",
      "r179",
      "r182",
      "r254",
      "r255",
      "r256",
      "r259",
      "r260",
      "r261",
      "r263",
      "r265",
      "r267",
      "r268",
      "r478",
      "r530"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenue",
        "verboseLabel": "Total revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r62",
      "r485",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount"
       }
      }
     },
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Schedule of Total Share-based Compensation Expense by Type of Award"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r470",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r201",
      "r205",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r201",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Goodwill by Reportable Segment"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r209",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units.",
        "label": "Schedule of Nonvested Performance-Based Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Transactions Related to Performance Share Units Under the Plans"
       }
      }
     },
     "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r226",
      "r233",
      "r234",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r228",
      "r229",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Summary of Restructuring and Employee Severance"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r224",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r155",
      "r158",
      "r164",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r351",
      "r352",
      "r354",
      "r355",
      "r356",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r375",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Transactions Related to Restricted Share Units Under the Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r357",
      "r373",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Transactions Under the Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r33",
      "r34",
      "r35",
      "r106",
      "r140",
      "r141",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r312",
      "r316",
      "r321",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "terseLabel": "Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r142",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r160",
      "r161",
      "r162",
      "r163",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r171",
      "r179",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r198",
      "r226",
      "r235",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r142",
      "r144",
      "r145",
      "r155",
      "r159",
      "r165",
      "r169",
      "r170",
      "r171",
      "r172",
      "r174",
      "r178",
      "r179",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]",
        "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Distribution, selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "verboseLabel": "Employee-related costs"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Canceled and forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Canceled and forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r367",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Nonvested at end of period (in shares)",
        "periodStartLabel": "Nonvested at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Restricted Share Units",
        "verboseLabel": "Performance Share Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r367",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Nonvested at end of period (in usd per share)",
        "periodStartLabel": "Nonvested at beginning of period (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value per Share",
        "verboseLabel": "Weighted-Average Grant Date Fair Value per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at end of period (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedTerseLabel": "Canceled and forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Canceled and forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r390"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of outstanding options at period end"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r358",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "periodStartLabel": "Outstanding at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r358",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end of period (in usd per share)",
        "periodStartLabel": "Outstanding at beginning of period (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price per Common Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r354",
      "r355",
      "r356",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r375",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Target performance goal (as a percent)",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r390"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of exercisable options at period end"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r6",
      "r142",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r160",
      "r161",
      "r162",
      "r163",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r171",
      "r179",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r198",
      "r216",
      "r226",
      "r235",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]",
        "verboseLabel": "Operating and Reportable Segment"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r53",
      "r69",
      "r70",
      "r71",
      "r114",
      "r115",
      "r116",
      "r118",
      "r123",
      "r125",
      "r139",
      "r183",
      "r323",
      "r330",
      "r391",
      "r392",
      "r393",
      "r406",
      "r407",
      "r468",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r486",
      "r494",
      "r557",
      "r558",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "verboseLabel": "Statement of Stockholders' Equity"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r139",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r34",
      "r35",
      "r323",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r34",
      "r35",
      "r323",
      "r330",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r34",
      "r35",
      "r330",
      "r374"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r35",
      "r39",
      "r40",
      "r109",
      "r181",
      "r182",
      "r478",
      "r497"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Cardinal Health, Inc. shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders\u2019 equity/(deficit):"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r70",
      "r109",
      "r114",
      "r115",
      "r116",
      "r118",
      "r123",
      "r182",
      "r183",
      "r330",
      "r391",
      "r392",
      "r393",
      "r406",
      "r407",
      "r421",
      "r422",
      "r434",
      "r468",
      "r478",
      "r480",
      "r481",
      "r486",
      "r494",
      "r558",
      "r559"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "totalLabel": "Total shareholders\u2019 equity/(deficit)"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r107",
      "r308",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r322",
      "r330",
      "r333",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityOtherShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of increase (decrease) in shares of stock classified as other.",
        "label": "Stockholders' Equity, Other Shares",
        "terseLabel": "Stockholders' Equity, Other Shares"
       }
      }
     },
     "localname": "StockholdersEquityOtherShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SubsegmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business subsegments.",
        "label": "Subsegments [Axis]",
        "terseLabel": "Subsegments [Axis]"
       }
      }
     },
     "localname": "SubsegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsegmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Subsegments [Domain]",
        "terseLabel": "Subsegments [Domain]"
       }
      }
     },
     "localname": "SubsegmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r487",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r487",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r487",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Tax Credit Carryforward [Line Items]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "TaxCreditCarryforwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.",
        "label": "Tax Credit Carryforward [Table]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "TaxCreditCarryforwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.",
        "label": "Treasury Stock Acquired, Average Cost Per Share",
        "terseLabel": "Treasury shares acquired, average price per share (in usd per share)"
       }
      }
     },
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r52",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock",
        "verboseLabel": "Treasury Shares"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r52",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "negatedPeriodEndLabel": "Treasury, balance at end of period (in shares)",
        "negatedPeriodStartLabel": "Treasury, balance at beginning of period (in shares)",
        "terseLabel": "Common shares in treasury"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r35",
      "r323",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "negatedLabel": "Treasury shares acquired (in shares)",
        "negatedTerseLabel": "Treasury Stock, Shares, Acquired"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r52",
      "r331",
      "r332"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Common shares in treasury, at cost: 54 million shares and 36 million shares at March\u00a031, 2022 and June 30, 2021, respectively",
        "negatedPeriodEndLabel": "Treasury, balance at end of period",
        "negatedPeriodStartLabel": "Treasury, balance at beginning of period"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r323",
      "r330",
      "r331"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Treasury Stock, Value, Acquired, Cost Method"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r223",
      "r224",
      "r233",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r395",
      "r401"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r399"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Unrecognized tax benefits, interest and penalties accrued"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r402"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r133"
     ],
     "calculation": {
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "terseLabel": "Employee stock options, restricted share units, and performance share units (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]",
        "terseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r128",
      "r133"
     ],
     "calculation": {
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted-average common shares\u2013diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r127",
      "r133"
     ],
     "calculation": {
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted-average common shares\u2013basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Weighted-average number of common shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=2122178"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "https://asc.fasb.org/topic&trid=2175745"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126966630&loc=d3e41228-113958"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a)(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r577": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r578": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r579": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r580": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r581": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r582": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868656-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3581-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>84
<FILENAME>0000721371-22-000032-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000721371-22-000032-xbrl.zip
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M>H6K@J^,:RM]F7&*^3*"O18L56F]4D,68";?*OU)65PB1I0"5J:Y*/FRY3D
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M;WM1A0X!J96]6^61*S7UK[_+YF[5G?X74$L#!!0    ( %B"I52-*;[>ZP0
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ML\UE>6D=*2:(&8,;;W&K>>5_%"$3A-I,WQ5YX#:L^BROH>V%^/[?4$L#!!0
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M6(-=7!F]AFWSN$P$8 &O,,P/#98!0$KC?$N?^V6F9K9KL[)K.Z<SO<+I)D@
MOH&Y^,]?X"]8+FUD"510YTC#C7;$*V#M9]E'F!(V!G;&PR?[O/.1-+6_9S4
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MT51R02EWL0VFCV\S[WW;I.4X:F&Q]UI;##2-IE.&[\CZ["K4*D(,L&"Z4-X
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M!&N7T\)JXP(-"GFQ-,19M"-B>B0#&$$<HLXS8ICB4B-M$5*1DD!QH'1I2+8
M1\04!2NDXTR:)G\K0PD01A6=H4 @IW48:3VT!.ZB>0$&-#4/B3#>.QF)-  8
MM-=:4"NTLDH*QXF+2T.:N0*&Z=''<ZF"\ 9,8<F\"@"YDV=<.#")K?-F:>@S
M/\ P/>(P1BD7T=I %.!N99)Y&XVAS(*N4V%IB+-HP#!%>=(*VT@(UH$S3X.5
ME"DA4;22!:?<TI!L 8!A>E0*08#-ZDCD8+9:"^8KB@@[@ J<IBWU^5%I43-
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MJDEK\HJWZ\O;"\$D*!IK!-C^VEK&@S6,4Q(U2EF*1: U3@TPSU#BNGALO ?
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M_)$:FS0$;>?%\W\D 8WQ]PCLV8ZFFW7.GO^OC2(SG=:.*8K\Y'\]+4VO;)?
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M('@?O!>D_/5?1P?DP_B9O^!=O/=YOP]C.0*MX*&O'_%V%]K>A&<^?>Y\WOP
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MCP3VGJ>H'WQ$J&XQ]1M5$,4MYT;NB*NO0RD\M4[8HTKA-2K2OJ[9<J_QS5,
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M7EMOE9/GP$XV5-0ECI5W%2REK;<U%%ACBNS (YGK*FY9X/B;++^T\90U[*3
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MOV LL9Z"]S9)9BDS!$\)GO.PPF ^%<)@A8Z),76+RKFTM%Q3Z1=8Q"$(*U=
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MK,)RIV6QI.LC<YL)"V)BAU-8.6^\>"-EQ :BS;E 3-D,&4SL1_K8%G'2=/T
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M%L<=_PBT-\Q%B-9 VN\.UCXZ<?C!X;$)#>W.9@SM%I<.AD=KRA^6UXH'T*9
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MHGW1UG[#(WIEN\_PWDM0T:GL@C7+HZ5=#FY':5[B@R+S61"2Y^5<]KN#5-8
MWXG2M*%7$P7X*AC91B9:;I3I<-OMQ0)%*3,S/H+,+ (-TN(Q95JVA;N1K#FY
M_'O0^Y8?V7![R9,I=KYL.P26QO<;$3!H#T;Z7]^B"T7<Q?D'Z\?$1=G!-Y\P
M@X:<,+P%$47^,A9].K"9?U_ O?AH@(;/QG43)B5<0> 0\+D-:?C9;2;WE50(
M+5+R#IT;B3U =KS4&:"VX)$ICBHBEAZ;AS;5#X4>C]A*$4QIGZ@ #UZ>>X'1
MIAY%PT$=1#,35P@,9L/N^-[ [!N,SV\T(PJLAO@T&0ZZ6N(@H<'HM =")7/Z
MJ+X&+Q]"'_S'L5"[4OJ[OQ_*O20L>\R1-GM2R#+NGN:"PPN)?Y)W,>W.\U )
MQ+?/N&[A@^,'7KA45Z#7=P7:KV1VRUV]N=?JI\AKQ9TA[A+T,,GC9P..H<;I
MWP].Y 2A1+T\5<S=2SEG+$_0D>XWT*MV[ ;=J+:QBJZ;L"[-F(PK)",>:G//
M6**WT?S&;>#,3SSVZ-J/-*&4/_$YMB2YOY#/(&G,\D]BAV32;D8P*3\QUEVP
MN3)P84PU!\SV);]%)FHXQ?6!KJ6%RRM<10OOG_*WVZ>Y4Z8QSMV &P*FEX,]
M:BW#I5A(V76D';O)"8H5RC3E;GRK)W^P!JSQT/_'WY[S5OQ=?&.H<U9[L7]D
MC;O%]$HQU*)R''(!:R'9E$NXF-+EU$CGO>%-R&:"EE3%B(0#@21O:@ 6M-9K
MCP:88XBN$V)'D3B0GX1J69<KV^(^'.XCAFO3+#IW31>L4 ,3Q]4-ZF0R6.[,
M^L5UYC=?T2&!M=HD?=S >B#W%7WS#Q??@ZF<C=MB&W0SK77=>QBIO<#%>Y6-
M]"&'32)<TQ*'E-2G,ERS I))!28.OM@).(FH"(I[)HZ<07N84GN7PV1N;K(&
M;$<%CL7E8!O#R(-1ZA*$PW3;0WWX5XT7 B/8 ))#Y'#CMDZ&[_Q%&^SIG"IV
MRT]4L+=22=BI0OB*>4&'2:,YN@#:)2#2>0HZ?R(!!H ./PQ6RD!<EAM:J1N;
M2DU6J<DJ-5FE)M<O-;FO4I-5:K)*35:IR1M<SRK+6&49JRQCE67<H"SCD^;^
M54PJ5E$O%?5ZJ0<Q@\WR@+@S'R+<F<\"D@21(AOG/<SQ=QDI#)0HF6C/"#U%
M0) 48D$O961%_G_D<9M9-CZ'Z<H(_849[I01->JG,J_:VC\$Q +\!K/933$9
MD5 EDE%XACS'==:[PL^8" =%V>E8=B\@.2P_BM X(A"TO0K?QQ@@<'U16/2?
ME]T)7+D#DMHI/!R>#V;(+!N:U>7M<+B68NA'J6$BER^!?-4&Z64*\W(_F)=#
MCGG95'SJ(=UP&COW42V01G?"ULZ674P9[%.[W<0 8.TMQ7>4R8MD5Z;B69J*
M)S (?^5E9K_$969Y&?J-,P9_X^;/Y; ]ZG"3) K<FJ87HO61G]"4,/JDS;%6
MB4=YOM+.BRT_8811E4.<HPR[]I'9[BKJ&9!T+Z+5]-6C4D!?&*XT A@^TE]
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M.X>B$Z^E; -F1QCHD^>5X?LRZ=E>#Y#(:*_/,'%7S-KRIG&.-+I7,E"<(EP
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M2*H,294AJ3(D58:TQS*D4US9\]5D_?P>/(3%HUE799S,J5L[3QGW8#8.-6?
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M*!X:O \HK@&D?\H;!.!3,^!SL(@6D&95WF3CV13KZ->H1_MUTZ.EL& BI6F
M;@6U:8&,@*6%)@C*-1AZKN>P9VW&Z-0']D=[*U(&"6E**X2,,*5W+GP%%J/$
M6,;MM4 3*@AL1KK&F(-!0_^ZPF\PQ;C;>?L0/W G'Z"O]+?7">M);,_$<.(%
MCX8?:$OC=Q<,M6?\4'0ALXTG/[1 @\PLFV]2GYJ4X0ZS7=Y;%PCHX%BH.8!"
M:.BUM7>14:>%CO4'_ 7&7NCQ7_H@(M8,Q,4QF9Q!W@I:D5DLF=!*<D&,* 8
M5J!FLOR(H,B<)R.MYNP2W'_-%[5!([?K+'U6:E,7MJ[C1OL8MO&E'A]_OX?3
M.1<U_"%84 &>"C,K\).;$=;ITOW->P:I"STZWD#;VW"HX#$)/X%C#+:+:1O6
M4EKQG.YX#HE[' SV&>:Z-$P6!BFS@;_S-4O;:U[[L)$[+7$PROL$_YX?@^U.
M;+-EK>*9Y?E!_B&H9P]!>?Q$4\K:P_IF*W2#5=GOI&\WJ6,:G07K/@)-N =T
MW./HVEE[L[3"-[XY-A&3+RWP2\3O! -U!7?_B#;X/JY:?/C;"+0G-[2GVL(
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M/Z)';]^QSW_^UCK#1S_.\)OFB;_GR>D;=W*H\5\9E<)9;8$SF05^/1P02&'
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M5>LO+W[O]J<*^SYALXP7GSIR:)I^K(O#N1F'9YMD/(UUB.X#I@SM$2:J;X4
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M89>DP"TX 5[)>%BZU2C*<.\VO&#M-2H[G;M2Y*M6D_:WS3U['="\%GZ0&[(
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M#??F&]I;4B)H^SHR;XLO[+#9&@ZL^8DZK&R?"ZE<HX1"ZZ/08M52HG/%.&2
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M6Y/>".$* TIS Q1A$&BA,D\++10HE+1=!)6G$^[[YLFLG>B8[^6LQGZ7T^[
M7ZA[5P+9@UTMZTY?K=!ON_PPR?U^#U0[>;5X/#<CA!KD !;40QO,*/"*B@.=
MYSRW$HO<> -H:SMWW1?0-ASY>U@1C&<+0=N5!90@Z'X0-.^#H9Y8>=TA@3(4
M :JP B(C#H3BK! *:+/009!5% !,4+ 54+"MJ4()%.X'"O,>')(QH7*# 7?!
M,8MP#H3S)A=&5#B7YQ+F=F>?DH<G_B1 V I V"[G3(*!^\' O-,%YYE%+K=
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M/=F%.AZ=;L7_GW3ZR3P=Q,[8?KN153HW$S>B+.4:Y1JED_,M*6T#:O.RMJQ
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M&9*\-FR^'0YB=UPPLSYF+ECX7'#BK+)(B)!CJ U!!A@@XA5PH(I0M;2/U^9
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MMB9C7:?]:K:Q6@T)KTDJN39P@8OKDQ-OFF RT4"M23'>2Z]T=M/'CD:=5_T
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M^)5R(>2>5]P*'80EDZ87>-;T@ER?>IJV8(+RP3'\>S JQS>U,+B[<&ZK.0?
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MJF*"\T)5ZW1QF0JJU4*UQ1(&081((N>(I8E'')A$6G*'\LL08K6B6SOT-HV
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M/_ZH=Q&0 !=ZJ0$W?'&=$<)W>NZYZ<//\.!_!],9GK7,D/QW[SRTWO8Z(UR
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M<[Y3Y/<K]'M3LR+;T4H_? UE:%:O5GKXSFGV@=/(Q%R@]K0*4'[^@%2^%:G
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M-[[.]Y7Y+_M[NY\_=/\\^_#UXM/!WIN/(-N7!_D^]'<,,GSV\?#HX-/!'R]
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MWMOS#;XNWRG[5X<8/POC/=Q[)P[W7I^XPGM+;4X8J$B$ZRP03;.,Y JV$O,
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M)<'6_.^W?MV&0^?=SML=8E,2P6DUDQ=GIG]N7!BE0[X,W\.)_7S-Q"*%(TP
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MV*]@U20"QU:)H&@. F26?QF4J=>=ROE3S@T:+J;3@3=QO4'I<^\'T/CZY2@
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MZD*A=!%5B1QXHX/^]I#\-%7[.Z@/M,(7<W[1"=MUFX,RIK/*/TK>Y%*#J$)
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MU_(68W-RV7B-ACEC<3:WCG?Q3NR?6.4<M382;9%L&'1*8@NI28RB8%I'%ES
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MST-AE!=!:>-C\%YQY7X:%IUK#.:D*H7J(LA,W5),+.9K+-N-\XZ@8ZJ\S[K
M4NLEI;X-77?6*K,WV]W6K >E=/1-,C'-[(V4PU;JR&-[0PA"6<RA'>/\-8UU
ME&>19I1*GAD ;U.H/%)G I7.^%N"$+);W,9EV,%A_+ON_F?.7)SV"K^[W-]S
M)WEF50&P0+AT!>'*4(*Y!T08^#5EF;0^WWHFV6*(P4U^MBKH(+F:>N<@XU<K
M76:@!Q.]5J.JWDPJY-OZ<]2Y:HDZ@VQW1EIMP.A4D,DZ91FC>L*B$$\)Z'-C
M\4[S.;J0RV$]K^YZ_[LL&U*Z?R?1\BL,'*N3E"12]7C1E5>Z@<L1(=DYNA>O
MPK"L,(->M$E)U2-\FQ4HRRM.];H42)UC.$U@7?H7AV6#9>D*O#;IE][E;BB3
M/<=\4]4-]Z0\"D8;88(HLEO'3N]RJAS%H$PF3#%5&UF0XMK(30^'-RY/?3>!
MQ;@78E:[]27%M#A-Q6%<GS$9%J[?4NKZIXXY Q-E7,ZAZFI:^MHSGM-LNZK2
M78XV>5]O3<NX+COILKI]&)8QXP]&)G0_YHK;</SOLB1R&5)6QY+]Q/#]0AQ\
M/3UAOA"&:D-XE(IP;RU1D07B&9R=N3<A7>HM):F8!-Q/A/DZ8HJI,)7E0CX5
MKW0YCBA+]UYEEEM9O2!5[$CQK9-8,]0?9@(A<2=,XAYO"L3<//S!,KJ]H>EL
MCV^.GB /J%C866,"CC=P5/0_KUB*].?+^7G!]X]>P_/P[]ZGK] _.\D,+T1!
M.9$\&LP4C<12'TD>;$0*4UL(ADD_Q2U9/U7!%9#UX?+@M'$>T'?)%)N7D.=8
MH&75=-&?+]IB7E".^0FG8,*$F)'(=$XX<Y)8Q00)U!M) Q6:!4!F=FN<4\V9
M5BJ75:Q@)3QU,9WV5!A\66L)+V?GOHI'?+\T<Y.N.#1?9I!]NK&[12&N'LI'
M9PO?)S LJ8/,EU;-'GO'JLV%B\$R:63(/!=1&5,P[J@JM&2*,Y8,R!LJW]^
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M31Y/X; J<S!MKS*^.Q>$?+X8T&W$4"J$VD L&_+6SI*G$O5:=]3,=YR]0C7
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M)L/0$*8*2)6^8MGS(S'_-=GW".Z,+F&Q!C&FP<\>7C4$J9[8==,"WXJ4*.>
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M/7A#1%MO],X+LB++_(F8C=4:YD'!\KJ'=#^T?MA6%/(V_= ZVMO1&PMP4WN
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M3J9DV/_[_RE*Z+^V%"%^1$'@[WCK;X)*MNYB;'?OMWM\LSV^X'-02KT'P(E
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M,*")<\U$]HV,<E8;QJVW>B4;*X"O.;02H$L#S(%)L7*$9O^\"V0E#HJY@)<
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M^]8-&Y\-7AAO.K4Q[<$?[U<EAAO"=WL9#V;8TTO_?:I /14Z.>N"UCR"QYJ
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MI)*FPOB@ J.3NCZ]R>R<,\2RN ;/2Q.">4"<K0B[/!!N>;6'M4R*((N565K
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ML5@7B#$_?5F>PH$5+ PH]1E>B_H8)Y./DE/E/0].Z&B4)83R9+3!PI349PF
M;+P)#--82Q(=$BH(Q+F(0'UT0IXF2N#_BJBPL<WYIIX@0[,BW&=)HUNE/,,+
MM=/C6'$5B&+&<T$=6"X6R6N*(R4!EY1J29!HA%(Q+*G#%+PN'@/BFDFD"25(
M42JBDYIRYC:VF=FD:ER:;TD18=U#0G?4&4BISC 9CBQUW"LM$W>)"\(<8UPY
MPVF20L04IB!&/TCY]RM!SWA?%RZE)]8+E $(O#GXH8,V*!9JKA'P)VOQC?=G
M*,49EI(KS#([!4[&*)9[J3 .\]%0[8*+2D@/#@WG4Y"%<G8N>':.QEH2MC@0
MF)@N #$@F1@XJI#'C)-D8W+! #%8CME9:C.4V@S+D%2U)G6Z<X>E-%/$DY2C
M&XQ3[XR!6\26^8AIY#*68:DEP/SQCC4Z&954(LA+8@#X87ATULMRD2?A"%!J
MIP=AJ0D-*%8R+%4J,_QPB%\J,[Q("VB37') &:U37*O@6(B:*\F<2IXY7(;_
ME@/Q1UB^T9$:E<-_BJ<AXA/I4(Q<1:<4"?XZ_#=WH\1E0=Y9=!GD&E3<*?.\
M\K='B]CXEL'/JXTK*^Z6K."J!J^4!7=EP5U9<%<6W)4%=V7!W;Q]&JBF6&$/
MGD#@P2I'([#,1$VP+E++2UW.QSR!TZ/3YK>CT]].ZJV][\#L@<U_%OL[GX'1
MAU;M]#.P^EJK^O& CFNTU5K[7S[!>Q\:]=-=?'3XZ;26]=<.CR_RN6J'M=,J
MK5\<[62-MO&"N^B)=IXH1'6PB,,0(1MRWQC&C5<1&\U-EN7$FX:-1_U7,OBS
M-,&=LN)NW5%U_OA*-"[QR+U)F#LAM&,!?'+)2) *T+14OEP.5!V5N%<J$*L2
M(B1@Q*7Q2">MD2+"1I/;P-M"^%)N<KK@ $N97U66W+T8R9-8,V6M-I0Z#L:L
MF1-$&<HU_,,/2^Y*DO>V<#1><@=+2,(Q<&2L-X@S+9"E7*$4@=AY*4FD=&.;
M;3(V7D"S(A2OS/E:3@+C;4A&L!"4EES[J#47RE+FF(G!N+)A\I(@Q@B!D2:2
M&*Q&- F!>- !&>8IPE'+7+)B 4@R8G Y=WKX\N2#K6"^5UER5[9$+H'L!LC&
M2^ZDQ80[SY'70@+U40YI+3BRV%C&HJ*4BK(E<EES]^:87;9$7CLH&N%446A/
MG,/(F:AR6]((OQ$//XPP,1(LDRA;(B\9E2J+[LJ6R"N'/>-%=TPP2QUQR"7M
M$:<FY(0_AH@7#EBLB,&KLB7R,D[/LB7R.D[/$6I@<99QX0EIQ6%Z.B&0<7E3
MGF/P4:R3CJNR)?+RAF'*LKNR[*YLB5R"_B.@/UYVYTR@V'N"/"$2<1LITA)C
M1 S09A:DH\F5'9'+NKO5AORR[J[LB/SC0OX(S_<8"Q@S SQ? N2G8)#3TJ,0
M-*S@$;QP6S9$7IV.G,O4$'EI.G+>-N!<LE:.8SR[&,2_A@_@SVXG-?HS-(Y=
MCDZ47V!<_['-\SSPUV-Y%KL%B+=]K#A;]-EMW[Y9W.=FQ;8Z[>/A4+>B[9UW
M8V^K\M>]3U4:O=',@<U*,_9N7_6=7C\;TTUG;("/,/*9 $;8;;BB1^\FO-J$
MNSC>K!S'=NS"4\@69P-89OX86.<_L?+3QE\?_\NVSGY]O_%S)7X_B^W>W8N[
M?O/F+;!EWSP/\ 1.;#>BP3W[3BN_.[#WX2=SD^\+N(#\]ZU-^YNI<W/ W&^X
M.%BHI/-V ;^]S>%I<LO/VZ_ 8[;',5_7YIU7$TPT>/R;PU\:P_OTPW:Q%9^[
MCP]/<-U(?+-R<@Y'@R?=ZYQWBQ<:[<%JG&^A'_U)&TSJ^'*S.%8S'E\?%>ZT
MV1B<[\XE B;;1KO2;/0;QX-#A)B*IY!'#9[G[^/WG2_KP<E^:TPGT08/:TT_
M#_4_L9E-P,%X9IL!4_BGD<M)[T")'=1-#X^<+V4$-T:GVT@%M<L]=']MV>]H
M4+O+MH0B__H5C ;=5!#G%T8KJCMG&],>?/RKPR)LKJ^[C*X '+1B_Z03LI4T
M\HS)?6K!G,Z;N6=]?S +BY& D06<SI2RVRGFXV YB'FYR#;0S96R>1 O&OV3
MQBAZS-)?>SF>"\!DZ-Q;R@K+ONWAV^C'5B\_%IAZ-P;_KC+#C=Y;D]ED!8$7
MIBU3/HS_^@]-J?QU\=QEJO./D!>Q15A^#$W;RT\& +,+OW3. 5H @W_:^)^]
M#_L;/V=@@_6GW^E>5CS YG'L_?*3!_1L]'L__UH.TZL-$_"$XPR3E>/.15ZJ
MX-?F8#WYY2=8>V!Q^_G7<C1>:S0R8'>!=YUW,X;E!3<"%>A<QKQHPXJ6.4$Y
M'*\V',"I@41<#1C.+?VQ_G_/&[U&?A5U8W/(.6'*E$/S:D/3:)W91G= 8_/(
M_'0,W/CG7YH=<%0R,P9*V.G9@LC:7B^68_.:2_^MA_)3)IX 7,!>?_YEN-!O
M5MJQ7P['ZRWQ6>JCTCEK=!JAF R]WC "T+SV"L^Z#2!GJ9'#P97+:+OE='F]
M\1DL*M=LZY>A[U[.DE=>4(;^<J5\_F^S: Q7;@"?YB4,0A\^ BSKI( J6,5#
M=/W2,7R]\1@A5,"E8AZ&"-2W?WD378)?*FW[3^._HVWV3WX%%[\<H=<:H2(P
MV\LL*T>W!\M'I6^_Q]XLTV0YXGE[X%_!/0ZV%*XCW3E$U.L7 - #3 [%-L/U
MFV?9->NTB]VP0E(..$POYO!QS,\"7LH[#_<V#6X]N.O#%;'1QS?$*GOC5W&]
MU]&\O-ZIZ W"CT6L*_.GP4>+@;FYX&[G-.8ME?Z)S>0+)E*WN-1NL=L #_+V
M?O,.R#"@V6T5/LSPX62/YBSF;16XBMN=E-^BM^=Y.^0L&P5\*)\8O@\OW9RV
MT0,,S5=5 &K>0HG^O'A(=[<\+G*LN+C>P==O=Q+ZM_L+DQ_*,+1\NPMQ87N5
M_WP+N7EO3][].;COW[-?OM^^O=[W[;"?;>"OX66O=X+$T;]/L&_]W;9?S/E^
MZ^]OM:M=7#W\H[%_>""R6/'1SH$XVOE\>;2SRXY.Z]_KI_ZR_J5*_GUU<+6_
ML_O5QUP22QGR/C=WMBPA)[U )DE,#978")I%%,=R&ZX5.(M)-XL1+$R!NC2"
MQ1C!\5>EC S4)N2QC8CKX)%EPJ$DF,9!.6^CV=CF#]O $(W@3S<"W'0*C=IX
MJU$[2(1A9+.2YW5A,GEL-V<VGH5ESI;&LP#C@>NI?C622>Z30E(!>'!F5.Z1
M"H B@D_,,Y$"WMAFX[(3ST:0A>72E4:P"".H[;S_"JL'3'9A$76>(BZ210#Q
ML* 8RR1C6:&>;VR3<>FT,0AI9Y7K&1 $G)0S&#^@.<W+U=OF!EH,IMV. YO/
M!*MX"(7WU6A5CCN=< $/J'(;#:_TP4 S&[M^8-48BOV]K/N;TV1"H^?/>[TB
M$:9;D.'&;?;& S>8T@LY-H^H>/\_NQP74H$U"U#E/QHV,06FFK2ACC,AM2&2
M>$DLEL$RKK\:LK%=ZP#OA970OD ^_Y0V,^3POG/<AF^%B48RC,1GSV(F9.6*
MA>0Q-R)R:J.C$N";*95R"TB,9^X']7%X;7LWE_8_G=Z:YRP_'TOS.>J\>OJ9
M[._4O^\#KG+A-7:>(0L^$BRN3" ;A42!BF M(<81!LQ,C7.S 6 ^=XD5RJ1H
ML ^<.R[ $P #B"3*% 0->.BIS5*A-(\AF!_.$*J7^X?')%_O_N%G5CNM?LW^
MD9.PHII  N)46623CRAZ9JS'X$*YG(B^]9"ZEQL:0AAD'MR2]6P94ZVY]Y=:
M *&3AC\!*.I>!Q1R!N&]&,*ZK,;#G;4[NY[E,ON"RRP0]N$Z*Y=JG;65LV[N
M#?1]N+K.NK@JGZ)CTDIP6($A:VL5XYYH<+Z9!FA_RFU1HYCZ/S<&^5?L]YM%
M@&]W$,XK@?4!;X57#[]]M2RIR&5 QG""N#<.&:LQ2D;!@AN)8SX+^VSA\?K]
M>VCZB&G&2!7ELYLFFZH&XBF@>;E)<6?]F&;5(-?+!"#FY%7B_B)QKQQE :&?
MT9HY.*)O-!O%I-E/^]>1]D$M268D'[J=UK!LH7?8^;W3+LJK\L;!(5S);SGS
M_(>;-)])[73W*W&6*><U8H+G(*$SR%F@(2%B)[AUQ'LU0+Q&^SR&]QE[+#?$
M$4.]%Y(3I8Q2P:IHB96>.@SX$P&*SF"(^MWSN!H9^X?WTM"+[/Q>7AEZQ5[)
M_7(<=PE6GS>R!EWHAF]FRG4S =Y-R9+R[NGPE5SY)QYZ'JO2\$[@+8GIXGO(
MT2U.S<(;WI$MQJ?K3#?CQ1(ZW3/X$1O>'18.2MGQKNQX5W:\*SO>/7S#?X([
MUK(^GA=7,TGW\65U:=="FVE%A#CFUEX2V%G*##=)4!YC[FH0F-$DY2TJ',3,
M(>X;)V*O2- :A#57/(0]D-WHD.JI!^Y_?'ETN"OJIW5<@_/N[WR^JNY\.JF?
M[HK:E]VKH\.JJ/X^(KMQ^OFR5ES7'\WJ8;-1.SU@5;K':X?5B]K'#PUPPDG]
ML-:L7GV[F-3D3E*J,4\!"4,2 D^=(!?!7U>.<R$I4>"A;VQSK=9#96EI5)3*
M!G?KCI]S"QEI+BBV00M%-<<I:1N=3<DGFKQ6W$V=OE7BYP+Q<U2YG"@<@N/(
MVA@1QYHA%P!)C=0DIUYJ+M/&MI@@'[RD.+;NJN7#)(X?2*]\EHT3:8UB3GGO
M)-<&:V^T2YKE_RR\4%*V5X><\99URN1,7L60X98B3KQ#.DF'@A=&!QDU]1P@
MI^Q75ZJE+Y2/P)+FL/!",,FX5U;'Q%1*CCGJP<LC)1]Y"W 8X2-$>:P=L2C2
MJ!'W7B- <(P43$%-I, BY@W7!].85E T?05%T2?/Q?O]Z,[NJ^[],#V@YB8Q
MQLGDH^04: P/3NAHE"6$\F2 THB2Q+P^3HTWGTM6 Z4TN1"&!L2MIL@!1B&J
M\U:WPPP&"D@,EZO*8I8T[E0VGGLA<L2QXBH0Q8SG@CK-"1;):XHC)0&GDAR]
M!>B,D"/*2=)!.21=M+D$4R$CN4(61HEP"636Z(UMJ<>+9Y9T\J][L.8F=^<'
M"M?,TK_*4@>>F):)N\0%88XQKISA-$DA8@I34)T'^E>5\#,O_$SH-"<)<1@[
M)!C#N;* #WRSE'3R,FA-M 3XX>,=+LM6<TO)#V:9J@(G8Q0+U@3&87(:8+K!
M126D!W^%\RD(0CE57VZJCC %Z21.G!F$60BY3E\CXP2X)RHPEVR2-/J-;5JV
MG5O6",MC;>?NR+[8;AO^[OWR4Q9G>FXRTWIU)2H;T;T(55N (D^)_R^$_^,-
MZ)A/@EL.W$PHCWA2##D=!&*4)29L4#Y[BF8\*^KM,*1L_[9B0%NV?WN)0-S"
M1*]*>%T@O(XV>Z-8<XDEXL(EQ)6+2*>0>ZY[8:@BB@>1Q1;&/>'U:?0V=4.P
M:>O1!H_$=7_9OE_H=GNZ8<F@'>ZCC);!#:><HEE0M#-0Y7]72%LW_HG#,K3A
M?+SSK>%5XMNO6 </\+S_\%<>+3@<U'@\<C\S'^C5"_6T8,\IU&-TBS"Q\-HW
ME@OU]$L<EK#I*O6&[NF(G8F" LQ2(#0L]9Z[T.@UCO-"E7+%#'C-2MP)>Y\O
M>/K)?A;G(XCV\$#-\5RO#_$0%KWJ$__==N$^X& #.>C'9 B>*X PW;/_OS=1
M0"A.?<#>[*[?[J8_##I'%-I['[)D,<'H8&;S'X>B:_(QY0T=-EJQ5ZG%B\JG
M3LNVYROD7X@^T2/4IOAYTKU]",<1N6ZTWY!-,'_?V>:%O>QM_'+_U'#>NXQG
M:K+R3&KRZD0$;F4+#VYG5B9"^9;4BY<,$'C+D.?* CQRM62+X)F8R/11C\A)
M8F+$@;A+ 0;O+W!#?;@M\$+ EM6>BF:.'VZZK_Z5F]H4,BS35X _^2"FYU2S
M'6K6CMDSP<FB@>G.\<:FY'Q-5_DP*'+7HQN&(F#E<%Q$PT/BA$CK&;/8*18=
M)<ZS4>$8$W&@1$I!>.1&!ZNY<U*XX!*W+)"'SO.DX,P3'NT22*K, 9" 9)RS
MEY I84*^B*;*"UWL='[ECZBI4LNB7:6D2BFI4DJJE)(JI:1**:FR@-(6;G6R
MTBG//>;,4!N(CDQ:S)7$8BAL.HM8],3-K766#!_L?)TUJCMU6O^R>PGGOZH?
M?H9S>5+_\J%U]*5^L?_EJ%%K57']].2D?CFR\]7:NZB='IW4#_>N:CNUD]HA
MW-?5WR?U+T?-H]/WXJBU1^M7GQK['S^<3M);B=YPR2U'*HL&<$VSNG1T2,3D
ME).)!F\WMLDF(RM;O[NDE2^EXLJZP^O\N0-4&*QL)")9SH-W6&/J!>8^>N*U
MGKK=30FOKP6O(XD%+C#BO>9(^V00)UP@1ZE'-"6L%:.))5K *QTO+%Q2F%OW
M&I]2D.411)(VA20281P'3KPTG"3A/3$IT9@460SA*T%G!M 9%V1QA-HHB4>&
M4(6XDP89&"0$A$XYX0(,EP//EHT7"ZP(HRN+BI:3K\!\]SY)S D3W%JME2#8
M&X.94=CS)_M<E.CP$N@P2DEP(A9'@Q+0#\23CD@'(9#24I@D%#92Y*J_\<:O
MI2++6\_%4I%E(2S&*8J%)89@H?,NHY,2.$M2PL7D,0MEV&JY0&Q<KL4[$@E.
M"KG<P9H3$Q%04(TBEUC(1 U7659J4XAQH<L5(3E+&K8J!5M>ACMY0"(686'F
MR7%.A9-$\:BD$,YBDD@9ZUDZ3!HA5MH#M5(JH!B#0]Q$0"?/LA>6C#$\8)%[
MJ9--(\M8SY+,SU+/Y0E0(N 4A$"4<HESZ7( 6CO,K/;8:3>Y\]KSBX1+=%H4
M.HV+O4BC9&")( ?$%W&O%++6,12I"SHZ(QC)0:%-HDNYEZ6;R?/+O6A''$LX
M2H8-]])9C<$0+&8D"NJUG()>E#/YC6;R",_ VCBJ?$#*:@$\PWED>6 H!&R\
M"AA>(9EG2#'.,THUF*5@(Z4:S'+D::V)2,'\1.]9+79_<#68UUH!QM5@I.!2
M69?#74PC3C1!.D2-@C-)&4%QPGAC6T[8X"OE8$HYF%(.YBVW2*7%@7NAB2/<
M@5\=0O!6<BMT$)9,P\-+?%TXOHZJ+2IN8*0%PE0JQ"T&AIUL0,QBR>&_R+3=
MV&9D[BW290'96:L8A^=$&9K>$3VQ?&[P4J,=8KO_#N4/O>[,+"J][Y0OO.ZI
M1QX1SG<_4EHQTC&^T?;-\Q![X  T.HV "J&;&"K-1K]Q/"AT##'%=B\6;>1A
MLI\U&[;M(_S:Z_<V*^Z\7PD=.$"[<W.TBJUT<DEBHQ6'=9;'11]Z&,EN.UY6
M4HR53JK\Y^L*!PX0S-N3=[_?7-/[X25]B'&]PP='_S[!OO5WVWXQY_NMO[_5
MKG9Q]?"/!@"/J)Y^@F,=B*.=SY='.[OLZ+3^O7[J+^M?JN3?5]5+ "B2KW?_
M\#.K[1Q_Y5*HY$Q$2G"&N%8<.6TYXIA0CG4(2H:-;:(?P*EA%5PVEO-N%VPM
MG'>SX]D_B? GMV#/EM;.A8.M0>%@O"T<'!R"D<V!-L2UN?8[Q==3%@MI7 WL
M%BPLO_97[/>;165WY?TQ'#W_ME79.8_77P*K^U_X5]OVS[N#<V>GHI%@NF0[
M?^0PF\6G\[O7YKYYU]Z'1QP> (Q^$WYI]&XN.D^#"]N[GC4!?KD[[W[J1M\!
M &W$WL^_>)C%QQ'F6SOF:58<$4X5\LS,T[)=P'-QV-Y-)7L^]8@[OU5Y#PB1
MCV^;S<O-RMFCZ# <F0?&HG(S#/DN!L)7_\3F9:71.H,1AX^Y2X""6::YH41X
MI8-BQG''C(G6BN04,51A20?3G #_&1 50A^;YG^<A^)N/G2Z0%#Z?Q;WM.9A
MPN?/\\\7M:N#KP&>J*,ZH)2B0%P0AXR4#EFCH](NB4%ESD-[B==S^W3XZ/.S
MKH#A75M4[^Z,A96Q4^C[="_!"LZ[L,8TP!::S>C[YV",\!6@F?W+2L$E>A7?
MM(W6UHC$P)B@VSU!N07$&^X3WT\P)]N^ 6M@/MM^>M_KQ7[O0[?3^FLP=0X[
MO]^9C(=P[M^RDL&/9TZD=KKW-6%A3+(2":MA@8B$(F.T1E$QH5DT.9-[5(O!
MZ^"\U]*%!.N+U,9'%E*R1*DD!,<;E0B3] P&I=\]CS-HZMT7K'@M/:."$1[F
M!:#3;'8NBI6N$'@XZ\9>@=+](@)K"TLJ)DRT *[=>-;I#J4@AJB<5YN;S6.@
M4^^FE11Z7#SQ[20"I2'/TIV@6T0\_/8<"CH"/^^P3^E.3*?+,_/%3B=G46HK
M3'_'2R:?<"N6D=5UIA13F$$O81F?Q.1HUQ_GP$$9OGD0<^HC!)+_6YF4H?M.
M_-21GN%=KF0D>-X]MYGO?1DBO7,GF=/@J?.8)6\5EUIH&A,X3UG7BKD4Q->]
MZ7++![QVO7VE8<#WV_['ZM7^EUJC!D>&Z\1'+;C.+_6+*MUCM9T_3FNM75YO
M'7T[:HP&? ]X_:HJZG2/PEU<U:X^M>JMNC@Z?7\%1!A76U5:/SQI'+4^M?Y]
MM3O>PAPS*C%F2'"-$7=!(.<51\H'!038I)3(QC85FUR-QWQ7))]\UEGXTAMV
M([@_]9[;*B/IO'MJ*XFD<^^9V=Q#068HI9X3ATV$5Q262@"L"A8+)"58,EPB
MZ:LCZ<C6&0R-M4Y3Q+7)809&D289216L?L%B2[+@ 66;DL[=\OVU$&W=L^"'
MB@=9ZZOR$WW8;5OE#-JYZ5P@CO,8%!41<^^5<0$3,&8?99*<EW3NS4!H7-3*
M:*-L#FXF&RP@$7?(4"P1)5%&*:PRC&]L$[I))I3BK B=*S/MEY.L4"QX3(9%
M [!@E',\"OA/>RR]L,F69.4-<6*$K!C%HK9)@,<'$,%=)$@;"5Z@9R;J)+3U
M"G "W#[\T!;Z2N33KUB([79CY5E49,+=+A7$S$U%F%64<RL\UIK#_S1 #@M*
M4N*"U@:75.2M(&9<B\D;9@@!8%%<98@!5\C2Z)!C6!#*B4A*;VSS3:[$JC*1
MR>CREK&CM8")N9F(2%9+3VER4G)/@Q:,<J^3949&@(V2B;PA3(PP$8$-S1L#
M*#B"$<>,(R<-1S@YRI0E%'!B8QN("!W7,WF[Z?H4$?DAZ_<&V2,/#<<Z5HK,
MN#^X5@4A<Y,Y<!45]T[ZZ#SG.%KGK:8V1N\3D4J59.ZM4'I<=<I&:;!W"=B;
M((B#[XB<,T#FI("_864EU .9HYN$K(KLU%M7GKS@RO'0CN(Z0O",&XMK!<%S
M$V7F>'+6YI@Q0#'+$:%((X$_E/D@=$F4WQ""1T6V6&(AQH# >;:(>\*1$1(C
MI3236<J&>)(;]&YR,6NS]K>&PK(([S6*\ :3=-:B-RH<!S>:80N><TQ4,TZ4
MAG-JGX+F:C:(V$\[C=Y9IV>;'\$U.]LKJH[@.N'5FP3\85UOIST=GI@5Q9,Y
MRAHNX;-?A;"Y@B$@@4E$7&F!C$\<1<^-IM1K$G,(?VN<CU7<L$+&-\%E:Z1&
M#."[54YB,Q2I_S Z<;2J[?=<)=.KP+2,,+V*FK*+V(VW=6,7C?Y)HUVYWE&W
M_<IUMFSE;J;LE--@H4V/)Y3KW%;G3"K?60_PF=PM],DNHR.5,,#N*0]>\R0#
M#[E>";Z-72(L"F6C?N@\3U?0C'0_-81+Y2/.NL24.BVSH!.CV%&-/<X9]CE!
M8VRL)KRR+( [^<$\]X$^_8"NYUXWIER^UIL)YX4R*8*/%SAW7&!J$CCF),H4
M! UX6-P\BS+TQTXG7 #0[+7.;*.;:X>F%TC[\3#]7H4SK^WL?:4QBS$HABB,
M.N)",F1Y3N7@@.W<8<]QKH+<>FA_]AKD8;T_'@Y%410[&(O*L)BWD@M\N\/"
M7S"(=AQ82H;SHA*RVVA-_'X_KP/MXV+!R O$M?%]!A/+Z'^_.G=0I;P3?6RY
MV+U^F6Q-,Z$G%)@-^AXGIAAS21OJ.!, ,402+XG%,EC&]5<@RAO7WWJD(C/G
M6":'+;9.<:V" YH-Q$8RIY)G#@\MG]P3)KEOZYF^-#L]6!7WT^^=UEEL]XIK
M_S181'_/,@5_P0./O]E>#'_:RZ(T>GD*,P^&UMX!+V3OJG;ZC8*%\EH++/WP
MX*)^^%F ]8.%[EY4=XXOJZV_3ZJCUGYZ -=5!4_EZ%L5/)9LZ;6=WTYJATVP
M_CU1/7Q_L;^S=WGT9??[OZ_V,)SC:XI2!Q$L4B$FQ&/0"+BF0PIKH)LD2*_&
MFF3#\&CJ,$P- N"7+#BOPF0ST+G9!@G3%V8^V/IZPL(1(U64SUZ8R9Z*F18+
M-6%;E<(Z4&$>E;L6M/C5C,BI+FK:LL[EJ6_]$BLM"Y %?^"\,*TR.85Y!I2U
M<M:$ U=^RO6C&>"R0L!F 5O_]1^P_N)?_\SO%[^37W^^P307VS%+$ "$>O!?
M\X'AU\YY%_Y*#7BIMPF,&!"TW^GV"H2+K;-FYS+&WM;(\WO9BO"__$D,Y\T1
M],FP\Z'3'0.>]]VN;1\/Y!G>-P& AG7DMQ\</4KOM\O\A ZSA_Y#H];A[E>>
M(M?)$81%7I=9"LAJBY%GDDD1G#)\!A1:GNDSN3R\\T\C*_,,RL-[!4@Y.Y#[
MN#612OQ^5LCSN,M*__*LD!NQ%[8;WCT%(LM3"4XPWL*#^.G,I>!XB_/IRJ!G
MJJZF6\!J7J04_(4N5B^R%/S!U!:SU)7##VR0%YI"U4XA7[-[7[YFEB+BU4AD
M7&2=_"S!YR4V@"G+YN?K,;/"3VWR5M;\-?8C+:>7>]YL;'\"KQH(8B&AE1?;
M(F)SO;R^7,_H)=K/7:S,]8ILY,Z=2R.,]80+SUG4/ BMG1$A:6T)3\$+,;4T
MX<UVS< OB&&R4[ [L,@EVM1]GC,PV-3M7.6-W/J7^L71EZ/3&A#]ZLX>KQ_F
M[^[BZL<]4J=PC*M==O.=ZTW=TV(C%Z[UM^91"Z[W]."B>GIR4@-'HIK/>_KW
MZ='.;Z?50_]]4KV6LIY&(2D*,!B(DZ20AE<0>'O2",>E('*BC.%RYM2L2BNW
M.>6N5PM1%RMGO2*(.G=JC J*RV0)LT)R*HC6/DG#;3#<$*_=Q*APB:BOCZ@C
M:3(V).&3B4A8GFOQ-4,:6X:(P%$Z1:GB)A/+-6E$=QW^@#N)CX/A:WURW34#
M_HS=8@LSZ_(^S='7HC1X;GJJDI?),&LLHSQB:AC/>]<B1 L<![N2GBX#F(ZG
M?;N@-)<!(PM_(6X81=8*AP@%4U68P> !/5W9^KU226 YN1>85]*$DD0IXUIX
M9V'I9I(E1Y6,2I;<:TG@8H1[<>6]8,H@XFA 7'B "ZTMHH$:D_-6K,C]^69-
M3UXJ18$7:%PR-=6YLW]V-\'0O'!ZX6,U?P]M"8ZD7/[([:3*QGTO02D7UHRE
M7"-><(T8[\;,HP9'/&KDJ,WUW@+6"($9"E03HHT#CQUGF;Q5Y93+TMBJ[!ZX
M5%&#'QSNYW8)GI6D6\+]Z\/]B$O  F%):XF8H09Q92RRT3GD?5(VLF2<2!O;
M;&Z78%E@]_%2QC+-K4QS6^<TMUINTE9FN959;F666YGE5F:YE5EN"]Y&%%HY
M'"ECPG*CI(V!ZKR7F$PA!#ISC>H/Y02< ?%O-H"TD^K5>U[;J<+KM9/]PV^7
MM:L/K=J7@\OZESU:^_+'26W4"0#BO_]E[WMMY_,5'!>N\=-)G>Z*_<,]5OU2
M)T<[?YS43^NDWMHED[+<<+#)>N.1B$HA3KE"FGN)4A*:>DY)DF1C>X)LR4K&
M?)8FIE-FN:T[HLX=5M&:)VVQ-D)*CI5U6.. P4&GU"0A:(&H^!I1R[#*FR'J
M2%@%QL)AEKL[F-S3-D2"#!$1468,L=(R*BP@ZD,MDI<.V<HLMR4#SC++;78P
MC5Y;A07FG#ENB7>"I]P+40A,G-*II*?+ *;C66X8ECP?54!90@1QISW2@47$
M+!>$1F(X=;EISJK2TS+-;3G)EP?$D4J#^0G"F8T%#W,Q8FQ]"$F7Y&M)\&*$
M?%&&.9&.H^"M01Q0'QD![JRGW/@0DXHR;&S3E6Z<4Z:YE6EN99K;VW/*9XD#
ME6O$*Z\1$]+<%)%1"8>28 YQ"S^,I0Q%31SS.@I.^,:V7-G2B67)MRC3W)8J
M;/"#P_W\/32EQ8%[ 2A!N%/*A0 D4W(K=!"6R-(E6!*X'Q7G5]R2A .RF! $
MWD% &GN!*'%"&X^39G%C6\_=^'M98'="FMNHK/:*2-X-E.WZ]ON-VN,=Y?,'
M!>\N[&SJR@NO5M@="DW^%;O_-'R</+L/[???!C?UH=MI39SWJ]&QX]65'D7U
MXJM*,3FB(F+!<@06))'5(2$L@PI*2*.,W]@>W[2^3OPJ!$%G,9*%YSB71O*2
M1E*]J+[/71@8S&&:M]\2XD(I9&W$B&AB$[SI57*3*J1OC.1::[9?* 2V!KF3
M\39W<K! 7.MH%S:5!W\38*IW=JME.ZNM+=RO+&WM16T-UPZ^,@%+A[$*Z>0I
MXC$%9#SUB&HN.>-&,D4WMLWB &GA;+0TDA<U$E(]_AHB@ [#'D7N&.(N*.2
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M7,840E@$QUNN/)C\[^&&G!T"\>!SHUM.PYFC<O>OLTZOV,)Z5^Q<-?Z)MYM
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M,O>,;C;20RF%TZSDB]9<6\HMRY>J*)HWR/^PT,VGZ['^_7:H#V.W12>6%64
M7/7-@"\?FON'Q[A./U_4K][CVNFG5OWTMV]'7_*FP+?O^X=P-U_^;E8;8YL!
MI/[EL]C?^71Z=/C;:77G@-8^'C6J'S\UZZV#?'^B=NJ_'WWY?#DIURXI:I4,
M%+D0+>+1161#;L,=C5 ZZB"-V]AFX^'TYT^M6=CQNDS/1_?E)D[/)#7F7OF8
M@N-$<XUC),P*8K!*3.-B>N+KZ4G*Z;D>TW-DKPXKH@*V'FF:'.+$6F2L3^C_
M;^_:GQHWLO6_HF+WWDVJD% _)25;5!$>"<G 3&!F<V=_H5JM%BAC6QY)'F#^
M^GNZ)1N#;?#[J:K4!-NRW.H^Y_1W'OV=, 0O1G'%$(OZ:%"&JF== S4IEAA2
M%365P9M](FLX,5W-P)CV:O@IY=I>C6FO!JNB7!8&2A)B8Q\K !$*V:&*N"T8
M(0 S6(QUZ?Y\X,2\ZH&V4X,W$G'4&KQ\#7Z!.*@7(TE9;/M4-TF//<\. S>P
M==$75;$;>Q$;"W'TXM,C"F_FG</';VUA)F3X065&7EI26484K4^MI"_H/T,P
M?5D)TH'G,-2(IJ@OMS1Y1Y=J9&397ZOB*'RF_DKZPG.92RD)J4 R9#3&$6S=
MS$6AY\=O]%XXOSSKYY#XCR;DZ7:32UHF1 D#OJY8'#><16L&)A!\\?WBAKNA
M3G-P6WD,VQ1'@$PCW[-A6@,D8T4#W>J-#%3@V7H>=75^;^VK2GUC4"U88R'O
M$O7-V%J-9/,V+% ,EK[_.[<IK)AC_=+]CN99 C'07RG2BLK&<"^!["N0*2U=
MU7VC?:M+HF16TFJ*1\M8=RO.TN:$(L=\0@054G"D*"(LX$11QG@0\L!WH[=$
M;C@)W#3;C_FG$MDKK64Y"*X.!L/.\V8;#QOOGA03V'YN< ";0<2)S0..;.J'
MX)PRJFP,VT<02"[=V'VE^'BH2"#N1I( W*"<4L6YC[ ,E<2"<LY9B+5(:$!2
MBH1;B\1ZB82GHH#YGK(Y-XT*O, 6@1_:$8X"-PQC&F(0"3U70PY&O&37 F,T
MF?!XG*M0BEA2WZ, 8 ,>NP@A'(<T\I@2:R@\H\C8=E&"Z,7)^8V+.!,X8#9W
MF0<2I +;5YZFBJ0NBOP@#D,TJ5$A82"HZT68>!$E02 BC!3A/D$DH+ !#?5L
M:KE8*[G L#$$GA!@68+0IHR[MA^ZGJT$);'+?.D2N7>(J3N&86F7DZX!TA/.
ML81>'$LTP?\O]%J8S^)>(:)K>CMJ^;!N30MW\[H&/#LB@Y??SV\X%AJ><YN#
M_; I\<%+]DAHRQ"'@<\8\F,Z8G>;?#/S0Q1+3B3(0TR9I*'O>=@7-&">(CZA
M:R@KM=%Z)C"W-U@BSP\QMKDGP6A%RK,#P6([<H4O  Y%3(*?A\D@CWW/1@T:
M(ES:'\<:%0,04F8=94F1WUE1HKGXP%"IKYWD&ZR&-ES%G2B,5]<6CR;)T6F#
M.'XKE[AK%8TYS)=".MD347FGHDY#O8][-*1]SVC\51.M.8(Y^I84C[O.1>E>
M_OWGC1>3D"*/V;'/(IN& )U@EY'P3T1HB#P74[DEW))6WFG"<.$F(.2-AE6
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M372.(L"*N&ZH <Z@.S8^P*G#-37 F:O^=\"(U>AF[J;A!;KAGA=PR@,[=./
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MY_V,/1TZ+ PD7]8Q_B*4Y(\F9K]&S"6T">\$7/W8FJ>0"]Z$:0JO?Q6PQ4'
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M<UW35VC[9)Z.Z/,XIQGVT=%'K//A>K)=R1;FZ0L^7Q_JZW<\[I:GI_UWPIB
M7'R^SKQ-V+>8#=/X*[*2$MJPF8"^^'16YX:G.$52U,C0^J.2<5 L*Z"D]>"T
M<* M8\$S67PR>V'B%U"V89'XS")X.#3:3>N-*; ?3FO+6>2D)/( %+DSS$/0
M-M,/+Z3*"46P#W5"N[VFUQ#J%UY@'*EDH]51@C3<T*A/Y/IA1C#.:W(%G9,H
M&FMH XPA3=5#X>/-0;NK]9H-V./%"<Y)P-EU0.NY9.04$Y;[ IFD)1DI0/#:
M>$B"T3\!F;&L-:.^B>B6,_B_)[G:V;3APK 2[ ($!2[&HTE@?:385*$'+]$
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M,75//1&2:"DH,9I)[4-*B;6.-#?A&%3RHC4I=E;\SA1(X63TY'0V7XS_KU=
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MW"[>@K<UGS/$Z**65MK6X[,VVP!]91?SK>:4]XA=&Q7[7 >DV)KH$;*IKUL
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MV(N7EN'8,$ 'J)O0S#N<X^PSCKS%$#C6DI6@0 E)T(H.H"-RD5)R-K7.>'H
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M]X[-_C">IROMAOE:N=4(\E(1OBE7F&L(\2<B%7WZTW0>SM^4C?]N)(V26%0
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MT46='I2A.TRBP_!S'Z(-S<>5!A B$$-"A.P$&7TL&3J!:,?.^ZRY\D';3BF
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ME.ORPW=A@>^_A$\K5-)Y%AERLF8RUIHNA%AK*IR)-MOBF6*M^R%L1G)"_&]
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ML\Q*F-"JF<B!,5)""@H!D]*IZB!3Z-Z?\A2R#V>._O0#:?),Q"'$O-9,Q%%
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MI_$<13!F ^38F3E/A'ISU5E99< Z5]D>8*,@NF2;-4_"JFH*]AAQN8R7L/D
M?_[M:PSCYWK^&$+3:WK[&H71D'>0?1@\%_C*AY1C+6"51:;-&XBU"LAH2DQ6
MBS!L4,^B0!__]M4=\S%\G?'M2Y#VB7*!5%A-&LH>DA %%&M-5,$:7WMG$R_[
M[6L43@/?OL8P>=:WKU()E6V64K0)C"0/R'XAY(I9&VN#LKU+EY;^]G4(_GT8
MW?FF_QBW_63-X,7M4.]B47F62(R;)# 3(4@TX$NH*:"*P0\JZWOFJG^4@%=A
M]_5A?^>TIRT7[I.T%?\A1'6T_1XE9'[CKQ-0JZFXW/M:>)0XI;5$%$Q2E@*,
M;>_TEHV@4C.1=<DX[&$!S@S]$R;@G,B/86[/UZW5S>7UU8>S7W\^LR@S"55!
M.E[<N)0A-,VDG/%)QX "G[+XUI3_^=WJCW_9?N(MPML?/@'\:;UYU7HGQJ\.
MXMH$)AP;%+_>69-LA&AAD2T()P*8RK9*\KPQKS-598P0M7>ZVKWE3QG/0[EY
MK#>QK]9KNEY/W);CV44F>>L:M[6==RWM*=50 ]5<C*D859*%[?>82*F0XP/O
M6L^N-\-\KYS("=F"U$JU1#B3V<6P?)=$_JWQB-%V[W0W@*Y#[ZA;UIXYCT&V
MXGII-+LZA20;RC*",%DDP2<VA-Z#96]7/G[)^\%H[UY4>[!T N5S2\4/];/"
MGZ?K?LZRLS7)($$+E&!239"*(@B"[]FBC"NQMY+:@\P7*S+3@35!;/*OJU7Y
MW_.+B[_]_A[/KQI[-GU;5 VM@9F'2F';KS:*@A W P?8^J[=^^H\3,D+E)(.
M+)^@.\8^<[D%WX;>"@\J1W;1L#9+SB*(H+6A9!.FWO6D>Y"YJ.&!APC.U! M
M^(V\5)]S"P&TGHM\.,A#T,&"$_QM\"%*-6AXX$F\D<^&]_-/Y&/X/M<KZ1":
M7M,3^2B,ACR7[L/@V9[(C2ZT,9)456"":X5,'J$]'0F7^':5/=Y-EOY$WAWS
M,7R=\8F<31^^T40%'5O=FG$& F8#J&(R2<60Z94]D8_!:> 3^1@FS_I$[H5#
M4TN$%$OKWLNBOG&52FU5T=FKN%M-\/*?R _ OP^C9R\/30))MBD<2K>V@:UV
M-2D3P&KM1;5%:.H]I7R1Y:%SF8/]49G"7?VL1&<(,:^U'G044$]6!^[#Y<GK
M04,M*L:8H:A6\1Q( @;3"J!#0.NE<=@[Y+WT>M!^B(]A[ASUH%$7@94R^(P(
M1K&>"LK7=D2:W$GOS9#FS4NL!QW%ZN?J0<?P:=)Z4)1"ND(1HFRY=^0<)%0)
ME&()E=JR_2(' +:H>M!]D=J?,]T[8E^5\_6WYW_0^OK\^N:*-K>&I4"BM#)7
MIUOYCK>0/+N4H=9<C2I.:S4 J@<__*6;3'VXVK%MQH,$;>5W"$D/&TO# #^&
M*=0)@*?@/(![4Y_?N[9NFEC!M_P9EUKS%U69-/82M0G)E!"]W764C@_H(X;.
M?'B.8=K4.&Y50_5\^Y>L05EDU> ,DU3XPDO6M5<C23ALK/K#'S]OJ7$7MC\%
MXQX\FR"&]5&O_,K,O$U?K4(FS&P;4!L;+WV"B"JW*:+2"]N4?&^_Y LB7KK:
M[</]+\7!=!6'N[SS 21-%*-X@)SC1"H.!.HIV _@\@0QBH=(0T^Y]?T RC*"
MR6S[IRHU6&FI%,T^F>X]R6LVX)^)5TR/^QCF=E;C6[^N$;-51KH4)83R4&,I
MO+G6ZR<G#3&%)'U(+I81\Q@_??#\GN_!K/[2_]V33X\J[;[YW[_A%7V-:RK?
MK'Y_S]*]457?XU5[./N##LCY'O;!/?*\]]C";F[W)O=>QFH$F20Q(%HEC$Z"
MDK0FG U<X\ X[X.+?,5K7+Z[#7Y^^/0G/^*']JNO_I?Y\?=/+4F2$%1C@A9.
M::+J *.K@*@Q.3*4NY=K'$[U(7?1/YI9?/GN1[HZ7[%<?""\6K/%M5EQ?28I
MVJJ% EDSG]R4!80V$M4(@SY(A4H,Z6#SY")'B,[-*R?WK[1^[)[ )_F.KZ75
M!Z*?Z>J/\S;'XB$V_8)_?DV7C-)U:S=V_U^^^[-]2V<F$'K)9*/PE3VK*B :
MY2!7[Y7,NN38NV*B#^6O1A*/"/@4SWO[,G'SY;,3*<^\+@95]$"NI=L*-E,2
M>05.:.E;SHO)9BD*X 'Z7YT('PW\"5(4!AW'[U>7+91%MQM8_[*ZQHO[__[-
M:GW]_>KZO^BZ=0=_=WG^?U3.G% RD!;@8\YL-VO')G-R0%4:Q]\)K+T]R<DV
M\^I$?!EB,4&+]LDV=GN>_[*ZVOZJ_1V?;J6M=IZ B@E@5)* #EE-M4D)R9EL
MTZ"2@"4<@@=W^'8REB- '6/$S6_X[D^ZRN?K%OB^I>V'^N,%7J[_=OE?S84X
M"SHFY;(!EX1I'= R!$,%V L3(L8@LQF2-O',,J]&P'JS_$MIL%VLWO0\9])3
MAL]/Y^]^NU[S]C+_*[ZCLY@J<Z6P\QDD^YTJ(V 5&:2)P:MLE923F+^]-_)J
M)'4YXO"EC+N.):;/<7?]&'NWCX5!1A>]:[.LF+5M3EHL58,D'U0TQLG2?6)0
M+^)G*T<]L@0?!>QCE[!^[ 2P(9__>//8)=''(+*'K(EUB\L*0C8&JO+61C32
MEMYSTC\C8 %Y '/*P&Y7AKVQ.$9TZU%&?-K&96F6R[WIOD/V-%7YPP3[.4YN
MP@%B,C:(-1?&IR*_%*W*P1N@H)N>48YM;\^G.Z%1PB-YT7OPQNG([3.I%0L7
MVS'03B"N'T,*UZO\WS^\;QO:YAX8J9+63K>Y(QZ,Q Q1L6FLJD0J7NF@>G>X
M>928!;HWDV/]6.SG(* FR>Q<7U^=YVLJ&]):]LKZIY]_W1+G$K'UH2R4R!LU
M,0I(7FM(,:GDA-=I=_Q1AYRN)PAZDZ2.@$UP'[$SODF O=R&-^]*\(FW&ZSR
MD H)8 (+A.H<^$JZ,L&UZ-X>PB.DO$E0%Y Z-PW_J?'B=CB&2.P#&0&Y8&1/
MJ!H(14J(?!M&'X7WR@V1E&<:H'Q<\'7ZCOOS? K@M_(WA(R.C8_N+3U_KZ,]
MF;\+WP&<Z]S1Z#XYJ3A-CJ^/(@N+94T5@N3+B93.IAHM];#PY;$!?*)O45_\
MQC"L,V[_P9SZ_>;W.T&B5)'7 ^G2G?F0M8-68E1TLJ4,L_>>0>ZS1>?M/+,W
MVU<]>-;1@-\0@G_>(\3*DD04$H1I^4!9!K;]6)TKM(7%4 LA!S63>@Z\^XN>
M('A[\VRF%NT/F@-WYL*J;C("'OZC;89C^M!LQE7=V B]4_H/)F2R$H"^+-HI
M&0@Y*G2&):Z0D=Z$8JK5Q@E31779/&+E'TS3T4L,@E+%A4R@K%?L%)@(T=<$
MI?C6L;<@<V8I&:9_[]9N_F+S-^QB/P78&2%22B&TP1T9C'6>+>\HFQ%02*4B
M:^X=8QM&V0*=W+Z2]L4;6'_ )HBU]?/YC(KH4V1/$V5EM54,H&$UB#FBRY;O
MJ-R]\.<5)@@<(I+' 7N9"0*./#N?5"#8%J=HC0M"VT:Q(N=<A';=IY*\L 2!
M43+P9(+ &"Q.Y8%UR)[>$@1&)0B,$I,Y7EKWP?A4Y!=3">1(@&[36XWA(QYT
MMN!2M-54GT6<W<A>C-R.2A!8G-B.@7:21AU/O18*G:5PL?7/C$R<9@JC\0FP
M(#NZV@B[VV_R[7FW-^:CGG?' #9ER?4760P2O<U8%+1I/JW5!0)J)4$;I12)
MG+3JW<3ZI:>;'")%?8":,4' VIQ]0 TYD&H=!#0@R382-QOG+!.]VYWS+4%@
M,NGI =*C[\2S!LN_*F6S!EY\B]?X$UVT&-'UZMZQ6$\7(!^Q^ Q!\7U9L1,(
MSTQ?Q9HR\\%8&2-S1(:@ HE@1;3/!L)'T''TX+?1)8MJ#,1D#:O;("!IEX&U
M;$BFQBQ2]^;K1P]^3U? '2O;XJTTJV;9:A!104C!@-#)D"VD3.@][^2MKG]?
M>9ZOKG^,6$P1E=^7K]O;ZH>;Z_4U7I9-^T^VW=EMS?_ BQLZ\ZZ$ZC4;5]*T
MP4-* ";^,;@<K3="H4M+N3Z>V\RKD_=EB,54$:Q]:F^W&[M7:?[YQN0914<E
M.SZZ)$M[+Y$00TF0B_,B*Q]D[?T@.MUN7J?$'U\PIIBF=.#.[IWE_Z16=<X*
M[@^ZPG?LJC1D^???K'C+F*]O\.(7NOI=G0F!/JMB 8-J6LUODO#YQYREM9+=
M;S%);\9YM_EV2!8F2A,T/NIX+PS<LCS+,CH9JVY#&HFWS-8A6LN*4I(Q/IE"
MM+33L\<VWT[/PD1I@E[Y_7( $B;VA@2"2KJ"$25#J]<!$7S-/D1KZJ#2F+>D
MG^GD^RA@+S/IQTA26N@ L@UR-B:T"6"A *7D@_ >B^O=Q.:%)?V,DH$GDW[&
M8'$J21-#]O26]#,JZ6>4F,R1/;$/QJ<BO]*;FE*;#M&>\4UL);R"(E0AA,U%
M^]J]:]+IR.VHI)_%B>T8:&?M"E*]JJPT"A3;IG)&9A>VWF>.2,OB0PJ[\TK?
MTC1Z8CTX36,,4,<<'7/O7??BXA=FY)I=K^:I?7S8O9?0U#YAD]#TZR63>?T;
M;3J43O@ ?RA)<SS+=V7;[J";J+)2,3FGDN&OP27V7PJQ#X/54'K^L?Y0ZH[^
MA$^JF-P&#Y? &L&P.H!$+H&H.KN<I"E^,1,2EO^$_W"GZ8HNF&(<"!GYLM+\
M!45QD(N@K+1N)5>G\J[_<EJ5CY'\([<J'R- QYHDM%=J0RK1J2PU%&8Y&.0M
MQJ@(V(MW.>843.B=UOB6\;+X0S!*+)8T@NB[_[DYO_[PMTM6_C<;>_D'UO=7
MO_R&E]OX_$=N_+2ZN.!3WOZC,V?1:B<*Y% 9@VP)D+($B[5*89%*7DP6W5X[
M?'4G8\$"-%7VP+2[_?YFX_4%88O.28#'0F <J\"42X6<E<F5JO-J,?,<QV[N
MA [)#%(Z_X':0\1.2O7\E3_B>OVWRUL+\\P7Y02*#,5K!!.)(/E00:JDJC3&
MYG@Z2N?SO;V=I*.<I ,$[*24TC\V>'S<IU+61!2)N1\BF*)-&Y>9(&_J;(6/
M"D]')WV^M[>#=)2#=(" 397=-LD^&85*Y_>W*K-.I>U-NX:'TZJ-EI<012I8
M*5BG%Q.,'+^]M^-TE.-TF)A-D?$VFS&+1@2I8@85V80U(1($2@0V,A;LT9)Q
MO0O*CN0O+1*%G13,C8'T+5[37_#\:I/X?__PF!A(>:$A\AEBK$A 1%<ARIC:
M..Y,KG<H=&$L.*'[\63"1).)X$E9&L/9<89%)$=2 >L!U71#@."M 2^KBCHF
M2_IT_.+A^SZAL[<$X5_@01XEN2<<N7J>$4Y676WQ(*OW8$@%P(H*2BT"I2LD
M)9[,$1ZY^;=SO,QS/*4,GW#T['E&I.1K)I(@HY)@C$<(6AAP9+2+2K=Q3B=S
MF$=N_NTP+_,P3RG#)V57;T,K-U>T'L %#"9%J4&7-DHB&MF:4 I(?-=A]!:M
M6TRG_*X[?SO&RSS&DTGO:<8,G^>!396W61"JP-;N75D(.2.4D"L5);V/I_/4
MM:]O?,P*Y_;60SHY$+29:N@E1,?.7DDUIAC0VFC?*IR/&],["MC+K' N)95:
M<X287 #3)D-$+!&"$0)1*B-=[PJ^%U;A/$H&GJQP'H/%J52(#MG36X7SJ KG
M46(R1ZGH/AB?BOQJ]@F5T@64LFQ/(7^7+!5PT3@V-RU;QK,_^2U&;D=5."].
M;,= ._M8 TG>A(H9LM 63*$$P4<$::*06N:J?.]ZM-<PUF 4YJ/&&HP!;-:Q
M!BKE6A23XR1[]X:B 91.,&%"I<(NL;.]8SHOO5[^$"GJ ]0RYK@^5EJ]VWQ_
M"07SPVDZ8L7\GHS;*9FGK$.4-F9GK5$50ZK>)^.TS[D2Q;U+YH>3=_2:^6HS
M.U\"@5VQ D9&"4B!CZBQ#ETJ'KN/!3J<ZJ-UN=Q\:4\FYY?O?FJAMC5#G?E?
M\1V=J9R\TSH"59-9LQ4+,5*%C)1=SE;;_CW[IMC( I5/7SGNUJFRFS@LJ=7]
M?OG2):$PR;""5[ZRUY("A,0&GM>JBJJ"-*FW'3[O#E_GJ5BF )U4RM=N(KMW
M0JK:^D=YV])A"K:,_0A66(8DEA+MZ62!O+;"WU%2>K3"WS$B=E)G::<N4Y'$
M[$(%FVHK)S,*T-< +E,*.>8L\^G4A+RRPM]EGJ0#!.R$4Q?/#+,^*9<A;5Z)
MBR0(JBJH-F19E4TV]>[?/-?>W@[240[2 0)VBFF#][;JM6?SND2(-6%[YU:\
M:5>AA&BBCFUPXF(F@;T5_I[(<3I,S$XSB6]KS&K-:&B;H43?IA@;OCHB?RF>
MMU@R8NX^2?)(_M(B41B5')NCLE(:"]$+%LKD/ 2O!;B$5M6"VOON27W+8L$)
MW8\G$R::3 1/RF0?D=Q<JDG4KDR7D5J/U0C)!&I?BA:HG4SZ!1[#$SI[2Q#^
M!1[D49)[PI&KYQFA)=^\OEBV>H0$4X,"MG8T8- QLR\5DYE]8LA;X>_K/L=3
MRO!)J>*Q19.Z8C&>;S6CD1EA989D<P9O<I14DA-X.H?YK?#W11SF*67X%"-X
MPTHG,<E:1#&0@VQ<J,BF21&@; U4E6LS^T[F)+\5_I[^,9Y,>D\S9O@\#X)4
M.09%X!46AM$(B-DXJ")GY@]%$TXP_6+RPM_I!F18]$4;MA(-MH"[S"R4Y"5X
M)VVLR:*DDYDH=$*W9)_HWS+$8@)[8^ZI2#*8G 4S/50VL837D+RK#$14CIQT
M5'KW^7H;JW6:)^-P 5J2:K^?0GV[,WGF2=:$I$$[T7IS2 ^IH (I2_%&:/8W
M%O/B]P#]KT[4CP;^EX)LE]/@) ;,PO$15)LR-9D%A)@\B)2SJXZ,%>*MP<EQ
M!?<H8"^SP4G.L027(TAR!DQDWS"*%NYQ7FI)U47_UN"DGPP\V>!D#!:GTB!B
MR)[>&IR,:G R2DSFZ!2Q#\:G(K_"INIS,("F!C"J%L!HV3W5-A;^KJ*<O6'<
M8N1V5(.3Q8GM&&@G$-?=:O'UML]!2I&$)LM\HL@NG540!#7U$JKTT@E,O27N
M$5(6Z-%,CO.J/TB/5OD^THQB^^OV)?$V__6?_A]02P,$%     @ 6(*E5'_^
MEMQ$2P  Q%D  !,   !C86@M,C R,C S,S%?9S$N:G!G[+MY/%3AWS=^9-^:
MLB99RE8AV<LV10A)$K).10DQE61DF@E9"Z$HRA2ALDSV0L8RJ&07(6:12I$S
M9)S,]AS?^WL_]W>Y[]?KOI_GN9_?'[_G>%UGS,PYU[D^G^OS>7_>[^N<X7WB
M48%-CG8.=@#?!C[@%/P'\'X!&P\&HL^<!<X"\,;'FP1L@ U\Z]OZ?L/Z)L"_
MOA<4$. 7$!(4$OI+$Q85@9NPD)"(N(BHV/H&_R<A+B:Q_F:]DW\Y=8,@/[^@
MF+"0L-A_>>.U IM%^.YLD.'GVP%LV,S'OYF/1P94X#$*_F5X?,!?-[X-_ *"
M0L+P,,3A ^HVP</GYX<'+0B/&/[V.OP](+!94&J[_D$A:=?3PCLNR1C$9CX1
M4;.N:I,]/@BJ&YZY'"<J)B>_16&KAJ;6SEV[C8Q-3/?M-[,Y9&MG?]C!T>V$
MNX?G22_O@,"SYX+.!X=$7(F\&H6)OA9_,R$Q*3DE-2O[[KV<W/L/\@J+GA:7
ME#Y[_J*ZIK:NON'5Z\;V#G)G5_?;=^^'AD<^CHY]&I^@T6>^S'[]]GWN!V-I
M^?<*<Q7ZL[9N%Q_ S_>OV[]KUV;8K@WK<R"\;A??AJCU S8+"&[7%Y(ZZ"I\
M^I+T#H-8$1GKS"=5;:)JAL=!V3.7!\7DU(UH&HQUT_YBV7_.L+C_)<O^IV'_
M9M<$(,'/!T\>_V8 "7#8A:D[@?_7_E_[/]CXE^VY&^LX3[@6W \$\(BS.=UT
M?HZ12^8*,@0(,K_+3$>;M2KZ3U\970S%]HOFR'GL[-QTKT_4=0XEP!;B 7'N
M/*!M$%6K,C]'[9_ T[K9LDL>0U@TM=><O":7C6?TD.>P88NZ:HV)"B?&MWB$
M9>U^N2QQNMHT<]GS$P&,-F47VCOQ@.J.(OR<\A-4_D\>(#@*=\OAMJI4(=OU
M)'\2:KXE-&\'AQ9IW,RG6#W&:!EU?XG/@I6EV>:@W9\5<V._A9YUN-JXX5/
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M(<CJG/B5M^6'F5ZB15  /BI$AG;[3INVV2DPBB^5+0C'4IP_UAY^<84CM9H
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M'[8&-6R'^62/4U!_KOJ"T4"''%OJV9"PFF1#L,0!JY%*0VK2@BRHQKP'+O"
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M.?F/>I;_- E%GSZ@@ >#?Q7'7(>QY@@4&19UL2\'MYTA8_*^V\I;R>.K<]%
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MUV4ZY2=?OK9A3V2/"TYDH55X?O;_@LB3->8(VS(\$F)H&9OG[DS/3=Q[FM/
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ML##'("U^_.5EQ!F^!?]W_T0)OPXSU\6I%U33JJ*L_(V>VV6)]@,]XR(KS-W
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MH8/7]XLM^]$OX85AM4V;,[3(1 2.K&S8,(KUT:CY.18GK$FKH&WJ;#NR9U-
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MX,1Y?0R]HW-US:[FV1RD'/9F=O21CF2$3*5$FB([=FK<6FX_$YE.4,)MYGZ
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M7\>& ^9O%.V&+,R?>D/XCC7WNH2$A&J?3Y_&6ZMLT&([3Z1M/G#"]AAP# "
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M)5!AZ6[N2X1YV/;BY$2GY_]86'BQ>RK*U617F>^JK0EG#(<6>;-"OQ*$KFJ
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M^;83QA1;2/4Y91Z%A$R>X7-G75A(<*?+?(O\,(ADS)P'T,Q2J&A#1\DR46*
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MXJ9>7WR#_V.9[M=?Q,XN= #D>!*6_YQV/IVNXOX"&FG&TG-8/6FA*KO?3_Q
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M]A,(DET;"=^?/00LXNS" P@@86OJGYJK5KODLS<<V_4J(Z9035R]%B!O(7_
M0F?PXTN(E!SJ9F_X,@L#:P7'\^PA+M,V?F[N*]S8M*5WUB![ID\SH$(YXN9Q
M*3M-:WL711WSU@_G<=N9%",2H:]I%2KP.AJS#MQ "D"OH\F/+K,TX,G ;\&G
M!++D4"U&.( ^,J;V:W:RU#7UH/B16S6WW;J5[FW,"[/+;!"A]-LFD Q8%/&
M AN(DG AI,'XRON 8C<-F=461P>!\WR=4 &P!@[ON$;XWJ33>Z%6=X_X+K=
MQ1*C([9'2F,P7_9A,QG0Q6]=)OPZG#^81*O):7.$MV*;&3$"0"P$K!GE[6;/
MQY$5QOV1+;1='Q]=R/\E;7NI=)7A4:]3IS(>'ZEW@[40"30^1#>!L.E[SB=^
M$<Z'0B_@^+*7$FO3U\/YDP9K?DS*5R955%R<VQX<5^+RE<A[3W@Q+]/OOW1_
M6Y8MHVNQQ\_'K]C-UJN8;BVR[N$AK_@=)<K140_7 FHQI1/$X+9Z>C<M<3Y$
M2J=6RNA\#2U[2-E?X=6-*Z;:%LWFO6),"D_Y1PG/902-UFJPMBL9,8-5>3NG
M'<):N<YLQP2-R.XG#(^?*5>-2['S-@MW]GQ6V/3;<Z4&'^#7Z=&8N3C(+3@=
M7QG>R;BAMBFG':?<9.@&7[7/E\W0S-L56(^<^:UWUR_^T/SQ@^<_?J';OFM)
M6+Q^4J4U7PE<1TVAM(6)G3I$NC/8G1OYR/O;9UGO2YZ.&[HTHW!K4'GBZ8IY
M4^GP[E(.%QJNQMSS>SI)K!J>V7'YU1[S(T_;+*HDJ&@I8>:CG<XI714-A0J&
M:M-N<JL J,/-3DR!L@%[\U^]RKEA;+%ANLZT6SQS/57=D+6U]E7"VW/?[0_V
M*6AWOSRQ[%W&D"&B"-C /83M%Q<R<<SM_5=ZJDWGGG8#_N?)M0/-GZ_NP\;C
M5R.Z8,M%'+.0!EDQZ-/3X9T.]FXOJMGE,=B8)KEZZ+-B?=6/+8MG MGC1CML
M+28:7!5K$\B<G///7D[C%'BK^*_ \[YHHFV%J9S5_'LX9O[>R5*NS8R:XA!^
M"I=>UJA%V#7NSUDRB @OZ09?5IS>/7O[W;JL@S8BPKUV?-<H>=%C@'#4-A2(
M@VO\G>MSLY-8XRIFJ0?P)LAU]X.IO_#<_EU19[CW<P'DBGG 5#>F'83.S]\(
MB=1<WG/1").X,!J847"^S8Q8Q/FN?@V[[:OB\NX_5#H#5E?B/<9S4$Q1M9,U
MS]^4W'3W<92D]G_SF":;(GU8%';[@F+81%R-8R=%BJAB]?N@?2FQVK-^@!DA
MKF%#-7L:OFFC]GNUUH9MR"4<\WD&3X%?A6-^/<_/HC&+<#5KGT"HOW/B0BPL
MW[>-,.@2?D'*W05MD>F6/OY!<1VSU(TY>K2PK3>K9D_OPTS.CWWC3/+3: 0[
MJC[HBZ,G-),M7@P,1/(I<:03A.L65>>!!6NY'&N-J/51$M\)@P3(;-J/IY+'
MIG#L^<_)4L@X#MHG %#XFG>@DH;TCH"UY$VCZX,.&AXPL;[BAJMUFVC18#=:
M?6A.;=$X] SG06,^PD''J2OK(0E0&.8FHS8\K6B@/%2J.N#A]U<>CUX.AJ9$
M->2:^>]7J:N0,JNRN7?LHY3V)K4E:Y(SFE!H"L;\1:/8@L8L\=S="#M!8AUJ
MFWMYW@3_I4NP?=?>DV'..<,_D"KWJ](#5B8?OF2<_[WJ2]V<:#R-)S^ 2(%<
M<;!%FUH3+$WNS]<:,<;*$^IHA.=0>&S(FWEC&;\7Q?1"5Y]D[7/;RYYY6F]W
MXJP>'=]G^?IQDR2,0^O5%G3J'4WF/#MTXCR6<UJC_;.?%"6J=V5OV12$#!1Y
MUB"V8\%MA]8T1C__)';:QOFTSUG"(_YCD$D#H:/8,2O. SB.J\F+A&/+B=?;
M:6O,<6O+J9_.?(^;T[(K+_NUN;XVY,J2TMKZ7B'E8H_/MYY^ "P'']/V@GX]
M\%X\(J'*7FK.-V5/,#HPZV %DM03 > _^<-S;Y_LY.\3];O*-HUV!1E-??F0
M:=-TS$MK7EA><D-.+XZ9BX?PCJ-BB.0CMKHSO(=K,9.OTT=R?>+R>M$3RZY+
M5[B_'/=X;]GM<2/#[HW1]INU7<\+U5]H/@=8#C]NVHJ:_#;8THR%'''PUIYV
M>\=84(UD.^4 =CHK5DYXP.[-KXXXU[L%-<;N?'MEP$':*1B[J^OK!DE679"/
MUAAX%@-KS\\^6%F"@U&*J(+SP6";2KW\PCD.A,.#^@YUCPK/9'W:_#(Z:=OA
MA8HG!9?6#@>51V%"']-,:X/AO51$0J> I#I,-I@D#G3NZ2<=#'$'I=+7:''J
MBB^5--G6W_@@]]9:]Y6KFI%HUA77*,M:[D[42Z&TLWCZ &</G,0ED+39!HG@
M<TOY@$P\S&W+S4ZK_.EV4E?NW9.'KJX:LAI7+IS/R+AYL2%6%Q#B:.<JWBL?
M]MFU)=Z_;4V+W299B[68SY$Z0[PEL*4>"[D^P'2"D%-P*EF-7]JD3>SIL#3A
M/^*=>.1*VO.ZL?;W5/QD1^T]T4;*;O?=Q\V>QM@JSV)-@'F^>*]8L@<JUV$:
M\SX]\E,=2H?JYUL.:<78I/G[PB6%NIU,9JGPY5O[1=9=<_:#$CAY_#S07_.E
M8Q2M!AO-NS@<T#1+M.K(OI81??4F;>QS9('Y^27J5S]$_ 2:%F?XV6C2/\=M
MI/F/X^GN74VXWA'64J+14E]Z=*V]BO?.II=#(DWA]+)?X=ZS&7/CU2IY9E4[
M&[B18 LN! .;EB*2?5Q3(@4E''-3$UZ-]B7TB;JL*;/W$<8*Z=P#9NXIKOG#
MVL?="4^?$&/^'B:[KK8#HC SJY/_TA!)-#%$7?FIJ !9C+4U#"PRE&_2&!,9
M%K$9^A8?HK(Y_%E@]_H3.O&R;QZMV_4KT_:@Z%#X11^Q6VA<^8$MEW%GJ?"V
MCP7/8$=.$-NWM@@NM:GA^LS'FOL4;<TN##(5,=V9^"5;IT#Z79EW1K*B1TNX
MSB8LO@^_D]Q"@4[WC!DBDCIL@RFM%D8T9HJ E>-M;TAC=.2:)B\Z^1@='7 4
MCCA[B-MJ?_$[WR3;<?YD-@B==ARS.H7.GMZ#FJZJE]+^*J%#15<NO(2?8H,I
M<K'1$UV:KR"UU/QU7-\Y\/M=RB DM-BM\'>:&P"V]. @>\IH+">&QL_E79["
MK(>I[7M56=5LHTF17J_&ZKZ*.RQF;D#%9LP6-54OV3MGG9[/O+-\#-7SY TX
MI^!8[KI &G2,$8]?)P!86V&? J*M$UOAUY."<<,S^K4W=]E?E8GFO#JS*6FP
MG>NRHZ7SZCZU,6NR/\\&A=65(#,3C[%<!^.G6N&<+N7/3;JF^GXL!TS;I:;2
M !%3S$6_EW87U9-% M0CH]Z_'KPHD4:8 6_@H9..8U+3M-D-*!BV0>2)'Y=<
MX*LL*B;0K8[V.>!+J)20E[!#*&%KP[K3+)FKU;O/OGGW(:ULGV7"XT8MCLX_
MUAM05EC?,UN/FXN$9/YT0G&UW8NRJGY'%$?<YU;[MGN-WPSY1@E$V4A,&!KC
M)T ?/*PSWQHLPPODYU)KW]1@)7]J'1G68MO<K=/?V"IR_[F:]YJ8/?+9&MZ4
MP\#RWF3>&[8S3[4!=<=UB-JU@;P6NP&>=AI@#JXI1'#]C9J:O8/Q]'[=B-89
ME^B>'M6&U<*Z+]8Y_M"*:0Q@&20BF/ZF3;!8>[;;QX2* (CQ?;DN[U*U^Z3[
MX>BI7-/C5@7JJT4N[9<7*K:6/R;TWS7PV3CH!'Z4@$@(H?'?SR\Q0!NW/8[N
MA\C,TYU9G0FA:^88\1<T,J<F.R=#;.N;TOR'50J3";=.R9Z\$U%VJNZBPO(#
M?#+V'VNRICSY!-823S[, -:E\63>'[?C>3TMO )3VDZ/#-_RV$^LFZ*[%J1!
MY:\G7K=+-EW0"_^;=U=W7@6P5. _$@#GL; .@Z=<SJYOP=?@VPSHI]^W"P!,
MH_648=#6IO3PRT'>Y7?OV&U-*RYZYRKSY(;E6YDG.C55;])**6?1N(H"_0F4
M9 ;D 8Y-.=AR"&RQSF!Q(L@:3J#Z@V(UU^VT7K#E/.S#KVN<$TGVWGQ9]=6[
M&-,UJA7]XF_+'8+11HYV1BG4[R@^\L<*NX(MIXUJ8!#E;\H)#R)>U_PT3M/4
MX5"J7.F'%KK#MVVRS@Z>Z)1H$[H37(UC-N*@0W@Z;1J=,G8%HU+@K8.G97AG
M8 -"4+$[[$MXH=^!4 AF/0&?C=OT]/J,J@LZ=(7T3@2MN2/.Q$J2G-FXN6BN
M'3H['K6_ !B_RKF.AN%Z4C L87"#Y%$X"O^:P<73,^DSUR*:TO;XWGL\\#!M
MD]Z7E_%V*GL2GVKHG74N1CYBUUABD3$:1#3HI,(!%.E1.&VD^9HQZD$CC["Q
MB_H'ATV60[.HO\Z+JIR_:K<W9JW&*L=&0\\1KBQ/&;5@,BU( ,#:(S= @B.L
MO;TZ$A)C4:*#O.P%0 (BSC;*#O/4]E?][![^/)GS^9U&5G0N(;LE*<QVY,LT
MCEF.AQP$ 'VY#9'\(<:3MT+$7[/?MR@Q-J0VKB/^9A40WQ^./57SREW^QH?A
M^JJRX^X]WE\V;+E-B!$I;?BP9KW8751Y] *^/3'8ZGJ>:A!W^QF>+.29Q1KE
M$2)8D=?;E8^F^F=#JOMF1NK*+VVY*6JE$=:GV*SRP..C_6UG8T84#N6T_A38
MXFJGFAS\EOD:U^ZV/:MHE( =I=<^ZPFRZ*;%+$X+99J*GM$HRP3VJQ2<^=IH
MU4D3HEWLB<=#EW-F'TQA8>V<CO<8)1*>_;6 )0!DX9@>&Y>.XH0YYQ.-];%'
M$]Y);7!A56_O-)9JLOUJ=0^_Z-R,JDT9/V&-FJ^(1$!S:.,@(AV!7QT*2G<$
M%,/O$5D+X\:QA/@+>H?YM\ZHU J 0_$N"[W1"[\^]J^/(H5/4T>_<<+8-)Z:
M'P$B.,/V#TUC/7>;6T>P3O4_=I>8WPQ1Z$.Y0)/KZE]&]P8K5.L5Q2Y73($)
M^1*P,1JPE42S_; [B[!&^.B(N7%H^-, NO5C]_%&*G/\MWK$Y:B'U:V9)F(?
M_GIGVE$+5C#0!82.]C@Q!^L54?&Q6+:O4AONO.4N 7 C'34_VMS%6RK'.8XU
MD53$TC&'HH7M>$ S5L/]VZFY#)[J3B8%UOYZ#_+NA@T+B;[N#K:=>"CC1^F7
M(R1#\)S2;#S3HW[Y8)]MUHWTO+"PF&;AW[J<'7PJR8]%@?6"YZRY)^%T1")X
M.IA>VEZOMF-HMFP1Y=[^)P+Q4/(!^AUVJ3G!+T1NAWM7D,JZ0MN-R1+2K4W5
MJ'G#2&+<DT0Q1$J=39LZR(".@LDT(<NUI)-0ZJ]'?BRJ JQUK'(@I/N V4_7
M(*;=U]IXV9,.Y"VI!^;L#C]M'5Z:0P&5R ]4CQ:P!:6S3W$R(/,A [+MB5,6
M:Z>)D[RNY]'D85WG7!/%<&?#R"+BUWI"7H"J]=N(1]F31QZ_Z7LA13&<P<";
M;6=7[L0&0F(I9 UD& >= M/5M@3ANY8R<0E-,G93G4T#),NME)Y<UMDT5_UR
MN\WJR>M=_EY.P/RVE!=F4F'#'LXQ6)B=,F4[MY6=/C7?&BG<H5P7]_3'-<L;
MR*;^QXWVZ[=3CEVGZF\]?:P_8H?.!;] A8\;HK_CF)^P:'617L3!>F)S#.YV
MC'" ,QFH'3)^H(+(Z'+%OSW/[AQO=S;I'6^4796NW-YA\EQ=)'G9#UD3\V_N
MHT!'N9CT6\@H936.A0E6AO/L&J W_W#]H.68]!;NA^!%E:3&QH@^MF9_^*6U
M:S&P.HXGY\T9XM\!F50!4,N8LV-SF32.6+2E-C'G3 .T'6UW$FIYH?SB-5V)
MF@UQC7F$),V$D+74)"?QC^)K.@#2>P&P.HXD QM,4>C7.;5L?%*3#!'O-&2N
M,&T!P*;':;WZ12]Z[3\1H_&SQ_<JUGZJ["Q^IYNA'+MD@R/]A'(0B6CN*K"%
M0&/>14$/58UX@C72K&^) C6_#DS2L0GB>)>LIXN]/%U:R;1J_,P^3Y9/_-F<
M3+&4]WYO-ZU:]9)/?XCYG(=(H-559)3_<H6ZR8+^XY31JYRV1MBU%-9RJ<LY
M-C#WAV_ED-Z.N6I9S"%.$C152-5!FT2'HGZ_7?_-<@+5@8'T4*H9<RNK6(>'
MT)"%=8+3&\%2<A\H56MWL7$SRU%EQG=J>.;WT5M)I+$BOUSWTCVGGKB8BK3[
M[F^T89*CP99J"G2$.@XB$G_85SE9:,V/@.P1&15LHG)%JND-/]01MQUHW&O[
M+Y>:%P=E?>C4+PT5:H^68'1>&F72F'4TR 8SG@O".@EM-'@;A2=KRXILJIT^
M1"V?;R04%"<:\7>><*K2KO2H']^^R<[[5;T L,TUUJ!H9XM]1%G0RN)?-R]H
MA(IC?L>MI=X$S^-DR+UNSFU8Z8"DASPUB'\SYT3@-%?3X^"NEHUR]Q1U2V]?
MWK1P=Y>[0O"=RP5,"T=.(SR.JK\,8[AA/ 7T<OJD0#XEQ.J9BS]>)JZGK?RP
MQ=ZONDE:-:\&+VJXBV^.([^]\FQV&OM]YO-G.;PSV.*%8]ZE04X8-?(06FA
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MVSJOQQH)@'--IL]KRX[.ZR++F!JMO$WI8KZ,<0-8*WAVB4WC>/#34.MY<^[
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M&Q?Q![AFRS/"\@_C_J(5AOX=+8MH:RM!:RW*A;@>$:_EA7Y@H5[PC[8 ^"P
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MDYDD5CN8.IT)4!*?$W;INC2OV+$GS2_9R.S>J?>^+RCP%LMTE@"0^(3T6HK
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MB[H];$8+5#YUHE;44-]<D8*M1,B3!$N&SV?@?]X1@)(1G-?ZL :AA^)A(SV
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MG/5NJSE0XM1O_,!*<;>3<JL0T?&X.5*(L*6* K1=Y;#Z^5V$[:_,(?'V5?0
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MM(=Z_A/CH^*18_ET>36< T,^?M$*2S-2FI_ZF/)XJN1-3L6\ZO#,U)P-4]_
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MO_'\WWY-V_]O_[_].QM2./F_ %!+ P04    " !8@J54N<(=S,)=  !U<0
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MYG1/<7WWTT(GT>JO9J')FLQ4>]>+E89VFI4_YM31 0(''OO&U5_%B%RJG\Z
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MB#[_TVD,%H#,W^D;#^A9CE47*PFO=!AZDW;6ZRFWLP/(8=M;!89>9PYP)JP
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M$H$*N C,M-N(8CN+GD+!PG',;O;7$1X0BE&()M+6)FRDRMP"5>3?07XU^WF
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MM.0M#6YZKO'(BWRC/<^N-3;&SSQG1MDRGGO#F$K)Z%%9/U;' X(,-@0\4^E
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MIXP:C:BE"4N#;(T2EU+*:ZK3<Y-3Q]_]V"_5\I(XX"6KCC915>EDU3MR\WC
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MQE[/FL^<>\WGB3LXDKZRG(C<*BRO=SW!PV2CE 0'GYVUE34)>'_E:F-H^=S
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M?O),++@;+5 )Z;.:[OD"B4TLZM;9>C_X"/ST1-!H^[:P%7EDCT&V84MA>>5
M6E#QCCV3)X-.HO5>-77-;Q_&^Y:> 2F=+6//*BH6KD;Y?FO)RNH<V##6EJJ[
M/S!FAZ_FF;WGG+8E&$G<%D+B&0I!U(LO-%-U7C1$H54@UKN<B+>-S":5$<-\
MYH1DCKK9G"M_ILH@[[>K+65E?^_B)B,8ON09D5:/ HX0E<'.WWW%OQ>==>:K
M'B^8T>>'K+L12G>+KQF8V6A )PO?IA9PE3/S;E^V\4(H\:+BE /QUFI?7R$D
M$M'B:[!.1:;P<+A\=*\\J]KNT1G?(TR#!.\RP[NYQK55[E.;#BU$>;:+BT;A
M=52.*^./+9%OA;\$5)(LSD2ZONJM8!Z\+@>6%L*.NVMXM371I,+/,1(SE0YI
MD:7;%06FX : [@RB ,\.+712&^+!62'9:;C>Q:"IL8&T(_7ODQM=U,X'#IBK
M&>2Z7LE+>B) @S$/!(=&D*KANE8CG#97RN3<_-?B31.I3;'CO$?;HRS<5)I'
MS"WL"C<A"IN_>__W6G)Z?B8)MCJS*5-#3'(6*@BK*YK8%[H,3+B O!4<#6_W
M4.?8ZZFLG5_A!R8==Q7%;OESU7J$ZE+-H(,F5B65"_0&TJ+-HX7&O;,S;_F.
M>?ERJ8EEI,4;[V3O2Z\.2T"P0R;7#PFT?_/=1,,2G70 C=@@T&T%,QZ$-AWH
M-@=#&+3WRQ=K:"YAC[(_^R+EF_GN#H?;/WLYT;2K/[^UYQ5Q/06;I5B5O=3)
MD"X_Z;8)_'ZNGJ9M(%\KU(KWUB Z?#KOHT<L4OW0 0/KB;VS)N<RO8LT<G_$
M8YY.(^+;MC!;ZXA,NM2WJRKUP5KAILB__JG:EO?F\5^OM]Z0!5-$LJW!(3$0
MED@)$W<TUZ<[H+.*>WMQ-&,HK3C?R_SY)P\]9K=H) Z'$6G*5[PIH&%( C50
M,9VN=KZ8?PHL>B2P$SYH0+VX62U2LZK@/;A1=6:VJ4ASLZM9ET9!KGX#R<C9
M\BU$4>@=ZS>+-")!' ?GF8(AI;A8;P#325>=%1 @\#)W3GXSCU#T/=NEEA%R
MO7'A<9#UFSM'M6'?M9)A5>X'0T1RZS6M" RXX\LB&M6SK#@;QL51>\[^HB;;
MJD17TPP:KZI/R.@W" >C]/L-K(9[+'J4-%KU'*2&, >A:36H$*, ]2AQEM+4
M\]2I%1ZK%21SJ:R83Y]?<>7Z_+8#R-8P(DOH+N>\O.=9\,O6VFRC;<G2(?L.
M!<EI[7)K<0Q@;";,0D2;/)GRK\II27^05BIZ?W9G$E>?I9@9./XEA:50P0P-
MY"JF"R*>S/HX/[+0"#NOKC1D(INAW3C)F>.Q!Z5^6O-<WA-V@5C>:3"$2<^.
MK9T%I[N8O(P(MG9:Q?R/A:I V;E6:YNT0B?G)5?"/OP&2 O,$VF[J1?(,\@5
M'C1Q0HYHPM")U'&=,T9>7 8"T!+A38T$S0:/:5L[W'BC&0U9=6GCQZZ]C;ZE
MRLQ-F*8UF"S2"*?.)G;2Y?%A(.89\0(NI&=UP_TFYIS+X@B-UZK]4OG&M;;F
MO"#2E<OZ$3$>FEWKKAOJOZE$*18VF7B!#NK1%U?6#<S"VBL0!)J2NJ[%"!U9
MO2762:1LI'H_Y8W)A&.CEVV5VAOV&XSYDT^7K]&^8WSQGNL]</P1X&Y'@7*+
M" 7NC+S'6(/)?5O-?RXR!AU9RQ*@4ZB2%]CJ4O0@X><14P:._K8IW#.O;.Z3
M^99WFS^@@./HC:!]]QH,.(F8J24JXSQ=/^@BLEJ.=?\>W_?F)-'?>ZLX@^$Y
M/^V14_[58U?%U^N^KTKJK_W@<+:=8?ODGMAR2,+@SB\+L3_:#-1T1@\1N*30
M# 3RC+F81(I%A 3SIQN.PGOW?LE4RVC">Q0;7%\/=%6Q(]X*RR=(2A^]>W0U
M#N1@(L/)P(FAJ3G417@:L>DWY^@UYI"F]P6"]*@%5C'LOC4@K,_7W?!^T;]D
M^9:[CTU?+<M9*VQK^0WQO'Z/BW\P J75-^]F>*^$+<&-]>G6Q.GCRT&9XG3N
M[H9(I^\KYO!JE=F) ?*_NA*$+&*Y]B)9J2@HS/J$M=0+X>2D-9@X$C[E=8&H
MOGVD_J#'$I^E5KG[:/3&.(/1IY_#PZ59N/*7ET^7G_]1L"'VL50MD;:]#<ZW
MPU6+9.*Y-ZG^B,W?B(H_29J"6*[K[\71Q[@ZI_P;.E*=*@M[3:)[SCM<S6K)
M' >>3_JRY^X:E*#!;9B.:O)4&8O*N0FXN($ES\!Q_A&0'2:L8BTKO]'EGVF[
M=Z3V/FLAX(#%'1?]B/YI:<V+04)?OAAA&O/"D_,*, %G>#+<L4?-#+3L!?NN
M?5FH+L^6XUKX<=[X#SDGSA*'<2Y-$@@,N"B6D)BW#5<@4!X0H3$\]AJL=KUI
MT6,>^1 \\C_JG0L$ZC8B-S'^D378E.D'ZD]?/)&_G3!#!,*;NC&;! A04RJQ
M77*!@)JX:.$J8\$GQRF,^GY7*;=B[2QV-?:_6M)8I,G[^+%Q/^4YBM%,_Y&J
M.&THZH^L6(,]_#Z&"AI*IBL\$!83-!=N@U)'7<H!JZS=/L_RI'."U"[=9C9^
MM+HVY#,LU4<$3FJ8$AGYT!/:'0A9O*Y(K\'J1%OP#NE#S"\<A'R;X^L7AP^'
MMF_/^7OK->6(QAS *?6AD>GV:BA\3Z#BJ<K4"!M$)A$X34HM;G\ '01-PK"?
M3@NPW,%OYM@.4"1 +8L<BWYV:BTKO,CI0] AVID_1\R6++]!82NY=VC]=[RP
M= 27]P$G/RGE$W>TVP#^>)O2DO$DG8V.1P4O3^Y!D$0HNE0*7@IX:!I^*GMD
M'W5QO/CRF_>];>(]IRY0+A\J51Q27&]^H</?3>A:OZM/(M:J+_X!EKM6!,06
M;D%2/2F!8#SR4R.BS>X)KM:8[QSYJVQW9)%8UIZ=)453FX^EGE$T(=5;0I!J
M2%KD2'%N<D^)9&7XIS%@=&_^ZE#BE;?&1YYSZ2F<\A? GBQ_K#G=Q'W6IK(@
MRH 497R7=&[#Y;]?H(K6_UN IAB!<J W^/XQD>9"9923&]^VK<%T+/G7%O$[
M&*_Q8BSC5^;,R(1W-(L!]0QTZ*>6G/TO6]U="H).U3??:8;PL)5(^QL5L ;+
M( ,GP\G@3C+G'O_4+-X,E $61OI.@=7A%5_/-LPM=_MZ_)W]65YQ</3IH_";
M2*/Y77LT\L)\"B<VV)=*C:$ K.X_>L)T00@+*QGJ>1W=.:0$'1;"4\#0N26-
MK490*/YY,RL@2Q3Z(,QCX<@I@9FXF;3ALBP7-0GG#0LA[1ZI&(\!R 3:_('Z
M";P4,PLM4BK,2DFF6!2:&#8V-MT^ZXB-Q4KL-E"98?^OJ+\1_+]+?_ZX0,!Z
M%Z3Q907RZW<&A'>ZMNL.06_0#YW\7F#(Q5L;LR#N;-40S.LK'K2[%YQPV7L;
MLQ'?_I#J4<T@3Y?9OU\O"=P@%!9;S!$=&]J;4))MEWKE!F+R9)2GSG'..81*
M1/,V<ZF"S96\I>=@$I,R*<4D==[T#0 F>(;="/!HNRK1_\VJWZ/:!PWYCK5-
MU_0*O?OO>O@7QO]EXXH/81*G4WB/A,E(>7!&)/\3<"BKP@@@B+K5,M-)K,.D
M/\OI)W=,M\P>+Y[--6+S=X]K=^>D*+5=TDM6:B ,A/HI Y5)@Y5=2(W1GVRD
M+3LP>"ORO'G6#.R=613Y%$9!<+&V[HY(82^H@^/E6 SPK7#5%Q_M/1/HUB@A
M11&;)7:0JDH5'F% O2^+/^@*$#.F3($7HGP$QL+[E,@8XZ&4XD>I!58$\P_S
M;UD)J[_WJ#KK#$ZH!ZGF!.6>=]\2_G8-%H10P.\FB>2^<-M7>#8 H:@,)]%%
ME*A_*L66$NCQHF;"8OWV'R@;NE"A)V[=DG)B)=>=:J8^R;"*-A1LE8$^[8DF
M80)2"Y1CP),)%MYX:ZYU;Y8?^\0]5O!X3O1C1,)/)TD,=DR_L2';^7R+.(X=
MOX7 +S!I]POW%DG7\4.)-*T8NBR-OQ%"C7T$6S3KJ6?7JLY0FNVAZ92DF'O>
M0M],X&ALM=\<QJNS0%T9':6P?.^JYFE51PU9,381HI'GR=,NC"&!.IL9VT.<
MD>!EP3<3]/!VH#%;+LM!1V]P^BM!I[:I];FWK_GQI/8HU0 OS0J\[;-/4_9J
MIJM-&"7!M3787;YHB,P[U ;1H8KBX)O-_Q]4 /_/^)_Q?S[@:U/_!5!+ P04
M    " !8@J54#G,FR.A/  ";8   $P   &-A:"TR,#(R,#,S,5]G-"YJ<&?L
MO'L\5&&_-[SD,#E%CI68DJ(D*5+(D)R2).484TEH8BJ$&K-$SJ0H2C&*SIB<
M.V!R/B6G<BPS0Y%3UDAC9=:L>5;W>^_GV?=][_=]]M[/OI_WG[U\KO499M:U
M?L?O[_N[UC4$ P(6('O RM8*$%HF!)S ?@#!#V"%^6GR*1_ !\ .(<$P8 $L
M$_IS_#DO^W.("/\YBXJ("(N(B8J)_67@Q)=C R<FMEQRN;C$GP-[)24I(?7G
MES^3_#^7+A,5%A:5P(GA)/[#A^ =L'*YT(UE"L)"ZL"RE4+"*X4$#0 >DU'T
M+^() 7\]A)8)BXB*X3 Q)+$/E,MBX@L+8T*+8A)C[T9@[P,B*T7EUNN9B\D[
MGL2I7U#8<?7F@^4;]A77*A[IAC1VGKH8)2ZAI+QJ]9J-FS2U-F_1-]AEN'N/
MD<5^2RMK&]L#3D>/.;NXNKE[G_8YX^OG?S8H..12:%CXY>AK,;%Q\0F):>FW
M;F=DWKF;]3 O_]'C)T^?/2\I+2NOJ'SU^DU=?4-C4W-+:UM/[\=/??T#@T/L
MT;&OW\8GOD].<>9_+OSB+L*_E_[H)00("_W+\6_JM1+3:]D?'^#^Z"6T+/3/
M!U:*B*[7$Y,S=\2=O""OON/J<H5]-Q\4UXIOV'D$4CQUL5M"24.?O9'S1[6_
M:/;O4RSJ/Z79_U3L?^DU!$@)"V'.$UX)$  ^\C!1"_CO\=_COV LRTR@6#\(
M,Z[/BDNJ<GQNX?W8W_G(R%G#2ND*XS#U??,VS27/GVDL2: AF=Q; B#JDP"H
M;2>4&Z8L"( !PEC1$XC$\HV:NZ84NAU.G+.L='6MO,E]?>[H9Z^1@_$^VW]*
M;?#[O3N<X"< 6,5#L=6/P5HM@M\T4[HL*9@ABE@9-F:WK^P==W/U?KQA6]"P
M(@=$5A=ZL^^!L$8-/?RAM?+P-M/M))Q;L/"%^VZ3;&&\'^4A[L%BKDP2(LPS
MQV3QQR8>286U=.O!JP*@HK,Y(&@,7T=.4)Z6Z2SRFJY8=*8&7_C<<:J?Q+U'
M>DO<LS%,0>0\2[6VGKZP<9261),PD1D-T*ZE&L#9[%F\6[^/:YF]YM&^W,K7
M']>^,GMIN2'N5H;/85DY6^%G]-HY5;!VG% &U@]_?,-A(')%PP?4SKUT^S(U
MHEM5^7.[%2ME4\[.^YO7J=658F+-N)H$<7RY3/[U@IJUI" _-0W.H>OKNWZI
MN-TQI86'/!TL.))7M$HA7"%V%6&;E31 G:?HP0( PH_Y_"A\C*R!!]EXY>-^
MRJ!/_PFH.4&'S+2G:80[%<CIQ<P7[*J1P5W75@*'\=S]Y?!C4]$OU$\$Z3%.
M\6O>;B@X9W=OTXL)7S7BH-3()40 K/C<_U5YMI^G3#$2 -&G05:Z %"F$'ER
MB"LG9BZ%:CCMCKMFG40Q-WA5W7-!^FMZ]8MA2^7;;U:&'>;#(S;#5U9][$\-
M<T&EC\.;1\FP^@RQPI+9V*D$UG$^4I7!NKIRL**1?\MP$/2S?ERVB; ]77QE
MV4@@6T^W369K)+@_5%G6W6S1Q2G?<7_,US0KB:>YI],<S'"7?^HN0X<9Q6 C
M7A6L*X)]>5X478YR0G*L'ON+9/-2R!>4<Y\^.'HWOZ6V97B(@:.X\,*I@_B*
M2F2-$WVJSU2]WX L2S&%4\DL1H+1KZJ2O3\>L)\>48G)"B5F9P9\NB6_AV!D
MN<'&QE=S AP<8X<B*J6\XY2M,(F%%Z=V,U>"/L24(?N1^TN+URFGTL]F!3X+
M7>O]P<_W.GM=Z?O:T]?9'4]3_455$@'T.<5S3$8\3+@^-&<'AYD8/"MOTSOZ
MD_S+TVO)F$3R^YDR;[=>(JGEZXT]1036Q"R)MP7M=H_I2^>9HKT$F:J0D%,Q
M<P%5*F/&JH?L0J3+,CW\C^=^:3JT9Y2Q!HN5.;>:;; URV&F. ^>)G+PR36R
M0Z2+],:]#I9W V3B=1\F-K>D61_F6.AW25NR=Y]V#E^.\Z/CL80,1U9BYQ5H
M-Z,RLY:>C,7/0>:P=S.Q-/4ZLO.%M8D D*JZ\K@]Z,(HZ:IZ0'EE==9D+G&/
M5)<MD.%M=.#!J2,JYW$+)&(''ED[R /!6C-T&996;H@=]()+YK\TU8(MZONH
MXCVZ3O6H/*?PU^V"_4.K-]VRD'J>>T-23[AX$^-1&QK"8!6 RPCL)R!K(AMD
MB3@3_=YPB#.+] '_XME6Y4*6Y_'A[:IM'S:<_%$FM"@ $ 5M5,)ME+$"K*U<
MB7[!RYA<N9(?UMY,E*PR7G'SQ61HH>B7(OK3>Z[;LC8?CK4]R0RNO14EI1&=
M!?]$I5?S2\$ <,B:^Q*N9Y&'2KGWX+BQ>'W"LJ$.WT=P?V/HY2C7SRK?K()M
MOYY4F6U+VWZAD;*WD/K)O7/61P"(F/-O$5B9(VOZDG/6?P3]]SJ9^ZVL/' J
MA7W%K/[9/E3CV$'(O@+W>6R."1MZU*]QB2:PJL!*,-I$^UQ&A9%#O$&[SB[5
MUZZGDAK2K=>P5MY0-&NR/@#PX^!2GB^UF0$@]LI1-48H!I32%.6"#\^[_-5T
M.'VTQU]L"G8\.O7J[MHHHQ-!GO=ILA11F2B'AM<4<KYNG&C<L$.\RI%XUZ2
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MF_#3 "CMF/&NPX80@X4E["?>JK!H5F=D6:IDZZBG2UV<>YQ9[UC9]2GS4?&
MY**;HD?&EQ4K-1VPREU0S,8N3("%L?,VS/87P=HS55@C)AK.SP)]WN*31J0X
M@4G^:TO.>LFG>U;T..KS/(SCMYV,3)@9B+BA'ZI=ONR@?/C[>.H+[.)*L'87
M(8 X%(1*7N!I4OMIPC626.."&,.^3[_O@)D-?U2H8 X^"Z#O_=S<\NJ5[?BP
MD SF_KUB'HFUV 2QU X&Y-4YJ(E*./VA@&8$UKV<S1]K#&!<PV4/#T]$G1.7
M]"BGTUQ.PXNRTK4S=%E\<K$&Q_9LW?XSIT\/B-\0CL:2#F2P\IG009EA0^YO
MCF:"?N? EF96Y:SN*%_]!ZF0:-7W8UMP-55K+*5HM/+:K>MM1UZ*CZR7^7 J
MS>HV;8\#O*6A-,P87='"OU[EPA[UKOI8M?KQX$@X1>FZO85'Y45J\8&VB(PW
M>'BC(2(OCTK8<IZ@$NSG8.V?QW!/B!(47>BM6T7/1'0]%0?UUM=,C7ONGJP)
M:E;X>6?,P_?>A2RGG6U3EZXM>T%Q[#K-IV,7<1C+_9=.1;RPY]-,5UH&T>\T
M.2OQ-G8T[-DKI&ST[0E#Y!)+F'OQG]W:84,B"XU^"+_85PTUQR^TD(-G#_38
M>?",;TFOA5H>J>W"/2])6_Y#FH+UN")G,&]=H+C]69G"G"( 9CI&B0F7K1,H
M.,.&I%DRF^3>NJ>FM^SMC;R9S%/[CZYXK$]I>K_ZVZVOY[5GSOY_/SBE)S%8
MF2!TD!B/+\$U=PX)<VOY^287<N',4=]F736[IP;]<<AX18_^_DM7/)8/!5MO
M/!CCD:P8)=1ZO'](_["0I<)_C__7X0-'-U'70&7%]4537A8''^6IV56832^:
M%V#8XT&3(7P_(0!:;1EP(C"I541&E2;J.Y=6$>:/D%'UU/_C#V0K-Z8"]EOJ
ME1@9ER3R9DKF'9!ED49;M!Y&2ORSQCAU!V(I &)LH5)/.).?RG_ 3WJRMW^@
MIOM;^# 81^T;_E6[Y&+OY<OS 5L+X&FT<5( W,B5N0^R.>"O0-KO4'!Q(QZ"
M&4N5#LA;!B^M9N/#2-,A 1"'H?6G-^"W+P+@\RVP'BNG4U\(\S\$P(\#<$8B
MP".A>&4!X(S-EADJ "XZ"@"9) 'P(E@ M&-$X+7VJ+N6\"P=IA#Y'D]03R:_
ME6B+MA/*9!#]RKI&.%, +,_D;INU(A&+(QBSA"DN,HR43;]]O+O9'4FC]Y#A
MC4^0K#9PH#X<R<N5R?L7CO]3!FOBYN5Z&=/7:$NR=%.Z.2P !,!Z'6/T%59^
M'TC\G/J?G'U+A"ZZSUD _/I"6%A_^.@2$;E6* "FWX#?]T6:)OPSMT;0=_)+
M&%_[*"$"X-2" &AQ>>QR%V,+\R13(P%0?!G\JB4\[_6OL8EARV!ET.9)FP6
MM_3$_'7&+M+"/50<8T^;2FC<[2.@UG?A[U-_];E)_9@ 0*Z5S2VQ-=%KVITO
MNJ@$["9VAP1 D1RF7-52I,26_#4_XD(*C\.!PVYEZ8XEE;%7VI?_4.@0.7)7
M:;.JT.?GXYOW%0-Z*9SL)TK?_R+SLP7&;W$/ ="/>; KQMQI$IR7J\1FG/QC
M56!ITS]UU:V3VR8 TMTX_?RD7LR;7G?_(5Y;+X^B)M0NH@3A#%/H,V4_7#GZ
M-F)7FR)97?FNR&*:$&W+\L&K&?L(UR(NN_@3[S$A#U73.0OX-9N!#UNL4WY3
M><T7!I]-&FTM7M8UN?0UQ]_VSFFMW7[+.S7VNUFLXICA'WB)<!:C:C1A]_XF
MI@SEV,F"2<-G;X8/]P:F^=%P(H%'K,Q;-CQ=%]WR5-=4"]G3BZX;HFC6<&KN
M*B?09[+F.\VO-"@[>13-M!5/7' L_MUDZC3II<A;9\]3H0CSLTT\.7263*-D
M$G/9<>+QZ:PJ)\^X)-N[WF)V80_T\F]D/S1P96Y[9]W:HOFM<W"G*_R"@T,E
M[K($0"JH])!$HL6C*SZ&S"K;70QZ,ND36#B['@NK8X%%RWEU9LT9^D)+9]\_
M??0E$CB==MEE,XN02A"A;B:%UJR!29S0^LOH@\<3LWWNIN6B[U\"Y^VVGK,!
M[OL^#IOV\L5XD&$?XH$Q^ &+T5V/6'>?7.?QU%=YSK9*5?1X6JBVMGPWB<LT
M':0G(AZY:">^U#!1 /C@DVBESD]\ ^@DA],Y6] /']^7G%7JE3R:/>'9[*V7
M-;IC>U7:*_Z A-#272)&5.P<?AO<PN(^]N=O:^(]@R5[K+R6_7&W V\5F7 K
M6&@A1,'13!0;:B>Q2HON<P_EG\?:AWV*+$(Y\;K)!:B9ZP7?Y&BRK^<$(G;L
M.2'2&EI<X7Y3W^P(T5L][^X1DG:H2X5^T&;6_&T>.(Q5-G[!L7"U1"7*1<ZA
MA.=GW8G1B'%XP92ST<8W]J$&U64Z^DERQ@]+9ZS>;<U=PMK\?'XDP_M9C0%R
MH)MQ%C^(Y];USU$W3**B\(51AB+,\.2D?.$SXC49;_H)E65O88OM0\Y?U&T.
M1 N;5;W8^1KS"JSEFVJ*I_Q9#4\C$25-=X&UAQ"09Q*F_ Z4*'-NCJ)J@76F
M(9Z7T"6NV6J5BQT5?1H:US[G+G/5":N<]601(_%B%(<Q$-X,(O+33C3V^.O'
ML"$[,\E$)3_LP(+[)+KYGN>G7ZZ!9;P76@.-AME2CF?T >U]S7@*C8$H0OVH
M>#NGF3L!?PH(@C1M^DRW?;],3?#AR$TTK7$9%FU,[C,OE,X/M=<@"5W;8G-R
MOU2+R+T[PF9J=WG*R,8N5 KM?$.(J=+CV84Q1L?O!O><71-Z'2&/EO?10Y9K
MDO7T+D5N?1EI=O!"Y:I-531N-O\&:H1^8I05SC(;P2%#K&C(U"R'B;60Z54?
M:+BIQZ__34[9O$V_869OTX-KSIR"?;M;-[^:FVD+ZX35(P3 -0J.9XIX=IOL
M&54AD6.-\+/K1ZN-V<<:&R&E"]]/A8DX#MM,2..&LB8/1X6N_:5).P73"Z@M
M^(JYADY5L'8WN@=6#[@T7>]NE4Z?=A<KTJBH^!C@&^JW36=D\[%QUT?)VCG+
MC-=]70#&":Q4QAI3322 G^IQ#+XW-DQ;+2,#3WA!B['(E;"\#H[S3>\(#:6L
M]!*D9.?#V1TR-=Y;;4_9+I7:80!TF\$/=> O=VDD0%:J[@+ &O)M(@\NUM?H
M5G-P]7,Q^#7E!$EDQR?RG'1[[2-+T2K:X/2>UKLZ^3='732R7QUGF^%)_O\G
MB#I/&%KD8BU#[%'H<?HH")L3*AGE!DKE\X1RT_9OIW;P*L./!$XFGX@@O?O7
ME1V(*+>DV/U=;=;ZN^HNQ/VDR-%%3'710@Q]M\VA7_/^MK@?Q@T?=6E@_"N6
MD/JO"KL9/L#1#5W9SV!O@1[?'05+PO%#[L&&7M9WW[;_W. R_%9X]X>=5VD'
MNOZJBG8;)8BCW?2&D*1;UF'H/L^*]2Q^,IBW>Q7NV1$_X4]/Z=G43>BG)(CX
M[C*M$9]$5"SK7!$6:E7Y\Y>]K^LNR&-XT[ZH#VU N^)AH]+M@)P95FU3":P"
MYC(&65KSV$?P#)A:L69F:>/GKJDLQXI8[?9@VZ\)V]8H>8X<K/&"OS9)O)D@
M^9CAACZZ='II\I]N,U$N\*/B.>0&OK%]#6=;_A 8-S-GVKGV34I7K&WR]F?'
M6T:U\B^*G7]J?TX U'V&XP2 !0X]8"$ &@[C*AR)FF'-J,1.B,B>:+R"OVJZ
MEU]@(I,7UGM$+PDO,97%I8DB'9M,RF7WR&2V#.AEHFO['_Y;TWCY0NVC,DF(
MQ6A+68>WR\]<O^R[IIUKOEZ]V?;48/(6X&BI /P=B]#NU7XO ,[1?QO05,&!
M:L*\@M!O7>)*L-:#X$],Q"_7OX<10]-U<*AO!#31K(:K*JWL?U!R\T> 00$A
MX_JX@XY3_!WI!]?'?33;U6N^%.@F,%>8;.9<8:-TJ+E9R>%"/BE#U_^IQ=I'
MJ_,N1,>N?;:PX:89/INP#/2>6TGM)^+0'9KOSF2^P\L@%\8"-HW575HJ+TB0
M_E2>]5E_IABC,D?GVR6W[<AMK$3=6(?QI?VS(*L3WFQ=3XLSU>(_T0F1D=>,
M;OQRO5HL:\-UIFVBQPVN^O9(H'UM[MH+XS('^(3**&U7N2'1H9NY1QT'A*XZ
MY,K0RAV&E??#V?G(>4CFJJDX,8QV%'8)# @ARTPYK*FEBUO653D&R&6(KLO\
M=KK=Y^B*,-B73;X&GB$.I8_1ZW0EJ,VTTI$'[/9VO*SY*#ZQTE#NN(-2U@W]
M<P%Y6;X4Z]MWMBT3TU46^:H[O=<RX*3WZ9Z]V;<<5],H35IUF>2YM2&FXY$;
M_XZ=TCNR^)LPM'?'^,H3?K(AK<T(6#+Z:^+*;/][?OJBW=C>JL>3<+C\>IAF
M2EZ.^(T=-LG;CUUE18F+J)5_9^ %P->-3\!^<8RT>D68X54H:[#)UZ$-!%$!
M0#*>&]I9#TKH$$JW/NC=ALBP_<M)DP5EJEZKZ5]?55T?<G-?22M[=]+^T8G@
MVWG+B098!I=;(_+&7 -^296/+T=E++->\BYBX?NX(BODBV2#X="Q+QW1>F?*
M<NSVY.VLL]7T_C&<7KEZS^)S+>$V$R?>"K2-NIU_?X$QJ.D*[_'&UQ<J>>S1
M9TA.5H8J'7['+2ULV*HVLO_&S1T)JS*,!])XE6N_4C\QH$-S@X;<KKX%FA(2
M H<'F58_&&HE/8:3]O73]0OW&;MH5)<Z^&XE:VADF'ID'':+!XHUAY_FKK!C
M^;X#K^%+K>MFM5F5[U*!@3#?NJ6M5GN-;7L_SJ1N=;M[-R%<]4Z&_]K24CG7
MM"#/QU@?L5X;7/J!-0-/_X;OF^'W=V,9X_CO&T+SAHCB!&KK$$.8.8E1C_T&
M%'$B5IUJO<"OMV GM&DU8<'"Y=TMH=^_>%8H!IH5+@D,?Q)3DMJN)M.;WTT1
M'YVN7N7_LZ#D<U@BRG1XFS.*2UFK;)8Q__M"T:H6]75IPRZ33#7J$!4'Z_!V
M^N/Q-29^+B.K/H;8ZZGIXKSVUZ%V\W=)N[LC3UDL,WP);)8:#B*N1_L9(@8,
M8?1C'ZWLR<P&3O^!:LZ*XM'AL1=A9R1;MA7.E"=%;/MQ)4H [,Q-LU'Z9O):
M84=51^QAIFX?L50WP42:=Q'M9*[XLW\ZD; B>#C%JZLSQ%>JN[3>!U3H\;#3
MMVFX[B[7XG'A8/+:Y"Y1 KQI<78O!\>MY.<\AHLYF]KM*QE8A4[[\6%W\*LU
MN_M6]6TRCSVSL28H/2="VX[['H[FD<(DZNOGT28F3A^O[!!DT-+?ZWE#J]QR
MY>^-.T/)BPGI)I5?5(U_&R*R$^C!APZ\M7,"8.&XXL)<TUS")8)8C4Q8WFA3
MWII6Y;A@E4*+-N]4@X<)V=Y+I0##R0RO1VU@5KC,,CAON3G]J"@2 5NP^&LZ
MZ[).9C:D?U]YH,?M^"LG$1W=X4WQI<L:<D5CFSY(9/&4:C"8CCJ&&#"@)S,O
M?#F$QHL&S0E4C;,NIILXHDC]CD.+<GBM]'ZQ=?3K5Q^![DN'(@FG_SQ_;-T,
M-?.3^HA+Z[4?%%UAXY$TFA0&JSX"X*'<FS5_:2FUZTTW@2V+S\#^"P(@-W'1
M".I,H,WOG2+^^@Q^5X\TW8C=N3-,OJEF,S^;(CU&ED$V?:RZDHL0X':,8RLB
M9I#535_NBVR2>9E_3:^$1\ZV U4WWI\RV7YM(I+T'F3=Q*KN2^*LP>@O_B-4
M.NS'2HY+W>+(KI=]^BIN-8WA_(1G\/,E=(#H;B2N<<QVW>ESMU/N/_L=B^LF
M0H[XH1>C<3,^4&\=0[5J,\O/@(YSA7_4#8^^;W_\V=/3#UU[RZ9T:M>D9)3[
M:I.T01>5U=='#&6N"8 3#FLH:_E/&*P'S.4UZZFMSMU3F5[+/]9H3^%7FWCG
M^].EJX:L7A2=E7DP^/FX@J/)]9Y'[R^DN6UH]YX+ !9TA^RX5)B'J0=KDV<F
M>/NI730UZ_A#I1Q2@Y%+)$4US_V./D/Z^^;\D=;EZVO\YQX[RCOHO?O\5EGK
MJ?6D)R4:ZT$DL&Y@C)_"F'E. I=.O*53.7&S!M"]=\PRW6@&9G_9J4I'^&WS
M9:^\IV&7>HPUPQY%M2K^D&P3^[AN^[N]5P[COLHT$Y+ 8K".$ .6+\[<XQU"
M#'HI#IS^1H;\KR9H,=$RI?JSD]VSEVA]EOUQFK8M;[U?>ZW)R]_JN^JRWVMS
M[5AJT6.ZDA1)B!AKJCX]^2(L[A"4D4TJFKK9,:[S[>NEXOR?.$*8R=5[H91Q
MQG93(;1/ )3XSL1@K<QO^!%O&77@\CD.Y8R]=V,&=2.TD1E7M,U 1HTYY9+I
MX!-*JMBDG!2TMJ([__5ORDM;"<74[P1$OI[=W\"\1GSYI$XW%K^:\HUC%0TM
M'BCIRWV53LGXN;%$6-CP4O*I'1?#+5JGS?#6R"H!</.'S)^>/]JKW<L \D:M
M7Q'^+(-(7]$!%!PM <5QL,(%R>J\SICQHOV66&C[21C61NU]FXE<70<D!J#:
M_6M$=)DT1.1Z47L?#/&J4,?^\0YJ.EBK0_C:A\&=2N<W52!"]:^K:K@[%!#C
MP!G9 N"XQI_5@?!?EV6:!<!O<7_FK[H_M)CVOU;@_G;A(.I)SY]Z1A8 GABU
MW*<@M&#_UU[O?S?4/$#>.6J;N^?"TID'G':+Q-&A,XEA.<YM1FFK'=H_REI:
M"@#I3MX& =!]N0N<^RD . 8C=E ONV&^["="Z%;]DF1<<UM\J\.10R/VAJAB
M:#UA2?.R,BJQ7@",^@F/T6$M9K-,-$V-B@^[8@$[<BS,/P46A&3F3.G.VN0.
MKDZXM?;]836;52)9OV50V5EK-'J-#*K )2"7&2= M@ME)P8+H0] UD,\NBD5
M/L:4$@#?L[\382V,UR7DRHS;<3'V%;4_#*-WA+)&6H/N5?S:YMB%5+6PV"EP
ME?G)PH&6K(,EKE_$R0I)99W9XW8KEK>5#\LV4AVY^%K"(,,,QD%/+."]+!T+
M*WM-\V(E[F-084 _;6U&^-H$LVT_WL]&BKFRA!JIG_[RY0>L9LWMPPK6?@)B
MCX=>_'GDU6W<Q8 <902 O!D^$@M7.B+_TY.?R?"9)7&#>FMV?Q]*:7JA@[P,
MNRZ]KZU[5FU<,<7ME'*1[;X'5U>(FV:?U6;"FHNI(;0!YPGN'H[FK,[)YV=#
M,WHL@L8*K9W*LOR/S77T=T@R,\ZMG[?R^2XT.=\_-X=LF8L%%PXMZ"(*?XAM
MMP"0>,NF\>6K);$TE\5\I"\$,Z!2UJ/..JR7,5T+^_N/VHN-ZJ[XONORZ5#A
MAEUZOU^(;):-J D?OG&WZ=#.Y"PF5H&,'3&T;<*0(F9OJ@!0HP_@_][@>?_@
MX'935>H0H:0B!N+MZ_I%O.XNY>)\V:! 62\BMZ)5;J/S:B Z:GF+AG,G8DB8
MP6:UG#87 (Q.3.C^D'^4^A]L#)QG0)\QHQ+XRH4X5  0,#-;_]=-Y>4X1AL*
MY5+Z3-PBGDTR5NFO7I?EV<T8OG7ZQ(HXL9J;F"D\H4XT801#H*AX$,XB_%U(
M1IJZDH<T61:;G>'BW!M6RXVB@I;ZM2%R ZV$^(XLULHBQ#)E%[3W&GF2CWSR
MVO#,RO9U3746-^CF=9/!SUJH@D1>C"(W]=_ASOE.1-_E'6U)VT@&E7)",*X1
MFPC+8T;P_?,-JT0P)<+^WV,#R@-",V&P9^)PG/-K.(5]=UOAQZ0KF6_B6V7W
M[BO^%L14]$77:+,<^(K9. $@MADU^&7X[Q#N9V>][M ];@BTF*3^\5=J\F6I
M[5L/%0B  .DH*YQDNM?=?\20+_^.=%JK^P^>[OXOFZE?FF>']C%+71KPD=2M
MD,LU4_WOAI=SGN39B=ZN'$(8.RRZ L\K1-@NJ^[\^Z#_AZ@ $.H_ID_>?P+.
MFN=@BW+\DI0? 78:P)2;(K!7? 2_Z^4* +:#MP!H?L'%_?\H#2^(B^/GF8I0
M%&&Q&@GX'H=DWFN@5_#Y0P"C3([\I:;C2;!EYGVUG5E+F?][*=D@^[4 . TN
MZ;K+\%'PCP2!X" >3>K#A 9IF 1%T_^W9H%H25@']V2F?_3>].8RW90U4M-2
MATKP%:*U&MYSIUYAI,N/?I6PX!R,1U8]@?L_,O\^PJS_+DNZ<.T$J)NX#/Q>
M\)T ZSEP\OXS>?5?E?2E6-8H0IIHXH<_S[45!,":C'IN*BPMO;#3CD,VETA[
MH8=V'0(([DMQ_[<LW@[[\LPIRG![1,ACBBZ<\(04JN0H'OBPY.)!OT/":Z\V
MA14UE2Z0Q<.<ZM.J4#7H ^W$_+9!M;:VW4FI^XY*)7;]!Q;UKD]-]37UV0T/
MWV''KFKOT"]2=#1K/>4 "+5N8A#*\; N)IZ)2VA!6#_W.";?9;0+OPI5"KNX
M="7 8[3S*F6C_&2FE9BV2=9%^RVVX%H?UYU/'>?OGSX9C_NNH\CBTJ CS('>
MP_QK3["+;TPRE0-^F,I[?+=_UE'4&#A^=%@S+>"@"%G9*UPV7$/LIXW7Z"OZ
MH#$JT0Y-<&_!8SZ\W10S?I:I#K*:DQJO+U[.%/$G*)OH*F&6%-^5O8)I9&<=
M&WZT0^Z-?L4/Y_W.TE'"BL!2Q3\HJ=TD  )UATM9>$1^CC5$\8%_/3U[L3GB
MN44^3*JGJO:F_"@<53UT[O<NI5UMYEFAM>\V'@7LMJ_MPI4X$J41#%*C1L+.
M\,8T8ZC2U &P6+.),#A%C#=*\T<!#KZA8X5&3PBI7P <.[6XO:6N[X<#.]:\
ME?5R-^XCX]P<O#FT7@ ,XD?CXD#?3FE$"D[BD$9]$\K\?[W0!2C;NM6K:LI[
M3MZPW)07W&NG<(F+GCEE=::]9==3DQM""[<5OX'%E;,)4"AW'%Y/X@RS2J=>
MNNW*"WE\=DDS/KC7Y[G?Y>RR6.-L4^Z7A.W']X])W=UPH\W-57[JUM^M,(2!
M[W2'V]FAS?2AI-'FF5"9&!-S-EV5LN%-F5'1W='=)Y+/#H7T*%=\G''?3/Q0
M?B'25J+E_?.I_*MF:FQ+2BN'@4I<A3"L)<[*C#D,1K,79[",TAY-33)5HQC%
M-8YL*X8O/*REG/-^=<>2]&0VO'MD*<3THMGS(-EM-L#8!!V.[[3!@HF.9>4&
M5%69=TH U)VE[.57F6AB?ZH8YEGS=#MYA.&:3BYS9\M/1LCX6*  R-PS&DFP
MT:+'4G=@*7NARA *.@H'L)XQ6#GXL@S&F$."E^0;SEYZ_9Q,V(J1B"#KTLHW
MNWHDIRV"Z?*Q0\QMWR35Y<QW%S&XAI@3&Q%Q?@%JW,[3#JMD$1OI41@ZW;.)
M<+&%K)OHHME*<^XE!W^G#Z[<FK#;3-RGK4*QQ?GHQ5R\Q]\NXYPGEBLWAQ'.
MR Q.-PJ LKUS]339L)+^VC<:0^7H5;;KR?3#KRNN!=ZI2[==8ZQQ\NN6XW*R
M,>VR^<+5#ZOFV(398Y#QF.;,VSQT )7G5)=0"'TFZB8'WGR;B=(O>RF[^I$_
MUA(F'&M(/.28=S[<B;B5!F^3(Q'%$$G.&)N,R/&XCSG]<:;K_2N-KD>'L#KC
M+O7/JMX/U15Q.B0WMV@:YF"TT?OUP],4H"[2=.IAC20_A<"J,E7COZ)8L[Y3
MY<!: P'@_]UD\]C>PX.NB.W'&KP'6+?WK))OK-MX5>P/2]>\C#TK!\2&6MXE
M1Q_G7A4 N)4PL8F[1(\W509KMP@ $GTU'&331R]K19Q8S)B^I91K/6X?H..K
M'B5"<4.<RK4KDV6E 6IBM]<QWFKJH   0#(8.42>5>;M#GOL:6?&R/'PB-<-
M<!_Y:5]]+2;KPY38[P<Y.ZR.?I5M:W-S<UTJ_$LO^1\9E!0,X;]S!$!2S6JP
M5@WTPRN&J4WY&0BS5A?L[]);<<.S73%_9OG7E5(]%XU"Z*'\=--5,)[%F'D+
M81ZIMS<:Z3>'%J/*VE6W:!\5DM(;:GH 3WG,*4TU)NS1R.KB/Z2*ALEP<V#I
M,?Q@_VA,?GK8E294I:H[)"0F\N:)5S$/?9-O7&IY6ZGM'7OXBLNWN=0\K)8D
MH,+4#BJ>'XW*43]D4C4YAO7\0TTR<6"90Y3I.K^*K$MO'[D+*\B2LLX\35V'
M]]VB><QGA\E9QP^2-D)3>,B>%LG F03P[-$O^&):,JKF?WFQ7EJ9&]5CXI /
M7T0_[[U=\23B)/GI\>5CWZ.,GZJ'.$86Y ''=!-!!=,]<"8J60ZI+7)'8*QK
MET1DV.$FOH_0#T/CZ2]J"\S']IZ9'Q@V/FNXLD15+[\W[^>)4K][P6F*.W=N
MPN%Y*M1V(N2H13B)Q^B1I'X\Q0,:YKY^#;^C1(PZJ$RQ3T)SR;_$ _O" LJF
M7ZU*"&X]-VOYPGK^CMH1U:-RY9.M;!E8BX@H,+A%L.HH><B7NSZ=A:]G7/72
M-=7ON^?!::(5$,/2&_3<V\G^I%-;W:+<&WIM-W1L,_FT3DOD,.Y[]M\WXQ1Q
MGK6K.W(8LRH&HG0A>$KT53<B"N$;U72AZL)W[XG#3B/F)^9C3/03R&TYSZDG
MHSLB%HE8?:T]Q/"F#VF.$E-J5E$_$UYVC"2:&B#RC)H _#[.VG%IX\8W.@MV
MBFCJ!2T!</3#TU2IPOGF=7N&W[XW$P-K*515F#!*0.1P8]6,Y'6IJ 851_/J
M_I':OO%QWJGV$-+60WNL?YXZ)FJS^Z*1'NX!- JC3*X;M#C[#7+@NG2;KD.[
MJ)M@"_;;/;-SO^ RMQ ;'UD'G:K^'FOU1@6="Q?.RY_\W/KRQ*N3OQF\<#\\
MY$4?SB&O&H0[N5IP BLUTFAFC0K% [:72:7L+9SJK^ASN307CHO-&CQUCU*\
MS[/'VN=N4LRW:]:SJ<E4+*^C8B@2_%P3/9XGM0U?VIF(54YE#KTNA7#H8PVN
M,EXG>*]'[9M; 1,>3 LRI5V6*?*"; +\CN?\T(AI!,Y@UF)D39\EB)CN'$;L
MHGBV& /AF<-)GO D:WAVKTYZ_<BZFGF5F;ZK&V^?*>'I.X]K1\YL^CT<?<,4
MIM\$6;>9I3*SRE"_*]R."=!?H]QKHL=1&9N[GML?@A?^OO20:,'.WO6A8^O,
M5HW7J8NARI)R>AFNJ-56O:[^_J-_4ZY<)LB(TI@YQV7&<XP@A E&1L5@"I%$
M$VOFXAI3Q%1N"G&LH^@3KE^OWID(SN@_8FUBEKQLIMD8H'=O^1V*2MKQC)#3
M_$("*Y.IS/ E#R[6,J$;8>V-:Z2K:V*P[/3S&(IX?*RFXG9FQ^NTW>GB*O??
M/AU3M5$0<D'%%7D;828WC)^CB^I1NYPL(CBTL4L5J"%<_MRZ,S,B^&UNK_>>
MW94ED8_>K-LHY"8!_9HH% #:AIK\.TG@E%\Y=^[:UL RAOCD99\%K^/<H>"5
M!^]='9I>$[5CM\GU3_,_J>^9*JF(LCUX[@*+!E>,<0^2Q? K,53V %O.P?>)
M$>DSJ"]&<=3JW_\T86C#H3]^^PE?@QG8/921-0*@]"2'@&87;HE#E#4=2J'*
M!H>!^K$G<6Q7BD<>=6!$H4N_'8[=%&#L;'?'0-(R\.VF1/W/1BME.YS^;/^$
M)5&)U5 O*I$$M7._\9,9)S &[V7D?!4"7:"*TD=85>[JH>SDDI+>PD^<?^K>
MO0O=#':--ZZ!-H@QZAF1#.@('=;*G$V%&-SX/XP5[:A9#:M _:S8P@NCNN(4
MW=ZJ4/*HO8,G1Z6N:]C+\XO[TZOK*YS#-TB6+]Z7K4TPD^G^F^UCY[H:+\B;
MFQSX/G6LNW_]55:4C..AAY$$!8HC3QOM&A'BOS"QQOJ"[XA1FAT^$E1$'/$-
M/+RL^Y3:\1$\3.UMW53);CFJVOT[Z]9YCP:K"ZJ?DUD)*YA#,E(8MT,EH1$:
M:T[<KV\H\';^0*/O8_^^"\O9Y94)RZSEM-B.COLB=P-"1!V8SCT#?WD&U@92
MUO.\W,(TP?IJ76[@)Q.=B%'\K/;);V=[28>/-P=\76W"?:_5,;[\O?>JK2M$
M(WS,\,NQZ"QESE_[PR9^]38PE]+/EC&@P$PD[_$8VJZ,5:8% 1#JR41DA__<
M@Z<&UNJ@J] /8!DY"F2K<C+C:,>-FE+XCP)"N6 9*2OF(Z&Z/,V&%KRS 7/X
M_<#:^F6X%N;+OK=8B>O #$Y%Y#\)@#,R?_[-A=)6Q#L X\*+\2$!FLU&J;/*
M[.GE&HD"P"EGRC"M]6!:S+%;I\6%UP8[-0)70$3>P:$4OH+-$\VO05>$[5"L
M@-Y3UT'*B?*'*E5.5GSZY2D7'B)^?C?3N'%MP>7T_O*(W\3-8*TV>(J10BPU
MC#5=CP3SBTSL'DYA;5+-[K".*@>.''D%V8AZYYEL5+-MN>_O_-@^H;*=I[\-
M^$1*40O_@_NPM,=28>W0V1">#[5CB?ZN,P8L%B&L:$Y"MU/LR9*%S(9VR<&%
MZ=,\J46ASH%OM@H_DE8+P830:B BU9)R$L+7,Z'S-O"C)_19 XX*]Z":!.E*
M^2=B[1K->*;3=0N25D58QK<^3<F+)WR=?;ZL.K]*3X0$UNY@L!Y2M?AY-6*(
MQ4M^R3D*@45/(BRCV#_]#JX)?KL,\N]3E]GA9[";,A'JL7G6Y;WMZOA-FVTV
MFND+_>I0_-W(_HO,5XO0>HQB5A3=@V3VU;R"&SF)O;7,$C J4"?PW->JDJHW
M) ]5._?[+8URQ&VDM.+\$Y9K@(%;-M7][^:&QE")S9 \=PR.X*WZ\S7L<U3Y
M:2YS]<+>,]/LSF14;O"L$HGTW/_2=&CXXR_#(^WK_=#W[SF''MG.M_AH9$?B
M+W03[[@P(<<_#T":&S&*TD2$G!B#3+9F[=,:8?C0F"NCFZH65FB@SW%)J#)^
MY*#ODCD^J2'K]F$ZP.1&W:D3@%#5^V=@-Q:02B:ZG&E6YS7J'GA=!S]IS$'*
ME?3&>DAV*\VGJO+ZJ,X[^=A!]:^7NW .?[/GE7K.<-8#"ZRW_,>,<YVI##$!
M<$K'A>O;0\%#04W<+!$=CK%U_Z$'%\^\C/V^Y\IF=T/A]R>SGPU']U5B6$P?
MRD,EY7E":(N2 "@'9SWSD)6<^UYR\$V2;@-?D^V<]"([!W?[1"+IK5/HCC=,
MC_<^ET35-DB*&5,J-(07U!-_8SVC'G9[Z7Y386JGE]!;?DJA/EX%<82GZ9-O
M=-_Q=RQ4O:$^[#?73#]":PL)\A%]X#]BN4ZZ^^O3<]=WCN%F+;&+M\.U//>P
M.*XF/[JP1F$RDR&.J#R<PBO6;*38=X>LWCH7$F"EG#%4?ZBD_,Z./&M).XU4
MC7M*9K1P\QO"/PYH?R4.\#!4S87[N3H8$YU5X5VPR$5V]E&7APV[0.2F2R5O
M,R*VM#OWYB=HI'6T^/O$^KRJ\$N77N_?X!U>>XX):S@@"O7-('3DB_48.1FK
MYC']IC+01#2Z;MC?2[3[5X217<#AR2/^%8MZQ[U>%#>4AN>$'0/4#R1E#E='
MFK[_FQV@51:HA"//"O[)M>!'U6RE]M*DM@:WTV1A?&UH5D4JN6"XJJ+$0>[;
M_F<J>3LN1[9%3'\CQUVF(6O9'&TV&L-1L?H?[5Q95%/9M@U2A=)5$.G1Q(8"
M%2$V*%H@0:^*B!A[I)%8("!"3"D@H4QR5#H1,*!7L \6("ABI)=& @D0&V)
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M#[\;?$3<OJ<_)*IN45GITL5D)I.Z-,PR'S9/.)WA>G7+@:NB_\YK;"!L&W7
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M6& #P7"ZVX!B:E&&;30=J^>M#L0_S_BWF'AU55[M<[/:1>>\(P6CBL<+ARB
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MJN@?I2NW%<B7^8;\''0P*78#48VD&HIPDOC/>,1@)E84ES'27;!0G=Q9'Z*
MF]@NDFP?>1'W0]CSI*C*<^FEY-W/M_S?&F,#$409.T5W6LP$LD^#\UQG_(E^
M_"Z&F_JAX;K&TO /%C(WVE3O-_17[_W@N.T'\-9=<0A'/#_ <W\^ F8[I^<-
M'*](GOT^*IZ59B_]*NXS/6WWEIG-Q7'%*51-#VN&BX99:4&\5(*!&?0JTA6L
ME#+"A88N5J9XY*V=;'B8KEC2<.5SB:8?J>OKVS==75LR?:W@>2/!UC),Z,$
M9T*,M_< N@SW-&M3")'I[O,O6#W4=^&Q+[_PB\RG3ZT%CV]G^5 ?W9C9>VP)
M8?,EOW'3VG+A9WJB+]% +5KSLC3O/+^ =XC)<OJ';=YX/=4&+3*?M79*BRGR
MU*CBQY$MH:FU0L^FTOZP VIXZECXV;EYC%W9C)[VSQZ/A7,PHL%MQV_FUJ4?
M^+LE2+#3.AAV^370#W2%%TML"IE$ US0H)XU69QG-G7VQ\1/"PN+O[?;4BN<
M^PT+R8&S$J_N540?ZU3+?W;Q6?WM0GAP.&S=T0.)D)@>?7D;+K,=I1)FHX%W
M!TFWI#KN6WN;%;>I..<X.>^2L_H\FA%\,2,PM/_#28\;L1AGJ U3@UP<@%DI
M BH'<.WA(E16DXU,6'I_L3(W9X)>6U9_7R]CB+D-@0LX_O6JHWA=79:GITW5
M?__=A>)J]N)W>"Q#\!#7"1I#J6P@_AVQUGP/AC!%J+6LZ<%W9C-W=2H*ORET
M$"_YIZ?85;O>L&HN4SYQ]5KX[U"$P@F'_^FFN(Z$O=/K#<37/3PXI 3\@@N"
M 9LJ3.G_X,+A;8UH$ ZY0BJP#[FS?=[& !P YC@W^_ >%HN_"B=L:O/GQ\P*
MDRX.'TN1UW0P_.A=A%7]6;3'5?F:?6RLGR]L&<*%T*"EQ>+F9M]@<)W[#]1K
M63!3TU*ZA7>D;C!TXM2M+WL'KMA7<QCWI+3*S=X%U8I??'CQ?J;'!L(? YKT
M<#3!.:XE;S^X@6 K<YZ"!?7M!*&^*KZK<]^WW+ /KM$!4IUMVS.\G8\([CKN
MK(N(R(&K?/  AF,'8KCR1&K=W[G%4:XNN/.GKSC0<>\ZJF:L3=]5J\^F2/Y0
M6^O]*%>M;'<)DQJV# *Q&Z$N[P?/@NOF9LB2AAW*K$XF&M3VS:-42$([E5R8
M^MB:E-:[W_QZ.''H!W-=_)',Q6+YH]8E5!(*+B*HYV 7\C$3:J, ;L;Q-."$
M^Z@N]:9RVG5R$K2G?['RH_71U2-) =&O,;Y8/XD$E[X2)?,CQ_K/JSL0PGE[
M^(_1])H-A!H\1K*Z:G\D"MP=N%C"0(_>:D4A#19;?<T^A@B^#EZVM'\P,2FU
MXZZ%6$2U.?'@O<>H9WDA5I"$ /<@KH/S#^S)SF]NVHFQ,07;Z$24VPL\/B*0
M24E4Y2[D')JI!, LYC[L=;9C@*CV2L_7+>6*0O'=B-N=,#K],,(KA!%*C07+
MG;G#F^F^&"C20AG-/@82B\'"8^#+]S_'<NN[ PH?O\Q@A$WK#$TK7^N6=*W3
MELJ.V&:XVI-,I,^C0+V.#E>*&N\6/-AM(G5?"=X%T&3P?[P\SW:Z9UKBN/33
MV[[1O]M@J,))JF+]P!.F&#KCOL0'S&-^!]<;-/'H1=/AM!9$,4I2[,>B%I^&
M"IES4NX8:O1IK#8)UCPH#QS.64&#9A'M-*%W1'J\,+>UYIP7!Y.(MV4F@,DU
M022%()4>W;'3TXI<^69GOSN/68?5.X$*2&*=:P"N0F*R13!09ZHFMJS],\!#
MSP;GK,5.-;B$,=GBE>&OL[?7'\[L"GY^/3NHU41LAU?('IX^ P-:VD'B$0#-
M%2ADA7-]B%1C@]_8T9KVG.9S\[Z[>TM*F9^<M0P\[6L_/GKQ,31Y*?9%;)AU
M]<B"C1\<*40DH %,V1IK<PO??J CE4A_K)_? 4PY\%]4CJ/D1G'>U),_/3E>
MFHZ#*@[:]>--^R6K1_<47&/_FZ<O,>6TN+F/M7GS)PH/?:4!8]8V^.L>?KJU
M%=<21VZV4<$@.YFW'2KOL5B*H8$#NRPH(\4S1ZW?'&>>>F:987L0P1>&<1C=
MK$2L'387)?BYD#2ACU(Q?*?!9"I7@OG^C?53EF](? K7C*59ESR+TGY8_?N!
M;%YK.&8GH8\(7"_E*7C1=5/PAEPGD 2)W;AN#-?*Y]Z0FBUIR<\;:H;,QC4L
M7K%_)-GT8 W*A',.Y(E(UHYK);\^"FRRD$2GI<#66 IJZ"YZ W8=:%EK$^:$
M4_.:A>HM'(E:5TP+]NKM\+^G594[=;]3.7,F9ESDV %J:06%OI0KZ-P'DR%%
M7:GO-U>%63-@HXV[::62CI!Y.X)Q?.%T99?FSR#!&2)H'<AY#>:RHQAK3?!\
MX] ,PRZ:<(/MB^!)B]Y&;1ORU:+PHHDV0LKK)\3!)26"6T<V>:_8?L)YKU]>
M/-DX3A:_&'V9.))]C V7#$2NJ0]>GZU#?EN=^3I(^6; Q$N?^0=CXRK&1WSP
MT\Z^MA_QA8$[I B;FP[;MY(AJ7E^XO2%8]=)8M-D#&C?3>#PD)&9]-*X:4<A
MB_C*%=$EF^X="!R*I]@!B9.!.#@&<0U<N;9XI][7;.$/19<E"D"+9O/L"]LB
M;W$<;Y?L\ESQL_>,UAX;=T1(?DLF[K76@W5R)U+_L1$*R9,"VV#\84=]QZ^#
M0;SC:U5O^Q*7[=!;Y2KQ,E0C\:Q?SLK97?7A2@%GJIL#;!\%H,S.P/[@,^-.
MQQ1I,9;IGB1K34&R&IS>O6^\'_]"@I.[HU!:Y.30PHC(&Z>.FW][(.G7;'?J
M+#S^#MR"3\3I_KG,<]\;#C0*9!U,CV]C#+)>3UQI8E!Z,UCEG_QI([TB;2@
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MCE&1Q935KWI#*">>:8X*5'-<@LX?4K)\[4]V9]E_&WJFUM;M(:/;WKZ4"Z6
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MO((':J\>[%K?L^;S#JV?>>4W\_T(.]:&;5&]\:+SM4575(_7CK_#>?^A!^-
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M#3Z&!_6+42>\%[:^;>K[2> FV+[CO+20^<0(GH4V132+40.8D<1$P)^I*%2
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MH".L49@<&OXG=-K:#7$IX\W-&)_2@#7[R@0FJ7470VYNR/E@>&&>?S/._;'
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M.@,CBNH(L^ C<PV"H]5K6KN6D(\>&'^VZ/0AS-\D+60S-52&A[%!0KLIZ5O
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MCI6N)D<*#ZG1X^F+Z,*_2( [?@ GHDO7H#^X1I%%W0E8BTJX:E[#33X:(*F
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M>*U-V5=V-P:_&G]C/#VN(;S&)B?^=FK6M.02-,U>L(D'TDS7XUP,64EU ']
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MK*70!D3$^(J%E&P?.Y!5,(Z]^G5<[]%U-__G_0.\][I&[QC4\O+=@]#^Z&6
M>E5 2391F(&K(B=S@HFW,T=9LG01PA31[PK4"8:7D"5@>EX RXW 7%7S_-VK
MG7RG><Q.[W</';9>,7Z1&GAQH(9][]].DYF( 6[NE 8O=*L#&-(O0*I\0;=1
M.5SHK$OKT/*^&PH7=[#R^?AQ[Z9=OPS/IE3>>?KH\2/ O<S1?1\NM(ND"=LM
M%.2([*P;D=ULL'U8G7=X;A*G1'(6FI&6!?!_A=?M3]+D-X=M'TDBM(V7'Y(4
MK_=RZK]@IE0#H2*/ZTU80UT ?^^SZ,-!MM5&RCE8_>E0LXS4^/2P:][$''VR
M9->79(=JIQG)ZI;6"/,FP^F>1;,CVK]$\QCU90LU^0Z0);P8J.,LH2Y2ENI"
MOP>Q9D"2PY?"J:)_U)>,67A;S;B^E#XNJ*Z.ZWQOKE=Q\*\GN4?/\Y''D!;2
MQZER94JSQ4S0U W6PAX"U 1)_Z Q^35EADNS OV7?F%G%P<$1\AU>R.""LBL
MFKAO+?G+MDX8&J[TJR<TY[&7_2N'YSGP4[K0IOA<%_W\/(9WSY%Q"O0.%G:N
M/AM$U-C4/:(S-UGN:YYGQ<ZPW& 2/?#1;%NN1<K(HJLO#-S8 ?]=>^J/ZB#^
M>RQA!_A=S)2$B_"\"?%;5E1=$!W:M\MGG2QX-,'@+YWT:XK4FP<Z@O'O+3!K
M*JM'.8X3#?0@3G\!HO=*/(^I[TP4 &7SF-=TD0N,^L>=<@FN7W )Z9_'.&0.
M2 ;@,:03J25G5+G5)M5]PUS#E6(E"\67GN!!V?69IGE,U7=8*WT?^%:D&Z9;
M5 A;_@4;O_Z4'ZUX'OOLC35*36VVMJ2:IE$( 78G/-\3 2]&/]M-F\YU0-2\
MX1U@-EVHV"FO2$6T&:VUYEMM=[]]%CAJ?L3:8TDXV3PDQ"HE/?7;!^SDI-I<
MJ\\:Z"32C .ZZ178>GJR "@GEA)%SA3^3!..1^H7!"+\&8EQQ;2MX#="!^N#
M@',YHV7W_=';=OBFH4V@-;0=UJR1X1-F78VX0TL ?'R,VS7+4]LJLO?V&F(P
M5U^DY)X\:H-9M$=;YBDAYL$+C;B?(+PW)%B[5MP94XE; >,!CZ@7 9QR[!VK
MNRL]?\I_BHY!S=AK.>>LC^8U+SDK_'47*C$M6NAC1A=F"U:C)Z$ 5^Z3 >T!
MC>0Y;G$Z58AE:>]L;0U5T^#MJE+M7')B6]#I*W\DB68^[-S!GO6]<ONI;G&(
M/$"1P!$6D5:PMP<,F8-2U-8%\6+/F(J)B!=3=<KSF)5]N6,I FQ%FEFH_)4S
MW.^A.Z0K?VY]EUJVO\90:>&*.1F^*9N"M93%M$H45OP4";.Z2UL*_-;A*M*;
M5<,$_D+2JJ_J@L!2UF#6B;I[5!=U&R.R.2,C#WHEXC1.J5!-0'(N=2M@\&1;
M!7'E6-6;(TD7"IU8%56QY^(LW$PO;60T<*PX%P7@1F58FR0_ !2CP88WA:A^
M?J/&O&OK'"Y6N^5,]TM2F9LXUC/)C&P>;.X8_%;>:?3G]<FK&/?;&%P^4\76
M;KAD.6P.],42-E,/H'[':>+[1/D'BO$Z] L'4=D0+'!<;-+\DW=NDTW(WH/A
MU$<FOH)*9\S198I_(W X!FDIT1^EF5OH+41PBZ?TV4ND@0,<M=,4#J7ZR\BN
M]\YV6Y%B>[V@2];*AZJV['@?^L'^^ A_CUW0/^5R*KA%EM,M/W5/2)=VR<B'
M0:[8;G_KT5)9_%U?H%#OY//RP-!M]?MZKR)2+6^G!Z]Q]$#?=KV&A5SV\TSP
M(I$A,"#\AK+I=F0 E3"\X0@W=-/1L^\;F07IORM-[GXW8_L=.C2%IRE*A_?P
MKV7^O(2!F>@&89$6EH&&HHR +VB:2L0.[>CF^*V_"8G<ZB/L/ R][;LF1R(/
MAV<D$/S:'4*#_4?OKU&KL9_6/@GA$!7[!<$=(]\)?(P%6D7J41? *%FG^&Q3
M9D@#,>ZF.=1Q6(+O# ^SQ_F_9BE_R+RX=?%+_?AM;[&26$B+WKB5>A;\+CN.
MZ/C+?\+;&0F.S9P_D!8(+R?.&>\67!1\=Y8S9FWJ.DH5DN!AT]$IOB:R0@FZ
M29E"5+##>'"SJ:0/G=\_7D0K$3/43U/H1SX7$S _<HPBL4ZLI!7ET<-'ZVPT
M7&(?BN#JX:_3V3S^9J6O'&$.$7 KPLN/*U(ZN8SDN;@LF6KSD(7L9%\2VVS"
M*RTGU6N"L+FNQJ5F\M@6[)5W?R4N34B,7EH1$GLE)Q1UX;)_)=A7SV,D['[Z
MN%U!WUNDF;B,&$2,XJC.JJO0^@55Z3#>3>/KQ/1@/Z4<T>Z(CR.TGO^T+\%/
M[HVE?!O8Z(K_\\CP=ZG1\DH7^6E%TCQ&E$FP@J^#C2CET8>"$"R1D2NSEI/E
MCCQ.*?R6,-0I0?P7Y%)G"H?6+^-<Z;[_0/W*OR>JC.#![60X3TF>,(\I\WY)
M'WL#"/I?R1=N?X8"$1W09=A- \4"DBW^!45%C6C_ML=6A[DXK/JOFL_:A@]=
M;<\RLG5SE^'W4.NS!X,DC &F' T7<5T*!K(1:2,"* -H0'7WBI^QQ6$ATBF)
MH"HRYN.9<+9C!C:+,3EU9BYQDJ!%T4>TXQL$:M1=2 ]$AHW8N/)NPL"W<%+
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M1<A*1=JOYU&??TH]=E0PRO:,,MX;!85#"6WFF'!&4^=RBEL]$3A+Y#5RV4L
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M:5-;>T=G5_>+EZ_Z!P:'AD=&Q\99TS,?/G[Z_.7K-^["CY^+O"5H^==OOT0
M49%_/OY-OQ10OU;\CH'$;[]$5B3^OD!!3%S7<J7BYMT2AXXKZ5F=E53>DGN[
MFBZE;[V'HW+XQ#OIU08VK+7<WZ[]Y=F_S[&4_Y1G_Z]C_^+7." K*H(&3U0!
MP ,"N#3#&/B?\3_C_V"(,@G0GU&\#.@CWU0(T(WA_=Q47@)4]HCHT+F:;/3N
M8/V(C4.97,?N'F*ZWDHMT74Z?)_70H"S+0=:/]\]Z89(!O+=X$A!.;+^V_A\
M)_9L(MF@/GIO8-./6-DN^MJ!J^^7^,$O)?N\3..IH4(@M5X(?)0)LA("U;1V
M(? KZ"HTPT^ )KJQ-3D=^'$E1&J6*;>!V<GWC@!EXDND],5,\^N\1_)GL(FO
MFXJ(+[%$<\Q=X/2B$%AYG?P>W^C&]N%VSUB<$P)'O<;U.Z=L,UTY,:GWOQ20
M#0<OS1XQ'_?SWB=1?EUI*_D:=0"["J03:,SKVN:",CPKGV3'/P*I_^C^O,?^
MI+^F?^Z$[9=H6FCV!^K8!PKX0L]/IG#9:;*3[$"2CD[F64(S0D!\3S]YY917
M:!)GB?GLYE56SX3CG8;(V,.\ZC?7^)7JF#^T.T780:*<0IXIQ.=[@'1U6(DS
MP L7 BD:MMV7J(N2]=15R* _V+%)3\MC5U.@>P^<7?U>LN46[V5,F'1VNLZ>
MV1<2/\_S_9#W^!K"G DST^LBI9[6?5KF^;AW64)TW5A\Y+6>9&.@QEEV>__K
M??(!ATMNI8RNI&U"1$&Z"QS,WP;27Q0( 5F<!'E(":IE>M=RE*-.;<@IG5UQ
M6CNY6GUER7ZBXL-Y;PG91VM\5TAJ8[CYK&="@-TH!"14D5>TVGE8>>]SSI&&
M<8NYGD./OB$KN"NZ-UT=?L:3F2WN*-#Q7U<=K_JF[,0VTZL!)U:LHLU1^+8D
M<<%5/',>KT:R$MQH67,7BFJOA;6+]^+4W[+[-399?9I^T_LQ0RU?1MJRH]16
MQ.=-VYDG@"C;"]*3R&K5"R)A("H5CD47*8,8.S/^E:$46V2A^-7_V>NWQ)A>
ML]O!Y;UKWULFA>&+G"_=PI1,1@VUKD13]1"->8U65]Y5S7<@R0GJ8)5I"[67
M)IWA96,,>T'K5K$:_QX]4Y_H,SMU$PU6N#H9TL00&=(V[DA[++1AGC=(>5XX
MLCHOBE!WQQ]7$7^DT\\TQF!@STF#DWZJ2V;?:JV6J/U>OQ^C(028E_P3Y[SX
MZ^ (J)@:@5VY&"W=TWYJ*I5K[<HUI]PB0&7^Q5X>0QF??GU4FZS+TS^@M\+
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M!01!?W*["'+P']R590K))1;N+84>3YYF2&'T[/)\+F47']JO)BT.G+[.P01
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MLB7%%J1;@*Q^;(WGY[EZ(2#3C:S&C,.A250P!GV.M2"_MB]EW,+H)=^S*T%
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MG*OXZ2=UKW'3H*X8?RX#_UQZV8$WP?F),T?9X0C^("A]X("[[*GRSB0S;=^
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M@#<-.)JP-DG_J>3^]N1%Q^;D0P94$[9VI7YSW@D/2Z/*^"O ;A?E_QG_7^-
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MCT5WK #PN%9E.(23DX8VVZ.!1S[[#^HU/.E'I&:G9 =-[QU;VS@L^;1_^-W
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MJ!6+J'.,S^B4J*;_O7<;"5 ,.(9%,H=3A0!(^>O!_S7WJ=+@%0HJ:6'4BW@
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MR]-;9(.XGCS*MF$LU[ND:B3K4MT#ZEFLB6:P'CTC#WK#9S7-RU"UP>!<ZGY
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M-Y.23Y>RAT32^7P_4OB8I3(I/J1YOJ!1Q!E1^TB?TPA 'C*  C\&R/<QC%C
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M' 0@&KG Q]"5(:+29U;7D#UDF-LTWZD EEH'9Z>$4VFAW?R5'DZIB*,UL>2
M2T;,;&<V\CB,S"V-(?@PW!#TB 3K#>)@$6+V$DP<.=8;HN.(LOY-]2/,,C/#
M^SQ?"_ZF=/RH"\B7)UOE'V\>2O_:M]]$QI)<\$4<!1+#D($8:;X,PA!0U\>
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M_< ;*N#"LO=I0R[Z07,4=-&SF8'*5RC[3?U.9(]5\5/!*(?")\ -(-1^A2'
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M$CNUR)?XGIP W(RC!H1Q9&*Z",'+G%+.XS*&<\J)WI[/2>6\ZJW.*BVO]<Q
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MM<\[FYBL"KJI,LUZZ,;OV!%NGA6+GY-5<K^^KZ]* Y^7^Q;@A[K:8.P2@'%
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MRA5LVNVT68,MP3C*'VS[OGV(U^<[M:'5$0U5HN)WA"7+I$C$)EV;1%$DD0R
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MQC9!E ",*01@003&6/*<.I4+<>UP:I.^E3GI"MWDUF_%#KAKY@1\/R4, >?
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MC?=VZO1U/T-N\5;FI%J8_^RD]<T!UX>V&R%<#]Y86=U:P%YL)?W)8O?. ;N
M1&X.F$3+V-;7U\BIV1S4/L[!YO)20+*UPBTK%<4<2XYS8&P%!A##*>"%8H R
M**ED)-<<.B=;<^MS:C;%_RN<$H-YN\I<A^"R9W$ 8 >F&T=,_9.M.6+JD6PM
M/K9C)5N+\]WZ95WS0ZLOZYIC2^-E7?-3[4G6-<]70VN__G$KA(U/-2:G:7AA
M_BIJK\_ZXW)>B1_-GWOW&$&,*I&59G](#;?#DMK\:QA0Q&%)=,;3PLO-Z2O
MU(C^DQ)-!?D%6XC*["/WVB2?-VPAV4IZFI#>8^)F50Z)],#,;T3OXOI4^)ND
M$3SYO?W?0;R2H>A%*_;JV?W(I5[#P#DN]!K83M#]+/7V<6W8M5W=,T*(THH
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M#D=N^#K.;QHJNPXTP=.LS*@&&:>%S?=( *.P!! ACB%*&4:9S^H? MB8VZ1
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M,Q%:T=9OEZN/JZ502M;G:C9IJGI;+=A"/*EC.=-0BA)B#E+!*4"J2 $Q*SF
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M*N4&PW/(IN$-A><EK!HKSU#RDZ3FKZNUF"]M)-X^1!9#@H0J,E#FV-C9@FM
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M"09*A J>I@@2X76J[]#GU"C2BMRY9_S#)L;Y(VG$3FJYS4]JR3WO&#G [\:
MD4$=F.TBX.E_ <D=H5@WD1QZ'/=*DCL$1W>3/%Z-GQ%NE_*KQ JJLL2@2(D"
M"'(%F"#44!."@A0PIQ3Z.*A<.IV::^J+[:-)PY:()UF_JEKVGU_,FZQ?BR9Y
MUZ8G>5?X2 C%2JHPLVG!"4 XS0%'!0:9Q+A4G,+,+]8K^DB,42SK<N8UAP1J
MX6/@MC3$1G;@M2$.J%&STCU#CKGI98R[)O];I&QN)UK?S854059B6 *<9CE
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M@P,DL8H_]'4U;@$(!Z6/BD"XO!/,'4(IN7YK!-W&8W__I/3C0JYG&62D8)0
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M230UZNE4-^QZDHQ*R5ZGA*V35JON4S>)52QY857[J?^&V4##ZWA0,N:@#7W
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M:Y/U"_FO48;,">AH%<?<>AO08_:%?7^I%DI7&QMET/W-MC16QB3.<9$!(6P
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M@F1:8%1R+S]G+,FF1A^=\BBM&O5PWB0[5>IM:%<93X]GM#%E@BK%H01YJ3.
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MQ_7JZ?O&-K%X4G6FVNK<6*O]L7$53)@*E)E<$5#D!+O"V@7@&<+ X%0:RIC
M65 QII'DGAH9?)&/6CTMM%LHJZ"S\C+\,#'5G_2BC!1*OO"%[A9#.M9'$7)Q
M-JFA'I@!&^&32OJ[9"=_<JC P=5;_%C4D5&/>E,WO-0O<,,WVE!<OAD<K_N.
M"2-7FTUU:_F@E_+Y7LKU$U_<;U_Q]?K9_K*,TYTAK+G.,@H41>[< 1$@:*H!
M5")E&87VOZ!ER*O7J2TB3NCD0.JD%CLP':07X'X4'QW&@0DZ&,'P_(\AB,1*
M_NC5Y[B9'T-@.$O[&/1R1]?W13F66EV./JQSXLXXY$+J7 '.[ X5<TLYU!!K
M#7,B.2'$<!W$.W[=3HUX*E_.S4%I*WD@=*"CO!_P?OP3'\Z!">AF0:I:Y(A^
M]4$0Q?*S]^MT7+_[("#._/##W@Z_.?WBLHO,M\]O?LI']SE\L%_1+,\@DDAC
MH+-" 4QA :A2N3OOSR145#,_L^=:!U,CFD;&I!$R<5+Z7YY>!/'V[6E?:(8F
MC3!4@NY/VU3O=(%ZL<'1;E#;U#F\0FU][F62^1R<L;<F8:&92#/.&,A2(ERU
M$0.8R%,@4BI33A#,>#ZK:OG8O=]ZZV>8C"1]R*PZU6&X"78@?,*WB= /\^72
M_>!J(555D5XZ<8_OUY$A+&26,B!=@E9,,@SL&J& (H6!$',E):F_CC=+]0_^
M;30:C/9EZ*7Z!_PF_&SI"8[RB,9XWP1-1]?>_S!IF +';"()EWRE_H=*K10X
M%+&3*(5VW\U&^F0_(+U>ZZJ61W72*$V>VU4+@P)AY6X8): 9S4#!,).*:)&I
MH*0@%_J8VC;G_FG[N%K/_TNKTD,)_B%/T\3^ZFGC+@4W=?'JJIQQ_<1RM0P,
ME+V$M=]*T!/!@5E[)UU2BG?7)'RMX(K'K2TH1.+!2SV,REDM*I[R2]NCX8<=
MKU:66W8YME)I[+9%(U!D&0%88 %X1C7(: &QD@SAU(L!SEJ>VKPOA0O.778.
MV.T3C<XP##QYO1$(.L2XJ&VGTXOCED8[MKBHP.%YQ>4'NBW"K[78OML5JJT\
M.A0RE!24 @BS'&!C9Y^@.@4"2\T%):E.@URZ+_0QM<EXZ)+S?K5\ *Y&;^($
M3_:2WW;0\(;8;^WM"=S0.Z93S+YVPBQX+6Y!)=):?*F'4=?B%A5/U^*V1WO6
M"'FW_&XW N_U#[U ?];.!7@&<\:8A! 4128!UID&3!!F?RQPCF&N( W*4='2
MU]0HHI3M?_V/C*1_0!VK.5P U(\((L$T,"$<5ERH!+U+2E$3E/RMDG:(.@O7
M,8E=.>%"3R]3"^&ZRE>K&[2\THTF_KA:J=_GB\6[;]]M'XY\G*N&W<$71D*F
M@<Y</!B4&/ B+T"6%I!*RI&!*(0A+G<S-7)HI+0?_D[.Q D:QA17,/4CB?Y(
M#<P/X2 %DT([!I'XX$HGHU)!NZ*G+'#CZ8Y;AYVKZ$=S>,Y8II%P1X^;[>;L
MF''S5?_<_F8U^;\SQDB1&B9=W@?+%$1JP&&> FM(%-KN05+(95C\8D^)0J;*
M.!&-URXE C<@/0?*<[,R'O@C7@5=\,NR.QHK=%)*'7-;$P>_6%N@GM*,NUV*
M ]W9UBI2LU,-ZGH_7^IWMO7-K,"\L&9;"J1)N4L]F ..A0 T)0IFN*!9BJ<5
MV+63?6J68)UG;Z>[BWLNM4]*]<M(KST R0$"[G:Y2]"0@R(IL9A<A-C^"_-;
M0R;ZW0R\WDSSDYE@L-G9X/W#!)SM)?]O%G1V-B3C!YZ=B]#19[,^SSY>[-TJ
M_W:U/O>7."C67ON#VZ?K' EGOA>EK?#;\R>K?'E$NS>NLUSJG!<&0$4HP%@2
M0(5V67^)8)"J-%-AY=1?0HNI+<*'5Q-5O,J7@WB5(_>NVEG?,>E7*T<9D^U<
M80*]]U[DV_%;5"?_1;SL=NXN<4JX\7=:U-=5R2!;O!<=B5C^>B^BP[C>>R\Y
M3&>^?"\J3&!*'_XXLXW-[1)MC&/3,C.I@H(4&J8@+U(,,.49L N;L?]+>:JD
M( 9YW0A<;'UJ*\].P&HU"4GP>AF]=H[OC<G W!L=#K62Y45W^?T.!\M1-U.!
MQS];4IOZU3I@'RFY/44HJ](B77QGG Q);>+NDB6U/M31XM</;I _Z^^K]?:P
MT"<T&&EE*&"I+@"6R&6H+B@@R"#**<\Y"3H/N];1U-BKEC/9"=JYMNI5:#UM
MU@B #6U6=L$JW&2\ 40LJ^Y:-^,:7C>4/;.-;CW?C18^6&E7RZV5W#[T\&YI
M9Y[>;&N''5DHI5)$@"Z8M6:(Y0?!- 1(%UR*/",H"W*.;.ML:O1P+&O2"!O&
M#*WH^K%#+,P&9H@K< W@"^4#2"2F:.UJ5+;P4?J4,;S>"6.-S7IK-VEZR=?S
ME=V2:<EW7[.B4D(N$!"24H UXX!C H'&!49$06F$E[?D]2ZFQA"-=+>_<5\,
MVQDA#C(#\X _*-X3_[;>;=/=OGTPU>U/^VG>TO HD_NV8LV4]G@R_/3B W>7
M"C_TSEQ5'&J8%QAH0AC *+5[@EP)0&B!,8.4"^Q5J^92XU.;O(U\P4;_1>1N
M'USTP6/HI3LJ%/Z'%GT@&>G,(@2:H!.+:[JW'%B<O3+:><4U80^/*ZX^TS$Y
MYCX_\/VR"KU\7"WL^YLW?W^:;Y]GF$B*C": 0>."IS4##!<2Y()K;0V/-"UT
M2&7A6QT&\==H5887!VF4=Q'4M=QE_'3QAT27\O_++TJ;N9QO U-UW!P(OUU,
M3'@'IL/W)YA6 D9,E.D)1:P<F;>Z&S<]IJ?R9YDQ?=_K6A=>+OAF,[<SI$H?
MH?[S:;-U"\S'I^U'<R_M:O-4.D)^W#[JM;M7LO-,+S>6\>HZI#OO+RY(SI#D
M &6P #@7"C *<Y"BG!BHI<YH4,6_B+)-S0@[52W9ZY:LGK:E?\)>O:34+SE2
ML RI2/[VV>YQS6KM?!D"SVYCCKP?%;[0> [,FA&&LG8-',9A;P#4H]6.CR?9
MR"7GHT-Z7JD^?A==L[4O'UR<O M!/KCMEW93S!& S&4D)$4!>)H2( 0V,K6[
MYAP%)F<_[V1JG'V<,> N_*Z[%5%/:[(G3D-;D$<) OP@ZI!O_3H&T=*K7^AB
MY&SJUY4\3Y[>\FR_L%]G7KRMS(N90 PII@L@R\S$N<L50BD"!4229(HPH](N
M,;\'?4QMRC<B5G96\K:3H74)2[_9WA.A@2=[*#B=PWPOJ!\YQO>PAQ<)\+V@
MXK7HWDN/=G2,.=M,EK9$5?]O5A A&6<94+G* 1:I!D*E*4!4:"$%(=0$3??6
MWJ8V\0^%_>?Z(.2NMMTKB0,=95JA]F.#:  .S L]L MWG/'!));W3&M?X[K0
M^*A]YD?C]5+G,-:UYAO]6E=_OEO:#8R>_W#^QI9*J.2%*Q>=*RP!I@4'3!L,
M%"NH(AAQ6>2SI7YPVYFO0?&GUSOUFA"LFA!G70\W.1J9D_DRV:ZYTLEZ+W-P
M8&<+YGZ<TA_"T8(G*]A^:23]U2'XV0.[+A&.MS&)%Y/8TM?8482WU;X0]^?Q
M4F<'O;]L&G^\#%%JH 99FEL&X4("*@H-<F0X(Y KS&&@/U[3]M1,#RN:_3/0
MM>829GX,T!&)@>>[+PA=?.A.U8WG,K=K>6P/N5.5+CC$G3W2>5(JO9D_+-V"
M67]HJ>2<$DI!D5$!<)8KP) 6(&5%EG(-,Y0%!;=>Z&-ZDW2;O-[)F'!7RU<]
M5/Z?39;&[E/X#&'OJ=P'M\&G= S(NDSX:Z#$F_AG/8Q- -=4O$ $5Q_MG!_,
M/XC?U5QZO?K&Y\N9@0I2A') C'3'"PH!5L ,0$YS"HM":!YT6=Q1CJD1RW&>
MC[+J5_*W2M30A,0=!\:/:T: >V ^ZH1TEWQ??7"*E^>KDQ1CY_?J ]6%O%Z]
MFNM8[J3)#[:ZEW]_FJ_U;T^;^5)O-GKS06\_FE=\\UC_BYHY9YG4J!300F?6
M<((<,,H(("K/"3%$%50VYR)^+!C2?8<3DH')KY1L4Z:*<6X3FR>QF:LY7\]=
M;92E+GTII-4@X;4*@>510L;&CP:CXSU2P'8M=K)=);5XR5[RN^1#A;63OOGW
MF&56.H 6J_Y*2-?C%F;I ,I9Q98N;73V&[1ZS1?S.O5$3:7+AT_KE9F7B6??
M6AWKV$TKT2O+LJO%7%4'K4UN&\T+374.02$,!CBUNT:&*+16("SR@C)%6=#6
M,8Y84S,*FR#D2@F7Q*8*ABUSV-3_&.S\%V/X_$AR_$$9F#Z/%7),N5.I&:-?
MG%:_)FZ>-R-4LNVA:H-F(8H+>CR/OQA"C>WL%Q'("WY^,5N/5PL$UD=/O' 1
M[]8HE5!+@!$T@*JT*$/C"H)8JC@+R]_=TEO('!\G-_=!/1#8OQY( ZJ6&JI<
MV74.IQ!@4>2 4D2!4#F"&<LR4O"^!58Z0#I:@94D(I9^:U DA 9>6*[75H$C
MU5:!@QR1MO7TXK558/N1J<\K'<HA/JW7EM#?SC>2+_Y#\_6;I7IM.7U&C,AH
MBC.0BS0#+F,WL#\J(+! 1#!.<N:5E*BMDZEQ0BUG4@F:.$D3*VKB9 THF'@-
MTG:&B 74P-30":.PDHHW0.A67?%:H^,56KRAUE'-Q5O/=K.O_K)<6S/O8>G*
M_W[E/W_32VUMNTT5IV%_\4DO^:*.\&NRE=Q+N7YR9X28&,PX!3R5"& B)&"Y
M)$ 0 4TA62J*H%IL/629&FT<JI)L^<]$U,K<)?,F"X^+8_W>J)3P2I$PXZ//
MZ/D9)R.-R< ,=30<5NKDM]UPU %N[I>?]H-AAV:7+>G^QL@$&S<1,(UD_/21
M9%3C* )DI\93C";#\[O8AO_,M[:U,K(JHUFN<U=\R@@&,#8<<,NJ .4%4:DN
M#/5S3SEK>6I\Z*97)5UP"M9CQ-I9JQ<. W-0- C\D[ETAF*D3"[^D 3E<;FH
M=DL2E^/G1\O@<E',P_0MEQ\(YYR/W^>KN7K/?]\\68*KSR881CC5* .ID78S
MIVD*A*:6A$A*,6&L,,(K3/9:!U-CH$K&I!$RT /N*HRW^:@O. /3TD"X^)-4
M7WQ&XJI@G((HJPV$%N:Z^-IH!-8F]"&/M3X73F?W"SM,BK]:/2VWS_7G1@E+
MM4X9R*&R6U%G4E%$$2 "\13J@A#DG27O0OM3([-:Q*22L<.<O83A;2KKB<S
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MY18=6;IQ/:.'@?;,.7J@;CK&G\OR5FUC/W37;'T>9]>F#Q:T^G"7%R3-)"<
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M?7N'GQ?+]41['Q$C VVE!67)(D94"J011>;"DX^BB?+O++P3#D3_.#A&GIU
MXBTNIXO\\SR_HI-XDIV@LS0QX#PPPK32$)+7@%:'I!W/6;$F@+BU[$YPD/W#
MX7!9=@*&#\LP7TVKX"\ ;5+Q&KT#HYT$)<@S\"%&0*5#284IP5R;T^'.RCM!
M0O4/B:,D.C(J?IZOI^MOOTQG^/OY6<3E)'EC5? !#.>*'&A=(#J-@,YY=,2
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M?!JC-N M_Y.@9!1?,PJR@3&/V^?#D1L/Q3-N*>2*PK6^"1S2M+U/GS"?S^A
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MJR:2<9QUY-8XX8L<U&3W!>-@Y\NG;7,Y@EMX/(FGQLAVW7_,EY\QS<H,\TT
M72HOHN$0$24H%(%($@QQ.3IO$W<B#,KK?@DG3RU@.D^B 5,7K2G<"4Q^6EQA
M"LN;\7')NNPM1^">D=A(^D0N-@/O"EG.=<PA'W1S.1 C#]\^(4#:L'0'2(Z@
M[\3FQS\6B_SOV>7ESY\^A]G5;;P]8RA2: $NA#KMTFKRQ0H#F4M4FDYAZ]0
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M96"",2@"5XX/J='I)%S:C$W/1DOWH5D'FF&GQOSEMMFG]$PZ[@R4J'F=0V_
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M'[:%?(OY\L)EGI%Y R$7LAM,R."12[!2!JY]<5:U-OB&KZ[#',4VFFDD!G4
MO5WC@;>AG NC8G(Z1-"ECJ,N6" $4K2":^ED0E2J^5#%IY?38Q)3Z_CK<3SH
M $X_;%]+U"(S\NWJ(U[],@MQ=CFKEN6OBWFZOJK4ON!,V9!K1,<S!G1>&X@B
MD%F9-)->>Y92ZWNAH6OK,06AE8$U G<Z0-V=5KXS 4I"\J=C *9*S>\ABS (
MHE-.G+,</!>B=7;"CF7T>-O8./!_(,T[@$T=^K0YPC'?GN#U*F-]VK\MFRW6
M>/1/1%GZZ\^+9;A\6W;^NPMIE,2B G"-9'/R&(F8*.CT9Z*@3]ZPUH!KNH%A
M4#W'.X;I^-P!R'^[6I"5D-=;NR>SY7J>EQ>1-J*--L#D>E"SK<9J$8!:JR"#
MP("M0Q[/K6<8!,_QEJ(9%WH=//E3F%W]9[B\QG]BJ&/T-N.J'RQZT,C)W<]I
M,FQRP!(;C9F\?=/=6,'E[5S!:(M*PA4HF=4J1_(2"44".'>D1XPS(;0^)YY;
MS['Z9=>S[V:JAJ!=THI#)'L2E*=/GG$/(I2L1$[EJ[C6*)OM9*QM,UP\5B_M
MF'!6^F6=-]=,RVR?-IZNV;7<4V@<'ITN5M4+\%I_SW1MZZ(R9&E#U :M:GX!
M-Z;&>9\^8KZ^Q+?E]BUOEDM<U8NK>^[LEO+Y;0T,DU\[FW_X+BQG&R[<"8>)
M5BKT&J(,U6<AF\XIAX"9Q:Q8Y.%Q-?_Q=3(M-]"Q1ML'=U^5V$S&Y+/2@+<_
M7)0-><).\BSFX2%]#I\)/LHRQM.Y30ET"F6=F8HI6P1MR 50D;F:_N_!8D0C
MK-+<M;[@.8EY.%!ZZ0]^7=3;W\?"?,%Y3MXC DLID/L5/1&&/AD3F$TNZF):
MY](U6WS'2GH?O#UI=IZ4N1T$56XW_MV7VX__,<,K6M3'+[_@GWBY*4\VJ*RG
M S KDVA7-1XJB=1T]" +EFMO1O-^GEU9)W@\+6R> F\['O:$S)V'X.W^ME5K
M.BLI3'4RR?L$16@B6\USX"45:5F.60R:K' (0(<LL!.<-D3(4R!LSJZ>L/CS
M_//U:KFF&+^I<E3".QWHL/'1@<JUKWG6%F3.SAH7G=.CG>9?+Z<3G+4'P5-P
M.Y(CG8)+W&R%,4SDZD&1A20RU!E9C@70.A?I25S+XSYLHX!+3-G%KP]P'<*1
M@\'U)U[%Q8CPDC=CGQ5Z8[4&GG6ITULER4SF$))WG,B7C!LMGO;U<J8M#9L6
M7H=PI"?=]=V7>V3[Z6K=4R9]65L5CI64C1<@)490WLE:&T)^F7*^IA)F-9X.
M>WI9G>BR7AR')MSK"9"[-K257?0LVV09""4-J%C[M&I?YX=P5QL<%=&\.]"
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MZ!-P'-$[0,[-U/LZV_?]O\/G[2ZD\RPRY'0"U_1G1(18.((ST69;/%.L=?G
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MNIXCK=QN5RYJ3TMM/.2R;JO&-;A:!:I=Y*3D%,_"#V#VPZ=.XT@TYO,1A.K
MN+L[R7ZY;2RD#8]>FP1)V50K?@W$6"PPD;)D"5G*X]U!_[)7DUC;\PG?BL8=
MP.3[M1_S\_R/^16&R]G_Q7QS+?IV_O@6ZM[=*;_0P7&E(CG.*AN2*LL@JB!!
M)&$\>F&D:EUY>^A:>PF)'0B2QV[$*3C6 3)WWMG_NE@]FX)V>ZE?6U$5VC!&
M4R_,K*K-]0Q9=!E!1,6TE]8+=Y*V'/LLNI<07!NLGI:'78'VID/:%]HN<2]<
MOOFTN)ZO+D*DTR44!H%Y.G0L9J!3QH)R0;'L5,+FXU=?7%0OP;K6H&O!@PY
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MO8'C9@2O*A:EY9!$L:#0D.08(DW@SFJ3@RQQB'7ZQ..GLTP;,.PY]A] O=X
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MI2$5?KW>U"(RD23S&1R3BCSC1):BDADR4UXS$277'4O&9A-G:@0U1.9XPG(
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MJ%_^_X%VW-EQ 0!02P$"% ,4    " !8@J54*2)#Z>@%   ;&0  'P
M        @ $     83(R<3-?,3!Q># S,S$R,GAE>&AI8FET,3 R+FAT;5!+
M 0(4 Q0    ( %B"I52E(G:_^0<  #DG   ?              "  24&  !A
M,C)Q,U\Q,'%X,#,S,3(R>&5X:&EB:70S,3$N:'1M4$L! A0#%     @ 6(*E
M5#];1T( "   L"<  !\              ( !6PX  &$R,G$S7S$P<7@P,S,Q
M,C)X97AH:6)I=#,Q,BYH=&U02P$"% ,4    " !8@J54C2F^WNL$  !K%P
M'P              @ &8%@  83(R<3-?,3!Q># S,S$R,GAE>&AI8FET,S(Q
M+FAT;5!+ 0(4 Q0    ( %B"I50X@>UPSAH   JA   ?              "
M < ;  !A,C)Q,U\Q,'%X,#,S,3(R>&5X:&EB:70Y.3$N:'1M4$L! A0#%
M  @ 6(*E5/O=0.!_<@( U:$= !               ( !RS8  &-A:"TR,#(R
M,#,S,2YH=&U02P$"% ,4    " !8@J54OD$;Y.,2  #3R0  $
M    @ %XJ0( 8V%H+3(P,C(P,S,Q+GAS9%!+ 0(4 Q0    ( %B"I50\A&P&
MUQ<  .C@   4              "  8F\ @!C86@M,C R,C S,S%?8V%L+GAM
M;%!+ 0(4 Q0    ( %B"I507G1@W;FT  &#@!  4              "  9+4
M @!C86@M,C R,C S,S%?9&5F+GAM;%!+ 0(4 Q0    ( %B"I51__I;<1$L
M ,19   3              "  3)" P!C86@M,C R,C S,S%?9S$N:G!G4$L!
M A0#%     @ 6(*E5&(^23<@:P  [7X  !,              ( !IXT# &-A
M:"TR,#(R,#,S,5]G,BYJ<&=02P$"% ,4    " !8@J54N<(=S,)=  !U<0
M$P              @ 'X^ , 8V%H+3(P,C(P,S,Q7V<S+FIP9U!+ 0(4 Q0
M   ( %B"I50.<R;(Z$\  )M@   3              "  >M6! !C86@M,C R
M,C S,S%?9S0N:G!G4$L! A0#%     @ 6(*E5,81S:N%=@  6(<  !,
M         ( !!*<$ &-A:"TR,#(R,#,S,5]G-2YJ<&=02P$"% ,4    " !8
M@J54+#,R_8-<  "H;   $P              @ &Z'04 8V%H+3(P,C(P,S,Q
M7V<V+FIP9U!+ 0(4 Q0    ( %B"I53ZE\&0X%0  )%E   3
M  "  6YZ!0!C86@M,C R,C S,S%?9S<N:G!G4$L! A0#%     @ 6(*E5(I?
MTES;[   T<D) !0              ( !?\\% &-A:"TR,#(R,#,S,5]L86(N
M>&UL4$L! A0#%     @ 6(*E5$H(ANV^G0  K%$' !0              ( !
MC+P& &-A:"TR,#(R,#,S,5]P<F4N>&UL4$L%!@     2 !( S 0  'Q:!P
!  $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
